{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 107,
   "id": "c18b6907",
   "metadata": {},
   "outputs": [],
   "source": [
    "# !pip install lazypredict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "b1871418",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import re\n",
    "import torch\n",
    "import torch.nn as nn\n",
    "import torch.nn.functional as F\n",
    "import torch.optim as optim\n",
    "import torchvision.transforms as transforms\n",
    "from torch.utils.data import Dataset, DataLoader\n",
    "\n",
    "from torchmetrics.functional import accuracy as ACC\n",
    "\n",
    "import pytorch_lightning as pl\n",
    "from pytorch_lightning.callbacks import EarlyStopping\n",
    "from torch.utils.tensorboard import SummaryWriter\n",
    "from torch.nn.utils.rnn import pad_sequence\n",
    "from torchsummary import summary\n",
    "\n",
    "import time\n",
    "import nltk\n",
    "import json\n",
    "import random\n",
    "import unicodedata\n",
    "import contractions\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "from tqdm import tqdm\n",
    "\n",
    "import seaborn as sns\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "import warnings\n",
    "warnings.simplefilter(action=\"ignore\")\n",
    "\n",
    "#data cleaning methods\n",
    "import spacy\n",
    "from spacy.lang.en.stop_words import STOP_WORDS as stopwords\n",
    "from sklearn.feature_extraction.text import CountVectorizer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "fed1edc4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'cuda'"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "torch.manual_seed(42)\n",
    "random.seed(42)\n",
    "np.random.seed(42)\n",
    "\n",
    "device = 'cuda' if torch.cuda.is_available() else 'cpu'\n",
    "device"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "afc1cd1e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "index 2170\n"
     ]
    }
   ],
   "source": [
    "class Load_Preprocess():\n",
    "    def __init__(self):\n",
    "        self.word2index = {}\n",
    "        self.max_len = 0\n",
    "        \n",
    "        self.Label2num = {'Entailment': 1, \"Contradiction\": 0}\n",
    "\n",
    "        self.train_df = self.Preprocess_df(pd.DataFrame.from_dict(self.load_Processed_Data(self.load_Processed_cTAKES('ctakes/Train_Statements_cTAKES_Processed.json'), 'train')), Train=True)\n",
    "        self.val_df = self.Preprocess_df(pd.DataFrame.from_dict(self.load_Processed_Data(self.load_Processed_cTAKES('ctakes/Dev_Statements_cTAKES_Processed.json'), 'dev')))\n",
    "        self.test_df = self.Preprocess_df(pd.DataFrame.from_dict(self.load_Processed_Data(self.load_Processed_cTAKES('ctakes/Test_Statements_cTAKES_Processed.json'), 'test')))\n",
    "        \n",
    "    def load_Processed_cTAKES(self, split):\n",
    "        ctakes_tokens_path = split\n",
    "        with open(ctakes_tokens_path) as json_file:\n",
    "            ctakes_tokens = json.load(json_file)\n",
    "\n",
    "        preferred_text_dict = dict()\n",
    "        for i in range(len(ctakes_tokens)):\n",
    "            cm_dict = ctakes_tokens[i]['clinical_mention']\n",
    "            temp_list = []\n",
    "            for key in cm_dict.keys():\n",
    "                try:\n",
    "                    temp_list.append(cm_dict[key][0]['preferredText'])\n",
    "                except:\n",
    "                    continue\n",
    "            preferred_text_dict[ctakes_tokens[i]['UUID'][0]] = temp_list\n",
    "        return preferred_text_dict\n",
    "\n",
    "    def load_Processed_Data(self, ctakes, split):\n",
    "        preferred_text = []\n",
    "        statement = []\n",
    "        trail1 = []\n",
    "        trail2 = []\n",
    "        section = []\n",
    "        label = []\n",
    "        \n",
    "        with open(f\"training_data/{split}\" + \".json\") as file:\n",
    "            data = json.load(file)\n",
    "            uuid_list = list(data.keys())\n",
    "\n",
    "        for id in uuid_list:\n",
    "            statement.append(data[id]['Statement'])\n",
    "            if split != 'test':\n",
    "                label.append(self.Label2num[data[id]['Label']])\n",
    "            else:\n",
    "                label.append(-1)\n",
    "            section.append(data[id]['Section_id'])\n",
    "        \n",
    "            with open(f\"training_data/CT json/{data[id]['Primary_id']}\" + \".json\") as file: \n",
    "                ct = json.load(file)\n",
    "                trail1.append(self.join_list(ct[data[id]['Section_id']]))\n",
    "                \n",
    "            if data[id]['Type'] == \"Comparison\":  \n",
    "                with open(f\"training_data/CT json/{data[id]['Secondary_id']}\" + \".json\") as file:\n",
    "                    ct = json.load(file)\n",
    "                    trail2.append(self.join_list(ct[data[id]['Section_id']]))\n",
    "            else:\n",
    "                trail2.append(\"_\")\n",
    "                \n",
    "            preferred_text.append(','.join(ctakes[id]))\n",
    "\n",
    "        return {'preferred_text':preferred_text, 'statement':statement, 'trail1':trail1, 'trail2':trail2, 'section':section, 'label':label}\n",
    "        \n",
    "    def join_list(self, sentences):\n",
    "        return \", \".join([sent.strip() for sent in sentences])\n",
    "    \n",
    "    def Preprocess_df(self, df, Train=False):\n",
    "#         df['statement'] = df['statement'].apply(Preprocessing)\n",
    "#         df['trail1'] = df['trail1'].apply(Preprocessing)\n",
    "#         df['trail2'] = df['trail2'].apply(Preprocessing)\n",
    "\n",
    "        df[\"#Words1\"] = df[\"statement\"].apply(lambda n: len(n.split()))\n",
    "        df[\"#Words2\"] = df[\"trail1\"].apply(lambda n: len(n.split()))\n",
    "        df[\"#Words3\"] = df[\"trail2\"].apply(lambda n: len(n.split()))\n",
    "        \n",
    "        if Train:\n",
    "            self.Build_Vocabulary(df['statement'].tolist()+df['trail1'].tolist()+df['trail2'].tolist())\n",
    "        return df\n",
    "\n",
    "    def Build_Vocabulary(self, texts):\n",
    "        words = ['', 'UNK']+list(set(' '.join(texts).split()))\n",
    "        self.word2index = dict(zip(words, list(range(0, len(words)))))\n",
    "        self.max_len = self.get_max_length(texts)\n",
    "   \n",
    "    def get_max_length(self, Texts):\n",
    "        lens = [len(text.split(' ')) for text in Texts]\n",
    "        print('index', lens.index(max(lens)))\n",
    "        return max(lens)\n",
    "    \n",
    "    def Target_proportions(self, df):\n",
    "        print(df.label.value_counts())\n",
    "        sns.countplot(x=df['label']).set_title('Proportions of 0 vs 1')\n",
    "        plt.show()\n",
    "\n",
    "Data = Load_Preprocess()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "810dacab",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(1547, 19314)"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Data.max_len, len(Data.word2index)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "71e4388a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>preferred_text</th>\n",
       "      <th>statement</th>\n",
       "      <th>trail1</th>\n",
       "      <th>trail2</th>\n",
       "      <th>section</th>\n",
       "      <th>label</th>\n",
       "      <th>#Words1</th>\n",
       "      <th>#Words2</th>\n",
       "      <th>#Words3</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Primary operation</td>\n",
       "      <td>there is a 13.2% difference between the result...</td>\n",
       "      <td>Outcome Measurement:, Event-free Survival, Eve...</td>\n",
       "      <td>_</td>\n",
       "      <td>Results</td>\n",
       "      <td>0</td>\n",
       "      <td>15</td>\n",
       "      <td>122</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Ejection as a Sports activity,Primary operation</td>\n",
       "      <td>Patients with significantly elevated ejection ...</td>\n",
       "      <td>Inclusion criteria:, Inclusion Criteria:, Fema...</td>\n",
       "      <td>Premenopausal women 55 years of age or younger...</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>0</td>\n",
       "      <td>30</td>\n",
       "      <td>281</td>\n",
       "      <td>347</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Enterocolitis,Primary operation</td>\n",
       "      <td>a significant number of the participants in th...</td>\n",
       "      <td>Adverse Events 1:, Total: 20/167 (11.98%), Car...</td>\n",
       "      <td>Adverse Events 1:, Total: 112/458 (24.45%), Fe...</td>\n",
       "      <td>Adverse Events</td>\n",
       "      <td>0</td>\n",
       "      <td>17</td>\n",
       "      <td>94</td>\n",
       "      <td>84</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Primary operation</td>\n",
       "      <td>the primary trial does not report the PFS or o...</td>\n",
       "      <td>Outcome Measurement:, Local Control Using Ipsi...</td>\n",
       "      <td>_</td>\n",
       "      <td>Results</td>\n",
       "      <td>1</td>\n",
       "      <td>16</td>\n",
       "      <td>84</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Therapeutic procedure,fulvestrant</td>\n",
       "      <td>Prior treatment with fulvestrant or with a pho...</td>\n",
       "      <td>Inclusion Criteria:, Postmenopausal women with...</td>\n",
       "      <td>_</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>0</td>\n",
       "      <td>22</td>\n",
       "      <td>385</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>195</th>\n",
       "      <td>Oral cavity,Primary operation,Pharmaceutical P...</td>\n",
       "      <td>The the primary trial intervention involves on...</td>\n",
       "      <td>INTERVENTION 1:, Letrozole, Participants recei...</td>\n",
       "      <td>INTERVENTION 1:, Sentinel Lymph Node Biopsy, [...</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>0</td>\n",
       "      <td>21</td>\n",
       "      <td>21</td>\n",
       "      <td>8</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>196</th>\n",
       "      <td>Conjunctivitis,Primary operation</td>\n",
       "      <td>the secondary trial reported 1 single case of ...</td>\n",
       "      <td>Adverse Events 1:, Total: 16/48 (33.33%), Febr...</td>\n",
       "      <td>Adverse Events 1:, Total: 21/519 (4.05%), Anae...</td>\n",
       "      <td>Adverse Events</td>\n",
       "      <td>1</td>\n",
       "      <td>17</td>\n",
       "      <td>56</td>\n",
       "      <td>96</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>197</th>\n",
       "      <td>Primary operation</td>\n",
       "      <td>the secondary trial and the primary trial do n...</td>\n",
       "      <td>Outcome Measurement:, Number of Patients With ...</td>\n",
       "      <td>Outcome Measurement:, Disease Free Survival., ...</td>\n",
       "      <td>Results</td>\n",
       "      <td>1</td>\n",
       "      <td>17</td>\n",
       "      <td>200</td>\n",
       "      <td>112</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>198</th>\n",
       "      <td>Worse,Disease,Primary operation</td>\n",
       "      <td>the outcome measurement of the primary trial i...</td>\n",
       "      <td>Outcome Measurement:, Progression-free Surviva...</td>\n",
       "      <td>_</td>\n",
       "      <td>Results</td>\n",
       "      <td>1</td>\n",
       "      <td>30</td>\n",
       "      <td>168</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>199</th>\n",
       "      <td>Lesion,Structure of supramammillary nucleus,Pr...</td>\n",
       "      <td>All the primary trial patients had a minimum o...</td>\n",
       "      <td>Outcome Measurement:, Complete Response + Part...</td>\n",
       "      <td>_</td>\n",
       "      <td>Results</td>\n",
       "      <td>0</td>\n",
       "      <td>21</td>\n",
       "      <td>113</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>200 rows × 9 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                        preferred_text  \\\n",
       "0                                    Primary operation   \n",
       "1      Ejection as a Sports activity,Primary operation   \n",
       "2                      Enterocolitis,Primary operation   \n",
       "3                                    Primary operation   \n",
       "4                    Therapeutic procedure,fulvestrant   \n",
       "..                                                 ...   \n",
       "195  Oral cavity,Primary operation,Pharmaceutical P...   \n",
       "196                   Conjunctivitis,Primary operation   \n",
       "197                                  Primary operation   \n",
       "198                    Worse,Disease,Primary operation   \n",
       "199  Lesion,Structure of supramammillary nucleus,Pr...   \n",
       "\n",
       "                                             statement  \\\n",
       "0    there is a 13.2% difference between the result...   \n",
       "1    Patients with significantly elevated ejection ...   \n",
       "2    a significant number of the participants in th...   \n",
       "3    the primary trial does not report the PFS or o...   \n",
       "4    Prior treatment with fulvestrant or with a pho...   \n",
       "..                                                 ...   \n",
       "195  The the primary trial intervention involves on...   \n",
       "196  the secondary trial reported 1 single case of ...   \n",
       "197  the secondary trial and the primary trial do n...   \n",
       "198  the outcome measurement of the primary trial i...   \n",
       "199  All the primary trial patients had a minimum o...   \n",
       "\n",
       "                                                trail1  \\\n",
       "0    Outcome Measurement:, Event-free Survival, Eve...   \n",
       "1    Inclusion criteria:, Inclusion Criteria:, Fema...   \n",
       "2    Adverse Events 1:, Total: 20/167 (11.98%), Car...   \n",
       "3    Outcome Measurement:, Local Control Using Ipsi...   \n",
       "4    Inclusion Criteria:, Postmenopausal women with...   \n",
       "..                                                 ...   \n",
       "195  INTERVENTION 1:, Letrozole, Participants recei...   \n",
       "196  Adverse Events 1:, Total: 16/48 (33.33%), Febr...   \n",
       "197  Outcome Measurement:, Number of Patients With ...   \n",
       "198  Outcome Measurement:, Progression-free Surviva...   \n",
       "199  Outcome Measurement:, Complete Response + Part...   \n",
       "\n",
       "                                                trail2         section  label  \\\n",
       "0                                                    _         Results      0   \n",
       "1    Premenopausal women 55 years of age or younger...     Eligibility      0   \n",
       "2    Adverse Events 1:, Total: 112/458 (24.45%), Fe...  Adverse Events      0   \n",
       "3                                                    _         Results      1   \n",
       "4                                                    _     Eligibility      0   \n",
       "..                                                 ...             ...    ...   \n",
       "195  INTERVENTION 1:, Sentinel Lymph Node Biopsy, [...    Intervention      0   \n",
       "196  Adverse Events 1:, Total: 21/519 (4.05%), Anae...  Adverse Events      1   \n",
       "197  Outcome Measurement:, Disease Free Survival., ...         Results      1   \n",
       "198                                                  _         Results      1   \n",
       "199                                                  _         Results      0   \n",
       "\n",
       "     #Words1  #Words2  #Words3  \n",
       "0         15      122        1  \n",
       "1         30      281      347  \n",
       "2         17       94       84  \n",
       "3         16       84        1  \n",
       "4         22      385        1  \n",
       "..       ...      ...      ...  \n",
       "195       21       21        8  \n",
       "196       17       56       96  \n",
       "197       17      200      112  \n",
       "198       30      168        1  \n",
       "199       21      113        1  \n",
       "\n",
       "[200 rows x 9 columns]"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Data.val_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "757c0363",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'INTERVENTION 1:, Diagnostic (FLT PET), Patients with early stage, ER positive primary breast cancer undergo FLT PET scan at baseline and 1-6 weeks after the start of standard endocrine treatment. The surgery follows 1-7 days after the second FLT PET scan., Tracer used in the FLT PET (positron emission tomography) scanning procedure: [F18] fluorothymidine., Positron Emission Tomography: Undergo FLT PET, Laboratory Biomarker Analysis: Correlative studies - Ki67 staining of the tumor tissue in the biopsy and surgical specimen.'"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Data.train_df['trail1'].tolist()[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "b7e405a2",
   "metadata": {},
   "outputs": [],
   "source": [
    "Data.train_df['MergedColumn'] = pd.concat([Data.train_df['trail1'], Data.train_df['trail2'].astype(str)], axis=1).apply(''.join, axis=1)\n",
    "Data.val_df['MergedColumn'] = pd.concat([Data.val_df['trail1'], Data.val_df['trail2'].astype(str)], axis=1).apply(''.join, axis=1)\n",
    "Data.test_df['MergedColumn'] = pd.concat([Data.test_df['trail1'], Data.test_df['trail2'].astype(str)], axis=1).apply(''.join, axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "7de785b1",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>preferred_text</th>\n",
       "      <th>statement</th>\n",
       "      <th>trail1</th>\n",
       "      <th>trail2</th>\n",
       "      <th>section</th>\n",
       "      <th>label</th>\n",
       "      <th>#Words1</th>\n",
       "      <th>#Words2</th>\n",
       "      <th>#Words3</th>\n",
       "      <th>MergedColumn</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Primary operation</td>\n",
       "      <td>there is a 13.2% difference between the result...</td>\n",
       "      <td>Outcome Measurement:, Event-free Survival, Eve...</td>\n",
       "      <td>_</td>\n",
       "      <td>Results</td>\n",
       "      <td>0</td>\n",
       "      <td>15</td>\n",
       "      <td>122</td>\n",
       "      <td>1</td>\n",
       "      <td>Outcome Measurement:, Event-free Survival, Eve...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Ejection as a Sports activity,Primary operation</td>\n",
       "      <td>Patients with significantly elevated ejection ...</td>\n",
       "      <td>Inclusion criteria:, Inclusion Criteria:, Fema...</td>\n",
       "      <td>Premenopausal women 55 years of age or younger...</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>0</td>\n",
       "      <td>30</td>\n",
       "      <td>281</td>\n",
       "      <td>347</td>\n",
       "      <td>Inclusion criteria:, Inclusion Criteria:, Fema...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Enterocolitis,Primary operation</td>\n",
       "      <td>a significant number of the participants in th...</td>\n",
       "      <td>Adverse Events 1:, Total: 20/167 (11.98%), Car...</td>\n",
       "      <td>Adverse Events 1:, Total: 112/458 (24.45%), Fe...</td>\n",
       "      <td>Adverse Events</td>\n",
       "      <td>0</td>\n",
       "      <td>17</td>\n",
       "      <td>94</td>\n",
       "      <td>84</td>\n",
       "      <td>Adverse Events 1:, Total: 20/167 (11.98%), Car...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Primary operation</td>\n",
       "      <td>the primary trial does not report the PFS or o...</td>\n",
       "      <td>Outcome Measurement:, Local Control Using Ipsi...</td>\n",
       "      <td>_</td>\n",
       "      <td>Results</td>\n",
       "      <td>1</td>\n",
       "      <td>16</td>\n",
       "      <td>84</td>\n",
       "      <td>1</td>\n",
       "      <td>Outcome Measurement:, Local Control Using Ipsi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Therapeutic procedure,fulvestrant</td>\n",
       "      <td>Prior treatment with fulvestrant or with a pho...</td>\n",
       "      <td>Inclusion Criteria:, Postmenopausal women with...</td>\n",
       "      <td>_</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>0</td>\n",
       "      <td>22</td>\n",
       "      <td>385</td>\n",
       "      <td>1</td>\n",
       "      <td>Inclusion Criteria:, Postmenopausal women with...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>195</th>\n",
       "      <td>Oral cavity,Primary operation,Pharmaceutical P...</td>\n",
       "      <td>The the primary trial intervention involves on...</td>\n",
       "      <td>INTERVENTION 1:, Letrozole, Participants recei...</td>\n",
       "      <td>INTERVENTION 1:, Sentinel Lymph Node Biopsy, [...</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>0</td>\n",
       "      <td>21</td>\n",
       "      <td>21</td>\n",
       "      <td>8</td>\n",
       "      <td>INTERVENTION 1:, Letrozole, Participants recei...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>196</th>\n",
       "      <td>Conjunctivitis,Primary operation</td>\n",
       "      <td>the secondary trial reported 1 single case of ...</td>\n",
       "      <td>Adverse Events 1:, Total: 16/48 (33.33%), Febr...</td>\n",
       "      <td>Adverse Events 1:, Total: 21/519 (4.05%), Anae...</td>\n",
       "      <td>Adverse Events</td>\n",
       "      <td>1</td>\n",
       "      <td>17</td>\n",
       "      <td>56</td>\n",
       "      <td>96</td>\n",
       "      <td>Adverse Events 1:, Total: 16/48 (33.33%), Febr...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>197</th>\n",
       "      <td>Primary operation</td>\n",
       "      <td>the secondary trial and the primary trial do n...</td>\n",
       "      <td>Outcome Measurement:, Number of Patients With ...</td>\n",
       "      <td>Outcome Measurement:, Disease Free Survival., ...</td>\n",
       "      <td>Results</td>\n",
       "      <td>1</td>\n",
       "      <td>17</td>\n",
       "      <td>200</td>\n",
       "      <td>112</td>\n",
       "      <td>Outcome Measurement:, Number of Patients With ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>198</th>\n",
       "      <td>Worse,Disease,Primary operation</td>\n",
       "      <td>the outcome measurement of the primary trial i...</td>\n",
       "      <td>Outcome Measurement:, Progression-free Surviva...</td>\n",
       "      <td>_</td>\n",
       "      <td>Results</td>\n",
       "      <td>1</td>\n",
       "      <td>30</td>\n",
       "      <td>168</td>\n",
       "      <td>1</td>\n",
       "      <td>Outcome Measurement:, Progression-free Surviva...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>199</th>\n",
       "      <td>Lesion,Structure of supramammillary nucleus,Pr...</td>\n",
       "      <td>All the primary trial patients had a minimum o...</td>\n",
       "      <td>Outcome Measurement:, Complete Response + Part...</td>\n",
       "      <td>_</td>\n",
       "      <td>Results</td>\n",
       "      <td>0</td>\n",
       "      <td>21</td>\n",
       "      <td>113</td>\n",
       "      <td>1</td>\n",
       "      <td>Outcome Measurement:, Complete Response + Part...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>200 rows × 10 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                        preferred_text  \\\n",
       "0                                    Primary operation   \n",
       "1      Ejection as a Sports activity,Primary operation   \n",
       "2                      Enterocolitis,Primary operation   \n",
       "3                                    Primary operation   \n",
       "4                    Therapeutic procedure,fulvestrant   \n",
       "..                                                 ...   \n",
       "195  Oral cavity,Primary operation,Pharmaceutical P...   \n",
       "196                   Conjunctivitis,Primary operation   \n",
       "197                                  Primary operation   \n",
       "198                    Worse,Disease,Primary operation   \n",
       "199  Lesion,Structure of supramammillary nucleus,Pr...   \n",
       "\n",
       "                                             statement  \\\n",
       "0    there is a 13.2% difference between the result...   \n",
       "1    Patients with significantly elevated ejection ...   \n",
       "2    a significant number of the participants in th...   \n",
       "3    the primary trial does not report the PFS or o...   \n",
       "4    Prior treatment with fulvestrant or with a pho...   \n",
       "..                                                 ...   \n",
       "195  The the primary trial intervention involves on...   \n",
       "196  the secondary trial reported 1 single case of ...   \n",
       "197  the secondary trial and the primary trial do n...   \n",
       "198  the outcome measurement of the primary trial i...   \n",
       "199  All the primary trial patients had a minimum o...   \n",
       "\n",
       "                                                trail1  \\\n",
       "0    Outcome Measurement:, Event-free Survival, Eve...   \n",
       "1    Inclusion criteria:, Inclusion Criteria:, Fema...   \n",
       "2    Adverse Events 1:, Total: 20/167 (11.98%), Car...   \n",
       "3    Outcome Measurement:, Local Control Using Ipsi...   \n",
       "4    Inclusion Criteria:, Postmenopausal women with...   \n",
       "..                                                 ...   \n",
       "195  INTERVENTION 1:, Letrozole, Participants recei...   \n",
       "196  Adverse Events 1:, Total: 16/48 (33.33%), Febr...   \n",
       "197  Outcome Measurement:, Number of Patients With ...   \n",
       "198  Outcome Measurement:, Progression-free Surviva...   \n",
       "199  Outcome Measurement:, Complete Response + Part...   \n",
       "\n",
       "                                                trail2         section  label  \\\n",
       "0                                                    _         Results      0   \n",
       "1    Premenopausal women 55 years of age or younger...     Eligibility      0   \n",
       "2    Adverse Events 1:, Total: 112/458 (24.45%), Fe...  Adverse Events      0   \n",
       "3                                                    _         Results      1   \n",
       "4                                                    _     Eligibility      0   \n",
       "..                                                 ...             ...    ...   \n",
       "195  INTERVENTION 1:, Sentinel Lymph Node Biopsy, [...    Intervention      0   \n",
       "196  Adverse Events 1:, Total: 21/519 (4.05%), Anae...  Adverse Events      1   \n",
       "197  Outcome Measurement:, Disease Free Survival., ...         Results      1   \n",
       "198                                                  _         Results      1   \n",
       "199                                                  _         Results      0   \n",
       "\n",
       "     #Words1  #Words2  #Words3  \\\n",
       "0         15      122        1   \n",
       "1         30      281      347   \n",
       "2         17       94       84   \n",
       "3         16       84        1   \n",
       "4         22      385        1   \n",
       "..       ...      ...      ...   \n",
       "195       21       21        8   \n",
       "196       17       56       96   \n",
       "197       17      200      112   \n",
       "198       30      168        1   \n",
       "199       21      113        1   \n",
       "\n",
       "                                          MergedColumn  \n",
       "0    Outcome Measurement:, Event-free Survival, Eve...  \n",
       "1    Inclusion criteria:, Inclusion Criteria:, Fema...  \n",
       "2    Adverse Events 1:, Total: 20/167 (11.98%), Car...  \n",
       "3    Outcome Measurement:, Local Control Using Ipsi...  \n",
       "4    Inclusion Criteria:, Postmenopausal women with...  \n",
       "..                                                 ...  \n",
       "195  INTERVENTION 1:, Letrozole, Participants recei...  \n",
       "196  Adverse Events 1:, Total: 16/48 (33.33%), Febr...  \n",
       "197  Outcome Measurement:, Number of Patients With ...  \n",
       "198  Outcome Measurement:, Progression-free Surviva...  \n",
       "199  Outcome Measurement:, Complete Response + Part...  \n",
       "\n",
       "[200 rows x 10 columns]"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Data.val_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "fc995701",
   "metadata": {},
   "outputs": [],
   "source": [
    "class Long_texts_Summarizartion():\n",
    "    def __init__(self, texts, model_name = \"t5-small\", max_len = 1024):\n",
    "        \n",
    "        self.device = torch.device(\"cuda\" if torch.cuda.is_available() else \"cpu\")\n",
    "\n",
    "        self.tokenizer = AutoTokenizer.from_pretrained(model_name)\n",
    "        self.model = AutoModelForSeq2SeqLM.from_pretrained(model_name).to(self.device)\n",
    "        self.max_chunk_length = max_len\n",
    "        self.texts_summary = self.Texts_summarization(texts)\n",
    "        \n",
    "    def chunking_long_Seq(self, long_text):\n",
    "        chunks = [long_text[i:i + self.max_chunk_length] for i in range(0, len(long_text), self.max_chunk_length)]\n",
    "        return chunks\n",
    "    \n",
    "    def summarize(self, long_text):\n",
    "        summarized_text = \"\"\n",
    "        chunks = self.chunking_long_Seq(long_text)\n",
    "\n",
    "        for chunk in chunks:\n",
    "            input_ids = self.tokenizer.encode(\"summarize: \" + chunk, return_tensors=\"pt\", max_length=self.max_chunk_length, truncation=True).to(self.device)\n",
    "            summary_ids = self.model.generate(input_ids, max_length=150, length_penalty=2.0, num_beams=4, early_stopping=True).to(self.device)\n",
    "            summary = self.tokenizer.decode(summary_ids[0], skip_special_tokens=True)\n",
    "            summarized_text += summary + \" \"\n",
    "        return summarized_text\n",
    "    \n",
    "    def Texts_summarization(self, texts):\n",
    "        texts_summary = []\n",
    "        for i, text in enumerate(texts):\n",
    "            print(f\"\\rIndex: {i}\", end=\"\")\n",
    "            texts_summary.append(self.summarize(text))\n",
    "        return texts_summary"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "9bf89c9f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Index: 1699"
     ]
    },
    {
     "data": {
      "text/plain": [
       "['the surgery follows 1-7 days after the second FLT PET scan. patients receive oral capecitabine and oral lapatinib ditosylate. courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV, lapatinib ditosylate: Given PO and capecitabine: Given PO. ',\n",
       " 'clinical evidence of metastatic disease, Measurable disease, defined as at least one measurable lesion per RECIST criteria, No non-measurable disease only, defined as all other lesions, including small lesions (longest diameter  2 cm) and truly non-measurable lesions, including any of the following: Bone lesions, Leptomeningeal disease, Ascites, Pleural/pericardial effusion, Inflammatory breast disease, Lymphangitis cutis/pulmonis menopausal status not specified, Life expectancy 12 weeks, ECOG performance status 0-1, ANC 1,500/mm3, Platelet count 100,000/mm3, Hemoglobin 9.0 g/dL, AST and ALT 2.5 times upper limit of normal (ULN), Alkaline phosphatase 2.5 times ULN, Total bilirubin 1.5 times ULN, Creatinine 1.5 mg/dL, Urine protein:creatinine ratio  1 nancy within the past 5 years, no other active malignancy, except nonmelanoma skin cancer or carcinoma in situ of the cervix. patients who have recently started or adjusted antihypertensive medications are eligible. patients who have recently started or adjusted antihypertensive medications are eligible. rtery disease, Unstable angina, Cardiac arrhythmias not well controlled with medication, Myocardial infarction within the past 12 months, No comorbid systemic illnesses or other severe concurrent disease. prior adjuvant chemotherapy allowed, more than 6 months since prior adjuvant or neoadjuvant taxane therapy allowed, prior hormonal therapy in either adjuvant or metastatic setting allowed, more than 4 weeks since prior radiotherapy. therapy was completed, More than 4 weeks since prior cytotoxic chemotherapeutic agent or investigational drug, More than 2 weeks since prior and no concurrent acetylsalicylic acid, anticoagulants, or thrombolytic agents (except for once-daily 81 mg acetylsalicylic acid), More than 6 weeks since prior major surgery, chemotherapy, or immunologic therapy, More than 1 week since prior minor surgery. ',\n",
       " 'Febrile neutropenia 1/32 (3.13%), Supraventricular tachycardia 1/32 (3.13%), Hypersensitivity 2/32 (6.25%), Catheter site infection 1/32 (3.13%), Confusional state 1/32 (3.13%)Adverse Events 1:, Total: 285/752 (37.90%), Anaemia 2/752 (0.27%), Disseminated intravascular coagulation 2/752 (0.27%), Febrile neutropenia 51/752 (6.7 ',\n",
       " 'patients with bilateral breast cancer are eligible. patients should have intact primary tumor. patients should have a Karnofsky performance scale of greater than or equal to 70%. women who are not menopausal for 12 months or had no previous surgical sterilization must have study biopsies. patients with a history of other invasive malignancies diagnosed and treated within the previous 5 years, except non-melanoma skin cancer. patients with an active, bleeding diathesis or on oral anti-vitamin K medication. nal drug within the preceding 4 weeks. ',\n",
       " 'inTERVENTION 2:, Part B Abemaciclib: HR+, HER2+ breast cancer, abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. participants with hormone receptor positive HR+, HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. treatment may continue until discontinuation criteria are met. rticipants may continue to receive treatment until discontinuation criteria are met. ',\n",
       " 'subjects who received at least two courses of weekly paclitaxel therapy were considered to need to continue the therapy by the investigator/subinvestigator. subjects with advanced or recurrent breast cancer had met the selection criteria and participated in the preceding phase II clinical study. ECOG score of 0 or 1, Negative serum or urine beta-hCG pregnancy test at screening for patients of child-bearing potential. male patients are not eligible for this study, female patients with inoperable tumors or women with stage 4 disease diagnosed on CT, PET, PET/CT or bone scan. women with non-invasive disease or microinvasion are not eligible. women undergoing neoadjuvant chemotherapy are not eligible. women currently on tamoxifen and raloxifen for prevention are not eligible. ',\n",
       " 'patients with locally advanced disease who are planning to undergo preoperative neoadjuvant therapy are not eligible*. Primary tumor 5 cm (T3), Tumor of any size with direct extension to the chest wall or skin (T4a-c), Inflammatory breast cancer (T4d), Fixed axillary lymph node metastases (N2), Metastasis to ipsilateral internal mammary node (N3). patients with a prior history of contralateral breast cancer are eligible if they have no evidence of recurrence of their initial primary breast cancer, no locally recurrent breast cancer, no evidence of distant metastatic disease (i.e., lung, liver, bone, or brain metastases), Hormone receptor status not specified, PATIENT CHARACTERISTICS:, Menopausal status not specified, Eastern Cooperative Oncology Group (ECOG) performance status 0-1, ANC 1,000/ laces the patient at high risk of operative mortality, See Disease Characteristics, No prior chemotherapy for this primary breast cancer. at least 7 days since prior tamoxifen or raloxifene as a preventive agent. ',\n",
       " 'inTERVENTION 1:, Hypnotherapy, Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist. these sessions will be one week apart. ',\n",
       " 'female with histologically confirmed breast cancer, Stage II-IV disease, ER and/or PR positive, ECOG Performance Status 0-1, Tumor must be present following core needle biopsy. postmenopausal, No prior treatment for current breast cancer. use of other COX-2 inhibitors such as rofecoxib (Vioxx®, aspirin, trisalicylate (Trilisate®) is not permitted during the time on study. no washout period is required. ',\n",
       " 'all patients will receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions. a concurrent boost to the original tumor bed of 0.50 Gy will be delivered. ',\n",
       " 'the oncologist must have prescribed doxorubicin as part of the planned chemotherapy regimen. have acceptable organ function within 14 days of enrollment defined as:, liver function: total bilirubin, AST and ALT within normal institutional limits, kidney function. and third trimesters)_ ',\n",
       " '12/32 (37.50%), Anaemia 0/32 (0.00%), Neutropenia 1/32 (3.13%), Thrombocytopenia 4/32 (12.50%), Atrial fibrillation 1/32 (3.13%), Cardiac failure congestive 1/32 (3.13%), Myocardial ischaemia 1/32 (3.13%), Abdominal discomfort 0/32 (0.00%), Ascites 1/32 (3.13%), Constipation 0/32 (0.00%), Rectal ',\n",
       " 'recently confirmed unilateral ductal carcinoma in situ or invasive cancer of the breast, Confirmed by biopsy or fine needle aspiration (FNA) within the past 60 days. prior biopsy of the contralateral breast is allowed provided it was performed at least 6 months prior to study entry, no remote history of breast cancer, No new breast symptoms within the past 60 days. scular, no pacemaker, no magnetic aneurysm clips, Other, Not pregnant, No implanted magnetic device, No severe claustrophobia, No other contraindications to MRI, no psychiatric, psychological, or other condition that would preclude informed consent, PRIOR CONCURRENT THERAPY:, Biologic therapy, not specified, Chemotherapy, At least 6 months since prior anticancer chemotherapy, Endocrine therapy, No concurrent therapeutic hormonal therapy, ',\n",
       " 'Inclusion Criteria:, Age 52-75; Identification as Latina/Hispanic/Chicana female;, Residence in Pilsen, Little Village, East Side or South Chicago;, No history of health volunteerism;, no history of breast cancer; and, Lack of a mammogram within the last two years. ',\n",
       " 'subjects will be randomly selected to receive saline (placebo) if randomized to this arm, subjects will receive an intraoperative injection of saline. injection will be performed in certain locations of the breast area to cover the intercostal nerves supplying the breast tissue. subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine. with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively. ',\n",
       " 'in overweight/obese participants who completed Part A, provide a double dose of letrozole and monitor use for 28 days. measure blood levels of estrogens and vitamin D at start and end of period. ',\n",
       " \"the patient (male or female) is at least 18 years old at the time of signature of the informed consent form. the patient is diagnosed with confirmed invasive breast cancer with stage IV disease. the last dose of trastuzumab should not have been given less than three weeks before the first ASCI administration. a tumor lesion from the patient biopsied before or during screening shows either: overexpression of the HER2 protein, as determined by immunohistochemistry. ch a lesion is sufficiently easily accessible. the patient has at least one measurable lesion according to RECIST criteria. a serum bilirubin level 1.5 times the ULN and both AST and ALT levels 3 times the ULN will be accepted. the patient has a baseline Left Ventricular Ejection Fraction (LVEF) measured by MUGA scan equal to or greater than the LLN for the radiology facility. if the patient is female, she must be of non-childbearing potential. e, combined or progestogen oral contraceptives, injectable progestogen, implants of levonorgestrel, oestrogenic vaginal ring, percutaneous contraceptive patches or intrauterine device (IUS), vasectomy with documented azoospermia. azoospermia refers to outcome of investigator's medical examination of subject or review of subject's medical history for study eligibility. the patient must not be included in the study. the patient is receiving treatment with bisphosphonate UNLESS the biphosphonate treatment was initiated more than three weeks before the first ASCI administration. the patient has known coronary artery disease, arrhythmia requiring treatment, clinically significant valvular disease, cardiomegaly on chest X-ray, ventricular hypertrophy (found by ECG) or previous myocardial infarction. the patient has current active hepatic or biliary's disease. the patient has a known family history of congenital or hereditary immunodeficiency. the patient has any uncontrolled bleeding disorder or coagulation disorder or thrombocytopenia or pro-thrombotic disorder. the patient has a known hypersensitivity reaction or idiosyncrasy to drugs chemically related to Lapatinib. the patient has any other condition that might jeopardize the patient's safety. \",\n",
       " 'patients will be randomized to receive bevacizumab 15mg/kg i.v. every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. the patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent. letrozole, bevacizumab, nsent., letrozole, bevacizumab, nsent., letrozole, letrozole, bevacizumab, Fulvestrant. ',\n",
       " 'inTERVENTION 1:, FFDM and DBT, FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration, INTERVENTION 2:, FFDM only, FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration. ',\n",
       " 'Neutropenia 1/116 (0.86%), Thrombocytopenia 1/116 (0.86%), Myocardial infarction 0/116 (0.00%), Pericardial effusion 0/116 (0.00%), Abdominal pain 3/116 (2.59%), Ascite 1/116 (0.86%), Diarrhoea 3/116 (2.59%), Gingival bleeding 1/116 (0.86%), Intestinal haemorrhage 1/116 (0.8 l 1/54 (1.85%), Malignant Melanoma In Situ 1/54 (1.85%), Suicide Attempt 1/54 (1.85%), Dyspnoea 1/54 (1.85%) ',\n",
       " 'participants received lapatinib 1500 milligrams (mg) orally once daily (OD) with paclitaxel 175 mg/m2 IV intravenously (IV) over the course of 3 hours, every 3 weeks. treatment group stratified by sites of metastatic disease and stage of disease. participants were treated until disease progression, unacceptable toxicity, or consent withdrawal. ular dermal matrix SurgiMend PRS implanted at the time of tissue expander placement. ',\n",
       " 'an objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR) each patient with measurable disease at baseline was assessed for OR from the sequence of Response Evaluation Criteria in Solid Tumors (RECIST) scans were performed every 12 weeks (+/- 2weeks) from randomization data up to data cut-off (19th march 2008), Results 1:, Arm/Group Title: Fulvestrant 250 mg, Arm/Group Description: Fulvestrant 250 + Loading Dose, Arm/Group Description: Fulvestrant 250 mg + Loading Dose, Overall Number of Participants Analyzed: 51, Measure Type: Number, Unit of Measure: percentage of participants 17.6____________________________________________________________ ',\n",
       " '8/24 (33.33%), Restrictive Cardiomyopathy * 21/24 (4.17%), Palpitations * 21/24 (4.17%), GERD * 21/24 (4.17%), Fever * 21/24 (4.17%), Sepsis * 1/24 (4.17%), Urinary Tract Infection * 21/24 (4.17%), Influenza A * 21/24 (4.17%), Dehydration * 21/24 (4.17%), Hyponatremia * 21/24 (4.17%), ',\n",
       " 'all research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous injection following the schedule. all research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous injection following the schedule. ',\n",
       " 'subjects oncologist must have documented experience treating subjects with eribulin in a prior clinical study. subjects who meet all of the following criteria will be included in the treatment protocol. 1.5 x 109/L, hemoglobin >/= 10 g/dL, platelet count >/= 100 x 109/L. total bilirubin /= 1.5 x upper limit of normal (ULN) AP, alanine aminotransferase, and aspartate aminotransferase. perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Existing anti-cancer therapy-related toxicities of Grade >/= 2 are acceptable. be medically unfit to receive eribulin or unsuitable for any other reason. females who are pregnant (positive B-hCG test) or breastfeeding. be medically unfit to receive eribulin. subjects who have received any of the following treatments within the specified period before the start of treatment: any investigational drug, chemotherapy, radiation, or biological or targeted therapy within 1 week. ',\n",
       " 'interpretation and analysis was done with mammography and MBI together. inTERVENTION 1:, Arm 1 (6 mg Estradiol), 6 mg of estradiol daily (2 mg tid). ',\n",
       " '12/63 (19.05%), Febrile neutropenia * [1]4/63 (6.35%), Congestive heart failure * [2]1/63 (1.59%), Cardiac-ischemia/infarction * 1/63 (1.59%), Vomiting * [1]1/63 (1.59%), Acute Pharyngitis * 1/63 (1.59%), Infection * 3/63 (4.76%), Neutrophil count decreased * [1]1/63 (1.59%), P ',\n",
       " 'Outcome Measurement:, Objective Response (OR), Objective response (OR) including complete response (CR) and partial response (PR) according to the Response Evaluation Criteria in Solid Tumours criteria. ',\n",
       " 'Suramin and Paclitaxel will be infused weekly over 30 minutes. four hours after the completion of the suramin infusion the 1 hour infusion of paclitaxel will begin. ',\n",
       " '26/69 (37.68%), Anaemia 2/69 (2.90%), Febrile neutropenia 3/69 (4.35%), Neutropenia 4/69 (5.80%), Cardiac arrest 1/69 (1.45%), Cardiac failure congestive 1/69 (1.45%), Pericardial effusion 1/69 (1.45%), Abdominal pain 1/69 (1.45%), ascite 2/69 (1.45%), Gastritis 1/69 (1.45%), Gastriti ',\n",
       " 'the patient has had an absolute neutrophil count (ANC) Level  2.0 x 109/L after first cycle of chemotherapy. this dose of F-627 given only to subjects receiving TC chemotherapy. overall number of participants Analyzed: 35, Mean (Standard Deviation), Unit of Measure: days 0.6 (1.26) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatin ',\n",
       " 'HER2-targeted PET/CT, Pts with confirmed HER2- breast cancer will undergo HER2-targeted PET/CT. 89Zr-trastuzumab is a novel radiotracer which allows for specific visualization of HER2+ lesions. ',\n",
       " 'inTERVENTION 2:, Neratinib 240, Prior Trastuzumab, Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily. disease does not worsen in participants with prior trastuzumab treatment. ',\n",
       " 'skin metastases are not suitable for or patient refusing definitive surgical resection and radiation. skin metastases are non-responsive (stable or progressing) as assessed by investigator. lobin > or = 9.5 grams/deciliter, platelets >or = 75,000/microliter, total bilirubin. aspartate aminotransferase (AST)/Alanine aminotransferase (ALT)  or = 2.5X institutional upper limit of normal, creatinine  or = 1.5 X institutional upper limit of normal, Informed consent. patients on aspirin and other platelet agents are eligible. patients with known immunodeficiency or receiving immunosuppressive therapies are eligible. sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives. patients must meet laboratory criteria defined in the study within 21 days prior to randomization, Exclusion Criteria:, Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer. tu carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer, Known hypersensitivity to any study medication, Breastfeeding or pregnant. ',\n",
       " 'invasive breast cancer must be estrogen receptor alpha (ER)-positive, with ER staining present in greater than 50% staining of invasive cancer cells by IHC. invasive cancer must be human epidermal growth factor receptor 2 (HER2) negative. women must be either post-menopausal, or pre-menopausal having undergone oophorectomy. patients must meet clinical laboratory criteria: Absolute neutrophil count 1000/mm3 and platelet count 75,000/mm3. ',\n",
       " 'YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness, Text message management prompts, INTERVENTION 2:, Control, Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness. ',\n",
       " 'female patients 18-70 years of age; adenocarcinoma of the breast; previous invasive breast cancer if diagnosed >5 years before entering study; no evidence of metastatic disease. exclusion Criteria:, age 52-75 years old; identification as Latina/Hispanic/Chicana female;, residence in Pilsen, Little Village, East Side or South Chicago;, no history of health volunteerism;, no history of breast cancer. ',\n",
       " 'participants were asked, \"All things considered, which method of administration did you prefer?\" at the end of the crossover period. the percentage of participants who preferred each method of drug administration was reported. rossover period offered the opportunity to self-administer SC Herceptin via SID. the SC dose was 600 mg for all cycles where SC Herceptin was given. the IV dose was 6 mg/kg for all cycles where IV Herceptin was given. the IV dose was a loading dose of 8 mg/kg in Cycle 1 for de novo participants who started Herceptin treatment in the study. the SC dose was 600 mg for all cycles where SC Herceptin was given. ',\n",
       " 'Agranulocytosis 0/42 (0.00%), Anaemia 2/42 (4.76%), Febrile neutropenia 1/42 (2.38%), leukopenia 0/42 (0.00%), Neutropenia 1/42 (2.38%), Thrombocytopenia 1/42 (2.38%), Cardio-respiratory arrest 0/42 (0.00%), Melaena 0/42 (0.00%), Fatigue 1/42 (2.38%), Multi-organ failure 0/ PURA 0/145 (0.00%), DISSEMINATED INTRAVASCULAR COAGULATION 0/145 (0.00%), CARDIAC FAILURE 1/145 (0.69%), ATRIAL FIBRILLATION 1/145 (0.69%), Adverse Events 2:, Total: 11/144 (7.64%), ANAEMIA 1/144 (0.69%), LEUKOPENIA 0/144 (0.00%), NEUTROPENIA 0/144 ( ',\n",
       " '158/482 (32.78%), Anaemia 7/482 (1.45%), Disseminated intravascular coagulation 1/482 (0.21%), Lymphadenopathy 0/482 (0.00%), Neutropenia 0/482 (0.00%), Thrombocytopenia 2/482 (0.41%), Anaemia 28/482 (1.66%), Disseminated intravascular coagulation 21/482 (0.21%), Febrile neutropenia 21/482 (0.21%), Lympha ',\n",
       " 'breast cancer, Stage I or II disease (T1-T2, N0, M0/MX disease), no chest wall invasion by tumor, Medially or centrally located lesion, no multicentric disease, Multifocal disease allowed, no clinically positive axillary nodes, no enlarged internal mammary nodes by CT scan, Hormone receptor status not specified. ',\n",
       " \"IRF assessed PFS was defined as time (in months) from randomization until the date of first documented radiologic progressive disease per response evaluation criteria in solid tumors (RECIST) version 1.1. progression defined as 1) for target lesions: at least a 20% increase in the sum of target lesion measurements, compared to the smallest sum on study. participants received talazoparib 1 mg, orally, once daily until radiographic disease progression as determined by the central IRF, unacceptable toxicity, consent withdrawal, physician's decision to terminate treatment, or sponsor's decision to terminate treatment. one cycle was of 21 days. n each cycle; vinorelbine 30 mg/m2 as 6 to 10 minute IV infusion on day 1, 8, and 15 in each cycle; until radiographic disease progression as determined by the central IRF, unacceptable toxicity, consent withdrawal, physician's decision to terminate treatment, or Sponsor's decision to terminate trial. \",\n",
       " 'this group received CDP, which include MLD, short-stretch bandages, lymph-reducing exercises, and skin care. MLD was applied to the anterior trunk, posterior trunk, and the base of the neck. taping was applied to anterior and posterior axillo-axillary anastomosis and axillo-inguinal anastomosis. tape was started in the inguinal region of the affected side. strips of tape were applied so that they reached the affected side. ',\n",
       " 'Anaemia 2/52 (3.85%), Febrile neutropenia 4/52 (7.69%), Pancytopenia 1/52 (1.92%), Thrombocytopenia 0/52 (0.00%), Abdominal pain 1/52 (1.92%), Constipation 1/52 (1.92%), Pyrexia 2/52 (3.85%), Device related infection 1/52 (1.92%), Pneumonia 2/52 (3.85%), Sepsis 1/52 (1.92%), Adverse ',\n",
       " 'Adverse Events 1:, Total: 8/29 (27.59%), Leukopenia [1]1/29 (3.45%), Abscess [1]1/29 (3.45%), Breast Abscess 1/29 (3.45%), Fever/Sepsis [1]1/29 (3.45%), Neutropenic Fever [2]1/29 (3.45%), Peripheral Neuropathy [1]1/29 (3.45%), Seizure/Syncope [1]1/29 (3. ',\n",
       " 'ATRIAL FIBRILLATION 1/71 (1.41%), CARDIAC TAMPONADE 1/71 (1.41%), PERICARDIAL EFFUSION 1/71 (1.41%), SUPRAVENTRICULAR TACHYCARDIA 1/71 (1.41%), NAUSEA 1/71 (1.41%), VOMITING 1/71 (1.41%), CHEST PAIN 1/71 (1.41%), MALIGNANT PLEURAL EFFUSION 1/71 ( ',\n",
       " 'BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization. the primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip. all DXA scans were evaluated by a central reader. unit of measure: Percent Change 0.37 (-6.98 to 15.21) ',\n",
       " 'participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy received alobresib tablets at a dose of 0.6 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD. ',\n",
       " 'previous participation in study 971-ONC-0028-080. Subjects who had not previously participated in study 971-ONC-0028-080. Stage IV that is free of all known disease after eradication by surgery. stage II with at least 4 positive axillary nodes and completed adjuvant therapy no more than 24 months ago. Stage II with at least 4 positive axillary nodes and completed adjuvant therapy no more than 24 months ago. immunodeficiency or autoimmune disease, no other active cancer except basal cell or squamous cell skin cancer, PRIOR CONCURRENT THERAPY:, Biologic therapy:, At least 6 weeks since prior immunotherapy, No prior vaccine with any of the antigens in this study. ',\n",
       " '30/112 (26.79%), Thrombocytopenia 1/112 (0.89%), Dysphagia 1/112 (0.89%), haemorrhoidal haemorrhage 1/112 (0.89%), Oesophageal stenosis 1/112 (0.89%), Upper gastrointestinal haemorrhage 1/112 (0.89%), Asthenia 1/112 (0.89%), Disease progression 1/112 (0.89%), Hepatotoxicity 1/112 ( ',\n",
       " 'the proportion of lymph nodes detected intraoperatively by SentiMag and SiennaXP in relation to the proportion of lymph nodes detected by the combination of Technetium Sulfur Colloid and Isosulfan blue dye. a single dose of radioisotope (Technetium Tc99m Sulfur Colloid) and single dose of isosulfan blue dye is injection. DLTs were defined as grade 4 neutropenia persisting for more than 7 days. grade 3 or above febrile neutropenia; grade 4 thrombocytopenia or grade 3 thrombocytopenia requiring blood transfusion. day 8 administration was delayed or slammed. kipped as a result of the subject did not meet the dosing riteria within cycle. overall number of participants Analyzed: 6, Measure Type: Number, Unit of Measure: Participants 0, Results 2:, Arm/Group Title: E7389 With Tri-weekly Trastuzumab. ',\n",
       " 'patients with HER2 positive tumors must have received at least one prior regimen of chemotherapy for metastatic disease. patients may receive concurrent bisphosphonate therapy and/or erythropoetin therapy at any point while on study, ECOG performance status 0 or 1. rgery and radiation therapy, greater than 6 months since bone marrow or peripheral blood stem cell transplant, Exclusion Criteria:, Urgent need for cytotoxic chemotherapy, radiotherapy, or surgery in the next 60 days, Uncontrolled active infection or illness, Pregnant or nursing mothers, Evidence of HIV infection, Previous participation in an adenovirus-based trial, Concurrent invasive malignancy. ',\n",
       " 'data were collected separately for the T+OFS and E+OFS participants in the parent study, IBCSG 24-02 (SOFT) the sample size was small, so the analysis plan was revised to pre-specify collective analysis for all patients receiving OFS. ',\n",
       " 'anemia 0/25 (0.00%), Sinus tachycardia 0/25 (0.00%), Pericardial effusion 1/25 (4.00%), Gastrointestinal disorders - other, specify -stomatitis) 0/25 (0.00%), Vomiting 1/25 (4.00%), Fever 0/25 (0.00%), Injection site reaction 1/25 (4.00%), Catheter related infection 0/25 (0.00%), Activated partial thrombo ',\n",
       " '3/73 (4.11%), Chest Pain - cardiac 1/73 (1.37%), Myocarditis 1/73 (1.37%), Pericarditis 1/73 (1.37%), Ventricular tachycardia 1/73 (1.37%), Skin infection 0/73 (0.00%), Dermatitis radiation 0/73 (0.00%), Dyspnea 1/73 (1.37%), Adverse Events 2:, Total: 3/70 (4.29%), Chest Pain ',\n",
       " 'interleukin- 2 (IL-2) given subcutaneously at 9 million units 3 times a week for a total of 6 doses. no more than 8.0 x 107 cells/kg will be given. interleukin- 2 (IL-2) given at 9 million units 3 times a week for 6 doses. no more than 8.0 x 107 cells/kg will be given. ',\n",
       " 'Febrile Neutropenia * 3/56 (5.36%), Neutropenia * 1/56 (1.79%), Atrial Fibrillation * 1/56 (1.79%), Coronary Artery Disease * 1/56 (1.79%), Constipation * 1/56 (1.79%), Chest Pain * 1/56 (1.79%), Non-Cardiac Chest Pain * 1/56 (1.79%), Edema due to Cardiac Disease * 1/56 (1.79%), Cellulitis * ',\n",
       " 'Adverse Events 1:, Total: 8/29 (27.59%), Leukopenia [1]1/29 (3.45%), Abscess [1]1/29 (3.45%), Breast Abscess 1/29 (3.45%), Fever/Sepsis [1]1/29 (3.45%), Neutropenic Fever [2]1/29 (3.45%), Peripheral Neuropathy [1]1/29 (3.45%), Seizure/Syncope [1]1/29 (3. ',\n",
       " 'Thrombocytopenia 1/22 (4.55%), leucocytopenia 1/22 (4.55%), neutropenia 1/22 (4.55%), papilledema 1/22 (4.55%), papilledema 1/22 (4.55%), hyperglycemia 1/22 (4.55%)Adverse Events 1:, Total: 24/101 (23.76%), LYMPHADENOPATHY 0/101 (0.00%), FEBRILE NEUTROPENIA 20/ ',\n",
       " 'patients receive radiotherapy and healing touch therapy from a healing-touch therapist once a week for the duration of their radiotherapyINTERVENTION 2:, Control ARM (B) Participants with Stage 0-III breast cancer, women with Stage 0-III breast cancer, treated with breast conserving surgery or mastectomy and clear margins, will receive 15 doses of radiation over three weeks. the boost treatment will be given on the same days as the whole breast treatment. er day x 15 fractions. ',\n",
       " 'participants with dose limiting toxicities (DLTs) graded Using National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.0. the following events, if considered to be study-treatment-related by the Investigator, were considered a DLT:, Hematologic:, Grade 4 neutropenia lasting 8 days. participants received pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab (K) 200 mg in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m2 in Cycles 2-5 on Days 1, 8 and 15 (once each week; QW) each cycle was 21 days. pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 100 mg/m2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at Area Under the Curve (AUC) 6 in Cycles 2-5 on Day 1 (Q3W) all treatments were administered via IV infusion except for doxorubicin (A), which was administered via IV injection ',\n",
       " 'Adverse Events 1:, Total: 4/26 (15.38%), Febrile neutropenia * 1/26 (3.85%), Gastric volvulus * 20/26 (0.00%), General Malaise * 21/26 (3.85%), Hospitalisation for intrapleuric chemotherapy and thoracentesis * 21/26 (3.85%), Acute renal failure * 21/26 (3.85%), Adverse Events 2:, Total: 1/28 (3.57%), Febrile neutropenia * 0/ ',\n",
       " 'participants received a single dose of 50 g Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes. overall number of participants Analyzed: 133, Type of Units Analyzed: Lymph Nodes Measure Type: NumberNumber (95% Confidence Interval)Unit of Measure: Proportion of Lymph Nodes: 1.0000 (0.9840 to 1.0000) RECIST 1.1, time frame: 12 weeks from randomisation, Results 1:, Arm/Group Title: Afatinib Mono, Arm/Group Description: Afatinib monotherapy administered orally: starting dose 40 mg per day, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg. ',\n",
       " 'patients must have measurable disease, at least one measurable lesion as defined by the Response Evaluation Criteria in Solid Tumors (RECIST), Treated brain metastases (surgery or radiation therapy) allowed if clinically stable, Patients with leptomeningeal disease are ineligible. no pre-existing liver disease (i.e., cirrhosis or active viral hepatitis), no active gastrointestinal malabsorption illness, no clinically significant cardiac disease, including congestive heart failure, symptomatic coronary artery disease, and cardiac arrhythmias not well controlled with medication. no prior unanticipated severe reaction to fluoropyrimidine therapy, known hypersensitivity to fluorouracil, or known dihydropyrimidine dehydrogenas no concurrent anti-estrogen therapy, radiation therapy, or investigational systemic therapy, no concurrent investigational drugs, no concurrent use of the following drugs. warfarin for full anticoagulation, cimetidine, or azidothymidine (AZT), Mini-dose warfarin for prophylaxis of central venous catheter thrombosis allowed. no known CNS disease, Hormone receptor status not specified. life expectancy > 12 weeks, WBC 3,000/mcL, Absolute neutrophil count 1,500/mcL, Platelet count 100,000/mcL, Total bilirubin normal, AST and ALT 2.5 times upper limit of normal (ULN), Alkaline phosphatase 2.5 times ULN (unless bone metastasis is present in the absence of liver metastasis), Creatinine 1.5 mg congestive heart failure, unstable angina pectoris, Cardiac arrhythmia, Serious, non-healing wound, ulcer, or bone fracture, psychiatric illness/social situations that would limit compliance with study requirements. history of hypertensive crisis or hypertensive encephalopathy within the past 6 months. urine protein:creatinine ratio 1.0 OR urine dipstick for proteinuria 2+ must demonstrate 24-hour urine protein 1g, history of allergy or hypersensitivity to paclitaxel albumin-stabilized nanoparticle formulation, paclitaxel, bevacizumab, carboplatin, albumin, drug product excipients, or chemically similar agents. prior neoadjuvant or adjuvant chemotherapy allowed, More than 1 week since prior biopsy or other minor surgical regimen, no other concurrent investigational agents, Concurrent anticoagulation allowed, provided the criteria are met:, Stable dose of warfarin or low molecular weight heparin, INR within desired range (2-3), no evidence of active bleeding or coagulopathy, no concurrent combination antiretroviral therapy for HIV-positive patients. ',\n",
       " \"under the age of 50 at diagnosis, Finished active treatment within the past 2 months, English-speaking only, Must live within 30 miles of Magee Women's Hospital, Pittsburgh, Pennsylvania. INCLUSION CRITERIA (Patient Characteristics):, Female patients only, Must be able to communicate, EXCLUSION CRITERIA (Patient Characteristics):, Other prior malignancies except skin cancer, PRIOR CONCURRENT THERAPY:, See \",\n",
       " '18/50 (36.00%), Hypotension 0/50 (0.00%), Bradycardia 0/50 (0.00%), Cardiac Arrest 1/50 (2.00%), Diarrhea 2/50 (4.00%), Pain - Abdominal 1/50 (2.00%), Vomiting 0/50 (0.00%), Nausea 0/50 (0.00%), Dehydration 0/50 (0.00%), Diverticular Abscess 1/50 (2.00%), ',\n",
       " 'inclusion Criteria:, surgery for breast cancer with immediate breast reconstruction, Diagnosis of primary lymphedema, Metastatic or inflammatory breast cancer, Planned use of chemotherapy within the next 6 weeks, Surgical complications: infection, drainage issues, seroma, hematoma, Severe physical, cognitive, or psychiatric illness causing inability to follow the study protocol. women with non-inflammatory breast adenocarcinoma must be at least 21 years of age. participants must be prescribed concurrent hormone treatment with radiation treatment. participants must receive five sessions of radiation therapy per week for at least four weeks. the total dose prescribed to the whole breast should be 50 Gy or greater. participants must be able to understand English and complete assessment forms. participants must be able to swallow medication. patients with known radiosensitivity syndromes (e.g., Ataxia-telangiectasia) are not eligible. patients with known radiosensitivity syndromes, vasculitis, unhealed surgical sites, or breast infections are not eligible. ',\n",
       " 'Adverse Events 1:, Total: 2/6 (33.33%), Febrile neutropenia * 1/6 (16.67%), Neutropenia * 0/6 (0.00%), Thrombocytopenia * 1/6 (16.67%), Diarrhoea * 0/6 (0.00%), Pyrexia * 0/6 (0.00%), Thrombosis in device * 1/6 (16.67%), Fatigue * 0/6 (0.00%), Mucosal inflammation *  ',\n",
       " 'if 0/3 DLTs observed, the dose will be escalated to arm 3. if no additional DLTs are observed on arm 2, the dose will be escalated to arm 3. if more than 1/6 DLTs observed on arm 3, the dose will be de-escalated to arm 2. urse of treatment according to revised NCI CTC v 2.0, Time frame: 21 days, Results 1:, Arm/Group Title: Arm 1, Arm/Group Description: Capecitabine 800 mg/m2 BID for 14 days on days 2-15 of each 21 day cycle +GTI-2040 civ infusion 185 mg/m2/day on days 1-15 of cycle 1 and days 1-14 of each subsequent cycle. Overall number of participants Analyzed: 0, Measure Type: Number, Unit of Measure: Patients ',\n",
       " '83, Least Squares Mean (95% Confidence Interval), Unit of Measure: percent change from baseline -21.8 (-29.7 to -13.0), Results 2:, Arm/Group Title: Placebo + Lifestyle Intervention, Arm/Group Description: Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time, Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for ean (95% Confidence Interval), Unit of Measure: percent change from baseline -17.7 (-25.9 to -8.6) ',\n",
       " 'clinical benefit rate (CR Plus PR Plus SD), complete response (CR) + partial response (PR) + stable disease (SD) using RECIST 1.0, CR = disappearance of all target lesions, SD = at least a 30% decrease in the sum of the longest diameter of target lesions. SD is defined as lack of disease progression by 24 weeks. participants complete response (CR): 0, Partial response (PR): 1, Stable disease (SD): 8, CR+PR+SD: 9_________________________________________________________________________________ ',\n",
       " \"breast cancer, clinical stage I-III disease, Measurable disease defined as 1 unidimensionally measurable lesion 20 mm by conventional techniques OR 10 mm with spiral CT scan, HER2/neu 3+ by immunohistochemistry or positive by fluorescent in situ hybridization. no known brain metastases, Hormone receptor status unspecified, PATIENT CHARACTERISTICS:, Menopausal status not specified, Male or female, Life expectancy > 12 weeks, ECOG performance compounds of similar chemical or biologic composition to lapatinib, no ongoing or active infection, no symptomatic congestive heart failure, no unstable angina pectoris, no cardiac arrhythmia, no psychiatric illness or social situation that would preclude study compliance, no other uncontrolled illness, no gastrointestinal tract disease that would preclude ability to take oral medication, no malabsorption syndrome, no requirement for IV alimentation, no uncontrolled inflammatory GI disease (e.g., Crohn' cortisone (50 mg/day), Hydrocortisone (40 mg/day), Prednisone ( 10 mg/day), Methylprednisolone ( 8 mg/day), Phenytoin, Carbamazepine, Phenobarbital, Efavirenz, Nevirapine, Rifampin, Rifabutin, Rifapentine, Hypericum perforatum (St. John's wort), Mod inistration of study drug, no other concurrent investigational agents, no other concurrent anticancer therapy, including chemotherapy, radiotherapy, immunotherapy, or antitumor hormonal therapy, no concurrent herbal (alternative) medicines, no concurrent combination antiretroviral therapy for HIV-positive patients, Concurrent bisphosphonates allowed. \",\n",
       " 'patients may have a history of bilateral breast cancer, Premenopausal (estradiol level in premenopausal range, >20pg/ml, within the prior 28 days), Liver function tests and creatinine 2.5 times the upper limit of normal within the 28 days prior to enrollment, ECOG Performance Status 0-1, Must agree to use non-hormonal contraception (condoms, diaphragm, IUD, sterilization, abstinence, etc. tu of the cervix, women with evidence of current local recurrence or metastatic breast cancer, Pregnant women, Nursing women, women who are currently taking tamoxifen and are unwilling to stop this medication. women with a known deleterious BRCA 1 or BRCA 2 mutation are greater than or equal to () 18 years of age, with histologically-confirmed HER2-positive breast cancer. ignancy in the last 5 years except for basal cell cancer or cancer in situ of the cervix. ignancy in the last 5 years, except for basal cell cancer. ',\n",
       " 'preoperative stages II-III per AJCC 6th edition, based on baseline evaluation by clinical examination and/or breast imaging. patients must have completed preoperative (neoadjuvant) chemotherapy with a standard chemotherapy regimen. patients must have the presence of significant residual invasive disease. patients with metastatic disease may not be pregnant, expect to become pregnant, plan to conceive a child while on study, or breastfeeding, Uncontrolled intercurrent illness, Non-healing wounds or major surgical procedures are not permitted within 28 day prior to enrollment. patients with clinically significant peripheral arterial disease should also be excluded. tory of grade 3 or 4 allergic reactions to compounds of similar chemical or biologic composition to cyclophosphamide (such as other alkylating agents) or methotrexate (such as other antimetabolites), Prior history of malignancy treated without curative intent, excluding nonmelanomatous skin cancer. Current use of anticoagulants is allowed as long as patients have been on a stable dose for more than two weeks with stable INR. ',\n",
       " 'inTERVENTION 1:, Anastrozole and Simvastatin, adjuvant therapy. anastrozole: 1 milligram tablet PO QD for 14 days. anastrozole: 1 milligram tablet PO QD for 14 days. ',\n",
       " 'to be included in this study, you must meet the following criteria:, Metastatic breast cancer confirmed by biopsy, no more than one prior chemotherapy regimen for metastatic breast cancer, Able to perform activities of daily living with minimal assistance, Age 18 years or older, Give written informed consent, Exclusion Criteria:, You cannot participate in this study if any of the following apply to you. ualify for the trial, study personnel will explain the reasons. if you do qualify, study personnel will explain the trial in detail. ',\n",
       " 'atypical ductal hyperplasia, ductal carcinoma in situ, or lobular carcinoma in situ, Prior random periareolar fine needle aspiration (RPFNA) showing atypical hyperplasia, Family history consistent with hereditary breast cancer, as indicated by 1 of the following criteria. 5% on mammogram performed within 6 months prior to initiation of study drug. Has regular menstrual cycles (between 21 and 35 days) unless using extended regimen oral contraceptives or a contraceptive device. amin D for premenopausal bone health (1,200 mg calcium and 800 IU vitamin D daily), Negative pregnancy test prior to receiving study agent. Exclusion Criteria, pregnant or nursing within the past 6 months, nursing within the past 6 months, Known osteoporosis or severe osteopenia. ',\n",
       " 'FEBRILE NEUTROPENIA 1/202 (0.50%), LEUKOPENIA 0/202 (0.00%), NEUTROPENIA 2/202 (0.99%), CARDIAC FAILURE CONGESTIVE 0/202 (0.00%), CARDIO-RESPIRATORY ARREST 1/202 (0.50%), PERICARDIAL EFFUSION 1/202 (0.50%), CATARACT 1/202 (0.50%), OPTIC NEUROPATHY 0/202 ',\n",
       " 'hyperbilirrubinemia [1]1/436 (0.23%), hyperbilirrubinemia [2]1/436 (0.23%), heart failure [2]0/436 (0.00%), Infarction and cardiac arrest 0/436 (0.00%), Ischemia cardiac/Infarction [3]1/436 (0.23%), Coronary vasospam [3]1/436 (0.23%), Gastroenteritis and renal insuficience 1/436 (0.23% ',\n",
       " 'patients with unilateral primary cancer pathologically confirmed before neoadjuvant chemotherapy (NAC), who received NAC, with detectable lesion / clip marker on ultrasound, with cT1-T3 tumors, clinical and imaging complete or near-complete response on MRI, with informed consent. female patients 18 to 75 years of age with metastatic breast cancer histologically/cytologically confirmed not amenable to curative surgery or radiotherapy. n metastases or leptomeningeal involvement, pulmonary lymphangitis or symptomatic pleural effusion or symptomatic ascites, history of second primary malignancy, HIV infection, preexisting neuropathy, pregnancy or breast feeding. ',\n",
       " 'pre-menopausal women aged 18 years or over with histologically/cytologically-confirmed oestrogen receptor positive (ER +ve) breast cancer, world health organisation performance status of 0, 1, or 2, Provided written informed consent, Exclusion Criteria:, treatment with tamoxifen or other hormonal therapies as early breast cancer adjuvant in the previous 24 weeks. ',\n",
       " 'Outcome Measurement:, Objective Response (OR), Objective response (OR) including complete response (CR) and partial response (PR) according to the Response Evaluation Criteria in Solid Tumours criteria. ',\n",
       " 'given orally, paclitaxel: Given IV, doxorubicin hydrochloride: Given IV, cyclophosphamide: Given SC, conventional surgery: surgical procedures performed on patients, axillary lymph node dissection: correlative study. ',\n",
       " 'atrial fibrillation 1/67 (1.49%), Ventricular fibrillation 1/67 (1.49%), Gastrointestinal perforation 1/67 (1.49%), Periproctitis 1/67 (1.49%), General physical health deterioration 1/67 (1.49%), Escherichia sepsis 1/67 (1.49%), Pneumonia 1/67 (1.49%), Tumour pain 1/67 (1.49%), Renal failure acute 1/67 (1.49% ',\n",
       " 'ECOG Performance score > 2 OR too ill to participate as judged by physician/in medical record. past history of any cancer other than non-melanoma skin cancer, Currently participating in couple/marital therapy. ',\n",
       " '5/45 (11.11%), Neutrophils/granulocytes (ANC/AGC) * [1]0/45 (0.00%), Neutrophils/granulocytes (ANC/AGC) * [2]0/45 (0.00%), Diabetes decompensation * 0/45 (0.00%), Diarrhea * [2]0/45 (0.00%), Mucositis/stomatitis and Vomiting * [3]0/45 (0.00%), ',\n",
       " 'female 18+ years of age reporting no use of hormone replacement therapy, tamoxifen or raloxifene within the prior 6 months to eligibility screening. Pre or Post menopausal women reporting no use of hormone replacement therapy, tamoxifen or raloxifene within the prior 6 months. Glucose, Calcium, Albumin, Serum total protein (TP), Sodium, Potassium, Carbon dioxide, Chloride, Blood urea nitrogen (BUN), Creatinine, Alkaline phosphatase (ALP), Alanine amino transferase (AST), aspartate amino transferase (SGOT) and Bilirubin. ',\n",
       " 'patients receive tivantinib PO BID on days 1-21. courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. ',\n",
       " 'confirmed pathologic diagnosis of a solid tumor not curable with available therapies for which neratinib plus capecitabine is a reasonable treatment option. erbB-2 gene amplified tumor (FISH or CISH) or erbB-2 overexpression (IHC 3+, or IHC2+ with FISH or CISH confirmation), based on local testing, or centralized FISH testing prior to day 1. prior treatment with capecitabine, lapatinib (20 subjects with prior lapatinib exposure will be enrolled) or any erbB-2 targeted agents except trastuzumab. treatment must exceed 2 weeks (14 days) in order to be exclusionary. any other cancer within 5 years prior to screening with the exception of adequately treated cervical carcinoma in situ or basal or squamous cell carcinoma of the skin. ',\n",
       " 'the ORR was defined as the percentage of participants with best overall response (BOR) of confirmed complete response (CR) or partial response (PR), based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. possible CR and PR had to be confirmed no fewer than 4 weeks after the initial response assessment. ORR = CR + PR, Time frame: Cycle 1 (Day 1) until first evidence of disease progression, assessed up to the data cutoff date (30 Aug 2013) up to 2.5 years, Results 1:, Arm/Group Title: Eribulin mesylate. ',\n",
       " 'Ipsilateral biopsy-proven invasive breast cancer 5 cm in maximal dimension by Ultrasound or Mammography. no abnormal axillary nodes identified on grayscale AUS, or abnormal nodes with benign subsequent FNA biopsy. ',\n",
       " 'women who are not menstruating regularly may be entered with restrictions. their estrogen progesterone, and follicle stimulating hormone levels must be documented. subjects must be at increased risk for breast cancer. 10 yr Tyrer-Cuzick risk twice that of the population risk as listed in model, or RPFNA atypia, BMI 40 Kg/m3, A first degree relative with breast cancer under the age of 60. multiple prior biopsies or at least one prior biopsy exhibiting atypical hyperplasia with atypia within the last three years. subjects must be willing to continue the same hormonal milieu present at baseline throughout trial. subjects with history of AH, LCIS, or ER-positive DCIS must have had appropriate local therapy (lumpectomy plus radiation or mastectomy) only the contralateral (uninvolved breast) will be studied by RPFNA. subjects with a history of AH, LCIS, or ER-positive DCIS must have had appropriate local therapy. subjects of sufficient age and/or risk for a baseline mammogram must be willing to have an off-study mammogram performed 6 months after study entry. subjects must have had an RPFNA of the breast within six months prior to entering the interventional portion of the study and be willing to have another RPFNA at 6.5 months after starting LovazaTM. subjects must be willing to undergo phlebotomy at baseline, and 6 months and 6.5 months approximately 3 tablespoons of blood will be obtained at baseline. subjects must produce a spot urine sample at baseline, 6 months and at study conclusion. subjects must complete questionnaires regarding diet and supplement use, quality of life, relevant family history, personal health and reproductive history and medications at initiation and conclusion of the intervention. women who have undergone change in their hormonal milieu in the past 6 months this includes pregnancy, lactation, or stopping or starting hormonal contraceptives. women who regularly take NSAIDS (>7 tablets weekly) ',\n",
       " 'Adverse Events 1:, Total: 6/8 (75.00%), Thrombocytopenia 1/8 (12.50%), Hypertension 1/8 (12.50%), Hepatotoxicity 3/8 (37.50%), Pancreatectomy * 1/8 (12.50%). ',\n",
       " '5/26 (19.23%), Febrile neutropenia 1/26 (3.85%), Abdominal pain 0/26 (0.00%), Constipation 0/26 (0.00%), Nausea 1/26 (3.85%), Pancreatitis 1/26 (3.85%), Vomiting 2/26 (7.69%), Pain 0/26 (0.00%), Pneumonia 0/26 (0.00%), Urinary tract infection 1/26 (3.85%), Lumbar vertebral fracture 1/2 ',\n",
       " 'tumors over-expressing Her-2, Candidate for treatment with docetaxel/trastuzumab. Histology of inflammatory carcinoma, AST and/or ALT >1.5 x ULN concomitant with ALP >2.5 x ULNDISEASE CHARACTERISTICS. bin normal, aspartate aminotransferase or Alanine aminotranferease no greater than 1.5 times upper limit of normal (ULN), alkaline phosphatase no greater than 2.5 times ULN, Renal:, Not specified, Cardiovascular:, No pre-existing grade 2 or greater motor or sensory peripheral neuropathy except abnormalities due to cancer. no prior severe hypersensitivity reaction to docetaxel or other drugs formulated with Polysorbate 80, no other malignancy within the past no prior adjuvant or neoadjuvant chemotherapy regimen for primary disease, no prior docetaxel, no prior vinorelbine, Prior paclitaxel allowed, No concurrent hormonal therapy, Radiotherapy:, At least 3 weeks since prior radiotherapy, Surgery:, At least 2 weeks since prior surgery and recovered. ',\n",
       " \"inTERVENTION 1: BREASTChoice recruited patients scheduled for a plastic/reconstructive consult. investigators identified patients who completed a mastectomy, or were scheduled for one, and considering reconstruction, but didn't have an appointment with a plastic/reconstructive surgeon. investigators recruited patients scheduled for plastic/reconstruction consultation. they recruited patients who completed or scheduled a mastectomy. patients were randomized using computer random assignment. the overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed. the overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed. the overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed. l be 40.5 Gy to the breast and 48.0 Gy to the tumor bed. overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed. \",\n",
       " 'locally recurrent disease must not be amenable to surgical resection or radiation with curative intent. subject must have received and progressed on at least one prior standard HER2 directed therapy. subject must have adequate bone marrow, renal and hepatic function. more than 2 prior lines of cytotoxic chemotherapy. prior taxane therapy for metastatic breast cancer. ',\n",
       " 'inTERVENTION 1:, Study Participants, There are no arms or subgroups in this study. ',\n",
       " 'inTERVENTION 1:, Recruitment Population, Pre-randomization recruitment and enrollment. ',\n",
       " 'standard RECIST (Response Evaluation Criteria in Solid Tumors) Criteria. those who achieved either complete (disappearance of all target lesions) or partial (at least 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD) response. overall number of participants Analyzed: 26, Measure Type: Number, Unit of Measure: Participants Participants who had a complete tumor response: 2, Participants who had a partial tumor response: 13, Participants who did not have a tumor response: 11Outcome Measurement:, Objective Response Rate, Patient response rates will be measured by the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI. patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on days 1, 8, and 15 at 28-day intervals. overall number of participants Analyzed: 39, Measure Type: Number, Unit of Measure: percentage of patients 28 (14.9 to 45.0), Results 2:, Arm/Group Title: Abraxane Alone, Arm/Group Description: Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on days 1, 8, and 15 at 28-day ',\n",
       " 'Curcumin-based Gel: Applied topically, laboratory biomarker analysis: Correlative studies, Questionnaire administration: ancillary studies. patients apply HPR PlusTM topically TID approximately every 4-6 hours beginning on the first day of radiation therapy. ',\n",
       " 'Sodium, serum-low (hyponatremia) 1/20 (5.00%), Death - Disease progression NOS 1/20 (5.00%), Dyspnea (shortness of breath) 1/20 (5.00%), Hypoxia 1/20 (5.00%)Adverse Events 1:, Total: 39/39 (100.00%), Febrile Neutropenia 1/39 (2.56%), Heart failure 1/39 (2.56%), Diarrhea 3/39 (7.69%), Nausea/vomiting ',\n",
       " 'Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (ACT), Doxorubicin 60 mg/m2 IV bolus injection in combination with cyclophosphamide 600 mg/m2 IV bolus injection on Day 1 of every 3 weeks for 4 cycles. docetaxel 100 mg/m2 IV infusion every 3 weeks for another 4 cycles. ',\n",
       " 'female patients of Chinese origin with histologically or cytologically proven diagnosis of breast cancer. have at least one measurable lesion as defined by Response Evaluation Criteria In Solid Tumors. ',\n",
       " 'Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2, Cohort 1: Eligible patients were enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly. only in the phase I, the first cycle lasted 38 days. only in the phase I, the first cycle lasted 38 days. ',\n",
       " '0/23 (0.00%), NAUSEA *0/23 (0.00%), VOMITING *0/23 (0.00%), BILIRUBIN (HYPERBILIRUBINEMIA) *0/23 (0.00%), INFECTION (DOCUMENTED CLINICALLY ORMICROBIOLOGICALLY) WITH GRADE 3 OR 4 NEUTROPHILS (ANC 1.0 X 10E *0/23 (0.00%), NEUTROPHILS/ ',\n",
       " 'Adverse Events 1:, Total: 122/280 (43.57%), Agranulocytosis 0/280 (0.00%), Anaemia 10/280 (3.57%), Febrile neutropenia 30/280 (10.71%), Immune thrombocytopenic purpura 1/280 (0.36%), Leukopenia 3/280 (1.07%), Neutropenia 12/280 (4.29%), Thrombocytopenia 4/280 (1.43%), Acute myocardial in ',\n",
       " 'the patient is at least 18 years of age at the time of consent. the patient has an ECOG performance status of Grade 0 - 2. the patient has a clinical negative node status at the time of study entry. lymph node biopsy is part of the surgical plan. the patient is pregnant or lactating. the patient has a known hypersensitivity to Lymphazurin or Patent Bleu V. patient has bilateral primary breast cancers or multiple tumors within their breast. patients scheduled for bilateral mastectomy for any reason. female, 18-100 years old, not pregnant or breastfeeding. Patient  18 y/o or > 100 y/o, Pregnant or breastfeeding, Male, Breast implants, Multicentric disease or bilateral disease, Lesions > 5 cm in diameter, Lesions  1.0 cm from the skin, Need for mastectomy, Diffuse microcalcifications (as determined by the Investigator) ',\n",
       " 'primary tumor is larger than 2 cm in diameter (T2) as measured by caliper or ultrasound. Overexpression and/or amplification of HER2 is confirmed by immunohistochemistry (IHC) 3+ or fluorescence in situ hybridization (FISH) + when IHC 2+. le to take oral medications (i.e., no uncontrolled vomiting, inability to swallow, or diagnosis of chronic malabsorption) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. only Japanese women are eligible for the trial. patients receiving any medications or substances that are inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) are ineligible. patients who have uncontrolled intercurrent illness include, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations. ',\n",
       " 'Adverse Events 1:, Total: 7/15 (46.67%), Cardiac arrest * 1/15 (6.67%), Chest pain - cardiac * 1/15 (6.67%), Diarrhea * 1/15 (6.67%), Fatigue * 1/15 (6.67%), Fever * 1/15 (6.67%), Sudden death NOS * 1/15 (6.67%), Sepsis * 1/15 (6.67%), Skin infection * 1/15 (6.67%), Neutrophil count decreased * 1/15 (6.67%), Plate ial effusion 2/224 (0.89%), Sinus tachycardia 1/224 (0.45%), Abdominal pain 3/224 (1.34%), Colitis 0/224 (0.00%), colitis 0/224 (0.00%). ',\n",
       " 'RECIST progression defined as 20% increase in the sum of longest diameters of target measurable lesions over the smallest sum observed, unequivocal progression of non-measurable disease, the appearance of any new lesion/site, death due to disease without prior documentation of progression or symptomatic deterioration. a modified RECIST 1.0 criteria was used to assess CNS response for patients with new or progressing brain metastases. progressive disease for patients with lesions 1cm was defined as follows. irinotecan hydrochloride administered intravenously (IV) at a starting dose of 125 mg/m2 on days 1 and 15 of a 28 day cycle, temozolomide orally for seven days at a starting dose of 100 mg/m2 on days 1-7 and days 15-21 of a 28 day cycle. ',\n",
       " 'ANAEMIA 1/199 (0.50%), BONE MARROW FAILURE 1/199 (0.50%), FEBRILE NEUTROPENIA 11/199 (5.53%), LEUKOPENIA 1/199 (0.50%), PANCYTOPENIA 1/199 (0.50%), ACUTE MYOCARDIAL INFARCTION 1/199 (0.50%), ATRIAL FLUTTER 1/199 (0.50%), CARDIAC FAILURE 3/199 (1.51%), Ad Nausea 0/8 (0.00%), Stomatitis 0/8 (0.00%), Upper gastrointestinal haemorrhage 0/8 (0.00%), Vomiting 0/8 (0.00%), Chest pain 0/8 (0.00%), Adverse Events 2:, Total: 2/6 (33.33%), Anaemia 0/6 (0.00%), Febrile neutropenia 0/6 (0.00%), Polycythaemia 0/6 (0.00%), Acute coronary syndrome 0 ',\n",
       " 'RECIST is a set of published rules that define when tumors in cancer patients improve during treatment. only data collected until the cut-off date for RECIST 1.1 based endpoints were considered. participants received oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusion of Vinorelbine 25 mg/meter2 (meter=m) on days 1, 8, 15, and 22 of each course. the treatment was administered in treatment courses of 28 days. ding dose of 4 mg/kg and weekly 10 minutes intravenous infusion of Vinorelbine 25 mg/m2 on days 1, 8, 15 and 22 of each course. ',\n",
       " 'previous participation in study 971-ONC-0028-080. Subjects who had not previously participated in study 971-ONC-0028-080. Stage IV that is free of all known disease after eradication by surgery. stage II with at least 4 positive axillary nodes and completed adjuvant therapy no more than 24 months ago. Stage II with at least 4 positive axillary nodes and completed adjuvant therapy no more than 24 months ago. immunodeficiency or autoimmune disease, no other active cancer except basal cell or squamous cell skin cancer, PRIOR CONCURRENT THERAPY:, Biologic therapy:, At least 6 weeks since prior immunotherapy, No prior vaccine with any of the antigens in this study. ',\n",
       " 'inclusion criteria:, biopsy-proven breast cancer, metastatic (persistent or recurrent) must be 4 weeks since all of the following treatments (recovered from toxicity of prior treatment to Grade 1, excluding alopecia) ALT and/or aspartate aminotransferase (AST) 2.5xULN are allowed. Negative for hepatitis viruses B and C unless consistent with prior vaccination or prior infection with full recovery. inhaled or topical corticosteroids are allowed (if therapy is 5 days and is limited to systemic steroids as antiemetics); Cyclosporine A, tacrolimus, or sirolimus. patients with remote history of asthma or active mild asthma may participate. patients with history of deep venous thrombosis are allowed if treated, completely resolved. patients with history of deep venous thrombosis are allowed if treated, completely resolved, and no treatment for >4 months. rmed consent, consistent follow-up, or compliance with any aspect of the study; Pregnant or nursing women. ',\n",
       " 'stage II with at least 10 positive axillary nodes OR, Stage IIIA or IIIB, no histologically proven bone marrow metastasis, no CNS metastasis, Hormone receptor status known, PATIENT CHARACTERISTICS:, Age:, Physiological age 60 or under, Menopausal status:, Not specified, Life expectancy:, See Disease Characteristics, Hematopoietic:, Neutrophil count at least 1,500 at least 60% of predicted, pO_2 at least 85 mm Hg on room air, pCO_2 at least 43 mm Hg on room air, DLCO at least 60% lower limit of predicted, Other:, No other prior malignancy except squamous cell or basal cell skin cancer or stage I or carcinoma in situ of the cervix, HIV negative, No sensitivity to E. coli-derived products. ',\n",
       " 'inTERVENTION 1:, Glutamine, 10 grams three times a day (orally) for four days and then stop, glutamine, 10 grams three times a day (orally) for four days and then stop, INTERVENTION 2:, Placebo, 10 grams three times a day (orally) for four days. the interpretation and analysis was done with gamma imaging only. ',\n",
       " 'inTERVENTION 1:, Initial Cohort, Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 300 micrograms. all research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous injection following the schedule. eous (SC) injection followed the schedule. ',\n",
       " 'subjects with measurable brain metastases of at least 1 cm in any plane based on anatomic imaging. Age of study subject must be > 18 years. study subjects must have normal organ and marrow function. subjects who are allergic to gadolinium will have MRI scans without gadolinium contrast. subjects who are allergic to gadolinium will have MRI scans without gadolinium contrast. al primary cancer pathologically confirmed before neoadjuvant chemotherapy (neoadjuvant chemotherapy) who received NAC with detectable lesion / clip marker on ultrasound, with detectable lesion / clip marker on ultrasound. neoadjuvant chemotherapy (neoadjuvant chemotherapy), who received NAC, with informed consent. ',\n",
       " 'ductal breast cancer or Grade I or II DCIS measuring less than or equal to 2cm on pathology and/or mammography. Clips must be placed in the lumpectomy cavity at the time of final excision. the patient is currently active second malignancy other than non-melanoma skin cancers. ',\n",
       " 'the eligible participants were administered Ispinesib, intravenously as a one-hour infusion on day 1 of every 21-day treatment cycle. the dosing was repeated for up to multiple cycles, until disease progression or removal from treatment due to an unacceptable toxicity or withdrawal of consent. ',\n",
       " 'Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi. ',\n",
       " 'measurable disease defined as at least one lesion 10 mm by CT or MRI that can be accurately measured in at least one dimension. bone lesions: lytic or mixed (lytic + blastic) in the absence of measurable disease. on criteria:, transgender men and women;, women who have undergone prophylactic mastectomy;, women with visual impairment;, women with a diagnosis of severe mental illness. ',\n",
       " 'Febrile neutropenia 1/26 (3.85%), Neutropenia 0/26 (0.00%), Thrombocytopenia 0/26 (0.00%), Cardiac failure congestive 0/26 (0.00%), Extrasystoles 0/26 (0.00%), Nausea 1/26 (3.85%), Abdominal pain 0/26 (0.00%), Constipation 0/26 (0.00%), Gastrointestinal haemorrhage 0/ ',\n",
       " 'Febrile neutropenia * 10/298 (3.36%), Neutropenia * 9/298 (3.02%), leukopenia * 0/298 (0.00%), Lymphadenopathy * 1/298 (0.34%), Cardiac failure congestive * 0/298 (0.00%), Arrhythmia * 0/298 (0.00%), Myocardial infarction * 1/298 (0.34%), Angina pectoris * 1/298 (0.34%), Atrial fibrillation ',\n",
       " '17/94 (18.09%), Anaemia 2/94 (2.13%), Lymphadenopathy 0/94 (0.00%), Angina pectoris 0/94 (0.00%), Ischaemic cardiomyopathy 0/94 (0.00%), Myocardial infarction 1/94 (1.06%), Haemorrhoids 1/94 (1.06%), Ileus 1/94 (1.06%), Nausea 1/94 (1.06%), Vomiting 1/94 ( ',\n",
       " 'topical fluocinonide 0.05% cream is a single-arm, single-stage, open-label phase II trial. all subjects will receive topical fluocinonide 0.05% cream. duration of treatment will be 4 weeks. ',\n",
       " 'data were collected separately for the T+OFS and E+OFS participants in the parent study, IBCSG 24-02 (SOFT) the sample size for this co-SOFT substudy was small, so the analysis plan was revised to pre-specify collective analysis for all patients receiving OFS.INTERVENTION 1:, Single Drain, Insertion of a single drain. ultrasonography after removal of drains seroma under the flaps and in the axilla will be examined by ultrasonography. one day after removal of drains seroma under the flaps and in the axilla. ',\n",
       " 'Fulvestrant: Fulvestrant 500 mg Day 1 & 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus everolimus daily x 12 cycles. if no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity. Placebo for Everolimus (2 tablets) daily x 12 cycles. Placebo manufactured to mimic everolimus tablet. ',\n",
       " 'courses repeat every 28 days in absence of disease progression or unacceptable toxicity. courses repeat every 28 days. ',\n",
       " '\"Triple negative\" disease defined as tumor demonstrating no expression for estrogen, progesterone or human epidermal growth factor receptor 2(HER2)receptors. an interval of at least 1 week must have elapsed since prior chemotherapy or hormonal therapy. lets 100,000/L;, Hemoglobin 9 gm/dL;, Total bilirubin institutional upper limit of normal (ULN);, Aspartate transaminase (AST) and alanine aminotransferase (ALT) 5 times ULN;, Alkaline phosphatase 2.5 times ULN;, estimated creatinine clearance 60 mL/min., left ventricular ejection fraction (LVEF) 50%. ne for metastatic breast cancer; Known hypersensitivity to any component of any study drug; Known hypersensitivity to any component of any study drug; Known hypersensitivity to any component of any study drug; Current neuropathy grade 2; central nervous system metastases as determined by head CT with contrast;. ne for metastatic breast cancer; ne for metastatic breast cancer; ne for metastatic breast cancer; ne for metastatic breast cancer; ne for metastatic breast cancer;  within previous 6 months, Uncontrolled serious contraindicated medical condition or psychiatric illness. ',\n",
       " 'clinical benefit rate (CR + PR + SD > 6 months) per Response Evaluation Criteria. of MPA monotherapy and MPA + low dose oral cyclophosphamide and methotrexate (ldoCM) in patients with refractory hormone receptor negative metastatic breast cancer. Cyclophosphamide will be administered orally as a single daily dose. Methotrexate will be administered twice daily on days 1 and 2 of each week. participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily. Overall number of participants Analyzed: 60, Measure Type: Number, Unit of Measure: Percentage of Participants 1.7 (0.2 to 6.3), Results 2:, Arm/Group Title: Placebo + Letrozole, Arm/Group Description: Participants took matching Placebo (of alpelisib 300 mg once daily/buparlisib 100 mg once daily or 5 days on/2 days off ',\n",
       " 'inclusion Criteria: female patients, 18-70 years of age; histologically-proven invasive breast cancer; no prior or current neoplasm except for non-melanoma skin cancer. exclusion Criteria: pregnant or lactating women; pre-operative local treatment for breast cancer; clinically significant cardiac disease. ',\n",
       " 'grade 1 = minimal symptoms, normal diet; grade 2 = symptomatic, but able to swallow a modified diet; grade 3 = symptomatic, but unable to aliment or hydrate orally; and grade 4 = symptoms associated with life-threatening consequences. participants spat 10mL of dexamethasone steroid mouthwash 4 times daily (qid) orally for 2 minutes each for 8 weeks. 2: Not evaluable: 1_. ',\n",
       " 'women with Stage 0-III breast cancer, treated with breast conserving surgery or mastectomy and clear margins, will receive 15 doses of radiation over three weeks. participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment. e toxicity ',\n",
       " 'inTERVENTION 1:, Ixabepilone 25 mgm2 + Epirubicin 75 mgm2 Participants received 25 mg/m2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m2 epirubicin every 21 days. ',\n",
       " 'participants with any grade of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine safety and tolerability of Nivolumab and Daratumumab, Time frame: From first dose to 30 days post last dose (up to 34 months), Results 1:, Arm/Group Title: Nivolumab + Daratumumab (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab kg Q2W (weeks 9-24), Overall Number of Participants Analyzed: 21, Measure Type: Count of Participants, Unit of Measure: Participants 21 100.0%_. ',\n",
       " 'inTERVENTION 1:, Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi. ',\n",
       " 'a 95% confidence interval for the median PFS will be calculated. a lower bound greater than 8 months would be strong evidence that Nab-Paclitaxel- bevacizumab induction therapy is superior to paclitaxel and bevacizumab. patients receive paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15. bevacizumab IV over 30-90 minutes once every 14 or 21 days. treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. ',\n",
       " 'women >=18 years of age, HER2-negative metastatic breast cancer, Previous adjuvant chemotherapy or hormonal treatment, >=1 measurable target lesion, Exclusion Criteria:, Previous treatment with chemotherapy, an anti-angiogenic agent, or a biologic therapy for advanced or metastatic cancer. stage IIIB (T4, Any N, M0) or (Any T, N3, M0) disease judged primarily unresectable by an experienced breast surgeon. physical examination, chest x-ray and any scans needed for tumor assessment must be performed within 90 days prior to registration. patients with congestive heart failure or angina pectoris are NOT eligible. these tests must have been performed within 90 days prior to registration. patients must have an Absolute neutrophil count of 1,500/l and a platelet count of 100,000/l. women of reproductive potential may not participate unless they have agreed to use effective contraceptive method. ',\n",
       " 'oral capecitabine and lapatinib ditosylate are given as in arm I. courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV, lapatinib ditosylate: Given PO and capecitabine: Given PO, Overall Number of Participants Analyzed: 37, Median (95% Confidence Interval), Unit of Measure: Median survival and CI in months 4.9 (2.9 to 8.5) ',\n",
       " 'Adverse Events 1:, Total: 20/88 (22.73%), Cardiac Failure * 2/88 (2.27%), Intracardiac thrombus * 1/88 (1.14%), Abdominal pain * 1/88 (1.14%), Diarrhoea * 2/88 (2.27%), Enteritis * 1/88 (1.14%), Chest pain * 1/88 (1.14%), Death * 1/88 (1.14%), Erysipelas * 1/ ',\n",
       " '107/383 (27.94%), Anaemia 4/383 (1.04%), Febrile neutropenia 7/383 (1.83%), Haemoytique anaemia 0/383 (0.00%), leukopenia 1/383 (0.26%), Neutropenia 6/383 (1.57%), Thrombocytopenia 2/383 (0.52%), Anginal pectoris 1/383 (0.26%), cardiomyopathy 0/383 (0.00%), Ear pain 0/3 ECTORIS 1/2002 (0.05%), CARDIAC ARREST 1/2002 (0.05%), CARDIAC FAILURE 1/2002 (0.05%), CARDIAC TAMPONADE 1/2002 (0.05%), Adverse Events 2:, Total: 36/181 (19.89%), ANAEMIA 0/181 (0.00%), BONE MARROW FAILURE 0/181 (0.00%), DISSEMINATED INTRAVASCULAR COAGULATION ',\n",
       " 'anemia 1/23 (4.35%), Diarrhea 1/23 (4.35%), Nausea 1/23 (4.35%), Fracture 1/23 (4.35%), ALT 1/23 (4.35%), AST 1/23 (4.35%), INR 1/23 (4.35%), PTT 1/23 (4.35%), Glucose, high 1/23 (4.35%), Limb Pain 1/23 (4.35%), Ataxia 2/23 (8.70%), Neurology - Other 1/23 (4.35%), Asthenia * 0/20 (0.00%), Disease progression * 0/20 (0.00%), Mucosal inflammation * 0/20 (0.00%), Appendicitis * 0/20 (0.00%) ',\n",
       " 'recently confirmed unilateral ductal carcinoma in situ or invasive cancer of the breast, Confirmed by biopsy or fine needle aspiration (FNA) within the past 60 days. prior biopsy of the contralateral breast is allowed provided it was performed at least 6 months prior to study entry, no remote history of breast cancer, No new breast symptoms within the past 60 days. scular, no pacemaker, no magnetic aneurysm clips, Other, Not pregnant, No implanted magnetic device, No severe claustrophobia, No other contraindications to MRI, no psychiatric, psychological, or other condition that would preclude informed consent, PRIOR CONCURRENT THERAPY:, Biologic therapy, not specified, Chemotherapy, At least 6 months since prior anticancer chemotherapy, Endocrine therapy, No concurrent therapeutic hormonal therapy, ',\n",
       " 'patients undergo 18F-FLT PET/CT at baseline (prior to chemotherapy, FLT-1), early therapy (5-10 days after the first course of chemotherapy, FLT-2), and post therapy (within 3 weeks prior to surgery, FLT-3). patients undergo standard surgical resection of residual tumor following completion of neoadjuvant chemotherapy. myl 1401OTrastuzumab Intravenously + paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks. if SD or PR, CR at cycle 9 (week 24) proceed to myl 1401O( Mylan Trastuzumab) alone once every 3 weeks until DP or subject withdrawal. ',\n",
       " \"patients must be able and willing to give written informed consent prior to any study related procedures, Ambulatory, female patients with an age 18 years, Ambulatory, female patients with an age 18 years, Patients with histologically or cytologically proven diagnosis of breast cancer eligible for neoadjuvant or adjuvant chemotherapy. patients with baseline WBC LLN/3.5 x 109/L, ANC of 1.5 x 109/L, platelet count 100 x 109/ patients with myeloid malignancies and myelodysplasia or evidence of metastatic disease in bone marrow or brain, 5. patients currently receiving radiation therapy or have completed radiation therapy within 4 weeks before study entry or likely to receive radiotherapy during the study. patients with history of systemic antibiotic use within 72 hours prior to chemotherapy, 9. patients with active infection which may require systemic antimicrobial therapy. patients with seropositivity for HIV or HBV or HCV, 11. Known cases of Sickle Cell Anemia, 12. Patients with radiographic evidence of active pulmonary infections and/or recent history of pneumonia within 1 month of screening. patients with clinically evident splenomegaly confirmed by ultrasonography, 14. patients with any other clinically significant disease(s) which could compromise the patient's involvement in the study or overall interpretation of the data. women of child-bearing potential who are not willing to follow a reliable & effective contraceptive measure during the study. \",\n",
       " 'ascites 0/90 (0.00%), Nausea 0/90 (0.00%), Vomiting 0/90 (0.00%), Death NOS 1/90 (1.11%), Fever 0/90 (0.00%), Other general disorders, administration site conditions 0/90 (0.00%), Other hepatobiliary disorders 1/90 (1.11%), Lung infection 2/90 (2.22%), Sepsis 2/90 (2.22%), Spinal fracture 0/90 (0.00 ',\n",
       " '14/69 (20.29%), Febrile neutropenia 0/69 (0.00%), Anaemia 0/69 (0.00%), Atrial fibrillation 1/69 (1.45%), Cardiopulmonary failure 0/69 (0.00%), Supraventricular extrasystoles 1/69 (1.45%), Abdominal pain 1/69 (1.45%), Intestinal obstruction 0/69 (0.00%), Vomiting 1/69 (1.45%), Chills 1/69 (1.45% ervical cancer *1/255 (0.39%), nosocomial pneumonia *2/255 (0.78%), Venous thrombosis *1/255 (0.39%) ervical cancer *1/255 (0.39%), nosocomial pneumonia *2/255 (0.78%) ',\n",
       " 'invasive tumor must be hormone receptor-poor, defined as both estrogen receptor and progesterone receptor staining present in 10% of invasive cancer cells by Immunohistochemistry. HER- 2 negativity will be based on current ASCO-CAP guidelines for HER testing. female subjects age 18 - 70 years, ECOG Performance Status of 0-1, Adequate organ and marrow function as defined below:, Leukocytes 3,000/uL, Absolute neutrophil count 1500/uL, Platelets 100,000/uL, Total bilirubin 1.5mg/dL, AST(SGOT/ALT(SPGT) 2 x institutional upper limit of normal, Creatinine 1.5mg/dl and/or Creatinine Clearance 60mL subjects with clinical stage III disease must be already enrolled in P.R.O.G.E.C.T observational registry. Subjects with bilateral disease are eligible if they meet other eligibility criteria. subjects with congestive heart failure, myocardial infarction, unstable angina pectoris, an arterial thrombotic event, stroke or transient ischemia attack within the past 12 months, uncontrolled hypertension (Systolic BP>160 or Diastolic BP>90), uncontrolled or symptomatic arrhythmia. ',\n",
       " 'female patients >=18 years with proven diagnosis of HER2-overexpressing, histologically confirmed breast cancer, Locally advanced or metastatic disease, Must have biopsiable disease, Exclusion criteria:, Prior treatment with HER2-targeted small molecules or antibodies other than trastuzumab. postmenopausal defined as no menses for at least 12 months or bilateral oophorectomy. if a woman has a 20% chance of carrying a BRCA1/2 gene mutation by either model, she will meet eligibility criteria. subjects should be willing to abstain from use of hormonal therapies. tamoxifen, hormone replacement therapy, oral contraceptive pills, hormone-containing intrauterine devices (IUDs) will be offered as supportive care for women with menopausal symptoms. subject must have no evidence of disease at time of enrollment. current or recent use of hormonal medications, e.g. oral contraceptive pills, hormone replacement therapy, tamoxifen, raloxifene, IUD with progestins or corticosteroids. current use of phenytoin, carbamazepine, rifampin due to increased estrogen metabolism. history of bleeding disorder. ',\n",
       " 'Alpelisib + Letrozole, Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily. ',\n",
       " 'the Pass Criteria require adequate performance in non-cancer cases (recall rate) and in cancer cases (detection rate). the Pass Criteria require adequate performance in non-cancer cases (recall rate) and in cancer cases (detection rate). ',\n",
       " 'lesions should not be amenable to surgery or radiation of curative intent. prior radiation therapy is allowed to less than 25% of the bone marrow. participants must have recovered from the toxic effects of the treatment. antitumoral hormonal treatment must be discontinued prior to enrollment. participants must test negative for pregnancy within 7 days of enrollment. participants must be at least 18 years of age. participants have received more than one combination of anthracycline plus taxane. have serious concomitant systemic disorders that compromise the safety of the participant. have a prior malignancy other than breast cancer, carcinoma in situ of the cervix or nonmelanoma skin cancer. are unable or unwilling to take folic acid, vitamin B12 supplementation, or dexamethasone. Concurrent administration of any other antitumor therapy. ',\n",
       " 'the invasive tumor must be hormone receptor-poor, defined as both estrogen receptor and progesterone receptor staining present in 10% of invasive cancer cells by Immunohistochemistry. female subjects age 18 - 70 years, ECOG Performance Status of 0-1, Adequate organ and marrow function as defined below. ab values must be performed within 14 days of treatment initiation. subjects should have LVEF 50% by echocardiogram or MUGA scan within 4 weeks prior to treatment initiation. subjects with clinically/radiologically abnormal axillary lymph nodes should have pathological confirmation of disease. subject with metastatic disease, history of allergic reactions to compounds of similar chemical or biologic composition to carboplatin, docetaxel, doxorubicin, cyclophosphamide, paclitaxel, or other agents used in the study. Exceptions include, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements. lic BP>160 or Diastolic BP>90), uncontrolled or symptomatic arrhythmia, or grade 2 peripheral vascular disease. ',\n",
       " 'Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (ACT), Doxorubicin 60 mg/m2 IV bolus injection in combination with cyclophosphamide 600 mg/m2 IV bolus injection on Day 1 of every 3 weeks for 4 cycles. docetaxel 100 mg/m2 IV infusion every 3 weeks for another 4 cycles. ',\n",
       " 'RECIST is a set of published rules that define when tumors in cancer patients improve during treatment. only data collected until the cut-off date for RECIST 1.1 based endpoints were considered. participants received oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusion of Vinorelbine 25 mg/meter2 (meter=m) on days 1, 8, 15, and 22 of each course. the treatment was administered in treatment courses of 28 days. ding dose of 4 mg/kg and weekly 10 minutes intravenous infusion of Vinorelbine 25 mg/m2 on days 1, 8, 15 and 22 of each course. ',\n",
       " 'female patients will be considered for enrollment in this study if all of the following criteria are met. have either: locally advanced TNBC defined as invasive ductal cancer; ER- tumors with 10% of tumor nuclei immunoreactive; PR- tumors with 10% of tumor nuclei immunoreactive; T3 or T4 disease, regardless of nodal status. hil count (ANC) >1500/mm3, Platelet count 100,000/mm3, Hemoglobin >9 g/dL (in the absence of red blood cell transfusion), Adequate liver function, defined by:, AST and ALT 2.5 x the upper limit of normal (ULN), Total bilirubin 1.5 x ULN, Adequate renal function, defined by:, a. Serum creatinine 1.5 x ULN or calculated creatinine clearance of 60 a patient will be ineligible for inclusion in this study any of the following criteria are met. patients with intrathoracic metastatic adenopathy are eligible. tudy entry until at least 3 months after the last administration of study drug. patients with significant cardiac disease history within 1 year or ventricular arrhythmias requiring medication are also excluded. patients with severe and/or uncontrolled medical conditions could affect their participation. the oncologist must have prescribed doxorubicin as part of the planned chemotherapy regimen. at least 18 years old, Patient must have given written informed consent indicating understanding of the investigational nature of the study. Enalapril is Pregnancy Categories C (first trimester) and D (second and third trimesters) ',\n",
       " 'the cancer enhances on breast MRI imaging. exclusion Criteria:, age greater than or equal to 18 years. ',\n",
       " 'clinical benefit rate (CR + PR + SD > 6 months) per Response Evaluation Criteria. of MPA monotherapy and MPA + low dose oral cyclophosphamide and methotrexate (ldoCM) in patients with refractory hormone receptor negative metastatic breast cancer. Cyclophosphamide will be administered orally as a single daily dose. Methotrexate will be administered twice daily on days 1 and 2 of each week. participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily. Overall number of participants Analyzed: 60, Measure Type: Number, Unit of Measure: Percentage of Participants 1.7 (0.2 to 6.3), Results 2:, Arm/Group Title: Placebo + Letrozole, Arm/Group Description: Participants took matching Placebo (of alpelisib 300 mg once daily/buparlisib 100 mg once daily or 5 days on/2 days off ',\n",
       " 'patient had provided a signed study ICF prior to any screening procedure, Patient was a female 18 years of age, Patient has an ECOG performance status of 0-1, Patient has a unilateral (multifocal or multicentric disease allowed), histologically confirmed, newly diagnosed early breast cancer >2cm by clinical examination and/or >1.5 cm confirmed by ultrasound or MRI. patient has tumor tissue available for central review of ER, HER2 and PI3K status with centrally confirmed HER2- MUGA scan or ECHO, Patient has active cardiac disease or a history of cardiac abnormalities as defined in the protocol, Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKM120. Patient is currently receiving chronic treatment with corticosteroids or another immunosuppressive agent. ast cancer survivor, speak English or Spanish, Exclusion Criteria:, Inability to understand spoken English and/or Spanish and/or Cognitive impairment that precludes informed consent. ',\n",
       " 'the participants will answer questions on the tablet-PC to calculate their breast cancer risk. the program will immediately generate a personal feedback report containing information about her risk factors. ',\n",
       " 'LYMPHADENOPATHY 0/101 (0.00%), FEBRILE NEUTROPENIA 20/101 (0.00%), ATRIAL FIBRILLATION 1/101 (0.99%), ARRHYTHMIA 20/101 (0.00%), CARDIAC FAILURE 22/101 (1.98%), CORONARY OSTIAL STENOSIS 20/101 (0.00%), LACRIMAL DISORDER 0/101 (0.00%), BLINDNESS 21/ ',\n",
       " '3/31 (9.68%), Edema: limb * 2/31 (6.45%), Neutrophils/granulocytes (ANC/AGC) * 0/31 (0.00%), Cardiac General - Other (Specify,__) * [2]0/31 (0.00%), Left ventricular diastolic dysfunction * 0/31 (0.00%), Supraventricular and nodal arrhythmia. ',\n",
       " '18/50 (36.00%), Hypotension 0/50 (0.00%), Bradycardia 0/50 (0.00%), Cardiac Arrest 1/50 (2.00%), Diarrhea 2/50 (4.00%), Pain - Abdominal 1/50 (2.00%), Vomiting 0/50 (0.00%), Nausea 0/50 (0.00%), Dehydration 0/50 (0.00%), Diverticular Abscess 1/50 (2.00%), ',\n",
       " 'breast cancer survivors over 20 years-old, premenopausal at the time of diagnosis, treated with operation and chemotherapy, newly developed dyspareunia after cancer treatment, Exclusion Criteria:, recent ( 2 months) start or cessation of hormonal treatment (tamoxifen etc.), depression or other psychological problems, active vaginal infection, evidence of cancer recurrence, previously use of lactate-containing lubricants. ',\n",
       " 'Letrozole of 12.5 mg/day is given for three successive days just prior to the second MRI. healthy volunteers will be first screened for MRI contraindications. MRI workflow will be performed as follows. nts will be scanned in the first and second year, respectively. nts will be compared to prior FLASH-DCE methods. nts will be scanned in the first and second year. 10 and 30 patients will be scanned in the first and second year. SWIFT-DCE diagnostic performance will be comparable. ',\n",
       " 'postmenopausal status defined as cessation of menses for >1 year or FSH > 20 mIU/mL (within the past month), Age 21 years, No prior chemotherapy, radiation therapy, or surgery within 6 months of study entry. ',\n",
       " 'patients must have histologically confirmed adenocarcinoma with HER2/neu immunohistochemistry 3+ or FISH-amplified breast cancer with a ratio of 2.0, Tumor size of 3 cm and node-negative disease. nodes with single cells or tumor clusters  0.2 mm by H&E or IHC are considered node-negative. bilirubin must be 1.5 X institutional upper limit of normal (ULN), transaminases (SGOT or SGPT) 3.0 x ULN. LVEF by ECHO (with strain if possible) with LVEF of 50%. ast cancer., pregnant or breastfeeding patients. patients with concurrently active second malignancy. patients with unstable angina, congestive heart failure, or with a history of a myocardial infarction within 12 months. ',\n",
       " 'inTERVENTION 2:, All Study Participants, PA Compression Image Sets, All image sets (30 TC compression image sets) were evaluated for acceptability of overall clinical image quality by two (2) readers. ',\n",
       " 'participants received a daily dose of 5 tablets of lapatinib (1250 mg) at approximately the same time every day, either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast. participants also received capecitabine 2000 mg/m2) per day (divided and administered orally twice daily, 12 hours apart), for 14 days, every 21 days. participants received study medication until disease progression, unacceptable toxicity, or participant withdrawal. patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy, during 6 weeks of radiation therapy, and at least 2 weeks after radiation therapy) patients undergo radiation therapy QD 5 days a week for 6 weeks. ',\n",
       " 'an AE was defined as any untoward medical occurrence in a participant administered SC Herceptin. examples included unfavorable/unintended signs and symptoms, new or exacerbated disease, recurrence of intermittent condition, deterioration in laboratory value or other clinical test. percentage of participants with at least 1 AE during the treatment period was reported. participants received SC Herceptin as 600 mg every 3 weeks for a total of 18 doses/cycles. each dose was administered from a pre-filled SID. ',\n",
       " '59/199 (29.65%), Anaemia 7/199 (3.52%), Thrombocytopenia 2/199 (1.01%), Atrial fibrillation 1/199 (0.50%), Cardiac arrest 1/199 (0.50%), Cardiopulmonary failure 1/199 (0.50%), Left ventricular failure 1/199 (0.50%), Supraventricular tachycardia 0/199 (0.00%), Ventricular tachycardia 1/199 (0.50%), Adverse Events ',\n",
       " \"breast cancer, clinical stage I-III disease, Measurable disease defined as 1 unidimensionally measurable lesion 20 mm by conventional techniques OR 10 mm with spiral CT scan, HER2/neu 3+ by immunohistochemistry or positive by fluorescent in situ hybridization. no known brain metastases, Hormone receptor status unspecified, PATIENT CHARACTERISTICS:, Menopausal status not specified, Male or female, Life expectancy > 12 weeks, ECOG performance compounds of similar chemical or biologic composition to lapatinib, no ongoing or active infection, no symptomatic congestive heart failure, no unstable angina pectoris, no cardiac arrhythmia, no psychiatric illness or social situation that would preclude study compliance, no other uncontrolled illness, no gastrointestinal tract disease that would preclude ability to take oral medication, no malabsorption syndrome, no requirement for IV alimentation, no uncontrolled inflammatory GI disease (e.g., Crohn' cortisone (50 mg/day), Hydrocortisone (40 mg/day), Prednisone ( 10 mg/day), Methylprednisolone ( 8 mg/day), Phenytoin, Carbamazepine, Phenobarbital, Efavirenz, Nevirapine, Rifampin, Rifabutin, Rifapentine, Hypericum perforatum (St. John's wort), Mod inistration of study drug, no other concurrent investigational agents, no other concurrent anticancer therapy, including chemotherapy, radiotherapy, immunotherapy, or antitumor hormonal therapy, no concurrent herbal (alternative) medicines, no concurrent combination antiretroviral therapy for HIV-positive patients, Concurrent bisphosphonates allowed. \",\n",
       " 'atrial fibrillation 1/2240 (0.04%), Cardiac ischemia/infarction 2/2240 (0.09%), Valvular heart disease 1/2240 (0.04%), Endocrine 1/2240 (0.04%), Ocular - Other 1/2240 (0.04%), Colitis 2/2240 (0.09%), Diarrhea 1/2240 (0.04%), Dysphagia 1/2240 (0.04%), Gastritis 1/2240 (0.04%), Adverse Events 2:, Total: 13, Agranulo effusion 0/61 (0.00%), gastric ulcer haemorrhage 1/61 (1.64%), Melaena 1/61 (1.64%), Fatigue 1/61 (1.64%), Multi-organ failure 1/61 (1.64%). ',\n",
       " 'high-dose Chemotherapy, Carboplatin + Cyclophosphamide. target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion. ',\n",
       " 'inclusion Criteria: female patients, 18-70 years of age; histologically-proven invasive breast cancer; no prior or current neoplasm except for non-melanoma skin cancer. exclusion Criteria: pregnant or lactating women; pre-operative local treatment for breast cancer; clinically significant cardiac disease. ',\n",
       " 'Febrile neutropenia * 10/107 (9.35%), Neutropenia * 1/107 (0.93%), Left ventricular dysfunction * 0/107 (0.00%), Angina pectoris * 0/107 (0.00%), Cardiac failure congestive * 0/107 (0.00%), Diarrhoea * 2/107 (1.87%), Abdominal strangulated hernia * 0/107 (0.00%), Pyrexia * 1/107 ( ',\n",
       " 'patients must have histologically or cytologically confirmed early stage, ER-positive (Allred score 3), invasive breast cancer that is not either locally advanced by criteria other than size or inflammatory. patients must be candidates for surgical removal of the tumor by lumpectomy or mastectomy. patients must have a performance status 1 by Zubrod criteria. women of child-bearing potential must agree to use adequate contraception. negative serum pregnancy test must be obtained within 72 hours of receiving the first dose of the hormonal therapy. patients may not have received prior chemotherapy or endocrine therapy. patients must not have known brain or CNS disease, evidence of brain or CNS metastases or carcinomatous meningitis. patients must not have an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection. patients will be excluded if there is a known history of human immunodeficiency (HIV) virus infection, or a known history of hepatitis B or C infection. ',\n",
       " 'placebo cream applied to palms and soles twice daily. placebo cream applied to placebo cream. ',\n",
       " 'age 21, Diagnosis of breast cancer, Stage III, IV, or Stage I or II with metastasis or recurrence, Able to perform basic ADLs, Undergoing chemotherapy and/or hormonal therapy for breast cancer, Able to speak and understand English, Have access to a telephone, Able to hear normal conversation, Cognitively oriented to time, place, and person. ',\n",
       " '20/52 (38.46%), Febrile bone marrow aplasia * 5/52 (9.62%), Febrile neutropenia * 6/52 (11.54%), Leukopenia * 6/52 (11.54%), Atrial tachycardia * 1/52 (1.92%), Tooth loss * 1/52 (1.92%), Hyperthermia * 1/52 (1.92%), Malaise * 1/52 (1.92%), Pyrexia * 1/52 ( ',\n",
       " 'participants receive training on how to self-monitor their diet using the SparkPeople tool. participants receive weekly motivational reminders to log into the website for 3 months via email, text, or phone. participants enter maintenance phase for 3 months without reminders. tion, Yoga Intervention, Yoga: Yoga sessions, INTERVENTION 2:, Arm 2: Educational Wellness Group, Educational Wellness Group, education: Educational Wellness Group, education: educational wellness group, education: educational wellness group. ',\n",
       " '3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/minINTERVENTION 1:, Meso BioMatrix Acellular Peritoneum Matrix. after tissue expansion, the tissue expander was replaced with a breast implant during the second stage of reconstruction. ',\n",
       " 'inTERVENTION 1:, Neratinib 40 mg, Neratinb 40 mg qd, INTERVENTION 2:, Neratinib 80 mg, Neratinib 80 mg qd_______________________________________________________________ ',\n",
       " 'Anaemia 0/149 (0.00%), Febrile neutropenia 7/149 (4.70%), Neutropenia 1/149 (0.67%), Pancytopenia 1/149 (0.67%), Atrial fibrillation 2/149 (1.34%), Cardiac failure congestive 0/149 (0.00%), Abdominal pain 0/149 (0.00%), Diarrhoea 2/149 (1.34%), Dyspepsia 0/149 (0.00%), a fracture 1/95 (1.05%), Tibia fracture 1/95 (1.05%), Intervertebral disc protrusion 0/95 (0.00%), Adverse Events 2:, Total: 3/20 (15.00%), Febrile neutropenia 0/20 (0.00%), Neutropenia 0/20 (0.00%), Atrial fibrillation 1/20 (5.00%), Vomiting 0/20 (0.00%), Pryexia 0/20 (0.00%), Anaphylactic shock 0/20 ',\n",
       " 'resected specimen from surgery must be histologically free of invasive adenocarcinoma and ductal carcinoma in-situ. resected specimen must be histologically free of invasive adenocarcinoma and ductal carcinoma in-situ. patients of childbearing potential must implement adequate non-hormonal contraceptive measures during study treatment. patients of childbearing potential must implement adequate non-hormonal contraceptive measures. ticipation in another clinical trial with any investigational not marketed drug within 30 days before study entry. ',\n",
       " 'Outcome Measurement:, Recurrence-free Survival, 2 years for the primary analysis + 3 additional years for secondary analysis. Time frame: 5 years, Results 1:, Arm/Group Title: Ketorolac 30 mg, Arm/Group Description: Active drug to be compared with placebo, Ketorolac 30 mg IV, Overall number of participants Analyzed: 96, Measure Type: Count of participants, Unit of Measure: Participants 80 83.3%, Results 2:, Arm/ ',\n",
       " 'patients may have received adjuvant or neoadjuvant chemotherapy as long as treated was completed >12 months prior to relapse. prior hormonal therapy in the adjuvant or metastatic setting is permitted. imit of normal (ULN) or =5 x ULN in, presence of liver metastases, Total bilirubin =1.5 x ULN or calculated creatinine clearance of, >=40 ml/min, International normalized ratio (INR) =1.5 or prothrombin time (PT)/partial, thromboplastin time (PTT) within normal limits (WNL) of the institution. uria >=2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate 1 g of protein in 24 hours to be eligible. patients with previous history of invasive cancers (including breast cancer) are eligible if definitive treatment was completed more than 5 years prior to initiating current study treatment. patients with active brain metastases or meningeal metastases must be able to understand the investigational nature of the study. l patients must be able to understand the investigational nature of the study and give written informed consent prior to study entry. all patients with reproductive potential must agree to use effective contraception from time of study entry until at least 3 months after the last administration of study drug. uncontrolled hypertension defined as systolic blood pressure >150 mmHg or diastolic pressure >100 mmHg, despite optimal medical management. patients with clinical history of hemoptysis or hematemesis cannot be enrolled in this trial. history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to beginning bevacizumab. patients may not receive any other investigational or anti-cancer treatments while participating in this study. patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period. patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus) or its excipients. uations that would limit compliance with study requirements. ',\n",
       " 'Adverse Events 1:, Total: 12/538 (2.23%), Hypertension 0/538 (0.00%), Acoustic Neuroma 1/538 (0.19%), Diarrhea 0/538 (0.00%), Colitis 1/538 (0.19%), Elevated ALT or AST enzyme 7/538 (1.30%), Diagnosis of Uterine cancer 0/538 (0.00%), Motorcycle accident 0/538 (0.00%), Fall 0/538 (0.00%), Surgery 3/5 ',\n",
       " 'Sinus Tachycardia * 0/15 (0.00%), Acute coronary syndrome * 0/15 (0.00%), Obstruction Gastric * 0/15 (0.00%), Vomiting * 0/15 (0.00%), Duodenal ulcer * 0/15 (0.00%), Lipase Increased * 0/15 (0.00%), Adverse Events 2:, Total: 11/35 (31.43%), Sinus Tachycardia * 1/35 (2.86%), Acute coronary syndrome * 1/3 ',\n",
       " 'Febrile neutropenia * 0/41 (0.00%), Diarrhea * 1/41 (2.44%), Stomach pain * 1/41 (2.44%), Fever * 2/41 (4.88%), Cytokine release syndrome * 1/41 (2.44%), Skin infection * 2/41 (4.88%), Urinary tract infection * 1/41 (2.44%), Coagulopathy * 0/41 (0.00%), INR increased * 0/41 (0.00%), Lipase increased * ',\n",
       " 'CBR is defined as the percentage of participants receiving at least one dose of study medication who achieved a best overall response. a \"complete response\" is defined as the disappearance of all target or non-target lesions. \"stable disease\" is neither \"partial response\" nor \"disease progression\" ly administered at 1000 mg per square meter (mg/m2) twice daily on the first day through the fourteenth day of each 21-day cycle. overall number of participants Analyzed: 51, Measure Type: Number, Unit of Measure: percentage of participants 59____________________________________________________ ',\n",
       " 'angina pectoris 0/6 (0.00%), Pericardial effusion 0/6 (0.00%), Diplopia 0/6 (0.00%), Abdominal pain 0/6 (0.00%), Colitis 0/6 (0.00%), Gastritis 0/6 (0.00%), Nausea 0/6 (0.00%), Vomiting 0/6 (0.00%), Fatigue 0/6 (0.00%), General physical health deterioration 0/6 (0.00%), Generalised oe DIAL EFFUSION 0/2 (0.00%), TACHYCARDIA 0/2 (0.00%), ABDOMINAL PAIN 0/2 (0.00%), ABDOMINAL PAIN UPPER 0/2 (0.00%), Adverse Events 2:, Total: 0/1 (0.00%), ANAEMIA 0/1 (0.00%), FEBRILE NEUTROPENIA 0/1 (0.00%), LYMPHADENOPATHY 0/1 (0.00%) ',\n",
       " 'the systemic tumor response refers to the response at the time of best overall response. the response criteria are specially adapted from Response Evaluation Criteria in Solid Tumor for Immunotherapies. tion, Imiquimod, Overall Number of Participants Analyzed: 12, Measure Type: Number, Unit of Measure: proportion of tumors.25 (.06 to.57), Results 2:, Arm/Group Title: CTX/IMQ/RT, Arm/Group Description: Week -1 (day-7): cyclophosphamide 200mg/m2 IV as single infusion, Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, ',\n",
       " 'postmenopausal breast cancer (adenocarcinoma) estrogen (ER) and/or progesterone (PR) receptor positive that is locally advanced or locally recurrent and not able to be surgically removed OR with measurable and/or disease that is able to be assessed including isolated bone metastasis, Female patients 18 years or older. sient ischemic attacks in the last 6 months, no symptoms of peripheral vascular disease, no history of abdominal fistula, gastrointestinal perforation or intrabdominal abscess in the past 6 months. no known hypersensitivity to phosphate, trehalose or polysorbate, no serious non-healing wound, ulcer or bone fracture. ',\n",
       " 'Lapatinib,Whole Brain Radiation,Herceptin, Lapatinib before and during Whole Brain Radiation Therapy (WBRT), then Herceptin 4mg/kg IV weekly. ',\n",
       " 'clinical benefit rate is defined as complete response, partial response, or stable disease according to RECIST 1.1. subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC have centrally confirmed AR+ status. gx-024 softgel capsules will be administered once daily to a total dose of 18 mg, GTx-024. overall number of participants Analyzed: 52, Measure Type: Number, Unit of Measure: participants 15__ ',\n",
       " 'patients apply 2.5 mL mometasone furoate cream once daily to the treatment area as in arm A.INTERVENTION 1:, Afatinib monotherapy, Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets. patients could have dose reduced if 40 mg was not tolerated. n or 25 mg/m2 Vinorelbine concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy. ',\n",
       " 'BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization. the primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip. all DXA scans were evaluated by a central reader. unit of measure: Percent Change 0.37 (-6.98 to 15.21) ',\n",
       " 'CR is complete disappearance of all target lesions. PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions. disease assessments occurred every 6 cycles. IV administered once per cycle, MRI- Baseline, Cycle 2 Day 1 and every 2 cycles. one, 60 mg tablet daily of each 21 day cycle. number of Cycles: until progression or unacceptable toxicity develops. velops., Overall Number of Participants Analyzed: 7, Measure Type: Number, Unit of Measure: percentage of participants 14 (.4 to 58) ',\n",
       " 'disease free survival (DFS) defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 2.75 years. participants were to be switched to exemestane 25 mg QD. after 2.5 years to 3 years of tamoxifen, participants were to be switched to exemestane 25 mg QD. overall number of participants analysed: 4868, Measure Type: Number, Unit of Measure: Events. ',\n",
       " 'unilateral breast cancer with ipsilateral lumpectomy or mastectomy and lymph node dissection (sentinel biopsy or axillary dissection), stage II or III unilateral secondary upper extremity lymphedema. girth 2 cm circumferential difference and/or volume 200 mL compared to the uninvolved upper extremity at any 4 cm segment. 0 (morbid obesity) ',\n",
       " 'the needle is advanced to the tissue plane between the pectoralis major and pectoralis minor muscle at the vicinity of the pectoral branch of the acromiothoracic artery. 10 mL of 0.5% ropivacaine is deposited at the level of the third rib between the pectoralis minor muscle and the serratus anterior muscle. ',\n",
       " 'Adverse Events 1:, Total: 5/25 (20.00%), Hypertension 1/25 (4.00%), Dehydration 1/25 (4.00%), Infection With Normal Anc or Grade 1 or 2 Neutrophils 2/25 (8.00%), Pain 1/25 (4.00%), Dyspnea (Shortness Of Breath) 2/25 (8.00%). ',\n",
       " 'administration by an applicator inserted deep inside the vagina Dose: 1 g of gel containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application. inTERVENTION 2:, Placebo Vaginal Gel, Route: Vaginal. ',\n",
       " 'time to progression is defined as the time from treatment start until objective tumor progression. progression is defined per Response Evaluation Criteria in Solid Tumors (RECIST)v1.0 guidelines as a measurable increase in the smallest diameter of any target lesion. mg every 28 days., Overall Number of Participants Analyzed: 41, Median (95% Confidence Interval), Unit of Measure: Months 26.94. ',\n",
       " '111/669 (16.59%), leukocytes * [1]1/669 (0.15%), Hemoglobin * [2]0/669 (0.00%), CNS cerebrovascular ischemia * [1]0/669 (0.00%), CNS cerebrovascular ischemia * [3]0/669 (0.00%), Heart Failure * [1]3/669 (0.45%), Thrombosis/embolism * [3]0/669 (0.00%), Ad ',\n",
       " 'Sunitinib (SU011248) orally (PO) for 2 weeks every 3 weeks (2 weeks on, then 1 week off = Schedule 2/1) starting on day 2 (Cycle 2, Day 3 only for those subjects included in the PK study); starting dose 37.5 milligrams (mg daily) daily (QD) SU012662 C1D2: 6.0 (2.0 to 24.0), SU012662 C2D3: 6.0 (4.0 to 24.0), Total drug C1D2: 6.0 (2.0 to 8.0) ',\n",
       " 'tumor must be Her 2/neu 3+ by IHC (must be confirmed by Ohio State University pathology) or positive FISH, Histological confirmation of invasive breast cancer either from the original diagnosis and/or diagnosis of metastatic disease. a positive bone scan is allowed as the only site of disease. ilirubin 1.5 x ULN and liver enzymes (AST, ALT, or alkaline phosphatase) must have an ANC (absolute neutrophil count) > 1.5, platelets > 100,000, Hemoglobin >9.0 within 21 days of registration. no more than one prior Trastuzumab/chemotherapy or Trastuzumab/biotherapy combination for metastatic disease. patients may have received prior cisplatin or carboplatin for metastatic disease. no active infection at time of registration. pregnant women may not participate in trial. exclusion Criteria: evidence of metastatic disease, except ipsilateral (same side) axillary lymph nodes. previous systemic or local primary treatment. ',\n",
       " 'Tamoxifen or Letrozole, tamoxifen or letrozole work in treating women with ductal carcinoma in situ, letrozole, letrozole citrate, conventional surgery, neoadjuvant therapy. ',\n",
       " 'patients will be treated with HDR brachytherapy using Mammosite ML as a boost technique prior to standard external beam radiation after lumpectomy for breast cancer or DCIS. in 5 consecutive working days, inTERVENTION 2:, Boost, patients will be treated with HDR brachytherapy using Mammosite ML as a boost technique prior to standard external beam radiation after lumpectomy for breast cancer or DCIS. physioTouch: treatment 3 times a week for 4 weeks to the lymphedematous upper limb. ymph fluid, resulting in reductions in interstitial fluid. ',\n",
       " 'inTERVENTION 1:, Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi. ',\n",
       " 'disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions. a measurable increase in a non-target lesion, or the appearance of new lesions. week 12: 16 30.8%. ',\n",
       " 'Febrile neutropenia 0/95 (0.00%), Neutropenia 0/95 (0.00%), Pleuropericarditis 0/95 (0.00%), Vomiting 0/95 (0.00%), Pryexia 0/95 (0.00%), Anaphylactic shock 1/95 (1.05%), Gastroenteritis 0/95 (0.00%), Fibula fracture 1/95 (1.05%), Tibia fracture 1/95 (1.05%), Intervertebral disc ',\n",
       " \"women with prior histologically documented diagnosis of breast cancer. Subjects with metastatic disease who have already received and failed at least one chemotherapy regimen for metastatic disease. Subjects for whom trastuzumab treatment is not indicated, no longer effective or refused by the subjects. Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) = 2.5 x upper limit of normal. Amylase and lipase = 1.5 x the upper limit of normal. subjects with liver involvement of their cancer have the right to withdraw from the study at any time. patients must not be undergoing acute steroid therapy or taper (chronic steroid therapy is acceptable if the dose is stable for 1 month prior to and ft. the subject must not undergo acute steroid therapy or taper. subjects with seizure disorders requiring medication (such as steroid or anti-epileptics), history of organ allograft, Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results. pregnant or breast-feeding subjects must have a negative pregnancy test performed within seven days prior to the start of study drug. any bone marrow transplant or stem cell rescue within 4 months of the start of study drug, Radiotherapy during the study or within 3 weeks of the start of study drug, Use of biologic response modifiers, such as G-CSF, within 3 weeks of study entry, Investigational drug therapy outside of this trial. \",\n",
       " 'Sinus tachycardia * 1/10 (10.00%), Blurred vision * 1/10 (10.00%), Dyspnea * 2/10 (20.00%)Adverse Events 1:, Total: 13/24 (54.17%), FEBRILE NEUTROPENIA 5/24 (20.83%), HAEMATOTOXICITY 0/24 (0.00%), LYMPHADENOPATHY 0/24 (0.00%), PERICARDIAL EFFUSION 1/24 ',\n",
       " 'inTERVENTION 1:, no Cholecalciferol, Enrolled women with serum 25 (OH)D greater than or equal to 30 ng/ml received no intervention. ',\n",
       " 'Death not assoc w CTCAE term- Death NOS1/22 (4.55%), Liver dysfunction/failure1/22 (4.55%), Sodium, low (hyponatremia)1/22 (4.55%), Dyspnea (shortness of breath)2/22 (9.09%). ',\n",
       " 'inTERVENTION 1:, Low Dose Magnesium Oxide (800 mg/Day), Week 2:, Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)., Week 3:, Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD). ',\n",
       " 'During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application., LA-EP2006: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle eligible patients receive Neulasta® s.c. post chemotherapy application. ',\n",
       " 'outcome:, Event-free Survival, Event-free survival of patients treated for inflammatory (Stage IIIb) and responsive stage IV breast cancer with BUMELTT and PBSC support and low dose immunotherapy with IL2 and GM-CSF. ',\n",
       " 'Lesion >= 10 mm on CT scan (5 mm sections), Lesion >= 20 mm on CT scan or MRI (10 mm sections), Lytic bone lesions that are >= 10 mm on MRI, lesion >= 10 mm on physical exam. no brain metastases diagnosed within the past 6 months OR previously untreated brain metastases, Estrogen receptor-positive and/or progesterone receptor-positive. ECOG 0-2, More than 3 months, Absolute neutrophil count >= 1,500/mm3 Platelet count >= 100,000/mm3 No bleeding diathesis, Bilirubin = 1.5 times upper limit of normal (ULN AST and ALT = 2.5 times ULN, Systolic blood pressure (BP)  150 mm Hg and diastolic BP  100 mm Hg on at least one reading prior to study entry. no ongoing or active infection, no psychiatric illness or social situation that would preclude study compliance, no other active invasive malignancy within the past 5 years except nonmelanoma skin cancer or treated carcinoma in situ of the cervix, no other uncontrolled illness, More than 4 weeks since prior chemotherapy, No more than 2 prior chemotherapy regimens for metastatic disease. exclusion criteria:, estrogen receptor status unknown, history of myocardial infarction within 6 months, performance status 3, performance status 4, premenopausal, progesterone receptor status unknown, HIV positive. ',\n",
       " '26/69 (37.68%), Anaemia 2/69 (2.90%), Febrile neutropenia 3/69 (4.35%), Neutropenia 4/69 (5.80%), Cardiac arrest 1/69 (1.45%), Cardiac failure congestive 1/69 (1.45%), Pericardial effusion 1/69 (1.45%), Abdominal pain 1/69 (1.45%), ascite 2/69 (1.45%), Gastritis 1/69 (1.45%), Gastriti ',\n",
       " 'Adverse Events 1:, Total: 18/115 (15.65%), Febrile neutropenia * 7/115 (6.09%), Neutropenia * 1/115 (0.87%), Pancytopenia * 1/115 (0.87%), Diarrhoea * 0/115 (0.00%), Stomatitis * 0/115 (0.00%), Vomiting * 1/115 (0.87%), Asthenia * 1/115 (0.87%), Mucosal inflammation * 0/115 ',\n",
       " 'histologically confirmed breast cancer meeting criteria: primary tumor 3 cm by mammography, ultrasound, or palpation AND/OR palpable axillary lymph nodes > 1 cm. HER2 3+ or FISH (fluorescent in situ hybridization)+, Age 18 years, No prior trastuzumab. HER2/neu-negative tumor must be localized by exam or ultrasound to allow tumor injection, No stage IV or metastatic disease, HER2/neu-negative tumor by IHC, If 2+ or in the indeterminate range, further testing of HER2/neu overexpression by fluorescent in situ hybridization (FISH) is required. Fertile patients must use effective contraception during and for up to 6 months following completion of study therapy. ition that would interfere with study assessments and procedures or preclude study participation, PRIOR CONCURRENT THERAPY:, No prior chemotherapy or radiotherapy. ',\n",
       " 'patients must have cytologically/histologically documented locally advanced or metastatic breast cancer with either:, Progression on treatment with any aromatase inhibitor for metastatic disease;, Recurrence after having completed adjuvant tamoxifen for at least 12 months;, Patient who are not candidates for or are intolerant of aromatase inhibitor treatment;, patients are allowed (but not required to have one prior chemotherapy regimen for metastatic disease. women of childbearing age must have a negative pregnancy test. women must use an effective method of contraception during the study. women must have a negative pregnancy test. patients must not have received tamoxifen for metastatic disease. patients must be disease-free of prior invasive malignancies for > 5 years. patients must have discontinued their prior therapies for breast cancer and radiation therapy for a minimum of 3 weeks. patients are excluded if radiation therapy was given to a single measurable lesion. women with evidence of visceral crisis are not eligible for this study. women of 18 years of age or older will not be eligible. women who are pregnant will not be eligible. psychiatric or addictive disorders or other conditions would preclude the patient from meeting the study requirements. ',\n",
       " 'colitis [1]1/81 (1.23%), Multiple Sclerosis Relapse 1/81 (1.23%), Neurotoxicity [2]2/81 (2.47%), Community-acquired pneumonia 1/81 (1.23%), Local Infection Reservoir Area 1/81 (1.23%)Adverse Events 1:, Total: 20/52 (38.46%), Anaemia 0/52 (0.00%), Pancytopenia 1/52 (1.92%), Acute myocardial infarction 0/ ',\n",
       " 'participants receive training on how to self-monitor their diet using the SparkPeople tool. participants receive weekly motivational reminders to log into the website for 3 months via email, text, or phone. participants enter maintenance phase for 3 months without reminders. tion, Yoga Intervention, Yoga: Yoga sessions, INTERVENTION 2:, Arm 2: Educational Wellness Group, Educational Wellness Group, education: Educational Wellness Group, education: educational wellness group, education: educational wellness group. ',\n",
       " 'CNS objective response rate is the percentage of participants that achieve CNS complete or partial response as follows. complete resolution of all measurable (>= 1 cm in longest dimension [LD]) and non-measurable brain metastases, No new CNS lesions, Stable or decreasing steroid dose, No new/progressive tumor-related neurologic signs or symptoms, No progression of extra-CNS disease as assessed by RECIST. treatment duration was a median (range) of 8 cycles (1-20) which approximates months given the 4 week cycle length. participants received treatment until disease progression in either CNS or non-CNS site. objective response rate (ORR), Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. ',\n",
       " 'Edema, limb 1/31 (3.23%), Thrombosis1/31 (3.23%), diarrhea1/31 (3.23%), Pain 2/31 (6.45%), Pain, back1/31 (3.23%), Pain, extrimity limb 1/31 (3.23%), Syncope 1/31 (3.23%), hyponatremia 1/31 (3.23%), fever1/31 (3.23%), AST 1/31 (3.23%), infection1/31 (3.23%), anorexia 1/31 (3.23% ',\n",
       " 'Adverse Events 1:, Total: 8/101 (7.92%), Vertigo * 1/101 (0.99%), Infected lymphocele * 1/101 (0.99%), Ejection fraction decreased * 5/101 (4.95%), Lymphoedema * 1/101 (0.99%) ',\n",
       " \"the patient (male or female) is at least 18 years old at the time of signature of the informed consent form. the patient is diagnosed with confirmed invasive breast cancer with stage IV disease. the last dose of trastuzumab should not have been given less than three weeks before the first ASCI administration. a tumor lesion from the patient biopsied before or during screening shows either: overexpression of the HER2 protein, as determined by immunohistochemistry. ch a lesion is sufficiently easily accessible. the patient has at least one measurable lesion according to RECIST criteria. a serum bilirubin level 1.5 times the ULN and both AST and ALT levels 3 times the ULN will be accepted. the patient has a baseline Left Ventricular Ejection Fraction (LVEF) measured by MUGA scan equal to or greater than the LLN for the radiology facility. if the patient is female, she must be of non-childbearing potential. e, combined or progestogen oral contraceptives, injectable progestogen, implants of levonorgestrel, oestrogenic vaginal ring, percutaneous contraceptive patches or intrauterine device (IUS), vasectomy with documented azoospermia. azoospermia refers to outcome of investigator's medical examination of subject or review of subject's medical history for study eligibility. the patient must not be included in the study. the patient is receiving treatment with bisphosphonate UNLESS the biphosphonate treatment was initiated more than three weeks before the first ASCI administration. the patient has known coronary artery disease, arrhythmia requiring treatment, clinically significant valvular disease, cardiomegaly on chest X-ray, ventricular hypertrophy (found by ECG) or previous myocardial infarction. the patient has current active hepatic or biliary's disease. the patient has a known family history of congenital or hereditary immunodeficiency. the patient has any uncontrolled bleeding disorder or coagulation disorder or thrombocytopenia or pro-thrombotic disorder. the patient has a known hypersensitivity reaction or idiosyncrasy to drugs chemically related to Lapatinib. the patient has any other condition that might jeopardize the patient's safety. \",\n",
       " '14/41 (34.15%), Cardiac ischemia/infarction 2/41 (4.88%), Duodenal ulcer 1/41 (2.44%), Vomiting 2/41 (4.88%), Fever 2/41 (4.88%), Death NOS 1/41 (2.44%), Liver failure 1/41 (2.44%), Infection - port site 2/41 (4.88%), Infection - urinary tract 1/41 (2.44%), Disease progression 3/41 (7.32%), Confusion 1/41 (2.4 ',\n",
       " 'inTERVENTION 1:, Arm I: Yoga Therapy, Patients participated in a Hatha yoga session over 90 minutes twice weekly for 12 weeks. patients recorded their practice time in weekly logs. ',\n",
       " 'breast cancer according to immunohistochemistry, measured or evaluable-only disease, human epidermal growth factor receptor 2+ (HER2+) or HER2- breast cancer, Males and females 18 years of age, Females are post menopausal or surgically sterile, Recurrent or progressive advanced breast cancer (locally-advanced or metastatic) ng adenocarcinoma is defined as HER-2+ by immunohistochemistry. prior adjuvant Trastuzumab therapy is permitted. patients must not be eligible for therapy of known curative potential for metastatic cancer. orma, psoriasis, multiple sclerosis, hemolytic anemia, immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, or other rheumatologic disease is acceptable. not pregnant, and on appropriate birth control if of child-bearing potential. no history of other malignancies within the prior five years. adenocarcinoma is not amplified for HER-2/neu gene expression by at least 2-fold by FISH analysis, or that is less than IHC 3+ when FISH negative. ejection fraction less than lower limit of facility normal by multi-gated acquisition (MUGA) scan, or 45% by echocardiogram. tion therapy, or biologic therapy (except Trastuzumab) within 28 days prior to treatment on study. participation in an investigational new drug trial within 28 days prior to treatment on study. ',\n",
       " '7/37 (18.92%), gr 3port infection, 1/37 (2.70%), flu 1/37 (2.70%), Febrile Neutropenia 1/37 (2.70%), gr 4 sepsis, intubated [1]1/37 (2.70%), Diarrhea gr 2, Nausea gr 3, infection gr 3 1/37 (2.70%), infection normal ANC/viral grade 1 1/37 (2.70%), dehydration 3, Diarrhea 3, Vomit 3, HGB3, Nausea 3, K Vertigo1/503 (0.20%), Nausea7/503 (1.39%), Vomiting5/503 (0.99%), Diarrhoea1/503 (0.20%), Abdominal Pain1/503 (0.20%), Ascites1/503 (0.20%), Adverse Events 2:, Total: 64/247 (25.91%), Febrile Neutropenia3/247 (1.21%), Neutropenia0/247 (0.00%), Anaemia2/247 (0.81%), ',\n",
       " 'febrrile Neutropenia 1/39 (2.56%), heart failure 1/39 (2.56%), Diarrhea 3/39 (7.69%), Nausea/vomiting 4/39 (10.26%), Mucositis 3/39 (7.69%), infection 3/39 (7.69%), Urinary tract infection 2/39 (5.13%), Musculoskeletal pain 6/39 (15.38%), Syncope 1/39 (2.56%), Insomnia 3/39 (7.69 ',\n",
       " 'atrial fibrillation 0/214 (0.00%), Cardiac failure congestive 0/214 (0.00%), Pericardial effusion 1/214 (0.47%), Cataract 0/214 (0.00%), Macular fibrosis 0/214 (0.00%), Constipation 2/214 (0.93%), Diarrhoea 2/214 (0.93%), Enterocolitis 0/214 (0.00%), Ileus 1/214 (0.47%), Nause ',\n",
       " 'Febrile neutropenia 0/95 (0.00%), Neutropenia 0/95 (0.00%), Pleuropericarditis 0/95 (0.00%), Vomiting 0/95 (0.00%), Pryexia 0/95 (0.00%), Anaphylactic shock 1/95 (1.05%), Gastroenteritis 0/95 (0.00%), Fibula fracture 1/95 (1.05%), Tibia fracture 1/95 (1.05%), Intervertebral disc ',\n",
       " 'POMS-F is the Profile of Mood States - fatigue scale. it ranges from 0 to 28; higher values indicate greater fatigue. overall number of participants Analyzed: 122, Least Squares Mean (Standard Error), Unit of Measure: units on a scale 6.96 (0.71) ',\n",
       " 'neoadjuvant chemotherapy comprises sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks. patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks. ',\n",
       " 'Adverse Events 1:, Total: 8/56 (14.29%), Platelets * 1/56 (1.79%), Heart failure * 1/56 (1.79%), Diarrhea * 1/56 (1.79%), Infection with normal ANC or Grade 1 or 2 neutrophils - Bladder (urinary) * 1/56 (1.79%), Sodium, serum-low (hyponatremia) * 1/56 (1.79%), Fracture * 2/56 (3.57%) ',\n",
       " 'Adverse Events 1:, Total: 4/26 (15.38%), Febrile neutropenia * 1/26 (3.85%), Gastric volvulus * 20/26 (0.00%), General Malaise * 21/26 (3.85%), Hospitalisation for intrapleuric chemotherapy and thoracentesis * 21/26 (3.85%), Acute renal failure * 21/26 (3.85%), Adverse Events 2:, Total: 1/28 (3.57%), Febrile neutropenia * 0/ ',\n",
       " 'testosterone vaginal cream was supplied in pre-filled syringes. each 0.5 mL dose delivered 300 mcg of testosterone daily. treatment repeats every 21 days for 4 courses. patients receive trastuzumab IV once every 3 weeks for up to 52 weeks. starting 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks. given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: correlative studies. given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: correlative studies. ',\n",
       " 'ECOG performance status of 0 or 1, Histologically confirmed estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor 2 (HER2)-negative adenocarcinoma of the breast. locally advanced disease must not be amenable to resection with curative intent, Measurable disease. prior exposure to experimental treatment targeting rapidly accelerated fibrosarcoma (Raf), MAP kinase/ERK kinase (MEK) or the mitogen-activated protein kinase (MAPK) pathway, Brain metastases (symptomatic or nonsymptomatic) that have not been treated previously, are progressive, or require any type of therapy (e.g., radiation, surgery, or steroids) atezolizumab-Specific Exclusion Criteria (Cohorts II and III Only), history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins. idiopathic pulmonary fibrosis (including pneumonitis), drug induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest computed tomography scan. prior treatment with cluster of differentiation (CD) 137 (CD137) agonists or immune checkpoint blockade therapies, including anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), anti-programmed death-1 (anti-PD-1) or anti-programmed death ligand-1 (anti-PD-L1) therapeutic antibodies, treatment with systemic immunostimulatory agents (including but not limited to interferons or interlukin-2 [IL-2]) within women at any age with early stage breast cancer (stage I-II) and American Society of Anesthesiologists score of I-II. Exclusion Criteria: women at any age with early stage breast cancer (stage I-II) and American Society of Anesthesiologists score of I-II. cs within prior 3 months,, History of immunodeficiency, Having a remote infection,, Denial of signing the consent form. ',\n",
       " 'Anaemia * 0/109 (0.00%), leukopenia * 0/109 (0.00%), Cardiac failure * 0/109 (0.00%), Pyrexia * 1/109 (0.92%), Hepatic function abnormal * 1/109 (0.92%), Arthritis bacterial * 0/109 (0.00%), Lung infection * 0/109 (0.00%), Haemoglobin decreased * 1/109 (0.92%), Neutrophil count decreased * 0 ',\n",
       " 'Cohort A: Advanced Triple-Negative Breast Cancer (TNBC), 6 mg/kg IMGN853 IV Q3W. ',\n",
       " 'Coagulopathy 1/98 (1.02%), Febrile neutropenia 7/98 (7.14%), Pancytopenia 2/98 (2.04%), Cardiac failure 0/98 (0.00%), Cardiac failure congestive 0/98 (0.00%), Pericardial effusion 0/98 (0.00%), Appendicitis perforated 1/98 (1.02%), Colitis 1/98 (1.02%), Ileus 1/98 (1.02%), Ab ',\n",
       " '13/83 (15.66%), Cardiac failure congestive 1/83 (1.20%), Hypothyroidism 1/83 (1.20%), Nausea 2/83 (2.41%), Vomiting 2/83 (2.41%), Diarrhea 1/83 (1.20%), Gastrointestinal Haemorrhage 1/83 (1.20%), Asthenia 1/83 (1.20%), Hyperbilirubinaemia 1/83 (1.20%), Dehydration 3/ Gastrointestinal haemorrhage 0/10 (0.00%), death - unknown cause 0/10 (0.00%), Thrombosis in device 0/10 (0.00%) ',\n",
       " 'Febrile neutropenia 1/26 (3.85%), Neutropenia 0/26 (0.00%), Thrombocytopenia 0/26 (0.00%), Cardiac failure congestive 0/26 (0.00%), Extrasystoles 0/26 (0.00%), Nausea 1/26 (3.85%), Abdominal pain 0/26 (0.00%), Constipation 0/26 (0.00%), Gastrointestinal haemorrhage 0/ ',\n",
       " 'Inclusion Criteria:, Pregnant women, Patients who have had previous ipsilateral breast or thoracic radiation therapy. ',\n",
       " 'inclusion criteria:, no history of breast cancer, palpable breast mass, abnormal nipple discharge, or other focal complaints warranting diagnostic mammogram. ',\n",
       " 'no evidence of T4, N2-3, or M1 disease prior to surgery, node positive or high-risk node negative, prior breast-conserving therapy (BCT) and axillary node dissection or sentinel node biopsy required. patients with microscopically focally positive margins are candidates for breast radiotherapy plus a boost to the lumpectomy site. hemotherapy and/or hormonal therapy, high risk of regional and systemic recurrence due to one of the following:, Primary tumor greater than 5 cm, Primary tumor greater than 2 cm and less than 10 axillary lymph nodes excised and one of the following:, Estrogen receptor negative, Skarf-Bloom-Richardson grade 3, Lymphovascular invasion, Hormone receptor status known. us nonmalignant renal disease, Cardiovascular:, no serious nonmalignant cardiovascular disease, Pulmonary:, No serious nonmalignant pulmonary disease, Other:, Not pregnant or nursing, Fertile patients must use effective contraception, No other serious nonmalignant disease that would preclude definitive surgery or radiotherapy. radiotherapy:, See Disease Characteristics, Surgery:, See Disease Characteristics_. ',\n",
       " 'the subject must be female and 18 years of age or older. the subject must be a preoperative clinical Tis, T1, T2, T3, T4, as well as clinical N0 and clinical M0 breast cancer. the subject has a positive pregnancy test or is lactating. the subject has had prior surgery to the indicated breast. ',\n",
       " 'Results 1:, Arm/Group Title: AZD4547 80mg bd Cont + Ex 25mg, Arm/Group Description: 80 mg AZD4547 BD continuous + 25 mg exemestane, Overall Number of participants Analyzed: 5, Measure Type: Number, Unit of Measure: Participants 5, Results 2:, Arm/Group Title: AZD4547 40mg Cont + Ex 25mg, Arm/Group Description: 40 mg AZD4547 BD continuous + 25 ',\n",
       " 'HER-2/neu, defined as FISH negative or 0, 1+, or 2+ by IHC, Stage IV disease, Does not overexpress HER-2/neu, defined as FISH negative or 0, 1+, or 2+ by IHC, Stage IV disease, Must not be eligible for therapy of known curative potential for metastatic breast cancer, Measurable or evaluable disease. systemic immunosuppression includes inflammatory bowel disease, Systemic vasculitis, Scleroderma, Psoriasis, Multiple sclerosis, Hemolytic anemia or immune-mediated thrombocytopenia, Rheumatoid arthritis, Systemic lupus erythematosus, Sjogren syndrome, Sarcoidosis, Other malignancies within the past 5 years, except carcinoma in situ of the cervix, superficial nonmela ecur, No allergy to corn, PRIOR CONCURRENT THERAPY:, See Disease Characteristics, More than 28 days since prior and no other concurrent chemotherapy, radiation therapy, or biologic therapy (except trastuzumab), Concurrent endocrine therapy and supportive therapy with bisphosphonates allowed, More than 28 days since prior and no other concurrent participation in an investigational new drug trial. osis of noninvasive breast cancer is OK., must have adequate bone marrow, renal and liver function., Pregnant or lactating females not allowed., Preexisting peripheral neuropathy must be equal to or less than grade 1, must have archived tumor tissue for tissue testing. ',\n",
       " 'Total: 21/82 (25.61%), Neutrophils count decreased 1/82 (1.22%), Cardiac ischemia/infarction 1/82 (1.22%), Hypertension 1/82 (1.22%), Supraventricular and nodal arrhythmia 1/82 (1.22%), Anorexia 1/82 (1.22%), Gastrointestinal perforation 1/82 (1.22%), Vomiting 1/82 (1.22%), Dehydration 1/82 (1.22%), Diar ',\n",
       " 'a bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual. the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two separate individuals during the same visit. ',\n",
       " 'patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy. external beam radiation therapy (EBRT): Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks. ',\n",
       " '5/26 (19.23%), Febrile neutropenia 1/26 (3.85%), Abdominal pain 0/26 (0.00%), Constipation 0/26 (0.00%), Nausea 1/26 (3.85%), Pancreatitis 1/26 (3.85%), Vomiting 2/26 (7.69%), Pain 0/26 (0.00%), Pneumonia 0/26 (0.00%), Urinary tract infection 1/26 (3.85%), Lumbar vertebral fracture 1/2 ',\n",
       " 'infection with normal absolute neutrophil count (ANC) or grade 1 or 2 neutrophils * 21/72 (1.39%)Adverse Events 1:, Total: 52/133 (39.10%), Thrombocytopenia 2/133 (1.50%), Anaemia 1/133 (0.75%), Vertigo 0/133 (0.00%), Vomiting 3/133 (2.26%), Nausea 1/133 (0.75%), Colitis 1/133 (0.75%), Constipation 1/ dominal pain 2/67 (2.99%) ',\n",
       " 'time frame: 24 Weeks, Results 1:, Arm/Group Title: Arm I, Arm/Group Description: Patients receive donepezil hydrochloride PO QD. given PO, overall number of participants Analyzed: 31, Mean (Standard Error), Unit of Measure: percentage of participants 71.0 (8.3), Results 2:, Arm/Group Title: Arm II, Arm/Group Description: Patients receive placebo PO QD. ',\n",
       " 'radioactive occult lesion localization, hook wire, or other method of localization required for nonpalpable lesions. at least 1 micrometastatic (i.e., no greater than 2 mm) sentinel lymph node with no extracapsular extension, no clinical evidence of distant metastases. ormance status, Not specified, Life expectancy, Not specified, Hematopoietic, Not specified, Hepatic, See Disease Characteristics, Renal, Not specified, Other, Not pregnant or nursing, No other prior or concurrent malignancy except:. ',\n",
       " 'patients and healthy volunteers will be screened for MRI contraindications. the SWIFT MRI workflow will be performed as follows: an IV line is placed by nurse. ncer patients and healthy volunteers will be first screened for MRI contraindications. the SWIFT MRI workflow will be performed as follows. 10 and 30 patients will be scanned in the first and second year. patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Hydrophor daily, starting at the onset of radiation therapy (RT) and continuing until 2 weeks after the final RT session or until the RT site is healed. patients should not apply the Hydrophor within 4 hours of receiving RT. Medihoney application should include the entire treatment area. patients should not apply the Medihoney within 4 hours of receiving RT. patients should wash the application area daily with soap and tap water. ',\n",
       " 'ascites 2/25 (8.00%), Diarrhea 1/25 (4.00%), Nausea 1/25 (4.00%), Pancreatitis 1/25 (4.00%), Small intestinal obstruction 1/25 (4.00%), Vomiting 1/25 (4.00%), Bile duct obstruction 1/25 (4.00%), Portal hypertension 1/25 (4.00%)Adverse Events 1:, Total: 6/19 (31.58%), Febrile neutropenia [1]1/19 (5.26%), Fatigue [1] ',\n",
       " 'Adverse Events 1:, Total: 1/25 (4.00%), Diarrhoea 0/25 (0.00%), Breast cellulitis 0/25 (0.00%), Syncope 1/25 (4.00%), Adverse Events 2:, Total: 1/20 (5.00%), Diarrhoea 1/20 (5.00%), Breast abscess 1/20 (5.00%), Syncope 0/20 (0.00%). ',\n",
       " 'Neutropenia [1]0/77 (0.00%), Left ventricular dysfunction 0/77 (0.00%), Cardiac ischemia 0/77 (0.00%), Colitis 0/77 (0.00%), Febrile neutropenia 0/77 (0.00%), Pulmonary/upper respiratory infection 0/77 (0.00%), Diverticulitis 0/77 (0.00%), Motor neuropathy 0/77 (0.00%), Endometrial mucosa thinkening ',\n",
       " 'inTERVENTION 1:, Low Dose Magnesium Oxide (800 mg/Day), Week 2:, Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD)., Week 3:, Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD). ',\n",
       " '5/45 (11.11%), Neutrophils/granulocytes (ANC/AGC) * [1]0/45 (0.00%), Neutrophils/granulocytes (ANC/AGC) * [2]0/45 (0.00%), Diabetes decompensation * 0/45 (0.00%), Diarrhea * [2]0/45 (0.00%), Mucositis/stomatitis and Vomiting * [3]0/45 (0.00%), ',\n",
       " 'decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology. decision support workshop will be 2 hours in duration on the morning of the consultation. sonal experience, inTERVENTION 2:, standard care, pre-consultation education, standard care, routine pre-consultation education. sonal experience, inTERVENTION 2:, standard care, routine pre-consultation education, standard care. ',\n",
       " 'Rectal bleeding1/44 (2.27%), Chest pain2/44 (4.55%), Fever1/44 (2.27%), Catheter site infection1/44 (2.27%), Neutrophil count decreased1/44 (2.27%), Dizziness1/44 (2.27%)Adverse Events 1:, Total: 331/1634 (20.26%), Anemia 3/1634 (0.18%), Coagulation disorders 1/1634 (0.06%), Leukopenia 18/1634 (1.10%), Lymphadenopathy ',\n",
       " 'patients who have not received preoperative chemotherapy must have at least 2cm of disease in the largest diameter by clinical or radiographic findings. must have completed preoperative (neoadjuvant) chemotherapy with either a standard regimen (containing an anthracycline and/or a taxane) or on a clinical trial, HER2 positive tumors must have received at least one prior trastuzumab-based therapy, and may not receive concurrent trastuzumab therapy and vaccination  surgery should have occurred more than 28 days but within 12 weeks prior to enrollment. may receive concurrent hormonal therapy, such as tamoxifen, ovarian suppression, and aromatase inhibitors. primary tumor or metastasis must overexpress HER2. must have received 1-2 prior chemotherapeutic regiments for metastatic breast cancer. must have been off treatment for at least three weeks. mmunosuppressive agent, other malignancies in the past 3 years, except for adequately treated carcinoma of teh cervix or basal- or squamous-cell carcinoma of the skin, Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001. tive patients, Known hypersensitivity to RAD001 (everolimus) or other rapamycins. ',\n",
       " \"the patient must be greater than/equal to 18 years old. the diagnosis must have been made by core needle biopsy or limited incisional biopsy. the patient must have a primary breast tumor greater than/equal to 2.0 cm. alkaline phosphatase and AST may not both be greater than the ULN. patients with either skeletal pain or alkaline phosphatase that is greater than ULN but less than/equal to 2.5 x ULN are eligible for inclusion in the study if a bone scan or positron emission tomography does not demonstrate metastatic dialysis. patients with suspicious findings on bone scan or PET scan are eligible if suspicious findings are confirmed as benign by x-ray, magnetic resonance imaging (MRI), or biopsy. patients with AST or alkaline phosphatase greater than ULN are eligible for inclusion in the study. a pre-entry LVEF serves as the baseline for comparing subsequent LVEF assessments. if the baseline LVEF is greater than 65%, the MUGA scan or echocardiogram must be repeated prior to study entry. a sentinel lymph node biopsy for patients with clinically negative axillary nodes is permitted. a sentinel lymph node biopsy for patients with clinically negative axillary nodes is permitted. xception is hormonal therapy, which may have been given for up to a total of 28 days. hormonal therapy must stop at or before study entry and be re-started, if indicated, following chemotherapy. xception may have been given for up to a total of 28 days. tic event within 12 months before study entry. tic event within 6 months before study entry. serious bleeding within 6 months before study entry. europathy greater than/equal to grade 2 as defined by the NCI's Common Terminology Criteria for Adverse Events Version 3.0. conditions that would prohibit administration of corticosteroids. atypical ductal hyperplasia, ductal carcinoma in situ, or lobular carcinoma in situ, Prior random periareolar fine needle aspiration (RPFNA) showing atypical hyperplasia, Family history consistent with hereditary breast cancer, as indicated by 1 of the following criteria. d between days 1-10 of menstrual cycle within 3 months prior to screening baseline RPFNA. Exhibits hyperplasia with or without atypia with or without atypia. treatment, Fertile patients must use effective contraception during and for 3 months after completion of study treatment. ingest recommended dose of calcium and vitamin D for premenopausal bone health (1,200 mg calcium and 800 IU vitamin D daily), Negative pregnancy test prior to receiving study agent, Exclusion Criteria, pregnant or nursing within the past 6 months. ifene, or arzoxifene hydrochloride), Other concurrent chemopreventive agents, Concurrent anticoagulants, Bilateral breast implants. \",\n",
       " 'Afatinib Mono, Afatinib monotherapy administered orally: starting dose 40 mg per day, continuous treatment in a 3-weekly course. if well tolerated, the dose may be escalated to 50 mg. ',\n",
       " 'pCR in the breast was defined as no pathologic evidence of invasive disease (residual ductal carcinoma in situ [DCIS] or lobular carcinoma in situ [LCIS] was allowed) pCR in the axillary lymph node was defined as no evidence of breast cancer cells in the lymph node. 26 weeks of therapy comprised the 2-week run-in phase, 12 weeks of treatment with FEC. rmed, followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-FU 500 mg/m2, epirubicin 75 mg/m2, cyclophosphamide 500 mg/m2 x 4 cycles on Day 1), then paclitaxel (80 mg/m2 x 4 cycles on Day 1, Day 8, and Day 15) in combination with trastuzumab. l Number of Participants Analyzed: 29, Measure Type: Number, Unit of Measure: percentage of participants 45.0__. ',\n",
       " 'digital mammography performed with GE SenoClaire 3D Breast Tomosynthesis. consensus meeting decided whether to recall the woman or not. women selected for further assessment (positive screening exam) recalled. in the weekly logs., inTERVENTION 2:, Arm II: Wait-list, Wait-listed women were told to continue performing their usual activities. after their final assessment they were offered the yoga classes. ',\n",
       " 'women with oligometastatic disease may be included at the discretion of the principal investigator. a standard dose of aromatase inhibitor (AI) therapy must have been completed at the time of study enrollment. treatment with monoamine oxidase inhibitors (MAO-I) within 14 days of enrollment. chronic liver disease, end stage renal disease, or creatinine clearance  30 mL/min as defined by the Cockroft-Gault equation. hospitalization during course of study or compromise study participation. ',\n",
       " 'patients receive radiotherapy and healing touch therapy from a healing-touch therapist once a week for the duration of their radiotherapyINTERVENTION 2:, Control ARM (B) Participants with Stage 0-III breast cancer, women with Stage 0-III breast cancer, treated with breast conserving surgery or mastectomy and clear margins, will receive 15 doses of radiation over three weeks. the boost treatment will be given on the same days as the whole breast treatment. er day x 15 fractions. ',\n",
       " 'ANEMIA 1/486 (0.21%), NEUTROPENIA 4/486 (0.82%), FIBRILLATION ATRIAL 1/486 (0.21%), ABDOMINAL PAIN 2/486 (0.41%), BLOATING 1/486 (0.21%), COLITIS 1/486 (0.21%), DEHYDRATION 5/486 (1.03%), GASTRIC INFLAMMATION 1/486 (0.21%), NAUSEA ANDVOMITING 1/486 (0.21%), Adverse Events 2: ',\n",
       " 'inTERVENTION 1:, Recruitment Population, Pre-randomization recruitment and enrollment. ',\n",
       " 'Adverse Events 1:, Total: 14/67 (20.90%), Febrile Neutropenia * 5/67 (7.46%), Neutropenia * 3/67 (4.48%), Neutropenia * 0/67 (0.00%), Sinus Tachycardia * 0/67 (0.00%), Diarrhea * 0/67 (0.00%), Nausea * 1/67 (1.49%), Vomiting * 1/67 (1.49%), Pancreatitis * 1/67 ',\n",
       " \"participants received pertuzumab and trastuzumab intravenously (IV) plus taxane chemotherapy once of every 3 weeks per treatment cycle. taxane chemotherapy was docetaxel, paclitaxel, or nab-paclitaxel, per the investigator's choice. \",\n",
       " 'subjects were dosed with either the F 627 20 mg/dose PFS or Neulasta® 6 mg/dose as the study drug in each chemotherapy cycle. grade 4 neutropenia was defined as ANC 0.5  109/L within the first 12 days of chemotherapy. 0.2 (0.51), Results 2:, Arm/Group Title: Neulasta. results 2:, Arm/Group Description: 6 mg fixed dose Neulasta. ',\n",
       " 'Febrile neutropenia 3/65 (4.62%), Neutropenia 2/65 (3.08%), Pancytopenia 1/65 (1.54%), Thrombocytopenia 1/65 (1.54%), Myocardial infarction 1/65 (1.54%), Diarrhoea 5/65 (7.69%), Stomatitis 1/65 (1.54%), Vomiting 2/65 (3.08%), Fatigue 1/65 (1.54%), Jaundice  ',\n",
       " 'Nausea * 1/17 (5.88%), Pain - Abdomen NOS * 1/17 (5.88%)Adverse Events 1:, Total: 19/51 (37.25%), Febrile neutropenia 6/51 (11.76%), Anaemia 1/51 (1.96%), Leukopenia 1/51 (1.96%), Neutropenia 1/51 (1.96%), Thrombocytopenia 0/51 (0.00%), Pericarditis 1/51 (1.9 ',\n",
       " 'Anaemia 1/1408 (7.32%), Anaemia 1/1408 (0.07%), Angina pectoris 1/1408 (0.07%), Myocardial infarction 1/1408 (0.07%), Atrial fibrillation 0/1408 (0.00%), Tachycardia 0/1408 (0.00%), Vertigo 0/1408 (0.00%), Diarrhoea 22/1408 (1.56%), Vomiting 12/1408 (0.85%), Constipation 1/170 (0.59%), Diarrhoea 0/170 (0.00%), Gastroenteritis eosinophilic 0/170 (0.00%), Adverse Events 2:, Total: 0/1 (0.00%), Anaemia 0/1 (0.00%), Febrile neutropenia 0/1 (0.00%), Cardiac tamponade 0/1 (0.00%), Myocarditis 0/1 (0.00%), Peri ',\n",
       " 'omega-3 fatty acid: Given PO, laboratory biomarker analysis. patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy. ker Analysis: Correlative studies, Questionnaire administration: ancillary studies. ',\n",
       " 'metS will not exclude participants based on hormone receptivity, one exception is that we will exclude HER2 positive BCS, Pregnant patients, Resistant Hypertension, Steroid-dependent asthma or Chronic obstructive pulmonary disease, Cirrhosis or hepatic failure. those with a secondary cancer (except for nonmelanomatous skin cancers and carcinoma of the cervix in situ) taking weight loss medications, Current involvement in a behavioral program, Neuropsychiatric disorder or dementia. ',\n",
       " 'women with primary breast cancer without ongoing support for substance use. an AUDIT-C score >1 or more than one cigarette smoked per day. ',\n",
       " 'skin metastases are not suitable for or patient refusing definitive surgical resection and radiation. skin metastases are non-responsive (stable or progressing) as assessed by investigator. lobin > or = 9.5 grams/deciliter, platelets >or = 75,000/microliter, total bilirubin. aspartate aminotransferase (AST)/Alanine aminotransferase (ALT)  or = 2.5X institutional upper limit of normal, creatinine  or = 1.5 X institutional upper limit of normal, Informed consent. patients on aspirin and other platelet agents are eligible. patients with known immunodeficiency or receiving immunosuppressive therapies are eligible. sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives. patients must meet laboratory criteria defined in the study within 21 days prior to randomization, Exclusion Criteria:, Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer. tu carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer, Known hypersensitivity to any study medication, Breastfeeding or pregnant. ',\n",
       " 'Febrile neutropenia * 4/78 (5.13%), Neutropenia * 1/78 (1.28%), Thrombocytopenia * 0/78 (0.00%), Acute coronary syndrome * 1/78 (1.28%), Cardiac failure congestive * 1/78 (1.28%), Myocardial infarction * 1/78 (1.28%), Cardiomyopathy * 0/78 (0.00%), Abdominal pain * 1/78 (1.28%), Diarrh Nausea 1/30 (3.33%), Stomatitis/pharyngitis (oral/pharyngeal/mucositis) 1/30 (3.33%), Vomiting 1/30 (3.33%), Adverse Events 2: ',\n",
       " 'progressive disease (PD) was defined as a 20% relative increase in the sum of diameters (SOD) of target lesions, taking as reference the nadir SOD and an absolute increase of >5 mm in the SOD. per protocol, participants remained on assigned treatment until disease progression. participants received ridaforolimus 10 mg orally (PO) every 5 days (QD x 5) plus dalotuzumab 10 mg/kg intravenously (IV) every week (QW) plus exemestane 25 mg PO every day (QD) in 28-day cycles until documented disease progression or unacceptable toxicity. overall number of participants Analyzed: 40, Median (95% Confidence Interval), Unit of Measure: Weeks 23.29 (8.71 to 38. measure: Weeks 31.86 (16.00 to 39.29) ',\n",
       " '18/70 (25.71%), Cardiac arrest 1/70 (1.43%), Pericardial effusion 1/70 (1.43%), Ear pain 1/70 (1.43%), Blurred vision 1/70 (1.43%), Eye disorders - Other, specify 2/70 (2.86%), Abdominal Pain 5/70 (7.14%), Colitis 1/70 (1.43%), Diarrhea 2/70 (2.86%), Nausea 2/70 (2.86%), Death NOS  ',\n",
       " 'Adrenal insufficiency * 1/32 (3.13%), Endocrine disorder * 1/32 (3.13%), Chills * 1/32 (3.13%), Fatigue * 1/32 (3.13%), Fever * 1/32 (3.13%), Multi-organ failure * 1/32 (3.13%), Infection * 1/32 (3.13%), Sepsis * 1/32 (3.13%)Adverse Events 1:, Total: 30/112 (26.79%), Thrombocytopenia 1/112 (0.89% ',\n",
       " 'metastatic disease amenable to biopsy, Unresected tumor with no intention to undergo resection during study, Archival tissue from primary diagnosis or fresh biopsy from metastatic cancer site required. measurable disease only for phase II study, Available tumor estrogen (ER), progesterone (PR), and HER2 status from metastatic site tested by IHC or FISH OR results from the original tumor diagnosis. se can be treated with known standard therapy that is potentially curative or definitely capable of extending life expectancy, no known CNS metastasis, Hormone-receptor status:, ER and PR positive or negative (phase I), ER and PR negative (phase II), PATIENT CHARACTERISTICS:, ECOG performance status 0-1 (phase I) or 0-2 (phase II), Postmenopausal defined by 1 of the following: 60 years of age, 45 years illing to provide blood samples for correlative research purposes. no uncontrolled or intercurrent illness including, but not limited to, any of the following: Ongoing or active infection, Symptomatic congestive heart failure, Unstable angina pectoris, Cardiac arrhythmia, Psychiatric illness and/or social situations. no congenital long QT syndrome or QTcF>450 msec, including:, Complete left bundle block or use of a permanent cardiac pacemaker, history or presence of ventricular tachyarrhythmias, clinically significant resting bradycardia (50 beats per minute), no congestive heart failure requiring use of maintenance therapy for life-threatening ventricular arrhythmias. ors or inducers___________________________________________________________________________________________________________ ',\n",
       " 'Adverse Events 1:, Total: 50/198 (25.25%), Anaemia 1/198 (0.51%), Febrile neutropenia 1/198 (0.51%), Leukocytosis 1/198 (0.51%), Leukopenia 2/198 (1.01%), Neutropenia 1/198 (0.51%), Pancytopenia 0/198 (0.00%), Atrial fibrillation 0/198 (0.00%), Pericardial effusion 1/198 (0.51%), Supraventricular ',\n",
       " 'metastases must have demonstrated progression of brain metastases after prior treatment for brain metastases. new lesions in the CNS on an imaging study (contrast-enhanced CT scan or MRI), Progressive lesions on an imaging study (contrast-enhanced CT scan or MRI), New or progressive lesions that do not meet measurable disease definition allowed. ECOG performance status 0-2, Life expectancy 1 month, Hemoglobin 10 g/dL (transfusion allowed), ANC 1,500/mm3, Granulocyte count 1,500/mm3, Platelet count 100,000/mm3, Creatinine 1.5 mg/dL, Total bilirubin 1.5 times upper limit of normal (ULN), AST and ALT 3 times ULN. patients on an enzyme-inducing anti-epileptic agent (EIAE) or valproic acid are eligible if they are switched to an alternate non-EIAE medication, Concurrent coumadin allowed, No prophylactic use of filgrastim (G-CSF) during first course of treatment. ',\n",
       " 'inTERVENTION 2:, Part 1: Dose Escalation: Cohort 1, MM-121 - 20 mg/kg loading dose followed by 12 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV, inTERVENTION 2:, Part 1: Dose Escalation: Cohort 2, MM-121 - 40 mg/kg loading dose followed by 20 mg/kg weekly IV, Paclitaxel - 80mg/m2 weekly IV. ',\n",
       " \"women with prior histologically documented diagnosis of breast cancer. Subjects with metastatic disease who have already received and failed at least one chemotherapy regimen for metastatic disease. Subjects for whom trastuzumab treatment is not indicated, no longer effective or refused by the subjects. Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) = 2.5 x upper limit of normal. Amylase and lipase = 1.5 x the upper limit of normal. subjects with liver involvement of their cancer have the right to withdraw from the study at any time. patients must not be undergoing acute steroid therapy or taper (chronic steroid therapy is acceptable if the dose is stable for 1 month prior to and ft. the subject must not undergo acute steroid therapy or taper. subjects with seizure disorders requiring medication (such as steroid or anti-epileptics), history of organ allograft, Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results. pregnant or breast-feeding subjects must have a negative pregnancy test performed within seven days prior to the start of study drug. any bone marrow transplant or stem cell rescue within 4 months of the start of study drug, Radiotherapy during the study or within 3 weeks of the start of study drug, Use of biologic response modifiers, such as G-CSF, within 3 weeks of study entry, Investigational drug therapy outside of this trial. \",\n",
       " '102/403 (25.31%), Anaemia 1/403 (0.25%), Febrile neutropenia 1/403 (0.25%), Granulocytopenia 0/403 (0.00%), Neutropenia 1/403 (0.25%), Thrombocytopenia 1/403 (0.25%), Cardiac failure 1/403 (0.25%), Vertigo 1/403 (0.25%), Hypercalcaemia of malignancy 0/403 (0.00%), Vision blurred 1/403 (0.25%), Abdominal discomfort ',\n",
       " 'inTERVENTION 1:, Exercise, an acute bout of exercise performed 24 hours prior to each cycle of anthracyclines. no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines. ',\n",
       " 'pCR was defined as no histologic evidence of invasive tumor cells in the surgical breast specimen, axillary nodes, or sentinel node identified after neoadjuvant chemotherapy. participants were treated with intravenous (IV) doxorubicin (60 milligrams per meters squared [mg/m2]) and cyclophosphamide (AC) every 21 days for 4 cycles. weekly paclitaxel (WP) resumed at the same oral dose 4-6 weeks after surgery and was continued daily for 6 months. overall number of participants Analyzed: 93, Measure Type: Number, Unit of Measure: Participants 16_0. ',\n",
       " 'pathologic complete response: no invasive cancer in the residual breast. time frame: 12 weeks, Results 1:, Arm/Group Title: Lapatinib + Trastuzumab. ',\n",
       " 'patients must have measurable disease by the RECIST criteria, defined as at least one lesion that can be accurately measured in at least one diameter (at least 10 mm in longest diameter (LD) by spiral computer tomography (CT) scan, or at least 20 mm by standard techniques. patients must have had prior treatment with anthracycline and a taxane. chemotherapy for advanced/metastatic disease. resolution of all chemotherapy or radiation-related toxicities to less than grade 1 severity, Age 18 years, Age 18 years, Eastern Cooperative Oncology Group (ECOG) Performance Status (APPENDIX 4) of 0 or 1, Life expectancy of 3 months. patients who have received chemotherapy, radiation, hormonal therapy, or Herceptin within 2 weeks of treatment start, Radiation therapy encompassing > 10% of marrow, Failure to recover from any chemotherapy related or other therapy related toxicity at study entry that is clinically significant by the study investigator. patients with central Nervous System metastasis are considered eligible if they have completed local therapy and discontinued from corticosteroids for at least two weeks before starting treatment with E7389. postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. in the past six months, or serious cardiac arrhythmia, patients with organ allografts, patients with known positive HIV status, patients with a prior malignancy, other than carcinoma in situ of the cervix, or non-melanoma skin cancer. unless the prior malignancy was diagnosed and definitively treated 5 years previously with no subsequent evidence of recurrence, patients with pre-existing neuropathy > Grade 1, patients with hypersensitivity to halichondrin B and/or no history of breast cancer, palpable breast mass, abnormal nipple discharge, or other focal complaints warranting diagnostic mammogram. ',\n",
       " \"ER-positive is defined as 1% immunohistochemical (IHC) staining of any intensity. HER2 test result is negative if a single test (or both tests) performed show:, IHC 1+ or 0, In situ hybridization negative based on:, Single-probe average HER2 copy number  4.0 signals/cell. reening visit, OR, are surgically sterile, OR agree to practice 1 effective method of contraception and 1 additional effective (barrier) method, at the same time, from the time of signing the ICF through 90 days (or longer, as mandated by local labeling. reening visit, OR, Are surgically sterile, OR agree to practice 1 effective method of contraception and 1 additional effective (barrier) method, at the same time, from the time of signing the ICF through in the case of known Gilbert's syndrome, a higher serum total bilirubin [ 1.5 x ULN] is allowed, aspartate aminotransferase and alanine aminotransferase 1.5 x ULN, and alkaline phosphatase 1.5 x ULN. consent must be given before performing any study-related procedure not part of standard medical care. patient must be accessible for treatment and follow-up. patient must be willing to undergo breast biopsies. patients with non-melanoma skin cancer or carcinoma in situ are not excluded if they have undergone complete resection. patients with enteric stomata are also excluded. use of antihypertensive agents to control hypertension before week 1 is allowed. use of antihypertensive agents to control hypertension before week 1 is allowed. valvular disease, severe regurgitation, or stenosis by imaging independent of symptom control with medical intervention or history of valve replacement. patients receiving systemic corticosteroids within 1 week before administration of the first dose of the study drugs. patients unwilling or unable to comply with study protocol. patients previously treated with hormonal therapy (tamoxifen, AI) or PI3K, AKT, dual PI3K/mTOR, TORC1/2, or mTORC1 inhibitors. \",\n",
       " 'Adverse Events 1:, Total: 27/50 (54.00%), Febrile neutropenia * 4/50 (8.00%), Anaemia * 1/50 (2.00%), Neutropenia * 1/50 (2.00%), Diarrhoea * 1/50 (2.00%), Gastritis * 1/50 (2.00%), Nausea * 1/50 (2.00%), Oesophagitis * 1/50 (2.00%), Pyrexia * 7/50 (14.00%), intravascular coagulation 20/238 (0.00%), Febrile neutropenia 21/238 (0.42%), Lymphadenopathy 21/238 (0.42%), Neutropenia 21/238 (0.42%) intravascular coagulation 20/238 (0.00%), Febrile neutropenia 21/238 (0.42%), lymphadenopathy 21/238 (0.42%) ',\n",
       " 'Subjects will only be included in the study if they meet all of the following criteria: Subjects who have given informed consent, Subjects that agree not to drink alcoholic beverages or use any drugs during the study, Age: at least 18 years old, Patients with local, locally advanced or metastatic HER2+ breast carcinoma as diagnosed on biopsied tissue by immunohistochemistry. diolabeled compounds with a long half-life (>7h) for diagnostic or therapeutic purposes within the last 2 days. patients with absolute contra-indications for thyroid blockage with potassium iodide. patients with abnormal liver: ALT/AST > 2 times normal values; bilirubin > 1.5 time normal values. patients who participated in a previous trial with anti-HER2 VHH1 will not be included in the study if one of the following criteria applies: Pregnant subjects, Breast feeding subjects, Subjects with occupational exposure to ionizing irradiation, Subjects with clinical significant disease or on concomitant therapy. subjects with previous thyroid disorders received radiolabeled compounds with a long half-life (>7h) within the last 2 days. the investigator would either compromise subject safety or interfere with the evaluation of the safety of the test radiopharmaceutical. Subjects who cannot communicate reliably with the investigator, Subjects who are unlikely to cooperate with the requirements of the study, Subjects at increased risk of death from a pre-existing concurrent illness. ',\n",
       " 'anastrozole PO QD, letrozole PO QD, or exemestane PO QD for 6 weeks. courses repeat every 8 weeks in absence of disease progression or unacceptable toxicity. original doses were reduced following an Urgent Safety Measure in august 2012 due to a large proportion of patients requiring a dose reduction or treatment delay due to incidences of myelo-suppression. ',\n",
       " 'IPASINTERVENTION 1:, Zr89-trastuzumab PET/CT, Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm. ',\n",
       " 'the surgery follows 1-7 days after the second FLT PET scan. patients receive oral capecitabine and oral lapatinib ditosylate. courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. cixutumumab: Given IV, lapatinib ditosylate: Given PO and capecitabine: Given PO. ',\n",
       " '67/349 (19.20%), Anaemia * 3/349 (0.86%), Leukopenia * 1/349 (0.29%), Neutropenia * 3/349 (0.86%), Thrombocytopenia * 1/349 (0.29%), Atrial fibrillation * 2/349 (0.57%), Cardiac arrest * 1/349 (0.29%), Cardiac failure acute * 0/349 (0.00%), Cardio-respiratory arrest * 2/349 (0.57%), Cardiovascular ',\n",
       " \"age 18 and 85 years, Postmenopausal status defined as: no menstrual cycle in the past 12 months hysterectomy with bilateral oophorectomy hysterectomy with intact ovaries if age > 55 years. no menstrual cycle in the past 12 months hysterectomy with bilateral oophorectomy hysterectomy with intact ovaries if age > 55 years, Newly diagnosed with incident, primary, invasive, estrogen receptor positive clinical stage II or current (past 30 days) regular (at least once per week) use of reproductive hormone therapy, Tamoxifen, aromatase inhibitors, or other estrogen inhibitors, flaxseed, or antibiotics. history of Crohns' disease, ulcerative colitis, irritable bowel syndrome, celiac sprue, or other malabsorption syndrome, diverticulitis, diverticulosis, or other bowel diagnosis. \",\n",
       " 'inclusion Criteria:, Patient must provide informed consent, Patient must be 18 years of age. women of childbearing age unable or unwilling to use contraception. estrogen receptor positive women, aged 20 years and over, with operable and measurable breast cancer who have provided written informed consent. unwillingness to stop taking any drug known to affect sex hormone status. ',\n",
       " 'inTERVENTION 1:, Placebo Patch, Placebo patch: 1 patch was applied topically to the affected site(s) for 12 hours each day. Letrozole of 12.5 mg/day is given for three successive days just prior to the second MRI. ',\n",
       " '3/31 (9.68%), Edema: limb * 2/31 (6.45%), Neutrophils/granulocytes (ANC/AGC) * 0/31 (0.00%), Cardiac General - Other (Specify,__) * [2]0/31 (0.00%), Left ventricular diastolic dysfunction * 0/31 (0.00%), Supraventricular and nodal arrhythmia. ',\n",
       " 'a bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual. the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two separate individuals during the same visit. ',\n",
       " 'study will be deemed infeasible if more than 4 patients cannot be given treatment because her tumor is such that a dosimetrically satisfactory treatment plan cannot be devised for her. ',\n",
       " 'Hypertension 3/21 (14.29%), Edema 3/21 (14.29%), Nausea 2/21 (9.52%), Fracture 1/21 (4.76%), Dizziness 3/21 (9.52%), Headache 2/21 (9.52%), Dyspnea 2/21 (9.52%), Hypoxia 3/21 (14.29%)Adverse Events 1:, Total: 1/40 (2.50%), Hypertension 0/40 (0.00%), Headache 0/40 (0.00%) ',\n",
       " 'a higher serum total bilirubin ( 1.5 x ULN) is allowed, aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) 3.5 times ULN, alkaline phosphatase 2.5 times ULN. a higher serum total bilirubin ( 1.5 x ULN) is allowed. patients must use effective contraception (barrier method - condoms, diaphragm - also in conjunction with spermicidal jelly, or total abstinence. patient accepts to make available tumor samples for submission to central laboratory. preexisting peripheral neuropathy grade 2, Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled hypertension (180/110), unstable diabetes mellitus, dyspnea at rest, or chronic therapy with oxygen. subjects with ulcerative colitis are also excluded. patients have an active infection and require IV or oral antibiotics. an AUDIT-C score >1 or more than one cigarette smoked per day. ntervention focused on substance use. (Karnofsky Index >70). ',\n",
       " 'a response of PD is defined as a >=20% increase in target lesions. participants were also classified as having PD if their response at Week 12 was unknown or missing. mber of Participants Analyzed: 69, Measure Type: Number, Unit of Measure: percentage of participants Independently Evaluated: 36.2, Investigator Evaluated: 37.7_. ',\n",
       " 'stage I-III invasive breast cancer, stage I-III invasive breast cancer, at least 3 months since completion of all intended local and systemic therapy. at least 1 healthy intact breast, No prior radiotherapy or mastectomy, Prior biopsies allowed, Any hormone-receptor status, PATIENT CHARACTERISTICS:, Female, Pre- or post-menopausal, not pregnant or nursing, Negative pregnancy test. e A (HMG-CoA) reductase inhibitor or any of its components, No concurrent infectious, inflammatory, or autoimmune diseases. standard drink defined as 10 grams of alcohol, equivalent to 285 mL of beer, 530 mL of light beer, 100 mL of wine, or 30 mL of liquor. no selective estrogen receptor modulator or aromatase inhibitor within the past 3 months, no prior estrogen and/or progesterone HRT within the past tion > 8 ounces per day, no other concurrent agents or therapies intended to treat or prevent in situ or invasive breast cancer. ',\n",
       " 'premenopausal, estrogen receptor positive women, aged 20 years and over, with operable and measurable breast cancer who have provided written informed consent. unwillingness to stop taking any drug known to affect sex hormone status. ',\n",
       " 'Cardiac failure acute 0/167 (0.00%), Diarrhoea 5/167 (2.99%), Colitis 2/167 (1.20%), Enterocolitis 1/167 (0.60%), Stomatitis 1/167 (0.60%), Impaired healing 1/167 (0.60%), Sudden death 1/167 (0.60%), Postoperative wound infection2/167 (1.20%), Erysipelas 2/167 (0.60%), Bacterial diarrhoe ',\n",
       " '19/51 (37.25%), Febrile neutropenia 6/51 (11.76%), Anaemia 1/51 (1.96%), leukopenia 1/51 (1.96%), Neutropenia 1/51 (1.96%), Thrombocytopenia 0/51 (0.00%), Pericarditis 1/51 (1.96%), Visual impairment 0/51 (0.00%), Dysphagia 1/51 (1.96%), Abdominal pain 0/51 (0.00%), Chi ',\n",
       " 'patients enrolled in the study will meet standard criteria for whole breast XRT. subjects will be excluded for a number of medical conditions that are contraindications to XRT and/or might confound the relationship among fatigue, and inflammation. subjects using supplements or other natural products with one week of starting medications will be excluded. subjects using supplements or other natural products with one week of starting medications, excluding vitamins and calcium supplementation or at the discretion of the attending physician, will be excluded. patients who are at low risk for disease recurrence are not eligible. additional therapies are allowed including radiotherapy and biologic agents. patients with skeletal pain are eligible provided bone scan and/or roentgenological exam are negative for metastatic disease. Hepatic, Not specified, Renal, Creatinine 2 times upper limit of normal, Creatinine clearance 30 mL/min, No renal failure, Other, Not pregnant or nursing, Negative pregnancy test, Fertile patients must use effective contraception, no history of esophageal stricture or motility disorders, Gastroesophageal reflux disorder allowed, No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in nt therapy allowed, Prior bisphosphonates for bone density allowed, No other concurrent bisphosphonates as adjuvant therapy or for treatment of osteoporosis. Concurrent enrollment on any other locoregional or systemic therapy breast cancer study (including cooperative group studies) allowed. ',\n",
       " 'RECIST 1.1: Complete Response (CR): Disappearance of all non-target lesions. any pathological lymph node must have reduction in short axis to 10 mm. progressive disease (PD): 20% increase in sum of the diameters of target lesions. progressive disease (PD): Substantial, unequivocal progression of existing non-target lesions. PD: Substantial, unequivocal progression of existing non-target lesions. myl 1401OTrastuzumab Intravenously + paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint. overall number of participants Analyzed: 230, Measure Type: Count of Participants, Unit of Measure: Participants Complete Response: 3 1.3%, Partial Response: 157 68.3%, Stable Disease: 48 20 ne 4.8 (4.3 to 5.4), Results 2:, Arm/Group Title: Placebo, Arm/Group Description: [Not Specified], Overall Number of Participants Analyzed: 122, Least Squares Mean (95% Confidence Interval), Percent Change from Baseline -.7 (-1.3 to -.1) ',\n",
       " 'Adverse Events 1:, Total: 3/19 (15.79%), Febrile neutropenia 1/19 (5.26%), Colitis 1/19 (5.26%), Pain in extremity 0/19 (0.00%), Nephrolithiasis 0/19 (0.00%), Pulmonary embolism 1/19 (5.26%), Dyspnoea 0/19 (0.00%), Haematoma 0/19 (0.00%), Adverse Events 2:, Total: 4/30 (13.33%), ',\n",
       " 'objective response rate (ORR), Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response = CR + PR. time frame: up to 2 years. CT: Complete Response (CR), disappearance of all target lesions for a period of at least one month; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (ORR) = CR + PR. only descriptive statistics. ',\n",
       " 'treatment repeated every 4-6 weeks in the absence of disease progression or unacceptable toxicity. some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician. ',\n",
       " 'patient must be postmenopausal defined as meeting one or more of the following criteria: Age 60 years, Amenorrheic for at least 12 months, Surgically sterile- having undergone bilateral oophorectomy,, FSH level in postmenopausal range according to institutional standards. patient must have histological or cytologia. new diagnosis with plans for at least 6 months of neoadjuvant ET or any amount of neoadjuvant ET if surgery is planned. patient must have any one of the following types of breast cancer (primary or metastatic): ER+/PgR+/HER2- or ER+/PgR-/HER2-., PgR+ is defined as Allred score of at least 4 and greater. hepatic lesion eligibility will be made by the principal investigator or sub-investigator. patients with evaluable osseous metastasis may be eligible. patients with evaluable osseous metastasis may be eligible. non-melanoma skin cancer or cervical carcinoma in-situ patients are not eligible to participate. patients with non-measurable non-evaluable lesions pose an imminent risk for cord compression. ',\n",
       " 'locally recurrent disease must not be amenable to surgical resection or radiation with curative intent. subject must have received and progressed on at least one prior standard HER2 directed therapy. subject must have adequate bone marrow, renal and hepatic function. no prior therapy for breast cancer within the past 5 years. no prior therapy for breast cancer within the past 5 years. supplemental vitamin D other than from a standard multiple vitamin or from standard formulations of calcium and vitamin D. history of renal failure requiring dialysis or kidney transplantation. initial treatment of breast cancer will not be with breast-conserving surgery. l condition that would potentially interfere with vitamin D absorption, such as celiac sprue, ulcerative colitis. ',\n",
       " 'INTERVENTION 1:, CMRM Versus UMRM, [Not Specified]__. ',\n",
       " 'FEBRILE NEUTROPENIA 5/24 (20.83%), HAEMATOTOXICITY 0/24 (0.00%), NEUTROPENIA 3/24 (12.50%), LYMPHADENOPATHY 0/24 (0.00%), PERICARDIAL EFFUSION 1/24 (4.17%), APLASIA 0/24 (0.00%), NAUSEA 0/24 (0.00%), PYREXIA 1/24 (4.17%), EX ',\n",
       " 'pCR is defined as absence of invasive cancer in breast or lymph nodes after neoadjuvant chemotherapy. pCR is defined as absence of invasive cancer in breast or lymph nodes after neoadjuvant chemotherapy. patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes, Pertuzumab IV over 30-60 minutes, Docetaxel IV, and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. ',\n",
       " 'treatment repeats every 28 days in absence of disease progression or unacceptable toxicity. ',\n",
       " 'participants who had not progressed and were still alive at the time of clinical cut off were censored at the last disease assessment prior to the missing interval. progression-free survival (PFS) was censored at the last disease assessment prior to the missing interval. overall number of participants Analyzed: 1048, Median (95% Confidence Interval), Unit of Measure: Months 7.4 (7.1 to 7.6), Results 2:, Arm/Group Title: Epoetin Alfa, Arm/Group Description: Participants received SOC plus epoetin alfa 40,000 international units (IU) subcutaneously once a week. ',\n",
       " 'Adverse Events 1:, Total: 9/33 (27.27%), Febrile neutropenia * 1/33 (3.03%), Pyrexia * 2/33 (6.06%), Chest pain * 1/33 (3.03%), Cellulitis * 1/33 (3.03%), Sepsis * 1/33 (3.03%), Hip fracture * 1/33 (3.03%), Back pain * 1/33 (3.03%), Menorrhagia * 1/33 (3.03%), Thrombosis DEHYDRATION 0/53 (0.00%), DIARRHEA 0/53 (0.00%), NAUSEA 1/53 (1.89%), VOMITING 1/53 (1.89%), FEVER 1/53 (1.89%), RIGORS 1/53 (1.89%) ',\n",
       " 'patients will receive Abraxane at 100 mg/m2 X 3 doses on days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on days 1 and 15 for subsequent cycles. patients will be evaluated for response every 8 weeks. Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes. patients will be evaluated for response every 2 cycles (every 8 weeks) ',\n",
       " 'atrial fibrillation 0/4 (50.00%), Dehydration 1/4 (25.00%), Fatigue (asthenia, lethargy, malaise) 1/4 (25.00%), Pain - Back 1/4 (25.00%), Urinary tract infection 0/4 (0.00%), Dyspnea (shortness of breath) 0/4 (0.00%), Pericardial effusion 0/4 (0.00%), Thrombosis 0/4 (0.00%), Skin infection 0/4 ',\n",
       " 'inTERVENTION 2:, Part B Abemaciclib: HR+, HER2+ breast cancer, abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. participants with hormone receptor positive HR+, HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. treatment may continue until discontinuation criteria are met. rticipants may continue to receive treatment until discontinuation criteria are met. ',\n",
       " '3/24 (12.50%), Disseminated intravascular coagulation 0/24 (0.00%), Fatigue 0/24 (0.00%), Hepatic failure 1/24 (4.17%), Alanine aminotransferase increased 1/24 (4.17%), aspartate aminotransferase increased 1/24 (4.17%), Blood bilirubin increased 0/24 (0.00%), Ejection fraction decreased 1/24 (4.17%), Adverse Events 2:, Total: 9/22 ',\n",
       " 'Ejection fraction decreased * 1/69 (1.45%), Intestinal obstruction NOS * 1/69 (1.45%), Diarrhoea NOS * 2/69 (2.90%), Febrile neutropenia * 12/69 (17.39%), mucosal inflammation NOS * 1/69 (1.45%) ',\n",
       " 'tumor must be confined to either the breast or to the breast and ipsilateral axilla. patient must have (according to TNM 7th edition rules) women of childbearing potential must agree to use acceptable non-hormonal contraceptive methods of birth control from the day of the screening pregnancy test and up to 3 months after the last intake of darolutamide. women between menarche and menopause have not been permanently sterilized, capable of procreation. permanent sterilization includes hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy. prior treatment should be stopped at least 28 days prior to registration. prior or concurrent treatment should be stopped at least 28 days prior to registration. congestive heart failure NYHA Class III or IV, severe/unstable angina pectoris, myocardial infarction, uncontrolled hypertension, coronary/peripheral artery bypass graft, high-risk uncontrolled arrhythmias, stroke. any contraindication to oral agents or gastrointestinal disorder or procedure which expects to interfere significantly with absorption of protocol treatment. Known allergy to darolutamide or any of the excipients. major surgery defined as requiring a general anesthesia or respiratory assistance. ',\n",
       " 'negative serum Beta-Human Chorionic Gonadotropin (Beta-HCG) test for women of childbearing potential (premenopausal or not meeting the definition of postmenopausal), women who have not undergone surgical sterilization (i.e., absence of ovaries and/or uterus), women who have not undergone surgical sterilization (i.e., absence of ovaries and/or uterus) men must remain abstinent or use a condom during the treatment period. with pregnant female partners, men must remain abstinent or use a condom. agreement to refrain from donating sperm during this same period. iteria for Adverse Events (NCI CTCAE) history of other malignancies within the previous 5 years except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, synchronous or previously diagnosed HER2-positive breast cancer. history of receiving any anti-cancer drug/biologic or investigational treatment within 21 days prior to enrollment except hormone therapy, which can be given up to 7 days prior to enrollment. for patients who are known carriers of hepatitis B virus, active hepatitis B infection must be ruled out. for patients who are known carriers of hepatitis B virus, active hepatitis B infection must be ruled out. invasive breast cancer:, Primary tumor greater than 1 cm diameter, measured by clinical examination and mammography or ultrasound. any N,, No evidence of metastasis (M0) (isolated supra-clavicular node involvement allowed); over expression and/or amplification of HER2 in the invasive component of the primary tumor. aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) 3.5 times ULN, alkaline phosphatase 2.5 times ULN, Renal status: Creatinine 1.5mg/dL,, Cardiovascular: Baseline left ventricular ejection fraction (LVEF) 3 50% measured by echocardiography (ECHO) or multiple gate acquisition (MUGA) scan. patients with a prior malignancy diagnosed more than 5 years prior to randomization may enter the study. preexisting peripheral neuropathy grade 2, Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure. subjects with ulcerative colitis are also excluded; neoadjuvant cancer therapy. neoadjuvant cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy other than the trial therapies) d require IV or oral antibiotics. patients unwilling or unable to comply with protocol. ',\n",
       " 'PFS was defined as time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause. percentage of participants who had not experienced progression or death by Week 16 is reported. 39.6 (28.1 to 50.8) ',\n",
       " 'Phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. between 6 and 54 patients will likely be necessary to determine the MTD of dasatinib in combination with weekly paclitaxel. the next cohort will test dasatinib given with a different schedule, 5 days on and 2 days off, omitting dasatinib the day prior and the day of administration of paclitaxel. ',\n",
       " 'Febrile neutropenia [1]0/113 (0.00%), anemia with trombocytopenia 0/113 (0.00%), Neutropenia 1/113 (0.88%), paroxism of atrial fibrillation 0/113 (0.00%), Gastrointestinal hemorrhage 1/113 (0.88%), Death for unknown reason 1/113 (0.88%), Diarrhea with vomiting and weakness 0/113 (0.00%), Adverse Events 2:, Total: 13 ',\n",
       " 'Febrile neutropenia 4/120 (3.33%), Leukopenia 2/120 (1.67%), Neutropenia 8/120 (6.67%), Cardiac tamponade 0/120 (0.00%), Ventricular arrhythmia 1/120 (0.83%), Ascite 0/120 (0.00%), Oesophagitis 0/120 (0.00%), Large intestine polyp 0/120 (0.00%), Death 1/120 (0.83%), Coronary artery disease 0/254 (0.00%), Coronary artery stenosis 1/254 (0.39%), Adverse Events 2:, Total: 56/269 (20.82%), Anaemia 1/269 (0.37%), Febrile neutropenia 0/269 (0.00%), Lymphadenopathy 0/269 (0.00%), Acute myocardial infarction 0/269 (0.00%), Angina pectoris 3/269 (1.12%), Angina unstable 1/269 ',\n",
       " '107/383 (27.94%), Anaemia 4/383 (1.04%), Febrile neutropenia 7/383 (1.83%), haemoytique anaemia 0/383 (0.00%), leukopenia 1/383 (0.26%), Neutropenia 6/383 (1.57%), Thrombocytopenia 2/383 (0.52%), Anginal pectoris 1/383 (0.26%), cardiomyopathy 0/383 (0.00%), Ear pain 0/3 ',\n",
       " 'results 1:, Arm/Group Title: Pralatrexate, Arm/Group Description: Study drug 190 mg/m2 for 2 to 4 weeks. overall number of participants Analyzed: 22, Measure Type: Number, Unit of Measure: participants 1________________________________________________________ ',\n",
       " 'Grade 1 is a decline of left ventricular ejection fraction(LVEF) >=10% but 20% of baseline value. Grade 2 is LVEF below LLN (50%) or decline of LVEF >=20% of baseline value. the maximum allowed cumulative dose of PLD was 240 mg/m2. the maximum allowed cumulative dose of PLD was 240 mg/m2. overall number of participants Analyzed: 37, Measure Type: Number, Unit of Measure: participants Grade 1 After Cycle 4 (approx. 84 days): 12, Grade 1 After Cycle 8 (approx. 168 days): 8, Grade 1 After 30 days or more after last cycle: 10, Grade 2 After Cycle 4 (approx. 84 days): 0, Grade 2 After Cycle 8 (approx 168 days): 2, Grade 2 After 30 days or more after last cycle: 5, Grade 3 After Cycle 4 (approx  ',\n",
       " \"the patient must be greater than/equal to 18 years old. the diagnosis must have been made by core needle biopsy or limited incisional biopsy. the patient must have a primary breast tumor greater than/equal to 2.0 cm. alkaline phosphatase and AST may not both be greater than the ULN. patients with either skeletal pain or alkaline phosphatase that is greater than ULN but less than/equal to 2.5 x ULN are eligible for inclusion in the study if a bone scan or positron emission tomography does not demonstrate metastatic dialysis. patients with suspicious findings on bone scan or PET scan are eligible if suspicious findings are confirmed as benign by x-ray, magnetic resonance imaging (MRI), or biopsy. patients with AST or alkaline phosphatase greater than ULN are eligible for inclusion in the study. a pre-entry LVEF serves as the baseline for comparing subsequent LVEF assessments. if the baseline LVEF is greater than 65%, the MUGA scan or echocardiogram must be repeated prior to study entry. a sentinel lymph node biopsy for patients with clinically negative axillary nodes is permitted. a sentinel lymph node biopsy for patients with clinically negative axillary nodes is permitted. xception is hormonal therapy, which may have been given for up to a total of 28 days. hormonal therapy must stop at or before study entry and be re-started, if indicated, following chemotherapy. xception may have been given for up to a total of 28 days. tic event within 12 months before study entry. tic event within 6 months before study entry. serious bleeding within 6 months before study entry. europathy greater than/equal to grade 2 as defined by the NCI's Common Terminology Criteria for Adverse Events Version 3.0. conditions that would prohibit administration of corticosteroids. atypical ductal hyperplasia, ductal carcinoma in situ, or lobular carcinoma in situ, Prior random periareolar fine needle aspiration (RPFNA) showing atypical hyperplasia, Family history consistent with hereditary breast cancer, as indicated by 1 of the following criteria. d between days 1-10 of menstrual cycle within 3 months prior to screening baseline RPFNA. Exhibits hyperplasia with or without atypia with or without atypia. treatment, Fertile patients must use effective contraception during and for 3 months after completion of study treatment. ingest recommended dose of calcium and vitamin D for premenopausal bone health (1,200 mg calcium and 800 IU vitamin D daily), Negative pregnancy test prior to receiving study agent, Exclusion Criteria, pregnant or nursing within the past 6 months. ifene, or arzoxifene hydrochloride), Other concurrent chemopreventive agents, Concurrent anticoagulants, Bilateral breast implants. \",\n",
       " 'ascites 0/90 (0.00%), Nausea 0/90 (0.00%), Vomiting 0/90 (0.00%), Death NOS 1/90 (1.11%), Fever 0/90 (0.00%), Other general disorders, administration site conditions 0/90 (0.00%), Other hepatobiliary disorders 1/90 (1.11%), Lung infection 2/90 (2.22%), Sepsis 2/90 (2.22%), Spinal fracture 0/90 (0.00 ',\n",
       " 'Subject who went through Neoadjuvant period completely (24 weeks) will receive surgery within 3-6 weeks. primary endpoint, Pathological complete response, will be assessed using resected bio-specimens collected in breast and axilla during a surgery. total of 8 treatment cycles of the neoadjuvant treatment, surgery was performed within 3 to 6 weeks from the last dose of study. overall number of participants Analyzed: 248, Measure Type: Number, Unit of Measure: percentage of responders 46.77 (40.43 to 53.19), Results 2:, Arm/Group Title: Herceptin, Arm/Group Description: Patient received Herceptin at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of ',\n",
       " 'MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid. inTERVENTION 2:, Negative Pressure, PhysioTouch (negative pressure massage) treatment 3 times a week for 4 weeks to the lymphedematous upper limb, PhysioTouch: The PhysioTouch is a hand-held device that administers negative pressure under the treatment head. inTERVENTION 2:, Exercise, Exercise Arm: Exercise consisting of progressive walking and resistance band training, Calcitriol pill taken once per week. ',\n",
       " '28/348 (13.79%), Blood/Bone Marrow-Other 1/348 (0.29%), Febrile neutropenia 0/337 (0.00%), Febrile neutropenia 0/337 (0.00%), Hemoglobin 2/337 (0.59%), Atrioventricular block - 2nd degree Mobitz Type II 0/337 (0.00%), Cardiac-ischemia/infarction 1/337 (0.30%), Left ventricular diastolic dysfunction  ',\n",
       " 'Anaemia * 1/52 (1.92%), Febrile neutropenia 24/52 (7.69%), Neutropenia 28/52 (15.38%), Cardiac failure chronic 21/52 (1.92%), Vomiting 23/52 (5.77%), Diarrhoea 21/52 (1.92%), Gastric ulcer 21/52 (1.92%), Gastritis 21/52 (1.92%), Fatigue 21/52 (1.92%), Pyrexia 21/52 (1.92%), Gastro Urinary Tract Infection * 0/8 (0.00%), Enterocolitis infectious * 0/8 (0.00%) ',\n",
       " 'breast cancer subjects on hormonal therapy or trastuzumab only therapy and colorectal cancer subjects on adjunctive therapies not considered cytotoxic chemotherapy are eligible. participants will be allowed to receive concomitant adjuvant endocrine therapy for breast cancer. stomy reversal, Exclusion Criteria:, Concurrent other malignancy or history of other malignancy treated within the past 3 years. the patient is at least 18 years of age at the time of consent. the patient has an ECOG performance stout. the patient has a clinical negative node status at the time of study entry. if of child bearing potential, the patient has a negative pregnancy test within 72 hours prior to administration of Lymphoseek, has been surgically sterilized or has been postmenopausal for at least 1 year. patients with truncal or extremity primary melanoma have had a prior invasive melanoma that would occur on the same body region or potentially draining to the same nodal basin. patients with truncal or extremity primary melanoma have had a prior breast cancer potentially draining to the same nodal basin. preoperative radiation therapy to the affected breast or axilla. had preoperative radiation therapy to the affected breast or axilla. ',\n",
       " 'Febrile neutropenia 4/127 (3.15%), Neutropenia 1/127 (0.79%), Atrial fibrillation 2/127 (1.57%), Cardiac failure 0/127 (0.00%), Left ventricular dysfunction 4/127 (3.15%), Mitral valve disease 1/127 (0.79%), Myocardial ischaemia 1/127 (0.79%), Sinus tachycardia 1/127 (0.79%), Myocardial infarction 1/127 (0.79%), ',\n",
       " 'courses repeat every 7 days for up to 12 weeks in absence of disease progression or unacceptable toxicity. beginning 1 week later, patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once a week for 12 weeks. patients also receive trastuzumab IV over 30-90 minutes once a week for 1 year in the absence of disease progression or unacceptable toxicity. ',\n",
       " 'Adverse Events 1:, Total: 1/6 (16.67%), Goitre 0/6 (0.00%), Haemorrhoid Operation 0/6 (0.00%), Sciatica 0/6 (0.00%), Renal Failure 0/6 (0.00%), Varicose Vein 1/6 (16.67%), Adverse Events 2:, Total: 2/7 (28.57%), Goitre 1/7 (14.29%), Sciatica 1/7 (14.29%), Renal Failure 1/7 (1 ',\n",
       " 'patients with known HER-2 overexpressing MBC must have failed at least one prior trastuzumab-containing regimen for metastatic disease. patients must have failed at least one prior trastuzumab-containing regimen for metastatic disease. toxicity is allowed in case of alopecia, skin toxicity, fatigue and finger numbness. patients must agree to use a medically approved contraception method until at least six weeks after the last study drug administration. patients known to be infected by human immunodeficiency virus. impending need for immediate RT for symptomatic relief. ',\n",
       " \"inTERVENTION 1: BREASTChoice recruited patients scheduled for a plastic/reconstructive consult. investigators identified patients who completed a mastectomy, or were scheduled for one, and considering reconstruction, but didn't have an appointment with a plastic/reconstructive surgeon. investigators recruited patients scheduled for plastic/reconstruction consultation. they recruited patients who completed or scheduled a mastectomy. patients were randomized using computer random assignment. the overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed. the overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed. the overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed. l be 40.5 Gy to the breast and 48.0 Gy to the tumor bed. overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed. \",\n",
       " 'PFS is defined as the number of months from the date of randomization to the earlier of progressive disease (PD) or death due to any cause. from date of randomization to discontinuation due to disease progression or death up to primary completion date. entinostat 5 mg tablet orally once per week on days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor. overall number of participants Analyzed: 64, Median (95% Confidence Interval), Unit of Measure: months 4.28 (3.26 to 5.36) ',\n",
       " 'Febrile neutropenia 5/131 (3.82%), Hemoglobin decreased 7/131 (5.34%), Lymphatics 1/131 (0.76%), Transfusion: pRBCs 0/131 (0.00%), Arrhythmia supraventricular 0/131 (0.00%), Cardiac disorder 1/131 (0.76%), Edema 0/131 (0.00%), Left ventricular failure 0/131 (0.00%), Myocardial ischemia 1/131 ( ',\n",
       " 'stage I-III breast cancer, adjuvant or neoadjuvant anthracycline-based chemotherapy, Exclusion Criteria:, under age 18, pregnancy, metastatic or inoperable (including including inoperable) breast cancer, confounding underlying medical illnesses, history of mania, history of other axis-I psychiatric disorder, physical or psychological impairments. ',\n",
       " 'PFS was defined as time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause. percentage of participants who had not experienced progression or death by Week 16 is reported. 39.6 (28.1 to 50.8) ',\n",
       " 'female patients >=18 years with proven diagnosis of HER2-overexpressing, histologically confirmed breast cancer, Locally advanced or metastatic disease, Must have biopsiable disease, Exclusion criteria:, Prior treatment with HER2-targeted small molecules or antibodies other than trastuzumab. postmenopausal defined as no menses for at least 12 months or bilateral oophorectomy. if a woman has a 20% chance of carrying a BRCA1/2 gene mutation by either model, she will meet eligibility criteria. subjects should be willing to abstain from use of hormonal therapies. tamoxifen, hormone replacement therapy, oral contraceptive pills, hormone-containing intrauterine devices (IUDs) will be offered as supportive care for women with menopausal symptoms. subject must have no evidence of disease at time of enrollment. current or recent use of hormonal medications, e.g. oral contraceptive pills, hormone replacement therapy, tamoxifen, raloxifene, IUD with progestins or corticosteroids. current use of phenytoin, carbamazepine, rifampin due to increased estrogen metabolism. history of bleeding disorder. ',\n",
       " 'blood disorder 1/157 (0.64%), Hemoglobin decreased 1/157 (0.64%), Hemolysis 0/157 (0.00%), Arrhythmia 0/157 (0.00%), Cardiac disorder 0/157 (0.00%), Myocardial ischemia 1/157 (0.64%), Hearing impaired 0/157 (0.00%), Tinnitus 0/157 (0.00%), Cataract 0/157 (0.00%), Glaucoma 0/ ',\n",
       " 'Adverse Events 1:, Total: 8/101 (7.92%), Vertigo * 1/101 (0.99%), Infected lymphocele * 1/101 (0.99%), Ejection fraction decreased * 5/101 (4.95%), Lymphoedema * 1/101 (0.99%) ',\n",
       " 'Adverse Events 1:, Total: 3/30 (10.00%), Cholecystitis * [1]1/30 (3.33%), Increase in diarrhea * [2]1/30 (3.33%), Flank pain * [3]1/30 (3.33%) ',\n",
       " 'early stage breast cancer - stage I (tumor size greater than 1 cm), II and IIA. 3+ HER2 overexpression by IHC or 2+ HER2 overexpression and FISH positivity. postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. final eligibility for clinical trial is determined by the health professionals conducting the trial. sease free for greater than five years are eligible. evidence of sensory and/or peripheral neuropathy. major surgery within 4 weeks of the start of study treatment. ',\n",
       " 'the patient has received adjuvant Tamoxifen therapy for 2-3 years. there is evidence of a local relapse or distant metastasis of breast cancer. the patient must be postmenopausal woman. plasma estradiol must be in the premenopausal range, or, if tamoxifen is administered within the past 3 months, must be in the premenopausal range. either positive estrogen and/or progesterone receptor determination by immunohistochemistry or competitive binding assay on metastatic disease. breast cancer, in situ carcinoma of the cervix, or non-melanomatous skin cancers in the past 5 years. prior treatment with an aromatase inhibitor or inactivator, prior treatment with an luteinizing hormone-releasing hormone (LH/RH) agonist/antagonist, Adjuvant chemotherapy within 6 months of study entry. ',\n",
       " 'patients with node-negative, ER or PR-positive tumors 4 cm in size whose tumors are low risk are not eligible. patients for this study must be FISH negative if immunohistochemical stain is 2+ or 3+ positive; patients with negative, 0 or 1+ immunohistochemical stain for HER-2 are eligible. patients with reproductive potential must use an adequate contraceptive method (e.g., abstinence, intrauterine device, barrier device with spermicide or surgical sterilization) during treatment and for three months after treatment. life expectancy of less than 12 weeks. itivity to Doxil, doxorubicin, cyclophosphamide, cremophore (contained in teniposide, cyclosporine, and vitamin K) or to any component of Avastin, inadequately controlled hypertension (defined as blood pressure of >150/100 mmHg on antihypertensive medication), unstable angina pectoris, history of myocardial infarction or unstable angina within 12 patients must have a 2-d echocardiogram indicating an ejection fraction of > 50% within 42 days prior to first dose of study drug. method used at baseline must be used for later monitoring. no distant metastases on bone scan and on CT scans of chest and abdomen. ration or core needle biopsy within 7 days of beginning therapy, Urine protein:creatinine ratio 1.0 at initial screening, Known hypersensitivity to any component of Avastin, History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of beginning therapy. treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone. neurosurgical resection or brain biopsy performed within 3 months prior to day 1 will be excluded. ',\n",
       " 'patients will be treated with exemestane., exemestane: 25 mg daily by mouth for 6 to 12 months. patients will be treated with docetaxel and cytoxan. ',\n",
       " 'Febrile neutropenia * 6/106 (5.66%), leukopenia * 1/106 (0.94%), Neutropenia * 1/106 (0.94%), Arrhythmia * 1/106 (0.94%), Left ventricular dysfunction * 1/106 (0.94%), Myocardial infarction * 1/106 (0.94%), Supraventricular tachycardia * 0/106 (0.00%), Tachycardia * 0/106 (0.00%), Adverse Events 2: ',\n",
       " 'pathologically and radiologically confirmed metastatic triple negative breast cancer, Up to two prior lines of chemotherapy for metastatic breast cancer, Availability of a representative tumor specimen, At least one measurable lesion, Exclusion Criteria:, Have received previous treatment with PI3K inhibitors, Symptomatic central nervous system metastases (controlled and asymptomatic CNS metastases are acceptable) this study or has not recovered from side effects of such therapy, Major surgery within 28 days of starting therapy or has not recovered from major side effects of a previous surgery. Poorly controlled diabetes mellitus, History of cardiac dysfunction, Currently receiving treatment with QT prolonging medication and the treatment cannot be discontinued or switched to a different medication. use double barrier method for birth control throughout trial. use double barrier method for birth control. ',\n",
       " 'in overweight/obese participants who completed Part A, provide a double dose of letrozole and monitor use for 28 days. measure blood levels of estrogens and vitamin D at start and end of period. ',\n",
       " 'Adverse Events 1: Total: 3/9 (33.33%), Fatigue * 1/9 (11.11%), Non-cardiac chest pain * 1/9 (11.11%), Sepsis * 1/9 (11.11%), Urinary tract infection * 1/9 (11.11%), Syncope * 1/9 (11.11%), Anxiety * 1/9 (11.11%), Thromboembolic event * 1/9 (11.11%) ',\n",
       " 'patients receive 250 mg PO daily PI3K inhibitor BYL719 on days 1-21 and 3.6mg/kg IV over 30-90 minutes on day 1 ado-trastuzumab emtansine (T-DM1). courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Given IV, Pharmacological study: Correlative studies, Laboratory biomarker analysis: Optional correlative studies. ',\n",
       " 'doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m2) x 12 with concurrent standard dose trastuzumab (weekly x 12 then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatin ',\n",
       " 'Anaemia 1/1408 (7.32%), Anaemia 1/1408 (0.07%), Angina pectoris 1/1408 (0.07%), Myocardial infarction 1/1408 (0.07%), Atrial fibrillation 0/1408 (0.00%), Tachycardia 0/1408 (0.00%), Vertigo 0/1408 (0.00%), Diarrhoea 22/1408 (1.56%), Vomiting 12/1408 (0.85%), Constipation 1/170 (0.59%), Diarrhoea 0/170 (0.00%), Gastroenteritis eosinophilic 0/170 (0.00%), Adverse Events 2:, Total: 0/1 (0.00%), Anaemia 0/1 (0.00%), Febrile neutropenia 0/1 (0.00%), Cardiac tamponade 0/1 (0.00%), Myocarditis 0/1 (0.00%), Peri ',\n",
       " 'high-dose Chemotherapy, Carboplatin + Cyclophosphamide. target AUC of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion. ',\n",
       " 'Febrile neutropenia * 117/2264 (5.17%), Neutropenia * 98/2264 (4.33%), Febrile bone marrow aplasia * 14/2264 (0.62%), anemia * 8/2264 (0.35%), leukopenia * 8/2264 (0.35%), Thrombocytopenia * 6/2264 (0.27%), disseminated intravascular coagulation * 3/2264 (0.13%), Agranulocytosis * 1/2264 ( ',\n",
       " 'clinical stage breast cancer T2-3, N0-3, M0, Negative HER-2/neu expression. no prior treatment for primary invasive adenocarcinoma of the breast such as irradiation, chemotherapy, hormonal therapy, immunotherapy or surgery. women of childbearing potential (WOCBP) must agree to use a medically acceptable method of contraception to avoid pregnancy throughout the study. willingness to have core biopsies and/or FNA performed before the start of study treatment and at the end of 12 week on treatment. kcroft-Galt method found evidence of metastatic breast cancer following a standard tumor staging work-up. kcroft-Galt method found evidence of metastatic breast cancer following a standard tumor staging work-up, evidence of inflammatory breast cancer. at least 8 weeks since prior radiation to brain or CNS metastases, no concurrent steroids, no leptomeningeal disease, PATIENT CHARACTERISTICS:, Menopausal status not specified, ECOG performance status 0-2, Life expectancy 6 months, WBC > 1,500/mm3, Platelet count > 100,000/mm3, Creatinine clearance > 40 mL/min, Normal electrolytes (i.e., Na, K, and Ca normal; minor deviation geries that may interfere with the absorption of oral medications may interfere with the absorption of oral medications including:, uncontrolled nausea, vomiting, or diarrhea, Lack of the physical integrity of the upper gastrointestinal tract, Malabsorption syndrome, no known hypersensitivity to bendamustine hydrochloride, mannitol, or erlotinib hydrochloride. no prior malignancy in the past 5 years except for adequately treated basal cell or squamous cell skin carcinoma. viral therapy for HIV-positive patients, no other concurrent investigational agents. ',\n",
       " 'participants who received 6.4 mg/kg of DS-8201a as an intravenous (IV) infusion once every 3 weeks on Day 1 of each 21-day cycle. participants with HER2-expressing Metastatic and/or Unresectable breast cancer. ',\n",
       " 'Phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. between 6 and 54 patients will likely be necessary to determine the MTD of dasatinib in combination with weekly paclitaxel. the next cohort will test dasatinib given with a different schedule, 5 days on and 2 days off, omitting dasatinib the day prior and the day of administration of paclitaxel. ',\n",
       " 'women with proven diagnosis of advanced adenocarcinoma of the breast. women with proven diagnosis must be appropriate candidates for letrozole therapy. patients must be appropriate candidates for letrozole therapy. patients with adequately treated basal cell or squamous cell skin cancer may enter. active uncontrolled or symptomatic brain metastases are permitted. Previously treated and clinically stable, brain metastases are permitted. e staff members otherwise supervised by the investigator, or patients who are directly involved in the conduct of the study. ',\n",
       " 'patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily) a consensus meeting decided whether to recall the woman or not. women selected for further assessment (positive screening exam) was recalled. women selected for further assessment were recalled. digital mammography performed with GE SenoClaire 3D breast Tomosynthesis. ',\n",
       " 'Adverse Events 1:, Total: 112/458 (24.45%), Febrile neutropenia 8/458 (1.75%), Neutropenia 6/458 (1.31%), Anaemia 3/458 (0.66%), Thrombocytopenia 3/458 (0.66%), Pancytopenia 2/458 (0.44%), Myocardial infarction 0/458 (0.00%), Pericardial effusion 0/458 (0.00%), Tachycardia 0/458 (0.00%), ',\n",
       " '13/74 (17.57%), neutropenia 1/74 (1.35%), left ventricular dysfunction 1/74 (1.35%), fistula enterovesical 1/74 (1.35%), constipation and hypokalemia 1/74 (1.35%), nausea, vomiting and burning abdominal pain 2/74 (2.70%), nausea, vomiting and burning abdominal pain. ',\n",
       " 'inTERVENTION 1:, Placebo Patch, Placebo patch: 1 patch was applied topically to the affected site(s) for 12 hours each day. Letrozole of 12.5 mg/day is given for three successive days just prior to the second MRI. ',\n",
       " 'inTERVENTION 1:, Fulvestrant + Anastrozole, Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg, INTERVENTION 2:, Prone to Supine MRI Evaluated by Radiologist B, Radiologist B, number of participants successfully segmented, INTERVENTION 2:, Prone to Supine MRI Evaluated by Radiologist B, Radiologist B. ',\n",
       " 'patients receive oral pazopanib once daily on days 1-28. courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. ',\n",
       " '12/32 (37.50%), Anaemia 0/32 (0.00%), Neutropenia 1/32 (3.13%), Thrombocytopenia 4/32 (12.50%), Atrial fibrillation 1/32 (3.13%), Cardiac failure congestive 1/32 (3.13%), Myocardial ischaemia 1/32 (3.13%), Abdominal discomfort 0/32 (0.00%), Ascites 1/32 (3.13%), Constipation 0/32 (0.00%), Rectal ',\n",
       " 'Adverse Events 1:, Total: 28/36 (77.78%), Lymphocytopenia 210/36 (27.78%), Neutropenia 29/36 (25.00%), anemia 26/36 (16.67%), Thrombocytopenia 24/36 (11.11%), hyperglycemia 27/36 (19.44%), Nausea 213/36 (36.11%), Diarrhea 211/36 (30.56%), Fatigue 215/36 (41.67%), ',\n",
       " 'Febrile Neutropenia 2/218 (0.92%), Neutropenia 2/218 (0.92%), Anaemia 1/218 (0.46%), Thrombocytopenia 1/218 (0.46%), Pancytopenia 0/218 (0.00%), left Ventricular Dysfunction 4/218 (1.83%), Atrial Fibrillation 0/218 (0.00%), Angina Unstable 0/218 (0.00%), Arteriospasm Coronary 1/218 (0.46%), Cardiac perforation 1/82 (1.22%), Vomiting 1/82 (1.22%), Dehydration 1/82 (1.22%), Diarrhoea 1/82 (1.22%) ',\n",
       " '2 treatment courses were to be given in the trial. 2 treatment courses were to be given in the trial. ',\n",
       " 'Progression was defined according to 1 of the following criteria: new bone lesion(s) on bone scan or magnetic resonance imaging. increase in tumour marker CA 15.3 of more than 20 percent, compared with baseline, at 2 consecutive examinations. if a patient did not fulfil any criteria and was withdrawn because of clinical deterioration amounting to PD, they were considered having PD. it of Measure: Percentage of participants 28.57 (3.67 to 70.96), Results 2:, Arm/Group Title: Afatinib 40 mg With letrozole 2.5 mg over 28-day treatment cycles. overall number of participants Analyzed: 13, Measure Type: Number, Unit of Measure: Percentage of participants 0.00 (0.00 to 24,71) ',\n",
       " '2/38 (5.26%), Febrile neutropenia 0/38 (0.00%), Skin infection 0/38 (0.00%), Seizure 1/38 (2.63%)Adverse Events 1:, Total: 92/490 (18.78%), Anaemia * 1/490 (0.20%), Anaemia of malignant disease * 0/490 (0.00%), Febrile neutropenia * 0/490 (0.00%), Neutropenia * 0/490 (0.00%), Thro ',\n",
       " 'Progression-free Survival (PFS) defined as the interval from study entry until disease progression or death resulting from any cause, which ever occurred first. time frame: Interval from randomization until disease progression or death, whichever occurs first, assessed up to 5 years. overall number of participants Analyzed: 146, Median (95% Confidence Interval), Unit of Measure: months 4.7 (3.7 to 5.7) RECIST-based response assessment was done at Weeks (Wks) 4 and 8 and every 8 weeks thereafter. per RECIST, CR is the disappearance of all target and non-target lesions. on/recurrence was documented, assessed for up to 66 weeks. participants received oral lapatinib 1500 mg (6 x 250 mg tablets) in combination with placebo (matching to pazopanib; 2 tablets) once daily (QD). overall number of participants Analyzed: 38, Measure Type: Number, Unit of Measure: participants 17. ',\n",
       " 'Adverse Events 1:, Total: 9/2788 (0.32%), Anaphylaxis 5/2788 (0.18%), Infections and infestations - Other, specify 2/2788 (0.07%), Nervous system disorders - Other, specify 0/2788 (0.00%), Respiratory, thoracic and mediastinal disorders - Other, specify 1/2800 (0.04%), Respiratory, thoracic and mediastinal disorders. ',\n",
       " 'breast cancer according to immunohistochemistry, measured or evaluable-only disease, human epidermal growth factor receptor 2+ (HER2+) or HER2- breast cancer, Males and females 18 years of age, Females are post menopausal or surgically sterile, Recurrent or progressive advanced breast cancer (locally-advanced or metastatic) ng adenocarcinoma is defined as HER-2+ by immunohistochemistry. prior adjuvant Trastuzumab therapy is permitted. patients must not be eligible for therapy of known curative potential for metastatic cancer. orma, psoriasis, multiple sclerosis, hemolytic anemia, immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, or other rheumatologic disease is acceptable. not pregnant, and on appropriate birth control if of child-bearing potential. no history of other malignancies within the prior five years. adenocarcinoma is not amplified for HER-2/neu gene expression by at least 2-fold by FISH analysis, or that is less than IHC 3+ when FISH negative. ejection fraction less than lower limit of facility normal by multi-gated acquisition (MUGA) scan, or 45% by echocardiogram. tion therapy, or biologic therapy (except Trastuzumab) within 28 days prior to treatment on study. participation in an investigational new drug trial within 28 days prior to treatment on study. ',\n",
       " 'inclusion Criteria:, Female gender, Age 18 years, An invasive primary breast cancer of any histology arising from breast parenchyma, Patient must be status post mastectomy or partial mastectomy with an assessment of axillary nodes via sentinel lymph node biopsy. regional lymph nodes are defined as the ipsilateral axillary lymph nodes, ipsilateral supraclavicular lymph nodes, and ipsilateral internal mammary lymph nodes. primary breast cancer is a lymphoma or sarcoma histology. patients requiring radiation to the bilateral breasts. ',\n",
       " 'DLTs were defined as grade 4 neutropenia persisting for more than 7 days. grade 3 or above febrile neutropenia; grade 4 thrombocytopenia or grade 3 thrombocytopenia requiring blood transfusion; non-hematologic toxicity greater than or equal to grade 3. day 8 administration was delayed or skipped as the subject did not meet the dosing riteria within cycle. Eribulin mesylate (E7389) was administered intravenously on Day 1 and Day 8 of each 3 week cycle. Trastuzumab was administered intravenously tri-weekly, with an initial dose of 4 mg/kg followed by 2 mg/kg for the remaining doses. overall number of participants Analyzed: 6, Measure Type: Number, Unit of Measure: Participants 0, Results 2:, Arm/Group Title: E7389 With Tri-weekly Trastuzum ',\n",
       " '3/24 (12.50%), Disseminated intravascular coagulation 0/24 (0.00%), Fatigue 0/24 (0.00%), Hepatic failure 1/24 (4.17%), Alanine aminotransferase increased 1/24 (4.17%), aspartate aminotransferase increased 1/24 (4.17%), Blood bilirubin increased 0/24 (0.00%), Ejection fraction decreased 1/24 (4.17%), Adverse Events 2:, Total: 9/22 ',\n",
       " \"patients' recurrences must have histologically confirmed ductal carcinoma in-situ, invasive ductal, medullary, papillary, colloid (mucinous), or tubular histologies. if chemotherapy is planned, the radiation is delivered first and chemotherapy must begin no earlier than two weeks following completion of radiation. more than 25% of the invasive tumor is Ductal carcinoma in situ (DCIS) and DCIS present in adjacent breast tissue. more than 25% of the invasive tumor is Ductal carcinoma in situ (DCIS) patients with known BReast CAncer gene (BRCA)1/BRCA 2 mutations. \",\n",
       " 'a one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit. participants received Palbociclib orally once a day at 125 mg for 21 days followed by 7 days off treatment ofr each 28-day cycle. participants received Palbociclib orally once a day at 125 mg for 21 days. participants received Letrozole orally at 2.5 mg once daily as continuous daily dosing schedule. ',\n",
       " 'Ipsilateral biopsy-proven invasive breast cancer 5 cm in maximal dimension by Ultrasound or Mammography. no abnormal axillary nodes identified on grayscale AUS, or abnormal nodes with benign subsequent FNA biopsy. ',\n",
       " 'immunohistochemical studies will be performed on the tumor specimen to correlate the anti-tumor efficacy of OSI-774 and bevacizumab with pre-treatment molecular characteristics. systemic tumor response refers to the response at the time of best overall response. the response criteria are specially adapted from Response Evaluation Criteria in Solid Tumor for Immunotherapies (Wolchok, et al., 2009) Radiation, Imiquimod, Cyclophosphamide, Overall Number of Participants Analyzed: 12, Measure Type: Number, Unit of Measure: proportion of tumors.25 (.06 to.57), Results 2:, Arm/Group Title: CTX/IMQ/RT, Arm/Group Description: Week -1 (day-7): cyclophosphamide 200mg/m2 IV as single infusion, Weeks 1-2: RT given to one metastatic skin ',\n",
       " 'Adverse Events 1:, Total: 28/36 (77.78%), Lymphocytopenia 210/36 (27.78%), Neutropenia 29/36 (25.00%), anemia 26/36 (16.67%), Thrombocytopenia 24/36 (11.11%), hyperglycemia 27/36 (19.44%), Nausea 213/36 (36.11%), Diarrhea 211/36 (30.56%), Fatigue 215/36 (41.67%), ',\n",
       " 'HER-2 negative advanced breast cancer with chest wall metastasis confirmed by histology or cytological examination. if hormone receptor is positive, endocrine therapy must have been performed for the patients with recurrence or metastasis. if hormone receptor is positive, endocrine therapy must have been performed. neutrophil counts more than 1.5*109/L; platelet counts greater than 100*109/L; hemoglobin greater than 9 g/dL. serum creatinine less than 1.25 times the upper limit of normal value. women with fertility are willing to take contraceptive measures in the trial. medullary bone radiated should not exceed 30% of the total amount. medullary bone radiated should not exceed 30% of the total amount. with hypertension and blood pressure cannot be reduced to the normal range. sufficiency of grade III and IV or left ventricular ejection fraction (LVEF) less than 50% revealed by echocardiography. abnormal coagulation function (INR > 1.5 or prothrombin time (PT) > ULN+4 seconds or APTT >1.5 times the ULN) within 3 months before enrollment, clinically significant bleeding symptoms occur, or having obvious bleeding tendency, such as gastrointestinal bleeding, bleeding gastric ulcer, occult blood + + and above in baseline period. luding pleural effusion, ascites, pericardial effusion); with other possible conditions that can affect the clinical research or evaluation. ',\n",
       " 'Response Evaluation Criteria In Solid Tumors (RECIST) criteria defines when participants improve (\"respond\"), stay the same (\"stable\"), or worsen (\"progression\") during treatment. overall number of participants Analyzed: 6, Measure Type: Number, Unit of Measure: participants Complete Response: 0, Partial Response: 0, Long Stable Disease: 1, Stable Disease: 1, Not Evaluable: 2, Results 2:, Arm/Group Title: Dose Level 2, Arm/Group Description: Gemcitabine at 1000 mg/ of Participants Analyzed: 62, Measure Type: Number, Unit of Measure: participants Complete Response: 1, Partial Response: 4, Long Stable Disease: 4, Stable Disease: 16, Progressive Disease: 32, Not Evaluable: 5_. ',\n",
       " '0/3 (0.00%), cardiac tamponade 0/3 (0.00%), congestive heart failure 0/3 (0.00%), pulmonary emobolism 0/3 (0.00%), Adverse Events 2:, Total: 2/23 (8.70%), cardiac tamponade 0/23 (0.00%), congestive heart failure 1/23 (4.35%), pulmonary emobolism 1/23 (4.35%)Adverse Events 1:, Vomiting 0/20 (0.00%), Fatigue 0/20 (0.00%). Fatigue 0/20 (0.00%) ',\n",
       " 'inTERVENTION 1:, Letrozole + MRI, Protocol Therapy will consist of 6 months of letrozole, administered orally at a dose of 2.5 mg/day. ',\n",
       " 'Diabetes insipidus [1]0/21 (0.00%), Nausea 0/11 (9.09%), Ileus 1/11 (9.09%), Dehydration 1/11 (9.09%), Pain NOS [2]2/11 (18.18%), Pain - abdomen 0/11 (0.00%), Fracture [3]0/11 (0.00%), Progressive Disease 1/11 (9.09%), CNS Ischemia 1/11 (9.09%), Respiratory Failure 0/11 (0.00 ',\n",
       " 'Adverse Events 1:, Total: 128/425 (30.12%), Febrile neutropenia *2/425 (0.47%), Anaemia *2/425 (0.47%), Pancytopenia *2/425 (0.47%), Coagulopathy *1/425 (0.24%), Idiopathic thrombocytopenic purpura *0/425 (0.00%), Pericardial effusion *1/425 (0.24%), Acute coronary syndrome *1/425 (0.24%) ',\n",
       " 'time frame: 24 Weeks, Results 1:, Arm/Group Title: Arm I, Arm/Group Description: Patients receive donepezil hydrochloride PO QD. given PO, overall number of participants Analyzed: 31, Mean (Standard Error), Unit of Measure: percentage of participants 71.0 (8.3), Results 2:, Arm/Group Title: Arm II, Arm/Group Description: Patients receive placebo PO QD. ',\n",
       " 'oral itraconazole 200mg a day until disease progression or unacceptable toxicities. overall number of participants Analyzed: 12, Mean (Standard Deviation), Unit of Measure: ng/mL Week 2 Intraconazole Concentration: 230.7 (216.8), Week 2 6-OH Itraconazole Concentration: 454.8 (429.3), Week 4 6-OH Itraconazole Concentration: 501.6 (502.6)Outcome Measurement:, Dose Es report of Dose-Limiting Toxicities (DLTs) were assessed to determine the MTD. time frame: From date of first dose to 30 days after termination, the longest 163 weeks. ',\n",
       " 'Participant is female and 18 years of age or older if required by local laws or regulations. Participant has confirmed adenocarcinoma of the breast that is now metastatic or locally-recurrent and inoperable with curative intent. Participant has measurable and/or non-measurable disease. adjuvant biologic therapy at least 6 weeks prior to randomization, Participant completed all prior radiotherapy with curative intent 3 weeks prior to randomization. Participant may have received prior hormonal therapy for breast cancer in the (neo) adjuvant and/or the metastatic setting 2 weeks prior to randomization. participants have serum creatinine 1.5 x ULN. the calculated creatinine clearance should be > 40 milliliters/minute (mL/min) participants must have adequate coagulation function. on full-dose anticoagulation must be on a stable dose of oral anticoagulant or low molecular weight heparin. if on warfarin must have a INR between 2 and 3 and have no active bleeding (defined as within 14 days of randomization) Participant has not received prior biologic therapy for metastatic or locally recurrent and inoperable breast cancer. itivity to agents of similar biologic composition as ramucirumab or other agents that specifically target vascular endothelial growth factor (VEGF) Participant has a history of chronic diarrheal disease within 6 months prior to randomization. Participant has received irradiation to a major bone marrow area as defined as > 25% of bone marrow within 30 days prior to randomization. Participant has known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness. Participant has pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen. ECOG performance status 0-2, Male or female, Menopausal status not specified, Absolute neutrophil count (ANC) 1,500/mm3, Platelet count 100,000/mm3, Creatinine clearance > 50 mL/min, Fertile patients must use effective contraception, No history of another severe and/or life-threatening medical disease, No other active primary malignancy, Not pregnant or nursing, Negative pregnancy test, Liver dysfunction score 9. ine therapy, known hypersensitivity to fluorouracil, or known dihydropyrimidine dehydrogenase deficiency, No significant history of noncompliance to medical regimens, No clinically significant psychiatric disability that would preclude study compliance, PRIOR CONCURRENT THERAPY:, No previous capecitabine, Up to 3 prior cytotoxic regimens allowed for metastatic disease, Prior noncytotoxic therapy allowed. use of bisphosphonates allowed if initiated before beginning study therapy. use of megestrol acetate suspension as appetite stimulant allowed. ',\n",
       " '8/24 (33.33%), Restrictive Cardiomyopathy * 21/24 (4.17%), Palpitations * 21/24 (4.17%), GERD * 21/24 (4.17%), Fever * 21/24 (4.17%), Sepsis * 1/24 (4.17%), Urinary Tract Infection * 21/24 (4.17%), Influenza A * 21/24 (4.17%), Dehydration * 21/24 (4.17%), Hyponatremia * 21/24 (4.17%), ',\n",
       " 'the patient is ambulatory with a functional ECOG  2 status. the patient presents, at least one lesion measurable according to RECIST criteria. the patient is ambulatory with a functional ECOG  2 status. patients with severe intellectual impairment, unable to carry out basic daily routines and established depression. clinical significant cardiac disease or myocardial infarction within the last 12 months. patients with a history of uncontrolled convulsions, central nervous system disorders or psychiatric disability judged to be clinically significant should be excluded. patients under radiotherapy 4 weeks prior to study treatment or under previous radiotherapy on marker lesions be measured during the study. patients under major surgery within 4 weeks prior to study treatment or who have not completely recovered from the effects of major surgery. patients who lack upper gastrointestinal tract physical integrity or with malabsorption syndrome. patients Her2 + per FISH ó +++ ImmunohistochemistryInclusion Criteria:, Estrogen receptor or progesterone receptor positive breast cancer, premenopausal with regular menstrual cycles. ',\n",
       " 'alloDerm RTU, INTERVENTION 2:, SurgiMend PRS, Participants within this arm will have the acellular dermal matrix SurgiMend PRS implanted at the time of tissue expander placement. ',\n",
       " '223 treated patients included in the analysis. time frame: assessed on day 1 of cycles 5, 9, 17 and 25. each 6 months for 2-3 years from study entry. number, unit of measure: percentage of participants 2.5 (0.5 to 7.1) ',\n",
       " 'Anaemia 0/149 (0.00%), Febrile neutropenia 7/149 (4.70%), Neutropenia 1/149 (0.67%), Pancytopenia 1/149 (0.67%), Atrial fibrillation 2/149 (1.34%), Cardiac failure congestive 0/149 (0.00%), Abdominal pain 0/149 (0.00%), Diarrhoea 2/149 (1.34%), Dyspepsia 0/149 (0.00%), ',\n",
       " '18/364 (4.95%), Febrile neutropenia 3/364 (0.82%), Atrial fibrillation 1/364 (0.27%), Cardio-respiratory arrest 1/364 (0.27%), Sinus bradycardia 1/364 (0.27%), Ventricular extrasystoles 0/364 (0.00%), Enterocolitis 0/364 (0.00%), Faecaloma 0/364 (0.00%), Gastric ulcer perforation 0/364 (0.00%) thy *0/25 (0.00%), Syncope *0/25 (0.00%), Hand and Foot Syndrome *1/25 (4.00%), Adverse Events 2:, Total: 11/26 (42.31%), Neutropenia *3/26 (11.54%), Anemia *1/26 (3.85%), Febrile Neutropenia *1/26 (3.85%), Chest Pain *1/26 (3.85%), Diarrhea *1/26 (3.85%), Fatigue *0/26 (0.00%), Liver ',\n",
       " \"patients apply dakin's solution topically daily over 10 minutes within 60 minutes of radiation therapy for up to 6 weeks. doxorubicin hydrochloride: Given IV, cyclophosphamide: Given PO, paclitaxel: Given IV, filgrastim: Given SC, capecitabine: Given PO, methotrexate: Given IV, vinorelbine tartrate: Given IV, needle biopsy: Correlative studies, therapeutic conventional surgery: Undergo definitive \",\n",
       " \"patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cycles. the group will receive clinical management treatment only each session. clinical management will be assigned to both experimental group and controlled group in the first stage of intervention. subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction will receive CBT each session. treatment includes three steps:Concept stage (the first and second sessions): establishment of therapeutic relationships with subjects; Skills acquisition and repeat stage (the third to the 8th session): clarification of sources of stress, patients' cognitive and behavioral response to stress. \",\n",
       " 'Adverse Events 2:, Total: 2/60 (3.33%), Bronchial infection 0/60 (0.00%), Ankle fracture 1/60 (1.67%), Clear cell kidney cancer 0/60 (0.00%), Programmed peritoneal dialysis 1/60 (1.67%), Endometrial atrophy 0/60 (0.00%), Adverse Events 2:, Total: 3/58 (5.17%), Bronchial infection 1/58 (1.72%), Ankle fracture 0/ ',\n",
       " 'Febrile neutropenia 1/113 (0.88%), Neutropenia 1/113 (0.88%), Anaemia 0/113 (0.00%), Pancytopenia 1/113 (0.88%), Proctitis 1/113 (0.88%), Device related sepsis 1/113 (0.88%), Tooth infection 0/113 (0.00%), Hip fracture 0/113 (0.00%), Blood creatinine increased 1/113 (0.88%), Adverse Events 2:, Total: 6/112 ( ',\n",
       " 'patients with non-small cell lung carinoma (NSCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity. pegylated Irinotecan: Administered intravenously (IV) at 145 mg/m2 as monotherapy once every 21 days (1 cycle) ',\n",
       " 'PFS calculated as (Months) = (first event date minus randomization date plus 1) divided by 30.4. Time frame: Baseline up to Month 33, Results 1:, Arm/Group Title: docetaxel + Sunitinib, Arm/Group Description: Sunitinib 37.5 milligrams per square meter (mg/m2) every 3 weeks. Docetaxel 100 mg/m2 every 3 weeks, Overall Number of Participants Analyzed: 297, Median (95% Confidence Interval), Unit of Measure: months Independent radiology assessment: 8.3 (7.7 to 9.6) ',\n",
       " 'patients must have adenocarcinoma of the breast requiring comprehensive loco-regional irradiation. patients must have pathologic T 1, 2, 3 or 4, N 1, 2, or 3 Stage II or III disease. all patients must have left-sided breast cancer. formance status should be 0-2 by ECOG criteria. patients who have received prior RT may be enrolled on the present study. patients must be aware of the neoplastic nature of her/his disease. patients with a clinically unstable medical condition, patients with a life-threatening disease state, history or suspicion of serious life-threatening allergic reaction to Tc-99m imaging agents. patients that have had breast-conservation surgery with positive margins. ',\n",
       " 'febrile neutropenia 4/122 (3.28%), Neutropenia 0/122 (0.00%), Angina unstable 1/122 (0.82%), Coronary artery disease 1/122 (0.82%), Myocardial infarction 1/122 (0.82%), Diarrhoea 2/122 (1.64%), Colitis 1/122 (0.82%), Pyrexia 2/122 (0.82%), Chest pain 1/122 (0.82%), Pneumonia 1/122 (0.82% Vomiting 2/65 (3.08%), Fatigue 1/65 (1.54%), Jaundice 1/65 (1.54%), Neutropenic infection 2/65 (3.08%) ',\n",
       " 'female patient 18 years of age, Histologically proven stage II or III adenocarcinoma of the breast, Must be candidate for neoadjuvant treatment (Tumor size 2 cm, T2, T3, T4 and/or clinical N1 or N2)., HER-2/neu 1+ or 2+ by immunohistochemistry, Must have operable tumor. pretreatment lab values must be performed within 14 days of patient registration. women with tumors that are HER-2 neu 0+ or 3+ by immunohistochemistry. women with HER 2 FISH amplified tumors (FISH ratio >2.2) will be excluded. locally advanced, inoperable tumors will be excluded. patients with concomitant or previous malignancies within the last 5 years are excluded from study. patients with concomitant or previous malignancies within the last 5 years are excluded from study. status is assessed using self-reports due to problems in reliably measuring follicle-stimulating hormone levels and estradiol in tamoxifen users. exclusion criteria are depression, history of migraines or hepatitis, abnormal chemistry profile (e.g., sodium, potassium, glucose), or a positive urine drug screen for illegal substances. ',\n",
       " 'omega-3 fatty acid: Given PO, laboratory biomarker analysis. patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy. ker Analysis: Correlative studies, Questionnaire administration: ancillary studies. ',\n",
       " '4D Conformal Image-Guided Partial Breast RT: External beam partial breast radiation to target a portion of the breast twice a day for 5 days. a one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit. ',\n",
       " 'given orally, paclitaxel: Given IV, doxorubicin hydrochloride: Given IV, cyclophosphamide: Given SC, conventional surgery: surgical procedures performed on patients, axillary lymph node dissection: correlative study. ',\n",
       " 'a 95% confidence interval for the median PFS will be calculated. a lower bound greater than 8 months would be strong evidence that Nab-Paclitaxel- bevacizumab induction therapy is superior to paclitaxel and bevacizumab. patients receive paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15. bevacizumab IV over 30-90 minutes once every 14 or 21 days. treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. ',\n",
       " 'patients will be randomized to receive bevacizumab 15mg/kg i.v. every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. the patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent. letrozole, bevacizumab, nsent., letrozole, bevacizumab, nsent., letrozole, letrozole, bevacizumab, Fulvestrant. ',\n",
       " 'neoadjuvant therapy will consist of epirubicin (100 mg/m2) + cyclophosphamide (600 mg/m2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m2) every 2 weeks for 4 cycles + trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose] every 2 weeks for 4 treatments. ',\n",
       " 'inclusion Criteria:, Subjects with unknown clinical status not participating in FMSU004A protocol. you must meet the following criteria:, Locally advanced/inflammatory adenocarcinoma of the breast, 18 years of age or older, Normal heart function, Able to perform activities of daily living with minimal assistance. the study center will determine if you meet all of the criteria. if you do qualify, study personnel will explain the trial in detail. ',\n",
       " 'patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy, during 6 weeks of radiation therapy, and at least 2 weeks after radiation therapy) patients undergo radiation therapy QD 5 days a week for 6 weeks. ',\n",
       " 'patients and healthy volunteers will be screened for MRI contraindications. the SWIFT MRI workflow will be performed as follows: an IV line is placed by nurse. ncer patients and healthy volunteers will be first screened for MRI contraindications. the SWIFT MRI workflow will be performed as follows. 10 and 30 patients will be scanned in the first and second year. patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Hydrophor daily, starting at the onset of radiation therapy (RT) and continuing until 2 weeks after the final RT session or until the RT site is healed. patients should not apply the Hydrophor within 4 hours of receiving RT. Medihoney application should include the entire treatment area. patients should not apply the Medihoney within 4 hours of receiving RT. patients should wash the application area daily with soap and tap water. ',\n",
       " 'Febrile neutropenia * 10/107 (9.35%), Neutropenia * 1/107 (0.93%), Left ventricular dysfunction * 0/107 (0.00%), Angina pectoris * 0/107 (0.00%), Cardiac failure congestive * 0/107 (0.00%), Diarrhoea * 2/107 (1.87%), Abdominal strangulated hernia * 0/107 (0.00%), Pyrexia * 1/107 ( ',\n",
       " '19/213 (8.92%), Pancytopenia 0/213 (0.00%), Anaemia 1/213 (0.47%), Atrial fibrillation 0/213 (0.00%), Cardiac failure congestive 0/213 (0.00%), Myocardial infarction 0/213 (0.00%), Myocardial infarction 0/213 (0.00%), Colitis 0/213 (0.00%), Vomiting 1/213 (0.47%), Nausea 1/213 (0.4 ',\n",
       " '83/680 (12.21%), Hemoglobin 11/680 (1.62%), Transfusion: Platelets 0/680 (0.00%), Febrile neutropenia 49/680 (7.21%), Edema 1/680 (0.15%), Ischemia/infarction 0/680 (0.00%), Palpitations 0/680 (0.00%), Pericardial effusion 0/680 (0.00%), Keratitis 1/680 (0.15%), Colitis 1/680 ',\n",
       " 'a DLT is described any grade 3 or higher, clinically significant toxicity (excluding alopecia) experienced during the first 21 days following first dose of BYL719 that is determined to be at least possibly related to study medication. lower grades may also be considered DLTs if they lead to a dose interruption of more than 7 consecutive days of BYL719. itor BYL719 on days 1-21 and 3.6mg/kg IV over 30-90 minutes on day 1 ado-trastuzumab emtansine (T-DM1) courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. PI3K inhibitor BYL719: Given PO, Ado-trastuzumab emtansine: Given IV, Pharmacological study: Correlative studies, Laboratory biomarker the most common CYP2D6 alleles have been grouped by functional activity classifications with descending activity: ultra-rapid (UM), extensive (EM), intermediate (IM) or poor (PM) metabolism. a given patient has two alleles, giving them 10 possible allelic combinations, or diplotypes. ormation of the CYP2D6 genotype to allelic activity, Overall Number of participants Analyzed: 5, Mean (Standard Deviation), Unit of Measure: ng/mL Baseline endoxifen concentration: 5 participants, 8.4 (4.59), 4-Month endoxifen concentration: 4 participants, 15.35 (5.48), Results 2:, Arm/Group Title: Extensive Metabolizers. ',\n",
       " 'Progression-free Survival (PFS) defined as the interval from study entry until disease progression or death resulting from any cause, which ever occurred first. time frame: Interval from randomization until disease progression or death, whichever occurs first, assessed up to 5 years. overall number of participants Analyzed: 146, Median (95% Confidence Interval), Unit of Measure: months 4.7 (3.7 to 5.7) RECIST-based response assessment was done at Weeks (Wks) 4 and 8 and every 8 weeks thereafter. per RECIST, CR is the disappearance of all target and non-target lesions. on/recurrence was documented, assessed for up to 66 weeks. participants received oral lapatinib 1500 mg (6 x 250 mg tablets) in combination with placebo (matching to pazopanib; 2 tablets) once daily (QD). overall number of participants Analyzed: 38, Measure Type: Number, Unit of Measure: participants 17. ',\n",
       " \"participants initially received doxorubicin (60 mg/m2) plus cyclophosphamide (600 mg/m2) intravenously (IV) on Day 1, of every 14-day cycle for 4 cycles. in this Cohort growth factors, subcutaneous pegfilgrastim (6 mg) or filgrastim, could be used with eribulin therapy at the physician's discretion. Eribulin mesylate was administered following the doxorubicin plus cyclophosphamide regimen at a dose of 1.4 mg/m2 IV over 2 to 5 minutes. in this Cohort filgrastim was used with eribulin therapy at a dose of 300 micrograms for participants 60 kg or 480 micrograms for participants >60 kg. \",\n",
       " 'clinical evidence of metastatic disease, Measurable disease, defined as at least one measurable lesion per RECIST criteria, No non-measurable disease only, defined as all other lesions, including small lesions (longest diameter  2 cm) and truly non-measurable lesions, including any of the following: Bone lesions, Leptomeningeal disease, Ascites, Pleural/pericardial effusion, Inflammatory breast disease, Lymphangitis cutis/pulmonis menopausal status not specified, Life expectancy 12 weeks, ECOG performance status 0-1, ANC 1,500/mm3, Platelet count 100,000/mm3, Hemoglobin 9.0 g/dL, AST and ALT 2.5 times upper limit of normal (ULN), Alkaline phosphatase 2.5 times ULN, Total bilirubin 1.5 times ULN, Creatinine 1.5 mg/dL, Urine protein:creatinine ratio  1 nancy within the past 5 years, no other active malignancy, except nonmelanoma skin cancer or carcinoma in situ of the cervix. patients who have recently started or adjusted antihypertensive medications are eligible. patients who have recently started or adjusted antihypertensive medications are eligible. rtery disease, Unstable angina, Cardiac arrhythmias not well controlled with medication, Myocardial infarction within the past 12 months, No comorbid systemic illnesses or other severe concurrent disease. prior adjuvant chemotherapy allowed, more than 6 months since prior adjuvant or neoadjuvant taxane therapy allowed, prior hormonal therapy in either adjuvant or metastatic setting allowed, more than 4 weeks since prior radiotherapy. therapy was completed, More than 4 weeks since prior cytotoxic chemotherapeutic agent or investigational drug, More than 2 weeks since prior and no concurrent acetylsalicylic acid, anticoagulants, or thrombolytic agents (except for once-daily 81 mg acetylsalicylic acid), More than 6 weeks since prior major surgery, chemotherapy, or immunologic therapy, More than 1 week since prior minor surgery. ',\n",
       " 'all MCS110 treated patients, with 10mg/kg intravenous infusion, on day 1 and days 1 & 8, overall number of participants Analyzed: 34, Median (90% Confidence Interval), Unit of Measure: months 5.6 (4.5 to 8.7), Results 2:, Arm/Group Title: Carboplatin+Gemcitabine, Arm/Group Description: comparator. the best overall response (OR) for each patient is determined from the sequence of investigator overall lesion responses. to be assigned a best OR of complete responese (CR) at least two determinations of PR or better at least 4 weeks apart before progression are required. overall response rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48 weeks. 49, Measure Type: Number, Unit of Measure: participants Patients with measurable disease at baseline: 39, Patients with non-measurable disease at baseline: 10, Best at WK 48 - Complete Response (CR): 0, Best at WK 48 - Partial Response (PR): 7, Best at WK 48 - Stable Disease (SD): 18, Best at WK 48 - Progressive Disease (PD): 15, Unknown: 1, Missing: 8. ',\n",
       " 'patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity. each patient will receive accelerated partial breast brachytherapy with multiple plane implant. treatment is to be given over 5-7 days with minimum of 6 hours separation between fractions. ',\n",
       " 'cOR is defined as the documented evidence of complete response (CR) and partial response (PR) as assessed by ultrasound examination using Response Evaluation Criteria In Solid Tumors (RECIST) PR for TLs is defined as a >=30% decrease in the sum of the longest diameter (LD) of TLs. for non-TLs, it is defined as the persistence of >=1 non-TL and no new TLs or non-TLs. icipants analysed: 48, Measure Type: Number, Unit of Measure: percentage of participants CR: 2, PR: 58, Results 2:, Arm/Group Title: Letrozole + lapatinib, Arm/Group Description: Letrozole tablets in the dose of 2.5 mg plus lapatinib ditosylate monohydrate tablets in the dose of 1500 mg were administered orally once daily for 6 months prior to surgery. ',\n",
       " 'administration by an applicator inserted deep inside the vagina Dose: 1 g of gel containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application. inTERVENTION 2:, Placebo Vaginal Gel, Route: Vaginal. ',\n",
       " 'treatment repeats every 4-6 weeks in absence of disease progression or unacceptable toxicity. some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30 minutes weekly or every 3 weeks at the discretion of the treating physician. Dasatinib 140mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2 was administered orally once daily. only in the phase I, the first cycle lasted 38 days. ',\n",
       " 'prior treatment must include both chemotherapy, alone or in combination with another agent, and an anti-HER2 agent, alone or in combination with another agent. progression must occur during or after most recent treatment for LABC/mBC or within 6 months of completion of adjuvant therapy. the participant must have recovered from any resulting acute toxicity (to Grade /=1) prior to first study treatment. the participant must have recovered from any resulting acute toxicity (to Grade /=1) before first study treatment. Metastatic central nervous system (CNS) disease only, Brain metastases which are symptomatic, History of a decrease in LVEF to less than () 40% or symptomatic congestive heart failure (CHF) with previous trastuzumab treatment. history of a decrease in LVEF to less than () 40% or symptomatic congestive heart failure (CHF) with previous trastuzumab treatment. ',\n",
       " 'predicted 5-year modified Gail model risk of 1.67% or greater. prior history of ductal carcinoma in situ if no current tamoxifen use. postmenopausal defined as > 6 months since last menstrual period. prior tamoxifen or raloxifene use is allowed provided treatment is discontinued at least 28 days prior to enrollment. at least one breast available for imaging, provided treatment is discontinued at least 28 days prior to enrollment. ancer (including breast cancer) for which the participant has been disease-free for 5 years. history of kidney stones, hypersensitivity reactions to vitamin D. ',\n",
       " 'RECIST 1.1: Complete Response (CR): Disappearance of all non-target lesions. any pathological lymph node must have reduction in short axis to 10 mm. progressive disease (PD): 20% increase in sum of the diameters of target lesions. progressive disease (PD): Substantial, unequivocal progression of existing non-target lesions. PD: Substantial, unequivocal progression of existing non-target lesions. myl 1401OTrastuzumab Intravenously + paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint. overall number of participants Analyzed: 230, Measure Type: Count of Participants, Unit of Measure: Participants Complete Response: 3 1.3%, Partial Response: 157 68.3%, Stable Disease: 48 20 ne 4.8 (4.3 to 5.4), Results 2:, Arm/Group Title: Placebo, Arm/Group Description: [Not Specified], Overall Number of Participants Analyzed: 122, Least Squares Mean (95% Confidence Interval), Percent Change from Baseline -.7 (-1.3 to -.1) ',\n",
       " 'patients with non-small cell lung carinoma (NSCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity. pegylated Irinotecan: Administered intravenously (IV) at 145 mg/m2 as monotherapy once every 21 days (1 cycle) ',\n",
       " 'clinical management: Clinical management is a clear contrast method of psychological therapy. the group will receive clinical management treatment only each session. the subjects will receive standard CBT and clinical management. ized CBT treatment regularly for 9 sessions. each session will last for about 60 minutes. the treatment includes three steps:Concept stage (the first and second sessions) ated and disease does not worsen in participants with no prior trastuzumab treatment. ',\n",
       " 'study will be deemed infeasible if more than 4 patients cannot be given treatment because her tumor is such that a dosimetrically satisfactory treatment plan cannot be devised for her. ',\n",
       " 'participants with a confirmed diagnosis of clinical stage 1 or 2 breast cancer, participants with lumpectomy or mastectomy, participants with planned axillary sentinel node biopsy procedure, Exclusion Criteria:, Participants with clinically positive nodes, Participants with clinically positive nodes. participants with bilateral breast surgeries, Thyroid dysfunction, Hypersensitivity to iodine, Hepatic insufficiency, Renal insufficiencyInclusion Criteria:, more than 2 prior Herceptin (trastu Significant gastrointestinal disorder with diarrhea as major symptom. ',\n",
       " 'inTERVENTION 1:, Letrozole + MRI, Protocol Therapy will consist of 6 months of letrozole, administered orally at a dose of 2.5 mg/day. ',\n",
       " 'patients must be women with a histologically confirmed diagnosis of breast cancer that is more than 2 cm and/or lymph node positive. patients must have a multiple gated acquisition (MUGA) scan or echocardiogram scan performed within 90 days prior to registration. patients must have a serum creatinine and bilirubin the institutional upper limit of normal. a serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) 2x the institutional upper limit of normal. these tests must have been performed within 90 days prior to registration. women of reproductive potential may not participate unless they have agreed to use effective contraceptive method. urine pregnancy test is required for women of childbearing potential. ',\n",
       " 'participants received lapatinib 1500 mg orally OD with paclitaxel. paclitaxel was administered as a 1-hour IV infusion at a dose of 80 mg/m2. ',\n",
       " 'pCR is defined as no invasive disease in the breast of axilla at the time of definitive surgery. a patient is considered to have FASN expression if the positivity was >= 15% at the baseline or after 4-7 days of Omeprazole monotherapy. ',\n",
       " 'patients with progressive, radiographically measurable parenchymal brain metastases after whole brain radiation therapy (WBRT) patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. rt of patients with either leptomeningeal metastases (LMD) or unirradiated, asymptomatic brain metastasis from breast cancer (BCBM).Patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. ',\n",
       " 'Febrile neutropenia 1/42 (2.38%), Cardiac valve disease 1/42 (2.38%), Diarrhoea 0/42 (0.00%), Abdominal pain 1/42 (2.38%), Colitis 0/42 (0.00%), Nausea 0/42 (0.00%), Vomiting 0/42 (0.00%), Influenza like illness 1/42 (2.38%), Oedema peripheral 1/42 (2.38%), Fatigue 0/42 (0.00%), Ad Nausea 0/209 (0.00%), Nausea 0/209 (0.00%), Vomiting 1/209 (0.48%), Mucosal inflammation 0/209 (0.00%), Pain 1/209 (0.48%), Adverse Events 2:, Total: 29/216 (13.43%), Anaemia 2/216 (0.93%), Febrile neutropenia 2/216 (0.93%), Thrombocytopenia 2/216 (0.93%), Acute myocardial infarction 1/216 ',\n",
       " 'the patient must have a life expectancy of at least 10 years and a Zubrod performance status of 0 or 1. the interval between the last surgery for breast cancer staging or treatment must be no more than 84 days. patients must have an estrogen receptor (ER) analysis performed on the primary tumor prior to randomization. if ER analysis is negative, then progesterone receptor (PgR) analysis must be performed. patients must have had either a lumpectomy or a total mastectomy. patients with skeletal pain or alkaline phosphatase greater than ULN are eligible for inclusion in the study if bone scans fail to demonstrate metastatic disease. patients with aspartate transaminase (AST) or alkaline phosphatase greater than ULN are eligible for inclusion in the study if liver imaging fails to demonstrate metastatic disease. alkaline phosphatase must be less than or equal to 2.5 x ULN for the lab. postoperative serum creatinine must be less than or equal to ULN. within 3 months prior to entry, patient must have a baseline left ventricular ejection fraction (LVEF), measured by multiple gated acquisition scan or echocardiogram. non-breast malignancies are eligible if diagnosed and treated within the past 5 years. non-breast malignancies are eligible if they have been disease-free for 5 or more years prior to randomization. patients with margins positive for lobular carcinoma in situ (LCIS) are eligible without additional resection. radiation therapy o Postmastectomy chest wall and/or regional nodal irradiation is optional. or prior therapies are also ineligible for this study. a tumor that has been determined to be human epidermal growth factor receptor 2 (HER2)-positive by immunohistochemistry (3+) or by fluorescent in situ hybridization (positive for gene amplification) hormonal therapy may have been given for up to a total of 28 days before randomization. radiation therapy for patients enrolled in NSABP B-39 may have received RT prior to study entry. se medications are discontinued prior to randomization. angina pectoris that requires the use of anti-anginal medication. conditions that would prohibit administration of corticosteroids. women of reproductive potential must agree to use an effective non-hormonal method of contraception. women of reproductive potential must agree to use an effective non-hormonal method of contraception. lumpectomy patients will be ineligible if they undergo mastectomy. patients in whom the margins of the resected specimen are involved with invasive tumor or DCIS. ',\n",
       " 'Adverse Events 1:, Total: 1/24 (4.17%), Pericardial effusion *1/24 (4.17%), Other cardiac disorder *0/24 (0.00%), Ejection fraction decrease *0/24 (0.00%), Hypertension *0/24 (0.00%), Pleural effusion *0/24 (0.00%), Adverse Events 2:, Total: 6/30 (20.00%), Pericardial effusion *1/30 (3.33%), Other cardiac disorder *1/30 (3.33%), Ejection fraction ',\n",
       " 'Febrile neutropenia * 0/41 (0.00%), Diarrhea * 1/41 (2.44%), Stomach pain * 1/41 (2.44%), Fever * 2/41 (4.88%), Cytokine release syndrome * 1/41 (2.44%), Skin infection * 2/41 (4.88%), Urinary tract infection * 1/41 (2.44%), Coagulopathy * 0/41 (0.00%), INR increased * 0/41 (0.00%), Lipase increased * ',\n",
       " 'women of 18 years of age with proven diagnosis of advanced adenocarcinoma of the breast. ER-positive and/or PgR-positive breast cancer based on local laboratory results. patients must be appropriate candidates for letrozole or fulvestrant therapy. ',\n",
       " 'radioactive occult lesion localization, hook wire, or other method of localization required for nonpalpable lesions. at least 1 micrometastatic (i.e., no greater than 2 mm) sentinel lymph node with no extracapsular extension, no clinical evidence of distant metastases. ormance status, Not specified, Life expectancy, Not specified, Hematopoietic, Not specified, Hepatic, See Disease Characteristics, Renal, Not specified, Other, Not pregnant or nursing, No other prior or concurrent malignancy except:. ',\n",
       " 'inTERVENTION 1:, Anastrozole and Simvastatin, adjuvant therapy. anastrozole: 1 milligram tablet PO QD for 14 days. anastrozole: 1 milligram tablet PO QD for 14 days. ',\n",
       " 'Neratinib 160 mg + Paclitaxel 80 mg/m IV on days 1, 8, and 15 of a 28 day cycle. overall number of participants Analyzed: 3, Measure Type: Count of participants, Unit of Measure: Participants 0 0.0%. ipants with DLT in the first cycle (28 days) for the determination of the maximum tolerated dose (MTD) Important Limitations and Caveats are provided in the respective section. ts 2 ts 2. ',\n",
       " 'Death not associated with CTCAE term - Death NOS 1/95 (1.05%), Death - Disease progression NOS 2/95 (2.11%), CNS cerebrovascular ischemia 1/95 (1.05%)Adverse Events 1:, Total: 3/31 (9.68%), Edema: limb * 2/31 (6.45%), Neutrophils/granulocytes (ANC/AGC) * 0/31 (0.00%), Cardiac General - Other (Spec ',\n",
       " 'participants received lapatinib 1500 mg orally OD with paclitaxel. paclitaxel was administered as a 1-hour IV infusion at a dose of 80 mg/m2. ',\n",
       " 'infiltrating carcinoma of the breast meeting any of the following criteria:, T1-3, any N disease, Proven ductal carcinoma in situ, Unresected disease, Planned mastectomy as definitive surgical procedure. Nonpalpable tumor allowed (e.g., initial T2-3 tumor that responded to preoperative therapy), No inflammatory breast cancer or other T4 features. e patients must use effective contraception, no significant history of severe allergy to iodinated contrast material or debilitating anxiety that may not allow for a ductogram, PRIOR CONCURRENT THERAPY:, See Disease Characteristics, Prior preoperative chemotherapy, trastuzumab (Herceptin®), or hormonal therapy allowed provided it was completed 7-14 days prior to study treatment, No other prior procedure that may have altered the breast ductal system in the ipsilateral breast e Oncology Group (ECOG) performance status of 0 or 1, Baseline left ventricular ejection fraction (LVEF) at least 50%, Exclusion Criteria:, Pregnant, lactating, or women of childbearing potential who are not surgically sterile or not willing to use adequate contraceptive methods. Previous treatment with Herceptin or other anti-HER therapies, or any previous chemotherapy for advanced or metastatic disease. ',\n",
       " 'atypical ductal hyperplasia, ductal carcinoma in situ, or lobular carcinoma in situ, Prior random periareolar fine needle aspiration (RPFNA) showing atypical hyperplasia, Family history consistent with hereditary breast cancer, as indicated by 1 of the following criteria. 5% on mammogram performed within 6 months prior to initiation of study drug. Has regular menstrual cycles (between 21 and 35 days) unless using extended regimen oral contraceptives or a contraceptive device. amin D for premenopausal bone health (1,200 mg calcium and 800 IU vitamin D daily), Negative pregnancy test prior to receiving study agent. Exclusion Criteria, pregnant or nursing within the past 6 months, nursing within the past 6 months, Known osteoporosis or severe osteopenia. ',\n",
       " 'results 1:, Arm/Group Title: A (Sorafenib + Gemcitabine), Arm/Group Description: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours), Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily. Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine). overall number of participants Analyzed: 81, Median (95% Confidence Interval), Unit of Measure: Days 103 (83 to 128), Results 2:, Arm/Group Title: B (Placebo + Gemcitabine or Capecitabine), Arm/Group Description: Placeb dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine). Overall number of participants Analyzed: 79, Median (95% Confidence Interval), Unit of Measure: Days 81 (48 to 95) ',\n",
       " 'sentinel lymph nodes are found in 125-I Methylene blue dye. one arm diagnostic using 1 mCi of 1 mCi of 1 mCi of 125-I dye. ',\n",
       " 'Anaemia 2/40 (5.00%), Febrile Neutropenia 3/40 (7.50%), Neutropenia 2/40 (5.00%), Thrombocytopenia 5/40 (12.50%), Pericardial Effusion 1/40 (2.50%), Abdominal Pain Lower 1/40 (2.50%), Disease Progression 6/40 (15.00%), Fatigue 1/40 (2.50%), Pyrexia 3/40 (7.50%), Septic Shock 1/40 (2.50%), Streptococcal In ',\n",
       " 'anemia 0/25 (0.00%), Sinus tachycardia 0/25 (0.00%), Pericardial effusion 1/25 (4.00%), Gastrointestinal disorders - other, specify -stomatitis) 0/25 (0.00%), Vomiting 1/25 (4.00%), Fever 0/25 (0.00%), Injection site reaction 1/25 (4.00%), Catheter related infection 0/25 (0.00%), Activated partial thrombo ',\n",
       " 'female with histologically confirmed breast cancer, Stage II-IV disease, ER and/or PR positive, ECOG Performance Status 0-1, Tumor must be present following core needle biopsy. postmenopausal, No prior treatment for current breast cancer. use of other COX-2 inhibitors such as rofecoxib (Vioxx®, aspirin, trisalicylate (Trilisate®) is not permitted during the time on study. no washout period is required. ',\n",
       " 'inTERVENTION 1:, Mammography Only, For this reporting arm, the interpretation and analysis was done with gamma imaging only. ',\n",
       " 'the DXA devices of participating sites were cross-calibrated and the results were analyzed by a central reader. the results were compiled and analyzed by a central reader. participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months. overall number of participants Analyzed: 253, Mean (Standard Deviation), Unit of Measure: Percentage of BMD 1.955 (3.3658), Results 2:, Arm/Group Title: Zoledronic Acid Delayed-start, Arm/Group Description: zoledronic acid 4 mg i.v. overall number of participants Analyzed: 256, Mean (Standard Deviation), Unit of Measure: Percentage of BMD -2.325. ',\n",
       " 'oral itraconazole 200mg a day until disease progression or unacceptable toxicities. overall number of participants Analyzed: 12, Mean (Standard Deviation), Unit of Measure: ng/mL Week 2 Intraconazole Concentration: 230.7 (216.8), Week 2 6-OH Itraconazole Concentration: 454.8 (429.3), Week 4 6-OH Itraconazole Concentration: 501.6 (502.6)Outcome Measurement:, Dose Es report of Dose-Limiting Toxicities (DLTs) were assessed to determine the MTD. time frame: From date of first dose to 30 days after termination, the longest 163 weeks. ',\n",
       " 'overall survival is defined as the time from the date of randomization to the date of death from any cause. patients who are lost-to-follow-up or are alive at the time of analysis will be censored at the time they were last known to be alive. patients randomized to TPC will receive single-agent IV chemotherapy. eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel will be administered per standard of care. ',\n",
       " 'u-NTx is a biochemical index of bone resorption. participants provided urine specimens on Day 1 and at Week 4. overall number of participants Analyzed: 14, Mean (95% Confidence Interval), Unit of Measure: Percentage change -77 (-82 to -62) 71) ',\n",
       " 'Abraxane 100 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7. 10 Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Overall number of participants Analyzed: 28, Measure Type: Number, Unit of Measure: participants 16, Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV. Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10), Overall number of participants Analyzed: 27, Measure Type: Number, Unit of Measure: participants 2_ ',\n",
       " 'participants continued treatment until progressive disease (PD), unacceptable toxicity, required palliative radiotherapy or surgical intervention of lesion(s), withdrawal from study treatment, withdrawal of study consent, participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment. pants continued treatment until progressive disease (PD), unacceptable toxicity, required palliative radiotherapy, withdrawal from study treatment, withdrawal of study consent, participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment. ',\n",
       " 'the breast tissue expander is implanted following mastectomy. it is activated by remote control to release small doses of carbon dioxide from an internal reservoir. ',\n",
       " 'postmenopausal breast cancer (adenocarcinoma) estrogen (ER) and/or progesterone (PR) receptor positive that is locally advanced or locally recurrent and not able to be surgically removed OR with measurable and/or disease that is able to be assessed including isolated bone metastasis, Female patients 18 years or older. sient ischemic attacks in the last 6 months, no symptoms of peripheral vascular disease, no history of abdominal fistula, gastrointestinal perforation or intrabdominal abscess in the past 6 months. no known hypersensitivity to phosphate, trehalose or polysorbate, no serious non-healing wound, ulcer or bone fracture. ',\n",
       " 'the primary indicator of drug efficacy was CNS objective response rate. a CNS objective response rate was defined as either a Complete response (CR) or Partial response (PR) provided there was no progression of systemic disease outside of the CNS, increasing steroid requirements, or worsening of neurological signs and symptoms. Cohort A subjects had ECOG performance status 0-1, and one or two prior trastuzumab-containing regimens, in total, for treatment of breast cancer in adjuvant and/or metastatic settings. overall number of participants Analyzed: 94, Measure Type: Count of Participants, Unit of Measure: Participants Complete response (CR): 0 0.0%, Partial response (PR): 6 6.4%, Stable disease (SD): 40 42.6%, Progressive disease (PD: ts Complete response (CR): 0 0.0%, Partial response (PR): 9 6.3%, Stable disease (SD): 46 32.2%, Progressive disease (PD): 70 49.0%, Unknown: 18 12.6%. ',\n",
       " 'Chest pain *1/30 (3.33%), Abdominal pain *1/30 (3.33%), Diarrhea *2/30 (6.67%), Edema limbs *1/30 (3.33%), Hypersensitivity *2/30 (3.33%), Immune system disorder *1/30 (3.33%), Device related infection *2/30 (6.67%), Upper respiratory infection *1/30 (3.33%), Fracture *1/30 (3.33%)Adverse Events 1:, Total: 7/52 (13.46%), Feb * 0/30 (0.00%), Nervous system disorders - Other, specify * [1]0/30 (0.00%). ',\n",
       " '52/133 (39.10%), Thrombocytopenia 2/133 (1.50%), Anaemia 1/133 (0.75%), Disseminated intravascular coagulation 0/133 (0.00%), Atrial thrombosis 1/133 (0.75%), Cardiac failure 0/133 (0.00%), Vertigo 0/133 (0.00%), Vomiting 3/133 (2.26%), Nausea 1/133 (0.75%), Colitis 1/133 ',\n",
       " \"patient must have either measurable disease by RECIST 1.1 or bone lesions in absence of measurable disease. exclusion Criteria:, Patient with symptomatic visceral disease or disease burden that makes the patient ineligible for endocrine therapy per the investigator's best judgment. olled heart disease and/or recent cardiac events. \",\n",
       " 'treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. four weeks after the last combination dose, patients continue to receive anti-B7H1 monoclonal antibody MEDI4736 every 2 weeks. patients achieving PD or clinical benefit may be retreated with anti-B7H1 monoclonal antibody MEDI4736 for an additional 52 weeks. NTx & CTx. ',\n",
       " 'patients with either HER2 3+ positive tumors by immunohistochemistry (Dako Herceptest®) or gene amplification (> 2 copies) by fluorescence in-situ hybridation (FISH) are eligible. patients must have measurable disease as defined by RECIST guidelines. women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. women must have a negative serum or urine pregnancy test within 1 week prior to beginning treatment on this trial. treatment for systemic infections within 14 days of enrollment. patients with active brain metastases requiring treatment include surgery, radiation, and corticosteroids. patients with asymptomatic non- progressing brain metastases have completed treatment 30 days before enrollment. rvix., Ejection fraction 50% or below the lower limit of the institutional normal range, whichever is lower. patients may not be receiving any other investigational agents within 30 days before enrollment. pregnant women are excluded from this study because the investigational agents may have the potential for teratogenic or abortifacient effects. all herbal and alternative medications should be discontinued while on study. this includes but not limited to: Hydrastis canadensis (goldenseal) ',\n",
       " 'inTERVENTION 2:, Moderated Group, one 12-week online support group led by a professional healthcare provider, INTERVENTION 2:, non-facilitated (Peer-led), 12-week online support in a peer-led formatINTERVENTION 1:, Sentinel lymph nodes biopsy with radiolabeled Methylene blue. ',\n",
       " 'ANAEMIA 1/199 (0.50%), BONE MARROW FAILURE 1/199 (0.50%), FEBRILE NEUTROPENIA 11/199 (5.53%), LEUKOPENIA 1/199 (0.50%), PANCYTOPENIA 1/199 (0.50%), ACUTE MYOCARDIAL INFARCTION 1/199 (0.50%), ATRIAL FLUTTER 1/199 (0.50%), CARDIAC FAILURE 3/199 (1.51%), Ad Nausea 0/8 (0.00%), Stomatitis 0/8 (0.00%), Upper gastrointestinal haemorrhage 0/8 (0.00%), Vomiting 0/8 (0.00%), Chest pain 0/8 (0.00%), Adverse Events 2:, Total: 2/6 (33.33%), Anaemia 0/6 (0.00%), Febrile neutropenia 0/6 (0.00%), Polycythaemia 0/6 (0.00%), Acute coronary syndrome 0 ',\n",
       " 'Pericardial effusion [1]0/3 (0.00%), Abdominal muscle wall hemorrhage [2]0/3 (0.00%), Dehydration [3]0/3 (0.00%), Gastroenteritis 0/3 (0.00%), Vomiting [4]0/3 (0.00%), Colonic perforation [5]0/3 (0.00%), Abdominal pain 0/3 (0.00%), Lung infection 0/3 (0.00%), Wound infection 0/3 (0.00 Arrhythmia * 1/1755 (0.06%), Atrial fibrillation * 1/1755 (0.06%), Cardiac failure * 0/1755 (0.00%), Cardiac tamponade * 0/1755 (0.00%), Adverse Events 2:, Total: 64/868 (7.37%), Anaemia * 2/868 (0.23%), Neutropenia * 2/868 (0.23%), Thrombocytopenia * 1/868 (0.12%), ',\n",
       " \"patients must have histologically confirmed metastatic breast cancer. tissue (a minimum of 3 slides) from the biopsy is required for review. patients must have a life expectancy of greater than 12 weeks. must have a life expectancy of greater than 12 weeks. must have an ECOG performance status = 2. patients must be off any medications by the time of registration. patients with known brain metastases are NOT eligible for participation. patients with known brain metastases are NOT eligible for participation. cation, Malabsorption syndrome, Require intravenous (IV) alimentation, History of prior surgical procedures affecting absorption, Uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis) \",\n",
       " 'iv Vinflunine Plus Capecitabine, Vinflunine dose 280 mg/m2 on day 1 of each cycle every 3 weeks, Capecitabine 825 mg/m2 twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest. inTERVENTION 2:, arm B: Capecitabine, 1250 mg/m2 twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest. ',\n",
       " 'pCR was defined as no histologic evidence of invasive tumor cells in the surgical breast specimen, axillary nodes, or sentinel node identified after neoadjuvant chemotherapy. participants were treated with intravenous (IV) doxorubicin (60 milligrams per meters squared [mg/m2]) and cyclophosphamide (AC) every 21 days for 4 cycles. weekly paclitaxel (WP) resumed at the same oral dose 4-6 weeks after surgery and was continued daily for 6 months. overall number of participants Analyzed: 93, Measure Type: Number, Unit of Measure: Participants 16_0. ',\n",
       " 'Thrombocytopenia * 4/26 (15.38%), Neutropenia * 3/26 (11.54%), Epitasis * 1/26 (3.85%), Epitasis * 1/26 (3.85%), Peripheral arterial ischemia * 1/26 (3.85%), Weakness * 1/26 (3.85%), Pain * [2]2/26 (7.69%), Febrile neutropenia * 1/26 (3.85%), Aspartate Aminotransferase * ',\n",
       " 'at increased risk for the development or recurrence of breast cancer, defined as an estradiol level 9 pg/mL, No evidence of suspicious or malignant disease. breast cancer is defined as an estradiol level 9 pg/mL. the status of the ovaries is unknown AND follicle-stimulating hormone (FSH) level is in the postmenopausal range. follicle-stimulating hormone level is in the postmenopausal range. f the cervix, no osteoporosis, no hyperlipidemia, no mental health status resulting in cognitive or emotional impairment that would preclude study participation. PRIOR CONCURRENT THERAPY:, Biologic therapy, Not specified, Chemotherapy, Not specified, Endocrine therapy, More than 30 days since prior AND no concurrent use of any of the following hormonal agents. cteristics, no prior bilateral mastectomy, Other, More than 60 days since prior treatment for invasive breast cancer or DCIS, More than 30 days since prior bisphosphonates or calcitonin. no concurrent calcitonin, no concurrent bisphosphonate therapy, Concurrent cholecalciferol (vitamin D) and calcium to augment bone mineral density allowed. ',\n",
       " 'disease progression was defined as the appearance of any new lesion not previously identified or an estimated increase of 25% or more in existent bidimensionally or unidimensionally measurable lesions. for bidimensionally or unidimensionally measurable lesions of 1.0 cm or less an increase of 0.5 cm was required. in the Extension phase participants could cross-over to also receive trastuzumab 4 mg/kg initial loading dose intravenous (iv) over 90 minutes. weekly doses of 2 mg/kg iv over 30 minutes plus 1 mg oral dose of anastrozole every day for 24 Months in the Main phase. ',\n",
       " 'treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. four weeks after the last combination dose, patients continue to receive anti-B7H1 monoclonal antibody MEDI4736 every 2 weeks. patients achieving PD or clinical benefit may be retreated with anti-B7H1 monoclonal antibody MEDI4736 for an additional 52 weeks. NTx & CTx. ',\n",
       " 'for patients with more than one measureable lesion on the MRI, the sum over all measureable lesions on the MRI was calculated at each time point. a mean and 95% confidence interval will be constructed using two-sided t-tests. cubic centimeters -1.93 (-2.87 to -0.98). ',\n",
       " 'primary tumor or metastasis must overexpress HER2. primary tumor or metastasis must overexpress HER2. patients may have received prior radiation therapy. treatment with any investigational drug within 4 weeks, Long-term treatment, over 3 months, with a systemic steroid or another immunosuppressive agent. Other malignancies within the past 3 years, except for adequately treated carcinoma of teh cervix or basal- or squamous-cell carcinoma of the skin. rcurrent medical condition, psychiatric illness or a social situation could limit their ability to comply with the study requirements. pregnant or breast-feeding women, HIV positive patients, Known hypersensitivity to RAD001 or other rapamycins. ',\n",
       " 'patients will receive 3400 cGy delivered in 10 twice-daily fractions. treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions. CES unit passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes. nit once daily in weeks 1-18., sham intervention given once a day for 18 weeks. ',\n",
       " 'Adverse Events 2:, Total: 4/26 (15.38%), Disseminated intravascular coagulation 1/26 (3.85%), Cardiac failure congestive 1/26 (3.85%), Breast cellulitis 1/26 (3.85%), Cellulitis 1/26 (3.85%), Acute myeloid leukaemia 1/26 (3.85%), Seizure 0/26 (0.00%), Pulmonary embolism 1/26 (3.85%), Adverse Events 2:, Total:  ',\n",
       " 'males and females 18 years old diagnosed with HER2 positive breast cancer. Scheduled to receive neoadjuvant or adjuvant trastuzumab (Herceptin®) therapy. patients receiving herceptin® with their chemotherapy are permitted for eligibility work-up. patients with metastatic disease, Prior treatment with trastuzumab or anthracyclines prior to this chemotherapy regimen. current treatment with angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), such as losartan, -blockers or digoxin. ',\n",
       " 'cytologically confirmed breast cancer with biopsy showing invasive or non-invasive (DCIS) at least 1.0 cm greatest diameter on imaging. Surgical patients undergoing lumpectomy, subtotal or total mastectomy, 18 years of age or greater, female, available tissue blocks from diagnostic biopsy, negative pregnancy test, medical history of surgical sterilization, or 1 year post menopausal. leAG or related ginseng products should be discontinued within 6 weeks of starting study drug. history of allergic reactions attributed to compounds of similar chemical or biologic composition to LEAG. history of chronic inflammatory process includes, but not limited to, rheumatoid arthritis and lupus. pregnant women must be willing to use birth control throughout study duration. current investigational medications or treatment with an investigational agent within 6 weeks prior to biopsy, current coumadin therapy or who have been treated with coumadin within the 2 weeks prior to biopsy, current monoamine oxidase inhibitors treatment. ',\n",
       " 'female patient 18 years of age, Histologically proven stage II or III adenocarcinoma of the breast, Must be candidate for neoadjuvant treatment (Tumor size 2 cm, T2, T3, T4 and/or clinical N1 or N2)., HER-2/neu 1+ or 2+ by immunohistochemistry, Must have operable tumor. pretreatment lab values must be performed within 14 days of patient registration. women with tumors that are HER-2 neu 0+ or 3+ by immunohistochemistry. women with HER 2 FISH amplified tumors (FISH ratio >2.2) will be excluded. locally advanced, inoperable tumors will be excluded. patients with concomitant or previous malignancies within the last 5 years are excluded from study. patients with concomitant or previous malignancies within the last 5 years are excluded from study. status is assessed using self-reports due to problems in reliably measuring follicle-stimulating hormone levels and estradiol in tamoxifen users. exclusion criteria are depression, history of migraines or hepatitis, abnormal chemistry profile (e.g., sodium, potassium, glucose), or a positive urine drug screen for illegal substances. ',\n",
       " 'women who require left chest wall post-mastectomy radiation with or without bolus must agree to use adequate contraception. if a woman becomes pregnant, she should inform her treating physician immediately Ability to understand and the willingness to sign a written informed consent. subjects must not be pregnant or nursing due to congenital abnormalities. subjects must not be nursing due to potential for congenital abnormalities. ',\n",
       " 'patients with node-negative, ER or PR-positive tumors 4 cm in size whose tumors are low risk are not eligible. patients for this study must be FISH negative if immunohistochemical stain is 2+ or 3+ positive; patients with negative, 0 or 1+ immunohistochemical stain for HER-2 are eligible. patients with reproductive potential must use an adequate contraceptive method (e.g., abstinence, intrauterine device, barrier device with spermicide or surgical sterilization) during treatment and for three months after treatment. life expectancy of less than 12 weeks. itivity to Doxil, doxorubicin, cyclophosphamide, cremophore (contained in teniposide, cyclosporine, and vitamin K) or to any component of Avastin, inadequately controlled hypertension (defined as blood pressure of >150/100 mmHg on antihypertensive medication), unstable angina pectoris, history of myocardial infarction or unstable angina within 12 patients must have a 2-d echocardiogram indicating an ejection fraction of > 50% within 42 days prior to first dose of study drug. method used at baseline must be used for later monitoring. no distant metastases on bone scan and on CT scans of chest and abdomen. ration or core needle biopsy within 7 days of beginning therapy, Urine protein:creatinine ratio 1.0 at initial screening, Known hypersensitivity to any component of Avastin, History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of beginning therapy. treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone. neurosurgical resection or brain biopsy performed within 3 months prior to day 1 will be excluded. ',\n",
       " 'patients receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID. beginning 2 weeks later, patients undergo leukapheresis to isolate and collect peripheral blood mononuclear cells for T-cell expansion. ',\n",
       " '59/373 (15.82%), Neutropenia 14/373 (3.75%), Febrile neutropenia 10/373 (2.68%), leukopenia 1/373 (0.27%), Anaemia 2/373 (0.54%), Lymphadenopathy 0/373 (0.00%), cardiac failure 2/373 (0.54%), Atrial fibrillation 1/373 (0.27%), Pericardial effusion 2/373 (0.54%), Cardiac failure congestive 1/373 (0.27%), Cardio ',\n",
       " 'inTERVENTION 1:, Study Participants, There are no arms or subgroups in this study. ',\n",
       " 'inTERVENTION 1:, Celecoxib, Randomized to receive celecoxib daily for 12 months, inTERVENTION 2:, Placebo, Randomized to receive placebo daily for 12 months. placebo daily for 12 months. placebo daily for 12 months. placebo daily for 12 months. placebo daily for 12 months. placebo daily for 12 months. placebo daily for 12 months. placebo daily for 12 months. placebo daily for 12 months. placebo daily for 12 months. placebo daily for ',\n",
       " '12/66 (18.18%), Palpitations * 1/66 (1.52%), Haematemesis * 1/66 (1.52%), Performance status decreased * 1/66 (1.52%), Hepatic failure * 1/66 (1.52%), Cellulitis * 1/66 (1.52%), Device related infection * 1/66 (1.52%), Pneumonia * 1/66 (1.52%), Femur fracture * 0/66 (0.00%), Hypokalaemia * 1/66 (1.52%), ',\n",
       " 'patients will be treated with exemestane., exemestane: 25 mg daily by mouth for 6 to 12 months. patients will be treated with docetaxel and cytoxan. ',\n",
       " '146/573 (25.48%), Anaemia 4/573 (0.70%), Disseminated intravascular coagulation 0/573 (0.00%), Neutropenia 1/573 (0.17%), Thrombocytopenia 0/573 (0.00%), Acute coronary syndrome 1/573 (0.17%), Angina pectoris 1/573 (0.17%), Atrial fibrillation 2/573 (0.35%), Atrial flutter 0/573 (0.00%), Cardiac ',\n",
       " '13/74 (17.57%), neutropenia 1/74 (1.35%), left ventricular dysfunction 1/74 (1.35%), fistula enterovesical 1/74 (1.35%), constipation and hypokalemia 1/74 (1.35%), nausea, vomiting and burning abdominal pain 2/74 (2.70%), nausea, vomiting and burning abdominal pain. ',\n",
       " '20/52 (38.46%), Febrile bone marrow aplasia * 5/52 (9.62%), Febrile neutropenia * 6/52 (11.54%), Leukopenia * 6/52 (11.54%), Atrial tachycardia * 1/52 (1.92%), Tooth loss * 1/52 (1.92%), Hyperthermia * 1/52 (1.92%), Malaise * 1/52 (1.92%), Pyrexia * 1/52 ( ',\n",
       " 'Adverse Events 1:, Total: 25/60 (41.67%), Anaemia * 1/60 (1.67%), Febrile neutropenia * 2/60 (3.33%), Thrombocytopenia * 3/60 (5.00%), Cardiac failure * 1/60 (1.67%), Cardiac failure acute * 1/60 (1.67%), Cardiogenic shock * 1/60 (1.67%), Left ventricular dysfunction * 1/60 (1.67%), Anal fistula * 1/ ',\n",
       " \"patients with histologically confirmed HER-2/neu-overexpressing adenocarcinoma of the breast must not be eligible for treatment of known curative potential for metastatic breast cancer. prior adjuvant Trastuzumab therapy is permitted. inflammatory bowel disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia or immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, or other rheumatologic disease. not pregnant, and on appropriate birth control if of child-bearing potential. serum bilirubin > 2.0 is acceptable in the setting of known Gilbert's syndrome. Adequate cardiac reserve with a cardiac ejection fraction within the lower limit of facility normal by MUGA. no active major medical or psychosocial problems that could be complicated by study participation. chemotherapy, radiation therapy, or biologic therapy (except Trastuzumab) will be allowed. participation in an investigational new drug trial within 28 days prior to treatment on study. \",\n",
       " '2/38 (5.26%), Febrile neutropenia 0/38 (0.00%), Skin infection 0/38 (0.00%), Seizure 1/38 (2.63%)Adverse Events 1:, Total: 92/490 (18.78%), Anaemia * 1/490 (0.20%), Anaemia of malignant disease * 0/490 (0.00%), Febrile neutropenia * 0/490 (0.00%), Neutropenia * 0/490 (0.00%), Thro ',\n",
       " 'OR is defined as the best response recorded from the start of treatment until progressive disease (PD)/recurrence. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of TLs. PD is defined as at least a 20% increase in the sum of the LD of TLs. nses were confirmed at subsequent assessments made >=28 days after the original response. participants with an unknown or missing response are treated as non-responders. treatment was continued for 12 weeks or until disease progression or withdrawal from treatment. after week 12, participants with clinical benefit had the option to continue with the lapatinib therapy at the same dose and schedule, until disease progression. overall number of participants Analyzed: 69, Measure Type: Number, Unit of Measure: Participants CR: 0, PR: 18_. ',\n",
       " 'participants received a daily dose of 5 tablets of lapatinib (1250 mg) at approximately the same time every day, either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast. participants also received capecitabine 2000 mg/m2) per day (divided and administered orally twice daily, 12 hours apart), for 14 days, every 21 days. participants received study medication until disease progression, unacceptable toxicity, or participant withdrawal. patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy, during 6 weeks of radiation therapy, and at least 2 weeks after radiation therapy) patients undergo radiation therapy QD 5 days a week for 6 weeks. ',\n",
       " \"female, Histologically-confirmed Her2neu positive breast cancer. immunohistochemistry (IHC) 3+ or Fluorescence In Situ Hybridization (FISH)+, stage II/III breast cancer including any large primary tumor (> 2 cm), tumors of any size associated with skin or chest wall involvement, tumors of any size. al Bilirubin equal to or less than institutional upper limit of normal (ULN), aspartate aminotransferase (AST); alanine aminotransferase (ALT); and alkaline phosphatase must be within the range allowing for eligibility. the more abnormal of the two values (AST or ALT) should be used. patients who are medically-unstable include but not limited to active infection, acute hepatitis, deep vein thrombosis requiring anticoagulant therapy, gastrointestinal bleeding, uncontrolled hypercalcemia, diabetes, dementia, seizures, superior vena cava syndrome. GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis). formulated with polysorbate 80., Current active hepatic or biliary disease (with exception of patients with Gilberts syndrome, asymptomatic gallstones, or stable chronic liver disease per investigator assessment). \",\n",
       " 'ANAEMIA 0/145 (0.00%), LEUKOPENIA 2/145 (1.38%), LEUKOCYTOSIS 1/145 (0.69%), THROMBOCYTOPENIA 1/145 (0.69%), FEBRILE NEUTROPENIA 1/145 (0.69%), THROMBOCYTOPENIA 1/145 (0.69%), THROMBOTIC THROMBOCYTOPENIC PURPURA 0/145 (0.00%), CARDIAC F Mucosal inflammation 1/79 (1.27%), Performance status decreased 1/79 (1.27%), Sudden death 1/79 (1.27%), Adverse Events 2:, Total: 13/76 (17.11%), Anaemia 1/76 (1.32%), Right ventricular dysfunction 0/76 (0.00%), Diarrhoea 0/76 (0.00%), Vomiting 2/76 (2.63%), Abdominal pain 1/76 (1.32%), Colonic obstruction 1/76 (1.3 ',\n",
       " 'Clinical benefit included subjects with complete response (CR), partial response (PR) and long term disease stabilization (SD) for at least 24 weeks. time frame: Baseline, Week 8, 16, 24, and every 12 weeks beyond 24 up to week 108. type: Number, Unit of Measure: participants 24_23. ',\n",
       " 'CR is defined as disappearance of all target and non-target lesions. PR is defined as disappearance of all target and non-target lesions. participants were monitored for toxicity, and sunitinib and/or capecitabine dosing could be interrupted or reduced according to individual tolerance. participants with progressive disease (PD) or intolerable toxicity were considered for discontinuation from the study. ',\n",
       " 'Previously diagnosed with primary breast cancer, Must have received 412 - 6 years of aromatase inhibitor therapy (e.g., letrozole, anastrozole, or exemestane) either as initial therapy or after prior tamoxifen citrate. is not required for patients who have undergone bilateral complete mastectomy, Hormone-receptor status. is defined as a tumor receptor content of > 10 fmol/mg protein or receptor positive by immunocytochemical assay. is not required for patients who have undergone bilateral complete mastectomy. no other prior or concurrent malignancy except adequately treated, superficial squamous cell or basal cell skin cancer, carcinoma in situ of the cervix, or other cancer treated > 5 years ago. *Elevated levels allowed provided imaging examinations have ruled out metastatic disease, PRIOR CONCURRENT THERAPY:, See Disease Characteristics, No concurrent selective estrogen receptor modulator (e.g., raloxifene, idoxifene) ',\n",
       " '58/438 (13.24%), Febrile neutropenia 13/438 (2.97%), Neutropenia 5/438 (1.14%), Anaemia 0/438 (0.00%), Thrombocytopenia 0/438 (0.00%), Haemolytic anaemia 1/438 (0.23%), leukopenia 1/438 (0.23%), cardiac failure congestive 0/438 (0.00%), Supraventricular tachycardia 0/438 (0.00%) ',\n",
       " 'the patient is ambulatory with a functional ECOG  2 status. the patient presents, at least one lesion measurable according to RECIST criteria. the patient is ambulatory with a functional ECOG  2 status. patients with severe intellectual impairment, unable to carry out basic daily routines and established depression. clinical significant cardiac disease or myocardial infarction within the last 12 months. patients with a history of uncontrolled convulsions, central nervous system disorders or psychiatric disability judged to be clinically significant should be excluded. patients under radiotherapy 4 weeks prior to study treatment or under previous radiotherapy on marker lesions be measured during the study. patients under major surgery within 4 weeks prior to study treatment or who have not completely recovered from the effects of major surgery. patients who lack upper gastrointestinal tract physical integrity or with malabsorption syndrome. patients Her2 + per FISH ó +++ ImmunohistochemistryInclusion Criteria:, Estrogen receptor or progesterone receptor positive breast cancer, premenopausal with regular menstrual cycles. ',\n",
       " 'ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment. CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions. overall number of participants Analyzed: 45, Measure Type: Number, Unit of Measure: percentage of participants 35.6 (24 to 49), Results 2:, Arm/Group Title: Cohort 2: TNBC, Arm/Group Description: Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle. ',\n",
       " '14/81 (17.28%), Neutropenia1/81 (1.23%), Cataract1/81 (1.23%), Ascites1/81 (1.23%), Gastritis Hemorrhagic1/81 (1.23%), Nausea1/81 (1.23%), Stomatitis2/81 (2.47%), Malaise1/81 (1.23%), Pain1/81 (1.23%), Pyrexia1/81 (1.23%), Infection2/81 (2.47%), Upper Limb Fracture1/81 (1.23%), ',\n",
       " '127/368 (34.51%), ANAEMIA 3/368 (0.82%), LEUKOPENIA 0/368 (0.00%), COAGULOPATHY 3/368 (0.82%), LYMPHADENOPATHY 0/368 (0.00%), THROMBOCYTOPENIA 2/368 (0.54%), BONE MARROW FAILURE 0/368 (0.00%), FEBRILE NEUTROPENIA 4/368 (1.09%), ATRIAL FLUT ',\n",
       " 'Anaemia 1/254 (0.39%), Febrile neutropenia 1/254 (0.39%), Lymphadenopathy 1/254 (0.39%), angina pectoris 0/254 (0.00%), Angina unstable 0/254 (0.00%), Bundle branch block left 0/254 (0.00%), Cardiac failure 4/254 (1.57%), Coronary artery disease 0/254 (0.00%), Coronary artery stenosis 1/254 (0.39%), Adverse Events 2 ',\n",
       " 'patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy. treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity. participants received single oral dose of PD-0332991 125 mg capsule in lead-in period (7 days prior to Cycle 1 Day 1) followed by PD-0332991 125 mg capsule orally once daily continuously for 21 days. 7 days off treatment in each cycle of 28 days unless participants experienced disease progression or unacceptable toxicity or withdrew consent. ',\n",
       " 'INTERVENTION 1: Pemetrexed, 600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression. ',\n",
       " 'patients will be treated with exemestane., exemestane: 25 mg daily by mouth for 6 to 12 months. patients will be treated with docetaxel and cytoxan. ',\n",
       " 'Adverse Events 1:, Total: 128/425 (30.12%), Febrile neutropenia *2/425 (0.47%), Anaemia *2/425 (0.47%), Pancytopenia *2/425 (0.47%), Coagulopathy *1/425 (0.24%), Idiopathic thrombocytopenic purpura *0/425 (0.00%), Pericardial effusion *1/425 (0.24%), Acute coronary syndrome *1/425 (0.24%) ',\n",
       " 'HER-2 status can be determined either by immunohistochemistry (score, 3+) or by fluorescence in situ hybridization. history of trastuzumab resistance, defined as the development of progressive disease after trastuzumab-based therapy for metastatic breast cancer. a pregnancy test will be obtained if the patient is a woman of child-bearing potential, defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months. patients must have measurable disease using Response Evaluation Criteria in Solid Tumors (RECIST) ve received investigational agents within 15 days of enrollment. left ventricular ejection fraction determined by echocardiogram or multigated acquisition must be 50% or higher. a known history of HIV seropositivity, Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection) patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumadin), patients unwilling to comply with the protocol. ',\n",
       " 'stage I-III invasive breast cancer, stage I-III invasive breast cancer, at least 3 months since completion of all intended local and systemic therapy. at least 1 healthy intact breast, No prior radiotherapy or mastectomy, Prior biopsies allowed, Any hormone-receptor status, PATIENT CHARACTERISTICS:, Female, Pre- or post-menopausal, not pregnant or nursing, Negative pregnancy test. e A (HMG-CoA) reductase inhibitor or any of its components, No concurrent infectious, inflammatory, or autoimmune diseases. standard drink defined as 10 grams of alcohol, equivalent to 285 mL of beer, 530 mL of light beer, 100 mL of wine, or 30 mL of liquor. no selective estrogen receptor modulator or aromatase inhibitor within the past 3 months, no prior estrogen and/or progesterone HRT within the past tion > 8 ounces per day, no other concurrent agents or therapies intended to treat or prevent in situ or invasive breast cancer. ',\n",
       " 'invasive mammary carcinoma, Stage IV disease, Basal-like disease (triple-negative, hormone-refractory, HER2-negative), no locally recurrent breast cancer, no symptomatic brain metastases. patients with a history of brain metastases are eligible provided they are clinically stable for > 3 weeks after completion of radiotherapy and are not taking prophylactic anticonvulsants that are CYP3A4 modifiers. ents with Gilbert syndrome, serum glutamate oxaloacetate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) 1.5 times ULN ( 3 times ULN in the presence of liver metastasis), Alkaline phosphatase 3 times ULN (in the presence of liver metastasis), not pregnant or nursing, Negative pregnancy test, Fertile patients must use effective barrier contraception during uncontrolled hypertension (systolic BP > 180 mm Hg or diastolic BP > 100 mm Hg, found on 2 consecutive measurements separated by a 1-week period and despite adequate medical support) clinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment [grade 3 according to NCI Common Toxicity Criteria for Adverse hepatitis B or C, PRIOR CONCURRENT THERAPY:, See Disease Characteristics, Recovered from prior therapy, Prior total cumulative life-time dose of doxorubicin 360 mg/m2 or epirubicin 640 mg/m2. at least 2 weeks since prior investigational drugs, At least 14 days since prior and no concurrent CYP3A4 inducers, At least 7 days since prior and no concurrent CYP3A4 induce ',\n",
       " '5/32 (15.63%), Leukopenia 1/32 (3.13%), Neutropenia 1/32 (3.13%), Cataract 1/32 (3.13%), Infection 1/32 (3.13%), Completed suicide 1/32 (3.13%)Adverse Events 1:, Total: 4/6 (66.67%), Anemia 0/6 (0.00%), Takotsubo cardiomyopathy 1/6 (16.67%), Pericardial effusion 0/6 (0.00%), Vertigo 1/6 (16.67 ',\n",
       " 'Participant is willing and able to give informed consent for participation in the study;, Female, aged 18 years or above;, Diagnosed with breast cancer (invasive or dcis);, Willing to allow his or her general practitioner and consultant, if appropriate, to be notified of participation in the study. ',\n",
       " 'women of 18 years of age with proven diagnosis of advanced adenocarcinoma of the breast. ER-positive and/or PgR-positive breast cancer based on local laboratory results. patients must be appropriate candidates for letrozole or fulvestrant therapy. ',\n",
       " 'bevacizumab Plus Paclitaxel, Bevacizumab 10 mg/kg intravenous (i.v.), days 1 and 15, every 4 weeks, Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks, INTERVENTION 2:, Bevacizumab Plus Capecitabine, bevacizumab 15 mg/kg i.v., day 1, every 3 weeks, Capecitabine 1000 mg/m2 twice-daily, days 1 ',\n",
       " 'age 18 years, Stage 1-4 invasive breast cancer that is histologically confirmed at MSKCC. Status post mastectomy with axillary exploration (sentinel node biopsy and/or axillary lymph node dissection) to receive PMRT, ECOG Performance Status of 0 or 1, Exclusion Criteria:, Male, Patients with clinical evidence of gross disease. nts are allowed), psychiatric illness that would prevent patient from giving informed consent, Inability or unwillingness to comply with skin care instructions and follow-up, Allergy to either Eucerin or MF, Residual grade >1 skin toxicity, cellulitis, or incompletely healed wound(s) at intended site of study drug application at the time of the start of RT. treatment with palliative or pre-operative radiation. ',\n",
       " 'Adverse Events 1:, Total: 80/260 (30.77%), Anaemia * 2/260 (0.77%), Febrile neutropenia * 0/260 (0.00%), Neutropenia * 2/260 (0.77%), Thrombocytopenia * 0/260 (0.00%), Bundle branch block right * 0/260 (0.00%), Pericardial effusion * 0/260 (0.00%), Cardiopulmonary failure * 0/260 (0.00%), Aplasia febrile neutropenia 3/74 (4.05%), speech impairment 1/74 (1.35%), dyspnea, pain 1/74 (1.35%), hemorrhage/bleeding 2/74 (2.70%) ',\n",
       " \"patients must be able and willing to give written informed consent prior to any study related procedures, Ambulatory, female patients with an age 18 years, Ambulatory, female patients with an age 18 years, Patients with histologically or cytologically proven diagnosis of breast cancer eligible for neoadjuvant or adjuvant chemotherapy. patients with baseline WBC LLN/3.5 x 109/L, ANC of 1.5 x 109/L, platelet count 100 x 109/ patients with myeloid malignancies and myelodysplasia or evidence of metastatic disease in bone marrow or brain, 5. patients currently receiving radiation therapy or have completed radiation therapy within 4 weeks before study entry or likely to receive radiotherapy during the study. patients with history of systemic antibiotic use within 72 hours prior to chemotherapy, 9. patients with active infection which may require systemic antimicrobial therapy. patients with seropositivity for HIV or HBV or HCV, 11. Known cases of Sickle Cell Anemia, 12. Patients with radiographic evidence of active pulmonary infections and/or recent history of pneumonia within 1 month of screening. patients with clinically evident splenomegaly confirmed by ultrasonography, 14. patients with any other clinically significant disease(s) which could compromise the patient's involvement in the study or overall interpretation of the data. women of child-bearing potential who are not willing to follow a reliable & effective contraceptive measure during the study. \",\n",
       " 'inTERVENTION 1:, Active Control Group, Health Education Active Control Group, INTERVENTION 2:, My Surgical Success Treatment Group, My Surgical Success Intervention GroupINTERVENTION 1:, All Study Participants, PA Compression Image Sets, All image sets (30 TC compression image sets) were evaluated for acceptability of overall clinical image quality by two (2) readers. ',\n",
       " 'MM-111 will be combined with Herceptin, MM-111 and Herceptin: for Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV. overall number of participants Analyzed: 16, Measure Type: Number, Unit of Measure: participants 16Outcome Measurement:, number of participants with Trastuzumab-induced cardiotoxicity after 52 weeks of treatment. Participants 45 29.6%, Results 2:, Arm/Group Title: Arm II Coreg CR, Arm/Group Description: Patients receive oral Coreg CR once daily., Coreg CR : Given orally, Overall Number of Participants Analyzed: 147, Measure Type: Count of Participants, Unit of Measure: Participants 43 29.3%. ',\n",
       " 'women 18-75 years old with newly diagnosed breast cancer considered candidates for breast conserving surgery (i.e. lumpectomy). Exclusion Criteria:, Children (18 years old), Pregnant or Lactating women, Diabetic patients (Type I or II), Patients who are scheduled for a sentinel node procedure using radioactive Tc-99m within 24 hours of PEM. ',\n",
       " \"participants initially received doxorubicin (60 mg/m2) plus cyclophosphamide (600 mg/m2) intravenously (IV) on Day 1, of every 14-day cycle for 4 cycles. in this Cohort growth factors, subcutaneous pegfilgrastim (6 mg) or filgrastim, could be used with eribulin therapy at the physician's discretion. Eribulin mesylate was administered following the doxorubicin plus cyclophosphamide regimen at a dose of 1.4 mg/m2 IV over 2 to 5 minutes. in this Cohort filgrastim was used with eribulin therapy at a dose of 300 micrograms for participants 60 kg or 480 micrograms for participants >60 kg. \",\n",
       " 'females, 18 or older, recurrent or progressive locally advanced metastatic breast cancer, paraffin-embedded tissue block must be available, measurable disease, prior chemotherapy with anthracycline, a taxane, or both (neoadjuvant, adjuvant, or metastatic setting) ',\n",
       " 'the date of the event is the earliest date of the occurrence of an objective disease recurrence, a second primary cancer, or death from any cause without a prior event. par. who started additional anti-cancer adjuvant therapy prior to the recurrence of their disease were to be censored. y and did not experience a specified event or death were to be censored at the last visit date available at which progression was assessed. from randomization until date of the first occurrence of an objective disease recurrence, a second primary cancer, or death from any cause. treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer. withdrawal from study treatment due to unacceptable toxicity, or consent withdrawal. ',\n",
       " 'females 18 years, Histologically confirmed and documented invasive breast cancer, breast cancer without evidence of distant metastases (Stage 4) based on staging work-up, Chemotherapy naive, who have not received chemotherapy in the neoadjuvant setting. candidates for chemotherapy in the adjuvant setting of taxane/cyclophosphamide-based regimen, e.g., as background chemotherapy, Zubrod/WHO/ECOG performance status 2 lanine Aminotransferase (ALT) 3 x the upper limit of normal (ULN) of the reference lab. Serum creatinine of 1.5 x ULN for reference lab or estimated glomerular filtration rate (eGFR) of 60 mg/min, Body mass index (BMI) of 19 to 40 kg/m2. Subjects and their partners agree to use of an effective method of contraception. sexually active subjects must use contraception while on HSP-130 from admission to the final Follow-up Visit. able to understand verbal or written instructions and comply with all study requirements. subject will NOT be eligible for study participation if any of the following criteria are met. doxorubicin, no concurrent use of inhibitors and inducers of CYP3A4, CYP2D6, and/or P-gp or with trastuzumab due to increased risk of cardiac dysfunction, Chemotherapy other than that included in this study (taxane/cyclophosphamide-based regimen, e.g., TAC or TC) or known immunosuppressive agents including chronic oral corticosteroid use, or radiation therapy within rk heart association (NYHA) class III or IV heart failure, severe uncontrolled cardiac disease (unstable angina, clinically significant ECG abnormalities) or MI within the previous 6 months before the first administration of the HSP-130. Subjects planning to be pregnant or to breastfeed before, during, or within 12 months after administration of the HSP-130 are not permitted to enroll in the study. patients must have histologically-confirmed adenocarcinoma of the breast with operable or inoperable stage 1c (primary tumor > 1.0 cm), II or III disease. patients may not have had definitive primary surgery. current treatment with therapeutic doses of any anti-coagulant is allowed. Known human immunodeficiency virus (HIV) infection. dgment of investigator, excess risk associated with study participation or study drug administration would make the patient inappropriate for entry into this study. ',\n",
       " 'Adverse Events 1:, Total: 4/33 (12.12%), Diarrhea 1/33 (3.03%), Intracranial hemorrhage 1/33 (3.03%), Ischemia cerebrovascular 1/33 (3.03%), Confusion 1/33 (3.03%), Skin disorder 1/33 (3.03%)Adverse Events 1:, Total: 5/11 (45.45%), Nausea 1/11 (9.09%), Vomiting 1/11 (9.09%), Fever 1/11 ',\n",
       " 'female with non-inflammatory breast adenocarcinoma must be at least 21 years of age. participants must be prescribed concurrent hormone treatment with radiation treatment. participants must receive five sessions of radiation therapy per week for at least four weeks. participants must be able to understand English and complete assessment forms. participants must be able to swallow medication. patients with bilateral breast cancer are not eligible. patients with collagen vascular disease, vasculitis, unhealed surgical sites are not eligible. greater than or equal to Grade 2 change Hemoglobin (i.e., 25% decrease from baseline); greater than or equal to Grade 1 change in Platelets (i.e., less than 75,000/mm3); greater than or equal to Grade 2 change in PT and PTT (i.e., 1.5-2x upper level normal) ',\n",
       " 'subjects will be randomly selected to receive saline (placebo) if randomized to this arm, subjects will receive an intraoperative injection of saline. injection will be performed in certain locations of the breast area to cover intercostal nerves supplying the breast tissue. subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively. ',\n",
       " 'participants with dose limiting toxicities (DLTs) graded Using National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.0. the following events, if considered to be study-treatment-related by the Investigator, were considered a DLT:, Hematologic:, Grade 4 neutropenia lasting 8 days. participants received pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab (K) 200 mg in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m2 in Cycles 2-5 on Days 1, 8 and 15 (once each week; QW) each cycle was 21 days. pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 100 mg/m2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at Area Under the Curve (AUC) 6 in Cycles 2-5 on Day 1 (Q3W) all treatments were administered via IV infusion except for doxorubicin (A), which was administered via IV injection ',\n",
       " 'the time from randomization to the first occurrence of disease progression was determined by investigator review of tumor assessments by RECIST, v1.1 or death on study. participants randomlyised to receive paclitaxel 80 mg/m2, intravenously on Days 1, 8, and 15 along with ipatasertib 400 mg, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study. participants randomised to receive paclitaxel 80 mg/m2, intravenously on Days 1, 8, and 15 along with placebo matching ipatasertib, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study. ',\n",
       " 'Adverse Events 1:, Total: 16/56 (28.57%), Pancytopenia 0/56 (0.00%), Pericarditis 0/56 (0.00%), Abdominal pain 1/56 (1.79%), Anal fissure 1/56 (1.79%), Constipation 0/56 (0.00%), Diarrhoea 1/56 (1.79%), Nausea 0/56 (0.00%), Oesophageal pain 0/56 (0.00%) ',\n",
       " 'sentinel lymph nodes are found in 125-I Methylene blue dye. one arm diagnostic using 1 mCi of 1 mCi of 1 mCi of 125-I dye. ',\n",
       " 'preoperative stages II-III per AJCC 6th edition, based on baseline evaluation by clinical examination and/or breast imaging. patients must have completed preoperative (neoadjuvant) chemotherapy with a standard chemotherapy regimen. patients must have the presence of significant residual invasive disease. patients with metastatic disease may not be pregnant, expect to become pregnant, plan to conceive a child while on study, or breastfeeding, Uncontrolled intercurrent illness, Non-healing wounds or major surgical procedures are not permitted within 28 day prior to enrollment. patients with clinically significant peripheral arterial disease should also be excluded. tory of grade 3 or 4 allergic reactions to compounds of similar chemical or biologic composition to cyclophosphamide (such as other alkylating agents) or methotrexate (such as other antimetabolites), Prior history of malignancy treated without curative intent, excluding nonmelanomatous skin cancer. Current use of anticoagulants is allowed as long as patients have been on a stable dose for more than two weeks with stable INR. ',\n",
       " 'phase 1, Azacitidine (Vidaza): 50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle. Nab-paclitaxel (Abraxane): 100mg/m2 weekly for 3 weeks of each 4-week cycle. ',\n",
       " 'overall survival is defined as the time from the date of randomization to the date of death from any cause. patients who are lost-to-follow-up or are alive at the time of analysis will be censored at the time they were last known to be alive. patients randomized to TPC will receive single-agent IV chemotherapy. eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel will be administered per standard of care. ',\n",
       " 'Anaemia 1/254 (0.39%), Febrile neutropenia 1/254 (0.39%), Lymphadenopathy 1/254 (0.39%), angina pectoris 0/254 (0.00%), Angina unstable 0/254 (0.00%), Bundle branch block left 0/254 (0.00%), Cardiac failure 4/254 (1.57%), Coronary artery disease 0/254 (0.00%), Coronary artery stenosis 1/254 (0.39%), Adverse Events 2 ',\n",
       " 'febrrile Neutropenia 3/40 (7.50%), Neutropenia 2/40 (5.00%), Thrombocytopenia 5/40 (12.50%), Pericardial Effusion 1/40 (2.50%), Abdominal Pain Lower 1/40 (2.50%), Disease Progression 6/40 (15.00%), Fatigue 1/40 (2.50%), Pyrexia 3/40 (7.50%), Septic Shock 1/40 (2.50%), Streptococcal Infection 1/40 (2.50%)Ad arthria 0/1 (0.00%), Hepatic Encephalopathy 0/1 (0.00%), Confusional State 0/1 (0.00%), Dyspnoea 0/1 (0.00%), arthria 0/1 (0.00%), arthria 0/1 (0.00%), arthria 0/1 (0.00%), confusional state 0/1 (0.00%), arthria 0/1 (0.00%), arthr ',\n",
       " 'Adverse Events 1:, Total: 12/63 (19.05%), Febrile neutropenia * [1]4/63 (6.35%), Congestive heart failure * [2]1/63 (1.59%), Cardiac-ischemia/infarction * 1/63 (1.59%), Vomiting * [1]1/63 (1.59%), Acute Pharyngitis * 1/63 (1.59%), Infection * 3/63 (4.76%), Neutrophil count decreased * [1 ',\n",
       " 'inTERVENTION 1:, Letrozole, Letrozole, 2.5 mg daily for six monthsINTERVENTION 1:, Celecoxib, Randomized to receive celecoxib daily for 12 months, inTERVENTION 2:, Placebo, Randomized to receive placebo daily for 12 months. ',\n",
       " 'time to disease progression (TTDP) at initial treatment was defined as the number of months between date of randomization and the date of first documented disease progression date or the date of death due to disease under study. TTDP censored at earliest of: 1) date of death not due to disease; 2) date of last contact for participants alive without disease progression; or 3) start date of other anti-tumor therapy; or 4) first dose date of crossover treatment. treatment continues until progression of disease, at which time crossover treatment begins. overall number of participants Analyzed: 239, Median (95% Confidence Interval), Unit of Measure: months 9.28 (7.73 to 10.79), Results 2:, Arm/Group Title: docetaxel plus capecitabine. ',\n",
       " 'POMS-F is the Profile of Mood States - fatigue scale. it ranges from 0 to 28; higher values indicate greater fatigue. overall number of participants Analyzed: 122, Least Squares Mean (Standard Error), Unit of Measure: units on a scale 6.96 (0.71) ',\n",
       " 'Gastroenteritis viral 1/39 (2.56%), Parainfluenzae virus infection 1/39 (2.56%), Seizure 4/39 (10.26%), Headache 1/39 (2.56%), Hydrocephalus 1/39 (2.56%), Hypertension 1/39 (2.56%)Adverse Events 1:, Total: 20/70 (28.57%), NAUSEA 2/70 (2.86%), VOMITING 1/70 (1.43%), DIARRHOEA 2/70 (1.43% ',\n",
       " 'cytologically confirmed breast cancer with biopsy showing invasive or non-invasive (DCIS) at least 1.0 cm greatest diameter on imaging. Surgical patients undergoing lumpectomy, subtotal or total mastectomy, 18 years of age or greater, female, available tissue blocks from diagnostic biopsy, negative pregnancy test, medical history of surgical sterilization, or 1 year post menopausal. leAG or related ginseng products should be discontinued within 6 weeks of starting study drug. history of allergic reactions attributed to compounds of similar chemical or biologic composition to LEAG. history of chronic inflammatory process includes, but not limited to, rheumatoid arthritis and lupus. women must be willing to use birth control throughout study duration. current investigational medications or treatment with an investigational agent within 6 weeks prior to biopsy, current coumadin therapy or who have been treated with coumadin within the 2 weeks prior to biopsy, current monoamine oxidase inhibitors treatment. measurable disease (including bone only, pleural effusions, etc.), Receiving Herceptin therapy. women who are pregnant or lactating. ',\n",
       " 'Adverse Events 1:, Total: 7/7 (100.00%), Febrile neutropenia 3/7 (42.86%), Cardiac failure 1/7 (14.29%), Neutrophil count decreased 1/7 (14.29%), Muscular weakness 1/7 (14.29%), Epistaxis 1/7 (14.29%), Interstitial lung disease 1/7 (14.29%), Pleural effusion 2/7 (28.57%) ',\n",
       " 'Neutropenia 3/28 (10.71%), Hepatitis acute 1/28 (3.57%), Pneumonia 1/28 (3.57%), Septic shock 1/28 (3.57%), Infected neoplasm 1/28 (3.57%), Deep vein thrombosis 1/28 (3.57%)Adverse Events 1:, Total: 1/24 (4.17%), Pericardial effusion *1/24 (4.17%), Other cardiac disorder *0/24 (0.00%), Ejection fraction decrease *0 ',\n",
       " 'the Boyd method compared between arms compared with placebo in premenopausal women. overall number of participants Analyzed: 46, Mean (Standard Deviation) ',\n",
       " \"the study team will generate a Kaplan- Meier curve of CNS PFS. Response and progression by MR were evaluated using WHO/modified McDonald's criteria. the recommended starting dose of eribulin mesylate is 1.4 mg/m2. n study eribulin mesylate, Pre-Medication: Zofran: Zofran at 8mg orally. given at the discretion of the treating physician, overall number of participants Analyzed: 9, Measure Type: Number, Unit of Measure: percentage of participants 88.9 (51 to 99.7)_ \",\n",
       " 'investigators recruited patients scheduled for a plastic/reconstructive consult. they identified patients who completed a mastectomy or were scheduled for one. they offered them the option to complete pre-appointment procedures at home. investigators recruited patients scheduled for plastic/reconstruction consultation. they recruited patients who completed or scheduled a mastectomy. patients were randomized using computer random assignment. consultation duration, decision process quality, and shared decision making. patient participation was approximately 30 minutes. ',\n",
       " 'percent change from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr) calculated using ((Week 13 value - Baseline value) x 100. overall number of participants Analyzed: 38, Mean (Standard Deviation), Unit of Measure: Percent change -10.19 (208.84), Results 2:, Arm/Group Title: Denosumab 30 mg Q4W. ',\n",
       " 'Female, 18-100 years old, Not pregnant or breastfeeding, Pre-study radiologic documentation of:, size 5 cm, unicentric, unilateral, suspicious mass or calcification, BIRADS classification IV, location of abnormality > 1 cm from skin, Ductal or Infiltrating Ductal Carcinoma, Grade I-III on final pathology, Good general health, Zubrod Performance Status of 0,1, or 2, No previous chemotherapy, No palpable axillary or supraclavicular lymph ',\n",
       " 'inTERVENTION 1:, Arm 1 (Patients With Pain), Duloxetine 30 mg daily x 1 week, then 60 mg daily x 4 weeks, then 30 mg daily x 2 weeks. treatment continues until unacceptable adverse events or patient refusal to continue participation. ',\n",
       " 'postmenopausal status defined as cessation of menses for >1 year or FSH > 20 mIU/mL (within the past month), Age 21 years, No prior chemotherapy, radiation therapy, or surgery within 6 months of study entry. ',\n",
       " 'clinical benefit rate is defined as complete response, partial response, or stable disease according to RECIST 1.1. subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC have centrally confirmed AR+ status. gx-024 softgel capsules will be administered once daily to a total dose of 18 mg, GTx-024. overall number of participants Analyzed: 52, Measure Type: Number, Unit of Measure: participants 15__ ',\n",
       " '22/123 (17.89%), Cardiac Ischemia/Infarction [1]1/123 (0.81%), Pain - Chest 2/123 (1.63%), Dehydration 2/123 (1.63%), Death [2]1/123 (0.81%), Weakness 1/123 (0.81%), Pain - Liver 1/123 (0.81%), Infection - Skin [3]3/123 (2.44%), Infection - Gastrointestinal [4]1/123 (0.81%), ',\n",
       " 'the other breast will be imaged using Patient-Assisted Compression (PAC), followed by Technologist-controlled (TC) Compression., Patient-Assisted Compression (PAC): The technologist will properly position the breast and apply minimum compression. the technologist will then guide the subject to achieve appropriate compression level, sufficient but not excessive, and the image will be acquired. TC compression will be conducted per standard of care practices at the site. the Pass Criteria require adequate performance in non-cancer cases (recall rate) and cancer cases (detection rate). ',\n",
       " 'Gemcitabine: 800 mg/m2, 30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD. inTERVENTION 2:, Treatment Schedule (3 Weekly), Arm A, Docetaxel and Gemcitabine (3 Weekly), to be given 30 minutes prior to Gemcitabine. gemcitabine: 1000 mg/m2, 30 min IV infusion on days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD. eated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD. nal correlative studies, F-18 16 alpha-fluoroestradiol: Correlative studies, anastrozole: Given PO, letrozole: Given PO, exemestane: Given PO, gene expression analysis: Correlative studies, anastrozole: Given PO, letrozole: Given PO, letrozole: Given PO, exemestane: Given PO, gene expression analysis: Correlative studies, positron emission tom ',\n",
       " 'Outcome Measurement:, Recurrence-free Survival, 2 years for the primary analysis + 3 additional years for secondary analysis. Time frame: 5 years, Results 1:, Arm/Group Title: Ketorolac 30 mg, Arm/Group Description: Active drug to be compared with placebo, Ketorolac 30 mg IV, Overall number of participants Analyzed: 96, Measure Type: Count of participants, Unit of Measure: Participants 80 83.3%, Results 2:, Arm/ ',\n",
       " 'ANAEMIA 0/145 (0.00%), LEUKOPENIA 2/145 (1.38%), LEUKOCYTOSIS 1/145 (0.69%), THROMBOCYTOPENIA 1/145 (0.69%), FEBRILE NEUTROPENIA 1/145 (0.69%), THROMBOCYTOPENIA 1/145 (0.69%), THROMBOTIC THROMBOCYTOPENIC PURPURA 0/145 (0.00%), CARDIAC F Mucosal inflammation 1/79 (1.27%), Performance status decreased 1/79 (1.27%), Sudden death 1/79 (1.27%), Adverse Events 2:, Total: 13/76 (17.11%), Anaemia 1/76 (1.32%), Right ventricular dysfunction 0/76 (0.00%), Diarrhoea 0/76 (0.00%), Vomiting 2/76 (2.63%), Abdominal pain 1/76 (1.32%), Colonic obstruction 1/76 (1.3 ',\n",
       " 'Adverse Events 1:, Total: 6/8 (75.00%), Thrombocytopenia 1/8 (12.50%), Hypertension 1/8 (12.50%), Hepatotoxicity 3/8 (37.50%), Pancreatectomy * 1/8 (12.50%). ',\n",
       " \"Febrile neutropenia 1/45 (2.22%), Cardiac ischemia/infarction 1/45 (2.22%), Ventricular arrhythmia - left ventricular systolic dysfunction 1/45 (2.22%), Hemmorhage - GI 1/45 (2.22%), Pancreatitis 1/45 (2.22%), Infection - pneumonia 1/45 (2.22%), Streptococcus 1/45 (2.22%), Abcess of Bartholin's cyst \",\n",
       " 'ECOG performance status 0-1, Age 18 yrs, Absolute neutrophil count 1,500/mm3, Hemoglobin 9 g/dL, Platelet count 100,000/mm3, Creatinine 1.5 times upper limit of normal (ULN), Urine protein:creatinine ratio  1.0, AST (aspartate aminotransferase 2.5 times ULN, Bilirubin normal, women of childbearing potential must use effective contraception, left ventricular hemoptysis, recent hemoptysis, no known hepatitis B or HIV seropositivity, no inadequately controlled hypertension, defined as systolic blood pressure (BP) > 150 mm Hg and/or diastolic BP > 100 mm Hg despite antihypertensive medications. history of hypertensive crisis or hypertensive encephalopathy, history of stroke or transient ischemic attack at any the criteria for positivity HER 2 are immuno-histochemistry (IHC) 3+ (>10% of tumor cells with complete and intense membrane staining), IHC 2+ with fluorescent in situ hybridization (FISH) / Chromogenic in situ hybridization (CISH) / silver-enhanced in situ hybridization (SISH) + for HER 2 amplification (*), FISH / CISH / SISH. the patient must have been informed of the study and sign and date informed consent document for entry into the trial. the patient must be willing and able to comply with study procedures and be available to answer the study questionnaires. the patient has another active malignancy other than breast adenocarcinoma. documented history of congestive cardiac insufficiency (CCI), high-risk arrhythmias uncontrolled angina requiring medication, clinically significant valvular disease, history of myocardial infarction or evidence of transmural infarction poorly controlled. women should undergo pregnancy testing blood or urine within 14 days prior to inclusion as institutional rules. ',\n",
       " \"age 18 and 85 years, Postmenopausal status defined as: no menstrual cycle in the past 12 months hysterectomy with bilateral oophorectomy hysterectomy with intact ovaries if age > 55 years. no menstrual cycle in the past 12 months hysterectomy with bilateral oophorectomy hysterectomy with intact ovaries if age > 55 years, Newly diagnosed with incident, primary, invasive, estrogen receptor positive clinical stage II or current (past 30 days) regular (at least once per week) use of reproductive hormone therapy, Tamoxifen, aromatase inhibitors, or other estrogen inhibitors, flaxseed, or antibiotics. history of Crohns' disease, ulcerative colitis, irritable bowel syndrome, celiac sprue, or other malabsorption syndrome, diverticulitis, diverticulosis, or other bowel diagnosis. \",\n",
       " 'Safety was assessed from first dose of study drug through at least 30 days after the last dose. toxicity was considered a dose limiting toxicity (DLT) if it occurred in the first 21 days. participants were treated at each dose level (DL) for minimum of 21 days before accrual to the next DL. if 0 dose level toxicity (DLT) was observed in the first 3 participants in a cohort, then 3 additional participants were studied. ype: Number, Unit of Measure: participants 1, Results 2:, Arm/Group Title: 70 mg Dasatinib + 825 mg/m2Capecitabine, Arm/Group Description: Dose Level 2: 70 mg dasatinib oral tablet BID plus 825 mg/m2 capecitabine oral tablet BID., Overall Number of participants Analyzed: 9, Measure Type: Number, Unit of Measure: participants 1___________ ',\n",
       " '27/94 (28.72%), Anaemia 2/94 (2.13%), Febrile neutropenia 2/94 (2.13%), leukopenia 1/94 (1.06%), Neutropenia 0/94 (0.00%), Thrombocytopenia 1/94 (1.06%), Arrhythmia 0/94 (0.00%), Atrial fibrillation 0/94 (0.00%), Cardiac failure congestive 0/94 (0.00%), Cardiomyopathy  ',\n",
       " 'Neutropenia [1]0/77 (0.00%), Left ventricular dysfunction 0/77 (0.00%), Cardiac ischemia 0/77 (0.00%), Colitis 0/77 (0.00%), Febrile neutropenia 0/77 (0.00%), Pulmonary/upper respiratory infection 0/77 (0.00%), Diverticulitis 0/77 (0.00%), Motor neuropathy 0/77 (0.00%), Endometrial mucosa thinkening ',\n",
       " 'paclitaxel 80 milligrams per meters squared (mg/m2) weekly for 12 weeks, followed by intravenous (IV) fluorouracil 600 mg/m2, IV epidoxorubicin 75 mg/m2 and IV cyclophosphamide 600 mg/m2 once every 21 days for four treatment courses. first dose of trastuzumab was administered at 4 milligrams per kilogram (mg/kg) IV for 60 minutes treatments were administered for 26 weeks prior to surgery. lapatinib doses were reduced to 1250 mg/day orally on an empty stomach. ',\n",
       " 'anemia 1/96 (1.04%), Febrile neutropenia 4/96 (4.17%), Heart failure 1/96 (1.04%), Abdominal pain 1/96 (1.04%), Dysphagia 1/96 (1.04%), Mucositis oral 1/96 (1.04%), Nausea 1/96 (1.04%), Vomiting 2/96 (2.08%), Death NOS 0/96 (0.00%), Pain 1/96 (1.04%), Catheter related infection 1/ ',\n",
       " 'Diabetes insipidus [1]0/21 (0.00%), Nausea 0/11 (9.09%), Ileus 1/11 (9.09%), Dehydration 1/11 (9.09%), Pain NOS [2]2/11 (18.18%), Pain - abdomen 0/11 (0.00%), Fracture [3]0/11 (0.00%), Progressive Disease 1/11 (9.09%), CNS Ischemia 1/11 (9.09%), Respiratory Failure 0/11 (0.00 ',\n",
       " 'Gemcitabine: 800 mg/m2, 30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD. inTERVENTION 2:, Treatment Schedule (3 Weekly), Arm A, Docetaxel and Gemcitabine (3 Weekly), to be given 30 minutes prior to Gemcitabine. gemcitabine: 1000 mg/m2, 30 min IV infusion on days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD. eated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD. nal correlative studies, F-18 16 alpha-fluoroestradiol: Correlative studies, anastrozole: Given PO, letrozole: Given PO, exemestane: Given PO, gene expression analysis: Correlative studies, anastrozole: Given PO, letrozole: Given PO, letrozole: Given PO, exemestane: Given PO, gene expression analysis: Correlative studies, positron emission tom ',\n",
       " 'exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period. participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as per standard medical practice. ',\n",
       " \"patients who are/will be receiving standard adjuvant trastuzumab [Herceptin®] for high-risk disease will participate in this study during the single-agent trastuzumab portion of their therapy. no clinical or radiographical evidence of active disease, not eligible for therapy of known curative potential for metastatic breast cancer. unless elevation is due to known Gilbert's syndrome, AST/ALT 2 times upper limit of normal (ULN), Alkaline phosphatase 5 times ULN, Not pregnant or nursing, Negative pregnancy test, Fertile patients must use effective contraception, Cardiac ejection fraction normal by MUGA OR 45% by ECHO, No other malignancies within the past 5 years. no uncontrolled medical problems, no active major medical or psychosocial problems that could be complicated by study participation, no corn allergy, no known severe hypersensitivity to trastuzumab. any number of prior chemotherapy regimens for metastatic breast cancer allowed. age from 18 years to 75 years inclusive; female gender; Histologically confirmed breast cancer (BC); metastatic BC (stage IV according to TNM classification version 6; metastatic BC); metastatic BC (stage IV according to TNM classification version 6; metastatic BC); metastatic BC (stage IV according to TNM classification version 6; metastatic BC); metastatic BC (stage IV according to TNM classification version 6; metastatic BC); metastatic BC (stage IV according to TNM classification version 6; metastatic BC); meta previous anticancer therapy for metastatic BC, including cytotoxic chemotherapy, or previous anticancer therapy with signal transduction inhibitors (e.g. lapatinib), biological drugs (e.g. trastuzumab, bevacizumab), experimental (not approved for BC therapy) anticancer drugs are allowed. non-progressing metastases not requiring treatment with glucocorticosteroids and/or anticonvulsants within 4 weeks prior to randomization. uncontrolled hypertension comprises all cases of arterial hypertension when no decrease in blood pressure could be achieved. ULN (5  ULN for patients with liver metastases); alkaline phosphatase level 5  ULN; pregnancy or lactation. conditions limiting patient's adherence to protocol requirements. \",\n",
       " 'AZD8931 160 mg bd, Part A: AZD8931 160 mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle. inTERVENTION 2:, AZD8931 120 mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle. ',\n",
       " 'the other breast will be imaged using Patient-Assisted Compression (PAC), followed by Technologist-controlled (TC) Compression. the technologist will properly position the breast and apply minimum compression. the subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness. Technologist-controlled (TC) Compression: TC compression will be conducted per standard of care practices at the site. ',\n",
       " 'starting dose 200 mg, courses repeat every 28 days. starting dose 200 mg, courses repeat every 28 days. ',\n",
       " 'invasive carcinoma should be ER-apha receptor positive, the tumor should be approximately at least 1 cm, to account for variability in imaging and imaging occult disease (physical exam, mammography, ultrasound) the patient must have signed an approved consent form. male patients are not eligible for this study. female patients with inoperable tumors or women with stage 4 disease diagnosed on CT, PET, PET/CT or bone scan. women with non-invasive disease or microinvasion are not eligible. patients with a known mutation in p53 (Li Fraumeni syndrome) shall not receive any herbal/alternative therapies such as flaxseed or soy products or black cohosh. ',\n",
       " 'ANEMIA 1/486 (0.21%), NEUTROPENIA 4/486 (0.82%), FIBRILLATION ATRIAL 1/486 (0.21%), ABDOMINAL PAIN 2/486 (0.41%), BLOATING 1/486 (0.21%), COLITIS 1/486 (0.21%), DEHYDRATION 5/486 (1.03%), GASTRIC INFLAMMATION 1/486 (0.21%), NAUSEA ANDVOMITING 1/486 (0.21%), Adverse Events 2: ',\n",
       " 'patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive and HER2-negative breast cancer. patient must have either:, Measurable disease, i.e., at least one measurable lesion as per RECIST 1.1 criteria. patient has received > 1 chemotherapy for the treatment of advanced/metastatic breast cancer. completed prior therapy for CNS metastases 28 days prior to the start of study. patient has active cardiac disease or a history of cardiac dysfunction. ',\n",
       " 'females 18 years, Histologically confirmed and documented invasive breast cancer, breast cancer without evidence of distant metastases (Stage 4) based on staging work-up, Chemotherapy naive, who have not received chemotherapy in the neoadjuvant setting. candidates for chemotherapy in the adjuvant setting of taxane/cyclophosphamide-based regimen, e.g., as background chemotherapy, Zubrod/WHO/ECOG performance status 2 lanine Aminotransferase (ALT) 3 x the upper limit of normal (ULN) of the reference lab. Serum creatinine of 1.5 x ULN for reference lab or estimated glomerular filtration rate (eGFR) of 60 mg/min, Body mass index (BMI) of 19 to 40 kg/m2. Subjects and their partners agree to use of an effective method of contraception. sexually active subjects must use contraception while on HSP-130 from admission to the final Follow-up Visit. able to understand verbal or written instructions and comply with all study requirements. subject will NOT be eligible for study participation if any of the following criteria are met. doxorubicin, no concurrent use of inhibitors and inducers of CYP3A4, CYP2D6, and/or P-gp or with trastuzumab due to increased risk of cardiac dysfunction, Chemotherapy other than that included in this study (taxane/cyclophosphamide-based regimen, e.g., TAC or TC) or known immunosuppressive agents including chronic oral corticosteroid use, or radiation therapy within rk heart association (NYHA) class III or IV heart failure, severe uncontrolled cardiac disease (unstable angina, clinically significant ECG abnormalities) or MI within the previous 6 months before the first administration of the HSP-130. Subjects planning to be pregnant or to breastfeed before, during, or within 12 months after administration of the HSP-130 are not permitted to enroll in the study. patients must have histologically-confirmed adenocarcinoma of the breast with operable or inoperable stage 1c (primary tumor > 1.0 cm), II or III disease. patients may not have had definitive primary surgery. current treatment with therapeutic doses of any anti-coagulant is allowed. Known human immunodeficiency virus (HIV) infection. dgment of investigator, excess risk associated with study participation or study drug administration would make the patient inappropriate for entry into this study. ',\n",
       " '14/69 (20.29%), Febrile neutropenia 0/69 (0.00%), Anaemia 0/69 (0.00%), Atrial fibrillation 1/69 (1.45%), Cardiopulmonary failure 0/69 (0.00%), Supraventricular extrasystoles 1/69 (1.45%), Abdominal pain 1/69 (1.45%), Intestinal obstruction 0/69 (0.00%), Vomiting 1/69 (1.45%), Chills 1/69 (1.45% ervical cancer *1/255 (0.39%), nosocomial pneumonia *2/255 (0.78%), Venous thrombosis *1/255 (0.39%) ervical cancer *1/255 (0.39%), nosocomial pneumonia *2/255 (0.78%) ',\n",
       " 'Ejection fraction decreased * 1/69 (1.45%), Intestinal obstruction NOS * 1/69 (1.45%), Diarrhoea NOS * 2/69 (2.90%), Febrile neutropenia * 12/69 (17.39%), mucosal inflammation NOS * 1/69 (1.45%) ',\n",
       " 'survival duration will be censored at the date of last contact or last follow-up or the date of last news. for patients who have not died, survival duration will be censored. alkylating agent of physician choice registered in cancer: cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin. ',\n",
       " 'Response Evaluation Criteria in Solid Tumours Version (RECIST) 1.1. Best overall response of confirmed complete response (CR) or confirmed partial response (PR) recorded since first administration of trial medication. patients could have dose reduced if 40 mg was not tolerated. overall number of participants Analyzed: 74, Measure Type: Number, Unit of Measure: Percentage of participants 18 (10 to 28), Results 2:, Arm/Group Title: Afatinib and Paclitaxel or Vinorelbine Combination Therapy. lure on afatinib monotherapy, Overall Number of Participants Analyzed: 39, Measure Type: Number, Unit of Measure: Percentage of participants 31 (17 to 48) ',\n",
       " 'participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy received alobresib tablets at a dose of 0.6 mg orally once daily on Study Day 1 through C1D28 of 28 days cycle to determine the MTD. ',\n",
       " 'unilateral breast cancer with ipsilateral lumpectomy or mastectomy and lymph node dissection (sentinel biopsy or axillary dissection), stage II or III unilateral secondary upper extremity lymphedema. girth 2 cm circumferential difference and/or volume 200 mL compared to the uninvolved upper extremity at any 4 cm segment. 0 (morbid obesity) ',\n",
       " 'Adverse Events 1:, Total: 10/50 (20.00%), Anaemia 0/50 (0.00%), Febrile neutropenia 0/50 (0.00%), Neutropenia 0/50 (0.00%), Thrombocytopenia 0/50 (0.00%), Diastolic dysfunction 0/50 (0.00%), Nausea 1/50 (0.00%), Oesophageal spasm 0/50 (0.00%), Retching 0/50 ( ',\n",
       " 'women >=18 years of age;, >=1 target lesion; locally advanced or metastatic breast cancer; demonstrated resistance to anthracycline;, >=2 regimens of chemotherapy for advanced/metastatic disease. ',\n",
       " 'number of participants with dose limiting toxicities (DLT), number of participants with DLT in the first cycle (28 days) for the determination of the maximum tolerated dose. Important Limitations and Caveats are provided in the respective section. it., Overall Number of Participants Analyzed: 2, Measure Type: Number, Unit of Measure: Participants 2_. ',\n",
       " 'inclusion Criteria:, Histologically documented, locally advanced, or metastatic breast cancer; measurable and/or non-measureable but evaluable disease is permitted. a carcinoma in-situ with an elevated risk of micro-invasion is permitted. negative urine pregnancy test 72 hours prior to cycle 1 Day 1 for all women of childbearing potential. agreement to use one highly effective form of contraception or two effective forms of contraception for the duration of the study treatment(s) and for 4 months after the last dose of T-DM1 or 6 months after the last dose of pertuzumab. any chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or biologic therapy for the treatment of breast cancer within 2 weeks of the first study treatment. uired any type of therapy, including radiation, surgery, and/or steroids, to control symptoms from brain metastases within 60 days prior to first study treatment. history of cardiac disease, unstable angina, symptomatic congestive heart failure (CHF), myocardial infarction, or ventricular arrhythmia 6 months prior to cycle 1, Day 1, Implantable pacemaker or automatic implantable cardioverter defibrillator. nticipation of the need for major surgery during the course of study treatment. the need for major surgery during the course of study treatment. ',\n",
       " 'Exemestane, exemestane 25 mg by mouth (PO) every day for two years taken with calcium carbonate 1200 mg PO every day x 2 years. vitamin D 400 IU PO every day infused weekly over 30 minutes. ',\n",
       " 'Intracardiac Thrombus 1/31 (3.23%), Diarrhoea 2/31 (6.45%), Nausea 2/31 (6.45%), Vomiting 2/31 (6.45%), Ascites 0/31 (0.00%), Ileus 1/31 (3.23%), Small Intestinal Obstruction 1/31 (3.23%), Multi-Organ Failure 0/31 (0.00%), Sepsis 1/31 (3.23%), Weight Decreased 1/31 (3.23%), ',\n",
       " 'cyclophosphamide: Part of planned chemotherapy regimen, inTERVENTION 2:, Chemotherapy Plus Goserelin. patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy. ',\n",
       " 'patients receive Abraxane IV over 30 minutes on days 1, 8, and 15. treatment repeats every 28 days for up to 3 cycles in absence of disease progression or unacceptable toxicity. ',\n",
       " 'stage I-III breast cancer, adjuvant or neoadjuvant anthracycline-based chemotherapy, Exclusion Criteria:, under age 18, pregnancy, metastatic or inoperable (including including inoperable) breast cancer, confounding underlying medical illnesses, history of mania, history of other axis-I psychiatric disorder, physical or psychological impairments. ',\n",
       " 'During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application., LA-EP2006: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle eligible patients receive Neulasta® s.c. post chemotherapy application. ',\n",
       " 'six weeks after surgery, patients receive a brief initial post-operative care session describing lymphedema risk and prevention through oral instruction. patients complete physical assessments and questionnaires at 6 weeks and at 6, 12, and 18 months. patients complete a personalized physical therapy intervention, receive a refrigerator magnet, and a 15-minute video that reinforces information and exercises. ',\n",
       " 'patients with either HER2 3+ positive tumors by immunohistochemistry (Dako Herceptest®) or gene amplification (> 2 copies) by fluorescence in-situ hybridation (FISH) are eligible. patients must have measurable disease as defined by RECIST guidelines. women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. women must have a negative serum or urine pregnancy test within 1 week prior to beginning treatment on this trial. treatment for systemic infections within 14 days of enrollment. patients with active brain metastases requiring treatment include surgery, radiation, and corticosteroids. patients with asymptomatic non- progressing brain metastases have completed treatment 30 days before enrollment. rvix., Ejection fraction 50% or below the lower limit of the institutional normal range, whichever is lower. patients may not be receiving any other investigational agents within 30 days before enrollment. pregnant women are excluded from this study because the investigational agents may have the potential for teratogenic or abortifacient effects. all herbal and alternative medications should be discontinued while on study. this includes but not limited to: Hydrastis canadensis (goldenseal) ',\n",
       " 'participants received adjuvant or neoadjuvant chemotherapy and pegfilgrastim. they received neoadjuvant or neoadjuvant chemo and pegfilgrastim. ',\n",
       " 'Febrile Neutropenia 4/41 (9.76%), Neutropenia 1/41 (2.44%), Deep Vein Thrombosis 1/41 (2.44%), Pulmonary embolism 1/41 (2.44%), Femoral Artery occlusion 1/41 (2.44%), Constipation 1/41 (2.44%), Constipation 1/41 (2.44%), Fatigue 2/41 (4.88%), Headache 1/41 (2.44%), Nausea 1/41 (2.44%), Cellulitis 1/41 ( is 0/31 (0.00%), Weight Decreased 0/31 (0.00%), Dehydration 0/31 (0.00%), Hypokalaemia 1/31 (3.23%) ',\n",
       " 'Febrile neutropenia 3/65 (4.62%), Neutropenia 2/65 (3.08%), Pancytopenia 1/65 (1.54%), Thrombocytopenia 1/65 (1.54%), Myocardial infarction 1/65 (1.54%), Diarrhoea 5/65 (7.69%), Stomatitis 1/65 (1.54%), Vomiting 2/65 (3.08%), Fatigue 1/65 (1.54%), Jaundice  ',\n",
       " 'a candidate for primary systemic (neoadjuvant) therapy and for surgical resection of residual primary tumor following completion of neoadjuvant therapy. tumor size >2cm, measured on imaging or estimated by physical exam; no contraindications for primary chemotherapy;. Planned definitive breast surgery (mastectomy or lumpectomy/breast conservation);. or a minimum of one year, OR surgically sterile, OR not pregnant, confirmed by a pregnancy test as per institutional standard of care. able to understand and willing to sign a written informed consent document and a HIPAA authorization in accordance with institutional guidelines. nt has been disease free for less than 5 years. nt has been disease free for less than 5 years. nt has been disease free for less than 5 years. mestane (safety run-in) / fulvestrant (randomized phase IIa), or any agent known to inhibit FGFRs. more than 1 prior regimen of chemotherapy for breast cancer. recordings show significant abnormalities in cardiac rate, rhythm or conduction. ',\n",
       " '2/35 (5.71%), Gastroesophageal reflux disease * 1/35 (2.86%)Adverse Events 1:, Total: 22/41 (53.66%), Anemia 1/41 (2.44%), Dyspepsia 1/41 (2.44%), Mucositis oral 1/41 (2.44%), Nausea 3/41 (7.32%), Vomiting 1/41 (2.44%), Pain 3/41 (7.32%), Allergic reaction 1/41 (2.44%) ',\n",
       " 'primary breast cancer without known extension beyond the breast and axillary nodes. Isolated \"lumpectomy\" with axillary node dissection (anticipated removal of at least five nodes) Exclusion Criteria: Previous surgery for breast cancer. r mortality___ r mortality__ ',\n",
       " 'inclusion Criteria:, history of ductal carcinoma in situ, lobular carcinoma in situ or stages 1-3 breast cancer, not currently receiving chemotherapy or hormonal therapy, Postmenopausal, Exclusion Criteria:, Stage IV breast cancer or systemic recurrences, Prior malignancies of any type other than breast cancer, basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. use of any type of oral melatonin supplementation within the past 30 days, Use of warfarin (coumadin) within the past 30 days, Active seizure disorder requiring the use of daily anti-epileptic medication. ',\n",
       " 'Adverse Events 1:, Total: 1/6 (16.67%), Goitre 0/6 (0.00%), Haemorrhoid Operation 0/6 (0.00%), Sciatica 0/6 (0.00%), Renal Failure 0/6 (0.00%), Varicose Vein 1/6 (16.67%), Adverse Events 2:, Total: 2/7 (28.57%), Goitre 1/7 (14.29%), Sciatica 1/7 (14.29%), Renal Failure 1/7 (1 ',\n",
       " 'PFS defined as the time from randomization until the first documented sign of disease progression or death due to any cause. participants received Lapatinib 1000 milligram tablets orally daily 1 hour before or after breakfast. overall number of participants Analyzed: 146, Median (95% Confidence Interval), Unit of Measure: weeks 12.0 (8.1 to 16.0), Results 2:, Arm/Group Title: Lapatinib, Arm/Group Description: Participants received Lapatinib 1500 mg tablets time to progression (TTP) is defined as the interval between the date of randomization and the earliest date of progression of disease (PD) or death due to breast cancer. the investigator assessed PD based on radiological PD (imaging data) and clinical symptomatic progress. treatment group was stratified by sites of metastatic disease and stage of disease. participants received matching placebo orally OD with paclitaxel (175 mg/m2 IV) over 3 hours, every 3 weeks. participants were treated until disease progression, unacceptable toxicity, or consent withdrawal. overall number of participants Analyzed: 228 Median (Inter-Quartile Range), Unit of Measure: weeks 22.9 (12.0 to 38.3) ',\n",
       " 'Overall survival was defined as the time from randomization to death due to any cause. overall number of participants Analyzed: 96, Median (95% Confidence Interval), Unit of Measure: Months 12.7 (9.9 to 16.3), Results 2:, Arm/Group Title: Chemotherapy, Arm/Group Description: Participants received capecitabine, eribulin, gemcitabine, or vinorelbine as single agent chemotherapy chosen by the treating physician. Months 11.6 (8.3 to 13.7). ',\n",
       " 'Adverse Events 1: 1/4 (25.00%), Vertigo 0/4 (0.00%), Abdominal adhesions 0/4 (0.00%), Abdominal pain 0/4 (0.00%), Diarrhoea 0/4 (0.00%), Nausea 0/4 (0.00%), Vomiting 0/4 (0.00%), Disease progression 0/4 (0.00%), Influenza 0/4 (0.00%), Nasopharyngitis 0/4 (0.00%), Lumbar verte ',\n",
       " 'IPASINTERVENTION 1:, Zr89-trastuzumab PET/CT, Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm. ',\n",
       " 'Febrile neutropenia 5/131 (3.82%), Hemoglobin decreased 7/131 (5.34%), Lymphatics 1/131 (0.76%), Transfusion: pRBCs 0/131 (0.00%), Arrhythmia supraventricular 0/131 (0.00%), Cardiac disorder 1/131 (0.76%), Edema 0/131 (0.00%), Left ventricular failure 0/131 (0.00%), Myocardial ischemia 1/131 ( ',\n",
       " 'time to disease progression (TTDP) at initial treatment was defined as the number of months between date of randomization and the date of first documented disease progression date or the date of death due to disease under study. TTDP censored at earliest of: 1) date of death not due to disease; 2) date of last contact for participants alive without disease progression; or 3) start date of other anti-tumor therapy; or 4) first dose date of crossover treatment. treatment continues until progression of disease, at which time crossover treatment begins. overall number of participants Analyzed: 239, Median (95% Confidence Interval), Unit of Measure: months 9.28 (7.73 to 10.79), Results 2:, Arm/Group Title: docetaxel plus capecitabine. ',\n",
       " 'PFS defined as the time from randomization until the first documented sign of disease progression or death due to any cause. participants received Lapatinib 1000 milligram tablets orally daily 1 hour before or after breakfast. overall number of participants Analyzed: 146, Median (95% Confidence Interval), Unit of Measure: weeks 12.0 (8.1 to 16.0), Results 2:, Arm/Group Title: Lapatinib, Arm/Group Description: Participants received Lapatinib 1500 mg tablets time to progression (TTP) is defined as the interval between the date of randomization and the earliest date of progression of disease (PD) or death due to breast cancer. the investigator assessed PD based on radiological PD (imaging data) and clinical symptomatic progress. treatment group was stratified by sites of metastatic disease and stage of disease. participants received matching placebo orally OD with paclitaxel (175 mg/m2 IV) over 3 hours, every 3 weeks. participants were treated until disease progression, unacceptable toxicity, or consent withdrawal. overall number of participants Analyzed: 228 Median (Inter-Quartile Range), Unit of Measure: weeks 22.9 (12.0 to 38.3) ',\n",
       " 'TTP was calculated as first event date minus the date of first dose of study medication plus 1. time frame: Phase 2 double-blind baseline until tumor progression or death or discontinuation from study treatment, assessed every 9 weeks up to 129 weeks. placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo ',\n",
       " 'Sudden death unexplained 1/110 (0.91%), General body pain 1/110 (0.91%), Lymphangitis 1/110 (0.91%), Femur fracture 1/110 (0.91%), Depression worsened 1/110 (0.91%), Calculus urinary bladder 1/110 (0.91%), Pneumopathy 1/110 (0.91%)Adverse Events 1:, Total: 4/26 (15.38%), Disseminated intravascular coagulation 1/26 (3. ',\n",
       " '22/123 (17.89%), Cardiac Ischemia/Infarction [1]1/123 (0.81%), Pain - Chest 2/123 (1.63%), Dehydration 2/123 (1.63%), Death [2]1/123 (0.81%), Weakness 1/123 (0.81%), Pain - Liver 1/123 (0.81%), Infection - Skin [3]3/123 (2.44%), Infection - Gastrointestinal [4]1/123 (0.81%), ',\n",
       " 'Febrile neutropenia 21/67 (1.49%), Leukopenia 21/67 (1.49%), Neutropenia 21/67 (1.49%), Macular hole 21/67 (1.49%), Diarrhoea 22/67 (2.99%), Abdominal pain 21/67 (1.49%), Enteritis 21/67 (1.49%), Gastritis 21/67 (1.49%), Nausea 21/67 (1.49%), Vomiting 21/67 (1.49%), Pneumoni ',\n",
       " 'HER2-positive by fluorescence in situ hybridization (FISH) or immunohistochemistry 3+ staining confirmed in adjuvant or metastatic setting. no effusions or ascites as only sites of disease, no primary or metastatic brain or central nervous system tumor. no pre-existing grade 2 or greater motor or sensory peripheral neuropathy except abnormalities due to cancer, no prior severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80. no known sensitivity to E. coli-derived proteins, no pregnant or nursing, Negative pregnancy test. r adjuvant or neoadjuvant chemotherapy regimen for primary disease, No prior docetaxel, No prior vinorelbine, Prior paclitaxel allowed, Endocrine therapy:, At least 3 weeks since prior radiotherapy and recoveredInclusion Criteria:, Male and Female patients must be at least 18 years of age. metastases are permitted if treated and radiographically and clinically stable for at least 4 weeks prior to first dose of STA-9090. life expectancy of at least 3 months, Adequate hematologic function as defined by:, Absolute neutrophil count 1,500 cells/L, Platelets 100,000/L, Hemoglobin 9.0g/dL. female subjects of childbearing potential and males must agree to use adequate contraception. female subjects of childbearing age must have a negative serum pregnancy test at study entry. major surgery within 4 weeks prior to first dose of STA-9090. study drug administration via indwelling catheters allowed only if the catheter is made of silicone material. iretroviral therapy, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, ventricular arrhythmia, or psychiatric illness/social situations would limit compliance with study requirements, Other medications, or severe acute/chronic medical or psychiatric condition, or laboratory abnormality. heart failure with a history of dyspnea, orthopnea or edema that requires current treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor blockers or beta blockers. ',\n",
       " 'PFS = (first event date minus randomization date +1) divided by 30.4, Time frame: From date of randomization to the date of the first documentation of objective tumor progression or death due to any cause, whichever occurred first. escalation to 37.5 mg daily was permitted in the absence of complicated neutropenia. Paclitaxel could have been reduced to 65 mg/m2. re-escalation to 80 or 90 mg/m2 upon recovery was permitted. ',\n",
       " 'female patients had to have previously received anthracycline based regimens as a adjuvant therapy or neo-adjuvant chemotherapy. then progressed and developed metastatic disease, Adequate organ function, Exclusion Criteria:, Previous radiation therapy is allowed but must not have included whole pelvis radiation, Known or suspected brain metastasis. ignificant neurological or mental disorder, including seizures or dementia. ',\n",
       " 'capecitabine will be administered when patients receive radiation therapy. one of the two daily doses of capecitabine will be taken 2 hours before receiving radiotherapy. ',\n",
       " 'INTERVENTION 1:, CMRM Versus UMRM, [Not Specified]__. ',\n",
       " 'anemia 3/50 (6.00%), Febrile neutropenia 1/50 (2.00%), arrythmia 1/50 (2.00%), Ileus 1/50 (2.00%), Nausea 1/50 (2.00%), Pain-Abdominal 1/50 (2.00%), Vomiting 1/50 (2.00%), Bronchial infection 1/50 (2.00%), Sepsis 1/50 (2.00%), Neutropenia 2/50 (4.00%)Adverse Events 1 ',\n",
       " '102/403 (25.31%), Anaemia 1/403 (0.25%), Febrile neutropenia 1/403 (0.25%), Granulocytopenia 0/403 (0.00%), Neutropenia 1/403 (0.25%), Thrombocytopenia 1/403 (0.25%), Cardiac failure 1/403 (0.25%), Vertigo 1/403 (0.25%), Hypercalcaemia of malignancy 0/403 (0.00%), Vision blurred 1/403 (0.25%), Abdominal discomfort ',\n",
       " 'the other breast will be imaged using Patient-Assisted Compression (PAC), followed by Technologist-controlled (TC) Compression. the technologist will properly position the breast and apply minimum compression. the subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness. Technologist-controlled (TC) Compression: TC compression will be conducted per standard of care practices at the site. ',\n",
       " 'women will be excluded if they participated in formative focus groups. female patients with histologically or cytologically confirmed carcinoma of the breast. ns must have included anthracycline (eg, doxorubicin, epirubicin), a taxane (eg, paclitaxel, docetaxel) and capecitabine in any combination or order. patients with human epidermal growth factor receptor 2 (HER2/neu) over-expressing tumors must additionally have been treated with trastuzumab. a change in dosing is deemed necessary, the case needs to be discussed with the Sponsor. the date of treatment, doses, outcome of therapy and the reason for discontinuation of prior anthracycline, taxane, capecitabine, and trastuzumab therapy must be provided. radiographic evidence of progression, clinically documented increase in tumor progression, clinically documented increase in tumor progression. patients with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria defined as at least one lesion that can be accurately measured in at least one diameter (at least 10 mm in longest diameter [LD] by spiral computer tomography [CT] scan) if the only measurable lesion is a lymph node, it must measure at least 20 mm in LD. bilirubin 1.5 mg/dL and alkaline phosphatase, alanine transaminase (ALT) and aspartate transaminase (AST) 3 times the upper limits of normal (ULN) unless there are bone metastases, liver specific alkaline phosphatase must be separated from the total and used to assess the liver function. ic screening procedures with the understanding that the patient may withdraw consent at any time without prejudice. patients must not have received chemotherapy, radiation, or biologic therapy within two weeks, hormonal therapy within one week, or trastuzumab within three weeks, before treatment start. ',\n",
       " 'Adverse Events 1:, Total: 1/25 (4.00%), Diarrhoea 0/25 (0.00%), Breast cellulitis 0/25 (0.00%), Syncope 1/25 (4.00%), Adverse Events 2:, Total: 1/20 (5.00%), Diarrhoea 1/20 (5.00%), Breast abscess 1/20 (5.00%), Syncope 0/20 (0.00%). ',\n",
       " 'all study patients must have histologically confirmed invasive adenocarcinoma of the breast. their breast cancer must be resectable clinical stage I or II breast cancer. all subjects must be Age >18 years. women of childbearing potential must be using oral, implanted, injectable contraceptive hormones or mechanical products. women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to start of study therapy. significant cardiac disease, including uncontrolled high blood pressure, unstable angina, and congestive heart failure, myocardial infarction within the previous 3 months or serious cardiac arrhythmias will be excluded. females 18 years of age, Histologically confirmed breast cancer that is HER2/neu positive (3+ by IHC or FISH +) a subject must have progressed on hormonal therapy. a subject must have progressed on hormonal therapy. all hormonal therapy (including birth control pills) must be discontinued at study entry. metastatic disease is either measurable or evaluable for response. patients must have recovered from toxicities due to prior therapy. patients must implement an effective method of contraception during the study. ',\n",
       " '18/52 (34.62%), Anaemia 2/52 (3.85%), Febrile Neutropenia 1/52 (1.92%), leukopenia 1/52 (1.92%), Neutropenia 1/52 (1.92%), Thrombocytopenia 1/52 (1.92%), Cardiac failure congestive 1/52 (1.92%), Cardio-Respiratory Arrest 1/52 (1.92%), Abdominal Pain 1/52 (1.92%), Constipation 1/52 (1.9 Nausea 0/20 (0.00%), Vomiting 0/20 (0.00%), Catheter site erythema 0/20 (0.00%), Chest discomfort 0/20 (0.00%) ',\n",
       " 'Inclusion Criteria:, New diagnosis of breast cancer, New diagnosis if a previous breast cancer patient with negative surgical margins. Exclusion Criteria:, High risk benign lesions as the primary pathology diagnosis. ',\n",
       " '0/23 (0.00%), NAUSEA *0/23 (0.00%), VOMITING *0/23 (0.00%), BILIRUBIN (HYPERBILIRUBINEMIA) *0/23 (0.00%), INFECTION (DOCUMENTED CLINICALLY ORMICROBIOLOGICALLY) WITH GRADE 3 OR 4 NEUTROPHILS (ANC 1.0 X 10E *0/23 (0.00%), NEUTROPHILS/ ',\n",
       " 'patients may have a history of bilateral breast cancer, Premenopausal (estradiol level in premenopausal range, >20pg/ml, within the prior 28 days), Liver function tests and creatinine 2.5 times the upper limit of normal within the 28 days prior to enrollment, ECOG Performance Status 0-1, Must agree to use non-hormonal contraception (condoms, diaphragm, IUD, sterilization, abstinence, etc. tu of the cervix, women with evidence of current local recurrence or metastatic breast cancer, Pregnant women, Nursing women, women who are currently taking tamoxifen and are unwilling to stop this medication. women with a known deleterious BRCA 1 or BRCA 2 mutation are greater than or equal to () 18 years of age, with histologically-confirmed HER2-positive breast cancer. ignancy in the last 5 years except for basal cell cancer or cancer in situ of the cervix. ignancy in the last 5 years, except for basal cell cancer. ',\n",
       " 'HER-2-negative breast cancer or if HER-2-positive, must be unable to receive trastuzumab (Herceptin®) or have previously received trastuzumab in the past, measurable disease defined as at least one lesion that can be accurately measured in at least one dimension. no other concurrent malignancies within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix, Exclusion criteria:, Pre-existing neuropathy grade 1, Uncontrolled intercurrent illness including, but not limited to, any of the following:, Ongoing or active infection, Symptomatic congestive heart failure. 6 months, History of stroke or transient ischemic attack within the past 6 months, Significant vascular disease (e.g., aortic aneurysm, aortic dissection), Symptomatic peripheral vascular disease, Evidence of bleeding diathesis or coagulopathy, Significant traumatic injury within the past 28 days, Proteinuria, as demonstrated by either urine protein:creatinine ratio 1.0 OR urine dipstick for proteinuria 2+. or adjuvant chemotherapy allowed, More than 1 week since prior core biopsy or other minor surgical procedure, excluding placement of a vascular access device. at least 1 year since prior taxane regimen, No other concurrent investigational agents, Concurrent anticoagulation allowed, provided criteria are met. ',\n",
       " 'women with locally advanced, recurrent, or metastatic breast cancer along with confirmation of estrogen-receptor positive (ER+) measurable disease defined as at least one lesion 10 mm by CT or MRI that can be accurately measured in at least one dimension. ',\n",
       " 'treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity. cyclophosphamide, paclitaxel, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab subjects 98 (92.2 to 99.5). subjects 98 (92.2 to 99.5) ',\n",
       " 'lesions should not be amenable to surgery or radiation of curative intent. prior radiation therapy is allowed to less than 25% of the bone marrow. participants must have recovered from the toxic effects of the treatment. antitumoral hormonal treatment must be discontinued prior to enrollment. participants must test negative for pregnancy within 7 days of enrollment. participants must be at least 18 years of age. participants have received more than one combination of anthracycline plus taxane. have serious concomitant systemic disorders that compromise the safety of the participant. have a prior malignancy other than breast cancer, carcinoma in situ of the cervix or nonmelanoma skin cancer. are unable or unwilling to take folic acid, vitamin B12 supplementation, or dexamethasone. Concurrent administration of any other antitumor therapy. ',\n",
       " '81/353 (22.95%), Febrile neutropenia * 13/353 (3.68%), Anaemia * 21/353 (0.28%), Neutropenia * 25/353 (1.42%), Thrombocytopenia * 20/353 (0.00%), Hypercoagulation * 21/353 (0.28%), Leukopenia * 21/353 (1.42%), Atrial fibrillation * 1/353 (0.28%), Cardiac failure * 0/353 (0.00%), Myocardial in ',\n",
       " '4/104 (3.85%), Neutropenia 1/104 (0.96%), leukopenia 2/104 (1.92%), paranasal sinus reaction 1/104 (0.96%), cellulitis 1/104 (0.96%), Adverse Events 2:, Adverse Events 1:, Total: 1/4 (25.00%), Vertigo 0/4 (0.00%), Abdominal adhesion 0/4 (0.00%), Abdominal pain 0/4 (0.00%), Diarrhoea ',\n",
       " 'inTERVENTION 2:, Prone to Supine MRI Evaluated by Radiologist A, number of participants successfully segmented, INTERVENTION 2:, Physical Activity Intervention, Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up. topics covered include benefits of exercise; recommendations on type, duration, frequency and intensity of exercise; goal-setting; and advice on overcoming barriers. facility access: Subjects will have access to the exercise lab in the UT Southwestern Depression Center. equipment for aerobic exercise (treadmills, stationary bikes, etc.) ',\n",
       " 'Bevacizumab was to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. if still tolerated, over 30 minutes for subsequent infusions. overall number of participants Analyzed: 46, Measure Type: Number, Unit of Measure: Percentage of participants 47.8 (32.9 to 63.1), Results 2:, Arm/Group Title: Ixabepilone, 40 mg/m2. bevacizumab, 15 mg/kg, administered after ixabepilone as IV infusion every 3 weeks. if well tolerated, over 30 minutes for subsequent infusions. ',\n",
       " 'women aged 45-69 must have received prior treatment with trastuzumab (Herceptin®) or have a contraindication for trastuzumab. no evidence of active brain metastasis, including leptomeningeal. menopausal status not specified, life expectancy 12 weeks, ECOG performance status 0-1, ANC 1,500/mm3, Platelet count 100,000/mm3, Hemoglobin 9.0 g/dL, AST and ALT 2.5 times upper limit of normal (ULN), Alkaline phosphatase 2.5 times ULN, Total bilirubin 1.5 times ULN, Creatinine 1.5 mg/dL, Urine protein:creatinine ratio  1 paclitaxel, paclitaxel, gemcitabine hydrochloride, bevacizumab, albumin, drug product excipients, or chemically similar agents, no stage III or IV invasive, non-breast malignancy within the past 5 years. patients who have recently started or adjusted antihypertensive medications are eligible. no serious non-healing wound, ulcer, or fracture, no clinically significant cardiac disease defined as any of the following:, Congestive heart failure, Symptomatic coronary artery disease, Unstable angina, Cardiac arrhythmias not well controlled with medication, Myocardial infarction within the past 12 months, No comorbid systemic illnesses or other severe concurrent disease. prior radiotherapy to a target lesion is allowed provided there has been clear progression of the lesion since radiotherapy was completed. more than 4 weeks since prior cytotoxic chemotherapeutic agent or investigational drug, More than 2 weeks since prior and no concurrent acetylsalicylic acid, anticoagulants, or thrombolytic agents. Placement of a vascular access device within 7 days is allowed, More than 3 months since prior neurosurgery. this study may be allowed. this study may be allowed. ',\n",
       " 'Febrile neutropenia 84/1288 (6.52%), Neutropenia 69/1288 (5.36%), leukopenia 8/1288 (0.62%), Anaemia 1/1288 (0.08%), Thrombocytopenia 4/1288 (0.31%), Pancytopenia 1/1288 (0.08%), Febrile bone marrow aplasia 1/1288 (0.08%), Atrial fibrillation 4/1288 (0.31%), Cardiac failure congestive 6/1288 ( ection 1/148 (0.68%), Upper respiratory tract infection 1/148 (0.68%) ',\n",
       " 'RECIST version 1.0 is an at least 20% increase in the sum of the longest diameters (SLD) of the target lesions compared to the smallest since the study treatment started. for participants with bone metastasis only, at least 25% increase in the measurable lesion according to general rules for clinical and pathological study of breast cancer. rticipants: 147, Median (95% Confidence Interval), Unit of Measure: months 13.8 (10.8 to 16.5), Results 2:, Arm/Group Title: Anastrozole, Arm/Group Description: One tablet each of anastrozole 1 mg and exemestane placebo were orally administered once daily after a meal. ',\n",
       " 'the greater the change from baseline (randomization) in ER H-score, the greater the blockage of ER expression and the greater the potential anti-tumour activity. the greater the blockage of ER expression, the greater the potential anti-tumour activity. ts 2:, Arm/Group Title: Fulvestrant + Anastrozole, Arm/Group Description: Fulvestrant 500 mg once monthly injection + Anastrozole 1 mg once daily tablet, Overall number of participants Analyzed: 31, Mean (Standard Error), Unit of Measure: Percentage change from baseline -38 (5)__________________________________ ',\n",
       " 'objective response rate (ORR), Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response = CR + PR. time frame: up to 2 years. CT: Complete Response (CR), disappearance of all target lesions for a period of at least one month; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (ORR) = CR + PR. only descriptive statistics. ',\n",
       " 'INTERVENTION 1:, Arm Compression Only, [Not Specified] INTERVENTION 2:, Arm, Trunck and Chest Compression, [Not Specified] ',\n",
       " '2/81 (2.47%), Heart failure 0/81 (0.00%), Fever 1/81 (1.23%), Cold 0/81 (0.00%), Lack of strength in left leg 0/81 (0.00%), Ostenecrosis produced by biphosphonates 0/81 (0.00%), Gastric cancer 0/81 (0.00%), Stroke 0/81 (0.00%), Hematuria 1/81 (1.23%), nodule in left breast 0/81 ( ',\n",
       " 'patients who have not received preoperative chemotherapy must have at least 2cm of disease in the largest diameter by clinical or radiographic findings. must have completed preoperative (neoadjuvant) chemotherapy with either a standard regimen (containing an anthracycline and/or a taxane) or on a clinical trial, HER2 positive tumors must have received at least one prior trastuzumab-based therapy, and may not receive concurrent trastuzumab therapy and vaccination  surgery should have occurred more than 28 days but within 12 weeks prior to enrollment. may receive concurrent hormonal therapy, such as tamoxifen, ovarian suppression, and aromatase inhibitors. primary tumor or metastasis must overexpress HER2. must have received 1-2 prior chemotherapeutic regiments for metastatic breast cancer. must have been off treatment for at least three weeks. mmunosuppressive agent, other malignancies in the past 3 years, except for adequately treated carcinoma of teh cervix or basal- or squamous-cell carcinoma of the skin, Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001. tive patients, Known hypersensitivity to RAD001 (everolimus) or other rapamycins. ',\n",
       " 'participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity. overall number of participants Analyzed: 451, Median (95% Confidence Interval), Unit of Measure: Months 5.49 (5.32 to 5.59), Results 2:, Arm/Group Title: Atezolizumab Plus Nab-Paclitaxel, Arm/Group Description: Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression Proportion of Participants Progression Free at 6 Months, PFS at 6 months was defined as proportion of participants who neither progressed nor died before 6 months. ',\n",
       " 'heart failure 1/30 (3.33%), Vertigo 1/30 (3.33%), Small intestinal obstruction 1/30 (3.33%), Fever 1/30 (3.33%), Aspartate aminotransferase increased 1/30 (3.33%), Back Pain 1/30 (3.33%), Pleural effusion 1/30 (3.33%), Rash maculo-papular 1/30 (3.33%), Hypotension 1/30 (3.33%)Adverse Events 1:, Total: 2/3 (66.67%), Febrile neutropenia 1/3 (3 Dysphagia 0/3 (0.00%), Dysphagia 0/3 (0.00%), Intestinal mass 0/3 (0.00%), pancreatitis acute 0/3 (0.00%), small intestinal obstruction 0/3 (0.00%) ',\n",
       " 'treatment repeated every 4-6 weeks in the absence of disease progression or unacceptable toxicity. some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician. ',\n",
       " 'patients must have measurable disease, at least one measurable lesion as defined by the Response Evaluation Criteria in Solid Tumors (RECIST), Treated brain metastases (surgery or radiation therapy) allowed if clinically stable, Patients with leptomeningeal disease are ineligible. no pre-existing liver disease (i.e., cirrhosis or active viral hepatitis), no active gastrointestinal malabsorption illness, no clinically significant cardiac disease, including congestive heart failure, symptomatic coronary artery disease, and cardiac arrhythmias not well controlled with medication. no prior unanticipated severe reaction to fluoropyrimidine therapy, known hypersensitivity to fluorouracil, or known dihydropyrimidine dehydrogenas no concurrent anti-estrogen therapy, radiation therapy, or investigational systemic therapy, no concurrent investigational drugs, no concurrent use of the following drugs. warfarin for full anticoagulation, cimetidine, or azidothymidine (AZT), Mini-dose warfarin for prophylaxis of central venous catheter thrombosis allowed. no known CNS disease, Hormone receptor status not specified. life expectancy > 12 weeks, WBC 3,000/mcL, Absolute neutrophil count 1,500/mcL, Platelet count 100,000/mcL, Total bilirubin normal, AST and ALT 2.5 times upper limit of normal (ULN), Alkaline phosphatase 2.5 times ULN (unless bone metastasis is present in the absence of liver metastasis), Creatinine 1.5 mg congestive heart failure, unstable angina pectoris, Cardiac arrhythmia, Serious, non-healing wound, ulcer, or bone fracture, psychiatric illness/social situations that would limit compliance with study requirements. history of hypertensive crisis or hypertensive encephalopathy within the past 6 months. urine protein:creatinine ratio 1.0 OR urine dipstick for proteinuria 2+ must demonstrate 24-hour urine protein 1g, history of allergy or hypersensitivity to paclitaxel albumin-stabilized nanoparticle formulation, paclitaxel, bevacizumab, carboplatin, albumin, drug product excipients, or chemically similar agents. prior neoadjuvant or adjuvant chemotherapy allowed, More than 1 week since prior biopsy or other minor surgical regimen, no other concurrent investigational agents, Concurrent anticoagulation allowed, provided the criteria are met:, Stable dose of warfarin or low molecular weight heparin, INR within desired range (2-3), no evidence of active bleeding or coagulopathy, no concurrent combination antiretroviral therapy for HIV-positive patients. ',\n",
       " 'clinical stage breast cancer T2-3, N0-3, M0, Negative HER-2/neu expression. no prior treatment for primary invasive adenocarcinoma of the breast such as irradiation, chemotherapy, hormonal therapy, immunotherapy or surgery. women of childbearing potential (WOCBP) must agree to use a medically acceptable method of contraception to avoid pregnancy throughout the study. willingness to have core biopsies and/or FNA performed before the start of study treatment and at the end of 12 week on treatment. kcroft-Galt method found evidence of metastatic breast cancer following a standard tumor staging work-up. kcroft-Galt method found evidence of metastatic breast cancer following a standard tumor staging work-up, evidence of inflammatory breast cancer. at least 8 weeks since prior radiation to brain or CNS metastases, no concurrent steroids, no leptomeningeal disease, PATIENT CHARACTERISTICS:, Menopausal status not specified, ECOG performance status 0-2, Life expectancy 6 months, WBC > 1,500/mm3, Platelet count > 100,000/mm3, Creatinine clearance > 40 mL/min, Normal electrolytes (i.e., Na, K, and Ca normal; minor deviation geries that may interfere with the absorption of oral medications may interfere with the absorption of oral medications including:, uncontrolled nausea, vomiting, or diarrhea, Lack of the physical integrity of the upper gastrointestinal tract, Malabsorption syndrome, no known hypersensitivity to bendamustine hydrochloride, mannitol, or erlotinib hydrochloride. no prior malignancy in the past 5 years except for adequately treated basal cell or squamous cell skin carcinoma. viral therapy for HIV-positive patients, no other concurrent investigational agents. ',\n",
       " 'primary tumor must be larger than 2 cm in diameter (clinical T2-T3, N0-N1, M0) for patients without clinically suspicious axillary adenopathy, primary tumor must be larger than 2 cm in diameter (clinical T2-T3, N0-N1, M0). an ECOG performance score of 2, Normal bone marrow function as defined by:, absolute neutrophil count (ANC) >1,500/L;, platelets >100,000/L;, hemoglobin >10 g/dL., Left ventricular ejection fraction within the institutional limits of normal, whichever is lower, as measured by multi-gated acquisition scan or echocardiogram (ECHO). man becomes pregnant or suspects she is pregnant while participating in this study. men enrolled in the study must also agree to use a method of contraception acceptable to their physician during their study participation. ph node and/or axillary dissection prior to initiation of study treatment, completion at least 4 weeks prior to starting study treatment and well-healed wound. ph node and/or axillary dissection prior to initiation of study treatment, completion at least 4 weeks prior to starting study treatment. isease, current use of medications that alter cardiac conduction. if these medications are administered for other reasons (e.g., hypertension), the patient may be eligible. patients with cardiac arrhythmia, angina, or CHF may be eligible. use of CYP3A4 inhibitors must be discontinued at least 72 hours prior to initiation of study treatment. use of these agents must be discontinued at least 72 hours prior to initiation of study treatment. ith ovarian hormonal replacement therapy must be stopped prior to study enrollment. current therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulators must be discontinued prior to study enrollment. ',\n",
       " 'stage II with at least 10 positive axillary nodes OR, Stage IIIA or IIIB, no histologically proven bone marrow metastasis, no CNS metastasis, Hormone receptor status known, PATIENT CHARACTERISTICS:, Age:, Physiological age 60 or under, Menopausal status:, Not specified, Life expectancy:, See Disease Characteristics, Hematopoietic:, Neutrophil count at least 1,500 at least 60% of predicted, pO_2 at least 85 mm Hg on room air, pCO_2 at least 43 mm Hg on room air, DLCO at least 60% lower limit of predicted, Other:, No other prior malignancy except squamous cell or basal cell skin cancer or stage I or carcinoma in situ of the cervix, HIV negative, No sensitivity to E. coli-derived products. ',\n",
       " 'patients with triple-negative breast cancer who do not have a pathological complete response following neoadjuvant therapy and surgery will receive eribulin 1.4 mg/m2 every 21 days for 6 cycles via the intravenous route. eribulin 1.4 mg/m2 on days 1 and 8 every 21 days for 6 cycles via the intravenous route. ',\n",
       " 'inTERVENTION 1:, Breast Cancer Patients, Tomosynthesis Breast Scanning is done and breast CT Scanning is done. ',\n",
       " 'objective response rate was defined as percentage of patients with either complete response (CR - disappearance of all target lesions) or partial response (PR - at least 30% decrease in the sum of diameters of target lesions) all patients were followed up every 12 weeks for progression. an objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR) a patient has best overall response of CR if she had overall response of CR or PR on one visit and met the confirmation criteria per RECIST. each patient with measurable disease at baseline was assessed for OR from the sequence of Response Evaluation Criteria in Solid Tumors (RECIST) scan data up to data cut-off. participants 11.1, Results 2:, Arm/Group Title: Fulvestrant 250 mg + Loading Dose, Arm/Group Description: Fulvestrant 250 mg + Loading Dose, Overall Number of participants Analyzed: 51, Measure Type: Number, Unit of Measure: percentage of participants 17.6. ',\n",
       " 'inTERVENTION 1:, FFDM and DBT, FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration. 1 patch was applied topically to the affected site(s) for 12 hours each day. ',\n",
       " 'patients with no prior treatment with intracranial Response may be included unless ICR is emergently indicated. patients with no prior treatment with intracranial response may be included. navelbine therapy discontinued >/= 12 months from day 1 of treatment. last anti-cancer treatment (including any investigational drug) >/= 2 weeks from initiation. anticoagulation is allowed if target INR 2.0 on a stable dose of warfarin or if patient on a stable dose of low-molecular-weight heparin for >1 weeks at time of enrollment. patients who have received prior treatment with an mTOR inhibitor. patients with a known hypersensitivity to vinorelbine or to its excipients. patients with a known hypersensitivity to everolimus or other rapamycins. asymptomatic micro-hemorrhage is allowed. evidence of diffuse leptomeningeal disease on brain MRI or by previously documented Cerebrospinal fluid cytology. patients should not receive immunization with attenuated live vaccines within 1 week of study entry or during study period. patients should not receive immunization with attenuated live vaccines within 1 week of study entry or during study period. t could affect their participation in the study such as:, severely impaired lung function, defined as spirometry and diffusion lung capacity for carbon monoxide (DLCO) that is 50% of the normal predicted value and/or 02 saturation that is 88% at rest on room air, uncontrolled diabetes, defined as fasting serum glucose >1.5 x ULN. a detailed assessment of Hepatitis B/C medical history must be done at screening for all patients. al disease may significantly alter the absorption of everolimus. women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test within 7 days. male patients whose sexual partner(s) are WOCBP who are not willing to use adequate contraception during the study and for 8 weeks after the end of treatment. inability to comply with study and/or follow-up procedures. ',\n",
       " 'inTERVENTION 1:, PET Guided Biopsy, no comparison group. all participants were expected to undergo PET guided biopsy. ',\n",
       " 'breast cancer with metastasis in multiple organs, Performance Status 0-2, Functions below are maintained in major organs:, Leukocyte count: 4,000/mm3 to 12,000/mm3, Neutrophil count: >2,000/mm3 or more, Platelet count: >2,000/mm3 or more, Hemoglobin count: >9,000/mm3 or more, Total bilirubin: >1.5 mg/dL, AST(GOT): within twice a normal upper value in women who are potentially pregnant, pregnant, or breast-feeding, Severe drug allergy, Severe renal disorder, being treated with flucytosine, Complicated with the infection onset which a study doctor assesses to be inappropriate for this study. patients with inflammatory carcinoma are allowed on study if they have measurable disease. prior treatment with 5-fluorouracil (5-FU) and 5-FU derivatives. ',\n",
       " 'an exact 95% confidence interval (CI) will be calculated for the CEC response rate. with 26 patients, this CI will be no wider than 40%. if 13 of 26 patients respond, the CI is 30% to 70%. ',\n",
       " 'Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12. time frame: 12 months, Results 1:, Arm/Group Title: Denosumab 60 mg Q6M, Arm/Group Description: [Not Specified], Overall Number of participants Analyzed: 123, Least Squares Mean (95% Confidence Interval), Unit of Measure: Percent Change from Baseline -.7 (-1.3 to -.1). ',\n",
       " 'primary tumor must be >2 cm in diameter by physical examination or imaging studies. patients with clinically suspicious axillary adenopathy can be any size (clinical T1-3, N1-2, M0) bilateral, synchronous breast cancer is allowed if both primary tumors are HER2-negative. patients entering this study must be willing to provide release of tumor tissue collected at baseline during a diagnostic procedure if available. if tissue is not available, the patient will still be eligible for enrollment. negative hematologic function defined as:, Absolute neutrophil count (ANC) 1500/L, Hemoglobin (Hgb) 10 g/dL, Platelets 100,000/uL, Adequate liver function defined as:, Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 2.5 x the upper limit of normal (ULN), Total bilirubin the institutional ULN, Adequate renal function defined as:, Serum re approved by their study physician while receiving study treatment. re approved by their study physician while receiving study treatment. who are not breastfeeding, who have a negative serum pregnancy test. patients with acute or chronic liver or renal disease or pancreatitis. Known diagnosis of human immunodeficiency virus (HIV), Hepatitis B (HBV) or Hepatitis C (HCV) patients with stage I cancer who have received definitive local treatment at least 3 years previously are eligible. all patients with previously treated in situ carcinoma (i.e. non-invasive) are eligible. conditions that do not permit compliance with the protocol. inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol. ',\n",
       " 'Adverse Events 1:, Total: 4/36 (11.11%), Rectal hemorrhage * 1/36 (2.78%), Disease progression * 1/36 (2.78%), Skin infection * 1/36 (2.78%), Hypotension * 1/36 (2.78%)Adverse Events 1:, Total: 15/41 (36.59%), Febrile neutropenia * 0/41 (0.00%), Diarrhea * 1/41 (2.44%), Stomach pain * 1/41 (2.44%), Fever *  ',\n",
       " 'cytomorphologic evidence of hyperplasia +/- atypia and Ki-67 expression >1.5% in benign breast epithelial cells acquired by RPFNA, Serum level of 25-OH vitamin D of at least 30 ng/ml prior to study entry. will have a repeat random periareolar fine needle aspiration and mammogram at 6 months and 12 months. of more than 6 months of an aromatase inhibitor at any time in the past. ',\n",
       " \"inclusion Criteria:, Ability to understand and the willingness to sign a written informed consent document. the participant has an Eastern Cooperative Oncology Group (ECOG) performance stat. the participant has a histopathologically or cytologically confirmed diagnosis of breast adenocarcinoma that is metastatic or locally-recurrent and inoperable with curative intent. the participant has measurable and/or non-measurable disease, The participant's primary and/or metastatic tumor is human Epidermal Growth Factor Receptor 2 (HER2) negative. participants with previous treatment of malignancy are eligible, provided that she has been disease free for >3 years. the participant has a history of chronic diarrheal disease within 6 months prior to the study registration date. the participant has received any experimental agents within 4 weeks prior to the study registration date. the participant has Grade 3-4 bleeding within 3 months prior to the study registration date. the participant has an ongoing or active infection requiring antibiotic, antifungal, or antiviral therapy. the participant has uncontrolled hypertension, symptomatic congestive heart failure, psychiatric illness, brain metastases. \",\n",
       " '2/81 (2.47%), Heart failure 0/81 (0.00%), Fever 1/81 (1.23%), Cold 0/81 (0.00%), Lack of strength in left leg 0/81 (0.00%), Ostenecrosis produced by biphosphonates 0/81 (0.00%), Gastric cancer 0/81 (0.00%), Stroke 0/81 (0.00%), Hematuria 1/81 (1.23%), nodule in left breast 0/81 ( ',\n",
       " 'CBR is defined as the percentage of participants receiving at least one dose of study medication who achieved a best overall response. a \"complete response\" is defined as the disappearance of all target or non-target lesions. \"stable disease\" is neither \"partial response\" nor \"disease progression\" ly administered at 1000 mg per square meter (mg/m2) twice daily on the first day through the fourteenth day of each 21-day cycle. overall number of participants Analyzed: 51, Measure Type: Number, Unit of Measure: percentage of participants 59____________________________________________________ ',\n",
       " 'ONTAK IV repeats every 21 days for up to 6 courses. treatment repeats every 21 days for up to 6 courses. ',\n",
       " 'prior treatment must include both chemotherapy, alone or in combination with another agent, and an anti-HER2 agent, alone or in combination with another agent. progression must occur during or after most recent treatment for LABC/mBC or within 6 months of completion of adjuvant therapy. the participant must have recovered from any resulting acute toxicity (to Grade /=1) prior to first study treatment. the participant must have recovered from any resulting acute toxicity (to Grade /=1) before first study treatment. Metastatic central nervous system (CNS) disease only, Brain metastases which are symptomatic, History of a decrease in LVEF to less than () 40% or symptomatic congestive heart failure (CHF) with previous trastuzumab treatment. history of a decrease in LVEF to less than () 40% or symptomatic congestive heart failure (CHF) with previous trastuzumab treatment. ',\n",
       " 'clinical management: Clinical management is a clear contrast method of psychological therapy. the group will receive clinical management treatment only each session. the subjects will receive standard CBT and clinical management. ized CBT treatment regularly for 9 sessions. each session will last for about 60 minutes. the treatment includes three steps:Concept stage (the first and second sessions) ated and disease does not worsen in participants with no prior trastuzumab treatment. ',\n",
       " 'Tumor responses were assessed every 6 weeks using, Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and defined as: Complete response (CR) is the disappearance of all target lesions; Partial response (PR) occurs when at least a 30% decrease in the sum of diameters of target lesions from baseline; Progressive Disease- is at least a 20% increase in the sum of diameters of target lesions from nadir. participants received nab-Paclitaxel 125 mg/m2 on days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m2 on days 1 and 8 by IV administration of each 21-day treatment cycle. participants continued treatment until progressive disease (PD), unacceptable toxicity, required palliative radiotherapy or surgical intervention of lesion(s), withdrawal from study treatment, withdrawal of study consent, participant refusal or the investigator felt it was no longer in the best participants continued treatment until progressive disease (PD), unacceptable toxicity, required palliative radiotherapy or surgical intervention of lesion(s), withdrawal from study treatment, withdrawal of study consent, refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment. ',\n",
       " '0/161 (0.00%), Gastrointestinal-Other 0/161 (0.00%), Dehydration 0/161 (0.00%), Renal/Genitourinary-Other 0/161 (0.00%), Adverse Events 2:, Total: 13/34 (38.24%), Anemia 3/34 (8.82%), Diarrhea 7/34 (20.59%), Nausea 2/34 (5.88%), Sepsis 1/34 (2.9 ',\n",
       " 'inTERVENTION 1:, Hypnotherapy, Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist. these sessions will be one week apart. ',\n",
       " 'if (neo) adjuvant chemotherapy received, patient must have received at least 4 cycles. study entry must be within any of the following timelines: 3 months of the end of definitive breast surgery OR between 3 weeks and 4 months after day 1 of the last cycle of adjuvant chemotherapy OR 6 weeks of radiotherapy. ine less than 1.5 x upper normal limit, Negative pregnancy test for patients with child-bearing potential, Normal baseline ECG and clinical cardiovascular assessment after completion of all (neo) adjuvant chemotherapy, No previous or current evidence for metastatic disease, Be accessible for and consent to long term follow-up. oral corticosteroids, Known or suspected congestive heart failure and/or coronary heart disease, previous history of myocardial infarction, uncontrolled arterial hypertension, rhythm abnormalities requiring permanent treatment. patients with diabetes controlled by diet and oral medication are eligible for the study. no previous or concomitant malignancies except adequately treated squamous cell / basal cell carcinoma of the skin, in situ carcinoma of the cervix or ductal carcinoma in situ/lobular carcinoma in situ of the breast, unless there has been a disease-free interval of 10 years or more 18. psychiatric or addictive disorders which could preclude obtaining informed consent 19. ',\n",
       " 'During cycle 1 of Chemotherapy, Mean duration of severe neutropenia defined as number of consecutive days with ANC 0.5  109/l (grade 4 neutropenia). During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application. pegfilgrastim is injected s.c. post chemotherapy application. a median PFS of 13 months or greater is 13 months or greater. paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. given IV, bevacizumab: Given IV, erlotinib hydrochloride: Given PO, Overall Number of Participants Analyzed: 55, Median (95% Confidence Interval), Unit of Measure: Months 9.1 (7.2 to 11.1) ',\n",
       " 'patients with progressive, radiographically measurable parenchymal brain metastases after whole brain radiation therapy (WBRT) patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. rt of patients with either leptomeningeal metastases (LMD) or unirradiated, asymptomatic brain metastasis from breast cancer (BCBM).Patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. ',\n",
       " 'participants who had not progressed and were still alive at the time of clinical cut off were censored at the last disease assessment prior to the missing interval. progression-free survival (PFS) was censored at the last disease assessment prior to the missing interval. overall number of participants Analyzed: 1048, Median (95% Confidence Interval), Unit of Measure: Months 7.4 (7.1 to 7.6), Results 2:, Arm/Group Title: Epoetin Alfa, Arm/Group Description: Participants received SOC plus epoetin alfa 40,000 international units (IU) subcutaneously once a week. ',\n",
       " 'FEBRILE NEUTROPENIA * 12/305 (3.93%), NEUTROPENIA * 4/305 (1.31%), ANAEMIA * 2/305 (0.66%), LEUKOPENIA * 1/305 (0.33%), THROMBOCYTOPENIA * 1/305 (0.33%), PERICARDIAL EFFUSION * 1/305 (0.33%), Adverse Events 2:, Total: 50/304 (16.45%), FEBRILE NEUTROPENIA * 12/304 ypersecretion 1/52 (1.92%), Enteritis 1/52 (1.92%), Abdominal pain 1/52 (1.92%), Vomiting 1/52 (1.92%), Stomatitis 1/52 (1.92%), Haematemesis 1/52 (1.92%) ',\n",
       " 'to be included in this study, you must meet the following criteria:, Metastatic breast cancer confirmed by biopsy, no more than one prior chemotherapy regimen for metastatic breast cancer, Able to perform activities of daily living with minimal assistance, Age 18 years or older, Give written informed consent, Exclusion Criteria:, You cannot participate in this study if any of the following apply to you. ualify for the trial, study personnel will explain the reasons. if you do qualify, study personnel will explain the trial in detail. ',\n",
       " \"patients must be women with locally advanced or inflammatory breast carcinoma. histologic confirmation shall be by either core needle biopsy or incisional biopsy. punch biopsy is allowed if invasive breast cancer is documented. patients must have a serum creatinine and bilirubin the institutional upper limit of normal. patients must have an Absolute neutrophil count (ANC) of 1,500/l and a platelet count of 100,000/l. women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method. all patients must be informed of the investigational nature of this study. all patients must be informed of the investigational nature of this study. no dosing or adverse event data are currently available on the use of lapatinib in patients 18 years of age. women of childbearing potential must be willing to consent to using effective contraception while on treatment and for a reasonable period thereafter. ytes or = to 3,000/L, absolute neutrophil count or = 1,500/L, platelets or = 100,000/L, total bilirubin within normal institutional limits. if LVEF is greater than 70%, and ECHO should be performed as well. patients may not be receiving any concurrent anticancer therapy or investigational agents with the intention of treating breast cancer. pregnant women are excluded from this study because lapatinib is member of the 4-anilinoquinazoline class of kinase inhibitors with the potential for teratogenic or abortifacient effects. cy., uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris. patients with GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption,uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis). \",\n",
       " 'a patient with a T score of -2.1 is eligible for a breast cancer diagnosis. a patient with a T score of -2.1 is eligible for a breast cancer diagnosis. AST 3 times ULN, Creatinine  2.0 mg/dL, Creatinine clearance 45 mL/min, no hypercalcemia (i.e., calcium level > 1 mg/dL above ULN) or hypocalcemia (i.e., calcium level > 0.5 mg/dL below lower limit of normal) within the past 6 months, no other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma osteonecrosis of the jaw, Exposed bone in the mouth, Slow healing after dental procedures, No contraindication to spine dual energy x-ray absorptiometry (DXA) as defined by any of the following:, history of surgery at the lumbosacral spine, with or without implantable devices, Scoliosis with a Cobb angle > 15 degrees at the lumbar spine, Immobility, hyperostosis, or sc osteoclastic bone resorption (e.g., calcitonin, mithramycin, or gallium nitrate) more than 30 days since prior topical investigational drug and/or device. more than 7 days since prior topical investigational drug and/or device. ',\n",
       " 'female participants, age >/=18 years, advanced, inflammatory or early stage unilateral invasive breast cancer, HER2-positive breast cancer, baseline left ventricular ejection fraction (LVEF) >/=55%, Exclusion Criteria:, metastatic disease (Stage IV) or bilateral breast cancer, previous anticancer therapy or radiotherapy for any malignancy, other malignancy, except for basal cell carcinoma, clinically relevant cardiovascular disease, current chronic treatment with corticosteroids of >10mg ',\n",
       " 'Ileus 1/14 (7.14%), general disorders and administration site conditions - Other, disease progression 2/14 (14.29%), Infections and infestations. Fatigue * 1/9 (11.11%), Non-cardiac chest pain * 1/9 (11.11%), Sepsis * 1/9 (11.11%), Urinary tract infection * 1/9 (11.11%), Syncope * 1/9 (11.11%), Anxiety * 1/9 (11.11%), Thromboe ',\n",
       " 'PFS = (first event date minus randomization date +1) divided by 30.4, Time frame: From date of randomization to the date of the first documentation of objective tumor progression or death due to any cause, whichever occurred first. escalation to 37.5 mg daily was permitted in the absence of complicated neutropenia. Paclitaxel could have been reduced to 65 mg/m2. re-escalation to 80 or 90 mg/m2 upon recovery was permitted. ',\n",
       " 'inTERVENTION 1:, no Cholecalciferol, Enrolled women with serum 25 (OH)D greater than or equal to 30 ng/ml received no intervention. ',\n",
       " 'Febrile Neutropenia * 3/56 (5.36%), Neutropenia * 1/56 (1.79%), Atrial Fibrillation * 1/56 (1.79%), Coronary Artery Disease * 1/56 (1.79%), Constipation * 1/56 (1.79%), Chest Pain * 1/56 (1.79%), Non-Cardiac Chest Pain * 1/56 (1.79%), Edema due to Cardiac Disease * 1/56 (1.79%), Cellulitis * ',\n",
       " 'inTERVENTION 2:, Arm II (Placebo), Patients receive a placebo PO BID on days 1-7. treatment repeats every 7 days for up to 12 courses in absence of disease progression or unacceptable toxicity. the intervention also includes additional web-based information and resource lists, text-based reproductive health and study adherence. at completion of the 24 weeks of follow up, they will have access to their SCPR., Control: Web-based resource lists and study adherence reminders. ',\n",
       " 'interleukin- 2 (IL-2) given subcutaneously at 9 million units 3 times a week for a total of 6 doses. no more than 8.0 x 107 cells/kg will be given. interleukin- 2 (IL-2) given at 9 million units 3 times a week for 6 doses. no more than 8.0 x 107 cells/kg will be given. ',\n",
       " 'invasive triple negative breast cancer. Known status for the LCL161 predictive gene expression signature as determined during molecular pre-screening. ith corticosteroids at a dose 10 mg of prednisone per day (inhaled and topical steroids are allowed) or any other chronic immunosuppressive treatment that cannot be discontinued prior to starting study drug, Impaired GI function that may affect the absorption of LCL161, Pregnant or breast feeding (lactating) women, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 180 days after study ',\n",
       " 'age 65 or younger, Estrogen receptor (ER), PgR and HER2 expression have been determined. estimated risk of breast cancer recurrence is high (25% or higher within the first 5 years from the date of the diagnosis. ere cardiac arrythmia requiring regular medicationInclusion Criteria:, Females 18 years of age, Histologically confirmed invasive breast cancer, Planning for surgical resection of breast tumor and sentinel node or axillary lymph node resection, Planning neoadjuvant chemotherapy, HER2 positive disease, Measurable disease in the breast after diagnostic biopsy, defined as longest diameter 2.0 cm, Known estrogen receptor (ER) and progesterone receptor any history of congestive heart failure, current high-risk uncontrolled arrhythmias, current angina pectoris requiring a medicinal product, current clinically significant valvular disease, current clinically significant valvular disease, current evidence of transmural infarction on electrocardiogram. history of positivity for hepatitis B surface antigen, hepatitis C virus, or human immunodeficiency virus (HIV) subject has known sensitivity to any of the products to be administered during the study, including mammalian cell derived drug products, trastuzumab, murine proteins, or to any of the excipients. Subject previously has enrolled and/or has been randomized in this study. be available to complete all protocol required study visits or procedures, History or evidence of any other clinically significant disorder, condition or disease. be available to complete all protocol required study visits or procedures, History or evidence of any other clinically significant disorder, condition or disease. ',\n",
       " 'Clinical Benefit was defined as Complete Response (CR), Partial Response (PR) or Stable Disease (SD) lasting more than equal to 24 weeks from randomization in participants with measurable disease at baseline. clinical benefit was defined as CR, PR, or SD lasting more than equal to 24 weeks from randomization in participants with measurable disease at baseline. participants were administered Venetoclax 800mg orally QD and Fulvestrant 500mg IM on day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days) overall number of participants Analyzed: 51, Measure Type: Number, Unit of Measure: Percentage of Participants 11.8 (4.44 to 23.87), Results 2:, Arm/Group Title: Fulvestrant, Arm/Group Description: Participants were administered Fulvestrant 500mg only IM on ',\n",
       " 'exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period received the same dose of tamoxifen tablet-in-capsule orally once daily for the remainder of 5-year period. ',\n",
       " 'primary tumor must be >2 cm in diameter by physical examination or imaging studies. patients with clinically suspicious axillary adenopathy can be any size (clinical T1-3, N1-2, M0) bilateral, synchronous breast cancer is allowed if both primary tumors are HER2-negative. patients entering this study must be willing to provide release of tumor tissue collected at baseline during a diagnostic procedure if available. if tissue is not available, the patient will still be eligible for enrollment. negative hematologic function defined as:, Absolute neutrophil count (ANC) 1500/L, Hemoglobin (Hgb) 10 g/dL, Platelets 100,000/uL, Adequate liver function defined as:, Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 2.5 x the upper limit of normal (ULN), Total bilirubin the institutional ULN, Adequate renal function defined as:, Serum re approved by their study physician while receiving study treatment. re approved by their study physician while receiving study treatment. who are not breastfeeding, who have a negative serum pregnancy test. patients with acute or chronic liver or renal disease or pancreatitis. Known diagnosis of human immunodeficiency virus (HIV), Hepatitis B (HBV) or Hepatitis C (HCV) patients with stage I cancer who have received definitive local treatment at least 3 years previously are eligible. all patients with previously treated in situ carcinoma (i.e. non-invasive) are eligible. conditions that do not permit compliance with the protocol. inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol. ',\n",
       " 'adult women must have at least one lesion that can be accurately measured or bone lesions in the absence of disease. prior treatment for breast cancer with endocrine therapy (adjuvant or metastatic settings) is allowed but should be discontinued. anticancer therapy for locally advanced or metastatic breast cancer except for prior hormonal therapy. radiotherapy to 25% of the bone marrow within 4 weeks prior to randomization. ',\n",
       " 'Adverse Events 1:, Total: 4/42 (9.52%), Perforation, GI 1/42 (2.38%), Febrile neutropenia 1/42 (2.38%), Syncope 1/42 (2.38%), Rash/desquamation 1/42 (2.38%) ',\n",
       " '6/15 (40.00%), diarrhea and dehydration * 0/15 (0.00%), death progressive disease * 0/15 (0.00%), divetricular abscess * 0/15 (0.00%), fever * 1/15 (6.67%), febrile neutropenia * 3/15 (20.00%), Neutropenia * 0/15 (0.00%), Adverse Events 2:, Total: 4/14 (28.57%), diarrhea and dehydration * 0/14 (0.00%), hypokalemia * 0/ ',\n",
       " '116/396 (29.29%), Anaemia 3/396 (0.76%), Febrile neutropenia 20/396 (5.05%), Granulocytopenia 1/396 (0.25%), leukopenia 1/396 (0.25%), Neutropenia 19/396 (4.80%), Atrial fibrillation 3/396 (0.76%), Cardiac failure congestive 0/396 (0.00%), Coronary artery disease 0/396 (0.00%), Left ventricular dysfunction 7/396 ',\n",
       " 'adenocarcinoma is metastatic or locally advanced and not curable by local measures. there is no limit on number of prior chemotherapy regimens received. women of childbearing potential (WOCBP) and men with partners who are of childbearing potential must be using an adequate method of contraception to avoid pregnancy. women of childbearing potential (WOCBP) and men with partners who are of childbearing potential must be using an adequate method of contraception to avoid pregnancy. women who are using oral, implanted or injectable contraceptive hormones should be considered to be of child bearing potential. women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods should be considered to be of child bearing potential. prior treatment with ixabepilone may be jeopardized by complications of this therapy. patients may not be receiving any other concurrent chemotherapy, hormonal therapy, immunotherapy regimens or radiation therapy. patients may not be receiving any prohibited therapies and/or medications. women are excluded from the study because the risks to an unborn fetus or potential risks in nursing infants are unknown. ',\n",
       " 'patients with hormone receptor +/- and human epidermal growth factor receptor 2 protein (HER2) +/- breast cancer are eligible for neoadjuvant chemotherapy with 12 cycles of weekly taxane therapy (paclitaxel 80mg/m2 or Abraxane 100 mg/m2 if there is a shortage of paclitaxel) followed by 4 cycles of Adriamycin (60mg/m2) and cyclophosphamide (600 mg/m2) given every the biopsy prior to Taxol #1 is optional. the biopsy prior to taxol #1 is optional. the biopsy prior to taxol #1 is optional. ',\n",
       " 'Adverse Events 1:, Total: 5/41 (12.20%), Neutropenia 4/41 (9.76%), Febrile Neutropenia 0/41 (0.00%), SGPT (ALT) 1/41 (2.44%), Adverse Events 2:, Total: 5/40 (12.50%), Neutropenia 4/40 (10.00%), Febrile Neutropenia 1/40 (2.50%). ',\n",
       " 'ascites with hyponatraemia 0/22 (0.00%), febrile neutropenia with respiratory infection 1/22 (4.55%), urosepsis 1/22 (4.55%), dyspnoea 1/22 (4.55%), hypoxia 0/22 (0.00%), thromboembolism 0/22 (0.00%), Adverse Events 2:, Total: 4/17 (23.53%), ascites with hyponatraemia 1/17 (5.88%), dys ',\n",
       " 'Adverse Events 1:, Total: 4/33 (12.12%), Diarrhea 1/33 (3.03%), Intracranial hemorrhage 1/33 (3.03%), Ischemia cerebrovascular 1/33 (3.03%), Confusion 1/33 (3.03%), Skin disorder 1/33 (3.03%)Adverse Events 1:, Total: 5/11 (45.45%), Nausea 1/11 (9.09%), Vomiting 1/11 (9.09%), Fever 1/11 ',\n",
       " '5/11 (45.45%), Nausea 1/11 (9.09%), Vomiting 1/11 (9.09%), Fever 1/11 (9.09%), skin infection [1]1/11 (9.09%), Hip fracture 0/11 (0.00%), Confusion 1/11 (9.09%), Adverse Events 2:, Total: 1/12 (8.33%), Nausea 0/12 (0.00%), Vomiting 0/12 (0.00%), skin infection [1]0/12 (0.00%), Hip ',\n",
       " 'anemia 1/96 (1.04%), Febrile neutropenia 4/96 (4.17%), Heart failure 1/96 (1.04%), Abdominal pain 1/96 (1.04%), Dysphagia 1/96 (1.04%), Mucositis oral 1/96 (1.04%), Nausea 1/96 (1.04%), Vomiting 2/96 (2.08%), Death NOS 0/96 (0.00%), Pain 1/96 (1.04%), Catheter related infection 1/ ',\n",
       " 'the ORR was defined as the percentage of participants with best overall response (BOR) of confirmed complete response (CR) or partial response (PR), based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. possible CR and PR had to be confirmed no fewer than 4 weeks after the initial response assessment. ORR = CR + PR, Time frame: Cycle 1 (Day 1) until first evidence of disease progression, assessed up to the data cutoff date (30 Aug 2013) up to 2.5 years, Results 1:, Arm/Group Title: Eribulin mesylate. ',\n",
       " 'tumors must be human Epidermal Growth Factor Receptor 2 (HER2) negative. patients must be free of disease in the axilla (node negative) if lymphadenectomy is done, at least 10 nodes must be examined. patients with immunohistochemistry (HER2) 0 or +1 are eligible. if values of AST and ALT are associated with alkaline phosphatase > 2.5 UNL, patient is not eligible. all patients must have a bilateral mammogram, thorax x-ray, abdominal echography and computed tomography (CT)-scan. if bone pain, and/or alkaline phosphatase elevation, a bone scintigraphy is mandatory. pre-existing grade >=2 motor or sensorial neurotoxicity by the National Cancer Institute Common Toxicity Criteria (NCICTC) v-2.0. any other serious medical pathology, such as congestive heart failure, unstable angina, history of myocardial infarction during the previous year. patients with no clinical or radiological evidence of disease must have undergone prior antineoplastic therapy. must have at least one undissected axillary and/or inguinal lymph node basin. m3, Hemoglobin > 9 g/dL, AST and ALT 2.5 x upper limit of normal (ULN), Bilirubin 2.5 x ULN, Alkaline phosphatase 2.5 x ULN, Creatinine 1.5 x ULN, HIV negative, Not pregnant or nursing, Negative pregnancy test, Fertile patients must use effective contraception. prior or concurrent topical corticosteroids allowed, More than 4 weeks since prior and no concurrent other investigational medication. no prior vaccination with any synthetic peptides in this protocol, Vaccines for infectious disease (e.g., influenza) allowed, provided they are administered 2 weeks prior to or 2 weeks prior to or 2 weeks prior to or 2 weeks. after study vaccine, Short term therapy for acute conditions not related to breast cancer allowed, No concurrent illegal drugs. ',\n",
       " \"inTERVENTION 1:, Physician's Choice, Physician selection from 4 standard of care metastatic breast cancer chemotherapies. eribulin, vinorelbine or gemcitabine or capecitabine. \",\n",
       " 'female 20 years and pre-menopausal defined as last menses within 1 year of randomisation. Hormone sensitivity (ER positive) of primary or secondary tumour tissue. candidates to receive hormonal therapy as therapy for advanced breast cancer. ',\n",
       " 'an AE was defined as any untoward medical occurrence in a participant administered SC Herceptin. examples included unfavorable/unintended signs and symptoms, new or exacerbated disease, recurrence of intermittent condition, deterioration in laboratory value or other clinical test. percentage of participants with at least 1 AE during the treatment period was reported. participants received SC Herceptin as 600 mg every 3 weeks for a total of 18 doses/cycles. each dose was administered from a pre-filled SID. ',\n",
       " 'Adverse Events 1: Total: 3/9 (33.33%), Fatigue * 1/9 (11.11%), Non-cardiac chest pain * 1/9 (11.11%), Sepsis * 1/9 (11.11%), Urinary tract infection * 1/9 (11.11%), Syncope * 1/9 (11.11%), Anxiety * 1/9 (11.11%), Thromboembolic event * 1/9 (11.11%) ',\n",
       " 'participants were asked, \"All things considered, which method of administration did you prefer?\" at the end of the crossover period. the percentage of participants who preferred each method of drug administration was reported. rossover period offered the opportunity to self-administer SC Herceptin via SID. the SC dose was 600 mg for all cycles where SC Herceptin was given. the IV dose was 6 mg/kg for all cycles where IV Herceptin was given. the IV dose was a loading dose of 8 mg/kg in Cycle 1 for de novo participants who started Herceptin treatment in the study. the SC dose was 600 mg for all cycles where SC Herceptin was given. ',\n",
       " 'triptorelin plus exemestane will be evaluated when administered twice weekly. treatment cycles will be 21 days in length. 10 additional patients will be treated at the determined MTD. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. treatment cycles will be 21 days in length. ',\n",
       " 'FEBRILE NEUTROPENIA 1/41 (2.44%), LEUKOPENIA 1/41 (2.44%), NEUTROPENIA 2/41 (4.88%), THROMBOCYTOPENIA 2/41 (4.88%), DIARRHEA 1/41 (2.44%), DIARRHEA 1/41 (2.44%), FLATULENCE 1/41 (2.44%), MUCOSITIS 1/41 (2.44%), NAUSEA 2/41 (4.88%), VOMITING 2/41 tion 0/570 (0.00%), Atrial flutter 1/570 (0.18%), Cardiac arrest 0/570 (0.00%), cardiac failure 1/570 (0.18%) ',\n",
       " 'Anaemia * 1/52 (1.92%), Febrile neutropenia 24/52 (7.69%), Neutropenia 28/52 (15.38%), Cardiac failure chronic 21/52 (1.92%), Vomiting 23/52 (5.77%), Diarrhoea 21/52 (1.92%), Gastric ulcer 21/52 (1.92%), Gastritis 21/52 (1.92%), Fatigue 21/52 (1.92%), Pyrexia 21/52 (1.92%), Gastro Urinary Tract Infection * 0/8 (0.00%), Enterocolitis infectious * 0/8 (0.00%) ',\n",
       " 'Adverse Events 1:, Total: 3/8 (37.50%), Anaemia 0/8 (0.00%), Febrile neutropenia 0/8 (0.00%), Polycythaemia 0/8 (0.00%), Acute coronary syndrome 0/8 (0.00%), Vertigo 0/8 (0.00%), Eyelid oedema 1/8 (12.50%), Constipation 0/8 (0.00%), Diarrhoea 0/8 (0.00%), Nausea  ',\n",
       " 'neoadjuvant chemotherapy comprises sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks. patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks. ',\n",
       " 'MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid. inTERVENTION 2:, Negative Pressure, PhysioTouch (negative pressure massage) treatment 3 times a week for 4 weeks to the lymphedematous upper limb, PhysioTouch: The PhysioTouch is a hand-held device that administers negative pressure under the treatment head. inTERVENTION 2:, Exercise, Exercise Arm: Exercise consisting of progressive walking and resistance band training, Calcitriol pill taken once per week. ',\n",
       " 'patients will receive Abraxane at 100 mg/m2 X 3 doses on days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on days 1 and 15 for subsequent cycles. patients will be evaluated for response every 8 weeks. Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes. patients will be evaluated for response every 2 cycles (every 8 weeks) ',\n",
       " '78/284 (27.46%), Febrile neutropenia * 28/284 (9.86%), Neutropenia * 217/284 (5.99%), leukopenia * 23/284 (1.06%), Anaemia * 22/284 (0.70%), Thrombocytopenia * 20/284 (0.00%), Arrhythmia * 21/284 (0.35%), Coronary artery disease * 20/284 (0.00%), Left ventricular dysfunction * 21/284 (0.35%), Ad ',\n",
       " 'Lapatinib: 1500 mg (six 250 mg tablets) orally once daily. ',\n",
       " '52/133 (39.10%), Thrombocytopenia 2/133 (1.50%), Anaemia 1/133 (0.75%), Disseminated intravascular coagulation 0/133 (0.00%), Atrial thrombosis 1/133 (0.75%), Cardiac failure 0/133 (0.00%), Vertigo 0/133 (0.00%), Vomiting 3/133 (2.26%), Nausea 1/133 (0.75%), Colitis 1/133 ',\n",
       " 'tumor must be confined to either the breast or to the breast and ipsilateral axilla. patient must have (according to TNM 7th edition rules) women of childbearing potential must agree to use acceptable non-hormonal contraceptive methods of birth control from the day of the screening pregnancy test and up to 3 months after the last intake of darolutamide. women between menarche and menopause have not been permanently sterilized, capable of procreation. permanent sterilization includes hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy. prior treatment should be stopped at least 28 days prior to registration. prior or concurrent treatment should be stopped at least 28 days prior to registration. congestive heart failure NYHA Class III or IV, severe/unstable angina pectoris, myocardial infarction, uncontrolled hypertension, coronary/peripheral artery bypass graft, high-risk uncontrolled arrhythmias, stroke. any contraindication to oral agents or gastrointestinal disorder or procedure which expects to interfere significantly with absorption of protocol treatment. Known allergy to darolutamide or any of the excipients. major surgery defined as requiring a general anesthesia or respiratory assistance. ',\n",
       " 'results 1:, Arm/Group Title: A (Sorafenib + Gemcitabine), Arm/Group Description: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours), Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily. Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine). overall number of participants Analyzed: 81, Median (95% Confidence Interval), Unit of Measure: Days 103 (83 to 128), Results 2:, Arm/Group Title: B (Placebo + Gemcitabine or Capecitabine), Arm/Group Description: Placeb dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine). Overall number of participants Analyzed: 79, Median (95% Confidence Interval), Unit of Measure: Days 81 (48 to 95) ',\n",
       " 'the DXA devices of participating sites were cross-calibrated and the results were analyzed by a central reader. the results were compiled and analyzed by a central reader. participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months. overall number of participants Analyzed: 253, Mean (Standard Deviation), Unit of Measure: Percentage of BMD 1.955 (3.3658), Results 2:, Arm/Group Title: Zoledronic Acid Delayed-start, Arm/Group Description: zoledronic acid 4 mg i.v. overall number of participants Analyzed: 256, Mean (Standard Deviation), Unit of Measure: Percentage of BMD -2.325. ',\n",
       " 'any treatment-related hematologic toxicity specifically defined as: - Thrombocytopenia Grade 4 for 7 days, or Grade 3 or 4 associated with bleeding or requiring platelet transfusion; - Neutropenia Grade 4 for 7 days, or Grade 3 or 4 associated with infection or febrile neutropenia. any treatment-related AE leading to niraparib dose interruption per the following criteria: - a dose interruption for a non-DLT lab abnormality lasting 14 days Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle. overall number of participants Analyzed: 6, Measure Type: Count of participants, Unit of Measure: Participants 1 16.7%, Results 2:, Arm/Group Title: Phase 1: Niraparib 300mg + Pembrolizumab, Arm/Group Description: Niraparib 300 mg/day orally (PO). ',\n",
       " 'pCR in the breast was defined as no pathologic evidence of invasive disease (residual ductal carcinoma in situ [DCIS] or lobular carcinoma in situ [LCIS] was allowed) pCR in the axillary lymph node was defined as no evidence of breast cancer cells in the lymph node. 26 weeks of therapy comprised the 2-week run-in phase, 12 weeks of treatment with FEC. rmed, followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-FU 500 mg/m2, epirubicin 75 mg/m2, cyclophosphamide 500 mg/m2 x 4 cycles on Day 1), then paclitaxel (80 mg/m2 x 4 cycles on Day 1, Day 8, and Day 15) in combination with trastuzumab. l Number of Participants Analyzed: 29, Measure Type: Number, Unit of Measure: percentage of participants 45.0__. ',\n",
       " \"patients having tissue expanders or implants placed prior to radiation may be enrolled at the physician's discretion. Candidate for radiotherapy must not require bilateral radiotherapy, No metastatic (stage IV) breast cancer by AJCC staging criteria, Hormone receptor status not specified. ulN, bilirubin normal, Creatinine clearance > 50 mL/min, Negative pregnancy test, not pregnant or nursing. no serious, uncontrolled, concurrent infection(s), no diabetes with current or history of delayed wound healing or skin ulcers. no other cancers within the last five years except cured non-melanoma skin cancer and in-situ cervical cancer. uncontrolled seizures, psychiatric disability judged by investigator to be clinically significant, Physically intact upper gastrointestinal tract, No malabsorption syndrome, No uncompensated coagulopathy. Able to read and speak English, PRIOR CONCURRENT THERAPY:, Fully recovered from surgery and chemotherapy with completely healed surgical wounds. hemotherapy or radiation therapy, no concurrent allopurinol or cimetidine, Concurrent coumadin is allowed. \",\n",
       " '31/185 (16.76%), Anemic Shock [1]1/185 (0.54%), Febrile Neutropenia [2]13/185 (7.03%), Febrile Neutropenia 2/185 (1.08%), Febrile neutropenia [3]3/185 (1.62%), Neutrophil Count Decreased [2]2/185 (1.08%), Neutrophil Count Decreased [4]2/185 (1.08%), Colon Diverticulitis 1/185 (0.54%), Vomit ',\n",
       " 'the time interval from randomization date to recurrence, progression or death is documented. for subjects without recurrence, progression or death, it is censored at the last valid tumor assessment. the result is based on primary analysis data cut. overall number of participants Analyzed: 307, Mean (95% Confidence Interval), Unit of Measure: months 8.8 (7.8 to 9.8), Results 2:, Arm/Group Title: lapatinib Plus Capecitabine, Arm/Group Description: lapatinib 1250 mg orally, once daily, continuously in 21 day cycles. ',\n",
       " 'postmenopausal to limit sample variability (> 12 months amenorrhea), greater then 1 month but  5 years post-treatment for non-metastatic breast cancer. criteria allow inclusion of women successfully treated for recurrent breast cancer. ',\n",
       " 'tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen. tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin. participants received pertuzumab 840 mg (loading dose) and 420 mg (maintenance dose) IV infusion followed by trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w for rest of the cycles (12 cycles) in adjuvant period (up to a total of 18 cycles) overall number of participants Analyzed: 221, Measure Type: Number, Unit of Measure: Percentage of Participants 5 participants 44.4 (37.76 to 51.18). ',\n",
       " 'Total: 10/30 (33.33%), Hemoglobin decreased 2/30 (6.67%), Abdominal pain 1/30 (3.33%), Colitis 1/30 (3.33%), Diarrhea 7/30 (23.33%), Nausea 2/30 (6.67%), Rectal hemorrhage 1/30 (3.33%), Fatigue 1/30 (3.33%), Skin infection 1/30 (3.33%), Neutrophil count decreased 1/30 (3.33%) ',\n",
       " '78/284 (27.46%), Febrile neutropenia * 28/284 (9.86%), Neutropenia * 217/284 (5.99%), leukopenia * 23/284 (1.06%), Anaemia * 22/284 (0.70%), Thrombocytopenia * 20/284 (0.00%), Arrhythmia * 21/284 (0.35%), Coronary artery disease * 20/284 (0.00%), Left ventricular dysfunction * 21/284 (0.35%), Ad ',\n",
       " 'PFS is defined as the number of months from the date of randomization to the earlier of progressive disease (PD) or death due to any cause. from date of randomization to discontinuation due to disease progression or death up to primary completion date. entinostat 5 mg tablet orally once per week on days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor. overall number of participants Analyzed: 64, Median (95% Confidence Interval), Unit of Measure: months 4.28 (3.26 to 5.36) ',\n",
       " '223 treated patients included in the analysis. time frame: assessed on day 1 of cycles 5, 9, 17 and 25. each 6 months for 2-3 years from study entry. number, unit of measure: percentage of participants 2.5 (0.5 to 7.1) ',\n",
       " 'anemia * 1/48 (2.08%), Cardiac failure congestive * 1/48 (2.08%), Constipation * 2/48 (4.17%), Esophagitis * 1/48 (2.08%), Gastrointestinal hemorrhage * 1/48 (2.08%), Pain * 1/48 (2.08%), Cholecystitis * 1/48 (2.08%), Diverticulitis * 1/48 (2.08%), Cellulitis * 1/48 (2.08%), Gastroenteritis * 1/48 ',\n",
       " 'inclusion Criteria:, Operable breast cancer, Exclusion Criteria:, Inoperable breast cancer, BMI > 25, Neoadiuvant radioterapy, Carcinomastitis, Previous phlebitis of omolateral arm, Collagen diseaseInclusion Criteria:, Written informed consent of the patient signed by herself. ',\n",
       " '\"Triple negative\" disease defined as tumor demonstrating no expression for estrogen, progesterone or human epidermal growth factor receptor 2(HER2)receptors. an interval of at least 1 week must have elapsed since prior chemotherapy or hormonal therapy. lets 100,000/L;, Hemoglobin 9 gm/dL;, Total bilirubin institutional upper limit of normal (ULN);, Aspartate transaminase (AST) and alanine aminotransferase (ALT) 5 times ULN;, Alkaline phosphatase 2.5 times ULN;, estimated creatinine clearance 60 mL/min., left ventricular ejection fraction (LVEF) 50%. ne for metastatic breast cancer; Known hypersensitivity to any component of any study drug; Known hypersensitivity to any component of any study drug; Known hypersensitivity to any component of any study drug; Current neuropathy grade 2; central nervous system metastases as determined by head CT with contrast;. ne for metastatic breast cancer; ne for metastatic breast cancer; ne for metastatic breast cancer; ne for metastatic breast cancer; ne for metastatic breast cancer;  within previous 6 months, Uncontrolled serious contraindicated medical condition or psychiatric illness. ',\n",
       " 'no prior therapy for breast cancer within the past 5 years., 18 years of age or older., Ability to understand and the willingness to sign a written informed consent document. oadjuvant chemotherapy, hormonal therapy, or other systemic therapy, plans for preoperative radiation therapy, plans for breast cancer surgery, and does not allow for at least 10 days of vitamin D intervention. condition that would potentially interfere with vitamin D absorption, such as celiac sprue, ulcerative colitis. ',\n",
       " 'Bone Mineral Density (g/cm2) of the Lumbar Spine (L2-L4) measured by energy x-ray absorptiometry (DXA) all participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1. all participants took Letrozole tablets 2.5 mg/day for 5 years beginning on day 1. overall number of participants Analyzed: 418, Mean (Standard Deviation), Unit of Measure: Percentage change in BMD -3.617 (4.2151) ',\n",
       " 'clinical benefit rate is defined as the proportion of subjects experiencing a complete response (CR), partial response (PR) or stable disease (SD) for at least 24 weeks. clinical benefit rate is defined as the proportion of subjects experiencing a complete response (CR), partial response (PR) or stable disease (SD) for at least 24 weeks. patients receive temsirolimus IV over 30 minutes on days 1, 8, 15 and 22. courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. ',\n",
       " 'Sickle cell anaemia with crisis 1/76 (1.32%), Diarrhoea 1/76 (1.32%), Pyrexia 1/76 (1.32%), Chest pain 1/76 (1.32%), Complication associated with device 1/76 (1.32%), General physical health deterioration 0/76 (0.00%), Device related infection 2/76 (2.63%), Pneumonia 1/76 (1.32%), Atypical pneumonia 1/76 (1.32%), Dehydration 1/76 0/56 (0.00%), Vomiting 0/56 (0.00%), Disease progression 2/56 (3.57%), Infusion related reaction 1/56 (1.79%), Pain 0/56 (0.00%), Adverse Events 2:, Total: 11/37 (29.73%), Pancytopenia 1/37 (2.70%), Pericarditis 1/37 (2.70%), Abdominal pain 2/37 (5.41%), Anal fissure 0/37 (0.00%), Ascite  ',\n",
       " 'age 18 years, Stage 1-4 invasive breast cancer that is histologically confirmed at MSKCC. Status post mastectomy with axillary exploration (sentinel node biopsy and/or axillary lymph node dissection) to receive PMRT, ECOG Performance Status of 0 or 1, Exclusion Criteria:, Male, Patients with clinical evidence of gross disease. nts are allowed), psychiatric illness that would prevent patient from giving informed consent, Inability or unwillingness to comply with skin care instructions and follow-up, Allergy to either Eucerin or MF, Residual grade >1 skin toxicity, cellulitis, or incompletely healed wound(s) at intended site of study drug application at the time of the start of RT. treatment with palliative or pre-operative radiation. ',\n",
       " 'tumor must be Her 2/neu 3+ by IHC (must be confirmed by Ohio State University pathology) or positive FISH, Histological confirmation of invasive breast cancer either from the original diagnosis and/or diagnosis of metastatic disease. a positive bone scan is allowed as the only site of disease. ilirubin 1.5 x ULN and liver enzymes (AST, ALT, or alkaline phosphatase) must have an ANC (absolute neutrophil count) > 1.5, platelets > 100,000, Hemoglobin >9.0 within 21 days of registration. no more than one prior Trastuzumab/chemotherapy or Trastuzumab/biotherapy combination for metastatic disease. patients may have received prior cisplatin or carboplatin for metastatic disease. no active infection at time of registration. pregnant women may not participate in trial. exclusion Criteria: evidence of metastatic disease, except ipsilateral (same side) axillary lymph nodes. previous systemic or local primary treatment. ',\n",
       " 'metastatic adenocarcinoma of the breast (Stage IV), actively receiving endocrine therapy for at least 6 weeks (with or without HER2 therapy), Minimum age 18 years, ECOG Performance status of 0, 1 or 2, Normal organ and marrow function. aconazole, spironolactone, cimetidine, warfarin, erythromycin, or protease inhibitors, Conditions predisposing to renal failure secondary to rhabdomyolysis, Recent history of heavy alcohol use as judged by the treating physician. Known history of rhabdomyolysis on statin therapy, Known history of Hepatitis C or active hepatitis B infection (baseline testing not required) ',\n",
       " 'Adverse Events 1:, Total: 1/22 (4.55%), Blood bilirubin increased 1/22 (4.55%), alkaline phosphatase increased 1/22 (4.55%) ',\n",
       " 'the subject was then randomized to treatment Arm 1, neoadjuvant hormonal therapy, or treatment Arm 2, neoadjuvant chemotherapy. participants were treated with intravenous (IV) doxorubicin (60 milligrams per meters squared [mg/m2]) and cyclophosphamide (600 mg/m2) every 21 days for 4 cycles. weekly paclitaxel (WP) 80 mg/m2 IV on ',\n",
       " 'number of participants with dose limiting toxicities (DLT), number of participants with DLT in the first cycle (28 days) for the determination of the maximum tolerated dose. Important Limitations and Caveats are provided in the respective section. it., Overall Number of Participants Analyzed: 2, Measure Type: Number, Unit of Measure: Participants 2_. ',\n",
       " 'MM-121 + exemestane was more effective than placebo + exemestane. progression-free survival was defined as the number of months from the date of randomization to the date of death or progression. MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week plus exemestane (25 mg) administered orally once per day, Overall Number of participants Analyzed: 56, Median (95% Confidence Interval), Unit of Measure: weeks 15.9 (9.3 to 30.3), Results 2:, Arm/Group Title: Placebo + Exemestane, Arm/Group Description: Place ',\n",
       " 'Adverse Events 1:, Total: 12/538 (2.23%), Hypertension 0/538 (0.00%), Acoustic Neuroma 1/538 (0.19%), Diarrhea 0/538 (0.00%), Colitis 1/538 (0.19%), Elevated ALT or AST enzyme 7/538 (1.30%), Diagnosis of Uterine cancer 0/538 (0.00%), Motorcycle accident 0/538 (0.00%), Fall 0/538 (0.00%), Surgery 3/5 ',\n",
       " '6/15 (40.00%), diarrhea and dehydration * 0/15 (0.00%), death progressive disease * 0/15 (0.00%), divetricular abscess * 0/15 (0.00%), fever * 1/15 (6.67%), febrile neutropenia * 3/15 (20.00%), Neutropenia * 0/15 (0.00%), Adverse Events 2:, Total: 4/14 (28.57%), diarrhea and dehydration * 0/14 (0.00%), hypokalemia * 0/ ',\n",
       " 'the systemic tumor response refers to the response at the time of best overall response. the response criteria are specially adapted from Response Evaluation Criteria in Solid Tumor for Immunotherapies. tion, Imiquimod, Overall Number of Participants Analyzed: 12, Measure Type: Number, Unit of Measure: proportion of tumors.25 (.06 to.57), Results 2:, Arm/Group Title: CTX/IMQ/RT, Arm/Group Description: Week -1 (day-7): cyclophosphamide 200mg/m2 IV as single infusion, Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, ',\n",
       " 'TTP was calculated as first event date minus the date of first dose of study medication plus 1. time frame: Phase 2 double-blind baseline until tumor progression or death or discontinuation from study treatment, assessed every 9 weeks up to 129 weeks. placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo placebo ',\n",
       " 'Mean duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy, Mean duration of severe neutropenia defined as the mean number of consecutive days with Grade 4 neutropenia (ANC less than 0.5*109 cells/L), Time frame: 21 days (Cycle 1 of chemotherapy treatment), Results 1:, Arm/Group Title: EP2006 + EP2006. ',\n",
       " 'Agranulocytosis 0/42 (0.00%), Anaemia 2/42 (4.76%), Febrile neutropenia 1/42 (2.38%), leukopenia 0/42 (0.00%), Neutropenia 1/42 (2.38%), Thrombocytopenia 1/42 (2.38%), Cardio-respiratory arrest 0/42 (0.00%), Melaena 0/42 (0.00%), Fatigue 1/42 (2.38%), Multi-organ failure 0/ PURA 0/145 (0.00%), DISSEMINATED INTRAVASCULAR COAGULATION 0/145 (0.00%), CARDIAC FAILURE 1/145 (0.69%), ATRIAL FIBRILLATION 1/145 (0.69%), Adverse Events 2:, Total: 11/144 (7.64%), ANAEMIA 1/144 (0.69%), LEUKOPENIA 0/144 (0.00%), NEUTROPENIA 0/144 ( ',\n",
       " 'Letrozole and Imatinib Mesylate, Imatinib mesylate 400 mg by mouth twice a day daily for 28 days and Letrozole 2.5 mg once a day daily for 28 days cycle. ',\n",
       " 'Inclusion Criteria:, Estrogen receptor or progesterone receptor positive breast cancer, Premenopausal with regular menstrual cycles, Exclusion Criteria:, Current oral contraceptives__. ',\n",
       " 'early stage breast cancer - stage I (tumor size greater than 1 cm), II and IIA. 3+ HER2 overexpression by IHC or 2+ HER2 overexpression and FISH positivity. postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. final eligibility for clinical trial is determined by the health professionals conducting the trial. sease free for greater than five years are eligible. evidence of sensory and/or peripheral neuropathy. major surgery within 4 weeks of the start of study treatment. ',\n",
       " 'Dose-limiting toxcities (DLT) were defined as grade 3-4 febrile neutropenia, thrombocytopenia and non-hemtological toxicity attributed to therapy. any toxicity occurring during cycle 1 that resulted in dose reduction of vorinostat or paclitaxel or failure to complete all protocol specificed doses in the first cycle was also considered a DLT. Vorinostat dose escalation was carried out in the standard 3 + 3 phase I trial design based upon toxicity observed during the first cycle of therapy. overall number of participants Analyzed: 6, Measure Type: Number, Unit of Measure: mg 300________________________________________________________ ',\n",
       " '5/11 (45.45%), Nausea 1/11 (9.09%), Vomiting 1/11 (9.09%), Fever 1/11 (9.09%), skin infection [1]1/11 (9.09%), Hip fracture 0/11 (0.00%), Confusion 1/11 (9.09%), Adverse Events 2:, Total: 1/12 (8.33%), Nausea 0/12 (0.00%), Vomiting 0/12 (0.00%), skin infection [1]0/12 (0.00%), Hip ',\n",
       " '28/348 (13.79%), Blood/Bone Marrow-Other 1/348 (0.29%), Febrile neutropenia 0/337 (0.00%), Febrile neutropenia 0/337 (0.00%), Hemoglobin 2/337 (0.59%), Atrioventricular block - 2nd degree Mobitz Type II 0/337 (0.00%), Cardiac-ischemia/infarction 1/337 (0.30%), Left ventricular diastolic dysfunction  ',\n",
       " 'cytomorphologic evidence of hyperplasia +/- atypia and Ki-67 expression >1.5% in benign breast epithelial cells acquired by RPFNA, Serum level of 25-OH vitamin D of at least 30 ng/ml prior to study entry. will have a repeat random periareolar fine needle aspiration and mammogram at 6 months and 12 months. of more than 6 months of an aromatase inhibitor at any time in the past. ',\n",
       " 'clinical benefit rate (CR Plus PR Plus SD), complete response (CR) + partial response (PR) + stable disease (SD) using RECIST 1.0, CR = disappearance of all target lesions, SD = at least a 30% decrease in the sum of the longest diameter of target lesions. SD is defined as lack of disease progression by 24 weeks. participants complete response (CR): 0, Partial response (PR): 1, Stable disease (SD): 8, CR+PR+SD: 9_________________________________________________________________________________ ',\n",
       " 'patients receive oral pazopanib once daily on days 1-28. courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. ',\n",
       " 'primary early breast cancer, tumor size greater than or equal to 2 centimeters (cm), of Stages T2-T4/N0-2., Performance status 0-2 Eastern Cooperative Oncology Group (ECOG)., Exclusion Criteria:, prior anthracyclines as part of prior anticancer therapy. other investigational drugs within 6 months of study entry, Other serious intercurrent medical illness. ',\n",
       " 'Febrile neutropenia [1]0/113 (0.00%), anemia with trombocytopenia 0/113 (0.00%), Neutropenia 1/113 (0.88%), paroxism of atrial fibrillation 0/113 (0.00%), Gastrointestinal hemorrhage 1/113 (0.88%), Death for unknown reason 1/113 (0.88%), Diarrhea with vomiting and weakness 0/113 (0.00%), Adverse Events 2:, Total: 13 ',\n",
       " \"participants were followed for approximately 3 years after the last dose of the study treatment. the percentage of participants who completed the eribulin portion of the regimen without a dose omission, delay or reduction due to eribulin-related AE was estimated via the observed completion rate. participants initially received doxorubicin (60 mg/m2) plus cyclophosphamide (600 mg/m2) intravenously (IV) on Day 1 of every 14-day cycle for 4 cycles. in this Cohort growth factors, subcutaneous pegfilgrastim (6 mg) or filgrastim, could be used with eribulin therapy at the physician's discretion. participants initially received doxorubicin (60 mg/m2) plus cyclophosphamide (600 mg/m2) IV on Day 1 of every 14-day cycle for 4 cycles. eribulin therapy was administered at a dose of 300 micrograms for participants 60 kg or 480 micrograms for participants >60 kg. \",\n",
       " 'all MCS110 treated patients, with 10mg/kg intravenous infusion, on day 1 and days 1 & 8, overall number of participants Analyzed: 34, Median (90% Confidence Interval), Unit of Measure: months 5.6 (4.5 to 8.7), Results 2:, Arm/Group Title: Carboplatin+Gemcitabine, Arm/Group Description: comparator. the best overall response (OR) for each patient is determined from the sequence of investigator overall lesion responses. to be assigned a best OR of complete responese (CR) at least two determinations of PR or better at least 4 weeks apart before progression are required. overall response rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48 weeks. 49, Measure Type: Number, Unit of Measure: participants Patients with measurable disease at baseline: 39, Patients with non-measurable disease at baseline: 10, Best at WK 48 - Complete Response (CR): 0, Best at WK 48 - Partial Response (PR): 7, Best at WK 48 - Stable Disease (SD): 18, Best at WK 48 - Progressive Disease (PD): 15, Unknown: 1, Missing: 8. ',\n",
       " 'breast cancer subjects on hormonal therapy or trastuzumab only therapy and colorectal cancer subjects on adjunctive therapies not considered cytotoxic chemotherapy are eligible. participants will be allowed to receive concomitant adjuvant endocrine therapy for breast cancer. stomy reversal, Exclusion Criteria:, Concurrent other malignancy or history of other malignancy treated within the past 3 years. the patient is at least 18 years of age at the time of consent. the patient has an ECOG performance stout. the patient has a clinical negative node status at the time of study entry. if of child bearing potential, the patient has a negative pregnancy test within 72 hours prior to administration of Lymphoseek, has been surgically sterilized or has been postmenopausal for at least 1 year. patients with truncal or extremity primary melanoma have had a prior invasive melanoma that would occur on the same body region or potentially draining to the same nodal basin. patients with truncal or extremity primary melanoma have had a prior breast cancer potentially draining to the same nodal basin. preoperative radiation therapy to the affected breast or axilla. had preoperative radiation therapy to the affected breast or axilla. ',\n",
       " 'female with non-inflammatory breast adenocarcinoma must be at least 21 years of age. participants must be prescribed concurrent hormone treatment with radiation treatment. participants must receive five sessions of radiation therapy per week for at least four weeks. participants must be able to understand English and complete assessment forms. participants must be able to swallow medication. patients with bilateral breast cancer are not eligible. patients with collagen vascular disease, vasculitis, unhealed surgical sites are not eligible. greater than or equal to Grade 2 change Hemoglobin (i.e., 25% decrease from baseline); greater than or equal to Grade 1 change in Platelets (i.e., less than 75,000/mm3); greater than or equal to Grade 2 change in PT and PTT (i.e., 1.5-2x upper level normal) ',\n",
       " 'Adverse Events 1:, Total: 10/14 (71.43%), Hemoglobin 2/14 (14.29%), Lymphopenia 1/14 (7.14%), Hypertension 2/14 (7.14%), Constipation 1/14 (7.14%), Diarrhea 1/14 (7.14%), Heartburn/dyspepsia 1/14 (7.14%), Fatigue (asthenia, lethargy, malaise) 2/14 (7.14%), Rig ',\n",
       " 'you must meet the following criteria:, Adenocarcinoma of the breast confirmed by biopsy, Female Patients >18 years of age, Normal cardiac function, Ability to perform activities of daily living with minimal assistance, Adequate bone marrow, liver and kidney function, Sign an informed consent form, Sentinel lymph node and/or axillary dissection prior to enrollment, Exclusion Criteria:, You cannot participate in this study if any of the following apply to you:, Life expectancy of  than 6 fy for the trial, study personnel will explain the reasons. if you qualify, study personnel will explain the trial in detail. ',\n",
       " 'Adverse Events 1:, Total: 2/2 (100.00%), Febrile neutropenia * 2/2 (100.00%), Haemorrhage NOS * 0/2 (0.00%), Diarrhea * 0/2 (0.00%), Melaena * 0/2 (0.00%), Mucositis oral * 0/2 (0.00%), Nausea * 0/2 (0.00%), Vomiting * 0/2 (0.00%), Catheter related infection * 0/2 ',\n",
       " 'prior chemotherapy is permitted with no limit on the number of prior regimens. two weeks or more have elapsed since last chemotherapy or radiation treatment. is receiving concurrent immunotherapy, hormonal therapy or radiation therapy. participants with stable brain metastases who are off steroids at least 2 weeks are eligible, is pregnant or breast feeding. participants with stable brain metastases who are off steroids at least 2 weeks are eligible, is pregnant or breast feeding. ',\n",
       " 'Ileus 1/14 (7.14%), general disorders and administration site conditions - Other, disease progression 2/14 (14.29%), Infections and infestations. Fatigue * 1/9 (11.11%), Non-cardiac chest pain * 1/9 (11.11%), Sepsis * 1/9 (11.11%), Urinary tract infection * 1/9 (11.11%), Syncope * 1/9 (11.11%), Anxiety * 1/9 (11.11%), Thromboe ',\n",
       " 'outcome:, Event-free Survival, Event-free survival of patients treated for inflammatory (Stage IIIb) and responsive stage IV breast cancer with BUMELTT and PBSC support and low dose immunotherapy with IL2 and GM-CSF. ',\n",
       " 'this group received CDP, which include MLD, short-stretch bandages, lymph-reducing exercises, and skin care. MLD was applied to the anterior trunk, posterior trunk, and the base of the neck. taping was applied to anterior and posterior axillo-axillary anastomosis and axillo-inguinal anastomosis. tape was started in the inguinal region of the affected side. strips of tape were applied so that they reached the affected side. ',\n",
       " '100 mg Q-122, Dosage was 200 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days. inTERVENTION 1:, Treatment Period 1, Participants received AZD9496 - Variant A. ',\n",
       " 'the greater the change from baseline (randomization) in ER H-score, the greater the blockage of ER expression and the greater the potential anti-tumour activity. the greater the blockage of ER expression, the greater the potential anti-tumour activity. ts 2:, Arm/Group Title: Fulvestrant + Anastrozole, Arm/Group Description: Fulvestrant 500 mg once monthly injection + Anastrozole 1 mg once daily tablet, Overall number of participants Analyzed: 31, Mean (Standard Error), Unit of Measure: Percentage change from baseline -38 (5)__________________________________ ',\n",
       " 'infiltrating carcinoma of the breast meeting any of the following criteria:, T1-3, any N disease, Proven ductal carcinoma in situ, Unresected disease, Planned mastectomy as definitive surgical procedure. Nonpalpable tumor allowed (e.g., initial T2-3 tumor that responded to preoperative therapy), No inflammatory breast cancer or other T4 features. e patients must use effective contraception, no significant history of severe allergy to iodinated contrast material or debilitating anxiety that may not allow for a ductogram, PRIOR CONCURRENT THERAPY:, See Disease Characteristics, Prior preoperative chemotherapy, trastuzumab (Herceptin®), or hormonal therapy allowed provided it was completed 7-14 days prior to study treatment, No other prior procedure that may have altered the breast ductal system in the ipsilateral breast e Oncology Group (ECOG) performance status of 0 or 1, Baseline left ventricular ejection fraction (LVEF) at least 50%, Exclusion Criteria:, Pregnant, lactating, or women of childbearing potential who are not surgically sterile or not willing to use adequate contraceptive methods. Previous treatment with Herceptin or other anti-HER therapies, or any previous chemotherapy for advanced or metastatic disease. ',\n",
       " 'Inclusion Criteria:, HER-2 overexpressing breast cancer, Clinical stage 2-3B, Normal ejection fraction, Exclusion Criteria:, Metastatic disease, Low ejection fraction_. ',\n",
       " 'DLTs as per NCI CTCAE v3.0 were defined as: 1) Neutropenia Grade 4 that lasted at least 7 days, 2) Neutropenia Grade 3 or 4 complicated by fever and/or infection. 3) Thrombocytopenia Grade 4, 4) Thrombocytopenia Grade 3 complicated by bleeding and/or requiring platelet or blood transfusion. participants received eribulin mesilate 1.2 mg/m2, injection, intravenously, once, on Day 1 and capecitabine 1000 mg/m2, tablets, orally, twice daily from day 1 to 14 in each 21-day treatment cycle for as long as the treatment was clinically appropriate according to the judgment of the investigator. participants received eribulin mesilate 1.6 mg/m2, injection, intravenously, once, on Day 1 and capecitabine 1000 mg/m2, tablets, orally, twice daily from day 1 to 14 in each 21-day treatment cycle for as long as the treatment was clinically appropriate according to the judgment of the investigator or until the occurrence of PD, undue toxicity, the presence of other medical conditions that prohibit continuation of therapy, pregnancy, a delay of more than 14 days g Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes. 133, Overall Number of Participants Analyzed, Type of Units Analyzed: Lymph Nodes Measure Type: NumberNumber (95% Confidence Interval)Unit of Measure: Proportion of Lymph Nodes: 1.0000 (0.9840 to 1.0000) ',\n",
       " 'inTERVENTION 1:, Flexitouch Device, Lymphedema management via Flexitouch device, an intermittent pneumatic compression device (aka, lymphedema pump), inTERVENTION 2:, Manual Lymphatic Drainage (MLD) manual lymphatic drainage therapy. ',\n",
       " 'doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m2) x 12 with concurrent standard dose trastuzumab (weekly x 12 then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatin ',\n",
       " 'patients must have measurable disease by the RECIST criteria, defined as at least one lesion that can be accurately measured in at least one diameter (at least 10 mm in longest diameter (LD) by spiral computer tomography (CT) scan, or at least 20 mm by standard techniques. patients must have had prior treatment with anthracycline and a taxane. chemotherapy for advanced/metastatic disease. resolution of all chemotherapy or radiation-related toxicities to less than grade 1 severity, Age 18 years, Age 18 years, Eastern Cooperative Oncology Group (ECOG) Performance Status (APPENDIX 4) of 0 or 1, Life expectancy of 3 months. patients who have received chemotherapy, radiation, hormonal therapy, or Herceptin within 2 weeks of treatment start, Radiation therapy encompassing > 10% of marrow, Failure to recover from any chemotherapy related or other therapy related toxicity at study entry that is clinically significant by the study investigator. patients with central Nervous System metastasis are considered eligible if they have completed local therapy and discontinued from corticosteroids for at least two weeks before starting treatment with E7389. postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. in the past six months, or serious cardiac arrhythmia), patients with organ allografts, patients with known positive HIV status, patients with known positive HIV status, patients with a prior malignancy, other than carcinoma in situ of the cervix, or non-melanoma skin cancer. the prior malignancy was diagnosed and definitively treated 5 years previously with no subsequent evidence of recurrence. ',\n",
       " 'any treatment-related hematologic toxicity specifically defined as: - Thrombocytopenia Grade 4 for 7 days, or Grade 3 or 4 associated with bleeding or requiring platelet transfusion; - Neutropenia Grade 4 for 7 days, or Grade 3 or 4 associated with infection or febrile neutropenia. any treatment-related AE leading to niraparib dose interruption per the following criteria: - a dose interruption for a non-DLT lab abnormality lasting 14 days Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle. overall number of participants Analyzed: 6, Measure Type: Count of participants, Unit of Measure: Participants 1 16.7%, Results 2:, Arm/Group Title: Phase 1: Niraparib 300mg + Pembrolizumab, Arm/Group Description: Niraparib 300 mg/day orally (PO). ',\n",
       " 'Febrile neutropenia * 16/112 (14.29%), Neutropenia * 7/112 (6.25%), Anaemia * 1/112 (0.89%), Cardiac failure * 1/112 (0.89%), Coronary artery disease * 1/112 (0.89%), Pericardial effusion * 0/112 (0.00%), Hyperthyroidism * 1/112 (0.89%), Diarrhoea * 5/112 (4.46%), Vomiting * 3/112 (2.6 ',\n",
       " 'inTERVENTION 1:, Flaxseed, Patients receive 1 NutrigradTM flaxseed bar containing 7.5 grams flaxseed, 410 mg lignans,once daily., Placebo, Patients Identical looking bar with same calorie and total fat content but without flaxseed or lignans once daily. ',\n",
       " 'Adverse Events 1:, Total: 16/48 (33.33%), Febrile neutropenia grade 3 3/48 (6.25%), Neutropenia grade 3 1/48 (2.08%), Holocraneal cephalea 1/48 (2.08%), hypersensibility reaction grade 3 2/48 (4.17%), Palmoplantar erythrodysesthesia grade 3, stomatitis grade 3 1/48 (2.08%), Neutropenia grade 4, fever grade 1, oral mucositis grade 3 ',\n",
       " 'Febrile Neutropenia 2/218 (0.92%), Neutropenia 2/218 (0.92%), Anaemia 1/218 (0.46%), Thrombocytopenia 1/218 (0.46%), Pancytopenia 0/218 (0.00%), left Ventricular Dysfunction 4/218 (1.83%), Atrial Fibrillation 0/218 (0.00%), Angina Unstable 0/218 (0.00%), Arteriospasm Coronary 1/218 (0.46%), Cardiac perforation 1/82 (1.22%), Vomiting 1/82 (1.22%), Dehydration 1/82 (1.22%), Diarrhoea 1/82 (1.22%) ',\n",
       " 'a breast related adverse event was defined as any untoward medical occurrence related to a reconstructed breast. all subjects had the Meso BioMatrix Acellular Peritoneum Matrix implanted along with a tissue expander during the first stage of reconstruction. after tissue expansion, the tissue expander was replaced with a breast implant during the second stage of reconstruction. ',\n",
       " '19/213 (8.92%), Pancytopenia 0/213 (0.00%), Anaemia 1/213 (0.47%), Atrial fibrillation 0/213 (0.00%), Cardiac failure congestive 0/213 (0.00%), Myocardial infarction 0/213 (0.00%), Myocardial infarction 0/213 (0.00%), Colitis 0/213 (0.00%), Vomiting 1/213 (0.47%), Nausea 1/213 (0.4 ',\n",
       " 'Febrile neutropenia * 16/112 (14.29%), Neutropenia * 7/112 (6.25%), Anaemia * 1/112 (0.89%), Cardiac failure * 1/112 (0.89%), Coronary artery disease * 1/112 (0.89%), Pericardial effusion * 0/112 (0.00%), Hyperthyroidism * 1/112 (0.89%), Diarrhoea * 5/112 (4.46%), Vomiting * 3/112 (2.6 ',\n",
       " 'Pain 3/19 (15.79%), White blood cells (WBC) 5/19 (26.32%), Hemoglobin (Hgb) 1/19 (5.26%), Absolute neutrophil count (ANC) 5/19 (26.32%), Platelets 3/19 (15.79%), Elevated Aspartate Aminotransferase (AST) 1/19 (5.26%), Elevated Alanine Aminotransferase (ALT) 1/19 (5.26%), Dyspnea 3/19 ',\n",
       " 'Total: 20/93 (21.51%), Granulocytosis 1/93 (1.08%), Leukopenia 2/93 (2.15%), Angina pectoris 0/93 (0.00%), Atrial fibrillation 1/93 (1.08%), Cardiopulmonary failure 2/93 (2.15%), Retinal detachment 1/93 (1.08%), Diarrhoea 3/93 (3.23%), Nausea 1/93 (1.08%), Vomiting 1/93 ',\n",
       " 'Female, 18-100 years old, Not pregnant or breastfeeding, Pre-study radiologic documentation of:, size 5 cm, unicentric, unilateral, suspicious mass or calcification, BIRADS classification IV, location of abnormality > 1 cm from skin, Ductal or Infiltrating Ductal Carcinoma, Grade I-III on final pathology, Good general health, Zubrod Performance Status of 0,1, or 2, No previous chemotherapy, No palpable axillary or supraclavicular lymph ',\n",
       " 'inclusion Criteria:, surgery for breast cancer with immediate breast reconstruction, Diagnosis of primary lymphedema, Metastatic or inflammatory breast cancer, Planned use of chemotherapy within the next 6 weeks, Surgical complications: infection, drainage issues, seroma, hematoma, Severe physical, cognitive, or psychiatric illness causing inability to follow the study protocol. women with non-inflammatory breast adenocarcinoma must be at least 21 years of age. participants must be prescribed concurrent hormone treatment with radiation treatment. participants must receive five sessions of radiation therapy per week for at least four weeks. the total dose prescribed to the whole breast should be 50 Gy or greater. participants must be able to understand English and complete assessment forms. participants must be able to swallow medication. patients with known radiosensitivity syndromes (e.g., Ataxia-telangiectasia) are not eligible. patients with known radiosensitivity syndromes, vasculitis, unhealed surgical sites, or breast infections are not eligible. ',\n",
       " \"patients must have histologically confirmed metastatic breast cancer. tissue (a minimum of 3 slides) from the biopsy is required for review. patients must have a life expectancy of greater than 12 weeks. must have a life expectancy of greater than 12 weeks. must have an ECOG performance status = 2. patients must be off any medications by the time of registration. patients with known brain metastases are NOT eligible for participation. patients with known brain metastases are NOT eligible for participation. cation, Malabsorption syndrome, Require intravenous (IV) alimentation, History of prior surgical procedures affecting absorption, Uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis) \",\n",
       " \"subjects must agree to use at least one of the following types of contraception. intrauterine device, implantable progesterone device, progesterone intramuscular injection, or oral contraceptive. subject is scheduled to undergo 4 cycles of TA chemotherapy. the contraceptive patch or condom use with spermicide is also acceptable forms of contraception as long as they will be continually used throughout the duration of the trial. the contraceptive patch or condom use with spermicide is also acceptable forms of contraception as long as they will be continually used throughout the duration of the trial. splenomegaly, chronic constipation, diarrhea, irritable bowel syndrome, inflammatory bowel disease, ALT, AST, alkaline phosphatase, total bilirubin 2.5 upper limit of normal. subjects with active infection, or known to be infected with chronic active Hepatitis B within the last 1 year (unless shown at the time of study entry to be Hepatitis B antigen negative) patients that have received a prior chest X-ray for suspicion of tuberculosis are also excluded unless they have been confirmed to be PPD negative or they had latent tuberculosis that has been previously treated. subjects with Sickle Cell disease, subjects with known hypersensitivity to E.coli derived proteins' pegfilgrastim' filgrastim are also excluded. ope, and possible consequences of the study. \",\n",
       " 'six weeks after surgery, patients receive a brief initial post-operative care session describing lymphedema risk and prevention through oral instruction. patients complete physical assessments and questionnaires at 6 weeks and at 6, 12, and 18 months. patients complete a personalized physical therapy intervention, receive a refrigerator magnet, and a 15-minute video that reinforces information and exercises. ',\n",
       " 'measurable disease cannot be previously irradiated, unless progression was documented. disease must be measurable, i.e., bone-only disease or evaluable-only disease is not eligible. patients with brain metastasis may participate if they:, have undergone appropriate treatment, are at least 1 month post-treatment. patients must have received prior adjuvant or neo-adjuvant, chemotherapy. radiation therapy must be completed at least 14 days prior to study registration. all radiation-related toxicities must be resolved to grade 1 before the patient is, eligible for study inclusion. patients with an IHC 2+ will need to be validated as HER2-negative, by FISH. patients with an IHC 2+ will need to be validated as HER2-negative, by FISH. the INR should be measured prior to initiation of sorafenib. for patients on warfarin, the INR should be monitored at least weekly. the INR should be stable and therapeutic. s must agree to discontinue, breast-feeding until at least 3 weeks after their last dose of study, drug. s must agree to discontinue, breast-feeding until at least 3 weeks after their last dose. unstable angina (anginal symptoms at rest) or new onset angina. uncontrolled hypertension (systolic blood pressure >150 mmHg, or diastolic pressure >100 mmHg despite optimal medical, management) use of CYP3A4 inducers should be discontinued at least 72 hours, prior to study treatment. use of rifampicin should be discontinued at least 72 hours. Known or suspected allergy to sorafenib, Cremophor EL, (polyoxyethylated castor oil) or a drug formulated in, Cremophor EL such as paclitaxel. ',\n",
       " 'patients receive Abraxane IV over 30 minutes on days 1, 8, and 15. treatment repeats every 28 days for up to 3 cycles in absence of disease progression or unacceptable toxicity. ',\n",
       " 'Febrile neutropenia 1/32 (3.13%), Supraventricular tachycardia 1/32 (3.13%), Hypersensitivity 2/32 (6.25%), Catheter site infection 1/32 (3.13%), Confusional state 1/32 (3.13%)Adverse Events 1:, Total: 285/752 (37.90%), Anaemia 2/752 (0.27%), Disseminated intravascular coagulation 2/752 (0.27%), Febrile neutropenia 51/752 (6.7 ',\n",
       " '20/52 (38.46%), Anaemia 0/52 (0.00%), Pancytopenia 1/52 (1.92%), Acute myocardial infarction 0/52 (0.00%), Atrial fibrillation 0/52 (0.00%), Cardiac failure 1/52 (1.92%), Cardiogenic shock 1/52 (1.92%), Palpitations 0/52 (0.00%), Pericardial effusion 0/52 (0.00%), Right ventricular failure 1/ ',\n",
       " \"participants received niraparib 200 mg orally once daily in 28-day treatment cycles. after 2 cycles, participants either underwent surgery, received additional cycles of niraparib (maximum of 6 cycles total) or received neoadjuvant chemotherapy, at physician's discretion. \",\n",
       " 'Adverse Events 1:, Total: 24/32 (75.00%), Disseminated intravascular coagulation * 1/32 (3.13%), Febrile neutropenia * 1/32 (3.13%), Adrenal insufficiency * 1/32 (3.13%), Endocrine disorder * 1/32 (3.13%), Chills * 1/32 (3.13%), Fatigue * 1/32 (3.13%), Fever * 1/32 (3.13%), Multi-organ failure * 1/32 (3.13%), Hepatic ',\n",
       " 'Ki67 expression is defined as the percent of cells staining positive by validated central assay. all participants received 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole orally QD for an additional 14 weeks. total treatment duration was 16 weeks. ly Q12H plus 1 mg of anastrozole QD for an additional 14 weeks. total treatment duration was 16 weeks. actions BID over 5 treatment days, Partial Breast Irradiation (PBI), Overall number of participants Analyzed: 50, Measure Type: Number, Unit of Measure: percentage of participants 100. ',\n",
       " 'triptorelin plus exemestane will be evaluated when administered twice weekly. treatment cycles will be 21 days in length. 10 additional patients will be treated at the determined MTD. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. treatment cycles will be 21 days in length. ',\n",
       " 'women with Stage 0-III breast cancer, treated with breast conserving surgery or mastectomy and clear margins, will receive 15 doses of radiation over three weeks. participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment. e toxicity ',\n",
       " 'Febrile neutropenia 1/132 (0.76%), Haematotoxicity 1/132 (0.76%), Neutropenia 1/132 (0.76%), Sinus bradycardia 1/132 (0.76%), Tachycardia 1/132 (0.76%), Abdominal pain upper 1/132 (0.76%), Constipation 1/132 (0.76%), Large intestinal obstruction 1/132 (0.76%), Nausea 3/132 (2.27%)Adverse Events 1:, Total: 3/ ',\n",
       " 'Total: 10/30 (33.33%), Hemoglobin decreased 2/30 (6.67%), Abdominal pain 1/30 (3.33%), Colitis 1/30 (3.33%), Diarrhea 7/30 (23.33%), Nausea 2/30 (6.67%), Rectal hemorrhage 1/30 (3.33%), Fatigue 1/30 (3.33%), Skin infection 1/30 (3.33%), Neutrophil count decreased 1/30 (3.33%) ',\n",
       " 'inclusion criteria:, biopsy-proven breast cancer, metastatic (persistent or recurrent) must be 4 weeks since all of the following treatments (recovered from toxicity of prior treatment to Grade 1, excluding alopecia) ALT and/or aspartate aminotransferase (AST) 2.5xULN are allowed. Negative for hepatitis viruses B and C unless consistent with prior vaccination or prior infection with full recovery. inhaled or topical corticosteroids are allowed (if therapy is 5 days and is limited to systemic steroids as antiemetics); Cyclosporine A, tacrolimus, or sirolimus. patients with remote history of asthma or active mild asthma may participate. patients with history of deep venous thrombosis are allowed if treated, completely resolved. patients with history of deep venous thrombosis are allowed if treated, completely resolved, and no treatment for >4 months. rmed consent, consistent follow-up, or compliance with any aspect of the study; Pregnant or nursing women. ',\n",
       " 'PFS calculated as (Months) = (first event date minus randomization date plus 1) divided by 30.4. Time frame: Baseline up to Month 33, Results 1:, Arm/Group Title: docetaxel + Sunitinib, Arm/Group Description: Sunitinib 37.5 milligrams per square meter (mg/m2) every 3 weeks. Docetaxel 100 mg/m2 every 3 weeks, Overall Number of Participants Analyzed: 297, Median (95% Confidence Interval), Unit of Measure: months Independent radiology assessment: 8.3 (7.7 to 9.6) ',\n",
       " '6-Mercaptopurine: 6MP 75mg/m2 body surface area, administered orally once a day (od) in the morning 1 hour after eating, on a continuous schedule. one cycle is 28 days. Treatment is given continuously until disease progression. original doses were reduced following an Urgent Safety Measure in august 2012 due to a large proportion of patients requiring a dose reduction or treatment delay due to incidences of myelo-suppression. ',\n",
       " 'exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period received the same dose of tamoxifen tablet-in-capsule orally once daily for the remainder of 5-year period. ',\n",
       " \"subjects must agree to use at least one of the following types of contraception. intrauterine device, implantable progesterone device, progesterone intramuscular injection, or oral contraceptive. subject is scheduled to undergo 4 cycles of TA chemotherapy. the contraceptive patch or condom use with spermicide is also acceptable forms of contraception as long as they will be continually used throughout the duration of the trial. the contraceptive patch or condom use with spermicide is also acceptable forms of contraception as long as they will be continually used throughout the duration of the trial. splenomegaly, chronic constipation, diarrhea, irritable bowel syndrome, inflammatory bowel disease, ALT, AST, alkaline phosphatase, total bilirubin 2.5 upper limit of normal. subjects with active infection, or known to be infected with chronic active Hepatitis B within the last 1 year (unless shown at the time of study entry to be Hepatitis B antigen negative) patients that have received a prior chest X-ray for suspicion of tuberculosis are also excluded unless they have been confirmed to be PPD negative or they had latent tuberculosis that has been previously treated. subjects with Sickle Cell disease, subjects with known hypersensitivity to E.coli derived proteins' pegfilgrastim' filgrastim are also excluded. ope, and possible consequences of the study. \",\n",
       " 'patients with hormone receptor +/- and human epidermal growth factor receptor 2 protein (HER2) +/- breast cancer are eligible for neoadjuvant chemotherapy with 12 cycles of weekly taxane therapy (paclitaxel 80mg/m2 or Abraxane 100 mg/m2 if there is a shortage of paclitaxel) followed by 4 cycles of Adriamycin (60mg/m2) and cyclophosphamide (600 mg/m2) given every the biopsy prior to Taxol #1 is optional. the biopsy prior to taxol #1 is optional. the biopsy prior to taxol #1 is optional. ',\n",
       " 'inTERVENTION 2:, Arm II (Placebo), Patients receive a placebo PO BID on days 1-7. treatment repeats every 7 days for up to 12 courses in absence of disease progression or unacceptable toxicity. the intervention also includes additional web-based information and resource lists, text-based reproductive health and study adherence. at completion of the 24 weeks of follow up, they will have access to their SCPR., Control: Web-based resource lists and study adherence reminders. ',\n",
       " 'courses repeat every 7 days for up to 12 weeks in absence of disease progression or unacceptable toxicity. beginning 1 week later, patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once a week for 12 weeks. patients also receive trastuzumab IV over 30-90 minutes once a week for 1 year in the absence of disease progression or unacceptable toxicity. ',\n",
       " 'newly obtained specimen is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on day 1. newly obtained specimen is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on day 1. rimary tumor size greater than 1 cm, measured by any of clinical examination, mammography, ultrasound or magnetic resonance imaging, Any clinical nodal status, Any clinical nodal status, Any clinical nodal status, Have evaluable core biopsy for IHC, Demonstrate adequate organ function, all screening labs should be performed within 14 days of treatment initiation. female subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the study medication. male subjects of childbearing potential must agree to use an adequate method of contraception as described in Section 5.7.1- Contraception, until 120 after receiving the study therapy. subjects with grade 2 neuropathy are an exception to this criterion. subjects with grade 2 neuropathy are an exception to this criterion. subjects with grade 2 neuropathy are an exception to this criterion. replacement therapy is not considered a form of systemic treatment. has known history of (non-infectious) pneumonitis that required steroids or current pneumonitis. has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 agent or co-inhibitory T-cell receptor therapy. has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected) ',\n",
       " '18/364 (4.95%), Febrile neutropenia 3/364 (0.82%), Atrial fibrillation 1/364 (0.27%), Cardio-respiratory arrest 1/364 (0.27%), Sinus bradycardia 1/364 (0.27%), Ventricular extrasystoles 0/364 (0.00%), Enterocolitis 0/364 (0.00%), Faecaloma 0/364 (0.00%), Gastric ulcer perforation 0/364 (0.00%) thy *0/25 (0.00%), Syncope *0/25 (0.00%), Hand and Foot Syndrome *1/25 (4.00%), Adverse Events 2:, Total: 11/26 (42.31%), Neutropenia *3/26 (11.54%), Anemia *1/26 (3.85%), Febrile Neutropenia *1/26 (3.85%), Chest Pain *1/26 (3.85%), Diarrhea *1/26 (3.85%), Fatigue *0/26 (0.00%), Liver ',\n",
       " 'Musculoskeletal * 1/62 (1.61%), Mood Alteration: Depression * 1/62 (1.61%), renal - Other * 1/62 (1.61%), Obstruction, GU: Uterus * 1/62 (1.61%), sexual * 0/62 (0.00%), Pulmonary/Upper Respiratory: Dyspnea * 1/62 (1.61%), Ulceration * 1/62 (1.61%), Adverse Events 2:, Total: 1/64 ',\n",
       " 'Febrile Neutropenia * 0/3 (0.00%), Neutropenia * 0/3 (0.00%), Sudden Death * 0/3 (0.00%), Bronchitis * 0/3 (0.00%), Sepsis * 0/3 (0.00%), Lymphoedema * 0/3 (0.00%), Adverse Events 2:, Total: 6/41 (14.63%), Febrile Neutropenia * 1/41 (2.44%), Neutropenia * 1/41 (2.44%), Sudden Death * ',\n",
       " 'Adverse Events 1:, Total: 6/18 (33.33%), Skin infection [1]2/18 (11.11%), Radiation dermatitis 2 [1]4/18 (22.22%), Adverse Events 2:, _________________________________________________________________ ',\n",
       " '3D HI and SHI of UCA, Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)INTERVENTION 1:, MAESTRO, Baseline, baseline, baseline, baseline,. ',\n",
       " 'Sudden death unexplained 1/110 (0.91%), General body pain 1/110 (0.91%), Lymphangitis 1/110 (0.91%), Femur fracture 1/110 (0.91%), Depression worsened 1/110 (0.91%), Calculus urinary bladder 1/110 (0.91%), Pneumopathy 1/110 (0.91%)Adverse Events 1:, Total: 4/26 (15.38%), Disseminated intravascular coagulation 1/26 (3. ',\n",
       " 'phase 1 study used a 3+3 design with 7 indoximod dose levels (DL) then 800 mg, 1,200 mg, and 1,600 mg PO BID + up to 6 fixed doses Ad.p53 DC vaccinations q2wks. the MTD is the highest dose level below the maximumly administered dose (MAD) that is safely tolerated among 6 treated patients. treatment with 1-methyl-d-tryptophan repeats every 28 days for up to 12 courses. participants receive 1-methyl-d-tryptophan (indoximod) orally (PO) daily. ',\n",
       " 'inTERVENTION 1:, Pilocarpine 2 times per day for 6 weeks. patients receive 5mg of Pilocarpine 2 times per day. ',\n",
       " 'FEBRILE NEUTROPENIA 0/3 (0.00%), LYMPH NODE PAIN 0/3 (0.00%), NEUTROPHIL COUNT DECREASED 0/3 (0.00%), CHEST PAIN 0/3 (0.00%), DEHYDRATION 0/3 (0.00%), PULMONARY INFILTERATES 0/3 (0.00%), ALOPECIA 0/3 (0.00%) ',\n",
       " 'primary early breast cancer, tumor size greater than or equal to 2 centimeters (cm), of Stages T2-T4/N0-2., performance status 0-2 Eastern Cooperative Oncology Group (ECOG). ',\n",
       " 'the size of the lesion must be so that it can be safely treated to sterilizing radiation doses according to the rules. the size of the lesion must be so that it can be safely treated to sterilizing radiation doses according to the rules. Previously treated lesions are not eligible unless the prescribed dose can be safely delivered. the chemotherapy protocol type and schedule are at the discretion of the medical oncologist. ',\n",
       " '14/58 (24.14%), Constipation 1/58 (1.72%), Vomiting 1/58 (1.72%), Upper gastrointestinal haemorrhage 1/58 (1.72%), Asthenia 1/58 (1.72%), Chest pain 1/58 (1.72%), Pain 1/58 (1.72%), Sepsis 2/58 (3.45%), Fall 1/58 (1.72%), Spinal compression fracture 1/58 (1.72%), Neutrophil count decreased 1/58 (1.72%), De ',\n",
       " 'Subject who went through Neoadjuvant period completely (24 weeks) will receive surgery within 3-6 weeks. primary endpoint, Pathological complete response, will be assessed using resected bio-specimens collected in breast and axilla during a surgery. total of 8 treatment cycles of the neoadjuvant treatment, surgery was performed within 3 to 6 weeks from the last dose of study. overall number of participants Analyzed: 248, Measure Type: Number, Unit of Measure: percentage of responders 46.77 (40.43 to 53.19), Results 2:, Arm/Group Title: Herceptin, Arm/Group Description: Patient received Herceptin at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of ',\n",
       " \"patients must be women with locally advanced or inflammatory breast carcinoma. histologic confirmation shall be by either core needle biopsy or incisional biopsy. punch biopsy is allowed if invasive breast cancer is documented. patients must have a serum creatinine and bilirubin the institutional upper limit of normal. patients must have an Absolute neutrophil count (ANC) of 1,500/l and a platelet count of 100,000/l. women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method. all patients must be informed of the investigational nature of this study. all patients must be informed of the investigational nature of this study. no dosing or adverse event data are currently available on the use of lapatinib in patients 18 years of age. women of childbearing potential must be willing to consent to using effective contraception while on treatment and for a reasonable period thereafter. ytes or = to 3,000/L, absolute neutrophil count or = 1,500/L, platelets or = 100,000/L, total bilirubin within normal institutional limits. if LVEF is greater than 70%, and ECHO should be performed as well. patients may not be receiving any concurrent anticancer therapy or investigational agents with the intention of treating breast cancer. pregnant women are excluded from this study because lapatinib is member of the 4-anilinoquinazoline class of kinase inhibitors with the potential for teratogenic or abortifacient effects. cy., uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris. patients with GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption,uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis). \",\n",
       " 'patients will take 120 mg per day (60 mg BID), inTERVENTION 2:, Placebo, Placebo: 1 tablet BID_. ',\n",
       " 'Alpelisib + Letrozole, Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily. ',\n",
       " 'a response of PD is defined as a >=20% increase in target lesions. participants were also classified as having PD if their response at Week 12 was unknown or missing. mber of Participants Analyzed: 69, Measure Type: Number, Unit of Measure: percentage of participants Independently Evaluated: 36.2, Investigator Evaluated: 37.7_. ',\n",
       " 'exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period. participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as per standard medical practice. ',\n",
       " 'subjects will be randomly selected to receive saline (placebo) if randomized to this arm, subjects will receive an intraoperative injection of saline. injection will be performed in certain locations of the breast area to cover the intercostal nerves supplying the breast tissue. subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine. with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively. ',\n",
       " 'women in the vorinostat group were scheduled to receive 6 doses of oral vorinostat at 300 mg twice daily (bid), with the last dose administered approximately 2 hours before the scheduled breast surgery (or biopsy) patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. ',\n",
       " 'INTERVENTION 1:, Treatment Period 1, Participants received AZD9496 - Variant A (100 mg)., INTERVENTION 2:, Treatment Period 2, Participants received AZD9496 - Reference (100 mg). ',\n",
       " 'stage IV or recurrent adenocarcinoma of the breast, Measurable disease, Disease recurrence must not be within 1 year of receiving prior adjuvant docetaxel, Stable brain metastases allowed, Hormone receptor status:, Not specified, Performance status, ECOG (Eastern Cooperative Oncology Group) at least 3,000/mm3, Platelet count at least 100,000/mm3, Absolute neutrophil count at least 1,500/mm3, I or IV heart disease, no congestive heart failure, no unstable angina pectoris, no cardiac arrhythmia, no inadequately controlled hypertension, Negative pregnancy test, Fertile patients must use effective barrier contraception, no prior severe hypersensitivity reaction to docetaxel or drugs formulated with polysorbate 80, no other malignancy within the past 10 years except inactive nonmelanoma skin cancer, carcinoma in situ of the cervix, carcinoma in situ of the breast, or bilateral breast cancer Endocrine therapy, prior hormonal therapy allowed, Radiotherapy, not specified, Surgery, Not specified, Other, No other concurrent investigational agents. ',\n",
       " 'Lapatinib: 1500 mg (six 250 mg tablets) orally once daily. ',\n",
       " 'Nausea * 1/17 (5.88%), Pain - Abdomen NOS * 1/17 (5.88%)Adverse Events 1:, Total: 19/51 (37.25%), Febrile neutropenia 6/51 (11.76%), Anaemia 1/51 (1.96%), Leukopenia 1/51 (1.96%), Neutropenia 1/51 (1.96%), Thrombocytopenia 0/51 (0.00%), Pericarditis 1/51 (1.9 ',\n",
       " 'atrial fibrillation 1/110 (0.91%), Nausea 2/110 (1.82%), Abdominal pain 1/110 (0.91%), Constipation 1/110 (0.91%), Pancreatitis 1/110 (0.91%), Vomiting 1/110 (0.91%), Pyrexia 3/110 (2.73%), Axillary pain 2/110 (1.82%), Chest pain 1/110 (0.91%), Influenza like illness 1/110 (0.91%), Adverse Events 2: ',\n",
       " 'the date of the event is the earliest date of the occurrence of an objective disease recurrence, a second primary cancer, or death from any cause without a prior event. par. who started additional anti-cancer adjuvant therapy prior to the recurrence of their disease were to be censored. y and did not experience a specified event or death were to be censored at the last visit date available at which progression was assessed. from randomization until date of the first occurrence of an objective disease recurrence, a second primary cancer, or death from any cause. treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer. withdrawal from study treatment due to unacceptable toxicity, or consent withdrawal. ',\n",
       " '6-Mercaptopurine: 6MP 75mg/m2 body surface area, administered orally once a day (od) in the morning 1 hour after eating, on a continuous schedule. one cycle is 28 days. Treatment is given continuously until disease progression. original doses were reduced following an Urgent Safety Measure in august 2012 due to a large proportion of patients requiring a dose reduction or treatment delay due to incidences of myelo-suppression. ',\n",
       " 'patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cycles. patients were administered weekly (4mg/kg loading dose then 2mg/kg IV) starting on day 1. ',\n",
       " '3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/minINTERVENTION 1:, Meso BioMatrix Acellular Peritoneum Matrix. after tissue expansion, the tissue expander was replaced with a breast implant during the second stage of reconstruction. ',\n",
       " '13/34 (38.24%), Anemia 3/34 (8.82%), Diarrhea 7/34 (20.59%), Nausea 2/34 (5.88%), Sepsis 1/34 (2.94%), Urinary tract infection 1/34 (2.94%), alkaline phosphatase increased 1/34 (2.94%), Neutrophil count decreased 2/34 (5.88%), Dehydration 1/34 (2.94%), Headache 1/34 (2.94%), Thromboe ',\n",
       " 'YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness, Text message management prompts, INTERVENTION 2:, Control, Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness. ',\n",
       " 'Anaemia * 0/109 (0.00%), leukopenia * 0/109 (0.00%), Cardiac failure * 0/109 (0.00%), Pyrexia * 1/109 (0.92%), Hepatic function abnormal * 1/109 (0.92%), Arthritis bacterial * 0/109 (0.00%), Lung infection * 0/109 (0.00%), Haemoglobin decreased * 1/109 (0.92%), Neutrophil count decreased * 0 ',\n",
       " 'tamoxifen must be in the premenopausal range, or if tamoxifen is in the premenopausal range. plasma estradiol must be in the premenopausal range, or if not performed on their metastatic disease a positive result. irradiated site will NOT be evaluable for disease response. must be using effective contraception or not be of childbearing potential. must be using effective contraception or not be of childbearing potential. ',\n",
       " 'inTERVENTION 1:, Exercise, an acute bout of exercise performed 24 hours prior to each cycle of anthracyclines. no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines. ',\n",
       " '81/353 (22.95%), Febrile neutropenia * 13/353 (3.68%), Anaemia * 21/353 (0.28%), Neutropenia * 25/353 (1.42%), Thrombocytopenia * 20/353 (0.00%), Hypercoagulation * 21/353 (0.28%), Leukopenia * 21/353 (1.42%), Atrial fibrillation * 1/353 (0.28%), Cardiac failure * 0/353 (0.00%), Myocardial in ',\n",
       " 'inclusion Criteria:, Subjects with unknown clinical status not participating in FMSU004A protocol. you must meet the following criteria:, Locally advanced/inflammatory adenocarcinoma of the breast, 18 years of age or older, Normal heart function, Able to perform activities of daily living with minimal assistance. the study center will determine if you meet all of the criteria. if you do qualify, study personnel will explain the trial in detail. ',\n",
       " 'no upper limit on the number of prior endocrine regimens for metastatic breast cancer. no more than 6 prior chemotherapeutic regimens may have been given in the metastatic setting. RECIST 1.1 criteria include bone only disease and lesions  10 mm or lymph nodes  15 mm in short axis. the second CA 15-3 or CA 27.29 value must have at least a 20% increase over the first. the second CA 15-3 or CA 27.29 value must have at least a 20% increase over the first. women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Life expectancy of > 12 weeks, Exclusion Criteria:, Prior treatment with eribulin, Plan to administer any other systemic antitumor including endocrine therapy. nts with mild (Child-Pugh A) or moderate (Child-Pugh B) renal impairment, radiotherapy within 14 days of study treatment, major surgery within 21 days of study treatment. minor surgery within 2 weeks of study treatment; placement of vascular access device and biopsies allowed. tric or neurologic disorder which would compromise participation in the study, Pregnant or breast-feeding females. ',\n",
       " 'Febrile Neutropenia 24/70 (5.71%), Pericarditis 21/70 (1.43%), Sinus bradycardia 21/70 (1.43%), Abdominal Pain 2/70 (2.86%), Diarrhea 21/70 (1.43%), Lower gastrointestinal hemorrhage 21/70 (1.43%), Nausea 21/70 (1.43%), Non Cardiac-Chest pain 22/70 (2.86%), Fever 24/70 (5.71%), Skin infection 41/ ',\n",
       " 'survival duration will be censored at the date of last contact or last follow-up or the date of last news. for patients who have not died, survival duration will be censored. alkylating agent of physician choice registered in cancer: cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin. ',\n",
       " 'oral placebo taken daily for 4-10 weeks. afimoxifene: 2mg/breast applied daily in form of a gel for 4-10 weeks. ',\n",
       " '59/373 (15.82%), Neutropenia 14/373 (3.75%), Febrile neutropenia 10/373 (2.68%), leukopenia 1/373 (0.27%), Anaemia 2/373 (0.54%), Lymphadenopathy 0/373 (0.00%), cardiac failure 2/373 (0.54%), Atrial fibrillation 1/373 (0.27%), Pericardial effusion 2/373 (0.54%), Cardiac failure congestive 1/373 (0.27%), Cardio ',\n",
       " 'Participant is willing and able to give informed consent for participation in the study;, Female, aged 18 years or above;, Diagnosed with breast cancer (invasive or dcis);, Willing to allow his or her general practitioner and consultant, if appropriate, to be notified of participation in the study. ',\n",
       " 'for patients with more than one measureable lesion on the MRI, the sum over all measureable lesions on the MRI was calculated at each time point. a mean and 95% confidence interval will be constructed using two-sided t-tests. cubic centimeters -1.93 (-2.87 to -0.98). ',\n",
       " 'invasive breast cancer must be estrogen receptor alpha (ER)-positive, with ER staining present in greater than 50% staining of invasive cancer cells by IHC. invasive cancer must be human epidermal growth factor receptor 2 (HER2) negative. women must be either post-menopausal, or pre-menopausal having undergone oophorectomy. patients must meet clinical laboratory criteria: Absolute neutrophil count 1000/mm3 and platelet count 75,000/mm3. ',\n",
       " \"the corrected QT interval was calculated using Fridericia's correction (QTcF) data. each participant had triplicate QTcF intervals measured at each timepoint. each participant had triplicate QTcF intervals measured at each timepoint. overall number of participants Analyzed: 51, Mean (Standard Deviation), Unit of Measure: milliseconds Cycle 1, Day 1, 15 minutes post-dose [N=44]: 1.2 (8.3), Cycle 1, Day 1, 60 minutes post-dose [N=45]: -1.0 (6.3), Cycle 1, Day 8 [N=43]: -4.0 (13.4), Cycle 3, Day 1, 15 minutes pre-dose [N=35]: -0.1 (10.1), Cycle 3, Day 1, 15 minutes \",\n",
       " 'hyperbilirrubinemia [1]1/436 (0.23%), hyperbilirrubinemia [2]1/436 (0.23%), heart failure [2]0/436 (0.00%), Infarction and cardiac arrest 0/436 (0.00%), Ischemia cardiac/Infarction [3]1/436 (0.23%), Coronary vasospam [3]1/436 (0.23%), Gastroenteritis and renal insuficience 1/436 (0.23% ',\n",
       " 'FNA must have been taken during days 1-14 of the menstrual cycle for premenopausal women. must have color doppler transvaginal pelvic sonogram within past 6 months showing endometrial thickening no greater than 13 mm premenopausal or no greater than 8 mm postmenopausal. genetic counseling and genetic testing performed for BRCA1 and BRCA2. no active cancer (e.g., detectable disease), no retinal vein thrombosis. is, no concurrent severe poorly controlled migraine, No factor V Leiden mutation carrier, PRIOR CONCURRENT THERAPY:, At least 12 months since prior immunotherapy, Chemotherapy:, At least 3 months between completion of prior KUMC phase II difluoromethylornithine study and baseline aspiration. Must not have started or stopped hormone replacement therapy or oral contraceptives within 6 months of baseline aspiration, Must continue all hormone replacement therapy and/or oral contraceptives ',\n",
       " 'eligible patients must have had evidence of lymph node involvement in the axillary or internal mammary nodes, but not supraclavicular nodes. prior adjuvant selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs) or sequential combination of both. patients of any age who have had a bilateral oophorectomy must have biochemical evidence of definite postmenopausal status. patients 55 years old or younger must have biochemical evidence of definite postmenopausal status. patients who have received prior luteinizing-hormone releasing-hormone (LHRH) analogues within the last year are eligible. ous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, or contra- or ipsilateral in situ breast carcinoma. no other nonmalignant systemic diseases (cardiovascular, renal, lung, etc.) that would prevent prolonged follow-up, no psychiatric, addictive, or any other disorder that compromises compliance with protocol requirements. ',\n",
       " 'female 18+ years of age reporting no use of hormone replacement therapy, tamoxifen or raloxifene within the prior 6 months to eligibility screening. Pre or Post menopausal women reporting no use of hormone replacement therapy, tamoxifen or raloxifene within the prior 6 months. Glucose, Calcium, Albumin, Serum total protein (TP), Sodium, Potassium, Carbon dioxide, Chloride, Blood urea nitrogen (BUN), Creatinine, Alkaline phosphatase (ALP), Alanine amino transferase (AST), aspartate amino transferase (SGOT) and Bilirubin. ',\n",
       " 'inTERVENTION 1:, FFDM and DBT, FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration, INTERVENTION 2:, FFDM only, FFDM exam and DBT scan on Siemens MAMMOMAT Inspiration. ',\n",
       " 'from week 2 to week 4 in the 6-week Carboplatin treatment: Whole Breast 3D-RT or IMRT at 2.7 Gy X 15 fractions (5 times/wk x 3 wks=40.50 Gy), then the second and third Friday, 3 Gy to the tumor bed only X 2 fractions, Total dose to tumor bed = 46.5 GyINTERVENTION 1:, High-dose Chemotherapy, Carboplatin + Cyclophosphamide + Thi ',\n",
       " 'Febrile neutropenia * 117/2264 (5.17%), Neutropenia * 98/2264 (4.33%), Febrile bone marrow aplasia * 14/2264 (0.62%), anemia * 8/2264 (0.35%), leukopenia * 8/2264 (0.35%), Thrombocytopenia * 6/2264 (0.27%), disseminated intravascular coagulation * 3/2264 (0.13%), Agranulocytosis * 1/2264 ( ',\n",
       " 'women >=18 years of age, HER2-negative metastatic breast cancer, Previous adjuvant chemotherapy or hormonal treatment, >=1 measurable target lesion, Radiation therapy within 4 weeks of study treatment start or insufficient recovery from the effects of prior radiation therapy, Central nervous system metastases, Other malignancy within last 5 years. ',\n",
       " 'patients will be randomized to receive a one port or two port tissue expander for breast reconstructionINTERVENTION 1:, IUS Alone, IUS alone imaging, INTERVENTION 2:, Imagio (IUS+OA), IUS+OA imaging. ',\n",
       " 'disease free survival (DFS) defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 2.75 years. participants were to be switched to exemestane 25 mg QD. after 2.5 years to 3 years of tamoxifen, participants were to be switched to exemestane 25 mg QD. overall number of participants analysed: 4868, Measure Type: Number, Unit of Measure: Events. ',\n",
       " '3 patients were enrolled to the next cohort using a 5mg higher dose of ruxolitinib. the MTD is identified as the level BELOW the cohort where DLT occurred in less than one third of patients within the cohort. participants with stable disease or better will have the opportunity to continue on single agent Ruxolitinib at the established dose until disease progression, unacceptable toxicity or patient withdrawal. if no additional DLTs are observed on arm 2, the dose will be escalated to arm 3. arm 2 will be considered the MTD. if more than 1/6 pts experience a DLT, the dose will be de-escalated to arm 1. the remaining pts will be treated on arm 1 as the MTD. 14 days on days 2-15 of each 21 day cycle +GTI-2040 civ infusion 185 mg/m2/day on days 1-15 of cycle 1 and days 1-14 of each subsequent cycle. Overall number of participants Analyzed: 3, Measure Type: Number, Unit of Measure: Patients experiencing DLT 0. ',\n",
       " 'measurable disease cannot be previously irradiated, unless progression was documented. disease must be measurable, i.e., bone-only disease or evaluable-only disease is not eligible. patients with brain metastasis may participate if they:, have undergone appropriate treatment, are at least 1 month post-treatment. patients must have received prior adjuvant or neo-adjuvant, chemotherapy. radiation therapy must be completed at least 14 days prior to study registration. all radiation-related toxicities must be resolved to grade 1 before the patient is, eligible for study inclusion. patients with an IHC 2+ will need to be validated as HER2-negative, by FISH. patients with an IHC 2+ will need to be validated as HER2-negative, by FISH. the INR should be measured prior to initiation of sorafenib. for patients on warfarin, the INR should be monitored at least weekly. the INR should be stable and therapeutic. s must agree to discontinue, breast-feeding until at least 3 weeks after their last dose of study, drug. s must agree to discontinue, breast-feeding until at least 3 weeks after their last dose. unstable angina (anginal symptoms at rest) or new onset angina. uncontrolled hypertension (systolic blood pressure >150 mmHg, or diastolic pressure >100 mmHg despite optimal medical, management) use of CYP3A4 inducers should be discontinued at least 72 hours, prior to study treatment. use of rifampicin should be discontinued at least 72 hours. Known or suspected allergy to sorafenib, Cremophor EL, (polyoxyethylated castor oil) or a drug formulated in, Cremophor EL such as paclitaxel. ',\n",
       " 'inTERVENTION 1:, Pilocarpine 2 times per day for 6 weeks. patients receive 5mg of Pilocarpine 2 times per day. ',\n",
       " 'hypersensitivity reaction to Cisplatin 1/86 (1.16%), Infection with normal ANC 4/86 (4.65%), Neutrophil Count 1/86 (1.16%), Hypertension 1/86 (1.16%)Adverse Events 1:, Total: 20/88 (22.73%), Cardiac failure * 2/88 (2.27%), Intracardiac thrombus * 1/88 (1.14%), Abdominal pain * 1/88 (1.14%), Diarrhoe ',\n",
       " 'inTERVENTION 1:, Breast Cancer Patients, Tomosynthesis Breast Scanning is done and breast CT Scanning is done. ',\n",
       " 'RECIST 1.1 criteria (Part 2 only), Willing and able to consent for self to participate in study, Progressive or recurrent disease after prior systemic chemotherapy regimen, Age 18 years, ECOG performance status of 0 or 1, Resolution of all acute toxic effects of prior therapy to NCI CTCAE Grade 1 or baseline. prior to first dose of TRC105, history of brain metastasis, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease, Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, DVT, PTCA or CABG within the past 6 months. past medical history of acquired or inherited coagulopathy including patients with known Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness, Known active viral or nonviral hepatitis, history of hypersensitivity reaction to human or mouse antibodies, Lung cancer with central chest lesions, Pregnancy or breastfeeding. ',\n",
       " 'inTERVENTION 1:, Prone, Prone position, INTERVENTION 2:, Supine, Supine position. ',\n",
       " 'women in the vorinostat group were scheduled to receive 6 doses of oral vorinostat at 300 mg twice daily (bid), with the last dose administered approximately 2 hours before the scheduled breast surgery (or biopsy) patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. ',\n",
       " '4/104 (3.85%), Neutropenia 1/104 (0.96%), leukopenia 2/104 (1.92%), paranasal sinus reaction 1/104 (0.96%), cellulitis 1/104 (0.96%), Adverse Events 2:, Adverse Events 1:, Total: 1/4 (25.00%), Vertigo 0/4 (0.00%), Abdominal adhesion 0/4 (0.00%), Abdominal pain 0/4 (0.00%), Diarrhoea ',\n",
       " 'primary breast cancer without known extension beyond the breast and axillary nodes. Isolated \"lumpectomy\" with axillary node dissection (anticipated removal of at least five nodes) Exclusion Criteria: Previous surgery for breast cancer. r mortality___ r mortality__ ',\n",
       " 'if 0/3 DLTs observed, the dose will be escalated to arm 3. if no additional DLTs are observed on arm 2, the dose will be escalated to arm 3. if more than 1/6 DLTs observed on arm 3, the dose will be de-escalated to arm 2. urse of treatment according to revised NCI CTC v 2.0, Time frame: 21 days, Results 1:, Arm/Group Title: Arm 1, Arm/Group Description: Capecitabine 800 mg/m2 BID for 14 days on days 2-15 of each 21 day cycle +GTI-2040 civ infusion 185 mg/m2/day on days 1-15 of cycle 1 and days 1-14 of each subsequent cycle. Overall number of participants Analyzed: 0, Measure Type: Number, Unit of Measure: Patients ',\n",
       " 'no evidence of disease outside the breast or chest wall, except ipsilateral axillary lymph nodes. final eligibility for a clinical trial is determined by the health professionals conducting the trial. medical history of surgical sterilization, or 1 year post menopausal, must be willing to forego surgery for minimum of 5 days, ability and willingness to sign written consent, if hypertensive, on stable dose of medication at least 30 days, if diabetic, well controlled, ECOG status  2 or Karnofsky of 60% or greater, Exclusion Criteria: previous or current malignancy, excluding non-melanomic skin cancer, evidence of distant metastatic disease, history of chemotherapy rheumatoid arthritis and lupus include patients on concurrent systemic steroids or anti-inflammatory medications, active bleeding or a pathological condition that carries a high risk of bleeding. known diabetics who have experienced episodes of symptomatic hypoglycemia in the last 6 months are also considered poorly controlled. oxidase inhibitors treatment oxidase inhibitors. ',\n",
       " 'CR is measurable target lesions, disappearance of all central nervous system target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. nontarget lesions require disappearance CNS non-target lesions and no new CNS lesions. participants with hormone receptor positive HR+, HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. participants may continue to receive treatment until discontinuation criteria are met. participants may continue to receive treatment until discontinuation criteria are met. overall number of participants Analyzed: 52, Measure Type: Number, Unit of Measure: percentage of participants 5.8_. ',\n",
       " 'the eligible participants were administered Ispinesib, intravenously as a one-hour infusion on day 1 of every 21-day treatment cycle. the dosing was repeated for up to multiple cycles, until disease progression or removal from treatment due to an unacceptable toxicity or withdrawal of consent. ',\n",
       " 'inTERVENTION 1:, Initial Cohort, Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 300 micrograms. all research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous injection following the schedule. eous (SC) injection followed the schedule. ',\n",
       " '57/57 (100.00%), Dry eyes 13/33 (39.39%), Heartburn 9/33 (27.27%), Nausea after the CT (before day 7) 57/57 (100.00%), Herpetic eruption 0/33 (0.00%), Dry skin 15/33 (45.45%), Alopecia 57/57 (100.00%), Adverse Events 2:, Total: 23/23 (100.00%), Dry eyes 2/11 (18.18%), Heartburn 2/11 (18.18%), ',\n",
       " '67/736 (9.10%), Neutropenia *1/736 (0.14%), Anaemia *1/744 (0.13%), Thrombocytopenia *1/744 (0.13%), Atrial flutter *1/744 (0.13%), Cardiac arrest *1/744 (0.13%), Myocardial ischaemia *1/744 (0.13%), Arrhythmia *0/744 (0.00%), Cardiac failure congestive *0/744 (0.00%) Tumour pain 1/67 (1.49%), Renal failure acute 1/67 (1.49%), Pleurisy 1/67 (1.49%) ',\n",
       " 'Adverse Events 1:, Total: 3/30 (10.00%), Cholecystitis * [1]1/30 (3.33%), Increase in diarrhea * [2]1/30 (3.33%), Flank pain * [3]1/30 (3.33%) ',\n",
       " 'cases with stage II-IIIA breast cancer have completed adjuvant treatment with anthracyclines and/or taxanes + or -Radiation therapy within past 6 months(+/- 7 days) Must be aware of the nature of his current medical condition and must be willing to give consent after being informed of the experimental nature of therapy, alternatives, potential benefits, side-effects, risks and discomfort. use of estrogens (oral, dermal or vaginal), progesterone (oral or topical), androgens, androgens, Raloxifene or Tamoxifen during the previous 3 months. use of over the counter steroid hormonal supplements including dehydroepiandrosterone (DHEA), patients with advanced or Stage IIIIB or IV breast cancer or other cancers. l or psychiatric condition or laboratory abnormality may increase risk associated with study participation or study drug administration. investigator would make potential participant inappropriate for entry into this study. ',\n",
       " 'maleInclusion Criteria:, female patients, 18-70 years of age;, histologically-proven invasive breast cancer;, no prior or current neoplasm except for non-melanoma skin cancer;, no distant disease/secondary cancer. ',\n",
       " '22/96 (22.92%), anemia 1/96 (1.04%), lymphopenia 1/96 (1.04%), cardiac ischemia/infarction 1/96 (1.04%), sinus tachycardia 2/96 (2.08%), dehydration 5/96 (5.21%), colitis 1/96 (1.04%), diarrhea 5/96 (5.21%), ileus 1/96 (1.04%), nausea 2/96 (2.08%), vomiting 1/96 (1.04%), distal small  ',\n",
       " 'Progression-free survival was defined as the time from randomization to first occurrence of disease progression (either radiographic or clinical) or death from any cause. clinical disease progression was considered only when disease progression could not be confirmed by CT or MRI. participants received abiraterone acetate tablet at a total oral dose of 1000 milligram (mg) and 5 mg capsule of prednisone/prednisolone per day in 28-day treatment cycles. overall number of participants Analyzed: 89, Median (95% Confidence Interval), Unit of Measure: Months 3.65 (2.73 to 5.59) ',\n",
       " 'Neutropenia 1/116 (0.86%), Thrombocytopenia 1/116 (0.86%), Myocardial infarction 0/116 (0.00%), Pericardial effusion 0/116 (0.00%), Abdominal pain 3/116 (2.59%), Ascite 1/116 (0.86%), Diarrhoea 3/116 (2.59%), Gingival bleeding 1/116 (0.86%), Intestinal haemorrhage 1/116 (0.8 l 1/54 (1.85%), Malignant Melanoma In Situ 1/54 (1.85%), Suicide Attempt 1/54 (1.85%), Dyspnoea 1/54 (1.85%) ',\n",
       " 'FEBRILE NEUTROPENIA 0/3 (0.00%), LYMPH NODE PAIN 0/3 (0.00%), NEUTROPHIL COUNT DECREASED 0/3 (0.00%), THROMBOCYTOPENIA 0/3 (0.00%), CHEST PAIN 0/3 (0.00%), DEHYDRATION 0/3 (0.00%), PLEURAL EFFUSION 1/3 (33.33%), PNEUMONITIS 0/3 (0.00 ',\n",
       " 'RECIST 1.1 criteria (Part 2 only), Willing and able to consent for self to participate in study, Progressive or recurrent disease after prior systemic chemotherapy regimen, Age 18 years, ECOG performance status of 0 or 1, Resolution of all acute toxic effects of prior therapy to NCI CTCAE Grade 1 or baseline. prior to first dose of TRC105, history of brain metastasis, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease, Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, DVT, PTCA or CABG within the past 6 months. past medical history of acquired or inherited coagulopathy including patients with known Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness, Known active viral or nonviral hepatitis, history of hypersensitivity reaction to human or mouse antibodies, Lung cancer with central chest lesions, Pregnancy or breastfeeding. ',\n",
       " '82/217 (37.79%), Febrile neutropenia 21/217 (9.68%), Neutropenia 4/217 (1.84%), leukopenia 0/217 (0.00%), Anaemia 1/217 (0.46%), Thrombocytopenia 0/217 (0.00%), Atrial fibrillation 0/217 (0.46%), Arteriospasm coronary 0/217 (0.00%), Atrioventricular block first degree 0/217 (0.00%), ',\n",
       " 'Inclusion Criteria:, HER-2 overexpressing breast cancer, Clinical stage 2-3B, Normal ejection fraction, Exclusion Criteria:, Metastatic disease, Low ejection fraction_. ',\n",
       " 'Previously diagnosed with primary breast cancer, Must have received 412 - 6 years of aromatase inhibitor therapy (e.g., letrozole, anastrozole, or exemestane) either as initial therapy or after prior tamoxifen citrate. is not required for patients who have undergone bilateral complete mastectomy, Hormone-receptor status. is defined as a tumor receptor content of > 10 fmol/mg protein or receptor positive by immunocytochemical assay. is not required for patients who have undergone bilateral complete mastectomy. no other prior or concurrent malignancy except adequately treated, superficial squamous cell or basal cell skin cancer, carcinoma in situ of the cervix, or other cancer treated > 5 years ago. *Elevated levels allowed provided imaging examinations have ruled out metastatic disease, PRIOR CONCURRENT THERAPY:, See Disease Characteristics, No concurrent selective estrogen receptor modulator (e.g., raloxifene, idoxifene) ',\n",
       " 'MM-121 + exemestane was more effective than placebo + exemestane. progression-free survival was defined as the number of months from the date of randomization to the date of death or progression. MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week plus exemestane (25 mg) administered orally once per day, Overall Number of participants Analyzed: 56, Median (95% Confidence Interval), Unit of Measure: weeks 15.9 (9.3 to 30.3), Results 2:, Arm/Group Title: Placebo + Exemestane, Arm/Group Description: Place ',\n",
       " 'the proportion of lymph nodes detected intraoperatively by SentiMag and SiennaXP in relation to the proportion of lymph nodes detected by the combination of Technetium Sulfur Colloid and Isosulfan blue dye. a single dose of radioisotope (Technetium Tc99m Sulfur Colloid) and single dose of isosulfan blue dye is injection. DLTs were defined as grade 4 neutropenia persisting for more than 7 days. grade 3 or above febrile neutropenia; grade 4 thrombocytopenia or grade 3 thrombocytopenia requiring blood transfusion. day 8 administration was delayed or slammed. kipped as a result of the subject did not meet the dosing riteria within cycle. overall number of participants Analyzed: 6, Measure Type: Number, Unit of Measure: Participants 0, Results 2:, Arm/Group Title: E7389 With Tri-weekly Trastuzumab. ',\n",
       " 'Bone Mineral Density (g/cm2) of the Lumbar Spine (L2-L4) measured by energy x-ray absorptiometry (DXA) all participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1. all participants took Letrozole tablets 2.5 mg/day for 5 years beginning on day 1. overall number of participants Analyzed: 418, Mean (Standard Deviation), Unit of Measure: Percentage change in BMD -3.617 (4.2151) ',\n",
       " 'Fulvestrant: Fulvestrant 500 mg Day 1 & 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus everolimus daily x 12 cycles. if no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity. Placebo: Placebo for Everolimus (2 tablets) daily x 12 cycles. ',\n",
       " 'Febrile neutropenia 0/6 (0.00%), leukopenia 0/6 (0.00%), Neutropenia 0/6 (0.00%), Thrombocytopenia 0/6 (0.00%), Cardio-respiratory arrest 0/6 (0.00%), Cardiopulmonary failure 0/6 (0.00%), Vertigo 0/6 (0.00%), Visual impairment 0/6 (0.00%), Abdominal pain 0/6 (0.00%), Diarrhoea 0/6 ',\n",
       " 'age 21, Diagnosis of breast cancer, Stage III, IV, or Stage I or II with metastasis or recurrence, Able to perform basic ADLs, Undergoing chemotherapy and/or hormonal therapy for breast cancer, Able to speak and understand English, Have access to a telephone, Able to hear normal conversation, Cognitively oriented to time, place, and person. ',\n",
       " 'Coagulopathy 1/98 (1.02%), Febrile neutropenia 7/98 (7.14%), Pancytopenia 2/98 (2.04%), Cardiac failure 0/98 (0.00%), Cardiac failure congestive 0/98 (0.00%), Pericardial effusion 0/98 (0.00%), Appendicitis perforated 1/98 (1.02%), Colitis 1/98 (1.02%), Ileus 1/98 (1.02%), Ab ',\n",
       " 'Adverse Events 1:, Total: 18/115 (15.65%), Febrile neutropenia * 7/115 (6.09%), Neutropenia * 1/115 (0.87%), Pancytopenia * 1/115 (0.87%), Diarrhoea * 0/115 (0.00%), Stomatitis * 0/115 (0.00%), Vomiting * 1/115 (0.87%), Asthenia * 1/115 (0.87%), Mucosal inflammation * 0/115 ',\n",
       " 'HER2 positive breast cancer defined by immunohistochemical staining for HER2 protein of 3+ intensity and/or amplification of the HER2 gene on fluorescence in situ hybridization. LVEF  50% and 40% documented in echocardiogram done within the last 30 days, HER2 therapy nave or currently receiving non-lapatinib HER2 targeted therapy. patients of childbearing potential must implement contraceptive measures during study treatment and for 7 months after last dose of treatment drug. negative urine or serum pregnancy test within 7 days before registration. nificant acute toxicity, and radiation treatments must be completed more than 3 weeks from randomization, Exclusion Criteria:, Disease-Specific Exclusion Criteria:, HER2-positive status, prior adjuvant or neo-adjuvant chemotherapy is allowed. prior adjuvant or neo-adjuvant chemotherapy is allowed, provided its conclusion has been for at least 12 months prior to randomization, Investigational therapy within 28 days of randomization. ',\n",
       " 'percent change from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr) calculated using ((Week 13 value - Baseline value) x 100. overall number of participants Analyzed: 38, Mean (Standard Deviation), Unit of Measure: Percent change -10.19 (208.84), Results 2:, Arm/Group Title: Denosumab 30 mg Q4W. ',\n",
       " 'patients receive tivantinib PO BID on days 1-21. courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. patients undergo blood sample collection at baseline and periodically during study for c-Met expression. ',\n",
       " 'all patients will receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions. a concurrent boost to the original tumor bed of 0.50 Gy will be delivered. ',\n",
       " 'pCR is defined as absence of invasive cancer in breast or lymph nodes after neoadjuvant chemotherapy. pCR is defined as absence of invasive cancer in breast or lymph nodes after neoadjuvant chemotherapy. patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes, Pertuzumab IV over 30-60 minutes, Docetaxel IV, and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. ',\n",
       " 'Adverse Events 1:, Total: 10/14 (71.43%), Hemoglobin 2/14 (14.29%), Lymphopenia 1/14 (7.14%), Hypertension 2/14 (7.14%), Constipation 1/14 (7.14%), Diarrhea 1/14 (7.14%), Heartburn/dyspepsia 1/14 (7.14%), Fatigue (asthenia, lethargy, malaise) 2/14 (7.14%), Rig ',\n",
       " 'women with proven diagnosis of advanced adenocarcinoma of the breast. women with proven diagnosis must be appropriate candidates for letrozole therapy. patients must be appropriate candidates for letrozole therapy. patients with adequately treated basal cell or squamous cell skin cancer may enter. active uncontrolled or symptomatic brain metastases are permitted. Previously treated and clinically stable, brain metastases are permitted. e staff members otherwise supervised by the investigator, or patients who are directly involved in the conduct of the study. ',\n",
       " '500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given. patients will receive a tumor biopsy at the start of treatment and 4 weeks after the start of treatment. ',\n",
       " 'females with Stage II invasive breast cancer and documented axillary metastases by core biopsy, clinical examination, or fine-needle aspiration. Females > 21 years of age are scheduled to undergo an ALND. ',\n",
       " 'patients must have histologically or cytologically confirmed early stage, ER-positive (Allred score 3), invasive breast cancer that is not either locally advanced by criteria other than size or inflammatory. patients must be candidates for surgical removal of the tumor by lumpectomy or mastectomy. patients must have a performance status 1 by Zubrod criteria. women of child-bearing potential must agree to use adequate contraception. negative serum pregnancy test must be obtained within 72 hours of receiving the first dose of the hormonal therapy. patients may not have received prior chemotherapy or endocrine therapy. patients must not have known brain or CNS disease, evidence of brain or CNS metastases or carcinomatous meningitis. patients must not have an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection. patients will be excluded if there is a known history of human immunodeficiency (HIV) virus infection, or a known history of hepatitis B or C infection. ',\n",
       " 'Sunitinib (SU011248) orally (PO) for 2 weeks every 3 weeks (2 weeks on, then 1 week off = Schedule 2/1) starting on day 2 (Cycle 2, Day 3 only for those subjects included in the PK study); starting dose 37.5 milligrams (mg daily) daily (QD) SU012662 C1D2: 6.0 (2.0 to 24.0), SU012662 C2D3: 6.0 (4.0 to 24.0), Total drug C1D2: 6.0 (2.0 to 8.0) ',\n",
       " 'Adverse Events 1:, Total: 0/244 (0.00%), Pregnancy *0/244 (0.00%), Endocervical cancer *0/244 (0.00%), Nosocomial pneumonia *0/244 (0.00%), Venous thrombosis *0/244 (0.00%). ',\n",
       " '127/368 (34.51%), ANAEMIA 3/368 (0.82%), LEUKOPENIA 0/368 (0.00%), COAGULOPATHY 3/368 (0.82%), LYMPHADENOPATHY 0/368 (0.00%), THROMBOCYTOPENIA 2/368 (0.54%), BONE MARROW FAILURE 0/368 (0.00%), FEBRILE NEUTROPENIA 4/368 (1.09%), ATRIAL FLUT ',\n",
       " 'inTERVENTION 1:, Cohort A: Advanced Triple-Negative Breast Cancer (TNBC), 6 mg/kg IMGN853 IV Q3W. no prior biopsy, Low-power microwave breast imaging system. ',\n",
       " 'clinical benefit rate, clinical benefit = complete response (CR), partial response (PR), or stable disease (SD) lasting for at least 6 months. PR= disappearance of or at least 30% decrease in the sum of the longest diameters of target lesions. 141 eligible, treated patients were included. results 2:, Arm/Group Title: Fulvestrant and ZD1839, Arm/Group Description: [Not Specified], Overall Number of Participants Analyzed: 69, Measure Type: Number, Unit of Measure: percentage of participants 41 (29 to 53)Outcome Measurement:, Recurrence-free Survival, 2 years for the primary analysis + 3 additional years for secondary analysis. ',\n",
       " 'Confirmed tumor response was defined as the total number of efficacy-evaluable patients who achieved a complete or partial response according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria. the total number of patients who achieved a complete or partial response was defined as the total number of efficacy-evaluable patients. bisphosphonate IV Q4W, Arm/Group Description: Open label bisphosphonate every 4 weeks (Q4W) by intravenous infusion. Overall number of participants Analyzed: 38, Mean (Standard Deviation), Unit of Measure: Percent change -10.19 (208.84), Results 2:, Arm/Group Title: Denosumab 30 mg Q4W, Arm/Group Description: Denosumab 30 mg by subcutaneous injection every 4 weeks (Q ',\n",
       " '63/206 (30.58%), Febrile neutropenia * 14/206 (6.80%), Neutropenia * 9/206 (4.37%), Anaemia * 1/206 (0.49%), Leukopenia * 0/206 (0.00%), Thrombocytopenia * 1/206 (0.49%), Cardiac failure * 0/206 (0.00%), Cardiac failure congestive * 1/206 (0.49%), Cardiomyopathy * 0/206 (0.00%), Corona ',\n",
       " 'Pericardial effusion [1]0/3 (0.00%), Abdominal muscle wall hemorrhage [2]0/3 (0.00%), Dehydration [3]0/3 (0.00%), Gastroenteritis 0/3 (0.00%), Vomiting [4]0/3 (0.00%), Colonic perforation [5]0/3 (0.00%), Abdominal pain 0/3 (0.00%), Lung infection 0/3 (0.00%), Wound infection 0/3 (0.00 Arrhythmia * 1/1755 (0.06%), Atrial fibrillation * 1/1755 (0.06%), Cardiac failure * 0/1755 (0.00%), Cardiac tamponade * 0/1755 (0.00%), Adverse Events 2:, Total: 64/868 (7.37%), Anaemia * 2/868 (0.23%), Neutropenia * 2/868 (0.23%), Thrombocytopenia * 1/868 (0.12%), ',\n",
       " 'Febrile neutropenia [1]3/30 (10.00%), Lymphatics 1/30 (3.33%), Diarrhea (5/30 (16.67%), Abdominal pain or cramping 2/30 (6.67%), Colitis 1/30 (3.33%), Dehydration 1/30 (3.33%), Nausea 1/30 (3.33%), Stomatitis/pharyngitis (oral/pharyngeal/mucositis) 1/30 (3.33%), Vomiting ',\n",
       " '88/291 (30.24%), Febrile Neutropenia11/291 (3.78%), Neutropenia7/291 (2.41%), Thrombocytopenia2/291 (0.69%), Cardiac Arrest1/291 (0.34%), Pericardial Effusion1/291 (0.34%), Pericardial Effusion1/291 (0.34%), Pericardial Effusion1/291 (0.34%), Pericardial Effusion1/291 (0.34%), Pericardial COLITIS 1/102 (0.98%), DIARRHOEA 8/102 (7.84%), FEMORAL HERNIA 1/102 (0.98%), HAEMATEMESIS 1/102 (0.98%), ILEUS 1/102 (0.98%). ',\n",
       " 'Stage IV that is free of all known disease after eradication by surgery, radiotherapy, or chemotherapy, may not have elevated CA 15-3 or CEA levels. Rising CA 15-3 and CEA defined as a prior normal level increased on 2 consecutive occasions at least 2 weeks apart. Stage III completed adjuvant therapy no more than 24 months ago, Recurrence in the ipsilateral breast after lumpectomy and/or axillary dissection. Stage II with at least 4 positive axillary nodes and completed adjuvant therapy no more than 24 months ago. Stage IV that is stable on hormonal therapy, Hormone receptor status:, Not specified, age:, 18 and over, Sex:, Male or female, Menopausal status:, Not specified, Life expectancy:, Not specified, Hematopoietic:, Lymphocyte count at least 500/mm3, WBC at least 3,000/mm3, Hepatic t 6 weeks since prior immunotherapy, no prior vaccine with any of the antigens in this study, Chemotherapy:, See Disease Characteristics, At least 4 weeks since prior chemotherapy, No concurrent chemotherapy, Endocrine therapy:, See Disease Characteristics, Radiotherapy:, See Disease Characteristics, At least 4 weeks since prior radiotherapy, No concurrent radiotherapy, Surgery:, See Disease Characteristics, At least 4 weeks since prior surgery, Concurrent surgery for local recurrence allowed if ',\n",
       " 'women with primary breast cancer without ongoing support for substance use. an AUDIT-C score >1 or more than one cigarette smoked per day. ',\n",
       " 'the most common CYP2D6 alleles have been grouped by functional activity classifications with descending activity: ultra-rapid (UM), extensive (EM), intermediate (IM) or poor (PM) metabolism. a given patient has two alleles, giving them 10 possible allelic combinations, or diplotypes. results 2:, Arm/Group Title: Extensive Metabolizers, Arm/Group Description: Those with the most normal transformation of the CYP2D6 genotype to allelic activity. Overall number of participants Analyzed: 119, Mean (Standard Deviation), Unit of Measure: ng/mL Baseline endoxifen concentration: 119 participants, 10.00 (6.00), 4-Month endoxifen concentration: 106 participants, 9.30 (5.03) ',\n",
       " 'participants must have histologically confirmed hormone receptor positive (HR+) HER2 negative stage II (except T2N0) or stage III invasive breast cancer. evaluation for metastatic disease is not required in the absence of symptoms. men and pre- and postmenopausal women are eligible. ongoing use of any endocrine therapy, including tamoxifen, letrozole, anastrozole, or exemestane, is allowed. patients may enroll within 2 years of beginning endocrine therapy. the effects of palbociclib on the developing human fetus are unknown. ny medications or substances that are strong inhibitors or inducers of CYP3A isoenzymes are ineligible. current use of drugs known to prolong the QT interval. subjects with organ allograft requiring immunosuppression. ductal carcinoma in situ of the breast, cervical cancer in situ, and basal cell carcinoma of the skin. ',\n",
       " 'participants must have either breast-conserving surgery or mastectomy/nipple- or skin-sparing mastectomy. eligible participants must have either:, node-positive disease (pN more than or equal to [>/=] 1), any tumor size except T0; or node-negative disease (pN0) with pathologic tumor size >2.0 centimeters. female participants of childbearing potential must be willing to use one highly effective form of contraception or two effective forms of contraception. contraception must continue for the duration of study treatment and for 6 months after the last dose. malignancies within the 5 years prior to randomization, except for carcinoma in situ (CIS) of the cervix, CIS of the colon, melanoma in situ, and basal cell carcinomas of the skin. any clinical T4 tumor as defined by tumor-node-metastasis classification in UICC/AJCC 7th edition, including inflammatory breast cancer. participants who had their DCIS/LCIS treated with surgery only and/or contralateral DCIS treated with radiation are allowed to enter the study. participants with contraindication to RT while adjuvant RT is clinically indicated. active hepatitis B/C infection must be ruled out per local guidelines, Inadequate hematologic, renal or liver function, Pregnant or lactating women, Hypersensitivity to any of the study medications or any of the ingredients or excipients of these medications. subjects have at least one breast imaging finding on mammography and/or ultrasound which is assessed as highly suggestive of malignancy and recommended to biopsy. subject has type I diabetes mellitus or poorly controlled Type II diabetes mellitus. subject has had surgery or radiation therapy on the study breast or has had chemotherapy within the past 12 months. subject has not fasted for 4-6 hours prior to the procedure. ',\n",
       " 'triptorelin: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles. participants also received Zoledronic Acid 4 mg i.v. on day 1 and every 6 months until disease progression (recurrence)or the end of study. zoledronic acid 4 mg i.v. for every 6 months until disease progression (recurrence) or end of study. participants received s calcium (1000-1200 mg) and vitamin D (400-800 IU) daily. ',\n",
       " 'FEBRILE NEUTROPENIA 5/24 (20.83%), HAEMATOTOXICITY 0/24 (0.00%), NEUTROPENIA 3/24 (12.50%), LYMPHADENOPATHY 0/24 (0.00%), PERICARDIAL EFFUSION 1/24 (4.17%), APLASIA 0/24 (0.00%), NAUSEA 0/24 (0.00%), PYREXIA 1/24 (4.17%), EX ',\n",
       " 'bevacizumab Plus Paclitaxel, Bevacizumab 10 mg/kg intravenous (i.v.), days 1 and 15, every 4 weeks, Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks, INTERVENTION 2:, Bevacizumab Plus Capecitabine, bevacizumab 15 mg/kg i.v., day 1, every 3 weeks, Capecitabine 1000 mg/m2 twice-daily, days 1 ',\n",
       " 'Adverse Events 2:, Total: 4/26 (15.38%), Disseminated intravascular coagulation 1/26 (3.85%), Cardiac failure congestive 1/26 (3.85%), Breast cellulitis 1/26 (3.85%), Cellulitis 1/26 (3.85%), Acute myeloid leukaemia 1/26 (3.85%), Seizure 0/26 (0.00%), Pulmonary embolism 1/26 (3.85%), Adverse Events 2:, Total:  ',\n",
       " 'the participants will answer questions on the tablet-PC to calculate their breast cancer risk. the program will immediately generate a personal feedback report containing information about her risk factors. ',\n",
       " 'cases with stage II-IIIA breast cancer have completed adjuvant treatment with anthracyclines and/or taxanes + or -Radiation therapy within past 6 months(+/- 7 days) Must be aware of the nature of his current medical condition and must be willing to give consent after being informed of the experimental nature of therapy, alternatives, potential benefits, side-effects, risks and discomfort. use of estrogens (oral, dermal or vaginal), progesterone (oral or topical), androgens, androgens, Raloxifene or Tamoxifen during the previous 3 months. use of over the counter steroid hormonal supplements including dehydroepiandrosterone (DHEA), patients with advanced or Stage IIIIB or IV breast cancer or other cancers. l or psychiatric condition or laboratory abnormality may increase risk associated with study participation or study drug administration. investigator would make potential participant inappropriate for entry into this study. ',\n",
       " 'Response Evaluation Criteria in Solid Tumors (RECIST v1.0) is defined as a 20% increase in the sum of the longest diameter of target lesions. the percentage of patients without evidence of disease recurrence at the 2 year timepoint. patients with triple-negative breast cancer who do not have a pathological complete response following neoadjuvant therapy and surgery will receive eribulin 1.4 mg/m2 every 21 days for 6 cycles via the intravenous route. overall number of participants Analyzed: 53, Measure Type: Number, Unit of Measure: percentage of patients 56 (42 to 69), Results 2:, Arm/Group Title: Cohort B: ER/PR Positive/HER2-negative breast cancer breast cancer mber of Participants Analyzed: 42, Measure Type: Number, Unit of Measure: percentage of patients 83 (67 to 91) ',\n",
       " 'Overall Response Rate (ORR) was defined as the proportion of patients whose best overall response was either complete response (CR) or partial response (PR) according to RECIST 1.0 for target lesions. CT: Complete Response (CR), disappearance of all target lesions for a period of at least one month; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. cipants Analyzed: 43, Measure Type: Number, Unit of Measure: Percentage of Participants 37.2_ ',\n",
       " 'subject is pregnant, subject is actively lactating or discontinued breastfeeding less than 2 months ago, subject has breast implants, subject is scheduled for sentinel node procedure using radioactive Tc-99m within 24 hours of the PEM study. subject has type I diabetes mellitus or poorly controlled Type II diabetes mellitus, subject has had surgery or radiation therapy on the study breast or has had chemotherapy within the past 12 months. subject has not fasted for 4-6 hours prior to the procedure and/or have  ',\n",
       " 'inTERVENTION 1:, Glutamine, 10 grams three times a day (orally) for four days and then stop, glutamine, 10 grams three times a day (orally) for four days and then stop, INTERVENTION 2:, Placebo, 10 grams three times a day (orally) for four days. the interpretation and analysis was done with gamma imaging only. ',\n",
       " 'patients with inflammatory breast cancer must be able to have a core needle biopsy. doxorubicin/cyclophosphamide (AC) or 5-fluorouracil (FU)/epirubicin/cyclophosphamide (FEC) in a similar dose and schedule as described in the protocol. male patients should use condoms for the duration of the study. patients may enroll before or after AC/FEC chemotherapy has completed. non-cardiotoxic chemotherapy for malignancy treated > 5 years before study enrollment is allowed. patients receiving AC/FEC in similar fashion to study treatment prescribed for adjuvant or neoadjuvant treatment of breast cancer will be allowed to enroll in the study. y at Baseline._ ',\n",
       " 'invasive mammary carcinoma, Stage IV disease, Basal-like disease (triple-negative, hormone-refractory, HER2-negative), no locally recurrent breast cancer, no symptomatic brain metastases. patients with a history of brain metastases are eligible provided they are clinically stable for > 3 weeks after completion of radiotherapy and are not taking prophylactic anticonvulsants that are CYP3A4 modifiers. ents with Gilbert syndrome, serum glutamate oxaloacetate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) 1.5 times ULN ( 3 times ULN in the presence of liver metastasis), Alkaline phosphatase 3 times ULN (in the presence of liver metastasis), not pregnant or nursing, Negative pregnancy test, Fertile patients must use effective barrier contraception during uncontrolled hypertension (systolic BP > 180 mm Hg or diastolic BP > 100 mm Hg, found on 2 consecutive measurements separated by a 1-week period and despite adequate medical support) clinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment [grade 3 according to NCI Common Toxicity Criteria for Adverse hepatitis B or C, PRIOR CONCURRENT THERAPY:, See Disease Characteristics, Recovered from prior therapy, Prior total cumulative life-time dose of doxorubicin 360 mg/m2 or epirubicin 640 mg/m2. at least 2 weeks since prior investigational drugs, At least 14 days since prior and no concurrent CYP3A4 inducers, At least 7 days since prior and no concurrent CYP3A4 induce ',\n",
       " 'inTERVENTION 1:, Flaxseed, Patients receive 1 NutrigradTM flaxseed bar containing 7.5 grams flaxseed, 410 mg lignans,once daily., Placebo, Patients Identical looking bar with same calorie and total fat content but without flaxseed or lignans once daily. ',\n",
       " 'Stratum 1: TCH + Bevacizumab, HER2 positive participants were administered chemotherapy with docetaxel, carboplatin and trastuzumab (TCH) + bevacizumab every 3 weeks for 6 cycles. bevacizumab and trastuzumab every 3 weeks for a total of 52 weeks. ',\n",
       " 'HER-2/neu, defined as FISH negative or 0, 1+, or 2+ by IHC, Stage IV disease, Does not overexpress HER-2/neu, defined as FISH negative or 0, 1+, or 2+ by IHC, Stage IV disease, Must not be eligible for therapy of known curative potential for metastatic breast cancer, Measurable or evaluable disease. systemic immunosuppression includes inflammatory bowel disease, Systemic vasculitis, Scleroderma, Psoriasis, Multiple sclerosis, Hemolytic anemia or immune-mediated thrombocytopenia, Rheumatoid arthritis, Systemic lupus erythematosus, Sjogren syndrome, Sarcoidosis, Other malignancies within the past 5 years, except carcinoma in situ of the cervix, superficial nonmela ecur, No allergy to corn, PRIOR CONCURRENT THERAPY:, See Disease Characteristics, More than 28 days since prior and no other concurrent chemotherapy, radiation therapy, or biologic therapy (except trastuzumab), Concurrent endocrine therapy and supportive therapy with bisphosphonates allowed, More than 28 days since prior and no other concurrent participation in an investigational new drug trial. osis of noninvasive breast cancer is OK., must have adequate bone marrow, renal and liver function., Pregnant or lactating females not allowed., Preexisting peripheral neuropathy must be equal to or less than grade 1, must have archived tumor tissue for tissue testing. ',\n",
       " 'Exemestane, exemestane 25 mg by mouth (PO) every day for two years taken with calcium carbonate 1200 mg PO every day x 2 years. vitamin D 400 IU PO every day infused weekly over 30 minutes. ',\n",
       " 'results of independent review of subjects with ErbB-2-positive breast cancer treated at the MTD of neratinib in combination with vinorelbine per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions, and no new lesions. Neratinib 240 mg qd + Vinorelbine 25 mg/m IV on days 1 and 8 every 3 weeks, with prior Lapatinib exposure. Overall number of participants Analyzed: 15, Measure Type: Number, Unit of Measure: percentage of participants 13.3 (1.7 to 40.5)Outcome Measurement:, Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4), Lumbar spine (L2-L4) BMD dian (Full Range), Unit of Measure: Percent Change -4.63 (-14.21 to 4.32), Results 2:, Arm/Group Title: Tam-Let, Arm/Group Description: 20 mg Tamoxifen once daily (q.d. orally for 2 years followed by Letrozole 2.5 mg q.d. orally for 3 years. ',\n",
       " 'ECOG Performance status of 0, 1 or 2, Normal organ and marrow function as defined in the protocol, Exclusion Criteria:, Participants may not be receiving any other study agents, Actively receiving chemotherapy (exclusive of hormonal or HER2 therapy) within last 5 weeks. istory of Hepatitis C or active hepatitis B infection (baseline testing not required) Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, hepatitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia. ',\n",
       " 'patients with unilateral primary cancer pathologically confirmed before neoadjuvant chemotherapy (NAC), who received NAC, with detectable lesion / clip marker on ultrasound, with cT1-T3 tumors, clinical and imaging complete or near-complete response on MRI, with informed consent. female patients 18 to 75 years of age with metastatic breast cancer histologically/cytologically confirmed not amenable to curative surgery or radiotherapy. n metastases or leptomeningeal involvement, pulmonary lymphangitis or symptomatic pleural effusion or symptomatic ascites, history of second primary malignancy, HIV infection, preexisting neuropathy, pregnancy or breast feeding. ',\n",
       " 'overall survival was defined as the time in months from randomization until the date of death. survival duration was censored at the last date the patient was known to be alive. x 14 days, followed by 1 week of rest., Overall Number of Participants Analyzed: 612, Median (95% Confidence Interval), Unit of Measure: months 15.64 (13.86 to 17.02) ',\n",
       " 'Cardiac failure acute 0/167 (0.00%), Diarrhoea 5/167 (2.99%), Colitis 2/167 (1.20%), Enterocolitis 1/167 (0.60%), Stomatitis 1/167 (0.60%), Impaired healing 1/167 (0.60%), Sudden death 1/167 (0.60%), Postoperative wound infection2/167 (1.20%), Erysipelas 2/167 (0.60%), Bacterial diarrhoe ',\n",
       " 'pre-menopausal women aged 18 years or over with histologically/cytologically-confirmed oestrogen receptor positive (ER +ve) breast cancer, world health organisation performance status of 0, 1, or 2, Provided written informed consent, Exclusion Criteria:, treatment with tamoxifen or other hormonal therapies as early breast cancer adjuvant in the previous 24 weeks. ',\n",
       " ...]"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# train_LTS = Long_texts_Summarizartion(Data.train_df.MergedColumn.tolist())\n",
    "# train_LTS.texts_summary"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "2e090cc5",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Index: 199"
     ]
    },
    {
     "data": {
      "text/plain": [
       "['Outcome Measurement:, Event-free Survival, Event free survival, the primary endpoint of this study, is defined as the time from randomization to the time of documented locoregional or distant recurrence, new primary breast cancer, or death from any cause. patients receive oral exemestane (25 mg) once daily for 5 years. ',\n",
       " 'female patients age 18 years or older, Histologically proven breast cancer after failure or relapse of no more than three lines of chemotherapy including adjuvant. HER2-negative patients (HER2 1+ or negative, or HER2 2+ and FISH negative), At least one measurable tumour lesion (RECIST); Availability of tumour samples. ANC less than 1500/mm3 platelet count less than 100 000/mm3 platelet count less than 100 000/mm3, Bilirubin greater than 1.5 mg /dl (>26 and#61549 mol /L, SI unit equivalent), AST and ALT greater than 2.5 times the upper limit of normal or greater 5 times the upper limit of normal. previous treatment with trastuzumab, EGFR-, or EGFR/HER2-inhibitors patients unable to comply women with fewer than 4 menses in the last 6 months will be considered premenopausal if FSH level  20. women with breast density 25% (scattered fibroglandular densities or greater) are eligible. women who have taken these medications must have stopped for at least 4 months prior to study entry. rt vitamin D supplementation may continue if they are already taking 400 IUs daily or less. patients with a history of breast cancer are not eligible. patients with a history of breast implants or breast reduction are not eligible. laboratory values - Calcium  10.5 mg/dL. ',\n",
       " 'Cardiac failure acute 0/167 (0.00%), Diarrhoea 5/167 (2.99%), Colitis 2/167 (1.20%), Enterocolitis 1/167 (0.60%), Stomatitis 1/167 (0.60%), Impaired healing 1/167 (0.60%), Sudden death 1/167 (0.60%), Postoperative wound infection2/167 (1.20%), Erysipelas 2/167 (0.60%), Bacterial diarrhoe 0/458 (0.00%), Tachycardia 0/458 (0.00%), Acute myocardial infarction 1/458 (0.22%), Atrial fibrillation 0/458 (0.00%), Adverse Events 2:, Total: 39/221 (17.65%), Febrile neutropenia 5/221 (2.26%), Neutropenia 1/221 (2.26%), Anaemia 2/221 (0.90%), Thrombocytopenia 0/221 (0.00%), Pancytopenia ',\n",
       " 'patients will receive 3400 cGy delivered in 10 twice-daily fractions. treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions. ',\n",
       " 'postmenopausal women with histologically or cytologically confirmed locally advanced or metastatic estrogen receptor (ER) positive breast cancer, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, Participants for whom endocrine therapy is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the study. oncogene encodes for phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA)-mutation testing. a valid cobas PIK3CA mutation result by central testing is required. hematologic and end-organ function within 28 days prior to treatment initiation. treatment-related toxicity must have resolved to Grade less than or equal to (/=) 1 or be deemed stable by the Investigator. prior treatment with greater than (>) 1 cytotoxic chemotherapy regimen for metastatic breast cancer, Concurrent hormone replacement therapy. ',\n",
       " 'patients with a history of brain metastasis are eligible for study participation [USA only] as long as their brain metastases have been treated and they have no evidence of progression or hemorrhage after treatment. ECOG performance status of 0 or 1 for women of childbearing potential. hormone therapy alone is not allowed for subjects who have received prior anthracycline-based therapy. hormone therapy alone is not allowed for subjects who have received prior anthracycline-based therapy. major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0. history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0. basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. ly controlled basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. ',\n",
       " 'Progression-free survival will be measured from day 1 of study drug administration to disease progression defined by Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. ',\n",
       " 'participants with HER2+ breast cancer received treatment as follows:, cycles 1-3 (3-week cycles): trastuzumab 8 mg/kg, IV on Day 1 (Cycle 1 only; 6 mg/kg in Cycles 2 and 3), doxorubicin 60 mg/m2, IV, and paclitaxel 150 mg/m2, IV, on Day 1 followed by 2 weeks off. cycles 8-10 (3-week cycles): trastuzumab 6 mg/ IV and paclitaxel 150 mg/m2, IV, on Day 1 followed by 2 weeks off. Cycles 4-7 (3-week cycles): cyclophosphamide 600 mg/m2, IV, methotrexate 40 mg/m2, IV, and 5-fluorouracil 600 mg/m2, IV, followed by 1 week off. ',\n",
       " 'trial was designed as a single-stage phase II rather than usual two-stage design because of the progression free survival primary endpoint. it is impractical to wait to assess PFS for patients in the first stage. the trial was designed as a single-stage phase II rather than usual two-stage design because of the primary endpoint. measure: months 14.3 (9.3 to 35) ',\n",
       " 'Adverse Events 1:, Total: 1/35 (2.86%), congestive heart failure *1/35 (2.86%), Adverse Events 2:, Total: 0/40 (0.00%), congestive heart failure *0/40 (0.00%). ',\n",
       " 'the total number (N) of SNs detected is therefore N = (A + B + C); the proportion of SNs detected by the Tc method (PTc) is (A + B + C); and the proportion of SNs detected by the ICG method (PICG) is (A + C)/N. participants undergo Axillary Lymph Node Biopsy and surgery. Overall number of participants Analyzed: 92, Measure Type: Number, Unit of Measure: proportion of nodes Proportion of SNs (PTc) detected by Tc method: 0.86, Proportion of SNs (PICG) detected by ICG method: 0.95_. ',\n",
       " 'patients with sentinel node biopsy positive disease must have undergone axillary dissection, Tumor must be confined to the breast without detected metastases elsewhere, T4 disease with minimal dermal invasion allowed, no bilateral breast cancer (except in situ carcinoma) no distant metastases, no skeletal pain of unknown cause, elevated alkaline phosphatase, or bone scan showing hot spots that cannot be ruled out as metastases by x-ray, MRI. chemotherapy regimen within 8 weeks after definitive surgery, Negative surgical margins, Axillary clearance with at least 6 lymph nodes examined OR negative sentinel node biopsy, Known HER2 status by immunohistochemistry or fluorescence in situ hybridization, Hormone receptor status:, Estrogen and progesterone receptor negative, Less than 10% positive tumor cells by immunohistochemistry, PATIENT CHARACTERISTICS:, Age:, Not specified, Sex:, Not specified, Men no prior or concurrent malignancy except adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or contralateral or ipsilateral in situ breast carcinoma. no psychiatric or addictive disorders that would preclude study, no non-malignant systemic disease that would preclude study, no non-malignant systemic disease that would preclude study. herapy for breast cancer. ',\n",
       " 'the total number (N) of SNs detected is therefore N = (A + B + C); the proportion of SNs detected by the Tc method (PTc) is (A + B + C); and the proportion of SNs detected by the ICG method (PICG) is (A + C)/N. participants undergo Axillary Lymph Node Biopsy and surgery. Overall number of participants Analyzed: 92, Measure Type: Number, Unit of Measure: proportion of nodes Proportion of SNs (PTc) detected by Tc method: 0.86, Proportion of SNs (PICG) detected by ICG method: 0.95_. ',\n",
       " 'Nivolumab + Daratumumab (TNBC), Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24) ',\n",
       " 'inclusion Criteria Phase 1, Age greater than/equal to 18 years, Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ, Patient desire to undergo breast surgery, 3. Patients will have provided informed consent to participate, documented by their signature on the study consent form 4. consent form will be given to the patient prior to enrollment. an eligibility worksheet will be completed for each patient prior to enrollment. ',\n",
       " '59/199 (29.65%), Anaemia 7/199 (3.52%), Thrombocytopenia 2/199 (1.01%), Atrial fibrillation 1/199 (0.50%), Cardiac arrest 1/199 (0.50%), Cardiopulmonary failure 1/199 (0.50%), Left ventricular failure 1/199 (0.50%), Supraventricular tachycardia 0/199 (0.00%), Ventricular tachycardia 1/199 (0.50%), Adverse Events ',\n",
       " 'disease progression is defined as PD according to RECIST Ver. 1.1. Assessment period was from the day of randomisation until the first observation of lesion progression or death from any cause. ',\n",
       " 'Adverse Events 1:, Total: 0/0_. ',\n",
       " '17/65 (26.15%), Febrile neutropenia 3/65 (4.62%), Neutropenia 2/65 (3.08%), Pancytopenia 1/65 (1.54%), Thrombocytopenia 1/65 (1.54%), Cardiac arrest 2/65 (3.08%), Myocardial infarction 1/65 (1.54%), Diarrhoea 5/65 (7.69%), Stomatitis 1/65 (1.54%), Vomiting  c valve incompetence 1/238 (0.42%), Atrial fibrillation 0/238 (0.00%), Cardiac arrest 0/238 (0.00%), cardiac arrest 0/238 (0.00%). ',\n",
       " 'inclusion Criteria:, Previous treatment for advanced breast cancer (previous treatment for early breast cancer is allowed). ',\n",
       " 'breast cancer with metastasis in multiple organs, Performance Status 0-2, Functions below are maintained in major organs:, Leukocyte count: 4,000/mm3 to 12,000/mm3, Neutrophil count: >2,000/mm3 or more, Platelet count: >2,000/mm3 or more, Hemoglobin count: >9,000/mm3 or more, Total bilirubin: >1.5 mg/dL, AST(GOT): within twice a normal upper value in ulcer, severe nerve disorder, women who are potentially pregnant, pregnant, or breast-feeding, severe drug allergy, Severe suppression of the bone marrow, Severe renal disorder, being treated with flucytosine, Complicated with the infection onset which a study doctor assesses to be inappropriate. ',\n",
       " 'study drug 190 mg/m2 for 2 to 4 weeks. ',\n",
       " 'tumor samples must be obtained from primary and/or metastatic sites. Participants must have measurable disease that is evaluable as per RECI. participants must have measurable disease that is evaluable. ST v1.1, Eastern Cooperative Oncology Group Performance Status of 0 or 1, Negative serum pregnancy test within 7 days of enrollment for pre-menopausal women and for women less than 12 months after the onset of menopause. participants with severe infection within 4 weeks prior to randomization are deemed to be at low risk for recurrence, Cardiopulmonary dysfunction, symptomatic pleural effusion, pericardial effusion, or ascites. participants with severe infection within 4 weeks prior to randomization, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia, Current severe, uncontrolled systemic disease. participants with known central nervous system disease, Leptomeningeal disease, History of autoimmune disease, Prior allogeneic stem cell or solid organ transplantation, Active tuberculosis, Receipt of a live, attenuated vaccine within 4 weeks prior to randomization or anticipation that such a live, attenuated vaccine will be required during the study. participants with known central nervous system disease, Leptomeningeal disease, History of autoimmune disease, history of  trial participants who are breastfeeding, or intending to become pregnant during the study. ',\n",
       " 'Cardiac failure acute 0/167 (0.00%), Diarrhoea 5/167 (2.99%), Colitis 2/167 (1.20%), Enterocolitis 1/167 (0.60%), Stomatitis 1/167 (0.60%), Impaired healing 1/167 (0.60%), Sudden death 1/167 (0.60%), Postoperative wound infection2/167 (1.20%), Erysipelas 2/167 (0.60%), Bacterial diarrhoe 0/458 (0.00%), Tachycardia 0/458 (0.00%), Acute myocardial infarction 1/458 (0.22%), Atrial fibrillation 0/458 (0.00%), Adverse Events 2:, Total: 39/221 (17.65%), Febrile neutropenia 5/221 (2.26%), Neutropenia 1/221 (2.26%), Anaemia 2/221 (0.90%), Thrombocytopenia 0/221 (0.00%), Pancytopenia ',\n",
       " 'Adverse Events 1:, Total: 0/0_. ',\n",
       " 'Adverse Events 1:, Total: 4/65 (6.15%), Thrombocytopenia * 0/65 (0.00%), Anaemia * 20/65 (0.00%), Febrile neutropenia * 20/65 (0.00%), leukopenia * 20/65 (0.00%), Neutropenia * 20/65 (0.00%), Pericardial effusion * 20/65 (0.00%), Tachycardia * 20/65 (0.00%), Nausea * 0/65 ',\n",
       " 'female, Serum 25(OH) 30 ng/ml, Age 18 years, Pre or post-menopausal, ECOG Performance status 0-2, Adequate organ function as defined as GFR> 30 mls/min and serum calcium 10.4 mg/dl, Any race/ethnicity, English speaking, No changes to MBC treatments within 30 days of enrollment. informed consent or study questionnaires, psychiatric or other clinical conditions that preclude study compliance, Other important medical or safety considerations at the discretion of the investigator and/or study physician, including non-compliance with the study therapy or other activities. ',\n",
       " 'postmenopausal women with histologically or cytologically confirmed locally advanced or metastatic estrogen receptor (ER) positive breast cancer, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, Participants for whom endocrine therapy is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the study. oncogene encodes for phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA)-mutation testing. a valid cobas PIK3CA mutation result by central testing is required. hematologic and end-organ function within 28 days prior to treatment initiation. treatment-related toxicity must have resolved to Grade less than or equal to (/=) 1 or be deemed stable by the Investigator. prior treatment with greater than (>) 1 cytotoxic chemotherapy regimen for metastatic breast cancer, Concurrent hormone replacement therapy. ',\n",
       " 'women with a history of breast cancer (currently without malignant disease), Bothersome hot flashes (defined by their occurrence 28 times per week and of sufficient severity to make the patient desire therapeutic intervention) women with at least one ovary but without a uterus should be deemed postmenopausal by either age over 55 or combination of estrogen within a postmenopausal range. magnesium, no diabetes, no patients with conditions that are implicated in decreased absorption of magnesium (e.g., Crohn disease, ETOH abuse), no patients with diarrhea where magnesium might make it worse (per provider discretion), PRIOR CONCURRENT THERAPY:, none of the following current ( 28 days prior to registration) or planned therapies (tamoxifen, raloxifene, or aromatase inhibitors are allowed) is allowed, if it is planned to be continued at the same dose during the study period. no current use of magnesium for any indication (except one standard multiple vitamin dose is allowed per day) ',\n",
       " 'the achievement of a pCR is associated with a favorable long-term prognosis in all breast cancer subtypes. a pCR is commonly defined as the absence of residual invasive cancer in both the breast and axillary lymph nodes. articipants 35 35.7%, Results 2:, Arm/Group Title: Arm 2/3 (Nab-Paclitaxel/AC+PEG-G), Arm/Group Description: Received nP x 12 followed by ddAC x 6 first followed by nP x 12 without bevacizumab. overall number of participants Analyzed: 113, Measure Type: Count of Participants, Unit of Measure: Participants 24 21.2%Outcome Measure pe: Number, Unit of Measure: percentage of patients 79.6. ',\n",
       " 'Anaemia * 4/100 (4.00%), Febrile neutropenia * 3/100 (3.00%), Neutropenia * 1/100 (1.00%), Stress cardiomyopathy * 0/100 (0.00%), Abdominal pain * 0/100 (0.00%), Abdominal pain upper * 0/100 (0.00%), Ascite * 1/100 (1.00%), Adverse Events 2:, Total: 45/152 (29.61%), Anaemia * 0/152 (0.00%), ',\n",
       " 'Outcome Measurement:, Event-free Survival, Event free survival, the primary endpoint of this study, is defined as the time from randomization to the time of documented locoregional or distant recurrence, new primary breast cancer, or death from any cause. patients receive oral exemestane (25 mg) once daily for 5 years. ',\n",
       " 'resected specimen from surgery must be histologically free of invasive adenocarcinoma and ductal carcinoma in-situ. resected specimen must be histologically free of invasive adenocarcinoma and ductal carcinoma in-situ. patients of childbearing potential must implement adequate non-hormonal contraceptive measures during study treatment. patients of childbearing potential must implement adequate non-hormonal contraceptive measures. ticipation in another clinical trial with any investigational not marketed drug within 30 days before study entry. ',\n",
       " 'anemia 1/41 (2.44%), Febrile neutropenia 1/41 (2.44%), Eye disorders - Other, Visual disturbance 1/41 (2.44%), Abdominal pain 1/41 (2.44%), Constipation 1/41 (2.44%), Nausea 1/41 (2.44%), Fever 1/41 (2.44%), Pain 1/41 (2.44%), Skin infection 2/41 (4.88%), Alkaline phosphatase increased 1/41 (2.44%) ',\n",
       " 'Febrile Neutropenia * 3/56 (5.36%), Neutropenia * 1/56 (1.79%), Atrial Fibrillation * 1/56 (1.79%), Coronary Artery Disease * 1/56 (1.79%), Constipation * 1/56 (1.79%), Chest Pain * 1/56 (1.79%), Non-Cardiac Chest Pain * 1/56 (1.79%), Edema due to Cardiac Disease * 1/56 (1.79%), Cellulitis * ',\n",
       " 'Anaemia * 4/100 (4.00%), Febrile neutropenia * 3/100 (3.00%), Neutropenia * 1/100 (1.00%), Stress cardiomyopathy * 0/100 (0.00%), Abdominal pain * 0/100 (0.00%), Abdominal pain upper * 0/100 (0.00%), Ascite * 1/100 (1.00%), Adverse Events 2:, Total: 45/152 (29.61%), Anaemia * 0/152 (0.00%), ',\n",
       " 'NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous infusion on day 1 of each treatment cycle. patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents. ',\n",
       " 'Response is anyone who experiences CR, CR or SD in first 6 months. CR: Disappearance clinical evidence active tumor by evaluation, mammogram & ultrasound. dovitinib 500 mg single oral dose for 5 consecutive days followed by a 2-day rest period (5 days on/2 days off schedule) for every 28 day cycle. overall number of participants Analyzed: 19, Measure Type: Number, Unit of Measure: participants Complete Response (CR): 0, Partial Response (PR): 0, Stable Disease (SD: 1Outcome Measurement:, Percentage of participants with pathological complete response (pCR) in breast and axilla as Defined by  participants received placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles. paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses) overall number of participants Analyzed: 76, Measure Type: Number, Unit of Measure: percentage of participants 17.1 (9.82 to 27.25), Results 2:, Arm/Group Title: Placebo + Paclitaxel ',\n",
       " 'Abraxane, Avastin and Gemcitabine each treatment cycle is 28 days. participants will be treated until disease progression. ',\n",
       " 'subjects with operable, node-positive or high-risk node-negative breast carcinoma are eligible for the study. subjects must demonstrate willingness to and be able to participate in the study and to adhere to dose and visit schedules. subjects must be of female gender and >= 18 years of age. Subjects must have had complete resection (R0) of primary tumor and axillary lymph nodes (or must have negative sentinel node[s]), Baseline left ventricular ejection fraction (LVEF) by multiple gated acquisition scan or echocardiogram (ECHO) >=55%, Easter Cooperative Oncology Group (ECOG)-performance status of 0-1, Adequate postoperative bone marrow function with neutrophils >=1.5 x 109/l, plate tential (including women who are less than one year postmenopausal and will be sexually active during the study) must agree to use a medically accepted method of contraception, while receiving protocol-specified medication and for 30 days (or as per local requirements) after stopping the medication or be surgically sterilized prior to screening. subject who meets any of the following exclusion criteria will be disqualified from participation in the study. active angina pectoris requiring medication, serious ventricular arrhythmias requiring medication or implantable cardioverter-defibrillator (ICD) therapy, uncontrolled supraventricular arrhythmias, clinically significant valvular disease, poorly controlled arterial hypertension (systolic blood pressure (BP) >180 mmHg, diastolic BP >100 mmHg), Sensory/motor neuropathy > grade 2 as defined by national cancer institure dy, Is on staff, affiliated with, or a family member of staff personnel directly involved with this study, Usage of any investigational product within 30 days prior to enrollment. this would not prohibit the patient from participating in a quality of life, questionnaire, blood collection, or observational study. ',\n",
       " 'all patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking. ',\n",
       " 'Adverse Events 1:, Total: 0/23 (0.00%)Adverse Events 1:, Total: 0/655 (0.00%), Adverse Events 2:, Total: 0/580 (0.00%) ',\n",
       " 'HER2-overexpression breast cancer, Stage IV metastatic disease, Must have progressed on one prior trastuzumab treatment, no more than one prior trastuzumab based therapy regimen (either adjuvant or first-line), Must have received anthracycline and/or taxane based chemotherapy for adjuvant treatment of breast cancer. Must have (archived) tumour tissue sample available for central re-assessment of HER2-status. ed hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia. myocardial infarction within 6 months prior to randomisation. ',\n",
       " 'inclusion Criteria:, Must have received prior chemotherapy with Taxol (paclitaxel) or Taxotere (docetaxel)., Less than 3 different chemotherapy treatments for metastatic disease., Prior treatment with hormonal and/or radiation therapy., Must have disease that can be measured. ',\n",
       " 'female or male patients with diagnosis of invasive adenocarcinoma will be eligible. for the phase I portion, patients with any ER/PR/HER2 disease status are no longer eligible for hormonal therapy or HER2-targeted therapy. patients may be untreated in the metastatic setting or have received any number of prior cytotoxic regimens. prior taxane therapy, either in the adjuvant or in the metastatic setting, either deliver weekly, q 2 weeks or q 3 weeks, will be allowed. Adequate Organ Function, Total bilirubin 1.5 times the institutional Upper Limit of Normal (ULN), Hepatic enzymes 2.5 times the institutional ULN, Serum Na, K+, Mg2+, Phosphate and Ca2+ Lower Limit of Normal (LLN), Serum Creatinine 1.5 times the institutional ULN, Neutrophil count, Platelets, both Grade 0-1, PT (INR) and PTT Grade 0-1, except for patients on Coumadin or the concomitant use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving dasatinib therapy. antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of dasatinib. indinavir, nelfinavir, ritonavir, ciprofloxacin, ciprofloxacin, clarithromycin, diclofenac, doxycycline, enoxacin, imatinib, isoniazid, ketamine, nefazodone, nicardipine, propofol, quinidine, telithromycin, women of childbearing potential (WOC prior severe allergic reaction to paclitaxel therapy must be discontinued. prior hormonal therapy must be discontinued > or = to 3 weeks. patients with underlying cardiopulmonary dysfunction should be excluded from the study. subjects with hypokalemia or hypomagnesemia should be excluded from the study. ymptomatic brain metastases or brain metastases that have been previously irradiated are not grounds for trial exclusion. history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant. lusion criteria: Signed Informed Consent, ErbB2(HER2)overexpressing breast cancer. prior treatment of brain metastases with Whole Brain Radiotherapy (WBR) and stereotactic radiosurgery (SRS) ',\n",
       " 'Progression-free survival will be measured from day 1 of study drug administration to disease progression defined by Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. ',\n",
       " '0/34 (0.00%)Adverse Events 1:, Total: 6/62 (9.68%), Musculoskeletal * 1/62 (1.61%), Mood Alteration: Depression * 1/62 (1.61%), renal - Other * 1/62 (1.61%), Obstruction, GU: Uterus * 1/62 (1.61%), sexual * 0/62 (0.00%), Pulmonary/Upper Respiratory: Dyspnea * 1/62 (1.6 ',\n",
       " 'Adverse Events 1:, Total: 5/55 (9.09%), Infection 2/55 (3.64%), Pain * 1/55 (1.82%), Muscle Weakness * 1/55 (1.82%), Dyspnea 1/55 (1.82%) ',\n",
       " 'Placebo and Paclitaxel, Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received study drug plus paclitaxel, INTERVENTION 2:, Placebo and Paclitaxel, Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received placebo plus paclitaxel. ',\n",
       " 'preoperative stages II-III per AJCC 6th edition, based on baseline evaluation by clinical examination and/or breast imaging. patients must have completed preoperative (neoadjuvant) chemotherapy with a standard chemotherapy regimen. patients must have the presence of significant residual invasive disease. patients with metastatic disease may not be pregnant, expect to become pregnant, plan to conceive a child while on study, or breastfeeding, Uncontrolled intercurrent illness, Non-healing wounds or major surgical procedures are not permitted within 28 day prior to enrollment. patients with clinically significant peripheral arterial disease should also be excluded. tory of grade 3 or 4 allergic reactions to compounds of similar chemical or biologic composition to cyclophosphamide (such as other alkylating agents) or methotrexate (such as other antimetabolites), Prior history of malignancy treated without curative intent, excluding nonmelanomatous skin cancer. Current use of anticoagulants is allowed as long as patients have been on a stable dose for more than two weeks with stable INR. participants with histologically or cytologically confirmed nonsmall cell Lung Cancer (NSCLC), Exclusion Criteria:, Active brain metastases or leptomeningeal metastases. Any serious or uncontrolled medical disorder, Prior malignancy active within the previous 3 years, Other protocol defined inclusion/exclusion criteria could apply. ',\n",
       " 'Fulvestrant + Everolimus was administered intramuscularly (in the gluteus maximus) in a loading dose schedule as follows: 500 mg in two divided doses-one on each side on day 1, then 250 mg on day 14 and then 250 mg on day 28 and every 4 weeks  3 days thereafter. ',\n",
       " 'patients will receive 3400 cGy delivered in 10 twice-daily fractions. treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions. ',\n",
       " 'patients will be treated sequentially with preoperative trastuzumab and dose-dense ABI-007 followed by trastuzumab in combination with vinorelbine. patients will be treated sequentially with preoperative trastuzumab followed by trastuzumab in combination with vinorelbine. growth factor support with pegfilgrastim (Neulasta) is required 24 to 48 hours following completion of each cycle of ABI-007. beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles. overall number of participants Analyzed: 84, Mean (Standard Deviation), Unit of Measure: units on a scale -1.1 (1.9), Results 2:, Arm/Group Title: Arzoxifene, Arm/Group Description: LY353381, 20 mg daily, arzoxifene: one tablet daily, Overall Number of Participants Analyzed: 82, Mean (Standard Deviation), Unit of Measure: units on a scale -1.1 (1.9 ',\n",
       " 'intraductal arm, Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride. treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. ',\n",
       " 'complete Response is the total disappearance of clinically and radiologically detectable disease for at least 4 weeks. partial Response is at least a 50% reduction of all measurable lesions. no new lesions appearing for at least four weeks. ill met eligibility laboratory and performance status criteria. overall number of participants Analyzed: 42, Measure Type: Number, Unit of Measure: percentage of patients 28 (16 to 42), Results 2:, Arm/Group Title: Arm B - Docetaxel Then Liposomal Doxorubicin, Arm/Group Description: Weekly docetaxel 36 mg/m2 IV over 30 minutes on days 1, 8 and 15 followed by one week rest, administered on a q 28 day cycle. ',\n",
       " 'inclusion Criteria:, Previous treatment for advanced breast cancer (previous treatment for early breast cancer is allowed). ',\n",
       " 'disease progression is defined as PD according to RECIST Ver. 1.1. Assessment period was from the day of randomisation until the first observation of lesion progression or death from any cause. ',\n",
       " 'Outcome Measurement:, Patients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at 12 Months or Clinical Disease Recurrence) Number of patients event-free, Time frame: 12 month period following randomisation, Results 1:, Arm/Group Title: Fulvestrant + Anastrozole, Arm/Group Description: fulvestrant 500 mg + anastrozole 1 mg, Overall Number of participants Analyze ',\n",
       " 'the log ratio of tumor size at Cycle 2 to tumor size at baseline is calculated for each participant. the tumor size is the sum of the target lesion measurements at each assessment. ly2523355 administered intravenously as a 1-hour infusion on days 1, 2 and 3 of a 21-day Cycle for 2 Cycles. Ixabepilone administered intravenously as a 3-hour infusion on Day 1 of a 21-day Cycle for 2 Cycles. participants may have remained on study drug for additional cycles until a criterion for study discontinuation was met. ',\n",
       " 'adult women must have at least one lesion that can be accurately measured or bone lesions in the absence of disease. prior treatment for breast cancer with endocrine therapy (adjuvant or metastatic settings) is allowed but should be discontinued. anticancer therapy for locally advanced or metastatic breast cancer except for prior hormonal therapy. radiotherapy to 25% of the bone marrow within 4 weeks prior to randomization. ',\n",
       " '2/30 (6.67%), Dry Eyes [1]1/30 (3.33%), Diarrhea [2]1/30 (3.33%) ',\n",
       " 'female, Serum 25(OH) 30 ng/ml, Age 18 years, Pre or post-menopausal, ECOG Performance status 0-2, Adequate organ function as defined as GFR> 30 mls/min and serum calcium 10.4 mg/dl, Any race/ethnicity, English speaking, No changes to MBC treatments within 30 days of enrollment. informed consent or study questionnaires, psychiatric or other clinical conditions that preclude study compliance, Other important medical or safety considerations at the discretion of the investigator and/or study physician, including non-compliance with the study therapy or other activities. ',\n",
       " '5/101 (4.95%), BILATERAL CATARACTS * 0/101 (0.00%), ISCHEMIC COLITIS * 1/101 (1.98%), ISCHEMIC COLITIS * 1/101 (0.99%), ISCHEMIC COLITIS * 1/101 (0.00%), ACUTE MYELOID LEUKEMIA * 0/101 (0.00%), BREAST CANCER * 0/101 (0.00%), PRIMARY DCIS IN BRE ',\n",
       " 'the time interval from randomization date to recurrence, progression or death is documented. for subjects without recurrence, progression or death, it is censored at the last valid tumor assessment. the result is based on primary analysis data cut. overall number of participants Analyzed: 307, Mean (95% Confidence Interval), Unit of Measure: months 8.8 (7.8 to 9.8), Results 2:, Arm/Group Title: lapatinib Plus Capecitabine, Arm/Group Description: lapatinib 1250 mg orally, once daily, continuously in 21 day cycles. ',\n",
       " 'cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles, docetaxel: 75 mg/m2 IV every 21 days for 6 cycles, docetaxel: 75 mg/m2 IV every 21 days for 6 cycles, docetaxel: 75 mg/m2 IV every 14 days for 4 cycles. overall number of participants Analyzed: 1610, Measure Type: Number, Unit of Measure: percentage of patients 80.1 (78.0 to 82.0) 2 IV every 21 days for 6 cycles, Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles. Paclitaxel: 175 mg/m2 IV every 14 days for 4 cycles, doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles, group 2 and group 3: 60 mg/m2 IV every 14 days for 4 cycles. ',\n",
       " 'NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous infusion on day 1 of each treatment cycle. patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents. ',\n",
       " 'metastases must have demonstrated progression of brain metastases after prior treatment for brain metastases. new lesions in the CNS on an imaging study (contrast-enhanced CT scan or MRI), Progressive lesions on an imaging study (contrast-enhanced CT scan or MRI), New or progressive lesions that do not meet measurable disease definition allowed. ECOG performance status 0-2, Life expectancy 1 month, Hemoglobin 10 g/dL (transfusion allowed), ANC 1,500/mm3, Granulocyte count 1,500/mm3, Platelet count 100,000/mm3, Creatinine 1.5 mg/dL, Total bilirubin 1.5 times upper limit of normal (ULN), AST and ALT 3 times ULN. patients on an enzyme-inducing anti-epileptic agent (EIAE) or valproic acid are eligible if they are switched to an alternate non-EIAE medication, Concurrent coumadin allowed, No prophylactic use of filgrastim (G-CSF) during first course of treatment. ',\n",
       " 'inclusion Criteria:, Must have received prior chemotherapy with Taxol (paclitaxel) or Taxotere (docetaxel)., Less than 3 different chemotherapy treatments for metastatic disease., Prior treatment with hormonal and/or radiation therapy., Must have disease that can be measured. ',\n",
       " 'breast cancer with metastasis in multiple organs, Performance Status 0-2, Functions below are maintained in major organs:, Leukocyte count: 4,000/mm3 to 12,000/mm3, Neutrophil count: >2,000/mm3 or more, Platelet count: >2,000/mm3 or more, Hemoglobin count: >9,000/mm3 or more, Total bilirubin: >1.5 mg/dL, AST(GOT): within twice a normal upper value in ulcer, severe nerve disorder, women who are potentially pregnant, pregnant, or breast-feeding, severe drug allergy, Severe suppression of the bone marrow, Severe renal disorder, being treated with flucytosine, Complicated with the infection onset which a study doctor assesses to be inappropriate. ',\n",
       " 'atrial fibrillation 0/12 (0.00%), Congestive Heart Failure [2]0/12 (0.00%), Diverticulitis 0/12 (0.00%), Cholecystitis 0/12 (0.00%), Urosepsis 2/12 (16.67%), Rash [3]0/12 (0.00%)Adverse Events 1:, Total: 18/65 (27.69%), Anaemia 5/65 (7.69%), Febrile neutropenia 1/65 (1.54% ing 1/66 (1.52%), Condition aggravated 1/66 (1.52%), complication 1/66 (1.52%) ',\n",
       " 'patients will receive bilateral (both sides) breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla (the side of the affected breast), and ultrasound guided biopsy of axillary lymph node if suspicious. ',\n",
       " '3/39 (7.69%), Neutropenia 1/39 (2.56%), Bilateral Pulmonary Thromboembolism 0/39 (0.00%), Fever 1/39 (2.56%), Empyema associated with a permanent thoracic catheter 1/39 (2.56%), Adverse Events 2:, Total: 3/21 (14.29%), Neutropenia 1/21 (4.76%), Bilateral Pulmonary Thromboembolism 1/21 (4.76%), Fever 1/21 ( ',\n",
       " 'inTERVENTION 2:, Arm B - Flaxseed, Flaxseed 25 mg per day and 1 mg anastrozole pill per day, Anastrozole: 1 mg per day, flaxseed: 25 g per day ground, inTERVENTION 2:, Phase 1 - Cohort A, Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 175 mg orally once daily, or as specified per protocol, until disease progression for treatment of meta ',\n",
       " 'pathologically confirmed breast cancer determined to be a candidate for primary systemic (neoadjuvant) therapy and surgical resection of residual primary tumor following completion of neoadjuvant therapy. locally advanced breast cancer, not stage IV, with a tumor size >= 2 cm (as measured on imaging or estimated by physical exam) institutional limits OR creatinine clearance >= 30 mL/min/1.73 m2 for patients with creatinine levels above institutional normal. If female, postmenopausal for minimum of one year, OR surgically sterile, OR not pregnant, confirmed by institutional standard of care pregnancy test. Able to understand and willing to sign a written informed consent document and a HIPAA authorization. ents, Medically unstable, Condition requiring anesthesia for PET scanning and/or unable to lie still for 1.5 hours. history of allergic reactions attributed to compounds of similar chemical or biologic composition to F-18 fluorothymidine, Pregnant or nursing, Previous malignancy, other than basal cell carcinoma of the skin or in situ carcinoma of the cervix. ',\n",
       " 'Adverse Events 1:, Total: 0_ ',\n",
       " 'all patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking. ',\n",
       " 'patients with a history of brain metastasis are eligible for study participation [USA only] as long as their brain metastases have been treated and they have no evidence of progression or hemorrhage after treatment. ECOG performance status of 0 or 1 for women of childbearing potential. hormone therapy alone is not allowed for subjects who have received prior anthracycline-based therapy. hormone therapy alone is not allowed for subjects who have received prior anthracycline-based therapy. major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0. history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0. basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. ly controlled basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. ',\n",
       " 'Adverse Events 1:, Total: 0/655 (0.00%), Adverse Events 2:, Total: 0/580 (0.00%), Adverse Events 2:, Total: 0/15 (0.00%), Adverse Events 2:, Total: 0/16 (0.00%). ',\n",
       " '340/1612 (21.09%), Anemia 10/1612 (0.62%), Blood and lymphatic system disorders - Other, specify 3/1612 (0.19%), Febrile neutropenia 7/1612 (0.43%), Cardiac disorders - Other, specify 6/1612 (0.37%), Conduction disorder 2/1612 (0.12%), Myocardial infarction 6/1612 (0.37%), Palpitations 1/1612 (0.06%), Pericardial effusion 0/1612 (0.00%), ',\n",
       " 'patients with stable brain metastases are eligible for this trial. at least one prior chemotherapy regimen must be discontinued at least 2 weeks before treatment start. te of disease may enroll on this trial and will not undergo biopsy. patients with human epidermal growth factor receptor 2 (HER2) overexpressing disease must have been previously treated with trastuzumab. etastases, AST and ALT are permitted to be /= 5 times the ULN. no evidence of QT prolongation, no history of congenital long QT syndrome, and no use of drugs known to increase the risk of Torsades de Point. patients may be eligible for study if the drug can be changed to another agent with less risk. treatment with trastuzumab, bevacizumab or other targeted therapies within the past 2 weeks. prior treatment with eribulin, Severe, concurrent illness. inadequate bone marrow, renal, or hepatic function. ',\n",
       " 'inTERVENTION 2:, Arm B - Flaxseed, Flaxseed 25 mg per day and 1 mg anastrozole pill per day, Anastrozole: 1 mg per day, flaxseed: 25 g per day ground, inTERVENTION 2:, Phase 1 - Cohort A, Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 175 mg orally once daily, or as specified per protocol, until disease progression for treatment of meta ',\n",
       " 'Adverse Events 1:, Total: 1/35 (2.86%), congestive heart failure *1/35 (2.86%), Adverse Events 2:, Total: 0/40 (0.00%), congestive heart failure *0/40 (0.00%). ',\n",
       " 'patients will receive bilateral (both sides) breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla (the side of the affected breast), and ultrasound guided biopsy of axillary lymph node if suspicious. ',\n",
       " 'cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles, docetaxel: 75 mg/m2 IV every 21 days for 6 cycles, docetaxel: 75 mg/m2 IV every 21 days for 6 cycles, docetaxel: 75 mg/m2 IV every 14 days for 4 cycles. overall number of participants Analyzed: 1610, Measure Type: Number, Unit of Measure: percentage of patients 80.1 (78.0 to 82.0) 2 IV every 21 days for 6 cycles, Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles. Paclitaxel: 175 mg/m2 IV every 14 days for 4 cycles, doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles, group 2 and group 3: 60 mg/m2 IV every 14 days for 4 cycles. ',\n",
       " 'lapatinib 1500 mg, Participants received matching placebo orally once daily. treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer. ',\n",
       " 'participants with measurable and/or non-measurable disease are eligible, Known and documented HER2-positive, Known and documented LVEF of at least 50 percent (%), Adequate organ function, A negative serum beta-human chorionic gonadotropin (beta-HCG) test for women of childbearing potential (premenopausal, or less than [] 12 months of amenorrhea post-menopause. systemic non-hormonal anti-cancer therapy for metastatic or locally recurrent disease, Pregnant or lactating women, Current clinical or radiographic evidence of central nervous system metastases, Disease progression while receiving or within 12 months of completion of trastuzumab and/or lapatinib treatment. history of LVEF decline to below 50% during or after prior trastuzumab adjuvant or neo-adjuvant therapy. ',\n",
       " 'lesions should not be amenable to surgery or radiation of curative intent. prior radiation therapy is allowed to less than 25% of the bone marrow. participants must have recovered from the toxic effects of the treatment. antitumoral hormonal treatment must be discontinued prior to enrollment. participants must test negative for pregnancy within 7 days of enrollment. participants must be at least 18 years of age. participants have received more than one combination of anthracycline plus taxane. have serious concomitant systemic disorders that compromise the safety of the participant. have a prior malignancy other than breast cancer, carcinoma in situ of the cervix or nonmelanoma skin cancer. are unable or unwilling to take folic acid, vitamin B12 supplementation, or dexamethasone. are unable or unwilling to take any other antitumor therapy. ',\n",
       " '3.6 mg/kg of trastuzumab emtansine was administered to participants intravenously (IV) over 30-90 minutes on day 1 of 21 day cycle and was repeated every 3 weeks. overall number of participants Analyzed: 70, Measure Type: Count of Participants, Unit of Measure: Participants Grade 1: 53 75.7%, Grade 2: 40 57.1%, Grade 3: 18 25.7%, Grade 4: 2 2.9%, Grade 5: 12 17.1%. ',\n",
       " 'Anaemia * 0/219 (0.00%), Febrile neutropenia * 26/219 (11.87%), Neutropenia * 7/219 (3.20%), Thrombocytopenia * 1/219 (0.46%), Cardiac failure * 2/219 (0.91%), Sinus tachycardia * 1/219 (0.46%), left ventricular dysfunction * 2/219 (0.91%), Abdominal pain * 1/219 (0.46%), Abdominal pain * 1/219 (0.46%), Co ',\n",
       " 'participants with measurable and/or non-measurable disease are eligible, Known and documented HER2-positive, Known and documented LVEF of at least 50 percent (%), Adequate organ function, A negative serum beta-human chorionic gonadotropin (beta-HCG) test for women of childbearing potential (premenopausal, or less than [] 12 months of amenorrhea post-menopause. systemic non-hormonal anti-cancer therapy for metastatic or locally recurrent disease, Pregnant or lactating women, Current clinical or radiographic evidence of central nervous system metastases, Disease progression while receiving or within 12 months of completion of trastuzumab and/or lapatinib treatment. history of LVEF decline to below 50% during or after prior trastuzumab adjuvant or neo-adjuvant therapy. ',\n",
       " 'objective response rate was defined as percentage of participants achieving complete response (CR) or partial response (PR) per RECIST 1.1 for target lesions. CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions. AZD1775 will be administered 200 mg as twice daily oral dosing schedule. at least 10 patients will undergo a research biopsy within 5-48 hours after beginning cisplatin (Cycle 1 Day 1) and then again within 5-8 hours after the last dose of AZD1775 in cycle 2 (Cycle 2 Day 3). the proportions of SLNs flagged will be compared using a two-sided 95% confidence interval. participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. ',\n",
       " 'participants took lapatinib 1250 mg and capecitabine 2000 mg/m2. participants took lapatinib twice daily on the first day through the fourteenth day of each 21-day cycle. ',\n",
       " 'Dose Limiting Toxicity Incidence of Neratinib in combination with paclitaxel 80 mg/m2 IV on days 1, 8, and 15 of a 28 day cycle. overall number of participants Analyzed: 3, Measure Type: Count of participants, Unit of Measure: Participants 0 0.0%. ',\n",
       " 'the participant had an OR if her best overall response was either a complete response (CR) or a partial response (PR) according to the RECIST. the participant had an OR if her best overall response was either a complete response (CR) or a partial response (PR) according to the RECIST. RECIST Ver.1.1 defines the period from the day of randomization until the first observation of lesion progression or death from any cause. disease progression is defined as PD according to RECIST Ver.1.1. esults 2:, Arm/Group Title: Paclitaxel (80 mg/m2) on days 1, 8 and 15 of a 28-day cycle. Overall number of participants Analyzed: 211, Median (95% Confidence Interval), Unit of Measure: months 8.5 (6.9 to 11.5) ',\n",
       " 'Adverse Events 1:, Total: 5/55 (9.09%), Infection 2/55 (3.64%), Pain * 1/55 (1.82%), Muscle Weakness * 1/55 (1.82%), Dyspnea 1/55 (1.82%) ',\n",
       " 'as extracellular fluid accumulates (i.e. lymphedema develops) the LDex value increases. the average number of treaments is 9 conducted over a median of up to 4 weeks. survival is defined as the time from the date of randomization to the date of death from any cause. patients who are lost-to-follow-up or alive at the time of analysis will be censored at the time they were last known to be alive or at the date of event cut-off. patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel. ',\n",
       " 'an objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR) each patient with measurable disease at baseline was assessed for OR from the sequence of Response Evaluation Criteria in Solid Tumors (RECIST) scans were performed every 12 weeks (+/- 2weeks) from randomization data up to data cut-off (19th march 2008), Results 1:, Arm/Group Title: Fulvestrant 250 mg, Arm/Group Description: Fulvestrant 250 OR is defined as complete response (CR) and partial response (PR) and was assessed according to the Response Evaluation Criteria in Solid Tumours version 1.0 (RECIST) ',\n",
       " 'participants with no recorded post-baseline tumor assessment had PFS censored at the day of last follow-up. participants lost to follow-up were censored at the date of last follow-up. roup received a drug regimen that consisted of both fulvestrant and dasatinib. Fulvestrant: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1 (28-day cycle). in subsequent cycles, 500 mg IM administered on Day 1, up to 2 years. ',\n",
       " 'as extracellular fluid accumulates (i.e. lymphedema develops) the LDex value increases. the average number of treaments is 9 conducted over a median of up to 4 weeks. survival is defined as the time from the date of randomization to the date of death from any cause. patients who are lost-to-follow-up or alive at the time of analysis will be censored at the time they were last known to be alive or at the date of event cut-off. patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel. ',\n",
       " 'women >=18 years of age; newly diagnosed; infiltrating breast cancer. exclusion Criteria: evidence of metastatic disease, except ipsilateral lymph nodes. ',\n",
       " 'patients with stable brain metastases are eligible for this trial. at least one prior chemotherapy regimen must be discontinued at least 2 weeks before treatment start. te of disease may enroll on this trial and will not undergo biopsy. patients with human epidermal growth factor receptor 2 (HER2) overexpressing disease must have been previously treated with trastuzumab. etastases, AST and ALT are permitted to be /= 5 times the ULN. no evidence of QT prolongation, no history of congenital long QT syndrome, and no use of drugs known to increase the risk of Torsades de Point. patients may be eligible for study if the drug can be changed to another agent with less risk. treatment with trastuzumab, bevacizumab or other targeted therapies within the past 2 weeks. prior treatment with eribulin, Severe, concurrent illness. inadequate bone marrow, renal, or hepatic function. ',\n",
       " 'Adverse Events 1:, Total: 0/655 (0.00%), Adverse Events 2:, Total: 0/580 (0.00%), Adverse Events 2:, Total: 0/15 (0.00%), Adverse Events 2:, Total: 0/16 (0.00%). ',\n",
       " '59/199 (29.65%), Anaemia 7/199 (3.52%), Thrombocytopenia 2/199 (1.01%), Atrial fibrillation 1/199 (0.50%), Cardiac arrest 1/199 (0.50%), Cardiopulmonary failure 1/199 (0.50%), Left ventricular failure 1/199 (0.50%), Supraventricular tachycardia 0/199 (0.00%), Ventricular tachycardia 1/199 (0.50%), Adverse Events ',\n",
       " 'febrrile neutropenia grade 3 3/48 (6.25%), Neutropenia grade 3 1/48 (2.08%), hypersensibility reaction grade 3 2/48 (4.17%), Palmoplantar erythrodysesthesia grade 3, stomatitis grade 3 1/48 (2.08%), Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%), Catheter - related infection grade 3 1/48 (2.08%)Adverse Events 1:, Total: Conjunctivitis 1/532 (0.19%), Abdominal pain 1/532 (0.19%), Anal fissure 1/532 (0.19%), Constipation 1/532 (0.19%), Diarrhoea 6/532 (1.13%) ',\n",
       " '59/199 (29.65%), Anaemia 7/199 (3.52%), Thrombocytopenia 2/199 (1.01%), Atrial fibrillation 1/199 (0.50%), Cardiac arrest 1/199 (0.50%), Cardiopulmonary failure 1/199 (0.50%), Left ventricular failure 1/199 (0.50%), Supraventricular tachycardia 0/199 (0.00%), Ventricular tachycardia 1/199 (0.50%), Adverse Events ',\n",
       " 'Adverse Events 1:, Total: 0_ ',\n",
       " 'female patients age 18 years or older, Histologically proven breast cancer after failure or relapse of no more than three lines of chemotherapy including adjuvant. HER2-negative patients (HER2 1+ or negative, or HER2 2+ and FISH negative), At least one measurable tumour lesion (RECIST); Availability of tumour samples. ANC less than 1500/mm3 platelet count less than 100 000/mm3 platelet count less than 100 000/mm3, Bilirubin greater than 1.5 mg /dl (>26 and#61549 mol /L, SI unit equivalent), AST and ALT greater than 2.5 times the upper limit of normal or greater 5 times the upper limit of normal. previous treatment with trastuzumab, EGFR-, or EGFR/HER2-inhibitors patients unable to comply women with fewer than 4 menses in the last 6 months will be considered premenopausal if FSH level  20. women with breast density 25% (scattered fibroglandular densities or greater) are eligible. women who have taken these medications must have stopped for at least 4 months prior to study entry. rt vitamin D supplementation may continue if they are already taking 400 IUs daily or less. patients with a history of breast cancer are not eligible. patients with a history of breast implants or breast reduction are not eligible. laboratory values - Calcium  10.5 mg/dL. ',\n",
       " 'preoperative stages II-III per AJCC 6th edition, based on baseline evaluation by clinical examination and/or breast imaging. patients must have completed preoperative (neoadjuvant) chemotherapy with a standard chemotherapy regimen. patients must have the presence of significant residual invasive disease. patients with metastatic disease may not be pregnant, expect to become pregnant, plan to conceive a child while on study, or breastfeeding, Uncontrolled intercurrent illness, Non-healing wounds or major surgical procedures are not permitted within 28 day prior to enrollment. patients with clinically significant peripheral arterial disease should also be excluded. tory of grade 3 or 4 allergic reactions to compounds of similar chemical or biologic composition to cyclophosphamide (such as other alkylating agents) or methotrexate (such as other antimetabolites), Prior history of malignancy treated without curative intent, excluding nonmelanomatous skin cancer. Current use of anticoagulants is allowed as long as patients have been on a stable dose for more than two weeks with stable INR. participants with histologically or cytologically confirmed nonsmall cell Lung Cancer (NSCLC), Exclusion Criteria:, Active brain metastases or leptomeningeal metastases. Any serious or uncontrolled medical disorder, Prior malignancy active within the previous 3 years, Other protocol defined inclusion/exclusion criteria could apply. ',\n",
       " '5/101 (4.95%), BILATERAL CATARACTS * 0/101 (0.00%), ISCHEMIC COLITIS * 1/101 (1.98%), ISCHEMIC COLITIS * 1/101 (0.99%), ISCHEMIC COLITIS * 1/101 (0.00%), ACUTE MYELOID LEUKEMIA * 0/101 (0.00%), BREAST CANCER * 0/101 (0.00%), PRIMARY DCIS IN BRE ',\n",
       " 'Response is anyone who experiences CR, CR or SD in first 6 months. CR: Disappearance clinical evidence active tumor by evaluation, mammogram & ultrasound. dovitinib 500 mg single oral dose for 5 consecutive days followed by a 2-day rest period (5 days on/2 days off schedule) for every 28 day cycle. overall number of participants Analyzed: 19, Measure Type: Number, Unit of Measure: participants Complete Response (CR): 0, Partial Response (PR): 0, Stable Disease (SD: 1Outcome Measurement:, Percentage of participants with pathological complete response (pCR) in breast and axilla as Defined by  participants received placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles. paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses) overall number of participants Analyzed: 76, Measure Type: Number, Unit of Measure: percentage of participants 17.1 (9.82 to 27.25), Results 2:, Arm/Group Title: Placebo + Paclitaxel ',\n",
       " 'newly diagnosed with stage I-III cancer of the female breast. no prior history of carcinoma in situ, lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), or invasive breast cancer eligible. patients with basal cell and squamous cell cancer of the skin are eligible. ly one treatment arm is full axillary node dissection are not eligible. eligible patients must have arm measurements for axilla, elbow, and wrist that fall within the range for one of the six sleeve sizes. patients with double mastectomy, axillary node dissection and/or radiation on both arms are ineligible; patients who undergo these treatments (i.e., surgery and/or radiation) on the contralateral arm after registration to Step 2 are still eligible to remain in the study. however, it should be documented appropriately on form C-1628 at the conclusion of study participation. ',\n",
       " 'Fulvestrant + Everolimus was administered intramuscularly (in the gluteus maximus) in a loading dose schedule as follows: 500 mg in two divided doses-one on each side on day 1, then 250 mg on day 14 and then 250 mg on day 28 and every 4 weeks  3 days thereafter. ',\n",
       " 'the severity of radiation dermatitis was measured using the Radiation Dermatitis Severity Scale. the RDS scale is a revised form of the NIH Common Toxicity Criteria. the worst dermatitis (i.e., highest RDS score) at the end of treatment was used for the primary analysis of severity of radiation dermatitis in each treatment group. patients take placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT) (4-7 weeks) ',\n",
       " 'the time interval from randomization date to recurrence, progression or death is documented. for subjects without recurrence, progression or death, it is censored at the last valid tumor assessment. the result is based on primary analysis data cut. overall number of participants Analyzed: 307, Mean (95% Confidence Interval), Unit of Measure: months 8.8 (7.8 to 9.8), Results 2:, Arm/Group Title: lapatinib Plus Capecitabine, Arm/Group Description: lapatinib 1250 mg orally, once daily, continuously in 21 day cycles. ',\n",
       " 'participants with HER2+ breast cancer received treatment as follows:, cycles 1-3 (3-week cycles): trastuzumab 8 mg/kg, IV on Day 1 (Cycle 1 only; 6 mg/kg in Cycles 2 and 3), doxorubicin 60 mg/m2, IV, and paclitaxel 150 mg/m2, IV, on Day 1 followed by 2 weeks off. cycles 8-10 (3-week cycles): trastuzumab 6 mg/ IV and paclitaxel 150 mg/m2, IV, on Day 1 followed by 2 weeks off. Cycles 4-7 (3-week cycles): cyclophosphamide 600 mg/m2, IV, methotrexate 40 mg/m2, IV, and 5-fluorouracil 600 mg/m2, IV, followed by 1 week off. ',\n",
       " 'previous treatment with zoledronic acid every 3-4 weeks, for 9-12 infusions over no more than 15 months. previous treatment with zoledronic acid every 3-4 weeks, for no more than 15 months. osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures. recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants). women of childbearing potential not using effective methods of birth control. ',\n",
       " 'the severity of radiation dermatitis was measured using the Radiation Dermatitis Severity Scale. the RDS scale is a revised form of the NIH Common Toxicity Criteria. the worst dermatitis (i.e., highest RDS score) at the end of treatment was used for the primary analysis of severity of radiation dermatitis in each treatment group. patients take placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT) (4-7 weeks) ',\n",
       " \"no known soy intolerance, At increased risk of developing breast cancer in >= 1 previously unaffected breast, as defined by any of the following:, Gail score >= 1.66%, Gail score >= 0.1% for women age 20-29 years, Gail score >= 1.0% for women age 30-39 years, Estimated 5-year risk of developing breast cancer using the Claus model. ECOG performance status 0-1, Hemoglobin > 10.0 g/dL, Platelet count > 100,000/mm3, Absolute neutrophil count > 1,000/mm3, Creatinine  2.0 mg/dL, SGPT  82 U/L, SGOT  68 U/L, Bilirubin  3 mg/dL*. -containing foods, Fish oil supplements, Multivitamins, Vitamins C and E, Daily aspirin or nonsteroidal, Anti-inflammatory drugs, No concurrent investigational agents, No concurrent warfarin or other blood thinners, Female patient, Exclusion Criteria:, women previously diagnosed with breast cancer will not be eligible unless all systemic therapy (including endocrine therapy) was completed at least one year previously. patients with metastatic triple negative breast cancer (TNBC) eligible for treatment with paclitaxel. patients with pathologically documented metastatic triple negative breast cancer (TNBC) id is controlled. patients whose metastatic disease is TNBC are eligible even when their primary tumor expressed hormone receptors and/or HER2. if a taxane (i.e., paclitaxel or docetaxel) was administered as part of the (neo)adjuvant regimen, PD must have occurred > 12 months from the end of previous (neo)adjuvant treatment. serum bilirubin 1.5 x upper normal limit (UNL) except patients with Gilbert's syndrome, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) 2.5 x UNL but 5.0 x UNL in case of liver metastases. no history or evidence by CT scan or MRI, of brain metastases or leptomeningeal disease. lesions will not be considered as measurable disease. Less than four weeks since last radiotherapy (excluding palliative radiotherapy) \",\n",
       " 'newly diagnosed with stage I-III cancer of the female breast. no prior history of carcinoma in situ, lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), or invasive breast cancer eligible. patients with basal cell and squamous cell cancer of the skin are eligible. ly one treatment arm is full axillary node dissection are not eligible. eligible patients must have arm measurements for axilla, elbow, and wrist that fall within the range for one of the six sleeve sizes. patients with double mastectomy, axillary node dissection and/or radiation on both arms are ineligible; patients who undergo these treatments (i.e., surgery and/or radiation) on the contralateral arm after registration to Step 2 are still eligible to remain in the study. however, it should be documented appropriately on form C-1628 at the conclusion of study participation. ',\n",
       " 'Anaemia * 0/219 (0.00%), Febrile neutropenia * 26/219 (11.87%), Neutropenia * 7/219 (3.20%), Thrombocytopenia * 1/219 (0.46%), Cardiac failure * 2/219 (0.91%), Sinus tachycardia * 1/219 (0.46%), left ventricular dysfunction * 2/219 (0.91%), Abdominal pain * 1/219 (0.46%), Abdominal pain * 1/219 (0.46%), Co ',\n",
       " 'Total: 6, Atrial fibrillation 1/67 (1.49%), Ventricular fibrillation 1/67 (1.49%), Gastrointestinal perforation 1/67 (1.49%), Periproctitis 1/67 (1.49%), general physical health deterioration 1/67 (1.49%), Escherichia sepsis 1/67 (1.49%), Pneumonia 1/67 (1.49%), Tumour pain 1/67 (1.49%), Renal failure acute 1/67 ',\n",
       " 'intraductal arm, Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride. treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. ',\n",
       " 'participants with no recorded post-baseline tumor assessment had PFS censored at the day of last follow-up. participants lost to follow-up were censored at the date of last follow-up. roup received a drug regimen that consisted of both fulvestrant and dasatinib. Fulvestrant: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1 (28-day cycle). in subsequent cycles, 500 mg IM administered on Day 1, up to 2 years. ',\n",
       " '340/1612 (21.09%), Anemia 10/1612 (0.62%), Blood and lymphatic system disorders - Other, specify 3/1612 (0.19%), Febrile neutropenia 7/1612 (0.43%), Cardiac disorders - Other, specify 6/1612 (0.37%), Conduction disorder 2/1612 (0.12%), Myocardial infarction 6/1612 (0.37%), Palpitations 1/1612 (0.06%), Pericardial effusion 0/1612 (0.00%), ',\n",
       " 'resected specimen from surgery must be histologically free of invasive adenocarcinoma and ductal carcinoma in-situ. resected specimen must be histologically free of invasive adenocarcinoma and ductal carcinoma in-situ. patients of childbearing potential must implement adequate non-hormonal contraceptive measures during study treatment. patients of childbearing potential must implement adequate non-hormonal contraceptive measures. ticipation in another clinical trial with any investigational not marketed drug within 30 days before study entry. ',\n",
       " 'AZD8931 is an AE or laboratory abnormality related to AZD8931. CS rash remaining CTCAE grade 3 for 5 days despite optimal treatment. weekly visits for routine safety monitoring from Day 1 to Day 28 for each participant, Results 1:, Arm/Group Title: AZD8931 160mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle. Overall number of participants Analyzed: 6, Measure Type: Number, Unit of Measure: Number of Dose Limiting Toxicities Total: 2, Eye disorders: Keratitis: 1, Eye disorders: Photophobia: 1, Oesophagitis: 0, Infections and infestations: Rash pustular: 0_. ',\n",
       " 'inclusion criteria: Signed Informed Consent, ErbB2(HER2)overexpressing breast cancer. prior treatment of brain metastases with Whole Brain Radiotherapy. ',\n",
       " 'Adverse Events 1:, Total: 0/23 (0.00%)Adverse Events 1:, Total: 0/655 (0.00%), Adverse Events 2:, Total: 0/580 (0.00%) ',\n",
       " 'all patients will receive pegfilgrastim 6.0 mg sc on day #2 of each doxorubicin/cyclophosphamide neoadjuvant treatment cycle. patients will undergo either modified radical mastectomy or lumpectomy. ase and positive sentinel lymph node will undergo complete axillary lymph node dissection. overall number of participants Analyzed: 32, Measure Type: Number, Unit of Measure: percentage of participants 26_. ',\n",
       " 'patients with sentinel node biopsy positive disease must have undergone axillary dissection, Tumor must be confined to the breast without detected metastases elsewhere, T4 disease with minimal dermal invasion allowed, no bilateral breast cancer (except in situ carcinoma) no distant metastases, no skeletal pain of unknown cause, elevated alkaline phosphatase, or bone scan showing hot spots that cannot be ruled out as metastases by x-ray, MRI. chemotherapy regimen within 8 weeks after definitive surgery, Negative surgical margins, Axillary clearance with at least 6 lymph nodes examined OR negative sentinel node biopsy, Known HER2 status by immunohistochemistry or fluorescence in situ hybridization, Hormone receptor status:, Estrogen and progesterone receptor negative, Less than 10% positive tumor cells by immunohistochemistry, PATIENT CHARACTERISTICS:, Age:, Not specified, Sex:, Not specified, Men no prior or concurrent malignancy except adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or contralateral or ipsilateral in situ breast carcinoma. no psychiatric or addictive disorders that would preclude study, no non-malignant systemic disease that would preclude study, no non-malignant systemic disease that would preclude study. herapy for breast cancer. ',\n",
       " 'the study will be considered too toxic if >10% of enrolled patients have at least one of the following outcomes within 24 months of completion of PBI. the study will be deemed too toxic if >10% of enrolled patients have at least one of the following outcomes within 24 months of completion of PBI. Response Evaluation Criteria In Solid Tumors (RECIST) criteria defines when participants improve (\"respond\"), stay the same (\"stable\"), or worsen (\"progression\") during treatment. overall number of participants Analyzed: 35, Measure Type: Number, Unit of Measure: participants Complete Response: 1, Partial Response: 8, Stable Disease: 14, Progressive Disease: 9, Best Response Not Evaluable: 3. ',\n",
       " 'participants received docetaxel 100 mg/m2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles) participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal. ',\n",
       " 'inTERVENTION 1:, No Exercise, Multivitamin Arm + Calcitriol pill taken once per week, inTERVENTION 2:, Exercise, Exercise Arm: Exercise consisting of progressive walking and resistance band training, Calcitriol+ Exercise Arm: Calcitriol pill taken once per week + Exercise______________________________________________ ',\n",
       " 'metastatic breast cancer (stage IV) with measurable disease by RECIST criteria, no more than three prior chemotherapy regimens either in adjuvant or metastatic setting. no more than three prior chemotherapy regimens either in adjuvant or metastatic setting. HER-2 2+ by immunohistochemistry is usually negative by FISH. this confirmatory test should be performed when possible. patients may have received ies in adjuvant or metastatic setting. alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 2.5 x upper limit of normal (ULN) (or 5 x ULN in case of liver metastases); total bilirubin 1.5 mg/dL. women of child bearing potential must have documented negative pregnancy test within two weeks of study entry. platinum agent was used adjuvantly, the patient must have had at least 12 months disease-free interval prior to relapse. major medical conditions that might affect study participation (uncontrolled pulmonary, renal, or hepatic dysfunction, uncontrolled infection) ',\n",
       " '2/30 (6.67%), Dry Eyes [1]1/30 (3.33%), Diarrhea [2]1/30 (3.33%) ',\n",
       " 'Adverse Events 1:, Total: 14/41 (34.15%), Anemia 1/41 (2.44%), Febrile neutropenia 1/41 (2.44%), Eye disorders - Other, Visual disturbance 1/41 (2.44%), Abdominal pain 1/41 (2.44%), Constipation 1/41 (2.44%), Nausea 1/41 (2.44%), Fever 1/41 (2.44%), Pain 1/41 (2.44%), Skin infection 2/41 (4.88%), Alkaline phosphatase increased 1/41 ( ',\n",
       " 'inclusion criteria: Signed Informed Consent, ErbB2(HER2)overexpressing breast cancer. prior treatment of brain metastases with Whole Brain Radiotherapy. ',\n",
       " 'study drug 190 mg/m2 for 2 to 4 weeks. ',\n",
       " 'patients will be treated sequentially with preoperative trastuzumab and dose-dense ABI-007 followed by trastuzumab in combination with vinorelbine. patients will be treated sequentially with preoperative trastuzumab followed by trastuzumab in combination with vinorelbine. growth factor support with pegfilgrastim (Neulasta) is required 24 to 48 hours following completion of each cycle of ABI-007. beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles. overall number of participants Analyzed: 84, Mean (Standard Deviation), Unit of Measure: units on a scale -1.1 (1.9), Results 2:, Arm/Group Title: Arzoxifene, Arm/Group Description: LY353381, 20 mg daily, arzoxifene: one tablet daily, Overall Number of Participants Analyzed: 82, Mean (Standard Deviation), Unit of Measure: units on a scale -1.1 (1.9 ',\n",
       " 'CNS relapse is defined as the appearance of >=1 enhancing lesion measuring >=6 millimeters (mm) on T1Weighted (T1W) Magnetic Resonance Imaging (MRI) without CNS symptoms that were considered to be unequivocal based on all relevant radiological features. findings followed with a subsequent scan within 6 weeks. participants received daily dose of 5 tablets of lapatinib (1250 mg) at approximately the same time every day, either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast. participants also received capecitabine 2000 mg/m2) per day (divided and administered orally twice daily, 12 hours apart), for 14 days, every 21 days. eived an IV infusion of trastuzumab 8 mg/kg on Day 1 followed by a 6 mg/kg infusion every 3 weeks. participants also received capecitabine 2500 mg/m2 per day. participants received study medication until disease progression, unacceptable toxicity, or withdrawal. ',\n",
       " '59/373 (15.82%), Neutropenia 14/373 (3.75%), Febrile neutropenia 10/373 (2.68%), leukopenia 1/373 (0.27%), Anaemia 2/373 (0.54%), Lymphadenopathy 0/373 (0.00%), cardiac failure 2/373 (0.54%), Atrial fibrillation 1/373 (0.27%), Pericardial effusion 2/373 (0.54%), Cardiac failure congestive 1/373 (0.27%), Cardio ',\n",
       " 'Placebo + Paclitaxel received placebo (matching to ipatasertib) orally daily on days 1-21 of each 28-day cycle for 3 cycles. paclitaxel IV infusion QW for 3 cycles (12 total doses) ',\n",
       " 'Outcome Measurement:, Patients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at 12 Months or Clinical Disease Recurrence) Number of patients event-free, Time frame: 12 month period following randomisation, Results 1:, Arm/Group Title: Fulvestrant + Anastrozole, Arm/Group Description: fulvestrant 500 mg + anastrozole 1 mg, Overall Number of participants Analyze ',\n",
       " 'lapatinib 1500 mg, Participants received matching placebo orally once daily. treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer. ',\n",
       " 'women with a history of breast cancer (currently without malignant disease), Bothersome hot flashes (defined by their occurrence 28 times per week and of sufficient severity to make the patient desire therapeutic intervention) women with at least one ovary but without a uterus should be deemed postmenopausal by either age over 55 or combination of estrogen within a postmenopausal range. magnesium, no diabetes, no patients with conditions that are implicated in decreased absorption of magnesium (e.g., Crohn disease, ETOH abuse), no patients with diarrhea where magnesium might make it worse (per provider discretion), PRIOR CONCURRENT THERAPY:, none of the following current ( 28 days prior to registration) or planned therapies (tamoxifen, raloxifene, or aromatase inhibitors are allowed) is allowed, if it is planned to be continued at the same dose during the study period. no current use of magnesium for any indication (except one standard multiple vitamin dose is allowed per day) ',\n",
       " \"association between Ki-67 and Ki by FLT (KFLT) decline will be analyzed using the mid-P adjustment to Fisher's exact test to evaluate the potential clinical utility of change in FLT as a biomarker for early response. the surgery follows 1-7 days after the second FLT PET scan. disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. disease progression was defined as unequivocal progression of existing lesions. participants received placebo taken orally QD beginning at Cycle 1, Day 1 and fulvestrant 500 mg administered by IM injection at Cycle 1, Days 1 and 15, and then on day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor. overall number of participants Analyzed: 176, Median (95% Confidence Interval), Unit of Measure: months 5.39 (3.68 to 7.29), Results 2:, Arm/Group Title: Taselisib l Number of Participants Analyzed: 340, Median (95% Confidence Interval), Unit of Measure: months 7.43 (7.26 to 9.07) \",\n",
       " 'metastatic breast cancer (stage IV) with measurable disease by RECIST criteria, no more than three prior chemotherapy regimens either in adjuvant or metastatic setting. no more than three prior chemotherapy regimens either in adjuvant or metastatic setting. HER-2 2+ by immunohistochemistry is usually negative by FISH. this confirmatory test should be performed when possible. patients may have received ies in adjuvant or metastatic setting. alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 2.5 x upper limit of normal (ULN) (or 5 x ULN in case of liver metastases); total bilirubin 1.5 mg/dL. women of child bearing potential must have documented negative pregnancy test within two weeks of study entry. platinum agent was used adjuvantly, the patient must have had at least 12 months disease-free interval prior to relapse. major medical conditions that might affect study participation (uncontrolled pulmonary, renal, or hepatic dysfunction, uncontrolled infection) ',\n",
       " 'AZD8931 is an AE or laboratory abnormality related to AZD8931. CS rash remaining CTCAE grade 3 for 5 days despite optimal treatment. weekly visits for routine safety monitoring from Day 1 to Day 28 for each participant, Results 1:, Arm/Group Title: AZD8931 160mg (bd) plus weekly paclitaxel of 90mg/m2 on days 1, 8 and 15 of each 28 day cycle. Overall number of participants Analyzed: 6, Measure Type: Number, Unit of Measure: Number of Dose Limiting Toxicities Total: 2, Eye disorders: Keratitis: 1, Eye disorders: Photophobia: 1, Oesophagitis: 0, Infections and infestations: Rash pustular: 0_. ',\n",
       " 'tumor samples must be obtained from primary and/or metastatic sites. Participants must have measurable disease that is evaluable as per RECI. participants must have measurable disease that is evaluable. ST v1.1, Eastern Cooperative Oncology Group Performance Status of 0 or 1, Negative serum pregnancy test within 7 days of enrollment for pre-menopausal women and for women less than 12 months after the onset of menopause. participants with severe infection within 4 weeks prior to randomization are deemed to be at low risk for recurrence, Cardiopulmonary dysfunction, symptomatic pleural effusion, pericardial effusion, or ascites. participants with severe infection within 4 weeks prior to randomization, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia, Current severe, uncontrolled systemic disease. participants with known central nervous system disease, Leptomeningeal disease, History of autoimmune disease, Prior allogeneic stem cell or solid organ transplantation, Active tuberculosis, Receipt of a live, attenuated vaccine within 4 weeks prior to randomization or anticipation that such a live, attenuated vaccine will be required during the study. participants with known central nervous system disease, Leptomeningeal disease, History of autoimmune disease, history of  trial participants who are breastfeeding, or intending to become pregnant during the study. ',\n",
       " 'Dose Limiting Toxicity Incidence of Neratinib in combination with paclitaxel 80 mg/m2 IV on days 1, 8, and 15 of a 28 day cycle. overall number of participants Analyzed: 3, Measure Type: Count of participants, Unit of Measure: Participants 0 0.0%. ',\n",
       " 'participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of 24 weeks. ',\n",
       " 'female or male patients with diagnosis of invasive adenocarcinoma will be eligible. for the phase I portion, patients with any ER/PR/HER2 disease status are no longer eligible for hormonal therapy or HER2-targeted therapy. patients may be untreated in the metastatic setting or have received any number of prior cytotoxic regimens. prior taxane therapy, either in the adjuvant or in the metastatic setting, either deliver weekly, q 2 weeks or q 3 weeks, will be allowed. Adequate Organ Function, Total bilirubin 1.5 times the institutional Upper Limit of Normal (ULN), Hepatic enzymes 2.5 times the institutional ULN, Serum Na, K+, Mg2+, Phosphate and Ca2+ Lower Limit of Normal (LLN), Serum Creatinine 1.5 times the institutional ULN, Neutrophil count, Platelets, both Grade 0-1, PT (INR) and PTT Grade 0-1, except for patients on Coumadin or the concomitant use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving dasatinib therapy. antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of dasatinib. indinavir, nelfinavir, ritonavir, ciprofloxacin, ciprofloxacin, clarithromycin, diclofenac, doxycycline, enoxacin, imatinib, isoniazid, ketamine, nefazodone, nicardipine, propofol, quinidine, telithromycin, women of childbearing potential (WOC prior severe allergic reaction to paclitaxel therapy must be discontinued. prior hormonal therapy must be discontinued > or = to 3 weeks. patients with underlying cardiopulmonary dysfunction should be excluded from the study. subjects with hypokalemia or hypomagnesemia should be excluded from the study. ymptomatic brain metastases or brain metastases that have been previously irradiated are not grounds for trial exclusion. history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant. lusion criteria: Signed Informed Consent, ErbB2(HER2)overexpressing breast cancer. prior treatment of brain metastases with Whole Brain Radiotherapy (WBR) and stereotactic radiosurgery (SRS) ',\n",
       " 'HER2-overexpression breast cancer, Stage IV metastatic disease, Must have progressed on one prior trastuzumab treatment, no more than one prior trastuzumab based therapy regimen (either adjuvant or first-line), Must have received anthracycline and/or taxane based chemotherapy for adjuvant treatment of breast cancer. Must have (archived) tumour tissue sample available for central re-assessment of HER2-status. ed hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia. myocardial infarction within 6 months prior to randomisation. ',\n",
       " 'Placebo + Paclitaxel received placebo (matching to ipatasertib) orally daily on days 1-21 of each 28-day cycle for 3 cycles. paclitaxel IV infusion QW for 3 cycles (12 total doses) ',\n",
       " 'inclusion Criteria Phase 1, Age greater than/equal to 18 years, Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ, Patient desire to undergo breast surgery, 3. Patients will have provided informed consent to participate, documented by their signature on the study consent form 4. consent form will be given to the patient prior to enrollment. an eligibility worksheet will be completed for each patient prior to enrollment. ',\n",
       " 'INTERVENTION 1: Pemetrexed, 600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression. ',\n",
       " 'all patients will receive pegfilgrastim 6.0 mg sc on day #2 of each doxorubicin/cyclophosphamide neoadjuvant treatment cycle. patients will undergo either modified radical mastectomy or lumpectomy. ase and positive sentinel lymph node will undergo complete axillary lymph node dissection. overall number of participants Analyzed: 32, Measure Type: Number, Unit of Measure: percentage of participants 26_. ',\n",
       " 'participants received docetaxel 100 mg/m2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles) participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal. ',\n",
       " 'Nivolumab + Daratumumab (TNBC), Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24) ',\n",
       " 'lesions should not be amenable to surgery or radiation of curative intent. prior radiation therapy is allowed to less than 25% of the bone marrow. participants must have recovered from the toxic effects of the treatment. antitumoral hormonal treatment must be discontinued prior to enrollment. participants must test negative for pregnancy within 7 days of enrollment. participants must be at least 18 years of age. participants have received more than one combination of anthracycline plus taxane. have serious concomitant systemic disorders that compromise the safety of the participant. have a prior malignancy other than breast cancer, carcinoma in situ of the cervix or nonmelanoma skin cancer. are unable or unwilling to take folic acid, vitamin B12 supplementation, or dexamethasone. are unable or unwilling to take any other antitumor therapy. ',\n",
       " \"no known soy intolerance, At increased risk of developing breast cancer in >= 1 previously unaffected breast, as defined by any of the following:, Gail score >= 1.66%, Gail score >= 0.1% for women age 20-29 years, Gail score >= 1.0% for women age 30-39 years, Estimated 5-year risk of developing breast cancer using the Claus model. ECOG performance status 0-1, Hemoglobin > 10.0 g/dL, Platelet count > 100,000/mm3, Absolute neutrophil count > 1,000/mm3, Creatinine  2.0 mg/dL, SGPT  82 U/L, SGOT  68 U/L, Bilirubin  3 mg/dL*. -containing foods, Fish oil supplements, Multivitamins, Vitamins C and E, Daily aspirin or nonsteroidal, Anti-inflammatory drugs, No concurrent investigational agents, No concurrent warfarin or other blood thinners, Female patient, Exclusion Criteria:, women previously diagnosed with breast cancer will not be eligible unless all systemic therapy (including endocrine therapy) was completed at least one year previously. patients with metastatic triple negative breast cancer (TNBC) eligible for treatment with paclitaxel. patients with pathologically documented metastatic triple negative breast cancer (TNBC) id is controlled. patients whose metastatic disease is TNBC are eligible even when their primary tumor expressed hormone receptors and/or HER2. if a taxane (i.e., paclitaxel or docetaxel) was administered as part of the (neo)adjuvant regimen, PD must have occurred > 12 months from the end of previous (neo)adjuvant treatment. serum bilirubin 1.5 x upper normal limit (UNL) except patients with Gilbert's syndrome, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) 2.5 x UNL but 5.0 x UNL in case of liver metastases. no history or evidence by CT scan or MRI, of brain metastases or leptomeningeal disease. lesions will not be considered as measurable disease. Less than four weeks since last radiotherapy (excluding palliative radiotherapy) \",\n",
       " '0/34 (0.00%)Adverse Events 1:, Total: 6/62 (9.68%), Musculoskeletal * 1/62 (1.61%), Mood Alteration: Depression * 1/62 (1.61%), renal - Other * 1/62 (1.61%), Obstruction, GU: Uterus * 1/62 (1.61%), sexual * 0/62 (0.00%), Pulmonary/Upper Respiratory: Dyspnea * 1/62 (1.6 ',\n",
       " 'the participant had an OR if her best overall response was either a complete response (CR) or a partial response (PR) according to the RECIST. the participant had an OR if her best overall response was either a complete response (CR) or a partial response (PR) according to the RECIST. RECIST Ver.1.1 defines the period from the day of randomization until the first observation of lesion progression or death from any cause. disease progression is defined as PD according to RECIST Ver.1.1. esults 2:, Arm/Group Title: Paclitaxel (80 mg/m2) on days 1, 8 and 15 of a 28-day cycle. Overall number of participants Analyzed: 211, Median (95% Confidence Interval), Unit of Measure: months 8.5 (6.9 to 11.5) ',\n",
       " 'Adverse Events 1:, Total: 4/65 (6.15%), Thrombocytopenia * 0/65 (0.00%), Anaemia * 20/65 (0.00%), Febrile neutropenia * 20/65 (0.00%), leukopenia * 20/65 (0.00%), Neutropenia * 20/65 (0.00%), Pericardial effusion * 20/65 (0.00%), Tachycardia * 20/65 (0.00%), Nausea * 0/65 ',\n",
       " 'the log ratio of tumor size at Cycle 2 to tumor size at baseline is calculated for each participant. the tumor size is the sum of the target lesion measurements at each assessment. ly2523355 administered intravenously as a 1-hour infusion on days 1, 2 and 3 of a 21-day Cycle for 2 Cycles. Ixabepilone administered intravenously as a 3-hour infusion on Day 1 of a 21-day Cycle for 2 Cycles. participants may have remained on study drug for additional cycles until a criterion for study discontinuation was met. ',\n",
       " 'anemia 1/41 (2.44%), Febrile neutropenia 1/41 (2.44%), Eye disorders - Other, Visual disturbance 1/41 (2.44%), Abdominal pain 1/41 (2.44%), Constipation 1/41 (2.44%), Nausea 1/41 (2.44%), Fever 1/41 (2.44%), Pain 1/41 (2.44%), Skin infection 2/41 (4.88%), Alkaline phosphatase increased 1/41 (2.44%) ',\n",
       " '59/199 (29.65%), Anaemia 7/199 (3.52%), Thrombocytopenia 2/199 (1.01%), Atrial fibrillation 1/199 (0.50%), Cardiac arrest 1/199 (0.50%), Cardiopulmonary failure 1/199 (0.50%), Left ventricular failure 1/199 (0.50%), Supraventricular tachycardia 0/199 (0.00%), Ventricular tachycardia 1/199 (0.50%), Adverse Events ',\n",
       " 'Adverse Events 1:, Total: 13/61 (21.31%), Anaemia 1/61 (1.64%), Febrile neutropenia 1/61 (1.64%), Cardiac failure congestive 0/61 (0.00%), Pericardial effusion 0/61 (0.00%), Constipation 1/61 (1.64%), Intestinal perforation 1/61 (1.64%), Stomatitis 0/61 (0.00%), Non-cardiac chest pain 2/61 ( ',\n",
       " 'Total: 6, Atrial fibrillation 1/67 (1.49%), Ventricular fibrillation 1/67 (1.49%), Gastrointestinal perforation 1/67 (1.49%), Periproctitis 1/67 (1.49%), general physical health deterioration 1/67 (1.49%), Escherichia sepsis 1/67 (1.49%), Pneumonia 1/67 (1.49%), Tumour pain 1/67 (1.49%), Renal failure acute 1/67 ',\n",
       " 'Adverse Events 1:, Total: 14/41 (34.15%), Anemia 1/41 (2.44%), Febrile neutropenia 1/41 (2.44%), Eye disorders - Other, Visual disturbance 1/41 (2.44%), Abdominal pain 1/41 (2.44%), Constipation 1/41 (2.44%), Nausea 1/41 (2.44%), Fever 1/41 (2.44%), Pain 1/41 (2.44%), Skin infection 2/41 (4.88%), Alkaline phosphatase increased 1/41 ( ',\n",
       " '59/373 (15.82%), Neutropenia 14/373 (3.75%), Febrile neutropenia 10/373 (2.68%), leukopenia 1/373 (0.27%), Anaemia 2/373 (0.54%), Lymphadenopathy 0/373 (0.00%), cardiac failure 2/373 (0.54%), Atrial fibrillation 1/373 (0.27%), Pericardial effusion 2/373 (0.54%), Cardiac failure congestive 1/373 (0.27%), Cardio ',\n",
       " 'previous treatment with zoledronic acid every 3-4 weeks, for 9-12 infusions over no more than 15 months. previous treatment with zoledronic acid every 3-4 weeks, for no more than 15 months. osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures. recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants). women of childbearing potential not using effective methods of birth control. ',\n",
       " \"association between Ki-67 and Ki by FLT (KFLT) decline will be analyzed using the mid-P adjustment to Fisher's exact test to evaluate the potential clinical utility of change in FLT as a biomarker for early response. the surgery follows 1-7 days after the second FLT PET scan. disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. disease progression was defined as unequivocal progression of existing lesions. participants received placebo taken orally QD beginning at Cycle 1, Day 1 and fulvestrant 500 mg administered by IM injection at Cycle 1, Days 1 and 15, and then on day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor. overall number of participants Analyzed: 176, Median (95% Confidence Interval), Unit of Measure: months 5.39 (3.68 to 7.29), Results 2:, Arm/Group Title: Taselisib l Number of Participants Analyzed: 340, Median (95% Confidence Interval), Unit of Measure: months 7.43 (7.26 to 9.07) \",\n",
       " 'Placebo and Paclitaxel, Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received study drug plus paclitaxel, INTERVENTION 2:, Placebo and Paclitaxel, Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received placebo plus paclitaxel. ',\n",
       " 'inTERVENTION 1:, No Exercise, Multivitamin Arm + Calcitriol pill taken once per week, inTERVENTION 2:, Exercise, Exercise Arm: Exercise consisting of progressive walking and resistance band training, Calcitriol+ Exercise Arm: Calcitriol pill taken once per week + Exercise______________________________________________ ',\n",
       " 'atrial fibrillation 0/12 (0.00%), Congestive Heart Failure [2]0/12 (0.00%), Diverticulitis 0/12 (0.00%), Cholecystitis 0/12 (0.00%), Urosepsis 2/12 (16.67%), Rash [3]0/12 (0.00%)Adverse Events 1:, Total: 18/65 (27.69%), Anaemia 5/65 (7.69%), Febrile neutropenia 1/65 (1.54% ing 1/66 (1.52%), Condition aggravated 1/66 (1.52%), complication 1/66 (1.52%) ',\n",
       " 'participants took lapatinib 1250 mg and capecitabine 2000 mg/m2. participants took lapatinib twice daily on the first day through the fourteenth day of each 21-day cycle. ',\n",
       " 'women >=18 years of age; newly diagnosed; infiltrating breast cancer. exclusion Criteria: evidence of metastatic disease, except ipsilateral lymph nodes. ',\n",
       " 'Febrile Neutropenia * 3/56 (5.36%), Neutropenia * 1/56 (1.79%), Atrial Fibrillation * 1/56 (1.79%), Coronary Artery Disease * 1/56 (1.79%), Constipation * 1/56 (1.79%), Chest Pain * 1/56 (1.79%), Non-Cardiac Chest Pain * 1/56 (1.79%), Edema due to Cardiac Disease * 1/56 (1.79%), Cellulitis * ',\n",
       " '17/65 (26.15%), Febrile neutropenia 3/65 (4.62%), Neutropenia 2/65 (3.08%), Pancytopenia 1/65 (1.54%), Thrombocytopenia 1/65 (1.54%), Cardiac arrest 2/65 (3.08%), Myocardial infarction 1/65 (1.54%), Diarrhoea 5/65 (7.69%), Stomatitis 1/65 (1.54%), Vomiting  c valve incompetence 1/238 (0.42%), Atrial fibrillation 0/238 (0.00%), Cardiac arrest 0/238 (0.00%), cardiac arrest 0/238 (0.00%). ',\n",
       " 'complete Response is the total disappearance of clinically and radiologically detectable disease for at least 4 weeks. partial Response is at least a 50% reduction of all measurable lesions. no new lesions appearing for at least four weeks. ill met eligibility laboratory and performance status criteria. overall number of participants Analyzed: 42, Measure Type: Number, Unit of Measure: percentage of patients 28 (16 to 42), Results 2:, Arm/Group Title: Arm B - Docetaxel Then Liposomal Doxorubicin, Arm/Group Description: Weekly docetaxel 36 mg/m2 IV over 30 minutes on days 1, 8 and 15 followed by one week rest, administered on a q 28 day cycle. ',\n",
       " 'objective response rate was defined as percentage of participants achieving complete response (CR) or partial response (PR) per RECIST 1.1 for target lesions. CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions. AZD1775 will be administered 200 mg as twice daily oral dosing schedule. at least 10 patients will undergo a research biopsy within 5-48 hours after beginning cisplatin (Cycle 1 Day 1) and then again within 5-8 hours after the last dose of AZD1775 in cycle 2 (Cycle 2 Day 3). the proportions of SLNs flagged will be compared using a two-sided 95% confidence interval. participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. ',\n",
       " 'INTERVENTION 1: Pemetrexed, 600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression. ',\n",
       " 'adult women must have at least one lesion that can be accurately measured or bone lesions in the absence of disease. prior treatment for breast cancer with endocrine therapy (adjuvant or metastatic settings) is allowed but should be discontinued. anticancer therapy for locally advanced or metastatic breast cancer except for prior hormonal therapy. radiotherapy to 25% of the bone marrow within 4 weeks prior to randomization. ',\n",
       " '3/39 (7.69%), Neutropenia 1/39 (2.56%), Bilateral Pulmonary Thromboembolism 0/39 (0.00%), Fever 1/39 (2.56%), Empyema associated with a permanent thoracic catheter 1/39 (2.56%), Adverse Events 2:, Total: 3/21 (14.29%), Neutropenia 1/21 (4.76%), Bilateral Pulmonary Thromboembolism 1/21 (4.76%), Fever 1/21 ( ',\n",
       " '3.6 mg/kg of trastuzumab emtansine was administered to participants intravenously (IV) over 30-90 minutes on day 1 of 21 day cycle and was repeated every 3 weeks. overall number of participants Analyzed: 70, Measure Type: Count of Participants, Unit of Measure: Participants Grade 1: 53 75.7%, Grade 2: 40 57.1%, Grade 3: 18 25.7%, Grade 4: 2 2.9%, Grade 5: 12 17.1%. ',\n",
       " 'Abraxane, Avastin and Gemcitabine each treatment cycle is 28 days. participants will be treated until disease progression. ',\n",
       " 'Adverse Events 1:, Total: 13/61 (21.31%), Anaemia 1/61 (1.64%), Febrile neutropenia 1/61 (1.64%), Cardiac failure congestive 0/61 (0.00%), Pericardial effusion 0/61 (0.00%), Constipation 1/61 (1.64%), Intestinal perforation 1/61 (1.64%), Stomatitis 0/61 (0.00%), Non-cardiac chest pain 2/61 ( ',\n",
       " 'metastases must have demonstrated progression of brain metastases after prior treatment for brain metastases. new lesions in the CNS on an imaging study (contrast-enhanced CT scan or MRI), Progressive lesions on an imaging study (contrast-enhanced CT scan or MRI), New or progressive lesions that do not meet measurable disease definition allowed. ECOG performance status 0-2, Life expectancy 1 month, Hemoglobin 10 g/dL (transfusion allowed), ANC 1,500/mm3, Granulocyte count 1,500/mm3, Platelet count 100,000/mm3, Creatinine 1.5 mg/dL, Total bilirubin 1.5 times upper limit of normal (ULN), AST and ALT 3 times ULN. patients on an enzyme-inducing anti-epileptic agent (EIAE) or valproic acid are eligible if they are switched to an alternate non-EIAE medication, Concurrent coumadin allowed, No prophylactic use of filgrastim (G-CSF) during first course of treatment. ',\n",
       " 'a patient has clinical benefit from treatment if CR + PR + SD > 24 weeks. a patient has clinical benefit from treatment if CR + PR + SD > 24 weeks. ',\n",
       " 'subjects with operable, node-positive or high-risk node-negative breast carcinoma are eligible for the study. subjects must demonstrate willingness to and be able to participate in the study and to adhere to dose and visit schedules. subjects must be of female gender and >= 18 years of age. Subjects must have had complete resection (R0) of primary tumor and axillary lymph nodes (or must have negative sentinel node[s]), Baseline left ventricular ejection fraction (LVEF) by multiple gated acquisition scan or echocardiogram (ECHO) >=55%, Easter Cooperative Oncology Group (ECOG)-performance status of 0-1, Adequate postoperative bone marrow function with neutrophils >=1.5 x 109/l, plate tential (including women who are less than one year postmenopausal and will be sexually active during the study) must agree to use a medically accepted method of contraception, while receiving protocol-specified medication and for 30 days (or as per local requirements) after stopping the medication or be surgically sterilized prior to screening. subject who meets any of the following exclusion criteria will be disqualified from participation in the study. active angina pectoris requiring medication, serious ventricular arrhythmias requiring medication or implantable cardioverter-defibrillator (ICD) therapy, uncontrolled supraventricular arrhythmias, clinically significant valvular disease, poorly controlled arterial hypertension (systolic blood pressure (BP) >180 mmHg, diastolic BP >100 mmHg), Sensory/motor neuropathy > grade 2 as defined by national cancer institure dy, Is on staff, affiliated with, or a family member of staff personnel directly involved with this study, Usage of any investigational product within 30 days prior to enrollment. this would not prohibit the patient from participating in a quality of life, questionnaire, blood collection, or observational study. ',\n",
       " 'an objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR) each patient with measurable disease at baseline was assessed for OR from the sequence of Response Evaluation Criteria in Solid Tumors (RECIST) scans were performed every 12 weeks (+/- 2weeks) from randomization data up to data cut-off (19th march 2008), Results 1:, Arm/Group Title: Fulvestrant 250 mg, Arm/Group Description: Fulvestrant 250 OR is defined as complete response (CR) and partial response (PR) and was assessed according to the Response Evaluation Criteria in Solid Tumours version 1.0 (RECIST) ',\n",
       " 'pathologically confirmed breast cancer determined to be a candidate for primary systemic (neoadjuvant) therapy and surgical resection of residual primary tumor following completion of neoadjuvant therapy. locally advanced breast cancer, not stage IV, with a tumor size >= 2 cm (as measured on imaging or estimated by physical exam) institutional limits OR creatinine clearance >= 30 mL/min/1.73 m2 for patients with creatinine levels above institutional normal. If female, postmenopausal for minimum of one year, OR surgically sterile, OR not pregnant, confirmed by institutional standard of care pregnancy test. Able to understand and willing to sign a written informed consent document and a HIPAA authorization. ents, Medically unstable, Condition requiring anesthesia for PET scanning and/or unable to lie still for 1.5 hours. history of allergic reactions attributed to compounds of similar chemical or biologic composition to F-18 fluorothymidine, Pregnant or nursing, Previous malignancy, other than basal cell carcinoma of the skin or in situ carcinoma of the cervix. ',\n",
       " 'the study will be considered too toxic if >10% of enrolled patients have at least one of the following outcomes within 24 months of completion of PBI. the study will be deemed too toxic if >10% of enrolled patients have at least one of the following outcomes within 24 months of completion of PBI. Response Evaluation Criteria In Solid Tumors (RECIST) criteria defines when participants improve (\"respond\"), stay the same (\"stable\"), or worsen (\"progression\") during treatment. overall number of participants Analyzed: 35, Measure Type: Number, Unit of Measure: participants Complete Response: 1, Partial Response: 8, Stable Disease: 14, Progressive Disease: 9, Best Response Not Evaluable: 3. ',\n",
       " 'CNS relapse is defined as the appearance of >=1 enhancing lesion measuring >=6 millimeters (mm) on T1Weighted (T1W) Magnetic Resonance Imaging (MRI) without CNS symptoms that were considered to be unequivocal based on all relevant radiological features. findings followed with a subsequent scan within 6 weeks. participants received daily dose of 5 tablets of lapatinib (1250 mg) at approximately the same time every day, either 1 hour (or more) before breakfast or 1 hour (or more) after breakfast. participants also received capecitabine 2000 mg/m2) per day (divided and administered orally twice daily, 12 hours apart), for 14 days, every 21 days. eived an IV infusion of trastuzumab 8 mg/kg on Day 1 followed by a 6 mg/kg infusion every 3 weeks. participants also received capecitabine 2500 mg/m2 per day. participants received study medication until disease progression, unacceptable toxicity, or withdrawal. ',\n",
       " 'participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of 24 weeks. ',\n",
       " 'febrrile neutropenia grade 3 3/48 (6.25%), Neutropenia grade 3 1/48 (2.08%), hypersensibility reaction grade 3 2/48 (4.17%), Palmoplantar erythrodysesthesia grade 3, stomatitis grade 3 1/48 (2.08%), Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%), Catheter - related infection grade 3 1/48 (2.08%)Adverse Events 1:, Total: Conjunctivitis 1/532 (0.19%), Abdominal pain 1/532 (0.19%), Anal fissure 1/532 (0.19%), Constipation 1/532 (0.19%), Diarrhoea 6/532 (1.13%) ',\n",
       " 'the achievement of a pCR is associated with a favorable long-term prognosis in all breast cancer subtypes. a pCR is commonly defined as the absence of residual invasive cancer in both the breast and axillary lymph nodes. articipants 35 35.7%, Results 2:, Arm/Group Title: Arm 2/3 (Nab-Paclitaxel/AC+PEG-G), Arm/Group Description: Received nP x 12 followed by ddAC x 6 first followed by nP x 12 without bevacizumab. overall number of participants Analyzed: 113, Measure Type: Count of Participants, Unit of Measure: Participants 24 21.2%Outcome Measure pe: Number, Unit of Measure: percentage of patients 79.6. ',\n",
       " 'trial was designed as a single-stage phase II rather than usual two-stage design because of the progression free survival primary endpoint. it is impractical to wait to assess PFS for patients in the first stage. the trial was designed as a single-stage phase II rather than usual two-stage design because of the primary endpoint. measure: months 14.3 (9.3 to 35) ',\n",
       " 'a patient has clinical benefit from treatment if CR + PR + SD > 24 weeks. a patient has clinical benefit from treatment if CR + PR + SD > 24 weeks. ']"
      ]
     },
     "execution_count": 43,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# val_LTS = Long_texts_Summarizartion(Data.val_df.MergedColumn.tolist())\n",
    "# val_LTS.texts_summary"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "193be50e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Index: 5499"
     ]
    },
    {
     "data": {
      "text/plain": [
       "['Adverse Events 1:, Total: 0/733 (0.00%), Adverse Events 2:, Total: 0/765 (0.00%)Adverse Events 1:, Total: 0/88 (0.00%), Adverse Events 2:, Total: 0/86 (0.00%). ',\n",
       " \"participants must have histologically or cytologically proven metastatic or locally advanced solid tumors. no standard therapy exists or standard therapy has failed. disease must be measurable with at least 1 uni-dimensional measurable lesion by RECIST 1.1, except for participants with metastatic castrate-resistant prostate cancer. participants in the MBC cohort must have relapsed, refractory, or progressive disease following last line of treatment. Availability of tumor archival material or fresh biopsies is mandatory for eligibility in the expansion cohorts. participants in the NSCLC cohort will only be enrolled in USA, NSCLC first line: Stage IV or recurrent NSCLC that is histologically proven. participants should have received no more than 1 line of treatment for metastatic disease. participants with gastric cancer can enter in the study if their white blood cell (WBC) and lymphocyte count is as defined in the protocol, MBC: Participants must have histologically confirmed locally advanced or MBC. participants must have received no more than 3 prior lines of cytotoxic therapy for metastatic disease. pansion cohorts include gastric and GEJ cancer (third line), ovarian cancer (platinum Refractory + liposomal doxorubicin), urothelial carcinoma, and HNSCC. other protocol defined inclusion criteria for expansion phase could apply. basal or squamous cell carcinoma of the skin or cervical carcinoma in situ, Rapidly progressive disease (for example, tumor lysis syndrome), Active or history of central nervous system metastases, Receipt of any organ transplantation including allogeneic stem-cell transplantation. Known severe hypersensitivity reactions to monoclonal antibodies, any history of anaphylaxis, or uncontrolled asthma, Persisting toxicity related to prior therapy greater than Grade 1 NCI-CTCAE inflammatory bowel disease may impair Participant's tolerance of trial treatment. legal incapacity or limited legal capacity, non-oncology vaccine therapies for prevention of infection disease. vaccination while on study is also prohibited except for administration of the inactivated influenza vaccine. \",\n",
       " 'oral lapatinib, oral tamoxifen citrate, given orally, citrate, given orally. lapatinib ditosylate, given orally, citrate, given orally. ',\n",
       " 'treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity. cyclophosphamide, paclitaxel, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab subjects 98 (92.2 to 99.5). subjects 98 (92.2 to 99.5) ',\n",
       " 'Adverse Events 1:, Total: 0/34 (0.00%)Adverse Events 1:, Total: 0/1 (0.00%)Adverse Events 1:, Total: 0/1 (0.00%) ',\n",
       " 'change in Ki67 expression in tumors with 7 days of pre-surgical tamoxifen. all patients will take tamoxifen 20 mg po daily for 7 days prior to surgery. ',\n",
       " 'women may receive the AI on this study as initial adjuvant hormonal treatment or following tamoxifen. patients may have received preoperative chemotherapy, Postmenopausal status, defined as: >= 60 years of age; or  60 years of age and amenorrheic for >= 12 months prior to day 1 if intact uterus/ovaries. istory of bilateral oophorectomy; or prior radiation castration with amenorrhea for at least 6 months; or prior radiation castration with amenorrhea for at least 6 months;  60 years of age and taking medication designed to suppress ovarian function. women would have had to be taking the drug for at least 30 days prior to day 1. current bisphosphonate use (oral or intravenous); prior bisphosphonate users would be eligible as long as the use was > 1 month ago for oral bisphosphonates. prior bisphosphonate users would be eligible as long as the use was > 12 months ago for intravenous bisphosphonates. ',\n",
       " 'participants must have histologically or cytologically confirmed breast cancer or non-hodgkin lymphoma. doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2. doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2 and docetaxel 75 mg/m2. ncer in marrow), absolute neutrophil count >1,500/mcL (unless due to cancer in marrow), platelets >100,000/mcL (unless due to cancer in marrow), total bilirubin 1.5 X normal institutional limits, aspartate aminotransferase (AST) or serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase patients with known brain metastases should be excluded from this clinical trial. progressive neurologic dysfunction would confound evaluation of neuro-cognitive outcomes. patients requiring ongoing pharmacologic treatment of dementia excluded. e heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations would limit compliance with study requirements. pregnant women are excluded from this study because the chemotherapy agents have known teratogenic or abortifacient effects. allergy to all three antibiotics: cephalosporin, trimethoprim/sulfamethoxazole, and levofloxacin. non-English speaking patients without adequate interpreter assistance. ',\n",
       " 'a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 will be explored and will follow a 6 + 3 dose de-escalation design. participants with one of the following tumor types will be eligible for enrollment. ',\n",
       " \"severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 4.03. an AE that met one or more of the following outcomes was classified as serious:, Fatal, Life-threatening, Disabling/incapacitating. st Cancer (mBC) population, metastatic Urothelial cancer (mUC) population, and overall safety population. 68 participants with non-TNBC were enrolled in the study and received at least one dose of SG. hese 68 participants, 54 were confirmed as Hormone receptor-positive/Human epidermal growth factor receptor 2-negative (HR+/HER2-), had progressed on at least one prior hormonal therapy in the metastatic setting. these 54 participants were included in the analysis of safety and were referred to as the HR+/HER2-mBC Population. PR was defined by a 30% or more decrease in the sum of the longest diameters (SLD) + sum of shortest diameters (SSD) of target lesions, taking as reference the baseline SLD+SSD. participants with breast cancer who received talazoparib capsules at a dose of either 600 mcg/day, 900 mcg/day, 1000 mcg/day, 1100 mcg/day. a dose of either 25 mcg/day, 50 mcg/day, 100 mcg/day, 200 mcg/day, 200 mcg/day, 400 mcg/day, 600 mcg/day, 900 mcg/day, 1000 mcg/day, 1100 mcg/day. \",\n",
       " 'change in total body lean mass measured by dual energy x-ray absorptiometry (DEXA) from baseline to 4 months. time frame: Baseline to four months. ',\n",
       " '8/20 (40.00%), Anaemia 1/20 (5.00%), Lymphadenopathy 0/4 (0.00%), Thrombocytopenia 0/4 (0.00%), Acute coronary syndrome 0/4 (0.00%), Atrial fibrillation 0/4 (0.00%), Cardiac failure congestive 0/4 (0.00%), Cardiac tamponade 0/4 (0.00%), Adverse Events 2:, Total: 8/20 (40.00%), Anaemia 1 ',\n",
       " 'patients 18 years of age or older are eligible for the study. patients undergoing skin-sparing mastectomy are eligible for the study. patients who have not undergone autologous tissue breast reconstruction. must have completed surgery for stage I-III breast cancer. must have a plasma c-reactive protein level of >3mg/L. must have score of 4 (out of 10 points, 0 being no fatigue and 10 being severe, incapacitating fatigue) on a single Item Screening Scale for Fatigue. uncontrolled cardiovascular, metabolic, pulmonary or renal disease (as determined by medical history and laboratory testing), Current or past history of schizophrenia, Individuals with bipolar disorder who have experienced a manic episode within 6 months of study entry, or at the discretion of the study doctor. Individuals receiving antidepressants, mood stabilizers, antipsychotic medications or benzodiazepines or drugs known to affect the immune system (e.g. glucocorticoids, methotrexate), or at the ',\n",
       " 'Adverse Events 1:, Total: 0/7 (0.00%)Adverse Events 1:, Total: 0/11 (0.00%), Adverse Events 2:, Total: 0/11 (0.00%). ',\n",
       " 'the baseline dose is 100 mg three times daily for four months. the baseline dose is 100 mg three times daily for four months. participants in Cohort 1 received necitumumab Process C drug product. ',\n",
       " 'phase I part: patients with advanced/metastatic solid tumors, with at least one measurable lesion. phase II part: patients with advanced/metastatic solid tumors, with at least one measurable lesion. only patients with EGFR mutation-negative tumor are eligible. if more extensive EGFR mutation testing has been performed, the tumor must not harbor any known activating EGFR mutations in Exons 18-21. all patients must be tested for EGFR mutational status and for ALK translocation status if no mutation is detected in EGFR. patients with a corresponding inhibitor must have had disease progression following treatment with a corresponding inhibitor. patients must not be at short term risk for life threatening complications. patients must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy. exceptions may be granted after documented discussion with Novartis. subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. subjects with vitiligo, type I diabetes mellitus, psoriasis not requiring systemic treatment are permitted to enroll. eatment with any immunosuppressive medication (other than steroids) within 4 weeks of initiation of study treatment. use of any vaccines against infectious diseases (e.g. influenza, varicella, pneumococcus) rsing, Negative pregnancy test, Fertile patients must use effective contraception, Creatinine clearance 30 mL/min, No hypersensitivity to magnesium oxide, No medical or other condition(s) that may compromise the objectives of the study, PRIOR CONCURRENT THERAPY:, See Disease Characteristics, More than 4 weeks since prior and no concurrent antineoplastic chemotherapy, androgens, estrogens, progestational agents, or gabapentin. ',\n",
       " 'adults with histologically or cytologically confirmed breast adenocarcinoma, radiographic evidence of at least one bone mets, Easter Cooperative Oncology Group status of 0, 1 or 2; adequate organ function, Exclusion Criteria:, Current or prior IV bisphosphonate administration, current or prior oral bisphosphonates for bone mets, life expectancy of less than 6 monthsInclusion Criteria:, Patients must have disease that is metastatic (stage IV), HER2/neu negative disease histologic and/or cytologic confirmation of metastatic disease is encouraged whenever feasible, furthermore, the biopsy should confirm that the primary tumor is ER and/or PR-positive and HER2/neu negative. measurable disease (RECIST 1.1) or non-measurable (assessable) disease, patients must have had progressive disease during at least one line of endocrine therapy for metastatic disease or have recurrent disease while or within 12 months of receiving adjuvant endocrine therapy  patients must have normal organ and marrow function as defined below. postmenopausal status, defined as 60 years and older, being 45 years and older, having amenorrhea x 12 months or follicle stimulating hormone levels within postmenopausal range. on combination of exemestane with everolimus less than 4 weeks prior to study entry and discontinued everolimus due to poor tolerability. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris. ',\n",
       " 'the EORTC CIPN20 scoring algorithm was used for the sensory (items 31-36, 39, 40 and 48) subscale scores on a 0-100 scale. the aAUCpa for the subscale is calculated as the average of each AUC between each sequential assessment from pre-treatment-initiation to the week-12 assessment. positive scores represent symptoms has improved from baseline and negative scores represent symptoms has worsen from baseline. therapy repeats every week for a planned course of 12 weeks of adjuvant paclitaxel. overall number of participants Analyzed: 19, Median (Full Range), Unit of Measure: Average(subscale value*assessment) -1.4 (-11.7 to 6.8), Results 2:, Arm/Group Title: Arm II (Control), Arm/Group Description: Patients receive the standard of care only (paclitaxel at a dose of 80 mg/m2 IV) every week for ',\n",
       " \"if a taxane had been administered in the neoadjuvant or adjuvant setting, progression must have occurred >12 months after completion of this treatment. radiotherapy as palliative treatment for painful metastatic disease is permitted but must have been stopped within 2 weeks prior to any investigational treatment. ning disease is considered to be inapplicable to hormonal therapy. ning disease must have been stopped before the first dose of investigational treatment. an investigational drug within 30 days or five half-lives preceding the first dose of investigational treatment. unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or prior anti-cancer treatment. subjects with ulcerative colitis are excluded. metastases or leptomeningeal carcinomatosis would make subject inappropriate for study participation or any serious medical disorder that would interfere with subject's safety. subject must have histologically confirmed invasive breast cancer with Stage IV disease at primary diagnosis or at relapse after curative-intent surgery. neoplastic nature of the disease should have been confirmed by cytology or histology. subjects must have received no more than one prior chemotherapeutic regimen in the metastatic setting. prior therapy with radiation for this breast cancer population was permitted if it was administered in the neoadjuvant or adjuvant non metastatic setting. subject must have completed radiation treatment and recovered from all related toxicities. subject must have received all prior chemo treatment at least 4 weeks prior to enrollment in this study. prior therapy with trastuzumab in the neoadjuvant, adjuvant or metastatic setting was permitted. prior diagnosis of cancer was allowed as long as the subject was free of disease for 5 years. subjects with completely resected basal or squamous cell skin cancer, thyroid cancer or successfully treated cervical carcinoma in-situ were allowed into the study. women with oligomenorrhoea (severe), women who were perimenopausal and young women who had begun to menstruate must provide a negative serum pregnancy test at Screening. subjects must provide a negative serum pregnancy test and agree to 1 of the following: Complete abstinence from intercourse from 2 weeks prior to administration of the first dose of study medication until 5 days after the final dose of study medication. e Investigator to have a life expectancy of 6 months. Subjects must have had normal organ and marrow function as below. subject must have been free of gastrointestinal diseases that impede swallowing and retaining oral medications. bisphosphonate therapy for bone metastases was allowed; treatment must be initiated prior to the first dose of study medication. subjects without bone disease, except for osteoporosis, were included in the study if they met the following criteria. subjects who received more than one prior chemotherapeutic regimen were not eligible for the study. this included human immunodeficiency virus-positive subjects receiving combination anti-retroviral therapy because of possible pharmacokinetic interactions with lapatinib. uncontrolled inter-current illness includes, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would have limited compliance with study requirements. subjects with diseases affecting gastrointestinal function resulting in an inability to take oral medication. ation, prior surgical procedures affecting absorption e.g. gastric resection and uncontrolled inflammatory bowel disease (e.g., Crohn's, ulcerative colitis). subjects who had been disease-free for 5 years, or subjects with completely resected basal or squamous cell skin cancer, thyroid cancer or successfully treated cervical carcinoma in situ were eligible if it had been at least 1 year since definitive surgery. clinical investigator's Brochure (IB), SPM, and the nab-paclitaxel product label. \",\n",
       " 'inTERVENTION 2:, Part 1: Cohort 2a, MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW, inTERVENTION 2:, Part 1: Cohort 2a, MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW. ',\n",
       " 'a non-serious adverse event is any untoward medical occurrence. a serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions. congenital anomaly/birth defect or important medical events that jeopardize the patient or subject may require medical or surgical intervention. Total Dose 2 x 108 IU, Arm/Group Description: Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 1 injection (I injection = 2 x 108 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. patients with stable disease may continue to receive vaccine for up to 6 monthly doses. ',\n",
       " '0/4 (0.00%), Anaemia 0/4 (0.00%), Febrile neutropenia 0/4 (0.00%), Leukocytosis 0/4 (0.00%), Neutropenia 0/4 (0.00%), Pancytopenia 0/4 (0.00%), Acute coronary syndrome 0/4 (0.00%), Atrial fibrillation 0/4 (0.00%), Cardiac arrest 0/4 (0.00%), Pericardial effusion 0/4 (0.00%), Ad ',\n",
       " 'Progression Free Survival (PFS) was defined as the time from first study drug dosing (during the maintenance treatment phase) to the first documented disease progression or death, whichever occurred first. Progressive Disease (PD) was defined as a 20 percent increase in the sum of the Longest Diameter (LD) of the target lesions taking as reference the smallest sum LD recorded or appearance of new lesions. ll participants received bevacizumab 15 mg/kg IV on Day 1 of each 3 week cycle for a minimum of 3 cycles and a maximum of 6 cycles or until disease progression, unacceptable toxicity or participant request for withdrawal. participants with an objective response (PR or CR) or SD received 15 mg/kg bevacizumab IV on Day 1 of each 3 week cycle for a minimum of 3 cycles and a maximum of 6 cycles. ek cycle for a minimum of 3 cycles and a maximum of 6 cycles or until disease progression, unacceptable toxicity or withdrawal, whichever occurred first. participants with an objective response were randomized to receive bevacizumab 15 mg/kg IV on Day 1 of each 3-week cycle plus capecitabine 1000 mg/m2 twice daily on Days 1 to 14 of each 3 week cycle. if one of the drugs was discontinued before disease progression, treatment was continued with the second drug until disease progression, unacceptable ',\n",
       " 'Febrile neutropenia * 2/5 (40.00%), Anaemia * 0/4 (0.00%), Vertigo * 0/4 (0.00%), Nausea * 0/4 (0.00%), Stomatitis * 0/4 (0.00%), Vomiting * 0/4 (0.00%), Disease progression * 0/4 (0.00%), Mucosal inflammation * 0/4 (0.00%), Fatigue * 0/4 (0.00%), Pyrexia * 0/4 (0.00%), Ga ',\n",
       " 'Benign breast disease amenable to hormonal therapy. high risk breast lesions like epitheliosis, atypia or atypical hyperplasia. ECOG performance status 0 or 1, Pre- or post-menopausal, Must possess a compact disc player, Able to complete questionnaires alone or with assistance, No active medical conditions preventing compliance with a practice of slow deep breathing including active asthma, chronic obstructive pulmonary disease, or congestive heart failure. ntidepressants started within the past 30 days allowed. no concurrent hormonal agents and/or antineoplastic chemotherapy are allowed. ',\n",
       " 'Febrile neutropenia * 2/5 (40.00%), Anaemia * 0/4 (0.00%), Vertigo * 0/4 (0.00%), Nausea * 0/4 (0.00%), Stomatitis * 0/4 (0.00%), Vomiting * 0/4 (0.00%), Disease progression * 0/4 (0.00%), Mucosal inflammation * 0/4 (0.00%), Fatigue * 0/4 (0.00%), Pyrexia * 0/4 (0.00%), Ga ',\n",
       " \"if a taxane had been administered in the neoadjuvant or adjuvant setting, progression must have occurred >12 months after completion of this treatment. radiotherapy as palliative treatment for painful metastatic disease is permitted but must have been stopped within 2 weeks prior to any investigational treatment. ning disease is considered to be inapplicable to hormonal therapy. ning disease must have been stopped before the first dose of investigational treatment. an investigational drug within 30 days or five half-lives preceding the first dose of investigational treatment. unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or prior anti-cancer treatment. subjects with ulcerative colitis are excluded. metastases or leptomeningeal carcinomatosis would make subject inappropriate for study participation or any serious medical disorder that would interfere with subject's safety. subject must have histologically confirmed invasive breast cancer with Stage IV disease at primary diagnosis or at relapse after curative-intent surgery. neoplastic nature of the disease should have been confirmed by cytology or histology. subjects must have received no more than one prior chemotherapeutic regimen in the metastatic setting. prior therapy with radiation for this breast cancer population was permitted if it was administered in the neoadjuvant or adjuvant non metastatic setting. subject must have completed radiation treatment and recovered from all related toxicities. subject must have received all prior chemo treatment at least 4 weeks prior to enrollment in this study. prior therapy with trastuzumab in the neoadjuvant, adjuvant or metastatic setting was permitted. prior diagnosis of cancer was allowed as long as the subject was free of disease for 5 years. subjects with completely resected basal or squamous cell skin cancer, thyroid cancer or successfully treated cervical carcinoma in-situ were allowed into the study. women with oligomenorrhoea (severe), women who were perimenopausal and young women who had begun to menstruate must provide a negative serum pregnancy test at Screening. subjects must provide a negative serum pregnancy test and agree to 1 of the following: Complete abstinence from intercourse from 2 weeks prior to administration of the first dose of study medication until 5 days after the final dose of study medication. e Investigator to have a life expectancy of 6 months. Subjects must have had normal organ and marrow function as below. subject must have been free of gastrointestinal diseases that impede swallowing and retaining oral medications. bisphosphonate therapy for bone metastases was allowed; treatment must be initiated prior to the first dose of study medication. subjects without bone disease, except for osteoporosis, were included in the study if they met the following criteria. subjects who received more than one prior chemotherapeutic regimen were not eligible for the study. this included human immunodeficiency virus-positive subjects receiving combination anti-retroviral therapy because of possible pharmacokinetic interactions with lapatinib. uncontrolled inter-current illness includes, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would have limited compliance with study requirements. subjects with diseases affecting gastrointestinal function resulting in an inability to take oral medication. ation, prior surgical procedures affecting absorption e.g. gastric resection and uncontrolled inflammatory bowel disease (e.g., Crohn's, ulcerative colitis). subjects who had been disease-free for 5 years, or subjects with completely resected basal or squamous cell skin cancer, thyroid cancer or successfully treated cervical carcinoma in situ were eligible if it had been at least 1 year since definitive surgery. clinical investigator's Brochure (IB), SPM, and the nab-paclitaxel product label. \",\n",
       " 'ALT-801 0.015 mg/kg/Dose, 0.015 mg/kg/dose of ALT-801. ALT-801 0.040 mg/kg/Dose, 0.040 mg/kg/dose of ALT-801. ',\n",
       " 'AINTERVENTION 1:, Phase 1: MLN8237 10 mg, MLN8237 (alisertib) 10 milligram (mg), enteric-coated tablets, orally, twice daily for 7 days followed by 14 days of rest period in 21-day treatment cycles. or until progressive disease, unacceptable treatment-related toxicity, or initiation of a different anticancer therapy during Phase 1 portion of the study. treatment-related toxicity, or initiation of a different anticancer therapy during Phase 1 portion of the study. ',\n",
       " 'ALT-801 0.015 mg/kg/Dose, 0.015 mg/kg/dose of ALT-801. ALT-801 0.040 mg/kg/Dose, 0.040 mg/kg/dose of ALT-801. ',\n",
       " 'Adverse Events 1:, Total: 6/8 (75.00%), Thrombocytopenia 1/8 (12.50%), Hypertension 1/8 (12.50%), Hepatotoxicity 3/8 (37.50%), Pancreatectomy * 1/8 (12.50%). ',\n",
       " 'participants received enzalutamide 80 mg (two 40 mg) capsules orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including any seizure), noncompliance, withdrawal of consent, discontinuation by sponsor, or investigator. participants were followed-up until 30 days after last dose of study drug or before initiation of a new antitumor or investigational therapy, whichever occurred first. ver occurred first. ',\n",
       " 'ECOG performance status of 0 to 2, Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST), Exclusion Criteria:, prior or concurrent hormonal therapy for breast cancer, Histologically confirmed breast cancer, stage I-III disease, scheduled to undergo definitive surgery or other primary treatment. nant or nursing, Negative pregnancy test, Fertile patients must use effective contraception, No ongoing or active infection, No psychiatric illness or social situation that would preclude study compliance, No other uncontrolled intercurrent illness, No other uncontrolled intercurrent illness, No history of allergic reaction attributed to compounds of similar chemical or biologic composition to vorinostat, Concurrent vaginal hormone preparations (e.g., vagifem or estring) allowed, No concurrent birth control pills, No prior patients may not be taking valproic acid or another histone deacetylase inhibitor for at least 2 weeks prior to initiating SAHA. women who are pregnant may not be taking valproic acid or another histone deacetylase inhibitor for at least 2 weeks before initiating SAHA. ',\n",
       " 'all patients will receive GM-CSF at 250 mcg/m2 starting one day after the administration of chemotherapy x 7 days. patients with neutrophil counts below 1,000/mm3 on day 8 will continue GM-CSF therapy until the neutrophil count is greater than 1,000/mm3. ',\n",
       " 'patients must have histologically confirmed breast cancer that is ER positive and/or PR positive, and HER2/neu negative disease determined using commercially available/approved assay in local institutional or reference laboratory. ER/PR expression performed by standard immunohistochemical assay and classified as ER and/or PR-positive according to ASCO/CAP guidelines (1-100% expression) patients must have had progressive disease during at least one line of endocrine therapy. prior treatments include a non-steroidal aromatase inhibitor, tamoxifen, fulvestrant or combinations. patients taking bisphosphonates for bone disease are permitted to enter the trial. postmenopausal status defined as 60 years and older, 45 years and older, having amenorrhea x 12 months or follicle stimulating hormone levels within postmenopausal range, OR having a bilateral oophorectomy. patients may not be receiving any other investigational agents. having at least 6 weeks of treatment remaining, 21 years old, Able to understand written and spoken English, Able to swallow medication (until amendment omitting armodafinil treatment), Score of 3+ on the Sleep Disruption Evaluation form, OR a score of 8+ on Insomnia Severity Index (ISI), EXCLUSION CRITERIA, Prior treatment with armodafinil or modafinil (until amendment omitting armodafini history of uncontrolled, cardiac disease, hypertension, severe headaches, glaucoma, or seizures (until amendment omitting armodafinil treatment) of chronic, preexisting insomnia, sleep apnea, or restless leg syndrome (RLS) ',\n",
       " 'ECOG performance status of 0 to 2, Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST), Exclusion Criteria:, prior or concurrent hormonal therapy for breast cancer, Histologically confirmed breast cancer, stage I-III disease, scheduled to undergo definitive surgery or other primary treatment. nant or nursing, Negative pregnancy test, Fertile patients must use effective contraception, No ongoing or active infection, No psychiatric illness or social situation that would preclude study compliance, No other uncontrolled intercurrent illness, No other uncontrolled intercurrent illness, No history of allergic reaction attributed to compounds of similar chemical or biologic composition to vorinostat, Concurrent vaginal hormone preparations (e.g., vagifem or estring) allowed, No concurrent birth control pills, No prior patients may not be taking valproic acid or another histone deacetylase inhibitor for at least 2 weeks prior to initiating SAHA. women who are pregnant may not be taking valproic acid or another histone deacetylase inhibitor for at least 2 weeks before initiating SAHA. ',\n",
       " 'patients without liver involvement or history of liver disease will be treated at a dose of 98.7 mg/m2. patients will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance. patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2. patients will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance. CR and PR (for solid tumors) required a confirmation at least 4 weeks after the initial response observation. any pathological lymph nodes must have had reduction in short axis to 10 mm, PR=At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, SD=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. nt cycle was defined as 28 days. overall number of participants Analyzed: 105, Measure Type: Count of participants. ',\n",
       " 'treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity. cyclophosphamide, paclitaxel, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab subjects 98 (92.2 to 99.5). subjects 98 (92.2 to 99.5) ',\n",
       " 'Adverse Events 1:, Total: 0/344 (0.00%), Adverse Events 2:, Total: 0/342 (0.00%), Adverse Events 2:, Total: 0/24 (0.00%), Adverse Events 2:, Total: 0/24 (0.00%), Adverse Events 2:, Total: 0/344 (0.00%). ',\n",
       " 'participants enrolled in the dose escalation phase received PF-06647020 at 0.2 mg/kg on Day 1 of each 21-day cycle as an IV infusion over approximately 60 minutes on an outpatient basis. each participant received PF-06647020 until disease progression, unacceptable toxicity, withdrawal of consent, or study termination. ',\n",
       " 'inTERVENTION 1:, Adult Cancer Patients 65 Years of Age and Older, Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older. ',\n",
       " 'patients without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis using the Response Evaluation Criteria in Solid Tumors criteria. the human epidermal growth factor receptor 2 status of the tumor will be used to stratify patients. patients may have received prior chemotherapy and/or hormonal therapy for early stage breast cancer. the chemotherapy regimen may have included an anthracycline and/or a taxane as long as it has been > 6 months since completion. patients must have normal organ and marrow function. tests should be completed within 14 days prior to starting study treatment. patients must have normal organ and marrow function. mab must have received a cumulative dose of doxorubicin less than 360mg/m2 and/or an epirubicin cumulative dose less than 720mg/m2 for study entry. patients with known leptomeningeal carcinomatosis are excluded from this clinical trial. ',\n",
       " '0/49 (0.00%)Adverse Events 1:, Total: 12/20 (60.00%), Recurrent malignancy *1/20 (5.00%), Graft-versus-host disease *7/20 (35.00%), Infection *7/20 (35.00%), Altered mental status *2/20 (10.00%), Diffuse alveolar hemorrhage *1/20 (5.00%) ',\n",
       " 'patients are excluded if they are unable to give informed consent or pass screening for impaired mental function or psychosis. they are unable to hear or understand English. ',\n",
       " 'Adverse Events 1:, Total: 6/8 (75.00%), Thrombocytopenia 1/8 (12.50%), Hypertension 1/8 (12.50%), Hepatotoxicity 3/8 (37.50%), Pancreatectomy * 1/8 (12.50%). ',\n",
       " 'inTERVENTION 2:, Part 1: Cohort 2a, MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW, inTERVENTION 2:, Part 1: Cohort 2a, MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW. ',\n",
       " 'escalation to 37.5 mg daily was permitted in the absence of complicated neutropenia. if all 3 Cycle 1 paclitaxel doses were successfully administered at 90 mg/m2. ',\n",
       " \"tivantinib-naive participants must have a negative pregnancy test performed within 14 days of the start of study drug. both men and women must agree to use adequate birth control measures while enrolled in this study. on study, Exclusion Criteria:, Known or suspected allergy to ARQ 197, Substance abuse, medical, psychological or social conditions that may interfere with the participant's participation in the study. A serious uncontrolled medical disorder/condition that in the opinion of the Investigator would impair the ability of the participant to receive protocol therapy. participants must have histologically or cytologically proven metastatic or locally advanced solid tumors. no standard therapy exists or standard therapy has failed. disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1. participants must have relapsed, refractory, or progressive disease following last line of treatment. Availability of tumor archival material or fresh biopsies is mandatory for eligibility in the expansion cohorts. participants in the NSCLC cohort will only be enrolled in USA, NSCLC first line. participants must not have received treatment for their metastatic or recurrent disease. participants should have received no more than 1 line of treatment. participants with gastric cancer can enter in the study if their white blood cell and lymphocyte count is as defined in the protocol, MBC. participants must have histologically confirmed locally advanced or MBC. participants must have received no more than 3 prior lines of cytotoxic therapy for metastatic disease. ovarian cancer (platinum Refractory + liposomal doxorubicin), urothelial carcinoma, and HNSCC as defined in the protocol. other protocol defined inclusion criteria for expansion phase could apply. Exclusion criteria for dose escalation and expansion phase could apply. s cell carcinoma of the skin or cervical carcinoma in situ, Rapidly progressive disease (for example, tumor lysis syndrome), Active or history of central nervous system metastases, Receipt of any organ transplantation including allogeneic stem-cell transplantation. s cell carcinoma of the skin or cervical carcinoma in situ, Rapidly progressive disease (for example, tumor lysis syndrome), Active or history of any organ transplantation including allogeneic stem-cell transplantation. investigator's opinion might impair Participant's tolerance of trial treatment. legal incapacity or limited legal capacity, Non-oncology vaccine therapies for prevention of infection disease (for example, seasonal flu vaccine, human papilloma virus vaccine) Vaccination while on study is also prohibited except for administration of inactivated influenza vaccine. \",\n",
       " 'INTERVENTION 1:, Arm 1, Herceptin/navelbine, INTERVENTION 2:, Arm 2, Taxotere/carboplatin/herceptin_. ',\n",
       " '0/25 (0.00%)Adverse Events 1:, Total: 10/30 (33.33%), Hemoglobin decreased 2/30 (6.67%), Abdominal pain 1/30 (3.33%), Colitis 1/30 (3.33%), Diarrhea 7/30 (23.33%), Nausea 2/30 (6.67%), Rectal hemorrhage 1/30 (3.33%), Fatigue 1/30 (3.33%), Skin infection 1/30 (3.33%), Neutrophil count decreased 1/30 ( ',\n",
       " \"if a taxane had been administered in the neoadjuvant or adjuvant setting, progression must have occurred >12 months after completion of this treatment. radiotherapy as palliative treatment for painful metastatic disease is permitted but must have been stopped within 2 weeks prior to any investigational treatment. ning disease is considered to be inapplicable to hormonal therapy. ning disease must have been stopped before the first dose of investigational treatment. an investigational drug within 30 days or five half-lives preceding the first dose of investigational treatment. unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or prior anti-cancer treatment. subjects with ulcerative colitis are excluded. metastases or leptomeningeal carcinomatosis would make subject inappropriate for study participation or any serious medical disorder that would interfere with subject's safety. subject must have histologically confirmed invasive breast cancer with Stage IV disease at primary diagnosis or at relapse after curative-intent surgery. neoplastic nature of the disease should have been confirmed by cytology or histology. subjects must have received no more than one prior chemotherapeutic regimen in the metastatic setting. prior therapy with radiation for this breast cancer population was permitted if it was administered in the neoadjuvant or adjuvant non metastatic setting. subject must have completed radiation treatment and recovered from all related toxicities. subject must have received all prior chemo treatment at least 4 weeks prior to enrollment in this study. prior therapy with trastuzumab in the neoadjuvant, adjuvant or metastatic setting was permitted. prior diagnosis of cancer was allowed as long as the subject was free of disease for 5 years. subjects with completely resected basal or squamous cell skin cancer, thyroid cancer or successfully treated cervical carcinoma in-situ were allowed into the study. women with oligomenorrhoea (severe), women who were perimenopausal and young women who had begun to menstruate must provide a negative serum pregnancy test at Screening. subjects must provide a negative serum pregnancy test and agree to 1 of the following: Complete abstinence from intercourse from 2 weeks prior to administration of the first dose of study medication until 5 days after the final dose of study medication. e Investigator to have a life expectancy of 6 months. Subjects must have had normal organ and marrow function as below. subject must have been free of gastrointestinal diseases that impede swallowing and retaining oral medications. bisphosphonate therapy for bone metastases was allowed; treatment must be initiated prior to the first dose of study medication. subjects without bone disease, except for osteoporosis, were included in the study if they met the following criteria. subjects who received more than one prior chemotherapeutic regimen were not eligible for the study. this included human immunodeficiency virus-positive subjects receiving combination anti-retroviral therapy because of possible pharmacokinetic interactions with lapatinib. uncontrolled inter-current illness includes, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would have limited compliance with study requirements. subjects with diseases affecting gastrointestinal function resulting in an inability to take oral medication. ation, prior surgical procedures affecting absorption e.g. gastric resection and uncontrolled inflammatory bowel disease (e.g., Crohn's, ulcerative colitis). subjects who had been disease-free for 5 years, or subjects with completely resected basal or squamous cell skin cancer, thyroid cancer or successfully treated cervical carcinoma in situ were eligible if it had been at least 1 year since definitive surgery. clinical investigator's Brochure (IB), SPM, and the nab-paclitaxel product label. \",\n",
       " 'memantine hydrochloride: Estimate participation, accrual, adherence, and retention of cancer survivors who smoke. inTERVENTION 2:, Arm II - Placebo. ',\n",
       " 'female patients with histologically/cytologically proven metastatic breast carcinoma (stage IV, or recurrent with local or regional spread or distant metastatic disease), Adequate bone marrow, liver, and renal function. ',\n",
       " 'inTERVENTION 1:, wait-list, patients in wait-list control group will cross over and receive acupuncture twice weekly for six consecutive weeks. patients will be advised to continue their standard lymphedema treatments such as exercise or use of compression garments if these were in use prior to clinical trial participation. rmed after approximately 6 weeks on wait-list, before onset of acupuncture treatment. BMI will be measured at the same timepoints. ',\n",
       " 'non-inferiority analyses were performed by comparing area under the ROC curve (AUC) for the two algorithms. the ROC curve incorporates both sensitivity (true positive rate) and specificity (true negative rate) providing a single assessment incorporating both measures. women with negative or biopsy benign findings at baseline were followed for 1 year to confirm the negative status at 1-year follow-up mammography exam. women diagnosed with cancer were not followed up. the Lee Fatigue Scale consists of 18 items related to fatigue and energy. the mean of the 13 items in the fatigue subscale (range from 0-10) and the mean of the 5 items in the energy subscale (range from 0-10) are calculated. the women received reflexology treatment initiated at the beginning of radiation therapy, once a week (45 min each), for 10 weeks. the control group (no intervention,treatment as usual)included 25 breast cancer patients, scheduled for adjunctive radiation treatment. ',\n",
       " 'patients with vitamin D deficiency who experience myalgias, arthralgias and/or joint stiffness received epoetin beta (NeoRecormon®) at a dose of 30000 International Units (IU) as subcutaneous (SC) injection once every week. ',\n",
       " 'patients will receive whole breast radiation therapy at a dose of 180-200 cGy per fraction for 23-27 fractions to a total dose of 4600 - 4860 cGy. additional radiation to the lumpectomy bed (Boost) is at the discretion of the treating physician. participants received enzastaurin (250 mg; 2 tablets) or placebo administered orally twice daily (BID) in a 28-day cycle. ',\n",
       " 'disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as a 20% increase in the sum of the longest diameter of target lesions, or progression in a non-target lesion, or the appearance of new lesions. unit of measure: months 2.8 (1.6 to 3.2), Results 2:, Arm/Group Title: CDX-011. CDX-011 administered on day 1 of each 21 day cycle until disease progression, discontinuation due to toxicity, withdrawal of consent, or end of study. ',\n",
       " 'Adverse Events 1:, Total: 0/10 (0.00%)Adverse Events 1:, Total: 0/1699 (0.00%), Adverse Events 2:, Total: 0/2004 (0.00%) ',\n",
       " 'Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (ACT), Doxorubicin 60 mg/m2 IV bolus injection in combination with cyclophosphamide 600 mg/m2 IV bolus injection on Day 1 of every 3 weeks for 4 cycles. docetaxel 100 mg/m2 IV infusion every 3 weeks for another 4 cycles. ',\n",
       " 'Adverse Events 1:, Total: 8/87 (9.20%), Death * [1]8/87 (9.20%), Hospitalization [2]1/87 (1.15%), Hospitalization [3]1/87 (1.15%), Adverse Events 2:, Total: 0/28 (0.00%), Death * [1]0/28 (0.00%), Hospitalization [3]0/28 (0.00%)_______________________ ',\n",
       " 'participants received lenalidomide 5mg orally daily for 57 +/- 3 daysINTERVENTION 1:, Lapatinib 1500 mg, Oral lapatinib (1500 milligrams [mg] daily) for 6 weeks, followed by lapatinib plus weekly paclitaxel (80 mg per meters squared [mg/m2]) intravenous (IV) for an additional 12 weeks. ',\n",
       " 'Hemoglobin decreased 2/30 (6.67%), Abdominal pain 1/30 (3.33%), Colitis 1/30 (3.33%), Diarrhea 7/30 (23.33%), Nausea 2/30 (6.67%), Rectal hemorrhage 1/30 (3.33%), Fatigue 1/30 (3.33%), Skin infection 1/30 (3.33%), Neutrophil count decreased 1/30 (3.33%), Platelet count decreased 3/30 (10.00%), Dehydration 1/30 (3.33%) holelithiasis 0/6 (0.00%), Hepatic pain 1/6 (16.67%), Bacteraemia 0/6 (0.00%) holelithiasis 0/6 (0.00%), Hepatic pain 1/6 (16.67%), bacteraemia 0/6 (0.00%) ',\n",
       " 'in a woman of childbearing potential, a positive pregnancy test result, no pregnancy test result, or no reliable contraception, at baseline. a postmenopausal woman will be considered to be of childbearing potential until there has been amenorrhea for at least 12 consecutive months. prior anticancer therapy completed within four weeks prior to first day of study treatment. failure to have recovered from any toxicity of previous cancer treatment will not be excluded. ',\n",
       " 'inTERVENTION 2:, Part 1: Cohort 2a, MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW, inTERVENTION 2:, Part 1: Cohort 2a, MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW. ',\n",
       " 'a log ratio of expression was generated relative to reference in both the Up and DOWN arms of the gene signature. a log ratio value of zero indicated no change in expression between the two samples. overall number of participants Analyzed: 14, Measure Type: Number, Unit of Measure: Percentage of participants 28.6 (13.1 to 49.2), Results 2:, Arm/Group Title: Triple Negative (TN), Arm/Group Description: Triple Negative participants received a single dose of dalotuzumab 20 mg/kg infused over 60-120 minutes. ',\n",
       " 'inTERVENTION 2:, Part 1 and Part 2: Talazoparib (Ovarian/ Peritoneal Cancer) Participants with ovarian/ peritoneal cancer who received talazoparib capsules in Part 1 and 2 at a dose of either 600 mcg/day, 900 mcg/day, 1000 mcg/day, 1100 mcg/day. ',\n",
       " 'the women received reflexology treatment initiated at the beginning of radiation therapy, once a week (45 min each), for 10 weeks. the control group included 25 breast cancer patients scheduled for adjunctive radiation treatment. ',\n",
       " 'memantine hydrochloride: Estimate participation, accrual, adherence, and retention of cancer survivors who smoke. randomized to receive memantine (10 mg twice daily) or a matching placebo. ',\n",
       " '0/42 (0.00%)Adverse Events 1:, Total: 6/6 (100.00%), Anemia1/6 (16.67%), Constipation1/6 (16.67%), Mucositis1/6 (16.67%), Vomiting0/6 (0.00%), Dehydration0/6 (0.00%), Abdominal pain0/6 (0.00%), Ascites0/6 (0.00%), Diarrhea0/6 (0.00%), Fatigue0/6 (0.00%), Death NOS1 ',\n",
       " \"FACT-B consists of 5 subscale scores pertaining to 4 well-being dimensions. Response options were 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much. nuevo Amanecer is a cognitive-behavioral stress management program delivered by peers (Spanish-speaking Latinas who have had breast cancer) the program is designed to address the first year of survivorship. the primary effectiveness endpoint is a measure of intra-operative success in addressing positive margins as detected by permanent pathology. the device is 'positive' when all positive margins, as detected by histology, on the main specimen addressed intra-operatively. MarginProbe: Device use to assess margin status of excised specimen surface. overall number of participants analysed: 163, Measure Type: Number, Unit of Measure: percentage of participants analyzed 71.8. \",\n",
       " 'patients undergoing mastectomy surgery, number of individuals having mastectomy surgery who were approached for participation in the trialINTERVENTION 1:, HR+: MM-121+ Paclitaxel, Hormone-receptor positive (HR+) sub-group randomized to receive:, 2 week run-in of MM-121 (20 mg/kg weekly IV infusion over 60 minutes following a 40 mg/kg loading dose. ',\n",
       " \"participants must have histologically or cytologically proven metastatic or locally advanced solid tumors. no standard therapy exists or standard therapy has failed. disease must be measurable with at least 1 uni-dimensional measurable lesion by RECIST 1.1, except for participants with metastatic castrate-resistant prostate cancer. participants in the MBC cohort must have relapsed, refractory, or progressive disease following last line of treatment. Availability of tumor archival material or fresh biopsies is mandatory for eligibility in the expansion cohorts. participants in the NSCLC cohort will only be enrolled in USA, NSCLC first line: Stage IV or recurrent NSCLC that is histologically proven. participants should have received no more than 1 line of treatment for metastatic disease. participants with gastric cancer can enter in the study if their white blood cell (WBC) and lymphocyte count is as defined in the protocol, MBC: Participants must have histologically confirmed locally advanced or MBC. participants must have received no more than 3 prior lines of cytotoxic therapy for metastatic disease. pansion cohorts include gastric and GEJ cancer (third line), ovarian cancer (platinum Refractory + liposomal doxorubicin), urothelial carcinoma, and HNSCC. other protocol defined inclusion criteria for expansion phase could apply. basal or squamous cell carcinoma of the skin or cervical carcinoma in situ, Rapidly progressive disease (for example, tumor lysis syndrome), Active or history of central nervous system metastases, Receipt of any organ transplantation including allogeneic stem-cell transplantation. Known severe hypersensitivity reactions to monoclonal antibodies, any history of anaphylaxis, or uncontrolled asthma, Persisting toxicity related to prior therapy greater than Grade 1 NCI-CTCAE inflammatory bowel disease may impair Participant's tolerance of trial treatment. legal incapacity or limited legal capacity, non-oncology vaccine therapies for prevention of infection disease. vaccination while on study is also prohibited except for administration of the inactivated influenza vaccine. \",\n",
       " 'inTERVENTION 1:, Subjects enrolled with device placed and treated with partial breast irradiation. ',\n",
       " 'ECOG performance status of 0 to 2, Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST), Exclusion Criteria:, prior or concurrent hormonal therapy for breast cancer, Histologically confirmed breast cancer, stage I-III disease, scheduled to undergo definitive surgery or other primary treatment. nant or nursing, Negative pregnancy test, Fertile patients must use effective contraception, No ongoing or active infection, No psychiatric illness or social situation that would preclude study compliance, No other uncontrolled intercurrent illness, No other uncontrolled intercurrent illness, No history of allergic reaction attributed to compounds of similar chemical or biologic composition to vorinostat, Concurrent vaginal hormone preparations (e.g., vagifem or estring) allowed, No concurrent birth control pills, No prior patients may not be taking valproic acid or another histone deacetylase inhibitor for at least 2 weeks prior to initiating SAHA. women who are pregnant may not be taking valproic acid or another histone deacetylase inhibitor for at least 2 weeks before initiating SAHA. ',\n",
       " 'change in total body lean mass measured by dual energy x-ray absorptiometry (DEXA) from baseline to 4 months. time frame: Baseline to four months. ',\n",
       " 'Adverse Events 1:, Total: 1/208 (0.48%), Neutrophils/granulocytes (ANC/AGC) 1/208 (0.48%), Adverse Events 2:, Total: 0/201 (0.00%), Neutrophils/granulocytes (ANC/AGC) 0/201 (0.00%)Adverse Events 1:, Total: 0/34 (0.00%) ',\n",
       " 'the women received reflexology treatment initiated at the beginning of radiation therapy, once a week (45 min each), for 10 weeks. the control group included 25 breast cancer patients scheduled for adjunctive radiation treatment. ',\n",
       " 'treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity. cyclophosphamide, paclitaxel, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab subjects 98 (92.2 to 99.5). subjects 98 (92.2 to 99.5) ',\n",
       " 'results 1:, Arm/Group Title: Arm 1: Paclitaxel + Trastuzumab Then A C, Arm/Group Description: 4 cycles of paclitaxel 80 mg/m2 on days 1, 8 and 15 of a 28-day cycle. follow paclitaxel/trastuzumab, standard AC every 21 days for 4 cycles. Neratinib 240 mg orally once daily beginning on Day 1 of paclitaxel. standard AC every 21 days for 4 cycles. following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy. ',\n",
       " 'Adverse Events 1:, Total: 0/34 (0.00%)Adverse Events 1:, Total: 0/1 (0.00%)Adverse Events 1:, Total: 0/1 (0.00%) ',\n",
       " 'change in Ki67 expression in tumors with 7 days of pre-surgical tamoxifen. all patients will take tamoxifen 20 mg po daily for 7 days prior to surgery. ',\n",
       " 'patients with histologically documented cancer of the breast or DCIS or head and neck referred for definitive radiation with curative intent. minimum life expectancy of at least 12 months., Aged greater than 20 years., If female, pregnancy excluded., no documented history of collagen vascular disease., Exclusion Criteria:, Cognitively impaired patients, Prisoners, No histology available, Documented metastatic disease, Allergy to Trental, Life expectance of less than 12 months., Aged less tase inhibitors for breast cancer in women and anti-LHRH therapy for prostate cancer in men will be permitted. have a BMI of 25 kg/m2 or greater and weight =400 lbs., Willingness to accept randomization to each of the three arms, Willingness to change diet, physical activity, and weight. prior or planned bariatric surgery, have significant renal disease or dysfunction defined as Estimated glomerular filtration rate (eGFR)45, Have significant renal disease or dysfunction defined as Estimated glomerular filtration rate (eGFR)45, Have significant hepatic dysfunction [Aspartate aminotransferase (AST)/Alanine transaminase (ALT) 2 x upper limit of normal (ULN) or reported liver disease], Self-reported ',\n",
       " '0/49 (0.00%)Adverse Events 1:, Total: 12/20 (60.00%), Recurrent malignancy *1/20 (5.00%), Graft-versus-host disease *7/20 (35.00%), Infection *7/20 (35.00%), Altered mental status *2/20 (10.00%), Diffuse alveolar hemorrhage *1/20 (5.00%) ',\n",
       " 'overall response rate measured by physical exam and MRI if indicated using following definition. Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR = CR + PR., Time frame: Up to 8 months, Arm/Group Title: Arm A, Arm/Group Description: Arm A overall number of participants Analyzed: 37, Measure Type: Count of Participants, Unit of Measure: Participants 25 67.6%, Results 2:, Arm/Group Title: Arm B, Arm/Group Description: Arm B: Docetaxel 75 mg/m2 IV day 1 plus Capecitabine 1000 mg/m2/dose bid x 14d q3w, then surgery, then Epirubicin 90 mg/m2 day 1 IV and Cyclophosphamide 600 mg/m2 day 1 median time to first skeletal-related event could not be estimated in one treatment arm. median time to first skeletal-related event could not be estimated. ',\n",
       " 'ORR was defined as the proportion of participants who achieved a best response of either CR or PR. time frame: baseline & every 2 cycles (approximately 8 weeks) of treatment. bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days. overall number of participants Analyzed: 94, Mean (95% Confidence Interval), Unit of Measure: proportion of responders 0.489 (0.385 to 0.595), Results 2:, Arm/Group Title: paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G), Arm/Group Description: paclitaxel 90 mill ',\n",
       " 'neoadjuvant therapy will consist of epirubs, epirubs and epirubs. neoadjuvant therapy will consist of epirubs, epirubs, epirubs and epirubs. icin + cyclophosphamide (600 mg/m2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m2) every 2 weeks for 4 cycles + trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments. ',\n",
       " \"the participant has a histopathologically or cytologically confirmed diagnosis of breast adenocarcinoma that is metastatic or locally-recurrent and inoperable with curative intent. the participant has measurable and/or non-measurable disease, The participant's primary and/or metastatic tumor is human Epidermal Growth Factor Receptor 2 (HER2) negative. participants of reproductive potential agree to use adequate contraceptive methods during the study period and for 12 weeks after the last dose of study medication. participant has a concurrent active malignancy other than breast adenocarcinoma, adequately treated non-melanomatous skin cancer, or other non-invasive carcinoma or in situ neoplasm. articipant has received any experimental agents within 4 weeks prior to the study registration date, The participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders. the participant has an ongoing or active infection requiring antibiotic, antifungal, or antiviral therapy. for bone disease, stable disease (SD) is allowed. patient must have tumor assessed for estrogen-receptor (ER) and progesterone-receptor (PR) prior HDCT with autologous hematopoietic stem cell transplantation (AHST) in adjuvant setting. history of other malignancies except cured non-melanoma skin cancer. \",\n",
       " 'a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 will be explored and will follow a 6 + 3 dose de-escalation design. participants with one of the following tumor types will be eligible for enrollment. ',\n",
       " 'Adverse Events 1:, Total: 0/344 (0.00%), Adverse Events 2:, Total: 0/342 (0.00%), Adverse Events 2:, Total: 0/24 (0.00%), Adverse Events 2:, Total: 0/24 (0.00%), Adverse Events 2:, Total: 0/344 (0.00%). ',\n",
       " 'treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity. cyclophosphamide, paclitaxel, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab subjects 98 (92.2 to 99.5). subjects 98 (92.2 to 99.5) ',\n",
       " 'patients were intended to receive pain therapy, psychosocial assessment and care, and quality-of-life assessment, management of therapy complications, massage therapy, pain therapy, psychosocial assessment and care, quality-of-life assessment. patients received 3 no-touch therapy visits from massage therapists in initial week with a duration of 15-45 minutes. each participant received PF-06647020 until disease progression, unacceptable toxicity, withdrawal of consent, or study termination. each participant received PF-06647020 at 0.5 mg/kg on Day 1 of each 21-day cycle as an IV infusion over approximately 60 minutes on an outpatient basis. ',\n",
       " 'the women received reflexology treatment initiated at the beginning of radiation therapy, once a week (45 min each), for 10 weeks. the control group included 25 breast cancer patients scheduled for adjunctive radiation treatment. ',\n",
       " 'dexamethasone 8 mg, Dexamethasone 8 mg pre-operative, Dexamethasone: pre-operative intravenous administration. inTERVENTION 2:, Dexamethasone 24 mg, Dexamethasone 24 mg pre-operative. ',\n",
       " 'doxorubicin and cyclophosphamide may alter the concentration-time profile of doxorubicin or cyclophosphamide. the effects of doxorubicin and cyclophosphamide on pregnancy are unknown. participants unwilling to comply with study procedures. all other drugs will be reviewed during screening of the patientINCLUSION CRITERIA:, patients with histologically documented:, BRCA-positive ovarian cancer (documented deleterious BRCA1/2 mutation or a BRCAPRO score of greater than or equal to 30%), serous carcinoma or fallopian tube cancer (no requirement for BRCA status), triple-negative breast cancer (documented estrogen receptor (ER) negative, progesterone receptor (PR) negative, and human epidermal patients must have measurable disease defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as greater than or equal to 20 mm with conventional techniques or as greater than or equal to 10 mm with spiral computed tomography (CT scan) any prior therapy or radiotherapy must have been completed greater than or equal to 4 weeks. patients must be greater than or equal to 2 weeks since any investigational agent administered as part of a Phase 0 study. patients who have had prior treatment with any PARP inhibitors are eligible unless the PARP inhibitor was administered in combination with cyclophosphamide. children are excluded from this study. the effects of ABT-888 on the developing human fetus are unknown. cyclophosphamide hydrochloride is known to be teratogenic. women of childbearing potential must agree to use adequate contraception. breastfeeding should be discontinued while the patient is on this trial. there is a risk for adverse events in nursing infants secondary to treatment of the mother with cyclophosphamide. patients with history of central nervous system (CNS) metastases who have received treatment and have had no seizures x 3 months will be eligible. subjects with ulcerative colitis, inflammatory bowel disease, or a partial or complete small bowel obstruction are also excluded. ups are eligible for this trial. ',\n",
       " 'change in Ki67 expression in tumors with 7 days of pre-surgical tamoxifen. all patients will take tamoxifen 20 mg po daily for 7 days prior to surgery. ',\n",
       " 'if the patient had received the chemotherapy for breast cancer, it should be finished 30 days before the beginning of the study. if the patient had received the chemotherapy for breast cancer, it should be finished 30 days before the beginning of the study. patients of childbearing potential must implement reliable contraceptive measures during the study treatment, starting 4 weeks prior randomization and for 6 months after the last administration of the study drug. equirements: patient has received two or more chemotherapy regimens for metastatic breast cancer. uropathy, HIV, HCV, HBV, T.Pallidum infection(s);, acute or active chronic infections. patients must have a life expectancy of at least 1 year, excluding cancer diagnosis. patients must have a mass on clinical or radiological examination of >1 cm. bilirubin, serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate oxaloacetate transaminase (SGPT), alkaline phosphatase, and serum creatinine must all be  1.2 x upper limit of normal. patients with benign hyperbilirubinemia are also excluded. patients with non-breast malignancies are eligible if they have not received prior chemotherapy or extensive radiation therapy. patients with squamous or basal carcinoma of the skin that has been effectively treated are eligible. patients with prior or simultaneous lobular or ductal carcinoma in situ of the ipsilateral or contralateral breast are also eligible. patients will agree to continue contraception for 30 days from the date of the last study drug administration. patients who have received prior anthracycline therapy for any malignancy are not eligible. patients with a cardiac arrhythmia are eligible, provided the arrhythmia is not associated with concomitant heart failure or cardiac dysfunction. patients with a cardiac arrhythmia are eligible, provided the arrhythmia is not associated with concomitant heart failure or cardiac dysfunction. ness to give written informed consent. Unwillingness to participate or inability to comply with the protocol for the duration of the study. ',\n",
       " 'patients without liver involvement or history of liver disease will be treated at a dose of 98.7 mg/m2. patients will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance. patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2. patients will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance. ',\n",
       " 'patients will receive acupuncture treatment twice weekly for six consecutive weeks. each treatment will be 30 minutes in duration. patients will be advised to continue their standard lymphedema treatments. follow-up objective and subjective assessments of lymphedema will be performed after approximately 6 weeks on the wait-list. follow-up objective and subjective assessments of lymphedema will be performed after approximately 6 weeks on the wait-list, before onset of acupuncture treatment. ',\n",
       " 'neutropenic fever, weakness 1/50 (2.00%), urinary tract infection 1/50 (2.00%), cellulitis 4/50 (8.00%), wound dehiscence 1/50 (2.00%), hematoma 1/50 (2.00%), seroma 1/50 (2.00%), inflammation (red breast syndrome) 2/50 (4.00%) ',\n",
       " 'Chemotherapy with GM-CSF, Doxorubicin and Cyclophosphamide (AC) followed by Weekly Carboplatin/Nab- PaclitaxelINTERVENTION 1:, Neoadjuvant Chemotherapy, Doxorubicin (Adriamycin) + cyclophosphamide (Cytoxan) with pegfilgrastim or filgrastim growth factor support every 2 weeks for 4 cycles ',\n",
       " 'Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Docetaxel 80 mg/m2 1 hr IV infusion on Day 1 of each cycle. participants with disease progression after consent continued to open-label phase. ',\n",
       " '0/104 (0.00%)Adverse Events 1:, Total: 45/128 (35.16%), Anaemia 3/128 (2.34%), Febrile neutropenia 2/128 (1.56%), Arrhythmia 1/128 (0.78%), Cardiac arrest 1/128 (0.78%), Cardiopulmonary failure 1/128 (0.78%), Abdominal pain 2/128 (1.56%), Ascite 2/128 (1.56%), Intestinal obstruction 2/128 (1.56%), Melaena ',\n",
       " 'inTERVENTION 1:, arm A (ANA), patients receive oral anastrozole as 1 mg film-coated tablets. patients receive fulvestrant intramuscularly (250 mg/5 ml solution) on days 1, 14 and 28. ',\n",
       " 'Adverse Events 1:, Total: 0/147 (0.00%)__. ',\n",
       " \"2.3 Dental evaluation according to the dental exam checklist (carried out by the investigator, the investigator's designee, or by a qualified dental professional [dental hygienist or dentist]) if the patient has received prior oral bisphosphonate therapy within 8 weeks of registration, the evaluation should not be revoked. complete blood count (CBC)/differential within 2 weeks prior to registration, with adequate bone marrow function defined as follows: White blood cell count (WBC) 2400 cells/mm3; Absolute neutrophil count (ANC) 1,800 cells/mm3; Platelets 60,000 cells/mm3; Hemoglobin 8.0 g/dl (Note: The use of transfusion or other intervention to achieve the required hemoglobin is permitted) beam radiation therapy must be completed 14 days prior to registration. patients with no evidence of disease in the brain after treatment for brain metastases are eligible. prior treatment with Strontium-89 or Samarium-153 for bone metastases. prior treatment with IV bisphosphonates prior to study entry. current, active dental problems within 4 weeks of registration. the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. pregnant or lactating patients are excluded as treatment may be harmful to embryos and/or nursing infants. the study should be finished 30 days before the beginning of the study. if the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose of anthracyclines should not exceed 250 mg/m2 for doxorubicin or 540 mg/m2 for epirubicin. n or 660 mg/m2 for epirubicin, if in this study planned 4 cycles of chemotherapy. patients of childbearing potential must implement reliable contraceptive measures. f bone metastases) administration of any experimental drugs within 30 days prior randomization. conditions limiting patient's ability to follow protocol. \",\n",
       " 'participants received 1250 milligram (mg) tablets lapatinib once a day and vinorelbine 20 mg/meters squared (m2) intravenously on Day 1 and Day 8, and every 3 weeks. participants received 1250 milligram (mg) tablets lapatinib once a day. ticipants Analyzed: 25, Measure Type: Number, Unit of Measure: participants Week 12, CR: 0, Week 12, PR: 4, Week 12, SD: 12, Week 24, CR: 0, Week 24, PR: 4, Week 24, SD: 10_ ',\n",
       " '77/122 (63.11%), Anaemia 1/122 (0.82%), Thrombocytopenia 1/122 (0.82%), Pericardial effusion 3/122 (2.46%), Supraventricular tachycardia 2/122 (1.64%), Atrial fibrillation 1/122 (0.82%), Sinus tachycardia 1/122 (0.82%), Hypothyroidism 1/122 (0.82%), Abdominal pain 4/122 (3.28%)Adverse ',\n",
       " 'healthy women will be screened for magnetic resonance imaging (MRI) contraindications, and then undergo contrast injection, and SWIFT acquisition. 10 and 30 patients will be scanned in the first and second year. SWIFT-DCE diagnostic performance will be compared to prior FLASH-DCE methods. overall number of participants Analyzed: 8, Measure Type: Number, Unit of Measure: lesions 0, Results 2:, arm/group Title: Breast cancer patients will be screened for magnetic resonance imaging contraindications. then undergo contrast injection and SWIFT acquisition. 10 and 30 patients will be scanned in the first and second year. the results of this pilot study will provide evidence supporting the use of Medihoney in preventing and treating radiation dermatitis. patients will be instructed to apply a thin layer of the Hydrophor daily. the application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. patients should not apply the Hydrophor within 4 hours of receiving RT. Medihoney application should include entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. patients should not apply the Medihoney within 4 hours of receiving RT. ave been shown to have healing benefits:, Maintain a balanced environment for healing., Aids in reducing dermatitis., Reduce affected area pH.2-3, Overall number of participants Analyzed: 18, Measure Type: Number, Unit of Measure: participants radiation dermatitis: 15, hyperpigmentation: 15. ',\n",
       " 'healthy women will be screened for magnetic resonance imaging (MRI) contraindications, and then undergo contrast injection, and SWIFT acquisition. 10 and 30 patients will be scanned in the first and second year. SWIFT-DCE diagnostic performance will be compared to prior FLASH-DCE methods. overall number of participants Analyzed: 8, Measure Type: Number, Unit of Measure: lesions 0, Results 2:, arm/group Title: Breast cancer patients will be screened for magnetic resonance imaging contraindications. then undergo contrast injection and SWIFT acquisition. 10 and 30 patients will be scanned in the first and second year. the results of this pilot study will provide evidence supporting the use of Medihoney in preventing and treating radiation dermatitis. patients will be instructed to apply a thin layer of the Hydrophor daily. the application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. patients should not apply the Hydrophor within 4 hours of receiving RT. Medihoney application should include entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. patients should not apply the Medihoney within 4 hours of receiving RT. ave been shown to have healing benefits:, Maintain a balanced environment for healing., Aids in reducing dermatitis., Reduce affected area pH.2-3, Overall number of participants Analyzed: 18, Measure Type: Number, Unit of Measure: participants radiation dermatitis: 15, hyperpigmentation: 15. ',\n",
       " 'Contour Profile Tissue Expander is a tissue expander with a greater height to width ratio than traditional tissue expanders. this increased ratio allows for greater lower pole expansion, thus creating a more natural looking, ptotic breast. ',\n",
       " 'inTERVENTION 1:, intervention, Validated, web-based risk assessment is being used to assess personalized risk and generate a risk report. inTERVENTION 2:, Control, Usual care. ',\n",
       " 'sunitinib was administered orally from Day 1 to 14 every 21 days at a starting dose of 2,000 mg/m2/day. participants were monitored for toxicity, and sunitinib and/or capecitabine dosing could be interrupted or reduced according to individual tolerance. ',\n",
       " 'Outcome Measurement:, Recurrence-free Survival, 2 years for the primary analysis + 3 additional years for secondary analysis. Time frame: 5 years, Results 1:, Arm/Group Title: Ketorolac 30 mg, Arm/Group Description: Active drug to be compared with placebo, Ketorolac 30 mg IV, Overall number of participants Analyzed: 96, Measure Type: Count of participants, Unit of Measure: Participants 80 83.3%, Results 2:, Arm/ ',\n",
       " 'participants enrolled in the dose escalation phase received PF-06647020 at 0.2 mg/kg on Day 1 of each 21-day cycle as an IV infusion over approximately 60 minutes on an outpatient basis. each participant received PF-06647020 until disease progression, unacceptable toxicity, withdrawal of consent, or study termination. ',\n",
       " 'sunitinib was administered orally from Day 1 to 14 every 21 days at a starting dose of 2,000 mg/m2/day. participants were monitored for toxicity, and sunitinib and/or capecitabine dosing could be interrupted or reduced according to individual tolerance. ',\n",
       " 'Response is defined as corrected serum calcium (CSC) 11.5 mg/dL within 10 days after the first dose of denosumab. for all CSC values, if albumin was  4 g/dL, the following formula was used to calculate CSC. 8 subjects to receive 40 mg d-Methadone twice a day. overall number of participants analyzed. ',\n",
       " '8/20 (40.00%), Anaemia 1/20 (5.00%), Lymphadenopathy 0/4 (0.00%), Thrombocytopenia 0/4 (0.00%), Acute coronary syndrome 0/4 (0.00%), Atrial fibrillation 0/4 (0.00%), Cardiac failure congestive 0/4 (0.00%), Cardiac tamponade 0/4 (0.00%), Adverse Events 2:, Total: 8/20 (40.00%), Anaemia 1 ',\n",
       " 'ALT-801 0.015 mg/kg/Dose, 0.015 mg/kg/dose of ALT-801. ALT-801 0.040 mg/kg/Dose, 0.040 mg/kg/dose of ALT-801. ',\n",
       " 'inTERVENTION 1:, Patients - Intervention, Patients will be invited to view the educational DVD explaining end-of-life care options and meet with a lay health advisor for discussion. ',\n",
       " 'patients receive cabergoline oral (PO) twice weekly for weeks 1-4. courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. ',\n",
       " 'no evidence of disease outside the breast or chest wall, except ipsilateral axillary lymph nodes. Final eligibility for a clinical trial is determined by the health professionals conducting the trial. ',\n",
       " 'sunitinib was administered orally from Day 1 to 14 every 21 days at a starting dose of 2,000 mg/m2/day. participants were monitored for toxicity, and sunitinib and/or capecitabine dosing could be interrupted or reduced according to individual tolerance. ',\n",
       " 'patients with a histologically/cytologically confirmed diagnosis of advanced and/or unresectable disease of any of the following tumors: breast cancer, Epithelial ovarian cancer or gynecological cancer, Head and neck squamous cell carcinoma, Non-small cell lung cancer, Small cell lung cancer, Platinum-refractory germ-cell tumors. pre-menopausal women must have a negative pregnancy test before study entry. patients who have previously discontinued bevacizumab-containing regimes due to drug-related toxicity. more than three prior lines of chemotherapy, Less than three months since last taxane-containing therapy. ring dyspnea, known HIV infection, bleeding risk, muscular problems, peripheral neuropathy, symptomatic or progressive brain metastases or leptomeningeal disease. men or pre-menopausal women who are not using an effective method of contraception as previously described. ',\n",
       " 'patients with glioblastoma multiforme undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks. participants will be injected with less than 10 mCi of 18F-FPPRGD2. mCi of 18F-FPPRGD2 of 18F-FPPRGD2. ',\n",
       " 'patients without liver involvement or history of liver disease will be treated at a dose of 98.7 mg/m2. patients will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance. patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2. patients will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance. CR and PR (for solid tumors) required a confirmation at least 4 weeks after the initial response observation. any pathological lymph nodes must have had reduction in short axis to 10 mm, PR=At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, SD=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. nt cycle was defined as 28 days. overall number of participants Analyzed: 105, Measure Type: Count of participants. ',\n",
       " 'inTERVENTION 1:, Subjects enrolled with device placed and treated with partial breast irradiation. ',\n",
       " 'the EORTC CIPN20 scoring algorithm was used for the sensory (items 31-36, 39, 40 and 48) subscale scores on a 0-100 scale. the aAUCpa for the subscale is calculated as the average of each AUC between each sequential assessment from pre-treatment-initiation to the week-12 assessment. positive scores represent symptoms has improved from baseline and negative scores represent symptoms has worsen from baseline. therapy repeats every week for a planned course of 12 weeks of adjuvant paclitaxel. overall number of participants Analyzed: 19, Median (Full Range), Unit of Measure: Average(subscale value*assessment) -1.4 (-11.7 to 6.8), Results 2:, Arm/Group Title: Arm II (Control), Arm/Group Description: Patients receive the standard of care only (paclitaxel at a dose of 80 mg/m2 IV) every week for ',\n",
       " 'results 1:, Arm/Group Title: Arm 1: Paclitaxel + Trastuzumab Then A C, Arm/Group Description: 4 cycles of paclitaxel 80 mg/m2 on days 1, 8 and 15 of a 28-day cycle. follow paclitaxel/trastuzumab, standard AC every 21 days for 4 cycles. Neratinib 240 mg orally once daily beginning on Day 1 of paclitaxel. standard AC every 21 days for 4 cycles. following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy. ',\n",
       " 'Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (ACT), Doxorubicin 60 mg/m2 IV bolus injection in combination with cyclophosphamide 600 mg/m2 IV bolus injection on Day 1 of every 3 weeks for 4 cycles. docetaxel 100 mg/m2 IV infusion every 3 weeks for another 4 cycles. ',\n",
       " 'inTERVENTION 2:, Part 1: Cohort 2a, MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW, inTERVENTION 2:, Part 1: Cohort 2a, MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW. ',\n",
       " 'subjects who received at least two courses of weekly paclitaxel therapy were considered to need to continue the therapy by the investigator/subinvestigator. patients with advanced or recurrent breast cancer had met the selection criteria and participated in the preceding phase II clinical study. the patient is ambulatory with a functional ECOG  2 status (see appendix 2). fluoropyrimidines or with a known sensitivity to 5-fluorouracile. patients with previous convulsions, central nervous system diseases or psychiatric diseases, including dementia, may consider clinically significant. patients with severe intellectual impairment, unable to carry out basic daily routines and established depression. gnificant precludes informed consent or interfering with compliance for oral drug intake should be excluded. patients with an active infection should be excluded. patients under radiotherapy four weeks prior to the study treatment. patients under major surgery within 4 weeks prior to study treatment. patients who lack upper gastrointestinal tract physical integrity or with malabsorption syndrome. ',\n",
       " \"patients must have a tissue diagnosis of low, intermediate or high grade ductal carcinoma in situ or ductal carcinoma in situ with microinvasion. patients must be female at least 18 years of age. patients must have a signed tissue acquisition consent. subjects should be willing to abstain from use of hormonal therapies. hormone replacement therapy, oral contraceptive pills, hormone-containing intra-uterine devices, and E-string. if a woman becomes pregnant, she should inform her study physician. if a subject is of child-bearing potential, she must have a documented negative serum or urine pregnancy test before starting treatment. if a subject is of child-bearing potential, she must have a documented negative serum or urine pregnancy test. active diagnosis of psoriasis or currently receiving treatment for psoriasis. history of known Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency. history of epilepsy or seizures in the past 20 years. women enrolled in STAR trial at site participating in co-STAR, 65 years of age or older, have not started taking the study drug OR enrolled in STAR for a minimum of one year. previous diagnoses of chronic neurologic disease (Parkinson's disease, stroke, epilepsy, multiple sclerosis), history of head injury, depression, alcohol addiction, drug addiction, and other neurologic or psychiatric conditions will be recorded but will not serve as exclusion factors. \",\n",
       " 'measurable disease defined as at least one lesion 10 mm by CT or MRI that can be accurately measured in at least one dimension. bone lesions: lytic or mixed (lytic + blastic) in the absence of measurable disease. at least 18 years of age. Able to understand and willing to sign an IRB-approved written informed consent document. ',\n",
       " 'the outcome is reported as the proportion of subjects with a discernible pattern for expression of the set of 40 evaluated genes. the outcome is reported as the proportion of subjects with a discernible pattern for expression of the set of 40 evaluated genes. ',\n",
       " 'in a woman of childbearing potential, a positive pregnancy test result, no pregnancy test result, or no reliable contraception, at baseline. a postmenopausal woman will be considered to be of childbearing potential until there has been amenorrhea for at least 12 consecutive months. prior anticancer therapy completed within four weeks prior to first day of study treatment. failure to have recovered from any toxicity of previous cancer treatment will not be excluded. ',\n",
       " 'Suramin and Paclitaxel will be infused weekly over 30 minutes. four hours after the completion of the suramin infusion the 1 hour infusion of paclitaxel will begin. ',\n",
       " 'breast cancer has continued to grow after receiving treatment with an anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor. postmenopausal women have stopped having menstrual periods. ',\n",
       " 'patients will receive radiation therapy at a dose of 180-200 cGy per fraction for 23-27 fractions to a total dose of 4600 - 4860 cGy. treatments will be given Monday through Friday. E NOT treated with ABC A SPECT scan will be obtained at baseline and at 6 months follow to determine changes in cardiac perfusion. ',\n",
       " 'measurable disease defined as at least one lesion 10 mm by CT or MRI that can be accurately measured in at least one dimension. bone lesions: lytic or mixed (lytic + blastic) in the absence of measurable disease. at least 18 years of age. Able to understand and willing to sign an IRB-approved written informed consent document. ',\n",
       " 'the investigator must confirm postmenopausal status. postmenopausal status is defined either by:, age 55 years and one year or more of amenorrhea, age  55 years and one year or more of amenorrhea and postmenopausal levels of FSH and LH per local institutional standards. non-steroidal aromatase inhibitors (i.e. letrozole or anastrozole) do not have to be the last treatment prior to enrollment. other prior anticancer therapy, e.g. tamoxifen, fulvestrant, exemestane are also allowed. serum bilirubin 1.5  ULN, fasting serum cholesterol 300 mg/dl or 7.75 mmol/L and fasting triglycerides 2.5  ULN. alanine aminotransferase (ALT) 2.5  ULN (or 5 if hepatic metastases are present). patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose galactose malabsorption must have recovered from radiotherapy toxicities prior to enrollment. radiotherapy within four weeks prior to enrollment except in case of localized radiotherapy for analgesic purpose. patients with symptomatic visceral metastasis (e.g. significant dyspnoea related to pulmonary lymphangitic carcinomatosis and lung metastases), symptomatic brain or other central nervous system metastases (CNS) metastases. active, bleeding diathesis, or on oral anti-vitamin K medication. uncontrolled or whose control may be jeopardized by the complications of this study therapy. pulmonary function tests should be considered to exclude restrictive pulmonary disease, pneumonitis or pulmonary infiltrates. patients being treated with drugs recognized as strong inhibitors or inducers of the isoenzyme CYP3A. patients must have metastatic breast cancer; tissue (a minimum of 3 slides) from most recent biopsy is required for review and confirmation of eligibility. patients must have stage IV breast cancer, patients must have metastatic tumors (primary or metastatic) that stain positively for the prolactin receptor. women of childbearing potential must commit to the use of effective barrier (non-hormonal) contraception while on study. patients must have a life expectancy of greater than 12 weeks. patients must have a life expectancy of greater than 12 weeks. patients may have had a prior diagnosis of cancer if it has been > 5 years since their last treatment. systemic treatment is allowed with a 2 week washout period prior to registration. patients who are taking herbal (alternative) medicines are NOT eligible for participation. patients must be off any such medications by the time of registration. nary, pericardial, cardiac valvular, or retroperitoneal fibrotic disorders, Gastrointestinal (GI) tract disease resulting in an inability to take oral medication, Malabsorption syndrome, Require intravenous (IV) alimentation, Uncontrolled inflammatory GI disease. ',\n",
       " 'participants will be excluded for:, any active neurologic and/or psychiatric disease, history of significant head trauma followed by persistent neurologic deficits, or known structural brain abnormalities. current major depression or another major psychiatric disorder as described in DSM-5 criteria. lness or unstable medical condition which could lead to difficulty complying with protocol including: history of myocardial infarction in the past year or unstable, severe cardiovascular disease including angina or CHF with symptoms at rest. clinically significant and/or unstable pulmonary, gastrointestinal, hepatic, or renal disease, Insulin-requiring diabetes or uncontrolled diabetes mellitus, uncontrolled hypertension. AST and ALT 3 times upper limit of normal (ULN), Bilirubin 3 times ULN, alkaline phosphatase 3 times ULN, Creatinine 2 mg/dL, no known hypersensitivity to any component of the study regimen, PRIOR CONCURRENT THERAPY:, no chronic therapeutic warfarin > 1 mg dose per day, no other concurrent investigational agents, no concurrent oral contraceptives (except for stopping menses) ',\n",
       " 'Adverse Events 1:, Total: 3/12 (25.00%), Hemoglobin 1/12 (8.33%), Alkaline phosphatase 1/12 (8.33%), Dehydration 1/12 (8.33%), Syncope 2/12 (16.67%), Dyspnea 1/12 (8.33%), Hypotension 1/12 (8.33%)Adverse Events 1:, Total: 0/115 (0.00%), Deep vein thrombosis * [1]0/115 ',\n",
       " 'ECOG performance status of 0 to 2, Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST), Exclusion Criteria:, prior or concurrent hormonal therapy for breast cancer, Histologically confirmed breast cancer, stage I-III disease, scheduled to undergo definitive surgery or other primary treatment. nant or nursing, Negative pregnancy test, Fertile patients must use effective contraception, No ongoing or active infection, No psychiatric illness or social situation that would preclude study compliance, No other uncontrolled intercurrent illness, No other uncontrolled intercurrent illness, No history of allergic reaction attributed to compounds of similar chemical or biologic composition to vorinostat, Concurrent vaginal hormone preparations (e.g., vagifem or estring) allowed, No concurrent birth control pills, No prior patients may not be taking valproic acid or another histone deacetylase inhibitor for at least 2 weeks prior to initiating SAHA. women who are pregnant may not be taking valproic acid or another histone deacetylase inhibitor for at least 2 weeks before initiating SAHA. ',\n",
       " '0/3 (0.00%)Adverse Events 1:, Total: 4/14 (28.57%), Duodenitis [1]1/14 (7.14%), Gastrooesophageal reflux disease [1]1/14 (7.14%), Vomiting [1]1/14 (7.14%), Ascites [1]1/14 (7.14%), Death [1]1/14 (7.14%), Asthenia [1]1/14 (7.14%), general physical health deterioration [1]1/14 ',\n",
       " 'TAK-228 will be orally administered at 30 mg weekly for 16 weeks. Tamoxifen will be orally administered at 20 mg daily for 16 weeks. ',\n",
       " \"FACT-B consists of 5 subscale scores pertaining to 4 well-being dimensions. Response options were 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much. nuevo Amanecer is a cognitive-behavioral stress management program delivered by peers (Spanish-speaking Latinas who have had breast cancer) the program is designed to address the first year of survivorship. the primary effectiveness endpoint is a measure of intra-operative success in addressing positive margins as detected by permanent pathology. the device is 'positive' when all positive margins, as detected by histology, on the main specimen addressed intra-operatively. MarginProbe: Device use to assess margin status of excised specimen surface. overall number of participants analysed: 163, Measure Type: Number, Unit of Measure: percentage of participants analyzed 71.8. \",\n",
       " 'patients will receive radiation therapy at a dose of 180-200 cGy per fraction for 23-27 fractions to a total dose of 4600 - 4860 cGy. treatments will be given Monday through Friday. E NOT treated with ABC A SPECT scan will be obtained at baseline and at 6 months follow to determine changes in cardiac perfusion. ',\n",
       " 'Adverse Events 1:, Total: 3/12 (25.00%), Hemoglobin 1/12 (8.33%), Alkaline phosphatase 1/12 (8.33%), Dehydration 1/12 (8.33%), Syncope 2/12 (16.67%), Dyspnea 1/12 (8.33%), Hypotension 1/12 (8.33%)Adverse Events 1:, Total: 0/115 (0.00%), Deep vein thrombosis * [1]0/115 ',\n",
       " 'male subjects aged greater than or equal to 18 years must be postmenopausal. female subjects must be 55 or older and with postmenopausal follicle-stimulating hormone [FSH] levels. subjects may have more than one synchronous primary breast tumor. bilirubin less than or equal to 1.5 times the upper limits of normal (ULN) and alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 x ULN. male subjects must have had a successful vasectomy (confirmed azoospermia) male subjects must agree to use and have their female partners use a highly effective method of contra reement to provide written informed consent and willingness to comply with all aspects of the protocol, exclusion Criteria:, Stage III and IV invasive breast cancer, Prior chemotherapy, radiation therapy, immunotherapy or biotherapy for current breast cancer, Nonmalignant systemic disease (cardiovascular, renal, hepatic, etc.) Subjects with concurrently active second malignancy other than adequately treated nonmelanoma skin cancers or in situ cervical cancer, Subjects with pre-existing neuropathy greater than Grade 2, Subject gastrointestinal disease defined as at least one lesion 10 mm by CT or MRI that can be accurately measured in at least one dimension (CT scan slice thic thic thic thic thic thic thic thic thic thic thic thic thic thic thic thic thic thic thic thic. patients with only non-measurable lesions other than lytic or mixed (lytic + blastic) bone metastasis. previous treatment with exemestane, mTOR inhibitors, PI3K inhibitors or AKT inhibitors. ',\n",
       " '5/11 (45.45%), Hemorrhage, GI-abdomen NOS 21/11 (9.09%), Pain-liver 21/11 (9.09%), Infection-ulcer 20/11 (0.00%), Pain-rib cage due to vomiting 20/11 (0.00%), Obstruction-gu ureter 1/11 (9.09%), Pain-breast 21/11 (9.09%), Pleural effusion 22/11 (18.18%), Adverse Events 2:, Total: 0 ',\n",
       " \"patients must be taking chronic opioid therapy at a stable dose for a minimum of four days. the dose of as needed short acting oxycodone does not need to be stable. patients must have cancer related neuropathic pain secondary to post-chemotherapy. patients taking methadone or with a history of methadone treatment within one month of study enrollment. neurologic or psychiatric disease sufficient, in the investigator's opinion, to compromise data collection. contralateral surgery (lumpectomy/mastectomy) at time of mastectomy, surgery cannot be performed. glucocorticoids are used in the study period. \",\n",
       " 'Adverse Events 1:, Total: 5/14 (35.71%), Ileus 1/14 (7.14%), General disorders and administration site conditions - Other, disease progression 2/14 (14.29%), Infections and infestations - Other, pneumonia 1/14 (7.14%) ',\n",
       " 'inTERVENTION 1:, Adult Cancer Patients 65 Years of Age and Older, Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older. ',\n",
       " \"the participant has a histopathologically or cytologically confirmed diagnosis of breast adenocarcinoma that is metastatic or locally-recurrent and inoperable with curative intent. the participant has measurable and/or non-measurable disease, The participant's primary and/or metastatic tumor is human Epidermal Growth Factor Receptor 2 (HER2) negative. participants of reproductive potential agree to use adequate contraceptive methods during the study period and for 12 weeks after the last dose of study medication. participant has a concurrent active malignancy other than breast adenocarcinoma, adequately treated non-melanomatous skin cancer, or other non-invasive carcinoma or in situ neoplasm. articipant has received any experimental agents within 4 weeks prior to the study registration date, The participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders. the participant has an ongoing or active infection requiring antibiotic, antifungal, or antiviral therapy. for bone disease, stable disease (SD) is allowed. patient must have tumor assessed for estrogen-receptor (ER) and progesterone-receptor (PR) prior HDCT with autologous hematopoietic stem cell transplantation (AHST) in adjuvant setting. history of other malignancies except cured non-melanoma skin cancer. \",\n",
       " 'all patients will receive GM-CSF at 250 mcg/m2 starting one day after the administration of chemotherapy x 7 days. patients with neutrophil counts below 1,000/mm3 on day 8 will continue GM-CSF therapy until the neutrophil count is greater than 1,000/mm3. ',\n",
       " 'blood bilirubin increased 1/11 (9.09%), Febrile neutropenia [1]1/11 (9.09%), Ejection fraction decreased 1/11 (9.09%), Supraventricular and nodal arrhythmia::Sinus tachycardia 1/11 (9.09%), Lymphocyte count decreased 1/11 (9.09%), Neutrophil count decreased 1/11 (9.09%), Neutrophils/granulocytes (ANC/AGC) 1/11 (9.09 ',\n",
       " 'Total: 16/51 (31.37%), Blood disorder 1/51 (1.96%), Hypomagnesemia 1/51 (1.96%), Platelets count decrease 1/51 (1.96%), Thrombosis 1/51 (1.96%), Vision-blurred vision 1/51 (1.96%), Constipation 1/51 (1.96%), Radiation oesophagitis 1/51 (1.96%), Nausea 2/51 (3.92%), Vomiting 2/51 (3.92%), Head ',\n",
       " 'inTERVENTION 2:, Part 1 and Part 2: Talazoparib (Ovarian/ Peritoneal Cancer) Participants with ovarian/ peritoneal cancer who received talazoparib capsules in Part 1 and 2 at a dose of either 600 mcg/day, 900 mcg/day, 1000 mcg/day, 1100 mcg/day. ',\n",
       " 'inTERVENTION 1:, Imaging Session 1, Fluciclatide Injection (AH111585 (18F) Injection)INTERVENTION 1:, Chloroquine Standard Dose (500mg/week) patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month standard dose chloroquine (500 mg/week) patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month low dose chloroquine (250mg/week) for 1 month prior to surgical removal of the DCIS lesion. this biopsy is entirely voluntary and is not required to remain in the study. ',\n",
       " 'female patients with histologically/cytologically proven metastatic breast carcinoma (stage IV, or recurrent with local or regional spread or distant metastatic disease), Adequate bone marrow, liver, and renal function. ',\n",
       " 'at least 18 years of age, Female, Able to understand and willing to sign an IRB-approved written informed consent document, Exclusion Criteria:, Pregnant and/or breastfeeding, Prior history of breast cancer, Prior history of chest wall radiation, Prior history of breast reconstruction, reduction, or augmentationInclusion Criteria:, Patient must be 18 and older, Patients must have histologically confirmed (by routine H&E staining) invasive adenocarcinoma or Ductal Carcino women of child-bearing potential must use effective non-hormonal contraception while undergoing radiation therapy. patients must not have a serious medical or psychiatric illness which prevents informed consent or compliance with treatment. ',\n",
       " 'locally recurrent or metastatic breast cancer must not be amenable to resection with curative intent. prior hormonal therapy in adjuvant, recurrent, or metastatic setting allowed but must have been discontinued at least 2 weeks before randomization. at least 1 week since minor surgery and/or focal/palliative radiation therapy. at least 3 weeks from radiation; at least 4 weeks from major surgery. at least 8 weeks from liver resection, thoracotomy, or neurosurgery. cBP unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months after treatment with bevacizumab. women with a positive pregnancy test on enrollment or prior to study drug administration. thracyclines not within institutional normal limits. history of high dose chemotherapy with bone marrow transplant or peripheral blood stem cell transplant within 2 years. ',\n",
       " 'inTERVENTION 1:, Imaging Session 1, Fluciclatide Injection (AH111585 (18F) Injection)INTERVENTION 1:, Chloroquine Standard Dose (500mg/week) patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month standard dose chloroquine (500 mg/week) patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month low dose chloroquine (250mg/week) for 1 month prior to surgical removal of the DCIS lesion. this biopsy is entirely voluntary and is not required to remain in the study. ',\n",
       " 'Adverse Events 1:, Total: 8/87 (9.20%), Death * [1]8/87 (9.20%), Hospitalization [2]1/87 (1.15%), Hospitalization [3]1/87 (1.15%), Adverse Events 2:, Total: 0/28 (0.00%), Death * [1]0/28 (0.00%), Hospitalization [3]0/28 (0.00%)_______________________ ',\n",
       " 'postmenopausal breast cancer (adenocarcinoma) estrogen (ER) and/or progesterone (PR) receptor positive that is locally advanced or locally recurrent and not able to be surgically removed OR with measurable and/or disease that is able to be assessed including isolated bone metastasis, Female patients 18 years or older. sient ischemic attacks in the last 6 months, no symptoms of peripheral vascular disease, no history of abdominal fistula, gastrointestinal perforation or intrabdominal abscess in the past 6 months. no known hypersensitivity to phosphate, trehalose or polysorbate, no serious non-healing wound, ulcer or bone fracture. ',\n",
       " 'patients receive cabergoline oral (PO) twice weekly for weeks 1-4. courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. ',\n",
       " 'inTERVENTION 1:, Adult Cancer Patients 65 Years of Age and Older, Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older. ',\n",
       " \"patients must be taking chronic opioid therapy at a stable dose for a minimum of four days. the dose of as needed short acting oxycodone does not need to be stable. patients must have cancer related neuropathic pain secondary to post-chemotherapy. patients taking methadone or with a history of methadone treatment within one month of study enrollment. neurologic or psychiatric disease sufficient, in the investigator's opinion, to compromise data collection. contralateral surgery (lumpectomy/mastectomy) at time of mastectomy, surgery cannot be performed. glucocorticoids are used in the study period. \",\n",
       " 'pain intensity was assessed using a 0-100 mm visual analog scale. 0 represented \"no pain\" and 100 represented \"worst possible pain\" at 0. SPID30 was calculated as the time-weighted sum of the PID scores. patients received a dose of 100 to 1600 g determined in the open-label dose titration period of the current study. overall number of participants Analyzed: 92, Mean (Standard Deviation), Unit of Measure: Units on a scale 640.3 (458.8), Results 2:, Arm/Group Title: Placebo, Arm/Group Description: Participants received placebo 3 times randomly (out of 10 treatments total) to treat up to a maximum of 2 breakthrough pain episodes per day the effect of zoledronic acid administered every 6 months on bone loss associated with surgery is to be evaluated by measuring the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine. beginning 60-90 days after surgery, patients receive zoledronate IV over 15 minutes once in months 3, 9 and 15. Mean (Full Range), Unit of Measure: g/cm2 -0.086 (-0.308 to 0.067). ',\n",
       " 'perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell), Intraoperatively prior to mastectomy. following the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction). following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement. ',\n",
       " 'Adverse Events 1:, Total: 17/50 (34.00%), Fatigue 4/50 (8.00%), Papulopustular rash 1/50 (2.00%), Alanine aminotransferase increased 5/50 (10.00%), Alkalosis 1/50 (2.00%), Anorexia 1/50 (2.00%), Hyperglycemia 2/50 (4.00%), Nervous system disorders. ',\n",
       " 'circulating tumor cells (CTCs) measured at one month post autologous hematopoietic stem cell transplantation (AHST), considered both longitudinal values and compared to the baseline number of CTCs. circulating tumor cells (CTCs) measured at one month post AHST. ',\n",
       " 'optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W. Durvalumab and tremelimumab were administered as IV infusions over 60 (5) minutes. durvalumab infusions started at least 60 minutes after the end of the tremelimumab infusion on dual dosing days. ',\n",
       " \"patients must be taking chronic opioid therapy at a stable dose for a minimum of four days. the dose of as needed short acting oxycodone does not need to be stable. patients must have cancer related neuropathic pain secondary to post-chemotherapy. patients taking methadone or with a history of methadone treatment within one month of study enrollment. neurologic or psychiatric disease sufficient, in the investigator's opinion, to compromise data collection. contralateral surgery (lumpectomy/mastectomy) at time of mastectomy, surgery cannot be performed. glucocorticoids are used in the study period. \",\n",
       " 'patients 18 years of age or older are eligible for the study. patients undergoing skin-sparing mastectomy are eligible for the study. patients who have not undergone autologous tissue breast reconstruction. must have completed surgery for stage I-III breast cancer. must have a plasma c-reactive protein level of >3mg/L. must have score of 4 (out of 10 points, 0 being no fatigue and 10 being severe, incapacitating fatigue) on a single Item Screening Scale for Fatigue. uncontrolled cardiovascular, metabolic, pulmonary or renal disease (as determined by medical history and laboratory testing), Current or past history of schizophrenia, Individuals with bipolar disorder who have experienced a manic episode within 6 months of study entry, or at the discretion of the study doctor. Individuals receiving antidepressants, mood stabilizers, antipsychotic medications or benzodiazepines or drugs known to affect the immune system (e.g. glucocorticoids, methotrexate), or at the ',\n",
       " '1/9 (11.11%), Death, not otherwise specified 0/9 (0.00%), Pain, bone 1/9 (11.11%), Adverse Events 2:, Total: 1/9 (11.11%), Death, not otherwise specified 1/9 (11.11%), Pain, bone 0/9 (0.00%)Adverse Events 1:, Total: 1/208 (0.48%), Neutrophils/granulocytes (ANC/AGC) 1/208 (0.48%), Adverse Events 2:, Total: 0/ ',\n",
       " 'Adverse Events 1:, Total: 0/7 (0.00%)Adverse Events 1:, Total: 0/11 (0.00%), Adverse Events 2:, Total: 0/11 (0.00%). ',\n",
       " 'Adverse Events 1:, Total: 0/0, Adverse Events 2:, Total: 0/0Adverse Events 1:, Total: 0/15 (0.00%) ',\n",
       " 'Results 1:, Arm/Group Title: Aprepitant, Dexamethasone, Cytoxan & Kytril. Day 1: 1 mg of Kytril orally or I.V., 10 mg of Dexamethasone orally, and Aprepitant 125 mg orally. ',\n",
       " 'patients must have metastatic or unresectable non-small cell lung cancer, head and neck cancer, urothelial transitional cell carcinoma, or breast cancer whose disease has progressed after at least one line of standard therapy. patients must have measurable disease defined as at least one lesion that can be accurately measured in at least one dimension. patients should be at least six weeks out from nitrosoureas and mitomycin C. prior radiation should have been completed greater than or equal to 4 weeks prior to study enrollment. patients must be greater than or equal to 2 weeks since any investigational agent administered as part of a Phase 0 study. cytidine (FdCyd) and Tetrahydrouridine (THU) in patients less than 18 years of age are excluded from this study. children are excluded from this study, but may be eligible for future pediatric Phase I combination trials. pregnant women will be excluded from this trial. nursing women are also excluded. there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother. active or uncontrolled infection, immune deficiencies or confirmed diagnosis of human immunodeficiency virus (HIV) infection, active infection with Hepatitis B or Hepatitis C, uncontrolled diabetes, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia. ',\n",
       " 'the women received reflexology treatment initiated at the beginning of radiation therapy, once a week (45 min each), for 10 weeks. the control group included 25 breast cancer patients scheduled for adjunctive radiation treatment. ',\n",
       " 'Capcitabine will be administered twice weekly for 14 days out of every 21 days. treatment cycles will be 21 days in length. 10 additional patients will be treated at the determined MTD. Capecitabine will be paired with LBH589. treatment cycles will be 21 days in length. 10 additional patients will be treated at the determined MTD to further assess safety. ',\n",
       " 'inTERVENTION 2:, Trabectedin, 1.3 mg/m2 of trabectedin was administered as a 3-hour intravenous infusion on Day 1. ',\n",
       " 'intravascular coagulation * 1/32 (3.13%), Febrile neutropenia * 1/32 (3.13%), Adrenal insufficiency * 1/32 (3.13%), Endocrine disorder * 1/32 (3.13%), Chills * 1/32 (3.13%), Fatigue * 1/32 (3.13%), Fever * 1/32 (3.13%), Multi-organ failure * 1/32 (3.13%), Hepatic failure * 1/32 (3.13%), Infection * 1/32 (3.13%), Sepsis 0/5 (0.00%), Platelet count decreased 0/5 (0.00%), Dehydration 1/5 (20.00%), Dysarthria 0/5 (0.00%). ',\n",
       " '0/104 (0.00%)Adverse Events 1:, Total: 45/128 (35.16%), Anaemia 3/128 (2.34%), Febrile neutropenia 2/128 (1.56%), Arrhythmia 1/128 (0.78%), Cardiac arrest 1/128 (0.78%), Cardiopulmonary failure 1/128 (0.78%), Abdominal pain 2/128 (1.56%), Ascite 2/128 (1.56%), Intestinal obstruction 2/128 (1.56%), Melaena ',\n",
       " 'inTERVENTION 2:, arm B: 3 Days/Week Schedule, CUDC-101: CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 consecutively. ',\n",
       " 'FEBRILE NEUTROPENIA * 0/3 (0.00%), ANAEMIA * 0/3 (0.00%), THROMBOCYTOPENIA * 0/3 (0.00%), ATRIAL FLUTTER * 0/3 (0.00%), BRADYCARDIA * 0/3 (0.00%), VOMITING * 0/3 (0.00%), Adverse Events 2:, Total: 0/3 (0.00%), FEBRILE NEUTROPENIA * 0/3 ',\n",
       " 'ECOG performance status of 0 to 2, Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST), Exclusion Criteria:, prior or concurrent hormonal therapy for breast cancer, Histologically confirmed breast cancer, stage I-III disease, scheduled to undergo definitive surgery or other primary treatment. nant or nursing, Negative pregnancy test, Fertile patients must use effective contraception, No ongoing or active infection, No psychiatric illness or social situation that would preclude study compliance, No other uncontrolled intercurrent illness, No other uncontrolled intercurrent illness, No history of allergic reaction attributed to compounds of similar chemical or biologic composition to vorinostat, Concurrent vaginal hormone preparations (e.g., vagifem or estring) allowed, No concurrent birth control pills, No prior patients may not be taking valproic acid or another histone deacetylase inhibitor for at least 2 weeks prior to initiating SAHA. women who are pregnant may not be taking valproic acid or another histone deacetylase inhibitor for at least 2 weeks before initiating SAHA. ',\n",
       " 'Contour Profile Tissue Expander is a tissue expander with a greater height to width ratio than traditional tissue expanders. this increased ratio allows for greater lower pole expansion, thus creating a more natural looking, ptotic breast. ',\n",
       " 'treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity. cyclophosphamide, paclitaxel, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab subjects 98 (92.2 to 99.5). subjects 98 (92.2 to 99.5) ',\n",
       " 'phase I part: patients with advanced/metastatic solid tumors, with at least one measurable lesion. phase II part: patients with advanced/metastatic solid tumors, with at least one measurable lesion. only patients with EGFR mutation-negative tumor are eligible. if more extensive EGFR mutation testing has been performed, the tumor must not harbor any known activating EGFR mutations in Exons 18-21. all patients must be tested for EGFR mutational status and for ALK translocation status if no mutation is detected in EGFR. patients with a corresponding inhibitor must have had disease progression following treatment with a corresponding inhibitor. patients must not be at short term risk for life threatening complications. patients must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy. exceptions may be granted after documented discussion with Novartis. subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. subjects with vitiligo, type I diabetes mellitus, psoriasis not requiring systemic treatment are permitted to enroll. eatment with any immunosuppressive medication (other than steroids) within 4 weeks of initiation of study treatment. use of any vaccines against infectious diseases (e.g. influenza, varicella, pneumococcus) rsing, Negative pregnancy test, Fertile patients must use effective contraception, Creatinine clearance 30 mL/min, No hypersensitivity to magnesium oxide, No medical or other condition(s) that may compromise the objectives of the study, PRIOR CONCURRENT THERAPY:, See Disease Characteristics, More than 4 weeks since prior and no concurrent antineoplastic chemotherapy, androgens, estrogens, progestational agents, or gabapentin. ',\n",
       " 'the outcome is reported as the proportion of subjects with a discernible pattern for expression of the set of 40 evaluated genes. the outcome is reported as the proportion of subjects with a discernible pattern for expression of the set of 40 evaluated genes. ',\n",
       " 'inTERVENTION 2:, Part 1: Cohort 2a, MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW, inTERVENTION 2:, Part 1: Cohort 2a, MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW. ',\n",
       " 'unilateral breast cancer with ipsilateral lumpectomy or mastectomy and lymph node dissection (sentinel biopsy or axillary dissection), stage II or III unilateral secondary upper extremity lymphedema. girth 2 cm circumferential difference and/or volume 200 mL compared to the uninvolved upper extremity at any 4 cm segment. 0 (morbid obesity) ',\n",
       " 'Benign breast disease amenable to hormonal therapy. high risk breast lesions like epitheliosis, atypia or atypical hyperplasia. ECOG performance status 0 or 1, Pre- or post-menopausal, Must possess a compact disc player, Able to complete questionnaires alone or with assistance, No active medical conditions preventing compliance with a practice of slow deep breathing including active asthma, chronic obstructive pulmonary disease, or congestive heart failure. ntidepressants started within the past 30 days allowed. no concurrent hormonal agents and/or antineoplastic chemotherapy are allowed. ',\n",
       " 'Adverse Events 1:, Total: 0/733 (0.00%), Adverse Events 2:, Total: 0/765 (0.00%)Adverse Events 1:, Total: 0/88 (0.00%), Adverse Events 2:, Total: 0/86 (0.00%). ',\n",
       " 'Adverse Events 1:, Total: 0/15 (0.00%), Adverse Events 2:, Total:Adverse Events 1:, Total: 0/442 (0.00%), Adverse Events 2:, total: 0/442 (0.00%), Adverse Events 2:, total: 0/442 (0.00%), Adverse Events 2:, total: 0/442 (0.00%). ',\n",
       " 'patient must have histologically or cytologically confirmed locally advanced, unresectable or metastatic carcinoma of the breast. patient must have performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) performance scale and life expectancy > 3 months. patients with stable and clinically insignificant CNS disease are allowed. patients must be off steroids with no new CNS symptoms or findings on radiographic imaging for 1 month. patients must be off steroids with no new CNS symptoms or findings. patients with known active central nervous system metastases and/or carcinomatous meningitis would be eligible for the study provided they are clinically stable for at least 1 month prior to entry. patients with clinically insignificant brain metastases that do not require treatment are eligible for the study. rrent illness/infection, patients with other active, current primary malignancies, other than carcinoma in situ of the cervix or non-melanoma skin cancer, patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative, patients are pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study. ',\n",
       " '89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions. PET/CT imaging with these novel radiotracers will allow evaluation of all identifiable malignant lesions. ',\n",
       " 'Adverse Events 1:, Total: 0/7 (0.00%)Adverse Events 1:, Total: 0/11 (0.00%), Adverse Events 2:, Total: 0/11 (0.00%). ',\n",
       " '0/3 (0.00%)Adverse Events 1:, Total: 4/14 (28.57%), Duodenitis [1]1/14 (7.14%), Gastrooesophageal reflux disease [1]1/14 (7.14%), Vomiting [1]1/14 (7.14%), Ascites [1]1/14 (7.14%), Death [1]1/14 (7.14%), Asthenia [1]1/14 (7.14%), general physical health deterioration [1]1/14 ',\n",
       " \"the participant has a histopathologically or cytologically confirmed diagnosis of breast adenocarcinoma that is metastatic or locally-recurrent and inoperable with curative intent. the participant has measurable and/or non-measurable disease, The participant's primary and/or metastatic tumor is human Epidermal Growth Factor Receptor 2 (HER2) negative. participants of reproductive potential agree to use adequate contraceptive methods during the study period and for 12 weeks after the last dose of study medication. participant has a concurrent active malignancy other than breast adenocarcinoma, adequately treated non-melanomatous skin cancer, or other non-invasive carcinoma or in situ neoplasm. articipant has received any experimental agents within 4 weeks prior to the study registration date, The participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders. the participant has an ongoing or active infection requiring antibiotic, antifungal, or antiviral therapy. for bone disease, stable disease (SD) is allowed. patient must have tumor assessed for estrogen-receptor (ER) and progesterone-receptor (PR) prior HDCT with autologous hematopoietic stem cell transplantation (AHST) in adjuvant setting. history of other malignancies except cured non-melanoma skin cancer. \",\n",
       " 'Objective cognitive function measured with a computerized test battery of 7 tasks. performance speed is measured for Detection/Identification/Monitoring. performance accuracy is measured for memory/Learning/ISLT/ISLT-Delayed Recall. negative standardized score indicates below average results. patients complete assessments at baseline and 1 year after randomization to parent IBCSG 24-02 study. the analysis plan was revised to pre-specify collective analysis for all patients receiving OFS. overall number of participants Analyzed: 54, Mean (Standard Deviation), Unit of Measure: standardized units -0.21 (0.92). ',\n",
       " 'intraoperative handheld gamma camera (pIHGC) involves injection of 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid around at the tumor site. ',\n",
       " 'disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as a 20% increase in the sum of the longest diameter of target lesions, or progression in a non-target lesion, or the appearance of new lesions. unit of measure: months 2.8 (1.6 to 3.2), Results 2:, Arm/Group Title: CDX-011. CDX-011 administered on day 1 of each 21 day cycle until disease progression, discontinuation due to toxicity, withdrawal of consent, or end of study. ',\n",
       " 'doxorubicin hydrochloride: Given IV, cyclophosphamide: Given PO, paclitaxel: Given IV, filgrastim: Given SC, capecitabine: Given PO, methotrexate: Given IV, vinorelbine tartrate: Given IV, needle biopsy: Correlative studies, therapeutic conventional surgery: Undergo definitive breast surgery, immunohistochemistry staining method: Correlative studies, trastuzumab: Given ',\n",
       " 'ANAEMIA 13/2002 (0.65%), BONE MARROW FAILURE 1/2002 (0.05%), FEBRILE NEUTROPENIA 1/2002 (0.05%), THROMBOCYTOPENIA 11/2002 (0.55%), ACUTE CORONARY SYNDROME 3/2002 (0.15%), ANGINA PECTORIS 1/2002 (0.05%), CARDIAC ARREST 1/2002 (0.05%), CARDIAC TAMPONADE 1/2002 ',\n",
       " 'participants received 1250 milligram (mg) tablets lapatinib once a day and vinorelbine 20 mg/meters squared (m2) intravenously on Day 1 and Day 8, and every 3 weeks. participants received 1250 milligram (mg) tablets lapatinib once a day. ticipants Analyzed: 25, Measure Type: Number, Unit of Measure: participants Week 12, CR: 0, Week 12, PR: 4, Week 12, SD: 12, Week 24, CR: 0, Week 24, PR: 4, Week 24, SD: 10_ ',\n",
       " \"in case of Gilbert's syndrome, 2 x ULN is allowed, AST (SGOT/ALT(SGPT)= 2.5 X institutional upper limit of normal, Alkaline phosphatase = 2.5 x ULN, Creatinine within normal institutional limits, Cardiac ejection fraction within the institutional range of normal as measured by echocardiogram or MUGA scan. eligibility of patients receiving medications or substances known to affect, or with the potential to affect, the effects of lapatinib on the developing human fetus at the recommended therapeutic dose are unknown. women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation. prior treatment with EGFR targeting therapies, treatment with any other investigational agents, or with all herbal (alternative) medicines. history of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib. uncontrolled inter-current illness including, but not limited to, ongoing or active infection. ammatory GI disease (e.g., Crohn's, ulcerative colitis), concomitant requirement for medication classified as CYP3A4 inducers or inhibitors. \",\n",
       " \"in case of Gilbert's syndrome, 2 x ULN is allowed, AST (SGOT/ALT(SGPT)= 2.5 X institutional upper limit of normal, Alkaline phosphatase = 2.5 x ULN, Creatinine within normal institutional limits, Cardiac ejection fraction within the institutional range of normal as measured by echocardiogram or MUGA scan. eligibility of patients receiving medications or substances known to affect, or with the potential to affect, the effects of lapatinib on the developing human fetus at the recommended therapeutic dose are unknown. women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation. prior treatment with EGFR targeting therapies, treatment with any other investigational agents, or with all herbal (alternative) medicines. history of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib. uncontrolled inter-current illness including, but not limited to, ongoing or active infection. ammatory GI disease (e.g., Crohn's, ulcerative colitis), concomitant requirement for medication classified as CYP3A4 inducers or inhibitors. \",\n",
       " 'patients will take Vorinostat daily during radiation therapy. they will be recommended to swallow the capsule 60-90 minutes prior to estimate time of radiation. ',\n",
       " \"2.3 Dental evaluation according to the dental exam checklist (carried out by the investigator, the investigator's designee, or by a qualified dental professional [dental hygienist or dentist]) if the patient has received prior oral bisphosphonate therapy within 8 weeks of registration, the evaluation should not be revoked. complete blood count (CBC)/differential within 2 weeks prior to registration, with adequate bone marrow function defined as follows: White blood cell count (WBC) 2400 cells/mm3; Absolute neutrophil count (ANC) 1,800 cells/mm3; Platelets 60,000 cells/mm3; Hemoglobin 8.0 g/dl (Note: The use of transfusion or other intervention to achieve the required hemoglobin is permitted) beam radiation therapy must be completed 14 days prior to registration. patients with no evidence of disease in the brain after treatment for brain metastases are eligible. prior treatment with Strontium-89 or Samarium-153 for bone metastases. prior treatment with IV bisphosphonates prior to study entry. current, active dental problems within 4 weeks of registration. the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. pregnant or lactating patients are excluded as treatment may be harmful to embryos and/or nursing infants. the study should be finished 30 days before the beginning of the study. if the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose of anthracyclines should not exceed 250 mg/m2 for doxorubicin or 540 mg/m2 for epirubicin. n or 660 mg/m2 for epirubicin, if in this study planned 4 cycles of chemotherapy. patients of childbearing potential must implement reliable contraceptive measures. f bone metastases) administration of any experimental drugs within 30 days prior randomization. conditions limiting patient's ability to follow protocol. \",\n",
       " 'inTERVENTION 1:, wait-list, patients in wait-list control group will cross over and receive acupuncture twice weekly for six consecutive weeks. patients will be advised to continue their standard lymphedema treatments such as exercise or use of compression garments if these were in use prior to clinical trial participation. rmed after approximately 6 weeks on wait-list, before onset of acupuncture treatment. BMI will be measured at the same timepoints. ',\n",
       " 'asymptomatic women scheduled for screening mammography or have completed a screening mammogram within the past 30 days. subjects with prior lumpectomy (> 5 years prior) who receive only routine screening mammography views can be included. x 31 centimeter (cm) FFDM digital receptor without anatomical cut off during either FFDM or DBT examination. have participated in (within the prior 30 days) another trial of an investigational product expected to interfere with study procedures or outcomes. ',\n",
       " 'patients will take Vorinostat daily during radiation therapy. they will be recommended to swallow the capsule 60-90 minutes prior to estimate time of radiation. ',\n",
       " 'doxorubicin and cyclophosphamide may alter the concentration-time profile of doxorubicin or cyclophosphamide. the effects of doxorubicin and cyclophosphamide on pregnancy are unknown. participants unwilling to comply with study procedures. all other drugs will be reviewed during screening of the patientINCLUSION CRITERIA:, patients with histologically documented:, BRCA-positive ovarian cancer (documented deleterious BRCA1/2 mutation or a BRCAPRO score of greater than or equal to 30%), serous carcinoma or fallopian tube cancer (no requirement for BRCA status), triple-negative breast cancer (documented estrogen receptor (ER) negative, progesterone receptor (PR) negative, and human epidermal patients must have measurable disease defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as greater than or equal to 20 mm with conventional techniques or as greater than or equal to 10 mm with spiral computed tomography (CT scan) any prior therapy or radiotherapy must have been completed greater than or equal to 4 weeks. patients must be greater than or equal to 2 weeks since any investigational agent administered as part of a Phase 0 study. patients who have had prior treatment with any PARP inhibitors are eligible unless the PARP inhibitor was administered in combination with cyclophosphamide. children are excluded from this study. the effects of ABT-888 on the developing human fetus are unknown. cyclophosphamide hydrochloride is known to be teratogenic. women of childbearing potential must agree to use adequate contraception. breastfeeding should be discontinued while the patient is on this trial. there is a risk for adverse events in nursing infants secondary to treatment of the mother with cyclophosphamide. patients with history of central nervous system (CNS) metastases who have received treatment and have had no seizures x 3 months will be eligible. subjects with ulcerative colitis, inflammatory bowel disease, or a partial or complete small bowel obstruction are also excluded. ups are eligible for this trial. ',\n",
       " 'participants received lenalidomide 5mg orally daily for 57 +/- 3 daysINTERVENTION 1:, Lapatinib 1500 mg, Oral lapatinib (1500 milligrams [mg] daily) for 6 weeks, followed by lapatinib plus weekly paclitaxel (80 mg per meters squared [mg/m2]) intravenous (IV) for an additional 12 weeks. ',\n",
       " '0/33 (0.00%)Adverse Events 1:, Total: 5/16 (31.25%), ANAEMIA 1/16 (6.25%), LEUKOPENIA 1/16 (6.25%), NEUTROPENIA 3/16 (18.75%), THROMBOCYTOPENIA 1/16 (6.25%), FEBRILE INFECTION 1/16 (6.25%), PNEUMONIA 1/16 (6.25%), PNEUMONIA 1/16 (6.25%), PNEUMONIA 1/16 ( ',\n",
       " 'result at baseline minus result at baseline as a percentage of the result at baseline. back transformation of the least squares mean based on log transformed data. ',\n",
       " 'ER positive, HER2 negative invasive breast cancer (Group 1) or invasive triple-negative breast cancer (Group 2), Free of metastatic disease, 18 years old, Female, Had no prior treatment for any cancer, Eligible for treatment with paclitaxel, doxorubicin and cyclophosphamide. ',\n",
       " 'invasive disease-free survival time is defined as the time from date of randomization until time of event up to 2 years. time is defined as the time from date of randomization until time of event up to 2 years. patients who completed prior adjuvant trastuzumab received six placebo tablets (240 mg) taken orally once daily with food, preferably in the morning, continuously for one year. therapy continued until unacceptable toxicity, recurrent disease, death, or withdrawal of consent occurred. ',\n",
       " 'inTERVENTION 2:, Part A: V934 LD(3)+V935 LD, 3 IM injections of V934 (LD) were administered, 1 given every other week over a 3-week period. following a 4 week observation period, 2 IM injections of V935 (LD) were administered. ',\n",
       " 'Anaemia 1/106 (0.94%), Febrile neutropenia 1/106 (0.94%), Thrombocytopenia 1/106 (0.94%), Atrial fibrillation 1/106 (0.94%), Cardio-respiratory arrest 1/106 (0.94%), Palpitations 1/106 (0.94%), Pericardial effusion 2/106 (1.89%), Abdominal pain upper 1/106 (0.94%), Ascite 1/106 (0.94%), Constipation 1/106 ( ',\n",
       " 'Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W, Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W, INTERVENTION 2:, Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W. ',\n",
       " 'neoadjuvant therapy will consist of epirubs, epirubs and epirubs. neoadjuvant therapy will consist of epirubs, epirubs, epirubs and epirubs. icin + cyclophosphamide (600 mg/m2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m2) every 2 weeks for 4 cycles + trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments. ',\n",
       " 'Outcome Measurement:, Recurrence-free Survival, 2 years for the primary analysis + 3 additional years for secondary analysis. Time frame: 5 years, Results 1:, Arm/Group Title: Ketorolac 30 mg, Arm/Group Description: Active drug to be compared with placebo, Ketorolac 30 mg IV, Overall number of participants Analyzed: 96, Measure Type: Count of participants, Unit of Measure: Participants 80 83.3%, Results 2:, Arm/ ',\n",
       " 'Adverse Events 1:, Total: 6/50 (12.00%), Ventricular tachycardia 1/50 (2.00%), Fever [1]1/50 (2.00%), Flu like symptoms 1/50 (2.00%), Catheter related infection 2/50 (4.00%), Suicidal ideation * [2]1/50 (2.00%), Thromboembolic event 1/50 (2.00%). ',\n",
       " 'patients must have histologically confirmed breast cancer that is ER positive and/or PR positive, and HER2/neu negative disease determined using commercially available/approved assay in local institutional or reference laboratory. ER/PR expression performed by standard immunohistochemical assay and classified as ER and/or PR-positive according to ASCO/CAP guidelines (1-100% expression) patients must have had progressive disease during at least one line of endocrine therapy. prior treatments include a non-steroidal aromatase inhibitor, tamoxifen, fulvestrant or combinations. patients taking bisphosphonates for bone disease are permitted to enter the trial. postmenopausal status defined as 60 years and older, 45 years and older, having amenorrhea x 12 months or follicle stimulating hormone levels within postmenopausal range, OR having a bilateral oophorectomy. patients may not be receiving any other investigational agents. having at least 6 weeks of treatment remaining, 21 years old, Able to understand written and spoken English, Able to swallow medication (until amendment omitting armodafinil treatment), Score of 3+ on the Sleep Disruption Evaluation form, OR a score of 8+ on Insomnia Severity Index (ISI), EXCLUSION CRITERIA, Prior treatment with armodafinil or modafinil (until amendment omitting armodafini history of uncontrolled, cardiac disease, hypertension, severe headaches, glaucoma, or seizures (until amendment omitting armodafinil treatment) of chronic, preexisting insomnia, sleep apnea, or restless leg syndrome (RLS) ',\n",
       " 'circulating tumor cells (CTCs) measured at one month post autologous hematopoietic stem cell transplantation (AHST), considered both longitudinal values and compared to the baseline number of CTCs. circulating tumor cells (CTCs) measured at one month post AHST. ',\n",
       " 'result at baseline minus result at baseline as a percentage of the result at baseline. back transformation of the least squares mean based on log transformed data. ',\n",
       " '3/37 (8.11%), Sinus tachycardia 0/37 (0.00%), Heart failure 0/37 (0.00%), Dehydration 1/37 (2.70%), Death Not Associated with CTCAE: Death NOS 1/37 (2.70%), Lymphopenia 1/37 (2.70%), Neutropenia 1/37 (2.70%), Thrombocytopenia 0/37 (0.00%), Hyponatremia 1/37 (2.70%), Weight loss 0/37 ( ',\n",
       " 'one to three presumed brain metastases must be from a histologically confirmed extracerebral site (e.g., lung, breast, prostate), Histologic confirmation may have been from the primary tumor site, from another metastatic site (e.g., osseous metastasis, adrenal metastasis), or from the metastatic brain lesion(s) Each lesion must measure less than 3.0 cm by contrast MRI of the brain performed within the past 21 days. male patients must continue to use contraception for 3 months after the completion of radiotherapy. no pacemaker or other MRI-incompatible metal in the body, no known allergy to gadolinium, no known allergy to gadolinium. volunteers may have had a prior history of other cancers > 3 years which required only local resection, local radiation and/or hormonal therapy such as androgen blockade. d risk of the proposed study and be able to sign consent. e influenza vaccine, On-going neurologic disorder (mental status change, uncontrolled seizures, encephalopathy), Treatment or planned treatment with cyclophosphamide, ifosphamide, or > or = to 1 mg/kg prednisone or its equivalent 12 weeks within 12 weeks of vaccination. patients receiving the seasonal influenza vaccine may not have had it within 6 months of enrollment. ',\n",
       " 'patients receive doxorubicin HCl liposome IV 40mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28. inTERVENTION 2:, Placebo, Arm II: Patients receive doxorubicin HCl liposome IV 40mg/m2 over 1 hour on day 1. ',\n",
       " 'ECOG performance status of 0 to 2, Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST), Exclusion Criteria:, prior or concurrent hormonal therapy for breast cancer, Histologically confirmed breast cancer, stage I-III disease, scheduled to undergo definitive surgery or other primary treatment. nant or nursing, Negative pregnancy test, Fertile patients must use effective contraception, No ongoing or active infection, No psychiatric illness or social situation that would preclude study compliance, No other uncontrolled intercurrent illness, No other uncontrolled intercurrent illness, No history of allergic reaction attributed to compounds of similar chemical or biologic composition to vorinostat, Concurrent vaginal hormone preparations (e.g., vagifem or estring) allowed, No concurrent birth control pills, No prior patients may not be taking valproic acid or another histone deacetylase inhibitor for at least 2 weeks prior to initiating SAHA. women who are pregnant may not be taking valproic acid or another histone deacetylase inhibitor for at least 2 weeks before initiating SAHA. ',\n",
       " '0/42 (0.00%)Adverse Events 1:, Total: 6/6 (100.00%), Anemia1/6 (16.67%), Constipation1/6 (16.67%), Mucositis1/6 (16.67%), Vomiting0/6 (0.00%), Dehydration0/6 (0.00%), Abdominal pain0/6 (0.00%), Ascites0/6 (0.00%), Diarrhea0/6 (0.00%), Fatigue0/6 (0.00%), Death NOS1 ',\n",
       " 'cases with stage II-IIIA breast cancer have completed adjuvant treatment with anthracyclines and/or taxanes + or -Radiation therapy within past 6 months(+/- 7 days) Must be aware of the nature of his current medical condition and must be willing to give consent after being informed of the experimental nature of therapy, alternatives, potential benefits, side-effects, risks and discomfort. use of estrogens (oral, dermal or vaginal), progesterone (oral or topical), androgens, androgens, Raloxifene or Tamoxifen during the previous 3 months. use of over the counter steroid hormonal supplements including dehydroepiandrosterone (DHEA), patients with advanced or Stage IIIIB or IV breast cancer or other cancers. l or psychiatric condition or laboratory abnormality may increase risk associated with study participation or study drug administration. investigator would make potential participant inappropriate for entry into this study. ',\n",
       " 'measurable disease defined as at least one lesion 10 mm by CT or MRI that can be accurately measured in at least one dimension. bone lesions: lytic or mixed (lytic + blastic) in the absence of measurable disease. at least 18 years of age. Able to understand and willing to sign an IRB-approved written informed consent document. ',\n",
       " 'ECOG performance status of 0, Previous non-metastatic operable primary invasive HER2-positive breast cancer, Baseline LVEF >55%, Exclusion Criteria:, Healthy Participants (Part 1 only), Clinically significant abnormalities in laboratory test results or electrocardiogram. history of significant allergies, gastrointestinal, renal, hepatic, cardiovascular, or pulmonary disease, hypersensitivity or allergic reaction, spontaneous or following drug administration. bothersome hot flashes for 1 month prior to study entry, PATIENT CHARACTERISTICS:, Eastern Cooperative Oncology Group (ECOG) performance status 0-1, Life expectancy 6 months, Able to complete questionnaire(s) by themselves or with assistance, Women of childbearing potential not eligible. al estrogen is allowed if used for the past month and not planned to be discontinued, concurrent adjuvant targeted therapy (i.e., lapatinib, trastuzumab [Herceptin®] allowed in patients with no evidence of disease, Concurrent tamoxifen, raloxifene, or aromatase inhibitors on a constant dose for at least 4 weeks allowed provided the medication will not be stopped during the study period. ',\n",
       " 'Diarrhoea 1/6 (16.67%), Chest pain 1/6 (16.67%), General physical health deterioration 0/6 (0.00%), Biliary colic 1/6 (16.67%), Clostridium difficile colitis 0/6 (0.00%), Infusion related reaction 1/6 (16.67%), Hypokalaemia 0/6 (0.00%), Tumour lysis syndrome 0/6 (0.00%), Spinal cord compression 0/6 (0.00%), Acute kidney ',\n",
       " 'Isothiocyanate included sulforaphane in micromolar (M) concentration was measured following standard chemical measurement procedures and divided by creatinine values in millimolar (mM) concentration. patients receive oral placebo supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity. Numeric Pain Rating Scale - pain rating scale 0-10 (0= no pain to 10= most pain imaginable) participants were re-assessed after the 2 round of TC and 4th round of FECD. atment, Overall Number of Participants Analyzed: 22, Measure Type: Number, Unit of Measure: percentage of participants Percentage of Participants with Pain (1-10): 30, Percentage of Participants with no pain (0): 70, Results 2:, Arm/Group Title: Control, Arm/Group Description: chemotherapy as usual without physical therapy. ',\n",
       " 'postmenopausal breast cancer (adenocarcinoma) estrogen (ER) and/or progesterone (PR) receptor positive that is locally advanced or locally recurrent and not able to be surgically removed OR with measurable and/or disease that is able to be assessed including isolated bone metastasis, Female patients 18 years or older. sient ischemic attacks in the last 6 months, no symptoms of peripheral vascular disease, no history of abdominal fistula, gastrointestinal perforation or intrabdominal abscess in the past 6 months. no known hypersensitivity to phosphate, trehalose or polysorbate, no serious non-healing wound, ulcer or bone fracture. ',\n",
       " 'ductal breast carcinoma in situ (DCIS), or lobular carcinoma in situ (LCIS) (currently without evidence of malignant disease) OR a concern about taking estrogen for fear of breast cancer, Bothersome hot flashes (defined by their occurrence of >= 28 times per week) se inhibitors/serotonin?norepinephrine reuptake inhibitors are allowed. patient must have been on a constant dose for at least 28 days. if patient has history of GERD despite appropriate therapy. symptoms are well-controlled with medical treatment, patient is eligible, patient is eligible, Ulcerative colitis, Narrow-angle glaucoma, Urinary retention, Hypersensitivity to oxybutynin or any other components of the product, Current uncontrolled hyperthyroidism, Coronary heart disease (angina or prior myocardial infarction), congestive heart failure, Symptomatic cardiac arrhythmias, Current uncontrolled hypertension, Myasthenia gravis, Dement ',\n",
       " 'pain intensity was assessed using a 0-100 mm visual analog scale. 0 represented \"no pain\" and 100 represented \"worst possible pain\" at 0. SPID30 was calculated as the time-weighted sum of the PID scores. patients received a dose of 100 to 1600 g determined in the open-label dose titration period of the current study. overall number of participants Analyzed: 92, Mean (Standard Deviation), Unit of Measure: Units on a scale 640.3 (458.8), Results 2:, Arm/Group Title: Placebo, Arm/Group Description: Participants received placebo 3 times randomly (out of 10 treatments total) to treat up to a maximum of 2 breakthrough pain episodes per day the effect of zoledronic acid administered every 6 months on bone loss associated with surgery is to be evaluated by measuring the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine. beginning 60-90 days after surgery, patients receive zoledronate IV over 15 minutes once in months 3, 9 and 15. Mean (Full Range), Unit of Measure: g/cm2 -0.086 (-0.308 to 0.067). ',\n",
       " 'ovarian cancer patients should have one prior platinum-based, chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound. patients with platinum-sensitive and platinum resistant disease are NOT eligible. the effects of BMN 673 on the developing human fetus are unknowable. the effects of BMN 673 on the developing human fetus are unknown. men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 30 days after completing study treatment. men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for the duration of study participation. human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer should have received at least two lines of systemic therapy. patients with prostate cancer can continue to receive treatment with GnRH agonists while on study, as long as there is evidence of disease progression on therapy. nt of brain metastases are eligible to participate at the discretion of the principal investigator. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations would limit compliance with study requirements. patients who require use of coumarin-derivative anticoagulants are excluded. low-dose warfarin (less than or equal to 1 mg/day) is permitted. in subjects with documented liver metastases, the AST/ALT may be 5x ULN, Prothrombin time 1.5x ULN, unless receiving therapeutic anticoagulation, Serum magnesium and potassium within normal limits. subjects with documented liver metastases are eligible if controlled on a stable dose 10mg prednisone/day or its equivalent dose of steroids. Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C. subjects with liver cancer and hepatitis may be eligible. ',\n",
       " 'male subjects aged greater than or equal to 18 years must be postmenopausal. female subjects must be 55 or older and with postmenopausal follicle-stimulating hormone [FSH] levels. subjects may have more than one synchronous primary breast tumor. bilirubin less than or equal to 1.5 times the upper limits of normal (ULN) and alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 x ULN. male subjects must have had a successful vasectomy (confirmed azoospermia) male subjects must agree to use and have their female partners use a highly effective method of contra reement to provide written informed consent and willingness to comply with all aspects of the protocol, exclusion Criteria:, Stage III and IV invasive breast cancer, Prior chemotherapy, radiation therapy, immunotherapy or biotherapy for current breast cancer, Nonmalignant systemic disease (cardiovascular, renal, hepatic, etc.) Subjects with concurrently active second malignancy other than adequately treated nonmelanoma skin cancers or in situ cervical cancer, Subjects with pre-existing neuropathy greater than Grade 2, Subject gastrointestinal disease defined as at least one lesion 10 mm by CT or MRI that can be accurately measured in at least one dimension (CT scan slice thic thic thic thic thic thic thic thic thic thic thic thic thic thic thic thic thic thic thic thic. patients with only non-measurable lesions other than lytic or mixed (lytic + blastic) bone metastasis. previous treatment with exemestane, mTOR inhibitors, PI3K inhibitors or AKT inhibitors. ',\n",
       " 'patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3. overall number of participants Analyzed: 234, Mean (Standard Deviation), Unit of Measure: units on a scale 1.88 (1.27), Results 2:, Arm/Group Title: Arm III, Arm/Group Description: Patients receive palonosetron hydroch acebo: Given orally or IV, palonosetron hydrochloride : Given orally or IV, dexamethasone : Given orally or IV, overall number of participants Analyzed: 241, Mean (Standard Deviation), Unit of Measure: units on a scale 1.65 (1.15)_ ',\n",
       " '89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions. PET/CT imaging with these novel radiotracers will allow evaluation of all identifiable malignant lesions. ',\n",
       " 'Adverse Events 1:, Total: 0/733 (0.00%), Adverse Events 2:, Total: 0/765 (0.00%)Adverse Events 1:, Total: 0/88 (0.00%), Adverse Events 2:, Total: 0/86 (0.00%). ',\n",
       " 'Febrile neutropenia * 2/5 (40.00%), Anaemia * 0/4 (0.00%), Vertigo * 0/4 (0.00%), Nausea * 0/4 (0.00%), Stomatitis * 0/4 (0.00%), Vomiting * 0/4 (0.00%), Disease progression * 0/4 (0.00%), Mucosal inflammation * 0/4 (0.00%), Fatigue * 0/4 (0.00%), Pyrexia * 0/4 (0.00%), Ga ',\n",
       " '77/122 (63.11%), Anaemia 1/122 (0.82%), Thrombocytopenia 1/122 (0.82%), Pericardial effusion 3/122 (2.46%), Supraventricular tachycardia 2/122 (1.64%), Atrial fibrillation 1/122 (0.82%), Sinus tachycardia 1/122 (0.82%), Hypothyroidism 1/122 (0.82%), Abdominal pain 4/122 (3.28%)Adverse ',\n",
       " 'Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (ACT), Doxorubicin 60 mg/m2 IV bolus injection in combination with cyclophosphamide 600 mg/m2 IV bolus injection on Day 1 of every 3 weeks for 4 cycles. docetaxel 100 mg/m2 IV infusion every 3 weeks for another 4 cycles. ',\n",
       " 'TAK-228 will be orally administered at 30 mg weekly for 16 weeks. Tamoxifen will be orally administered at 20 mg daily for 16 weeks. ',\n",
       " 'intra-patient difference in hot flash activity between baseline (study week 1) and treatment termination (study week 7) is the primary endpoint. the daily hot flash score is computed by multiplying the mean grade of severity by the frequency during every 24 hour period. the average daily hot flash score during the baseline week was compared to the average daily value during week 7. patients receive 1 NutrigradTM flaxseed bar containing 7.5 grams flaxseed, 410 mg lignans,once daily. overall number of participants Analyzed: 77, Mean (Standard Deviation), Unit of Measure: units on a scale -4.9 (6.41), Results 2:, Arm/Group Title: Placebo, Arm/Group Description: Patients Identical looking bar with same calorie and total fat content but without flaxseed or lign ORR was defined as the proportion of participants who achieved a best response of either CR or PR. time frame: baseline & every 2 cycles (approximately 8 weeks) of treatment to measured progressive disease (PD) & post-therapy until PD or other therapy initiated. us Gemcitabine (PB+G), arm/group Description: paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by gemcitabine 1500 mg/m2 IV on days 1 and 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days. ',\n",
       " 'participants received lenalidomide 5mg orally daily for 57 +/- 3 daysINTERVENTION 1:, Lapatinib 1500 mg, Oral lapatinib (1500 milligrams [mg] daily) for 6 weeks, followed by lapatinib plus weekly paclitaxel (80 mg per meters squared [mg/m2]) intravenous (IV) for an additional 12 weeks. ',\n",
       " 'Adverse Events 1:, Total: 8/30 (26.67%), Heart Failure 1/30 (3.33%), Vertigo 1/30 (3.33%), Small intestinal obstruction 1/30 (3.33%), Fever 1/30 (3.33%), Aspartate aminotransferase increased 1/30 (3.33%), Alanine aminotransferase increased 1/30 (3.33%), Back Pain 1/30 (3.33%), Pleural effusion 1/30 (3.33%), Rash maculo-papular 1/30 (3.33%) ',\n",
       " 'have received at least 1 but no more than 4 prior systemic therapies, have adequate organ function, have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale, have estimated life expectancy greater than or equal to (12 weeks), have fully recovered from radiation therapy or surgery. have discontinued all chemotherapy, investigational therapy, molecularly-targeted therapy, and cancer-related hormonal therapy at least 14 days prior, biologic or immunotherapeutic therapy at least 21 days prior, or mit atic (excluding primary brain tumor), Phase 2 Have disease measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1, Have disease measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1, Have evidence of a solid tumor that is locally advanced and/or metastatic, and in:, Small Cell Lung Cancer (SCLC), must have failed platinum-containing therapy, be Estrogen Receptor positive and/or Progesterone Receptor positive disorder, organ transplant, pregnant or nursing, HIV, active Hepatitis B or C, cardiac disease, history of major surgery in upper gastrointestinal (GI) tract or GI disease, hypokalemia, hypomagnesaemia or hypocalcaemia that cannot be controlled. ',\n",
       " 'CR is defined as the disappearance of all lesions (target and/or non-target) PR is defined as at least a 30% decrease in the sum of the longest dimensions (LD) of target lesions taking as a reference the baseline sum LD, with non-target lesions not increased or absent. ast 6 cycles., Overall Number of Participants Analyzed: 60, Measure Type: Number, Unit of Measure: percentage of participants 53_. ',\n",
       " 'women with a clinically or mammographically identified suspicious breast mass likely to be biopsied or surgically removed. Exclusion Criteria:, Pregnancy, Ferromagnetic implants, history of shotgun wounds and shrapnel, Obesity (>250 pounds), Cardiac pacemaker, Incompatible implanted medical device, Severe asthma and allergies. ',\n",
       " 'a log ratio of expression was generated relative to reference in both the Up and DOWN arms of the gene signature. a log ratio value of zero indicated no change in expression between the two samples. overall number of participants Analyzed: 14, Measure Type: Number, Unit of Measure: Percentage of participants 28.6 (13.1 to 49.2), Results 2:, Arm/Group Title: Triple Negative (TN), Arm/Group Description: Triple Negative participants received a single dose of dalotuzumab 20 mg/kg infused over 60-120 minutes. ',\n",
       " 'asymptomatic women scheduled for screening mammography or have completed a screening mammogram within the past 30 days. subjects with prior lumpectomy (> 5 years prior) who receive only routine screening mammography views can be included. x 31 centimeter (cm) FFDM digital receptor without anatomical cut off during either FFDM or DBT examination. have participated in (within the prior 30 days) another trial of an investigational product expected to interfere with study procedures or outcomes. ',\n",
       " 'Adverse Events 1:, Total: 0/34 (0.00%)Adverse Events 1:, Total: 0/1 (0.00%)Adverse Events 1:, Total: 0/1 (0.00%) ',\n",
       " 'the women received reflexology treatment initiated at the beginning of radiation therapy, once a week (45 min each), for 10 weeks. the control group included 25 breast cancer patients scheduled for adjunctive radiation treatment. ',\n",
       " 'inTERVENTION 1:, arm A (ANA), patients receive oral anastrozole as 1 mg film-coated tablets. patients receive fulvestrant intramuscularly (250 mg/5 ml solution) on days 1, 14 and 28. ',\n",
       " \"19/149 (12.75%), Anaemia 0/149 (0.00%), Anaemia 0/149 (0.00%), Acute myocardial infarction 1/149 (0.67%), Prinzmetal angina 1/149 (0.67%), Meniere's disease 0/149 (0.00%), Vertigo 0/149 (0.00%), Cataract 2/149 (1.34%), Colitis ischaemic 1/149 (0.67%), Nausea 0/149 (0.00 \",\n",
       " '5/18 (27.78%), Anaemia 1/18 (5.56%), Febrile neutropenia 1/18 (5.56%), Pancytopenia 0/18 (0.00%), Thrombocytopenia 1/18 (5.56%), Acute myocardial infarction 1/18 (5.56%), Eye pain 1/18 (5.56%), Diarrhoea 1/18 (5.56%), Intestinal obstruction 1/18 (5.56%), Nausea 0/18 (0.00%), Small intestinal obstruction 0 ',\n",
       " 'women with a clinically or mammographically identified suspicious breast mass likely to be biopsied or surgically removed. Exclusion Criteria:, Pregnancy, Ferromagnetic implants, history of shotgun wounds and shrapnel, Obesity (>250 pounds), Cardiac pacemaker, Incompatible implanted medical device, Severe asthma and allergies. ',\n",
       " 'patients must have axillary lymph node involvement assessment and initiation of study treatment of less than or equal to 84 days. resected specimen must be free of invasive disease and/or ductal carcinoma in situ (DCIS) patients receiving anti-coagulation treatment with an agent such as warfarin may be allowed to participate. patients with HER2 positive breast cancer as determined by FISH or IHC3+ standing are ineligible for this trial. c blood pressure > 100 mmHg on antihypertensive medications. current therapy with raloxifene, tamoxifen or other selective estrogen receptor modulator. women who are pregnant must use effective birth control measures. g event NCI CTCAE v3.0 Grade 3 within 4 weeks of first dose of study drug. submit unstained representative tumor specimen, either as a paraffin block (preferred) or 10 unstained slides. ation known to be a potent CYP3A4 inducer or inhibitor. ',\n",
       " 'one to three presumed brain metastases must be from a histologically confirmed extracerebral site (e.g., lung, breast, prostate), Histologic confirmation may have been from the primary tumor site, from another metastatic site (e.g., osseous metastasis, adrenal metastasis), or from the metastatic brain lesion(s) Each lesion must measure less than 3.0 cm by contrast MRI of the brain performed within the past 21 days. male patients must continue to use contraception for 3 months after the completion of radiotherapy. no pacemaker or other MRI-incompatible metal in the body, no known allergy to gadolinium, no known allergy to gadolinium. volunteers may have had a prior history of other cancers > 3 years which required only local resection, local radiation and/or hormonal therapy such as androgen blockade. d risk of the proposed study and be able to sign consent. e influenza vaccine, On-going neurologic disorder (mental status change, uncontrolled seizures, encephalopathy), Treatment or planned treatment with cyclophosphamide, ifosphamide, or > or = to 1 mg/kg prednisone or its equivalent 12 weeks within 12 weeks of vaccination. patients receiving the seasonal influenza vaccine may not have had it within 6 months of enrollment. ',\n",
       " 'ORR was defined as the proportion of participants who achieved a best response of either CR or PR. time frame: baseline & every 2 cycles (approximately 8 weeks) of treatment. bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days. overall number of participants Analyzed: 94, Mean (95% Confidence Interval), Unit of Measure: proportion of responders 0.489 (0.385 to 0.595), Results 2:, Arm/Group Title: paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G), Arm/Group Description: paclitaxel 90 mill ',\n",
       " 'menopausal: 12 months spontaneous amenorrhea or > 6 but  12 months amenorrhea with a serum follicle stimulating hormone (FSH) level of > 40 mIU/mL. able to read, understand and complete the required subject diary. legal incapacity or limited legal capacity. chronic renal (serum creatinine > 2.0 mg/dL) or hepatic disease. untreated overt hyperthyroidism. rmal (a subject will not be excluded if a second measurement is less than twice the upper limit of normal), Creatinine > 2.0 mg/dLInclusion Criteria: adult patients, >=18 years of age; HER2-negative metastatic breast cancer candidates for taxane-based chemotherapy; ECOG performance status of 0 or 1. ',\n",
       " 'patients must have metastatic or unresectable non-small cell lung cancer, head and neck cancer, urothelial transitional cell carcinoma, or breast cancer whose disease has progressed after at least one line of standard therapy. patients must have measurable disease defined as at least one lesion that can be accurately measured in at least one dimension. patients should be at least six weeks out from nitrosoureas and mitomycin C. prior radiation should have been completed greater than or equal to 4 weeks prior to study enrollment. patients must be greater than or equal to 2 weeks since any investigational agent administered as part of a Phase 0 study. cytidine (FdCyd) and Tetrahydrouridine (THU) in patients less than 18 years of age are excluded from this study. children are excluded from this study, but may be eligible for future pediatric Phase I combination trials. pregnant women will be excluded from this trial. nursing women are also excluded. there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother. active or uncontrolled infection, immune deficiencies or confirmed diagnosis of human immunodeficiency virus (HIV) infection, active infection with Hepatitis B or Hepatitis C, uncontrolled diabetes, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia. ',\n",
       " 'Adverse Events 1:, Total: 8/30 (26.67%), Heart Failure 1/30 (3.33%), Vertigo 1/30 (3.33%), Small intestinal obstruction 1/30 (3.33%), Fever 1/30 (3.33%), Aspartate aminotransferase increased 1/30 (3.33%), Alanine aminotransferase increased 1/30 (3.33%), Back Pain 1/30 (3.33%), Pleural effusion 1/30 (3.33%), Rash maculo-papular 1/30 (3.33%) ',\n",
       " 'anemia*4 0/25 (0.00%), BLOOD/BONE MARROW:: Leukocytes (total WBC)*3 4/25 (16.00%), BLOOD/BONE MARROW:: Lymphopenia*3 2/25 (8.00%), BLOOD/BONE MARROW:: Neutrophils/granulocytes (ANC/AGC)*3 5/25 (20.00%), BLOOD/BONE MARROW:: Plate ',\n",
       " 'Adverse Events 1:, Total: 0/20 (0.00%)Adverse Events 1:, Total: 2/35 (5.71%), Gastroesophageal reflux disease * 1/35 (2.86%), Ductal carcinoma in situ * 1/35 (2.86%) ',\n",
       " 'Hemoglobin decreased 2/30 (6.67%), Abdominal pain 1/30 (3.33%), Colitis 1/30 (3.33%), Diarrhea 7/30 (23.33%), Nausea 2/30 (6.67%), Rectal hemorrhage 1/30 (3.33%), Fatigue 1/30 (3.33%), Skin infection 1/30 (3.33%), Neutrophil count decreased 1/30 (3.33%), Platelet count decreased 3/30 (10.00%), Dehydration 1/30 (3.33%) holelithiasis 0/6 (0.00%), Hepatic pain 1/6 (16.67%), Bacteraemia 0/6 (0.00%) holelithiasis 0/6 (0.00%), Hepatic pain 1/6 (16.67%), bacteraemia 0/6 (0.00%) ',\n",
       " '3 patients were enrolled to the next cohort using a 5mg higher dose of ruxolitinib. the MTD is identified as the level BELOW the cohort where DLT occurred in less than one third of patients within the cohort. the maximum tolerated dose (MTD) was defined as the highest dose level in which a DLT is experienced by fewer than two patients in a cohort of 3 - 6 patients. if a DLT is observed in at least two patients in a cohort of 3 - 6 patients, the MTD will be determined to have been exceeded. all participants, Overall Number of Participants Analyzed: 20, Measure Type: Number, Unit of Measure: mg/kg NA [1] ',\n",
       " '0/21 (0.00%)Adverse Events 1:, Total: 3/8 (37.50%), Anaemia 0/8 (0.00%), Febrile neutropenia 0/8 (0.00%), Polycythaemia 0/8 (0.00%), Acute coronary syndrome 0/8 (0.00%), Vertigo 0/8 (0.00%), Eyelid oedema 1/8 (12.50%), Constipation 0/8 (0.00%), Diarrhoea 0/8 ',\n",
       " '5/11 (45.45%), Hemorrhage, GI-abdomen NOS 21/11 (9.09%), Pain-liver 21/11 (9.09%), Infection-ulcer 20/11 (0.00%), Pain-rib cage due to vomiting 20/11 (0.00%), Obstruction-gu ureter 1/11 (9.09%), Pain-breast 21/11 (9.09%), Pleural effusion 22/11 (18.18%), Adverse Events 2:, Total: 0 ',\n",
       " 'pain intensity was assessed using a 0-100 mm visual analog scale. 0 represented \"no pain\" and 100 represented \"worst possible pain\" at 0. SPID30 was calculated as the time-weighted sum of the PID scores. patients received a dose of 100 to 1600 g determined in the open-label dose titration period of the current study. overall number of participants Analyzed: 92, Mean (Standard Deviation), Unit of Measure: Units on a scale 640.3 (458.8), Results 2:, Arm/Group Title: Placebo, Arm/Group Description: Participants received placebo 3 times randomly (out of 10 treatments total) to treat up to a maximum of 2 breakthrough pain episodes per day the effect of zoledronic acid administered every 6 months on bone loss associated with surgery is to be evaluated by measuring the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine. beginning 60-90 days after surgery, patients receive zoledronate IV over 15 minutes once in months 3, 9 and 15. Mean (Full Range), Unit of Measure: g/cm2 -0.086 (-0.308 to 0.067). ',\n",
       " 'Adverse Events 1:, Total: 3/12 (25.00%), Hemoglobin 1/12 (8.33%), Alkaline phosphatase 1/12 (8.33%), Dehydration 1/12 (8.33%), Syncope 2/12 (16.67%), Dyspnea 1/12 (8.33%), Hypotension 1/12 (8.33%)Adverse Events 1:, Total: 0/115 (0.00%), Deep vein thrombosis * [1]0/115 ',\n",
       " 'Variation in Serum Levels of Follicle Stimulating Hormone (FSH) compare to natural physiological variability (screening-baseline variation), Time frame: from baseline to 12 weeks of treatment. lacebo, Overall Number of Participants Analyzed: 11, Median (Inter-Quartile Range), Unit of Measure: mIU/ml 1.4 (-5.4 to 15.7)Outcome Measurement:, Ruxolitinib MTD in combination with paclitaxel 80 mg/m2 intravenously (IV) weekly is determined by the number of patients who have dose limiting toxicity (DLT) the observation period for MTD evaluation was the first 2 cycles of treatment. participants with stable disease or better will have the opportunity to continue on single agent Ruxolitinib. ',\n",
       " '8/20 (40.00%), Anaemia 1/20 (5.00%), Lymphadenopathy 0/4 (0.00%), Thrombocytopenia 0/4 (0.00%), Acute coronary syndrome 0/4 (0.00%), Atrial fibrillation 0/4 (0.00%), Cardiac failure congestive 0/4 (0.00%), Cardiac tamponade 0/4 (0.00%), Adverse Events 2:, Total: 8/20 (40.00%), Anaemia 1 ',\n",
       " 'a non-serious adverse event is any untoward medical occurrence. a serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions. congenital anomaly/birth defect or important medical events that jeopardize the patient or subject may require medical or surgical intervention. Total Dose 2 x 108 IU, Arm/Group Description: Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 1 injection (I injection = 2 x 108 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. patients with stable disease may continue to receive vaccine for up to 6 monthly doses. ',\n",
       " 'patients will receive acupuncture treatment twice weekly for six consecutive weeks. each treatment will be 30 minutes in duration. patients will be advised to continue their standard lymphedema treatments. follow-up objective and subjective assessments of lymphedema will be performed after approximately 6 weeks on the wait-list. follow-up objective and subjective assessments of lymphedema will be performed after approximately 6 weeks on the wait-list, before onset of acupuncture treatment. ',\n",
       " 'patients receive doxorubicin HCl liposome IV 40mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28. inTERVENTION 2:, Placebo, Arm II: Patients receive doxorubicin HCl liposome IV 40mg/m2 over 1 hour on day 1. ',\n",
       " 'TAK-228 will be orally administered at 30 mg weekly for 16 weeks. Tamoxifen will be orally administered at 20 mg daily for 16 weeks. ',\n",
       " '89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions. only those foci qualitatively positive by both readers will be considered as \"positive\" ',\n",
       " 'patients with vitamin D deficiency who experience myalgias, arthralgias and/or joint stiffness received epoetin beta (NeoRecormon®) at a dose of 30000 International Units (IU) as subcutaneous (SC) injection once every week. ',\n",
       " 'change in total body lean mass measured by dual energy x-ray absorptiometry (DEXA) from baseline to 4 months. time frame: Baseline to four months. ',\n",
       " 'Adverse Events 1:, Total: 1/208 (0.48%), Neutrophils/granulocytes (ANC/AGC) 1/208 (0.48%), Adverse Events 2:, Total: 0/201 (0.00%), Neutrophils/granulocytes (ANC/AGC) 0/201 (0.00%)Adverse Events 1:, Total: 0/34 (0.00%) ',\n",
       " 'patients must have histologically confirmed breast cancer that is ER positive and/or PR positive, and HER2/neu negative disease determined using commercially available/approved assay in local institutional or reference laboratory. ER/PR expression performed by standard immunohistochemical assay and classified as ER and/or PR-positive according to ASCO/CAP guidelines (1-100% expression) patients must have had progressive disease during at least one line of endocrine therapy. prior treatments include a non-steroidal aromatase inhibitor, tamoxifen, fulvestrant or combinations. patients taking bisphosphonates for bone disease are permitted to enter the trial. postmenopausal status defined as 60 years and older, 45 years and older, having amenorrhea x 12 months or follicle stimulating hormone levels within postmenopausal range, OR having a bilateral oophorectomy. patients may not be receiving any other investigational agents. having at least 6 weeks of treatment remaining, 21 years old, Able to understand written and spoken English, Able to swallow medication (until amendment omitting armodafinil treatment), Score of 3+ on the Sleep Disruption Evaluation form, OR a score of 8+ on Insomnia Severity Index (ISI), EXCLUSION CRITERIA, Prior treatment with armodafinil or modafinil (until amendment omitting armodafini history of uncontrolled, cardiac disease, hypertension, severe headaches, glaucoma, or seizures (until amendment omitting armodafinil treatment) of chronic, preexisting insomnia, sleep apnea, or restless leg syndrome (RLS) ',\n",
       " 'breast cancer has continued to grow after receiving treatment with an anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor. postmenopausal women have stopped having menstrual periods. ',\n",
       " 'patients with histologically documented cancer of the breast or DCIS or head and neck referred for definitive radiation with curative intent. minimum life expectancy of at least 12 months., Aged greater than 20 years., If female, pregnancy excluded., no documented history of collagen vascular disease., Exclusion Criteria:, Cognitively impaired patients, Prisoners, No histology available, Documented metastatic disease, Allergy to Trental, Life expectance of less than 12 months., Aged less tase inhibitors for breast cancer in women and anti-LHRH therapy for prostate cancer in men will be permitted. have a BMI of 25 kg/m2 or greater and weight =400 lbs., Willingness to accept randomization to each of the three arms, Willingness to change diet, physical activity, and weight. prior or planned bariatric surgery, have significant renal disease or dysfunction defined as Estimated glomerular filtration rate (eGFR)45, Have significant renal disease or dysfunction defined as Estimated glomerular filtration rate (eGFR)45, Have significant hepatic dysfunction [Aspartate aminotransferase (AST)/Alanine transaminase (ALT) 2 x upper limit of normal (ULN) or reported liver disease], Self-reported ',\n",
       " 'inTERVENTION 1:, Subjects enrolled with device placed and treated with partial breast irradiation. ',\n",
       " 'inTERVENTION 1:, Zoledronic Acid, Zoledronic acid, vitamin D and calcium supplements, plus Sr-89 or Sm-153. ',\n",
       " 'average pain was measured using a 0 (no pain) to 10 (worst pain imaginable) numeric rating scale on a daily basis. change in average pain intensity between the two intervention groups was evaluated from enrollment to the end of the study. follow-up visits to assess the sustainability of the intervention will be done at 2 weeks, 1 month and 3 months after the intervention. patients in both groups will be seen in their homes over the course of 10 weeks with phone calls conducted in between the home visits. patients in the LOW-DOSE group will receive 4 visits and 6 phone calls. follow-up visits to assess the sustainability of the intervention will be done at 2 weeks, 1 month and 3 months after the intervention. ',\n",
       " 'participants received 120 milligrams of denosumab injected subcutaneously every 4 weeks until denosumab was approved and available for sale. ',\n",
       " '0/3 (0.00%)Adverse Events 1:, Total: 4/14 (28.57%), Duodenitis [1]1/14 (7.14%), Gastrooesophageal reflux disease [1]1/14 (7.14%), Vomiting [1]1/14 (7.14%), Ascites [1]1/14 (7.14%), Death [1]1/14 (7.14%), Asthenia [1]1/14 (7.14%), general physical health deterioration [1]1/14 ',\n",
       " \"dose-limiting toxicities are assessed according to the national Cancer Institute's Common Terminology Criteria for Adverse Events classification. the classification usually encompasses all grade 3 or higher toxicities, Time frame: 28 days. given IV, pegylated liposomal doxorubicin hydrochloride: Given IV, overall number of participants Analyzed: 6, Measure Type: Number, Unit of Measure: participants 1__________________________________________________________________ \",\n",
       " '89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions. only those foci qualitatively positive by both readers will be considered as \"positive\" ',\n",
       " 'Anaemia 1/106 (0.94%), Disseminated intravascular coagulation 1/106 (0.94%), Febrile neutropenia 1/106 (0.94%), Lymph node pain 1/106 (0.94%), Neutropenia 2/106 (1.89%), Sinus tachycardia 1/106 (0.94%), Abdominal pain upper 0/106 (0.00%), Diarrhoea 2/106 (1.89%), Nausea 1/106 (0.94%), ',\n",
       " 'the investigator must confirm postmenopausal status. postmenopausal status is defined either by:, age 55 years and one year or more of amenorrhea, age  55 years and one year or more of amenorrhea and postmenopausal levels of FSH and LH per local institutional standards. non-steroidal aromatase inhibitors (i.e. letrozole or anastrozole) do not have to be the last treatment prior to enrollment. other prior anticancer therapy, e.g. tamoxifen, fulvestrant, exemestane are also allowed. serum bilirubin 1.5  ULN, fasting serum cholesterol 300 mg/dl or 7.75 mmol/L and fasting triglycerides 2.5  ULN. alanine aminotransferase (ALT) 2.5  ULN (or 5 if hepatic metastases are present). patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose galactose malabsorption must have recovered from radiotherapy toxicities prior to enrollment. radiotherapy within four weeks prior to enrollment except in case of localized radiotherapy for analgesic purpose. patients with symptomatic visceral metastasis (e.g. significant dyspnoea related to pulmonary lymphangitic carcinomatosis and lung metastases), symptomatic brain or other central nervous system metastases (CNS) metastases. active, bleeding diathesis, or on oral anti-vitamin K medication. uncontrolled or whose control may be jeopardized by the complications of this study therapy. pulmonary function tests should be considered to exclude restrictive pulmonary disease, pneumonitis or pulmonary infiltrates. patients being treated with drugs recognized as strong inhibitors or inducers of the isoenzyme CYP3A. patients must have metastatic breast cancer; tissue (a minimum of 3 slides) from most recent biopsy is required for review and confirmation of eligibility. patients must have stage IV breast cancer, patients must have metastatic tumors (primary or metastatic) that stain positively for the prolactin receptor. women of childbearing potential must commit to the use of effective barrier (non-hormonal) contraception while on study. patients must have a life expectancy of greater than 12 weeks. patients must have a life expectancy of greater than 12 weeks. patients may have had a prior diagnosis of cancer if it has been > 5 years since their last treatment. systemic treatment is allowed with a 2 week washout period prior to registration. patients who are taking herbal (alternative) medicines are NOT eligible for participation. patients must be off any such medications by the time of registration. nary, pericardial, cardiac valvular, or retroperitoneal fibrotic disorders, Gastrointestinal (GI) tract disease resulting in an inability to take oral medication, Malabsorption syndrome, Require intravenous (IV) alimentation, Uncontrolled inflammatory GI disease. ',\n",
       " 'unilateral breast cancer with ipsilateral lumpectomy or mastectomy and lymph node dissection (sentinel biopsy or axillary dissection), stage II or III unilateral secondary upper extremity lymphedema. girth 2 cm circumferential difference and/or volume 200 mL compared to the uninvolved upper extremity at any 4 cm segment. 0 (morbid obesity) ',\n",
       " 'inTERVENTION 2:, Part 1 and Part 2: Talazoparib (Ovarian/ Peritoneal Cancer) Participants with ovarian/ peritoneal cancer who received talazoparib capsules in Part 1 and 2 at a dose of either 600 mcg/day, 900 mcg/day, 1000 mcg/day, 1100 mcg/day. ',\n",
       " 'participants received 120 milligrams of denosumab injected subcutaneously every 4 weeks until denosumab was approved and available for sale. ',\n",
       " 'Adverse Events 1:, Total: 0/733 (0.00%), Adverse Events 2:, Total: 0/765 (0.00%)Adverse Events 1:, Total: 0/88 (0.00%), Adverse Events 2:, Total: 0/86 (0.00%). ',\n",
       " 'Outcome Measurement:, Recurrence-free Survival, 2 years for the primary analysis + 3 additional years for secondary analysis. Time frame: 5 years, Results 1:, Arm/Group Title: Ketorolac 30 mg, Arm/Group Description: Active drug to be compared with placebo, Ketorolac 30 mg IV, Overall number of participants Analyzed: 96, Measure Type: Count of participants, Unit of Measure: Participants 80 83.3%, Results 2:, Arm/ ',\n",
       " \"the subject must be a breast cancer survivor, at least three years beyond completion of cancer therapy, free of clinical disease, and eligible for surgical intervention. the subject must be a breast cancer survivor, at least three years beyond completion of cancer therapy, free of clinical disease. two consecutive measurements of limb volume (LV) in the affected limb must be within 10% of each other. a maximum of 3 measurements can be taken. clinical trial of any other investigational drug or therapy, regardless of indication, within 1 month before screening or 5 times the drug's half-life, whichever is longer, Recent initiation of ( 8 weeks), or intention to initiate, CDPT or maintenance physiotherapy for lymphedema at any time during the duration of the study. other medical condition that could result in symptoms overlapping those of lymphedema in the affected limb. patients with a high risk of recurrence based on multi-gene signatures, e.g. BRCA1, BRCA 2, Oncotype DX (high risk recurrence score) or Mammaprint (poor risk signature), undergoing chemotherapy or radiation therapy. women aged 30 years or older ( 30 years old); women scheduled for screening mammography or have completed a screening mammogram within the past 30 days. subjects with a history of breast cancer and are in active treatment. prior lumpectomy may include breasts too large to be adequately positioned on 24 x 31 centimeter (cm) FFDM digital receptor without anatomical cut off during either FFDM or DBT examination. \",\n",
       " '3/37 (8.11%), Sinus tachycardia 0/37 (0.00%), Heart failure 0/37 (0.00%), Dehydration 1/37 (2.70%), Death Not Associated with CTCAE: Death NOS 1/37 (2.70%), Lymphopenia 1/37 (2.70%), Neutropenia 1/37 (2.70%), Thrombocytopenia 0/37 (0.00%), Hyponatremia 1/37 (2.70%), Weight loss 0/37 ( ',\n",
       " 'Adverse Events 1:, Total: 5/25 (20.00%), Hypertension 1/25 (4.00%), Dehydration 1/25 (4.00%), Infection With Normal Anc or Grade 1 or 2 Neutrophils 2/25 (8.00%), Pain 1/25 (4.00%), Dyspnea (Shortness Of Breath) 2/25 (8.00%). ',\n",
       " 'ANAEMIA 13/2002 (0.65%), BONE MARROW FAILURE 1/2002 (0.05%), FEBRILE NEUTROPENIA 1/2002 (0.05%), THROMBOCYTOPENIA 11/2002 (0.55%), ACUTE CORONARY SYNDROME 3/2002 (0.15%), ANGINA PECTORIS 1/2002 (0.05%), CARDIAC ARREST 1/2002 (0.05%), CARDIAC TAMPONADE 1/2002 ',\n",
       " '3/24 (12.50%), Disseminated intravascular coagulation 0/24 (0.00%), Death NOS 0/24 (0.00%), Fatigue 0/24 (0.00%), Hepatic failure 1/24 (4.17%), Alanine aminotransferase increased 1/24 (4.17%), aspartate aminotransferase increased 1/24 (4.17%), Blood bilirubin increased 0/24 (0.00%), Ejection fraction decreased 1/24 (4.17%), ',\n",
       " 'patients receive cabergoline oral (PO) twice weekly for weeks 1-4. courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. ',\n",
       " 'participants received 1250 milligram (mg) tablets lapatinib once a day and vinorelbine 20 mg/meters squared (m2) intravenously on Day 1 and Day 8, and every 3 weeks. participants received 1250 milligram (mg) tablets lapatinib once a day. ticipants Analyzed: 25, Measure Type: Number, Unit of Measure: participants Week 12, CR: 0, Week 12, PR: 4, Week 12, SD: 12, Week 24, CR: 0, Week 24, PR: 4, Week 24, SD: 10_ ',\n",
       " 'patients are excluded if they are unable to give informed consent or pass screening for impaired mental function or psychosis. they are unable to hear or understand English. ',\n",
       " 'pain intensity was assessed using a 0-100 mm visual analog scale. 0 represented \"no pain\" and 100 represented \"worst possible pain\" at 0. SPID30 was calculated as the time-weighted sum of the PID scores. patients received a dose of 100 to 1600 g determined in the open-label dose titration period of the current study. overall number of participants Analyzed: 92, Mean (Standard Deviation), Unit of Measure: Units on a scale 640.3 (458.8), Results 2:, Arm/Group Title: Placebo, Arm/Group Description: Participants received placebo 3 times randomly (out of 10 treatments total) to treat up to a maximum of 2 breakthrough pain episodes per day the effect of zoledronic acid administered every 6 months on bone loss associated with surgery is to be evaluated by measuring the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine. beginning 60-90 days after surgery, patients receive zoledronate IV over 15 minutes once in months 3, 9 and 15. Mean (Full Range), Unit of Measure: g/cm2 -0.086 (-0.308 to 0.067). ',\n",
       " 'inTERVENTION 1:, Placebo, Buminate solution, Placebo: 20 transendocardial injections of 0.4ml allo-MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure) ',\n",
       " 'patients with a histologically/cytologically confirmed diagnosis of advanced and/or unresectable disease of any of the following tumors: breast cancer, Epithelial ovarian cancer or gynecological cancer, Head and neck squamous cell carcinoma, Non-small cell lung cancer, Small cell lung cancer, Platinum-refractory germ-cell tumors. pre-menopausal women must have a negative pregnancy test before study entry. patients who have previously discontinued bevacizumab-containing regimes due to drug-related toxicity. more than three prior lines of chemotherapy, Less than three months since last taxane-containing therapy. ring dyspnea, known HIV infection, bleeding risk, muscular problems, peripheral neuropathy, symptomatic or progressive brain metastases or leptomeningeal disease. men or pre-menopausal women who are not using an effective method of contraception as previously described. ',\n",
       " 'Anaemia 0/37 (0.00%), Febrile neutropenia 0/37 (0.00%), leukopenia 0/37 (0.00%), Neutropenia 0/37 (0.00%), arrhythmia 0/37 (0.00%), Abdominal pain 1/37 (2.70%), Diarrhoea 1/37 (2.70%), Intestinal obstruction 0/37 (0.00%), Fatigue 0/37 (0.00%), Pyrexia 0/37 ( Colitis 1/93 (1.08%), Constipation 1/93 (1.08%), Diarrhea 4/93 (4.30%), Duodenal ulcer 1/93 (1.08%), Dysphagia 4/93 (4.30%), Adverse Events 2: ',\n",
       " \"if a taxane had been administered in the neoadjuvant or adjuvant setting, progression must have occurred >12 months after completion of this treatment. radiotherapy as palliative treatment for painful metastatic disease is permitted but must have been stopped within 2 weeks prior to any investigational treatment. ning disease is considered to be inapplicable to hormonal therapy. ning disease must have been stopped before the first dose of investigational treatment. an investigational drug within 30 days or five half-lives preceding the first dose of investigational treatment. unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or prior anti-cancer treatment. subjects with ulcerative colitis are excluded. metastases or leptomeningeal carcinomatosis would make subject inappropriate for study participation or any serious medical disorder that would interfere with subject's safety. subject must have histologically confirmed invasive breast cancer with Stage IV disease at primary diagnosis or at relapse after curative-intent surgery. neoplastic nature of the disease should have been confirmed by cytology or histology. subjects must have received no more than one prior chemotherapeutic regimen in the metastatic setting. prior therapy with radiation for this breast cancer population was permitted if it was administered in the neoadjuvant or adjuvant non metastatic setting. subject must have completed radiation treatment and recovered from all related toxicities. subject must have received all prior chemo treatment at least 4 weeks prior to enrollment in this study. prior therapy with trastuzumab in the neoadjuvant, adjuvant or metastatic setting was permitted. prior diagnosis of cancer was allowed as long as the subject was free of disease for 5 years. subjects with completely resected basal or squamous cell skin cancer, thyroid cancer or successfully treated cervical carcinoma in-situ were allowed into the study. women with oligomenorrhoea (severe), women who were perimenopausal and young women who had begun to menstruate must provide a negative serum pregnancy test at Screening. subjects must provide a negative serum pregnancy test and agree to 1 of the following: Complete abstinence from intercourse from 2 weeks prior to administration of the first dose of study medication until 5 days after the final dose of study medication. e Investigator to have a life expectancy of 6 months. Subjects must have had normal organ and marrow function as below. subject must have been free of gastrointestinal diseases that impede swallowing and retaining oral medications. bisphosphonate therapy for bone metastases was allowed; treatment must be initiated prior to the first dose of study medication. subjects without bone disease, except for osteoporosis, were included in the study if they met the following criteria. subjects who received more than one prior chemotherapeutic regimen were not eligible for the study. this included human immunodeficiency virus-positive subjects receiving combination anti-retroviral therapy because of possible pharmacokinetic interactions with lapatinib. uncontrolled inter-current illness includes, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would have limited compliance with study requirements. subjects with diseases affecting gastrointestinal function resulting in an inability to take oral medication. ation, prior surgical procedures affecting absorption e.g. gastric resection and uncontrolled inflammatory bowel disease (e.g., Crohn's, ulcerative colitis). subjects who had been disease-free for 5 years, or subjects with completely resected basal or squamous cell skin cancer, thyroid cancer or successfully treated cervical carcinoma in situ were eligible if it had been at least 1 year since definitive surgery. clinical investigator's Brochure (IB), SPM, and the nab-paclitaxel product label. \",\n",
       " '5/18 (27.78%), Anaemia 1/18 (5.56%), Febrile neutropenia 1/18 (5.56%), Pancytopenia 0/18 (0.00%), Thrombocytopenia 1/18 (5.56%), Acute myocardial infarction 1/18 (5.56%), Eye pain 1/18 (5.56%), Diarrhoea 1/18 (5.56%), Intestinal obstruction 1/18 (5.56%), Nausea 0/18 (0.00%), Small intestinal obstruction 0 ',\n",
       " 'Adverse Events 1:, Total: 8/87 (9.20%), Death * [1]8/87 (9.20%), Hospitalization [2]1/87 (1.15%), Hospitalization [3]1/87 (1.15%), Adverse Events 2:, Total: 0/28 (0.00%), Death * [1]0/28 (0.00%), Hospitalization [3]0/28 (0.00%)_______________________ ',\n",
       " 'participants must have histologically or cytologically confirmed breast cancer or non-hodgkin lymphoma. doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2. doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2 and docetaxel 75 mg/m2. ncer in marrow), absolute neutrophil count >1,500/mcL (unless due to cancer in marrow), platelets >100,000/mcL (unless due to cancer in marrow), total bilirubin 1.5 X normal institutional limits, aspartate aminotransferase (AST) or serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase patients with known brain metastases should be excluded from this clinical trial. progressive neurologic dysfunction would confound evaluation of neuro-cognitive outcomes. patients requiring ongoing pharmacologic treatment of dementia excluded. e heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations would limit compliance with study requirements. pregnant women are excluded from this study because the chemotherapy agents have known teratogenic or abortifacient effects. allergy to all three antibiotics: cephalosporin, trimethoprim/sulfamethoxazole, and levofloxacin. non-English speaking patients without adequate interpreter assistance. ',\n",
       " 'average pain was measured using a 0 (no pain) to 10 (worst pain imaginable) numeric rating scale on a daily basis. change in average pain intensity between the two intervention groups was evaluated from enrollment to the end of the study. follow-up visits to assess the sustainability of the intervention will be done at 2 weeks, 1 month and 3 months after the intervention. patients in both groups will be seen in their homes over the course of 10 weeks with phone calls conducted in between the home visits. patients in the LOW-DOSE group will receive 4 visits and 6 phone calls. follow-up visits to assess the sustainability of the intervention will be done at 2 weeks, 1 month and 3 months after the intervention. ',\n",
       " 'a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 will be explored and will follow a 6 + 3 dose de-escalation design. participants with one of the following tumor types will be eligible for enrollment. ',\n",
       " 'patients without liver involvement or history of liver disease will be treated at a dose of 98.7 mg/m2. patients will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance. patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2. patients will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance. CR and PR (for solid tumors) required a confirmation at least 4 weeks after the initial response observation. any pathological lymph nodes must have had reduction in short axis to 10 mm, PR=At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, SD=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. nt cycle was defined as 28 days. overall number of participants Analyzed: 105, Measure Type: Count of participants. ',\n",
       " 'Adverse Events 1:, Total: 2/6 (33.33%), Abdominal pain 1/6 (16.67%), Fever 1/6 (16.67%), Death, NOS 1/6 (16.67%), Infections and Infestations - Other, Gram-negative bacteremia, 40 degree C fever 1/6 (16.67%), Adverse Events 2:, Total: 0/4 (0.00%), Abdominal pain 0/4 (0.00%), Fever 0/4 (0.00%), Death, NOS ',\n",
       " 'the Vaginal Symptom Measure (VSM) was used to evaluate the severity of vaginal dryness and dyspareunia. for each patient, the change in severity was calculated by subtracting the baseline from the week 12 reported score. negative score indicates a decrease in severity from baseline, zero indicates no reported affect and positive scores indicate a more severe report at week 12. treatment continues until unacceptable adverse events or patient refusal to continue participation on the study. overall number of participants Analyzed: 123, Median (Full Range), Unit of Measure: change in units on a scale -2 (-4 to 1), Results 2:, Arm/Group Title: Arm II High Dose DHEA, Arm/Group Description: Participants apply a high dose (6.5 mg) of vaginal prasterone (dehydroepiandrosterone [DHEA]) the percentage of HER2-negative metastatic breast cancer patients having an objective benefit from treatment per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. Includes patients with HER2 overexpression/activation as detected by PRO Onc Assay. ',\n",
       " 'result at baseline minus result at baseline as a percentage of the result at baseline. back transformation of the least squares mean based on log transformed data. ',\n",
       " 'all patients receive 3 doses of high-dose Methotrexate (HD-MTX) every 2 weeks given intravenously and 3 doses of Intrathecal (IT) Liposomal Cytarabine (Depocyt) every 2 weeks over 6 weeks. ',\n",
       " 'the outcome is reported as the proportion of subjects with a discernible pattern for expression of the set of 40 evaluated genes. the outcome is reported as the proportion of subjects with a discernible pattern for expression of the set of 40 evaluated genes. ',\n",
       " 'invasive disease-free survival time is defined as the time from date of randomization until time of event up to 2 years. time is defined as the time from date of randomization until time of event up to 2 years. patients who completed prior adjuvant trastuzumab received six placebo tablets (240 mg) taken orally once daily with food, preferably in the morning, continuously for one year. therapy continued until unacceptable toxicity, recurrent disease, death, or withdrawal of consent occurred. ',\n",
       " 'women may receive the AI on this study as initial adjuvant hormonal treatment or following tamoxifen. patients may have received preoperative chemotherapy, Postmenopausal status, defined as: >= 60 years of age; or  60 years of age and amenorrheic for >= 12 months prior to day 1 if intact uterus/ovaries. istory of bilateral oophorectomy; or prior radiation castration with amenorrhea for at least 6 months; or prior radiation castration with amenorrhea for at least 6 months;  60 years of age and taking medication designed to suppress ovarian function. women would have had to be taking the drug for at least 30 days prior to day 1. current bisphosphonate use (oral or intravenous); prior bisphosphonate users would be eligible as long as the use was > 1 month ago for oral bisphosphonates. prior bisphosphonate users would be eligible as long as the use was > 12 months ago for intravenous bisphosphonates. ',\n",
       " 'participants received 1250 milligram (mg) tablets lapatinib once a day and vinorelbine 20 mg/meters squared (m2) intravenously on Day 1 and Day 8, and every 3 weeks. participants received 1250 milligram (mg) tablets lapatinib once a day. ticipants Analyzed: 25, Measure Type: Number, Unit of Measure: participants Week 12, CR: 0, Week 12, PR: 4, Week 12, SD: 12, Week 24, CR: 0, Week 24, PR: 4, Week 24, SD: 10_ ',\n",
       " 'patients will take Vorinostat daily during radiation therapy. they will be recommended to swallow the capsule 60-90 minutes prior to estimate time of radiation. ',\n",
       " 'anemia*4 0/25 (0.00%), BLOOD/BONE MARROW:: Leukocytes (total WBC)*3 4/25 (16.00%), BLOOD/BONE MARROW:: Lymphopenia*3 2/25 (8.00%), BLOOD/BONE MARROW:: Neutrophils/granulocytes (ANC/AGC)*3 5/25 (20.00%), BLOOD/BONE MARROW:: Plate ',\n",
       " 'optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W. Durvalumab and tremelimumab were administered as IV infusions over 60 (5) minutes. durvalumab infusions started at least 60 minutes after the end of the tremelimumab infusion on dual dosing days. ',\n",
       " 'inTERVENTION 2:, Part A: V934 LD(3)+V935 LD, 3 IM injections of V934 (LD) were administered, 1 given every other week over a 3-week period. following a 4 week observation period, 2 IM injections of V935 (LD) were administered. ',\n",
       " '0/25 (0.00%)Adverse Events 1:, Total: 10/30 (33.33%), Hemoglobin decreased 2/30 (6.67%), Abdominal pain 1/30 (3.33%), Colitis 1/30 (3.33%), Diarrhea 7/30 (23.33%), Nausea 2/30 (6.67%), Rectal hemorrhage 1/30 (3.33%), Fatigue 1/30 (3.33%), Skin infection 1/30 (3.33%), Neutrophil count decreased 1/30 ( ',\n",
       " 'ORR was defined as the proportion of participants who achieved a best response of either CR or PR. time frame: baseline & every 2 cycles (approximately 8 weeks) of treatment. bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days. overall number of participants Analyzed: 94, Mean (95% Confidence Interval), Unit of Measure: proportion of responders 0.489 (0.385 to 0.595), Results 2:, Arm/Group Title: paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G), Arm/Group Description: paclitaxel 90 mill ',\n",
       " \"breast tumor 1 centimeter (cm) in diameter, HR+, HER2-. neoadjuvant endocrine monotherapy is deemed to be a suitable therapy. measurable disease, Bone metastases requires other disease present that can be measured. no brain metastases, unless documented to be controlled post-completion of local therapy for at least 4 weeks, no meningeal carcinomatosis, no malignant effusion as the only site. hat in the opinion of the treating physician would make study protocol unreasonably hazardous for the patient. hat in the opinion of the treating physician would make study protocol unreasonably hazardous for the patient or would preclude the patient's ability to comply with the study protocol. \",\n",
       " 'INTERVENTION 1:, Arm 1, Herceptin/navelbine, INTERVENTION 2:, Arm 2, Taxotere/carboplatin/herceptin_. ',\n",
       " 'dexamethasone 8 mg, Dexamethasone 8 mg pre-operative, Dexamethasone: pre-operative intravenous administration. inTERVENTION 2:, Dexamethasone 24 mg, Dexamethasone 24 mg pre-operative. ',\n",
       " 'participants able to receive iron supplement, if necessary, Exclusion Criteria:, Known or suspected contraindications to epoetin beta, Pregnancy or lactation period, Diagnosis of anemia only due to iron-deficiency, Epilepsy and/or cerebral metastasis, Blood transfusion or treatment with any erythropoietic factor within 4 weeks. patient has score of 0 or 1 on the neurotoxicity evaluation. previous diagnosis of diabetic neuropathy or peripheral neuropathy from any cause, Diagnosis of fibromyalgia. ',\n",
       " 'Adverse Events 1:, Total: 1/13 (7.69%), Rapid disease progression [1]1/13 (7.69%), Increased pleural effusion [2]0/13 (0.00%), Adverse Events 2:, Total: 1/4 (25.00%), Rapid disease progression [1]0/4 (0.00%), Increased pleural effusion [2]1/4 (25.00%). ',\n",
       " 'participants received enzalutamide 80 mg (two 40 mg) capsules orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including any seizure), noncompliance, withdrawal of consent, discontinuation by sponsor, or investigator. participants were followed-up until 30 days after last dose of study drug or before initiation of a new antitumor or investigational therapy, whichever occurred first. ver occurred first. ',\n",
       " 'unilateral breast cancer with ipsilateral lumpectomy or mastectomy and lymph node dissection (sentinel biopsy or axillary dissection), stage II or III unilateral secondary upper extremity lymphedema. girth 2 cm circumferential difference and/or volume 200 mL compared to the uninvolved upper extremity at any 4 cm segment. 0 (morbid obesity) ',\n",
       " 'treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity. cyclophosphamide, paclitaxel, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab subjects 98 (92.2 to 99.5). subjects 98 (92.2 to 99.5) ',\n",
       " 'Suramin and Paclitaxel will be infused weekly over 30 minutes. four hours after the completion of the suramin infusion the 1 hour infusion of paclitaxel will begin. ',\n",
       " 'patients must have had exposure to at least 1 and no more than 3 prior chemotherapy regimens for the treatment of metastatic breast cancer. must have tissue (excluding bone or brain) that is amenable to biopsy, ECOG performance status 0-1, Life expectancy of greater than 3 months. all prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events version 4 (CTCAE v4) grade = 1 (except alopecia) at the time of enrollment, Absolute neutrophil count >= 1,500/mcL, Platelets >= 75,000/mcL, Total bilirubin = 1.5  institutional upper limit of normal, Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal by echocardiogram (ECHO) or patients must be at least 4 weeks from last surgical procedure and recovered from all post-operative complications. women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study. patients with symptomatic or progressive brain metastases are ineligible. subjects with treated brain metastases are eligible if they have no radiographic or other signs of progression in the brain for >= 3 weeks. any corticosteroid use for brain metastases must have been discontinued without the subsequent appearance of symptoms for >= 3 weeks prior to study enrollment. history of allergic reactions attributed to compounds of similar chemical or biologic composition to trametinib monotherapy or trametinib in combination with GSK2141795, Current use of a prohibited medication. uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, history of hyperviscosity or hypercoagulability syndromes. visible retinal pathology as assessed by ophthalmic exam is considered a risk factor for RVO or CSR. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit ',\n",
       " 'the outcome is reported as the proportion of subjects with a discernible pattern for expression of the set of 40 evaluated genes. the outcome is reported as the proportion of subjects with a discernible pattern for expression of the set of 40 evaluated genes. ',\n",
       " 'sunitinib was administered orally from Day 1 to 14 every 21 days at a starting dose of 2,000 mg/m2/day. participants were monitored for toxicity, and sunitinib and/or capecitabine dosing could be interrupted or reduced according to individual tolerance. ',\n",
       " '89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions. only those foci qualitatively positive by both readers will be considered as \"positive\" ',\n",
       " 'TAK-228 will be orally administered at 30 mg weekly for 16 weeks. Tamoxifen will be orally administered at 20 mg daily for 16 weeks. ',\n",
       " \"the subject must be a breast cancer survivor, at least three years beyond completion of cancer therapy, free of clinical disease, and eligible for surgical intervention. the subject must be a breast cancer survivor, at least three years beyond completion of cancer therapy, free of clinical disease. two consecutive measurements of limb volume (LV) in the affected limb must be within 10% of each other. a maximum of 3 measurements can be taken. clinical trial of any other investigational drug or therapy, regardless of indication, within 1 month before screening or 5 times the drug's half-life, whichever is longer, Recent initiation of ( 8 weeks), or intention to initiate, CDPT or maintenance physiotherapy for lymphedema at any time during the duration of the study. other medical condition that could result in symptoms overlapping those of lymphedema in the affected limb. patients with a high risk of recurrence based on multi-gene signatures, e.g. BRCA1, BRCA 2, Oncotype DX (high risk recurrence score) or Mammaprint (poor risk signature), undergoing chemotherapy or radiation therapy. women aged 30 years or older ( 30 years old); women scheduled for screening mammography or have completed a screening mammogram within the past 30 days. subjects with a history of breast cancer and are in active treatment. prior lumpectomy may include breasts too large to be adequately positioned on 24 x 31 centimeter (cm) FFDM digital receptor without anatomical cut off during either FFDM or DBT examination. \",\n",
       " 'standard therapy either does not exist or has proven ineffective, intolerable or inacceptable for the patient. non-small cell lung cancer harboring a rearranged ALK gene/fusion protein or KRAS mutation. participants aged >65 years may be enrolled with objective evidence of disease as per PCWG2 criteria. participants aged 18 years at the time of informed consent may be enrolled with objective evidence of disease as per PCWG2 criteria. CRPC participants must maintain ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue, antagonist or orchiectomy. participants receiving bisphosphonate or denosumab therapy must be on stable doses for at least 4 weeks before initiating study treatment. cy or CNS involvement; history of prior or concomitant malignancies within 3 years of study entry; other serious illness or medical conditions; Known human immunodeficiency virus positivity; Participation in another clinical trial or treatment with any investigational drug within 30 days prior to study entry. low-dose (prophylactic) low molecular weight heparin (LMWH) is permitted; Pregnant or breast-feeding participants; men and women with childbearing potential not using concurrent hormone or Herceptin® (trastuzumab)treatment is okay, can have been treated by lumpectomy or mastectomy with or without adjuvant or neoadjuvant chemotherapy or hormonal treatment. can have had breast reconstruction, scheduled to receive 25-35 radiation treatment sessions (1 session per day) or 16-20 radiation treatment sessions (1 session per day) using Canadian irradiation fractionation (2.2-3.0 Gy per session) aspirin is allowed, known radiosensitivity syndromes (e.g., ataxia-telangiectasia), collagen vascular disease, unhealed surgical sites, or breast infections. ',\n",
       " 'Adverse Events 1:, Total: 0/34 (0.00%)Adverse Events 1:, Total: 0/1 (0.00%)Adverse Events 1:, Total: 0/1 (0.00%) ',\n",
       " 'TAK-228 will be orally administered at 30 mg weekly for 16 weeks. Tamoxifen will be orally administered at 20 mg daily for 16 weeks. ',\n",
       " 'patients will take Vorinostat daily during radiation therapy. they will be recommended to swallow the capsule 60-90 minutes prior to estimate time of radiation. ',\n",
       " 'patients will receive whole breast radiation therapy at a dose of 180-200 cGy per fraction for 23-27 fractions to a total dose of 4600 - 4860 cGy. additional radiation to the lumpectomy bed (Boost) is at the discretion of the treating physician. participants received enzastaurin (250 mg; 2 tablets) or placebo administered orally twice daily (BID) in a 28-day cycle. ',\n",
       " 'change in Ki67 expression in tumors with 7 days of pre-surgical tamoxifen. all patients will take tamoxifen 20 mg po daily for 7 days prior to surgery. ',\n",
       " 'a log ratio of expression was generated relative to reference in both the Up and DOWN arms of the gene signature. a log ratio value of zero indicated no change in expression between the two samples. overall number of participants Analyzed: 14, Measure Type: Number, Unit of Measure: Percentage of participants 28.6 (13.1 to 49.2), Results 2:, Arm/Group Title: Triple Negative (TN), Arm/Group Description: Triple Negative participants received a single dose of dalotuzumab 20 mg/kg infused over 60-120 minutes. ',\n",
       " 'women may receive the AI on this study as initial adjuvant hormonal treatment or following tamoxifen. patients may have received preoperative chemotherapy, Postmenopausal status, defined as: >= 60 years of age; or  60 years of age and amenorrheic for >= 12 months prior to day 1 if intact uterus/ovaries. istory of bilateral oophorectomy; or prior radiation castration with amenorrhea for at least 6 months; or prior radiation castration with amenorrhea for at least 6 months;  60 years of age and taking medication designed to suppress ovarian function. women would have had to be taking the drug for at least 30 days prior to day 1. current bisphosphonate use (oral or intravenous); prior bisphosphonate users would be eligible as long as the use was > 1 month ago for oral bisphosphonates. prior bisphosphonate users would be eligible as long as the use was > 12 months ago for intravenous bisphosphonates. ',\n",
       " 'neoadjuvant therapy will consist of epirubs, epirubs and epirubs. neoadjuvant therapy will consist of epirubs, epirubs, epirubs and epirubs. icin + cyclophosphamide (600 mg/m2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m2) every 2 weeks for 4 cycles + trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments. ',\n",
       " 'treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity. cyclophosphamide, paclitaxel, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab subjects 98 (92.2 to 99.5). subjects 98 (92.2 to 99.5) ',\n",
       " 'all subjects treated under this protocol will have histologically documented cancer of one of the following types:, A. Metastatic breast cancer (7 triple negative, 23 ER+ after the first 15 patients are enrolled on the non-CCND1cohort; in addition 10 HER2+ for combination trastuzumab and PD0332991 therapy) up to 55 total enrollment slots B. Advanced or metastatic esophageal and/or gastric cancer (15-30 enrollment slots) D. Cisplatin subjects will be > 18 years old, The subject has disease that is assessable by tumor marker, physical, or radiologic means. the subject has an Eastern Cooperative Oncology Group performance status of 0 or 1. subject is capable of understanding and complying with protocol requirements. sexually active subjects (male and female) must use accepted methods of contraception. female subjects of childbearing potential must have negative pregnancy test at screening. patients with HER2-overexpressing tumors may receive trastuzumab. subject has received any other type of investigational agent within 28 days. subject has not recovered from clinically-meaningful toxicity due to prior therapy. subject has untreated or uncontrolled brain metastases. the subject has a baseline corrected QT interval (QTc) > 470 ms. the subject is known to be positive for the human immunodeficiency virus. ',\n",
       " 'intravascular coagulation * 1/32 (3.13%), Febrile neutropenia * 1/32 (3.13%), Adrenal insufficiency * 1/32 (3.13%), Endocrine disorder * 1/32 (3.13%), Chills * 1/32 (3.13%), Fatigue * 1/32 (3.13%), Fever * 1/32 (3.13%), Multi-organ failure * 1/32 (3.13%), Hepatic failure * 1/32 (3.13%), Infection * 1/32 (3.13%), Sepsis 0/5 (0.00%), Platelet count decreased 0/5 (0.00%), Dehydration 1/5 (20.00%), Dysarthria 0/5 (0.00%). ',\n",
       " 'postmenopausal breast cancer (adenocarcinoma) estrogen (ER) and/or progesterone (PR) receptor positive that is locally advanced or locally recurrent and not able to be surgically removed OR with measurable and/or disease that is able to be assessed including isolated bone metastasis, Female patients 18 years or older. sient ischemic attacks in the last 6 months, no symptoms of peripheral vascular disease, no history of abdominal fistula, gastrointestinal perforation or intrabdominal abscess in the past 6 months. no known hypersensitivity to phosphate, trehalose or polysorbate, no serious non-healing wound, ulcer or bone fracture. ',\n",
       " 'all patients receive 3 doses of high-dose Methotrexate (HD-MTX) every 2 weeks given intravenously and 3 doses of Intrathecal (IT) Liposomal Cytarabine (Depocyt) every 2 weeks over 6 weeks. ',\n",
       " 'in a woman of childbearing potential, a positive pregnancy test result, no pregnancy test result, or no reliable contraception, at baseline. a postmenopausal woman will be considered to be of childbearing potential until there has been amenorrhea for at least 12 consecutive months. prior anticancer therapy completed within four weeks prior to first day of study treatment. failure to have recovered from any toxicity of previous cancer treatment will not be excluded. ',\n",
       " 'inTERVENTION 1:, Patients - Intervention, Patients will be invited to view the educational DVD explaining end-of-life care options and meet with a lay health advisor for discussion. ',\n",
       " 'Adverse Events 1:, Total: 4/31 (12.90%), Infection 1/31 (3.23%), Deflation 1/31 (3.23%), Asymmetry 1/31 (3.23%), Delayed Healing Wound 1/31 (3.23%) Adverse Events 2:, Total: 0/75 (0.00%), Adverse Events 2:, Total: 0/75 (0.00%) ',\n",
       " 'postmenopausal breast cancer (adenocarcinoma) estrogen (ER) and/or progesterone (PR) receptor positive that is locally advanced or locally recurrent and not able to be surgically removed OR with measurable and/or disease that is able to be assessed including isolated bone metastasis, Female patients 18 years or older. sient ischemic attacks in the last 6 months, no symptoms of peripheral vascular disease, no history of abdominal fistula, gastrointestinal perforation or intrabdominal abscess in the past 6 months. no known hypersensitivity to phosphate, trehalose or polysorbate, no serious non-healing wound, ulcer or bone fracture. ',\n",
       " '3 patients were enrolled to the next cohort using a 5mg higher dose of ruxolitinib. the MTD is identified as the level BELOW the cohort where DLT occurred in less than one third of patients within the cohort. the maximum tolerated dose (MTD) was defined as the highest dose level in which a DLT is experienced by fewer than two patients in a cohort of 3 - 6 patients. if a DLT is observed in at least two patients in a cohort of 3 - 6 patients, the MTD will be determined to have been exceeded. all participants, Overall Number of Participants Analyzed: 20, Measure Type: Number, Unit of Measure: mg/kg NA [1] ',\n",
       " 'intravascular coagulation * 1/32 (3.13%), Febrile neutropenia * 1/32 (3.13%), Adrenal insufficiency * 1/32 (3.13%), Endocrine disorder * 1/32 (3.13%), Chills * 1/32 (3.13%), Fatigue * 1/32 (3.13%), Fever * 1/32 (3.13%), Multi-organ failure * 1/32 (3.13%), Hepatic failure * 1/32 (3.13%), Infection * 1/32 (3.13%), Sepsis 0/5 (0.00%), Platelet count decreased 0/5 (0.00%), Dehydration 1/5 (20.00%), Dysarthria 0/5 (0.00%). ',\n",
       " 'patients must have had exposure to at least 1 and no more than 3 prior chemotherapy regimens for the treatment of metastatic breast cancer. must have tissue (excluding bone or brain) that is amenable to biopsy, ECOG performance status 0-1, Life expectancy of greater than 3 months. all prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events version 4 (CTCAE v4) grade = 1 (except alopecia) at the time of enrollment, Absolute neutrophil count >= 1,500/mcL, Platelets >= 75,000/mcL, Total bilirubin = 1.5  institutional upper limit of normal, Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal by echocardiogram (ECHO) or patients must be at least 4 weeks from last surgical procedure and recovered from all post-operative complications. women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study. patients with symptomatic or progressive brain metastases are ineligible. subjects with treated brain metastases are eligible if they have no radiographic or other signs of progression in the brain for >= 3 weeks. any corticosteroid use for brain metastases must have been discontinued without the subsequent appearance of symptoms for >= 3 weeks prior to study enrollment. history of allergic reactions attributed to compounds of similar chemical or biologic composition to trametinib monotherapy or trametinib in combination with GSK2141795, Current use of a prohibited medication. uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, history of hyperviscosity or hypercoagulability syndromes. visible retinal pathology as assessed by ophthalmic exam is considered a risk factor for RVO or CSR. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit ',\n",
       " 'Variation in Serum Levels of Follicle Stimulating Hormone (FSH) compare to natural physiological variability (screening-baseline variation), Time frame: from baseline to 12 weeks of treatment. lacebo, Overall Number of Participants Analyzed: 11, Median (Inter-Quartile Range), Unit of Measure: mIU/ml 1.4 (-5.4 to 15.7)Outcome Measurement:, Ruxolitinib MTD in combination with paclitaxel 80 mg/m2 intravenously (IV) weekly is determined by the number of patients who have dose limiting toxicity (DLT) the observation period for MTD evaluation was the first 2 cycles of treatment. participants with stable disease or better will have the opportunity to continue on single agent Ruxolitinib. ',\n",
       " 'patients will take Vorinostat daily during radiation therapy. they will be recommended to swallow the capsule 60-90 minutes prior to estimate time of radiation. ',\n",
       " 'Isothiocyanate included sulforaphane in micromolar (M) concentration was measured following standard chemical measurement procedures and divided by creatinine values in millimolar (mM) concentration. patients receive oral placebo supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity. Numeric Pain Rating Scale - pain rating scale 0-10 (0= no pain to 10= most pain imaginable) participants were re-assessed after the 2 round of TC and 4th round of FECD. atment, Overall Number of Participants Analyzed: 22, Measure Type: Number, Unit of Measure: percentage of participants Percentage of Participants with Pain (1-10): 30, Percentage of Participants with no pain (0): 70, Results 2:, Arm/Group Title: Control, Arm/Group Description: chemotherapy as usual without physical therapy. ',\n",
       " '3 patients were enrolled to the next cohort using a 5mg higher dose of ruxolitinib. the MTD is identified as the level BELOW the cohort where DLT occurred in less than one third of patients within the cohort. the maximum tolerated dose (MTD) was defined as the highest dose level in which a DLT is experienced by fewer than two patients in a cohort of 3 - 6 patients. if a DLT is observed in at least two patients in a cohort of 3 - 6 patients, the MTD will be determined to have been exceeded. all participants, Overall Number of Participants Analyzed: 20, Measure Type: Number, Unit of Measure: mg/kg NA [1] ',\n",
       " 'Outcome Measurement:, Recurrence-free Survival, 2 years for the primary analysis + 3 additional years for secondary analysis. Time frame: 5 years, Results 1:, Arm/Group Title: Ketorolac 30 mg, Arm/Group Description: Active drug to be compared with placebo, Ketorolac 30 mg IV, Overall number of participants Analyzed: 96, Measure Type: Count of participants, Unit of Measure: Participants 80 83.3%, Results 2:, Arm/ ',\n",
       " 'Results 1:, Arm/Group Title: Aprepitant, Dexamethasone, Cytoxan & Kytril. Day 1: 1 mg of Kytril orally or I.V., 10 mg of Dexamethasone orally, and Aprepitant 125 mg orally. ',\n",
       " 'inTERVENTION 1:, Patients - Intervention, Patients will be invited to view the educational DVD explaining end-of-life care options and meet with a lay health advisor for discussion. ',\n",
       " 'Anaemia 0/37 (0.00%), Febrile neutropenia 0/37 (0.00%), leukopenia 0/37 (0.00%), Neutropenia 0/37 (0.00%), arrhythmia 0/37 (0.00%), Abdominal pain 1/37 (2.70%), Diarrhoea 1/37 (2.70%), Intestinal obstruction 0/37 (0.00%), Fatigue 0/37 (0.00%), Pyrexia 0/37 ( Colitis 1/93 (1.08%), Constipation 1/93 (1.08%), Diarrhea 4/93 (4.30%), Duodenal ulcer 1/93 (1.08%), Dysphagia 4/93 (4.30%), Adverse Events 2: ',\n",
       " 'aprepitant plus standard therapy to placebo plus standard therapy in control of nausea and vomiting during conditioning therapy for autologous or allogeneic hematopoietic stem cell transplantation. retch/emesis free days during the study period, time frame: up to three weeks. ure: Participants 5__ ',\n",
       " 'phase I part: patients with advanced/metastatic solid tumors, with at least one measurable lesion. phase II part: patients with advanced/metastatic solid tumors, with at least one measurable lesion. only patients with EGFR mutation-negative tumor are eligible. if more extensive EGFR mutation testing has been performed, the tumor must not harbor any known activating EGFR mutations in Exons 18-21. all patients must be tested for EGFR mutational status and for ALK translocation status if no mutation is detected in EGFR. patients with a corresponding inhibitor must have had disease progression following treatment with a corresponding inhibitor. patients must not be at short term risk for life threatening complications. patients must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy. exceptions may be granted after documented discussion with Novartis. subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. subjects with vitiligo, type I diabetes mellitus, psoriasis not requiring systemic treatment are permitted to enroll. eatment with any immunosuppressive medication (other than steroids) within 4 weeks of initiation of study treatment. use of any vaccines against infectious diseases (e.g. influenza, varicella, pneumococcus) rsing, Negative pregnancy test, Fertile patients must use effective contraception, Creatinine clearance 30 mL/min, No hypersensitivity to magnesium oxide, No medical or other condition(s) that may compromise the objectives of the study, PRIOR CONCURRENT THERAPY:, See Disease Characteristics, More than 4 weeks since prior and no concurrent antineoplastic chemotherapy, androgens, estrogens, progestational agents, or gabapentin. ',\n",
       " \"19/149 (12.75%), Anaemia 0/149 (0.00%), Anaemia 0/149 (0.00%), Acute myocardial infarction 1/149 (0.67%), Prinzmetal angina 1/149 (0.67%), Meniere's disease 0/149 (0.00%), Vertigo 0/149 (0.00%), Cataract 2/149 (1.34%), Colitis ischaemic 1/149 (0.67%), Nausea 0/149 (0.00 \",\n",
       " 'menopausal: 12 months spontaneous amenorrhea or > 6 but  12 months amenorrhea with a serum follicle stimulating hormone (FSH) level of > 40 mIU/mL. able to read, understand and complete the required subject diary. legal incapacity or limited legal capacity. chronic renal (serum creatinine > 2.0 mg/dL) or hepatic disease. untreated overt hyperthyroidism. rmal (a subject will not be excluded if a second measurement is less than twice the upper limit of normal), Creatinine > 2.0 mg/dLInclusion Criteria: adult patients, >=18 years of age; HER2-negative metastatic breast cancer candidates for taxane-based chemotherapy; ECOG performance status of 0 or 1. ',\n",
       " 'overall response rate measured by physical exam and MRI if indicated using following definition. Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR = CR + PR., Time frame: Up to 8 months, Arm/Group Title: Arm A, Arm/Group Description: Arm A overall number of participants Analyzed: 37, Measure Type: Count of Participants, Unit of Measure: Participants 25 67.6%, Results 2:, Arm/Group Title: Arm B, Arm/Group Description: Arm B: Docetaxel 75 mg/m2 IV day 1 plus Capecitabine 1000 mg/m2/dose bid x 14d q3w, then surgery, then Epirubicin 90 mg/m2 day 1 IV and Cyclophosphamide 600 mg/m2 day 1 median time to first skeletal-related event could not be estimated in one treatment arm. median time to first skeletal-related event could not be estimated. ',\n",
       " 'change in total body lean mass measured by dual energy x-ray absorptiometry (DEXA) from baseline to 4 months. time frame: Baseline to four months. ',\n",
       " \"severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 4.03. an AE that met one or more of the following outcomes was classified as serious:, Fatal, Life-threatening, Disabling/incapacitating. st Cancer (mBC) population, metastatic Urothelial cancer (mUC) population, and overall safety population. 68 participants with non-TNBC were enrolled in the study and received at least one dose of SG. hese 68 participants, 54 were confirmed as Hormone receptor-positive/Human epidermal growth factor receptor 2-negative (HR+/HER2-), had progressed on at least one prior hormonal therapy in the metastatic setting. these 54 participants were included in the analysis of safety and were referred to as the HR+/HER2-mBC Population. PR was defined by a 30% or more decrease in the sum of the longest diameters (SLD) + sum of shortest diameters (SSD) of target lesions, taking as reference the baseline SLD+SSD. participants with breast cancer who received talazoparib capsules at a dose of either 600 mcg/day, 900 mcg/day, 1000 mcg/day, 1100 mcg/day. a dose of either 25 mcg/day, 50 mcg/day, 100 mcg/day, 200 mcg/day, 200 mcg/day, 400 mcg/day, 600 mcg/day, 900 mcg/day, 1000 mcg/day, 1100 mcg/day. \",\n",
       " 'memantine hydrochloride: Estimate participation, accrual, adherence, and retention of cancer survivors who smoke. inTERVENTION 2:, Arm II - Placebo. ',\n",
       " 'disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as a 20% increase in the sum of the longest diameter of target lesions, or progression in a non-target lesion, or the appearance of new lesions. unit of measure: months 2.8 (1.6 to 3.2), Results 2:, Arm/Group Title: CDX-011. CDX-011 administered on day 1 of each 21 day cycle until disease progression, discontinuation due to toxicity, withdrawal of consent, or end of study. ',\n",
       " 'a log ratio of expression was generated relative to reference in both the Up and DOWN arms of the gene signature. a log ratio value of zero indicated no change in expression between the two samples. overall number of participants Analyzed: 14, Measure Type: Number, Unit of Measure: Percentage of participants 28.6 (13.1 to 49.2), Results 2:, Arm/Group Title: Triple Negative (TN), Arm/Group Description: Triple Negative participants received a single dose of dalotuzumab 20 mg/kg infused over 60-120 minutes. ',\n",
       " 'Outcome Measurement:, Recurrence-free Survival, 2 years for the primary analysis + 3 additional years for secondary analysis. Time frame: 5 years, Results 1:, Arm/Group Title: Ketorolac 30 mg, Arm/Group Description: Active drug to be compared with placebo, Ketorolac 30 mg IV, Overall number of participants Analyzed: 96, Measure Type: Count of participants, Unit of Measure: Participants 80 83.3%, Results 2:, Arm/ ',\n",
       " 'female patients with histologically/cytologically proven metastatic breast carcinoma (stage IV, or recurrent with local or regional spread or distant metastatic disease), Adequate bone marrow, liver, and renal function. ',\n",
       " 'Avastin treatment must have been a minimum of 4 cycles (15 mg/kg) or 6 cycles (10 mg/kg) in combination with chemotherapy, ECOG performance status 0-2, At least 28 days since prior radiation therapy or surgery and recovery from treatment. Exclusion Criteria:, Anti-angiogenic therapy or anti-vascular endothelial growth factors other than Avastin for first-line treatment. ER-positive is defined as 1% immunohistochemical staining of any intensity. patients with stage II-III breast cancer are eligible if they are deemed appropriate for neoadjuvant endocrine therapy by the referring or treating medical oncologist. tmenopausal for at least 1 year before the screening visit, OR, Are surgically sterile, OR agree to practice 1 effective method of contraception and 1 additional effective (barrier) method, at the same time, from the time of signing the ICF through 90 days. male patients, even if surgically sterilized (i.e., status post-vasectomy) days after the last dose of the study drugs, OR, Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient. Agree not to donate sperm during the course of the study or within 120 days after receiving their last dose. consent must be given before performing any study-related procedure not part of standard medical care. patient must be accessible for treatment and follow-up. patient must be willing to undergo breast biopsies as required by study protocol. patients with non-melanoma skin cancer or carcinoma in situ are not excluded if they have undergone complete resection. patients with enteric stomata are also excluded. roid administration may be enrolled in the study if all other inclusion criteria and none of the other exclusion criteria are met. roid administration may be enrolled in the study if all other inclusion criteria and none of the other exclusion criteria are met. use of antihypertensive agents to control hypertension before week. patients receiving systemic corticosteroids within 1 week before administration of the first dose of the study drugs. daily or chronic use of a proton pump inhibitor (PPI) and/or having taken a PPI wit. patients unwilling or unable to comply with the study protocol. patients previously treated with hormonal therapy (tamoxifen, AI) or PI3K, AKT, dual PI3K/mTOR, TORC1/2, or mTORC1 inhibitors. ',\n",
       " 'a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 will be explored and will follow a 6 + 3 dose de-escalation design. participants with one of the following tumor types will be eligible for enrollment. ',\n",
       " 'all patients will receive GM-CSF at 250 mcg/m2 starting one day after the administration of chemotherapy x 7 days. patients with neutrophil counts below 1,000/mm3 on day 8 will continue GM-CSF therapy until the neutrophil count is greater than 1,000/mm3. ',\n",
       " 'Adverse Events 1:, Total: 4/31 (12.90%), Infection 1/31 (3.23%), Deflation 1/31 (3.23%), Asymmetry 1/31 (3.23%), Delayed Healing Wound 1/31 (3.23%) Adverse Events 2:, Total: 0/75 (0.00%), Adverse Events 2:, Total: 0/75 (0.00%) ',\n",
       " 'Avastin treatment must have been a minimum of 4 cycles (15 mg/kg) or 6 cycles (10 mg/kg) in combination with chemotherapy, ECOG performance status 0-2, At least 28 days since prior radiation therapy or surgery and recovery from treatment. Exclusion Criteria:, Anti-angiogenic therapy or anti-vascular endothelial growth factors other than Avastin for first-line treatment. ER-positive is defined as 1% immunohistochemical staining of any intensity. patients with stage II-III breast cancer are eligible if they are deemed appropriate for neoadjuvant endocrine therapy by the referring or treating medical oncologist. tmenopausal for at least 1 year before the screening visit, OR, Are surgically sterile, OR agree to practice 1 effective method of contraception and 1 additional effective (barrier) method, at the same time, from the time of signing the ICF through 90 days. male patients, even if surgically sterilized (i.e., status post-vasectomy) days after the last dose of the study drugs, OR, Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient. Agree not to donate sperm during the course of the study or within 120 days after receiving their last dose. consent must be given before performing any study-related procedure not part of standard medical care. patient must be accessible for treatment and follow-up. patient must be willing to undergo breast biopsies as required by study protocol. patients with non-melanoma skin cancer or carcinoma in situ are not excluded if they have undergone complete resection. patients with enteric stomata are also excluded. roid administration may be enrolled in the study if all other inclusion criteria and none of the other exclusion criteria are met. roid administration may be enrolled in the study if all other inclusion criteria and none of the other exclusion criteria are met. use of antihypertensive agents to control hypertension before week. patients receiving systemic corticosteroids within 1 week before administration of the first dose of the study drugs. daily or chronic use of a proton pump inhibitor (PPI) and/or having taken a PPI wit. patients unwilling or unable to comply with the study protocol. patients previously treated with hormonal therapy (tamoxifen, AI) or PI3K, AKT, dual PI3K/mTOR, TORC1/2, or mTORC1 inhibitors. ',\n",
       " 'Hemoglobin decreased 2/30 (6.67%), Abdominal pain 1/30 (3.33%), Colitis 1/30 (3.33%), Diarrhea 7/30 (23.33%), Nausea 2/30 (6.67%), Rectal hemorrhage 1/30 (3.33%), Fatigue 1/30 (3.33%), Skin infection 1/30 (3.33%), Neutrophil count decreased 1/30 (3.33%), Platelet count decreased 3/30 (10.00%), Dehydration 1/30 (3.33%) holelithiasis 0/6 (0.00%), Hepatic pain 1/6 (16.67%), Bacteraemia 0/6 (0.00%) holelithiasis 0/6 (0.00%), Hepatic pain 1/6 (16.67%), bacteraemia 0/6 (0.00%) ',\n",
       " 'disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as a 20% increase in the sum of the longest diameter of target lesions, or progression in a non-target lesion, or the appearance of new lesions. unit of measure: months 2.8 (1.6 to 3.2), Results 2:, Arm/Group Title: CDX-011. CDX-011 administered on day 1 of each 21 day cycle until disease progression, discontinuation due to toxicity, withdrawal of consent, or end of study. ',\n",
       " 'oral dexamethasone will be administered on Day 1 of each cycle (12 mg), netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle. on fixed-dose combination, dexamethasone: Oral dexamethasone (12 mg) Overall number of participants Analyzed: 202, Measure Type: Count of Participants, Unit of Measure: Participants 122 60.4%Outcome Measurement:, total sleep time as measured by polysomnography (PSG) it was measured as a change in total sleep time between the before and after 1st cycle of treatment with Lenalidomide. ',\n",
       " 'Contour Profile Tissue Expander is a tissue expander with a greater height to width ratio than traditional tissue expanders. this increased ratio allows for greater lower pole expansion, thus creating a more natural looking, ptotic breast. ',\n",
       " 'intra-patient difference in hot flash activity between baseline (study week 1) and treatment termination (study week 7) is the primary endpoint. the daily hot flash score is computed by multiplying the mean grade of severity by the frequency during every 24 hour period. the average daily hot flash score during the baseline week was compared to the average daily value during week 7. patients receive 1 NutrigradTM flaxseed bar containing 7.5 grams flaxseed, 410 mg lignans,once daily. overall number of participants Analyzed: 77, Mean (Standard Deviation), Unit of Measure: units on a scale -4.9 (6.41), Results 2:, Arm/Group Title: Placebo, Arm/Group Description: Patients Identical looking bar with same calorie and total fat content but without flaxseed or lign ORR was defined as the proportion of participants who achieved a best response of either CR or PR. time frame: baseline & every 2 cycles (approximately 8 weeks) of treatment to measured progressive disease (PD) & post-therapy until PD or other therapy initiated. us Gemcitabine (PB+G), arm/group Description: paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by gemcitabine 1500 mg/m2 IV on days 1 and 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days. ',\n",
       " 'menopausal: 12 months spontaneous amenorrhea or > 6 but  12 months amenorrhea with a serum follicle stimulating hormone (FSH) level of > 40 mIU/mL. able to read, understand and complete the required subject diary. legal incapacity or limited legal capacity. chronic renal (serum creatinine > 2.0 mg/dL) or hepatic disease. untreated overt hyperthyroidism. rmal (a subject will not be excluded if a second measurement is less than twice the upper limit of normal), Creatinine > 2.0 mg/dLInclusion Criteria: adult patients, >=18 years of age; HER2-negative metastatic breast cancer candidates for taxane-based chemotherapy; ECOG performance status of 0 or 1. ',\n",
       " 'postmenopausal breast cancer (adenocarcinoma) estrogen (ER) and/or progesterone (PR) receptor positive that is locally advanced or locally recurrent and not able to be surgically removed OR with measurable and/or disease that is able to be assessed including isolated bone metastasis, Female patients 18 years or older. sient ischemic attacks in the last 6 months, no symptoms of peripheral vascular disease, no history of abdominal fistula, gastrointestinal perforation or intrabdominal abscess in the past 6 months. no known hypersensitivity to phosphate, trehalose or polysorbate, no serious non-healing wound, ulcer or bone fracture. ',\n",
       " '89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions. only those foci qualitatively positive by both readers will be considered as \"positive\" ',\n",
       " 'Adverse Events 1:, Total: 8/30 (26.67%), Heart Failure 1/30 (3.33%), Vertigo 1/30 (3.33%), Small intestinal obstruction 1/30 (3.33%), Fever 1/30 (3.33%), Aspartate aminotransferase increased 1/30 (3.33%), Alanine aminotransferase increased 1/30 (3.33%), Back Pain 1/30 (3.33%), Pleural effusion 1/30 (3.33%), Rash maculo-papular 1/30 (3.33%) ',\n",
       " 'time to progression, time to progression (TTP) is defined as the time (in months) from the moment the patient starts the study treatment to the date of progressive disease. a patient has an event is she progresses or dies due to progressive disease. CR is defined as disappearance of all target and non-target lesions. PR is defined as 30% decrease in sum of the longest dimensions (LDs) of the target lesions taking as reference the baseline sum LD. sunitinib was administered orally from Day 1 to 14 every 21 days at a starting dose of 2,000 mg/m2/day. participants were monitored for toxicity, and sunitinib and/or capecitabine dosing could be interrupted or reduced according to individual tolerance. ',\n",
       " 'patients without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis using the Response Evaluation Criteria in Solid Tumors criteria. the human epidermal growth factor receptor 2 status of the tumor will be used to stratify patients. patients may have received prior chemotherapy and/or hormonal therapy for early stage breast cancer. the chemotherapy regimen may have included an anthracycline and/or a taxane as long as it has been > 6 months since completion. patients must have normal organ and marrow function. tests should be completed within 14 days prior to starting study treatment. patients must have normal organ and marrow function. mab must have received a cumulative dose of doxorubicin less than 360mg/m2 and/or an epirubicin cumulative dose less than 720mg/m2 for study entry. patients with known leptomeningeal carcinomatosis are excluded from this clinical trial. ',\n",
       " 'inTERVENTION 1:, Phase 1: Epacadostat 25 mg BID, Epacadostat 25 mg tablet orally twice daily (BID) starting on cycle 1 Day 1 in combination with pembrolizumab 2 mg/kg or 200mg administered intravenously every 3 weeks (Q3W) starting on cycle 1 Day 1. ',\n",
       " '89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions. only those foci qualitatively positive by both readers will be considered as \"positive\" ',\n",
       " 'Anaemia 0/37 (0.00%), Febrile neutropenia 0/37 (0.00%), leukopenia 0/37 (0.00%), Neutropenia 0/37 (0.00%), arrhythmia 0/37 (0.00%), Abdominal pain 1/37 (2.70%), Diarrhoea 1/37 (2.70%), Intestinal obstruction 0/37 (0.00%), Fatigue 0/37 (0.00%), Pyrexia 0/37 ( Colitis 1/93 (1.08%), Constipation 1/93 (1.08%), Diarrhea 4/93 (4.30%), Duodenal ulcer 1/93 (1.08%), Dysphagia 4/93 (4.30%), Adverse Events 2: ',\n",
       " 'INTERVENTION 1:, MM-111, All participants_. ',\n",
       " '0/7 (0.00%)Adverse Events 1:, Total: 21/337 (6.23%), Blood/Bone Marrow-Other 0/337 (0.00%), Febrile neutropenia 0/337 (0.00%), Hemoglobin 2/337 (0.59%), Atrioventricular block - 2nd degree Mobitz Type II 0/337 (0.00%), Cardiac-ischemia/infarction 1/337 (0.30%), Adverse Events 2:, Total ',\n",
       " 'healthy women will be screened for magnetic resonance imaging (MRI) contraindications, and then undergo contrast injection, and SWIFT acquisition. 10 and 30 patients will be scanned in the first and second year. SWIFT-DCE diagnostic performance will be compared to prior FLASH-DCE methods. overall number of participants Analyzed: 8, Measure Type: Number, Unit of Measure: lesions 0, Results 2:, arm/group Title: Breast cancer patients will be screened for magnetic resonance imaging contraindications. then undergo contrast injection and SWIFT acquisition. 10 and 30 patients will be scanned in the first and second year. the results of this pilot study will provide evidence supporting the use of Medihoney in preventing and treating radiation dermatitis. patients will be instructed to apply a thin layer of the Hydrophor daily. the application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. patients should not apply the Hydrophor within 4 hours of receiving RT. Medihoney application should include entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. patients should not apply the Medihoney within 4 hours of receiving RT. ave been shown to have healing benefits:, Maintain a balanced environment for healing., Aids in reducing dermatitis., Reduce affected area pH.2-3, Overall number of participants Analyzed: 18, Measure Type: Number, Unit of Measure: participants radiation dermatitis: 15, hyperpigmentation: 15. ',\n",
       " 'inTERVENTION 2:, Trabectedin, 1.3 mg/m2 of trabectedin was administered as a 3-hour intravenous infusion on Day 1. ',\n",
       " 'measurable disease defined as at least one lesion 10 mm by CT or MRI that can be accurately measured in at least one dimension. bone lesions: lytic or mixed (lytic + blastic) in the absence of measurable disease. at least 18 years of age. Able to understand and willing to sign an IRB-approved written informed consent document. ',\n",
       " 'women with a clinically or mammographically identified suspicious breast mass likely to be biopsied or surgically removed. Exclusion Criteria:, Pregnancy, Ferromagnetic implants, history of shotgun wounds and shrapnel, Obesity (>250 pounds), Cardiac pacemaker, Incompatible implanted medical device, Severe asthma and allergies. ',\n",
       " 'Capcitabine will be administered twice weekly for 14 days out of every 21 days. treatment cycles will be 21 days in length. 10 additional patients will be treated at the determined MTD. Capecitabine will be paired with LBH589. treatment cycles will be 21 days in length. 10 additional patients will be treated at the determined MTD to further assess safety. ',\n",
       " 'Benign breast disease amenable to hormonal therapy. high risk breast lesions like epitheliosis, atypia or atypical hyperplasia. ECOG performance status 0 or 1, Pre- or post-menopausal, Must possess a compact disc player, Able to complete questionnaires alone or with assistance, No active medical conditions preventing compliance with a practice of slow deep breathing including active asthma, chronic obstructive pulmonary disease, or congestive heart failure. ntidepressants started within the past 30 days allowed. no concurrent hormonal agents and/or antineoplastic chemotherapy are allowed. ',\n",
       " 'Objective cognitive function measured with a computerized test battery of 7 tasks. performance speed is measured for Detection/Identification/Monitoring. performance accuracy is measured for memory/Learning/ISLT/ISLT-Delayed Recall. negative standardized score indicates below average results. patients complete assessments at baseline and 1 year after randomization to parent IBCSG 24-02 study. the analysis plan was revised to pre-specify collective analysis for all patients receiving OFS. overall number of participants Analyzed: 54, Mean (Standard Deviation), Unit of Measure: standardized units -0.21 (0.92). ',\n",
       " '3/37 (8.11%), Sinus tachycardia 0/37 (0.00%), Heart failure 0/37 (0.00%), Dehydration 1/37 (2.70%), Death Not Associated with CTCAE: Death NOS 1/37 (2.70%), Lymphopenia 1/37 (2.70%), Neutropenia 1/37 (2.70%), Thrombocytopenia 0/37 (0.00%), Hyponatremia 1/37 (2.70%), Weight loss 0/37 ( ',\n",
       " '77/122 (63.11%), Anaemia 1/122 (0.82%), Thrombocytopenia 1/122 (0.82%), Pericardial effusion 3/122 (2.46%), Supraventricular tachycardia 2/122 (1.64%), Atrial fibrillation 1/122 (0.82%), Sinus tachycardia 1/122 (0.82%), Hypothyroidism 1/122 (0.82%), Abdominal pain 4/122 (3.28%)Adverse ',\n",
       " 'participants with metastatic breast cancer received a loading dose of 4 milligrams per kilograms (mg/kg) of trastuzumab intravenously (IV) followed by 2 mg/kg of trastuzumab IV once a week along with docetaxel 100 milligrams per meter square (mg/m2), every 3 weeks or paclitaxel 90 mg/m2 once a week. Herceptin 2 mg/kg by IV infusion weekly starting from Day 8. docetaxel 100 mg/m2 IV infusion on Day 2 of cycle 5. after completion of last cycle of chemotherapy, Herceptin 6 mg/kg IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose. ',\n",
       " 'inTERVENTION 1:, wait-list, patients in wait-list control group will cross over and receive acupuncture twice weekly for six consecutive weeks. patients will be advised to continue their standard lymphedema treatments such as exercise or use of compression garments if these were in use prior to clinical trial participation. rmed after approximately 6 weeks on wait-list, before onset of acupuncture treatment. BMI will be measured at the same timepoints. ',\n",
       " 'sunitinib was administered orally from Day 1 to 14 every 21 days at a starting dose of 2,000 mg/m2/day. participants were monitored for toxicity, and sunitinib and/or capecitabine dosing could be interrupted or reduced according to individual tolerance. ',\n",
       " 'patients will be instructed to apply a thin layer of the Hydrophor daily. the application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. patients should not apply the Hydrophor within 4 hours of receiving RT. Medihoney application should include the entire treatment area. patients should not apply the Medihoney within 4 hours of receiving RT. patients should wash the application area daily with perfume-free soap and tap water. each treatment cycle was defined as 21 days. participants received intravenous infusion of PF-05212384 90 mg once on Day -7 and Cycle 1 Day 2. participants received docetaxel 75 mg/m2 1-hour IV infusion once. the maximum duration of PF-05212384 treatment was 505 days. the maximum duration of docetaxel treatment was 445 days. ',\n",
       " 'all patients will receive GM-CSF at 250 mcg/m2 starting one day after the administration of chemotherapy x 7 days. patients with neutrophil counts below 1,000/mm3 on day 8 will continue GM-CSF therapy until the neutrophil count is greater than 1,000/mm3. ',\n",
       " 'this cohort received Zoledronic Acid 4 mg Q4W in the blinded treatment phase of the parent study 20050103 (NCT00321620) or 20050136 (NCT00321464) and received Denosumab 120 mg Q4W in this open-label extension study. inTERVENTION 1: Tamoxifen, Tamoxifen at a dose of 10 mg once daily from 5th day to 25th day of menstrual cycle for 3 months. ',\n",
       " 'participants with metastatic breast cancer received a loading dose of 4 milligrams per kilograms (mg/kg) of trastuzumab intravenously (IV) followed by 2 mg/kg of trastuzumab IV once a week along with docetaxel 100 milligrams per meter square (mg/m2), every 3 weeks or paclitaxel 90 mg/m2 once a week. Herceptin 2 mg/kg by IV infusion weekly starting from Day 8. docetaxel 100 mg/m2 IV infusion on Day 2 of cycle 5. after completion of last cycle of chemotherapy, Herceptin 6 mg/kg IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose. ',\n",
       " 'healthy women will be screened for magnetic resonance imaging (MRI) contraindications, and then undergo contrast injection, and SWIFT acquisition. 10 and 30 patients will be scanned in the first and second year. SWIFT-DCE diagnostic performance will be compared to prior FLASH-DCE methods. overall number of participants Analyzed: 8, Measure Type: Number, Unit of Measure: lesions 0, Results 2:, arm/group Title: Breast cancer patients will be screened for magnetic resonance imaging contraindications. then undergo contrast injection and SWIFT acquisition. 10 and 30 patients will be scanned in the first and second year. the results of this pilot study will provide evidence supporting the use of Medihoney in preventing and treating radiation dermatitis. patients will be instructed to apply a thin layer of the Hydrophor daily. the application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. patients should not apply the Hydrophor within 4 hours of receiving RT. Medihoney application should include entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. patients should not apply the Medihoney within 4 hours of receiving RT. ave been shown to have healing benefits:, Maintain a balanced environment for healing., Aids in reducing dermatitis., Reduce affected area pH.2-3, Overall number of participants Analyzed: 18, Measure Type: Number, Unit of Measure: participants radiation dermatitis: 15, hyperpigmentation: 15. ',\n",
       " 'patients will take Vorinostat daily during radiation therapy. they will be recommended to swallow the capsule 60-90 minutes prior to estimate time of radiation. ',\n",
       " 'patients with vitamin D deficiency who experience myalgias, arthralgias and/or joint stiffness received epoetin beta (NeoRecormon®) at a dose of 30000 International Units (IU) as subcutaneous (SC) injection once every week. ',\n",
       " 'Adverse Events 1:, Total: 1/29 (3.45%), Surgery * [1]1/29 (3.45%) ',\n",
       " 'ECOG performance status of 0, Previous non-metastatic operable primary invasive HER2-positive breast cancer, Baseline LVEF >55%, Exclusion Criteria:, Healthy Participants (Part 1 only), Clinically significant abnormalities in laboratory test results or electrocardiogram. history of significant allergies, gastrointestinal, renal, hepatic, cardiovascular, or pulmonary disease, hypersensitivity or allergic reaction, spontaneous or following drug administration. bothersome hot flashes for 1 month prior to study entry, PATIENT CHARACTERISTICS:, Eastern Cooperative Oncology Group (ECOG) performance status 0-1, Life expectancy 6 months, Able to complete questionnaire(s) by themselves or with assistance, Women of childbearing potential not eligible. al estrogen is allowed if used for the past month and not planned to be discontinued, concurrent adjuvant targeted therapy (i.e., lapatinib, trastuzumab [Herceptin®] allowed in patients with no evidence of disease, Concurrent tamoxifen, raloxifene, or aromatase inhibitors on a constant dose for at least 4 weeks allowed provided the medication will not be stopped during the study period. ',\n",
       " \"breast tumor 1 centimeter (cm) in diameter, HR+, HER2-. neoadjuvant endocrine monotherapy is deemed to be a suitable therapy. measurable disease, Bone metastases requires other disease present that can be measured. no brain metastases, unless documented to be controlled post-completion of local therapy for at least 4 weeks, no meningeal carcinomatosis, no malignant effusion as the only site. hat in the opinion of the treating physician would make study protocol unreasonably hazardous for the patient. hat in the opinion of the treating physician would make study protocol unreasonably hazardous for the patient or would preclude the patient's ability to comply with the study protocol. \",\n",
       " 'patient must have histologically or cytologically confirmed locally advanced, unresectable or metastatic carcinoma of the breast. patient must have performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) performance scale and life expectancy > 3 months. female patient of childbearing potential must have a negatio. ve serum or urine pregnancy test quantitative human chorionic gonadotropin (-hCG) within 72 hours prior to receiving the first dose of study medication is allowed. patients with stable and clinically insignificant CNS disease are allowed. patients must be off steroids with no new CNS symptoms. bevacizumab, hormone therapy within one week, trastuzumab within 2 weeks or lapatinib within one week of study Day 1. patients with known active central nervous system metastases and/or carcinomatous meningitis eligible for study. patients with clinically insignificant brain metastases that do not require treatment are eligible. clinically significant cardiac arrhythmia, history or current evidence of a myocardial infarction during the last 6 months, and/or a current ECG tracing that is abnormal in the opinion of the treating Investigator. patients with other active, current primary malignancies, other than carcinoma in situ of the cervix or non-melanoma skin cancer. ',\n",
       " 'inTERVENTION 2:, Part 1 and Part 2: Talazoparib (Ovarian/ Peritoneal Cancer) Participants with ovarian/ peritoneal cancer who received talazoparib capsules in Part 1 and 2 at a dose of either 600 mcg/day, 900 mcg/day, 1000 mcg/day, 1100 mcg/day. ',\n",
       " 'participants received 1250 milligram (mg) tablets lapatinib once a day and vinorelbine 20 mg/meters squared (m2) intravenously on Day 1 and Day 8, and every 3 weeks. participants received 1250 milligram (mg) tablets lapatinib once a day. ticipants Analyzed: 25, Measure Type: Number, Unit of Measure: participants Week 12, CR: 0, Week 12, PR: 4, Week 12, SD: 12, Week 24, CR: 0, Week 24, PR: 4, Week 24, SD: 10_ ',\n",
       " 'patients who undergo surgical oophorectomy survive longer than patients who undergo this surgery in the history-estimated mid-luteal phase of their menstrual cycles. time frame: up to 9 years, Results 1:, Arm/Group Title: A Mid-luteal Surgery, Arm/Group Description: [Not Specified], Overall Number of participants Analyzed: 115, Median (95% Confidence Interval), Unit of Measure: years 2.14 (1.53 to 2.67), Results 2:, Arm ',\n",
       " 'Adverse Events 1:, Total: 1/208 (0.48%), Neutrophils/granulocytes (ANC/AGC) 1/208 (0.48%), Adverse Events 2:, Total: 0/201 (0.00%), Neutrophils/granulocytes (ANC/AGC) 0/201 (0.00%)Adverse Events 1:, Total: 0/34 (0.00%) ',\n",
       " 'at least 18 years of age, Female, Able to understand and willing to sign an IRB-approved written informed consent document, Exclusion Criteria:, Pregnant and/or breastfeeding, Prior history of breast cancer, Prior history of chest wall radiation, Prior history of breast reconstruction, reduction, or augmentationInclusion Criteria:, Patient must be 18 and older, Patients must have histologically confirmed (by routine H&E staining) invasive adenocarcinoma or Ductal Carcino women of child-bearing potential must use effective non-hormonal contraception while undergoing radiation therapy. patients must not have a serious medical or psychiatric illness which prevents informed consent or compliance with treatment. ',\n",
       " \"in case of Gilbert's syndrome, 2 x ULN is allowed, AST (SGOT/ALT(SGPT)= 2.5 X institutional upper limit of normal, Alkaline phosphatase = 2.5 x ULN, Creatinine within normal institutional limits, Cardiac ejection fraction within the institutional range of normal as measured by echocardiogram or MUGA scan. eligibility of patients receiving medications or substances known to affect, or with the potential to affect, the effects of lapatinib on the developing human fetus at the recommended therapeutic dose are unknown. women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation. prior treatment with EGFR targeting therapies, treatment with any other investigational agents, or with all herbal (alternative) medicines. history of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib. uncontrolled inter-current illness including, but not limited to, ongoing or active infection. ammatory GI disease (e.g., Crohn's, ulcerative colitis), concomitant requirement for medication classified as CYP3A4 inducers or inhibitors. \",\n",
       " 'patient must have histologically or cytologically confirmed locally advanced, unresectable or metastatic carcinoma of the breast. patient must have performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) performance scale and life expectancy > 3 months. female patient of childbearing potential must have a negatio. ve serum or urine pregnancy test quantitative human chorionic gonadotropin (-hCG) within 72 hours prior to receiving the first dose of study medication is allowed. patients with stable and clinically insignificant CNS disease are allowed. patients must be off steroids with no new CNS symptoms. bevacizumab, hormone therapy within one week, trastuzumab within 2 weeks or lapatinib within one week of study Day 1. patients with known active central nervous system metastases and/or carcinomatous meningitis eligible for study. patients with clinically insignificant brain metastases that do not require treatment are eligible. clinically significant cardiac arrhythmia, history or current evidence of a myocardial infarction during the last 6 months, and/or a current ECG tracing that is abnormal in the opinion of the treating Investigator. patients with other active, current primary malignancies, other than carcinoma in situ of the cervix or non-melanoma skin cancer. ',\n",
       " 'Adverse Events 1:, Total: 0/60 (0.00%), Adverse Events 2:, Total: 0/60 (0.00%). ',\n",
       " 'Adverse Events 1:, Total: 5/14 (35.71%), Ileus 1/14 (7.14%), General disorders and administration site conditions - Other, disease progression 2/14 (14.29%), Infections and infestations - Other, pneumonia 1/14 (7.14%) ',\n",
       " 'asymptomatic women scheduled for screening mammography or have completed a screening mammogram within the past 30 days. subjects with prior lumpectomy (> 5 years prior) who receive only routine screening mammography views can be included. x 31 centimeter (cm) FFDM digital receptor without anatomical cut off during either FFDM or DBT examination. have participated in (within the prior 30 days) another trial of an investigational product expected to interfere with study procedures or outcomes. ',\n",
       " 'ALT-801 0.015 mg/kg/Dose, 0.015 mg/kg/dose of ALT-801. ALT-801 0.040 mg/kg/Dose, 0.040 mg/kg/dose of ALT-801. ',\n",
       " 'patients 18 years of age or older are eligible for the study. patients undergoing skin-sparing mastectomy are eligible for the study. patients who have not undergone autologous tissue breast reconstruction. must have completed surgery for stage I-III breast cancer. must have a plasma c-reactive protein level of >3mg/L. must have score of 4 (out of 10 points, 0 being no fatigue and 10 being severe, incapacitating fatigue) on a single Item Screening Scale for Fatigue. uncontrolled cardiovascular, metabolic, pulmonary or renal disease (as determined by medical history and laboratory testing), Current or past history of schizophrenia, Individuals with bipolar disorder who have experienced a manic episode within 6 months of study entry, or at the discretion of the study doctor. Individuals receiving antidepressants, mood stabilizers, antipsychotic medications or benzodiazepines or drugs known to affect the immune system (e.g. glucocorticoids, methotrexate), or at the ',\n",
       " 'inTERVENTION 1:, arm A (ANA), patients receive oral anastrozole as 1 mg film-coated tablets. patients receive fulvestrant intramuscularly (250 mg/5 ml solution) on days 1, 14 and 28. ',\n",
       " 'inTERVENTION 1:, arm A (ANA), patients receive oral anastrozole as 1 mg film-coated tablets. patients receive fulvestrant intramuscularly (250 mg/5 ml solution) on days 1, 14 and 28. ',\n",
       " 'Adverse Events 1:, Total: 0/34 (0.00%)Adverse Events 1:, Total: 0/1 (0.00%)Adverse Events 1:, Total: 0/1 (0.00%) ',\n",
       " 'Adverse Events 1:, Total: 11/25 (44.00%), Febrile neutropenia * 4/25 (16.00%), Neutropenia * 3/25 (12.00%), Diarrhoea * 1/25 (4.00%), Intestinal perforation * 1/25 (4.00%), Rectal haemorrhage * 1/25 (4.00%), Stomatitis * 1/25 (4.00%), Vomiting * 1/25 (4.00%), Fatigue * 1/25 (4.00%), ',\n",
       " 'Adverse Events 1:, Total: 4/31 (12.90%), Infection 1/31 (3.23%), Deflation 1/31 (3.23%), Asymmetry 1/31 (3.23%), Delayed Healing Wound 1/31 (3.23%) Adverse Events 2:, Total: 0/75 (0.00%), Adverse Events 2:, Total: 0/75 (0.00%) ',\n",
       " '89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions. only those foci qualitatively positive by both readers will be considered as \"positive\" ',\n",
       " 'Adverse Events 1:, Total: 0/15 (0.00%), Adverse Events 2:, Total:Adverse Events 1:, Total: 0/442 (0.00%), Adverse Events 2:, total: 0/442 (0.00%), Adverse Events 2:, total: 0/442 (0.00%), Adverse Events 2:, total: 0/442 (0.00%). ',\n",
       " 'patients with a histologically/cytologically confirmed diagnosis of advanced and/or unresectable disease of any of the following tumors: breast cancer, Epithelial ovarian cancer or gynecological cancer, Head and neck squamous cell carcinoma, Non-small cell lung cancer, Small cell lung cancer, Platinum-refractory germ-cell tumors. pre-menopausal women must have a negative pregnancy test before study entry. patients who have previously discontinued bevacizumab-containing regimes due to drug-related toxicity. more than three prior lines of chemotherapy, Less than three months since last taxane-containing therapy. ring dyspnea, known HIV infection, bleeding risk, muscular problems, peripheral neuropathy, symptomatic or progressive brain metastases or leptomeningeal disease. men or pre-menopausal women who are not using an effective method of contraception as previously described. ',\n",
       " 'patients with vitamin D deficiency who experience myalgias, arthralgias and/or joint stiffness who experience joint stiffness and joint stiffness. ',\n",
       " 'patients with vitamin D deficiency who experience myalgias, arthralgias and/or joint stiffness who experience joint stiffness and joint stiffness. ',\n",
       " 'male subjects aged greater than or equal to 18 years must be postmenopausal. female subjects must be 55 or older and with postmenopausal follicle-stimulating hormone [FSH] levels. subjects may have more than one synchronous primary breast tumor. bilirubin less than or equal to 1.5 times the upper limits of normal (ULN) and alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 x ULN. male subjects must have had a successful vasectomy (confirmed azoospermia) male subjects must agree to use and have their female partners use a highly effective method of contra reement to provide written informed consent and willingness to comply with all aspects of the protocol, exclusion Criteria:, Stage III and IV invasive breast cancer, Prior chemotherapy, radiation therapy, immunotherapy or biotherapy for current breast cancer, Nonmalignant systemic disease (cardiovascular, renal, hepatic, etc.) Subjects with concurrently active second malignancy other than adequately treated nonmelanoma skin cancers or in situ cervical cancer, Subjects with pre-existing neuropathy greater than Grade 2, Subject gastrointestinal disease defined as at least one lesion 10 mm by CT or MRI that can be accurately measured in at least one dimension (CT scan slice thic thic thic thic thic thic thic thic thic thic thic thic thic thic thic thic thic thic thic thic. patients with only non-measurable lesions other than lytic or mixed (lytic + blastic) bone metastasis. previous treatment with exemestane, mTOR inhibitors, PI3K inhibitors or AKT inhibitors. ',\n",
       " 'Adverse Events 1:, Total: 0/7 (0.00%)Adverse Events 1:, Total: 0/11 (0.00%), Adverse Events 2:, Total: 0/11 (0.00%). ',\n",
       " 'Adverse Events 1:, Total: 2/35 (5.71%), Gastroesophageal reflux disease * 1/35 (2.86%), Ductal carcinoma in situ * 1/35 (2.86%). ',\n",
       " 'average pain was measured using a 0 (no pain) to 10 (worst pain imaginable) numeric rating scale on a daily basis. change in average pain intensity between the two intervention groups was evaluated from enrollment to the end of the study. follow-up visits to assess the sustainability of the intervention will be done at 2 weeks, 1 month and 3 months after the intervention. patients in both groups will be seen in their homes over the course of 10 weeks with phone calls conducted in between the home visits. patients in the LOW-DOSE group will receive 4 visits and 6 phone calls. follow-up visits to assess the sustainability of the intervention will be done at 2 weeks, 1 month and 3 months after the intervention. ',\n",
       " '0/7 (0.00%)Adverse Events 1:, Total: 21/337 (6.23%), Blood/Bone Marrow-Other 0/337 (0.00%), Febrile neutropenia 0/337 (0.00%), Hemoglobin 2/337 (0.59%), Atrioventricular block - 2nd degree Mobitz Type II 0/337 (0.00%), Cardiac-ischemia/infarction 1/337 (0.30%), Adverse Events 2:, Total ',\n",
       " 'colorectal, breast, and cervical cancer screenings up to date status. participants assigned to the CCI group received the Prevention Care Management intervention. overall number of participants Analyzed: 378, Measure Type: Number, Unit of Measure: Percentage (%) of Participants Colorectal Cancer Screening - Baseline: 22.0, Colorectal Cancer Screening - Follow Up: 56.9, Breast Cancer Screening - Baseline: 43.9, Cervical Cancer Screening - Follow the PCM intervention consisted of cancer screening telephone support, including education, patient navigation, and motivational interviewing. overall number of participants Analyzed: 379, Measure Type: Number, Unit of Measure: Percentage (%) of Participants Colorectal Cancer Screening - Baseline: 26.9, Colorectal Cancer Screening - Follow Up: 52.8, Breast Cancer Screening - Follow Up: 66.8, Cervical Cancer Screening - Baseline: 41.7, Cerv ',\n",
       " '0/21 (0.00%)Adverse Events 1:, Total: 3/8 (37.50%), Anaemia 0/8 (0.00%), Febrile neutropenia 0/8 (0.00%), Polycythaemia 0/8 (0.00%), Acute coronary syndrome 0/8 (0.00%), Vertigo 0/8 (0.00%), Eyelid oedema 1/8 (12.50%), Constipation 0/8 (0.00%), Diarrhoea 0/8 ',\n",
       " 'inTERVENTION 1:, Adult Cancer Patients 65 Years of Age and Older, Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older. ',\n",
       " 'patients receive cabergoline oral (PO) twice weekly for weeks 1-4. courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. ',\n",
       " 'participants received 1250 milligram (mg) tablets lapatinib once a day and vinorelbine 20 mg/meters squared (m2) intravenously on Day 1 and Day 8, and every 3 weeks. participants received 1250 milligram (mg) tablets lapatinib once a day. ticipants Analyzed: 25, Measure Type: Number, Unit of Measure: participants Week 12, CR: 0, Week 12, PR: 4, Week 12, SD: 12, Week 24, CR: 0, Week 24, PR: 4, Week 24, SD: 10_ ',\n",
       " '0/25 (0.00%)Adverse Events 1:, Total: 10/30 (33.33%), Hemoglobin decreased 2/30 (6.67%), Abdominal pain 1/30 (3.33%), Colitis 1/30 (3.33%), Diarrhea 7/30 (23.33%), Nausea 2/30 (6.67%), Rectal hemorrhage 1/30 (3.33%), Fatigue 1/30 (3.33%), Skin infection 1/30 (3.33%), Neutrophil count decreased 1/30 ( ',\n",
       " 'one to three presumed brain metastases must be from a histologically confirmed extracerebral site (e.g., lung, breast, prostate), Histologic confirmation may have been from the primary tumor site, from another metastatic site (e.g., osseous metastasis, adrenal metastasis), or from the metastatic brain lesion(s) Each lesion must measure less than 3.0 cm by contrast MRI of the brain performed within the past 21 days. male patients must continue to use contraception for 3 months after the completion of radiotherapy. no pacemaker or other MRI-incompatible metal in the body, no known allergy to gadolinium, no known allergy to gadolinium. volunteers may have had a prior history of other cancers > 3 years which required only local resection, local radiation and/or hormonal therapy such as androgen blockade. d risk of the proposed study and be able to sign consent. e influenza vaccine, On-going neurologic disorder (mental status change, uncontrolled seizures, encephalopathy), Treatment or planned treatment with cyclophosphamide, ifosphamide, or > or = to 1 mg/kg prednisone or its equivalent 12 weeks within 12 weeks of vaccination. patients receiving the seasonal influenza vaccine may not have had it within 6 months of enrollment. ',\n",
       " 'the EORTC CIPN20 scoring algorithm was used for the sensory (items 31-36, 39, 40 and 48) subscale scores on a 0-100 scale. the aAUCpa for the subscale is calculated as the average of each AUC between each sequential assessment from pre-treatment-initiation to the week-12 assessment. positive scores represent symptoms has improved from baseline and negative scores represent symptoms has worsen from baseline. therapy repeats every week for a planned course of 12 weeks of adjuvant paclitaxel. overall number of participants Analyzed: 19, Median (Full Range), Unit of Measure: Average(subscale value*assessment) -1.4 (-11.7 to 6.8), Results 2:, Arm/Group Title: Arm II (Control), Arm/Group Description: Patients receive the standard of care only (paclitaxel at a dose of 80 mg/m2 IV) every week for ',\n",
       " 'FEBRILE NEUTROPENIA * 0/3 (0.00%), ANAEMIA * 0/3 (0.00%), THROMBOCYTOPENIA * 0/3 (0.00%), ATRIAL FLUTTER * 0/3 (0.00%), BRADYCARDIA * 0/3 (0.00%), VOMITING * 0/3 (0.00%), Adverse Events 2:, Total: 0/3 (0.00%), FEBRILE NEUTROPENIA * 0/3 ',\n",
       " 'Febrile neutropenia * 2/5 (40.00%), Anaemia * 0/4 (0.00%), Vertigo * 0/4 (0.00%), Nausea * 0/4 (0.00%), Stomatitis * 0/4 (0.00%), Vomiting * 0/4 (0.00%), Disease progression * 0/4 (0.00%), Mucosal inflammation * 0/4 (0.00%), Fatigue * 0/4 (0.00%), Pyrexia * 0/4 (0.00%), Ga ',\n",
       " '0/4 (0.00%), Anaemia 0/4 (0.00%), Febrile neutropenia 0/4 (0.00%), Leukocytosis 0/4 (0.00%), Neutropenia 0/4 (0.00%), Pancytopenia 0/4 (0.00%), Acute coronary syndrome 0/4 (0.00%), Atrial fibrillation 0/4 (0.00%), Cardiac arrest 0/4 (0.00%), Pericardial effusion 0/4 (0.00%), Ad ',\n",
       " 'FEBRILE NEUTROPENIA * 0/3 (0.00%), ANAEMIA * 0/3 (0.00%), THROMBOCYTOPENIA * 0/3 (0.00%), ATRIAL FLUTTER * 0/3 (0.00%), BRADYCARDIA * 0/3 (0.00%), VOMITING * 0/3 (0.00%), Adverse Events 2:, Total: 0/3 (0.00%), FEBRILE NEUTROPENIA * 0/3 ',\n",
       " 'Capcitabine will be administered twice weekly for 14 days out of every 21 days. treatment cycles will be 21 days in length. 10 additional patients will be treated at the determined MTD. Capecitabine will be paired with LBH589. treatment cycles will be 21 days in length. 10 additional patients will be treated at the determined MTD to further assess safety. ',\n",
       " '3 patients were enrolled to the next cohort using a 5mg higher dose of ruxolitinib. the MTD is identified as the level BELOW the cohort where DLT occurred in less than one third of patients within the cohort. the maximum tolerated dose (MTD) was defined as the highest dose level in which a DLT is experienced by fewer than two patients in a cohort of 3 - 6 patients. if a DLT is observed in at least two patients in a cohort of 3 - 6 patients, the MTD will be determined to have been exceeded. all participants, Overall Number of Participants Analyzed: 20, Measure Type: Number, Unit of Measure: mg/kg NA [1] ',\n",
       " 'the baseline dose is 100 mg three times daily for four months. the baseline dose is 100 mg three times daily for four months. participants in Cohort 1 received necitumumab Process C drug product. ',\n",
       " \"the participant has a histopathologically or cytologically confirmed diagnosis of breast adenocarcinoma that is metastatic or locally-recurrent and inoperable with curative intent. the participant has measurable and/or non-measurable disease, The participant's primary and/or metastatic tumor is human Epidermal Growth Factor Receptor 2 (HER2) negative. participants of reproductive potential agree to use adequate contraceptive methods during the study period and for 12 weeks after the last dose of study medication. participant has a concurrent active malignancy other than breast adenocarcinoma, adequately treated non-melanomatous skin cancer, or other non-invasive carcinoma or in situ neoplasm. articipant has received any experimental agents within 4 weeks prior to the study registration date, The participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders. the participant has an ongoing or active infection requiring antibiotic, antifungal, or antiviral therapy. for bone disease, stable disease (SD) is allowed. patient must have tumor assessed for estrogen-receptor (ER) and progesterone-receptor (PR) prior HDCT with autologous hematopoietic stem cell transplantation (AHST) in adjuvant setting. history of other malignancies except cured non-melanoma skin cancer. \",\n",
       " 'Variation in Serum Levels of Follicle Stimulating Hormone (FSH) compare to natural physiological variability (screening-baseline variation), Time frame: from baseline to 12 weeks of treatment. lacebo, Overall Number of Participants Analyzed: 11, Median (Inter-Quartile Range), Unit of Measure: mIU/ml 1.4 (-5.4 to 15.7)Outcome Measurement:, Ruxolitinib MTD in combination with paclitaxel 80 mg/m2 intravenously (IV) weekly is determined by the number of patients who have dose limiting toxicity (DLT) the observation period for MTD evaluation was the first 2 cycles of treatment. participants with stable disease or better will have the opportunity to continue on single agent Ruxolitinib. ',\n",
       " 'patient must have histologically or cytologically confirmed locally advanced, unresectable or metastatic carcinoma of the breast. patient must have performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) performance scale and life expectancy > 3 months. female patient of childbearing potential must have a negatio. ve serum or urine pregnancy test quantitative human chorionic gonadotropin (-hCG) within 72 hours prior to receiving the first dose of study medication is allowed. patients with stable and clinically insignificant CNS disease are allowed. patients must be off steroids with no new CNS symptoms. bevacizumab, hormone therapy within one week, trastuzumab within 2 weeks or lapatinib within one week of study Day 1. patients with known active central nervous system metastases and/or carcinomatous meningitis eligible for study. patients with clinically insignificant brain metastases that do not require treatment are eligible. clinically significant cardiac arrhythmia, history or current evidence of a myocardial infarction during the last 6 months, and/or a current ECG tracing that is abnormal in the opinion of the treating Investigator. patients with other active, current primary malignancies, other than carcinoma in situ of the cervix or non-melanoma skin cancer. ',\n",
       " 'ovarian cancer patients should have one prior platinum-based, chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound. patients with platinum-sensitive and platinum resistant disease are NOT eligible. the effects of BMN 673 on the developing human fetus are unknowable. the effects of BMN 673 on the developing human fetus are unknown. men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 30 days after completing study treatment. men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for the duration of study participation. human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer should have received at least two lines of systemic therapy. patients with prostate cancer can continue to receive treatment with GnRH agonists while on study, as long as there is evidence of disease progression on therapy. nt of brain metastases are eligible to participate at the discretion of the principal investigator. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations would limit compliance with study requirements. patients who require use of coumarin-derivative anticoagulants are excluded. low-dose warfarin (less than or equal to 1 mg/day) is permitted. in subjects with documented liver metastases, the AST/ALT may be 5x ULN, Prothrombin time 1.5x ULN, unless receiving therapeutic anticoagulation, Serum magnesium and potassium within normal limits. subjects with documented liver metastases are eligible if controlled on a stable dose 10mg prednisone/day or its equivalent dose of steroids. Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C. subjects with liver cancer and hepatitis may be eligible. ',\n",
       " 'Eribulin+Cyclophosphamide (ErC), Eribulin (Er): 1.4mg/m2 (Days 1 and 8 of each treatment cycle) by IV infusion, Cyclophosphamide (C): 600 mg/m2 IV (Day 1 of each treatment cycle) by IV infusion. inTERVENTION 2: Docetaxel+Cyclophosphamide (TC), Docetaxel (T): 75 mg ',\n",
       " 'the primary endpoint will allow to compare the efficacy of the single dose of Extimia® versus nonpegylated daily filgrastim. patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously. Placebo No2 is supplied as solution for injection 0.0083 ml/kg. overall number of participants Analyzed: 43, Mean (Standard Deviation), Unit of Measure: days 0.791 (1.013) empegfilrastim: Empegfilgrastim is to be administered 24 h after the chemotherapy at a dose of 6 mg subcutaneously. Empegfilrastim: Empegfilgrastim is supplied as solution for injection 3 mg/ml. ',\n",
       " 'inTERVENTION 2:, Part 1 and Part 2: Talazoparib (Ovarian/ Peritoneal Cancer) Participants with ovarian/ peritoneal cancer who received talazoparib capsules in Part 1 and 2 at a dose of either 600 mcg/day, 900 mcg/day, 1000 mcg/day, 1100 mcg/day. ',\n",
       " 'adults with histologically or cytologically confirmed breast adenocarcinoma, radiographic evidence of at least one bone mets, Easter Cooperative Oncology Group status of 0, 1 or 2; adequate organ function, Exclusion Criteria:, Current or prior IV bisphosphonate administration, current or prior oral bisphosphonates for bone mets, life expectancy of less than 6 monthsInclusion Criteria:, Patients must have disease that is metastatic (stage IV), HER2/neu negative disease histologic and/or cytologic confirmation of metastatic disease is encouraged whenever feasible, furthermore, the biopsy should confirm that the primary tumor is ER and/or PR-positive and HER2/neu negative. measurable disease (RECIST 1.1) or non-measurable (assessable) disease, patients must have had progressive disease during at least one line of endocrine therapy for metastatic disease or have recurrent disease while or within 12 months of receiving adjuvant endocrine therapy  patients must have normal organ and marrow function as defined below. postmenopausal status, defined as 60 years and older, being 45 years and older, having amenorrhea x 12 months or follicle stimulating hormone levels within postmenopausal range. on combination of exemestane with everolimus less than 4 weeks prior to study entry and discontinued everolimus due to poor tolerability. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris. ',\n",
       " 'adults with histologically or cytologically confirmed breast adenocarcinoma, radiographic evidence of at least one bone mets, Easter Cooperative Oncology Group status of 0, 1 or 2; adequate organ function, Exclusion Criteria:, Current or prior IV bisphosphonate administration, current or prior oral bisphosphonates for bone mets, life expectancy of less than 6 monthsInclusion Criteria:, Patients must have disease that is metastatic (stage IV), HER2/neu negative disease histologic and/or cytologic confirmation of metastatic disease is encouraged whenever feasible, furthermore, the biopsy should confirm that the primary tumor is ER and/or PR-positive and HER2/neu negative. measurable disease (RECIST 1.1) or non-measurable (assessable) disease, patients must have had progressive disease during at least one line of endocrine therapy for metastatic disease or have recurrent disease while or within 12 months of receiving adjuvant endocrine therapy  patients must have normal organ and marrow function as defined below. postmenopausal status, defined as 60 years and older, being 45 years and older, having amenorrhea x 12 months or follicle stimulating hormone levels within postmenopausal range. on combination of exemestane with everolimus less than 4 weeks prior to study entry and discontinued everolimus due to poor tolerability. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris. ',\n",
       " 'Response Evaluation Criteria in Solid Tumors (RECIST) criteria to evaluate tumor response after 24 doses. Complete Response (CR)= disappearance of all target lesions, Partial Response (PR) = at least 30% decrease in sum of longest diameter of target lesions, Progressive Disease = at least 25% increase in sum of longest diameter of target lesions. patients receive oral letrozole once daily for 12 months in absence of disease progression or unacceptable toxicity. letrozole is given orally, given orally, given zoledronic acid. ',\n",
       " 'patients must have histologically confirmed breast cancer that is ER positive and/or PR positive, and HER2/neu negative disease determined using commercially available/approved assay in local institutional or reference laboratory. ER/PR expression performed by standard immunohistochemical assay and classified as ER and/or PR-positive according to ASCO/CAP guidelines (1-100% expression) patients must have had progressive disease during at least one line of endocrine therapy. prior treatments include a non-steroidal aromatase inhibitor, tamoxifen, fulvestrant or combinations. patients taking bisphosphonates for bone disease are permitted to enter the trial. postmenopausal status defined as 60 years and older, 45 years and older, having amenorrhea x 12 months or follicle stimulating hormone levels within postmenopausal range, OR having a bilateral oophorectomy. patients may not be receiving any other investigational agents. having at least 6 weeks of treatment remaining, 21 years old, Able to understand written and spoken English, Able to swallow medication (until amendment omitting armodafinil treatment), Score of 3+ on the Sleep Disruption Evaluation form, OR a score of 8+ on Insomnia Severity Index (ISI), EXCLUSION CRITERIA, Prior treatment with armodafinil or modafinil (until amendment omitting armodafini history of uncontrolled, cardiac disease, hypertension, severe headaches, glaucoma, or seizures (until amendment omitting armodafinil treatment) of chronic, preexisting insomnia, sleep apnea, or restless leg syndrome (RLS) ',\n",
       " 'the women received reflexology treatment initiated at the beginning of radiation therapy, once a week (45 min each), for 10 weeks. the control group included 25 breast cancer patients scheduled for adjunctive radiation treatment. ',\n",
       " 'asymptomatic women scheduled for screening mammography or have completed a screening mammogram within the past 30 days. subjects with prior lumpectomy (> 5 years prior) who receive only routine screening mammography views can be included. x 31 centimeter (cm) FFDM digital receptor without anatomical cut off during either FFDM or DBT examination. have participated in (within the prior 30 days) another trial of an investigational product expected to interfere with study procedures or outcomes. ',\n",
       " '3 patients were enrolled to the next cohort using a 5mg higher dose of ruxolitinib. the MTD is identified as the level BELOW the cohort where DLT occurred in less than one third of patients within the cohort. the maximum tolerated dose (MTD) was defined as the highest dose level in which a DLT is experienced by fewer than two patients in a cohort of 3 - 6 patients. if a DLT is observed in at least two patients in a cohort of 3 - 6 patients, the MTD will be determined to have been exceeded. all participants, Overall Number of Participants Analyzed: 20, Measure Type: Number, Unit of Measure: mg/kg NA [1] ',\n",
       " 'intra-patient difference in hot flash activity between baseline (study week 1) and treatment termination (study week 7) is the primary endpoint. the daily hot flash score is computed by multiplying the mean grade of severity by the frequency during every 24 hour period. the average daily hot flash score during the baseline week was compared to the average daily value during week 7. patients receive 1 NutrigradTM flaxseed bar containing 7.5 grams flaxseed, 410 mg lignans,once daily. overall number of participants Analyzed: 77, Mean (Standard Deviation), Unit of Measure: units on a scale -4.9 (6.41), Results 2:, Arm/Group Title: Placebo, Arm/Group Description: Patients Identical looking bar with same calorie and total fat content but without flaxseed or lign ORR was defined as the proportion of participants who achieved a best response of either CR or PR. time frame: baseline & every 2 cycles (approximately 8 weeks) of treatment to measured progressive disease (PD) & post-therapy until PD or other therapy initiated. us Gemcitabine (PB+G), arm/group Description: paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by gemcitabine 1500 mg/m2 IV on days 1 and 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days. ',\n",
       " 'participants must have histologically or cytologically confirmed breast cancer or non-hodgkin lymphoma. doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2. doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2 and docetaxel 75 mg/m2. ncer in marrow), absolute neutrophil count >1,500/mcL (unless due to cancer in marrow), platelets >100,000/mcL (unless due to cancer in marrow), total bilirubin 1.5 X normal institutional limits, aspartate aminotransferase (AST) or serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase patients with known brain metastases should be excluded from this clinical trial. progressive neurologic dysfunction would confound evaluation of neuro-cognitive outcomes. patients requiring ongoing pharmacologic treatment of dementia excluded. e heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations would limit compliance with study requirements. pregnant women are excluded from this study because the chemotherapy agents have known teratogenic or abortifacient effects. allergy to all three antibiotics: cephalosporin, trimethoprim/sulfamethoxazole, and levofloxacin. non-English speaking patients without adequate interpreter assistance. ',\n",
       " \"participants must have histologically or cytologically proven metastatic or locally advanced solid tumors. no standard therapy exists or standard therapy has failed. disease must be measurable with at least 1 uni-dimensional measurable lesion by RECIST 1.1, except for participants with metastatic castrate-resistant prostate cancer. participants in the MBC cohort must have relapsed, refractory, or progressive disease following last line of treatment. Availability of tumor archival material or fresh biopsies is mandatory for eligibility in the expansion cohorts. participants in the NSCLC cohort will only be enrolled in USA, NSCLC first line: Stage IV or recurrent NSCLC that is histologically proven. participants should have received no more than 1 line of treatment for metastatic disease. participants with gastric cancer can enter in the study if their white blood cell (WBC) and lymphocyte count is as defined in the protocol, MBC: Participants must have histologically confirmed locally advanced or MBC. participants must have received no more than 3 prior lines of cytotoxic therapy for metastatic disease. pansion cohorts include gastric and GEJ cancer (third line), ovarian cancer (platinum Refractory + liposomal doxorubicin), urothelial carcinoma, and HNSCC. other protocol defined inclusion criteria for expansion phase could apply. basal or squamous cell carcinoma of the skin or cervical carcinoma in situ, Rapidly progressive disease (for example, tumor lysis syndrome), Active or history of central nervous system metastases, Receipt of any organ transplantation including allogeneic stem-cell transplantation. Known severe hypersensitivity reactions to monoclonal antibodies, any history of anaphylaxis, or uncontrolled asthma, Persisting toxicity related to prior therapy greater than Grade 1 NCI-CTCAE inflammatory bowel disease may impair Participant's tolerance of trial treatment. legal incapacity or limited legal capacity, non-oncology vaccine therapies for prevention of infection disease. vaccination while on study is also prohibited except for administration of the inactivated influenza vaccine. \",\n",
       " 'female patients with histologically/cytologically proven metastatic breast carcinoma (stage IV, or recurrent with local or regional spread or distant metastatic disease), Adequate bone marrow, liver, and renal function. ',\n",
       " \"the subject must be a breast cancer survivor, at least three years beyond completion of cancer therapy, free of clinical disease, and eligible for surgical intervention. the subject must be a breast cancer survivor, at least three years beyond completion of cancer therapy, free of clinical disease. two consecutive measurements of limb volume (LV) in the affected limb must be within 10% of each other. a maximum of 3 measurements can be taken. clinical trial of any other investigational drug or therapy, regardless of indication, within 1 month before screening or 5 times the drug's half-life, whichever is longer, Recent initiation of ( 8 weeks), or intention to initiate, CDPT or maintenance physiotherapy for lymphedema at any time during the duration of the study. other medical condition that could result in symptoms overlapping those of lymphedema in the affected limb. patients with a high risk of recurrence based on multi-gene signatures, e.g. BRCA1, BRCA 2, Oncotype DX (high risk recurrence score) or Mammaprint (poor risk signature), undergoing chemotherapy or radiation therapy. women aged 30 years or older ( 30 years old); women scheduled for screening mammography or have completed a screening mammogram within the past 30 days. subjects with a history of breast cancer and are in active treatment. prior lumpectomy may include breasts too large to be adequately positioned on 24 x 31 centimeter (cm) FFDM digital receptor without anatomical cut off during either FFDM or DBT examination. \",\n",
       " '1/9 (11.11%), Death, not otherwise specified 0/9 (0.00%), Pain, bone 1/9 (11.11%), Adverse Events 2:, Total: 1/9 (11.11%), Death, not otherwise specified 1/9 (11.11%), Pain, bone 0/9 (0.00%)Adverse Events 1:, Total: 1/208 (0.48%), Neutrophils/granulocytes (ANC/AGC) 1/208 (0.48%), Adverse Events 2:, Total: 0/ ',\n",
       " 'Adverse Events 1:, Total: 5/25 (20.00%), Hypertension 1/25 (4.00%), Dehydration 1/25 (4.00%), Infection With Normal Anc or Grade 1 or 2 Neutrophils 2/25 (8.00%), Pain 1/25 (4.00%), Dyspnea (Shortness Of Breath) 2/25 (8.00%). ',\n",
       " '77/122 (63.11%), Anaemia 1/122 (0.82%), Thrombocytopenia 1/122 (0.82%), Pericardial effusion 3/122 (2.46%), Supraventricular tachycardia 2/122 (1.64%), Atrial fibrillation 1/122 (0.82%), Sinus tachycardia 1/122 (0.82%), Hypothyroidism 1/122 (0.82%), Abdominal pain 4/122 (3.28%)Adverse ',\n",
       " 'patients older than 70 years and included either before any first-line treatment, or between any two steps of a pre-defined first-line treatment sequence. chemotherapy, endocrine therapy, targeted treatment, surgery or radiotherapy were available. ',\n",
       " 'circulating tumor cells (CTCs) measured at one month post autologous hematopoietic stem cell transplantation (AHST), considered both longitudinal values and compared to the baseline number of CTCs. circulating tumor cells (CTCs) measured at one month post AHST. ',\n",
       " 'Adverse Events 2:, Total: 3/6 (50.00%), Anaemia 0/6 (0.00%), Febrile neutropenia 0/6 (0.00%), Neutropenia 0/6 (0.00%), Bradycardia 0/6 (0.00%), Diarrhoea 0/6 (0.00%), Pancreatitis 0/6 (0.00%), Vomiting 0/6 (0.00%), Disease progression 0/6 (0.00%), Fatigue 0/6 (0.00%), Pyrexia ',\n",
       " 'participants received intravenous infusion of PF-05212384 90 mg once on Day -7 and Cycle 1 Day 2. docetaxel 75 mg/m2 1-hour IV infusion once followed by PF-05212384 90 mg once. maximum duration of docetaxel treatment was 445 days. participants received docetaxel 75 mg/m2 1-hour IV infusion once on cycle 1 Day 1. maximum duration of PF-05212384 treatment was 505 days. maximum duration of docetaxel treatment was 445 days. ',\n",
       " 'post-menopausal women newly diagnosed with early stage breast cancer, who would be treated with an aromatase inhibitor, Serum 25OHD levels  40 ng/ml, Exclusion Criteria:, Severe or debilitating musculoskeletal pain, Known metastatic disease, History of renal stones, History of hypercalcemia or hyperthyroidism, Currently receiving adjuvant or neoadjuvant chemotherapy. history of hypersensitivity or allergic reaction, spontaneous or following drug administration, history of cardiac conditions, HER2-Positive females, Metastatic disease, concurrent other malignancy requiring therapy of any modality. ',\n",
       " '0/3 (0.00%)Adverse Events 1:, Total: 4/14 (28.57%), Duodenitis [1]1/14 (7.14%), Gastrooesophageal reflux disease [1]1/14 (7.14%), Vomiting [1]1/14 (7.14%), Ascites [1]1/14 (7.14%), Death [1]1/14 (7.14%), Asthenia [1]1/14 (7.14%), general physical health deterioration [1]1/14 ',\n",
       " 'standard therapy either does not exist or has proven ineffective, intolerable or inacceptable for the patient. non-small cell lung cancer harboring a rearranged ALK gene/fusion protein or KRAS mutation. participants aged >65 years may be enrolled with objective evidence of disease as per PCWG2 criteria. participants aged 18 years at the time of informed consent may be enrolled with objective evidence of disease as per PCWG2 criteria. CRPC participants must maintain ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue, antagonist or orchiectomy. participants receiving bisphosphonate or denosumab therapy must be on stable doses for at least 4 weeks before initiating study treatment. cy or CNS involvement; history of prior or concomitant malignancies within 3 years of study entry; other serious illness or medical conditions; Known human immunodeficiency virus positivity; Participation in another clinical trial or treatment with any investigational drug within 30 days prior to study entry. low-dose (prophylactic) low molecular weight heparin (LMWH) is permitted; Pregnant or breast-feeding participants; men and women with childbearing potential not using concurrent hormone or Herceptin® (trastuzumab)treatment is okay, can have been treated by lumpectomy or mastectomy with or without adjuvant or neoadjuvant chemotherapy or hormonal treatment. can have had breast reconstruction, scheduled to receive 25-35 radiation treatment sessions (1 session per day) or 16-20 radiation treatment sessions (1 session per day) using Canadian irradiation fractionation (2.2-3.0 Gy per session) aspirin is allowed, known radiosensitivity syndromes (e.g., ataxia-telangiectasia), collagen vascular disease, unhealed surgical sites, or breast infections. ',\n",
       " 'Adverse Events 1:, Total: 4/31 (12.90%), Infection 1/31 (3.23%), Deflation 1/31 (3.23%), Asymmetry 1/31 (3.23%), Delayed Healing Wound 1/31 (3.23%) Adverse Events 2:, Total: 0/75 (0.00%), Adverse Events 2:, Total: 0/75 (0.00%) ',\n",
       " 'patients were intended to receive pain therapy, psychosocial assessment and care, and quality-of-life assessment, management of therapy complications, massage therapy, pain therapy, psychosocial assessment and care, quality-of-life assessment. patients received 3 no-touch therapy visits from massage therapists in initial week with a duration of 15-45 minutes. each participant received PF-06647020 until disease progression, unacceptable toxicity, withdrawal of consent, or study termination. each participant received PF-06647020 at 0.5 mg/kg on Day 1 of each 21-day cycle as an IV infusion over approximately 60 minutes on an outpatient basis. ',\n",
       " 'inTERVENTION 1:, arm II, Patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1. oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3. r IV, dexamethasone: Given orally or IV, dexamethasone: Given orally or IV, dexamethasone: Given orally or IV, dexamethasone: Given orally or IV, dexamethasone: Given orally orally or IV, dexamethasone: Given orally orally or IV, dexamethasone: Given orally orally or IV, dexamethasone: Given orally orally ',\n",
       " 'participants received 120 milligrams of denosumab injected subcutaneously every 4 weeks until denosumab was approved and available for sale. ',\n",
       " 'change in Ki67 expression in tumors with 7 days of pre-surgical tamoxifen. all patients will take tamoxifen 20 mg po daily for 7 days prior to surgery. ',\n",
       " 'primary or metastatic tumor must be estrogen response (ER) and/or parathyroid hormone receptor (PtR) positive. participants are resistant to aromatase inhibitors (AI) therapy. Previous radiation therapy is allowed, but should have been limited. have received treatment within the last 4 weeks with a drug that has not received regulatory approval for any indication at the time of study entry. have received supplemental estrogen or progesterone within 4 weeks prior to study entry, Are hormone estrogen receptor (HER2)-positive, Are unable to discontinue use of anticoagulants, Have hypercalcemia, Have a second primary malignancy that is clinically detectable at the time of consideration for study enrollment. have documented central nervous system metastases, symptomatic pulmonary lymph Subjects who are able to understand the study cannot be effectively reconstructed with the use of ADM product, Pregnancy, Bovine allergy. Subjects that are less than 18 years of age cannot be effectively reconstructed with the use of ADM product. ',\n",
       " 'participants will be excluded for:, any active neurologic and/or psychiatric disease, history of significant head trauma followed by persistent neurologic deficits, or known structural brain abnormalities. current major depression or another major psychiatric disorder as described in DSM-5 criteria. lness or unstable medical condition which could lead to difficulty complying with protocol including: history of myocardial infarction in the past year or unstable, severe cardiovascular disease including angina or CHF with symptoms at rest. clinically significant and/or unstable pulmonary, gastrointestinal, hepatic, or renal disease, Insulin-requiring diabetes or uncontrolled diabetes mellitus, uncontrolled hypertension. AST and ALT 3 times upper limit of normal (ULN), Bilirubin 3 times ULN, alkaline phosphatase 3 times ULN, Creatinine 2 mg/dL, no known hypersensitivity to any component of the study regimen, PRIOR CONCURRENT THERAPY:, no chronic therapeutic warfarin > 1 mg dose per day, no other concurrent investigational agents, no concurrent oral contraceptives (except for stopping menses) ',\n",
       " 'Adverse Events 1:, Total: 17/50 (34.00%), Fatigue 4/50 (8.00%), Papulopustular rash 1/50 (2.00%), Alanine aminotransferase increased 5/50 (10.00%), Alkalosis 1/50 (2.00%), Anorexia 1/50 (2.00%), Hyperglycemia 2/50 (4.00%), Nervous system disorders. ',\n",
       " 'Neoadjuvant therapy will consist of epirubicin (100 mg/m2) + cyclophosphamide (600 mg/m2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m2) every 2 weeks for 4 cycles. ',\n",
       " 'patients who undergo surgical oophorectomy survive longer than patients who undergo this surgery in the history-estimated mid-luteal phase of their menstrual cycles. time frame: up to 9 years, Results 1:, Arm/Group Title: A Mid-luteal Surgery, Arm/Group Description: [Not Specified], Overall Number of participants Analyzed: 115, Median (95% Confidence Interval), Unit of Measure: years 2.14 (1.53 to 2.67), Results 2:, Arm ',\n",
       " 'patients receive cabergoline oral (PO) twice weekly for weeks 1-4. courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. ',\n",
       " \"patients must have a tissue diagnosis of low, intermediate or high grade ductal carcinoma in situ or ductal carcinoma in situ with microinvasion. patients must be female at least 18 years of age. patients must have a signed tissue acquisition consent. subjects should be willing to abstain from use of hormonal therapies. hormone replacement therapy, oral contraceptive pills, hormone-containing intra-uterine devices, and E-string. if a woman becomes pregnant, she should inform her study physician. if a subject is of child-bearing potential, she must have a documented negative serum or urine pregnancy test before starting treatment. if a subject is of child-bearing potential, she must have a documented negative serum or urine pregnancy test. active diagnosis of psoriasis or currently receiving treatment for psoriasis. history of known Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency. history of epilepsy or seizures in the past 20 years. women enrolled in STAR trial at site participating in co-STAR, 65 years of age or older, have not started taking the study drug OR enrolled in STAR for a minimum of one year. previous diagnoses of chronic neurologic disease (Parkinson's disease, stroke, epilepsy, multiple sclerosis), history of head injury, depression, alcohol addiction, drug addiction, and other neurologic or psychiatric conditions will be recorded but will not serve as exclusion factors. \",\n",
       " 'dexamethasone 8 mg, Dexamethasone 8 mg pre-operative, Dexamethasone: pre-operative intravenous administration. inTERVENTION 2:, Dexamethasone 24 mg, Dexamethasone 24 mg pre-operative. ',\n",
       " 'escalation to 37.5 mg daily was permitted in the absence of complicated neutropenia. if all 3 Cycle 1 paclitaxel doses were successfully administered at 90 mg/m2. ',\n",
       " '1/9 (11.11%), Death, not otherwise specified 0/9 (0.00%), Pain, bone 1/9 (11.11%), Adverse Events 2:, Total: 1/9 (11.11%), Death, not otherwise specified 1/9 (11.11%), Pain, bone 0/9 (0.00%)Adverse Events 1:, Total: 1/208 (0.48%), Neutrophils/granulocytes (ANC/AGC) 1/208 (0.48%), Adverse Events 2:, Total: 0/ ',\n",
       " 'Adverse Events 1:, Total: 0/7 (0.00%)Adverse Events 1:, Total: 0/11 (0.00%), Adverse Events 2:, Total: 0/11 (0.00%). ',\n",
       " 'patients receive cabergoline oral (PO) twice weekly for weeks 1-4. courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. ',\n",
       " 'Stratum 1 (AC->T + Bevacizumab), HER2-negative participants administered, doxorubicin and cyclophosphamide (AC) + bevacizumab for 4 cycles followed by, docetaxel (T) + bevacizumab for 4 cycles followed by, bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed. ',\n",
       " '3/24 (12.50%), Disseminated intravascular coagulation 0/24 (0.00%), Death NOS 0/24 (0.00%), Fatigue 0/24 (0.00%), Hepatic failure 1/24 (4.17%), Alanine aminotransferase increased 1/24 (4.17%), aspartate aminotransferase increased 1/24 (4.17%), Blood bilirubin increased 0/24 (0.00%), Ejection fraction decreased 1/24 (4.17%), ',\n",
       " 'results 1:, Arm/Group Title: Arm 1: Paclitaxel + Trastuzumab Then A C, Arm/Group Description: 4 cycles of paclitaxel 80 mg/m2 on days 1, 8 and 15 of a 28-day cycle. follow paclitaxel/trastuzumab, standard AC every 21 days for 4 cycles. Neratinib 240 mg orally once daily beginning on Day 1 of paclitaxel. standard AC every 21 days for 4 cycles. following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy. ',\n",
       " \"2.3 Dental evaluation according to the dental exam checklist (carried out by the investigator, the investigator's designee, or by a qualified dental professional [dental hygienist or dentist]) if the patient has received prior oral bisphosphonate therapy within 8 weeks of registration, the evaluation should not be revoked. complete blood count (CBC)/differential within 2 weeks prior to registration, with adequate bone marrow function defined as follows: White blood cell count (WBC) 2400 cells/mm3; Absolute neutrophil count (ANC) 1,800 cells/mm3; Platelets 60,000 cells/mm3; Hemoglobin 8.0 g/dl (Note: The use of transfusion or other intervention to achieve the required hemoglobin is permitted) beam radiation therapy must be completed 14 days prior to registration. patients with no evidence of disease in the brain after treatment for brain metastases are eligible. prior treatment with Strontium-89 or Samarium-153 for bone metastases. prior treatment with IV bisphosphonates prior to study entry. current, active dental problems within 4 weeks of registration. the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. pregnant or lactating patients are excluded as treatment may be harmful to embryos and/or nursing infants. the study should be finished 30 days before the beginning of the study. if the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose of anthracyclines should not exceed 250 mg/m2 for doxorubicin or 540 mg/m2 for epirubicin. n or 660 mg/m2 for epirubicin, if in this study planned 4 cycles of chemotherapy. patients of childbearing potential must implement reliable contraceptive measures. f bone metastases) administration of any experimental drugs within 30 days prior randomization. conditions limiting patient's ability to follow protocol. \",\n",
       " 'TAK-228 will be orally administered at 30 mg weekly for 16 weeks. Tamoxifen will be orally administered at 20 mg daily for 16 weeks. ',\n",
       " 'a non-serious adverse event is any untoward medical occurrence. a serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions. congenital anomaly/birth defect or important medical events that jeopardize the patient or subject may require medical or surgical intervention. Total Dose 2 x 108 IU, Arm/Group Description: Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 1 injection (I injection = 2 x 108 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. patients with stable disease may continue to receive vaccine for up to 6 monthly doses. ',\n",
       " 'a higher serum total bilirubin ( 2 x ULN) is allowed, aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 2.5 times ULN, Alkaline phosphatase 2.5 times ULN, Renal status: Creatinine. patients must use effective contraception (barrier method - condoms, diaphragm - also in conjunction with spermicidal jelly, or total abstinence) patient accepts to make available tumour samples for submission to central laboratory to conduct translation studies. han 10 years prior to randomisation may enter the study. patients must have been curatively treated with surgery alone. prior diagnoses of breast cancer or melanoma are excluded. subjects with ulcerative colitis are also excluded. subjects with ulcerative colitis are also excluded. rdiogram (ECG), 18 years of age or above, Able to understand and sign informed consent, Pilot study only:, CRC, TNBC, ER/PR Breast Cancer, NSCLC, Pancreatic Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal Junction (GEJ) adenocarcinoma, Head and Neck Cancer, Expansion Phase Additional Criteria:, Locally advanced or metastatic breast cancer, Received at least one cytotoxic xytol, Inability to undergo MRI, Active infection, Pregnant or breast feeding, Prior chemotherapy administered within 3 weeks, or within a time interval less than at least 5 half-lives of the agent. prior to the first scheduled day of dosing in this study, received radiation therapy in the last 14 days, Treated with parenteral iron in the previous 4 weeks. ',\n",
       " '0/4 (0.00%), Anaemia 0/4 (0.00%), Febrile neutropenia 0/4 (0.00%), Leukocytosis 0/4 (0.00%), Neutropenia 0/4 (0.00%), Pancytopenia 0/4 (0.00%), Acute coronary syndrome 0/4 (0.00%), Atrial fibrillation 0/4 (0.00%), Cardiac arrest 0/4 (0.00%), Pericardial effusion 0/4 (0.00%), Ad ',\n",
       " 'intraoperative handheld gamma camera (pIHGC) involves injection of 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid around at the tumor site. ',\n",
       " 'CBT-I: Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)INTERVENTION 1:, Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W, Phase Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W, INTERVENTION 2:, Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W, INTERVENTION 2:, ',\n",
       " 'inTERVENTION 1:, intervention, Validated, web-based risk assessment is being used to assess personalized risk and generate a risk report. inTERVENTION 2:, Control, Usual care. ',\n",
       " 'Chemotherapy with GM-CSF, Doxorubicin and Cyclophosphamide (AC) followed by Weekly Carboplatin/Nab- PaclitaxelINTERVENTION 1:, Neoadjuvant Chemotherapy, Doxorubicin (Adriamycin) + cyclophosphamide (Cytoxan) with pegfilgrastim or filgrastim growth factor support every 2 weeks for 4 cycles ',\n",
       " '5/11 (45.45%), Hemorrhage, GI-abdomen NOS 21/11 (9.09%), Pain-liver 21/11 (9.09%), Infection-ulcer 20/11 (0.00%), Pain-rib cage due to vomiting 20/11 (0.00%), Obstruction-gu ureter 1/11 (9.09%), Pain-breast 21/11 (9.09%), Pleural effusion 22/11 (18.18%), Adverse Events 2:, Total: 0 ',\n",
       " 'treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity. cyclophosphamide, paclitaxel, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab subjects 98 (92.2 to 99.5). subjects 98 (92.2 to 99.5) ',\n",
       " 'a log ratio of expression was generated relative to reference in both the Up and DOWN arms of the gene signature. a log ratio value of zero indicated no change in expression between the two samples. overall number of participants Analyzed: 14, Measure Type: Number, Unit of Measure: Percentage of participants 28.6 (13.1 to 49.2), Results 2:, Arm/Group Title: Triple Negative (TN), Arm/Group Description: Triple Negative participants received a single dose of dalotuzumab 20 mg/kg infused over 60-120 minutes. ',\n",
       " 'time to progression, time to progression (TTP) is defined as the time (in months) from the moment the patient starts the study treatment to the date of progressive disease. a patient has an event is she progresses or dies due to progressive disease. CR is defined as disappearance of all target and non-target lesions. PR is defined as 30% decrease in sum of the longest dimensions (LDs) of the target lesions taking as reference the baseline sum LD. sunitinib was administered orally from Day 1 to 14 every 21 days at a starting dose of 2,000 mg/m2/day. participants were monitored for toxicity, and sunitinib and/or capecitabine dosing could be interrupted or reduced according to individual tolerance. ',\n",
       " 'patients will take Vorinostat daily during radiation therapy. they will be recommended to swallow the capsule 60-90 minutes prior to estimate time of radiation. ',\n",
       " 'patients with histologically documented cancer of the breast or DCIS or head and neck referred for definitive radiation with curative intent. minimum life expectancy of at least 12 months., Aged greater than 20 years., If female, pregnancy excluded., no documented history of collagen vascular disease., Exclusion Criteria:, Cognitively impaired patients, Prisoners, No histology available, Documented metastatic disease, Allergy to Trental, Life expectance of less than 12 months., Aged less tase inhibitors for breast cancer in women and anti-LHRH therapy for prostate cancer in men will be permitted. have a BMI of 25 kg/m2 or greater and weight =400 lbs., Willingness to accept randomization to each of the three arms, Willingness to change diet, physical activity, and weight. prior or planned bariatric surgery, have significant renal disease or dysfunction defined as Estimated glomerular filtration rate (eGFR)45, Have significant renal disease or dysfunction defined as Estimated glomerular filtration rate (eGFR)45, Have significant hepatic dysfunction [Aspartate aminotransferase (AST)/Alanine transaminase (ALT) 2 x upper limit of normal (ULN) or reported liver disease], Self-reported ',\n",
       " 'invasive disease-free survival time is defined as the time from date of randomization until time of event up to 2 years. time is defined as the time from date of randomization until time of event up to 2 years. patients who completed prior adjuvant trastuzumab received six placebo tablets (240 mg) taken orally once daily with food, preferably in the morning, continuously for one year. therapy continued until unacceptable toxicity, recurrent disease, death, or withdrawal of consent occurred. ',\n",
       " 'intra-operative digital mammography compared with standard specimen mammography. overall number of participants Analyzed: 36, Median (Full Range), Unit of Measure: Minutes Procedure Time: 48.5 (17 to 138), OR Time: 68 (29 to 180), Results 2:, Arm/Group Title: Standard Mammography, Arm/Group Description: Standard Specimen Mammography, Standard Mammography: There is not an added device associated with this arm. participants received immediate breast reconstruction using a sub-muscular tissue expander (TE) and acellular dermal matrix (ADM) sling during the same surgery. post-mastectomy radiation therapy (PMRT) no sooner than a minimum of 6 weeks and optimally 6 months. the prescribed chest-wall dose was 50 -50.4 gray (Gy) in 25-28 fractions given once daily over 5-7 weeks with a 0.5-centimeter (cm) bolus to the scar every other day. ',\n",
       " 'Outcome Measurement:, Recurrence-free Survival, 2 years for the primary analysis + 3 additional years for secondary analysis. Time frame: 5 years, Results 1:, Arm/Group Title: Ketorolac 30 mg, Arm/Group Description: Active drug to be compared with placebo, Ketorolac 30 mg IV, Overall number of participants Analyzed: 96, Measure Type: Count of participants, Unit of Measure: Participants 80 83.3%, Results 2:, Arm/ ',\n",
       " 'inTERVENTION 1:, Paced Breathing (15 Min Twice Daily, 6 Breaths/Min), Patients practice paced breathing for 15 minutes once daily, 6 breaths/min, 5-7 days weekly. ',\n",
       " 'patients must have had exposure to at least 1 and no more than 3 prior chemotherapy regimens for the treatment of metastatic breast cancer. must have tissue (excluding bone or brain) that is amenable to biopsy, ECOG performance status 0-1, Life expectancy of greater than 3 months. all prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events version 4 (CTCAE v4) grade = 1 (except alopecia) at the time of enrollment, Absolute neutrophil count >= 1,500/mcL, Platelets >= 75,000/mcL, Total bilirubin = 1.5  institutional upper limit of normal, Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal by echocardiogram (ECHO) or patients must be at least 4 weeks from last surgical procedure and recovered from all post-operative complications. women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study. patients with symptomatic or progressive brain metastases are ineligible. subjects with treated brain metastases are eligible if they have no radiographic or other signs of progression in the brain for >= 3 weeks. any corticosteroid use for brain metastases must have been discontinued without the subsequent appearance of symptoms for >= 3 weeks prior to study enrollment. history of allergic reactions attributed to compounds of similar chemical or biologic composition to trametinib monotherapy or trametinib in combination with GSK2141795, Current use of a prohibited medication. uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, history of hyperviscosity or hypercoagulability syndromes. visible retinal pathology as assessed by ophthalmic exam is considered a risk factor for RVO or CSR. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit ',\n",
       " 'the investigator must confirm postmenopausal status. postmenopausal status is defined either by:, age 55 years and one year or more of amenorrhea, age  55 years and one year or more of amenorrhea and postmenopausal levels of FSH and LH per local institutional standards. non-steroidal aromatase inhibitors (i.e. letrozole or anastrozole) do not have to be the last treatment prior to enrollment. other prior anticancer therapy, e.g. tamoxifen, fulvestrant, exemestane are also allowed. serum bilirubin 1.5  ULN, fasting serum cholesterol 300 mg/dl or 7.75 mmol/L and fasting triglycerides 2.5  ULN. alanine aminotransferase (ALT) 2.5  ULN (or 5 if hepatic metastases are present). patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose galactose malabsorption must have recovered from radiotherapy toxicities prior to enrollment. radiotherapy within four weeks prior to enrollment except in case of localized radiotherapy for analgesic purpose. patients with symptomatic visceral metastasis (e.g. significant dyspnoea related to pulmonary lymphangitic carcinomatosis and lung metastases), symptomatic brain or other central nervous system metastases (CNS) metastases. active, bleeding diathesis, or on oral anti-vitamin K medication. uncontrolled or whose control may be jeopardized by the complications of this study therapy. pulmonary function tests should be considered to exclude restrictive pulmonary disease, pneumonitis or pulmonary infiltrates. patients being treated with drugs recognized as strong inhibitors or inducers of the isoenzyme CYP3A. patients must have metastatic breast cancer; tissue (a minimum of 3 slides) from most recent biopsy is required for review and confirmation of eligibility. patients must have stage IV breast cancer, patients must have metastatic tumors (primary or metastatic) that stain positively for the prolactin receptor. women of childbearing potential must commit to the use of effective barrier (non-hormonal) contraception while on study. patients must have a life expectancy of greater than 12 weeks. patients must have a life expectancy of greater than 12 weeks. patients may have had a prior diagnosis of cancer if it has been > 5 years since their last treatment. systemic treatment is allowed with a 2 week washout period prior to registration. patients who are taking herbal (alternative) medicines are NOT eligible for participation. patients must be off any such medications by the time of registration. nary, pericardial, cardiac valvular, or retroperitoneal fibrotic disorders, Gastrointestinal (GI) tract disease resulting in an inability to take oral medication, Malabsorption syndrome, Require intravenous (IV) alimentation, Uncontrolled inflammatory GI disease. ',\n",
       " \"dose-limiting toxicities are assessed according to the national Cancer Institute's Common Terminology Criteria for Adverse Events classification. the classification usually encompasses all grade 3 or higher toxicities, Time frame: 28 days. given IV, pegylated liposomal doxorubicin hydrochloride: Given IV, overall number of participants Analyzed: 6, Measure Type: Number, Unit of Measure: participants 1__________________________________________________________________ \",\n",
       " 'patients with vitamin D deficiency who experience myalgias, arthralgias and/or joint stiffness received epoetin beta (NeoRecormon®) at a dose of 30000 International Units (IU) as subcutaneous (SC) injection once every week. ',\n",
       " 'a log ratio of expression was generated relative to reference in both the Up and DOWN arms of the gene signature. a log ratio value of zero indicated no change in expression between the two samples. overall number of participants Analyzed: 14, Measure Type: Number, Unit of Measure: Percentage of participants 28.6 (13.1 to 49.2), Results 2:, Arm/Group Title: Triple Negative (TN), Arm/Group Description: Triple Negative participants received a single dose of dalotuzumab 20 mg/kg infused over 60-120 minutes. ',\n",
       " 'Adverse Events 1:, Total: 4/31 (12.90%), Infection 1/31 (3.23%), Deflation 1/31 (3.23%), Asymmetry 1/31 (3.23%), Delayed Healing Wound 1/31 (3.23%) Adverse Events 2:, Total: 0/75 (0.00%), Adverse Events 2:, Total: 0/75 (0.00%) ',\n",
       " 'change in Ki67 expression in tumors with 7 days of pre-surgical tamoxifen. all patients will take tamoxifen 20 mg po daily for 7 days prior to surgery. ',\n",
       " 'Adverse Events 1:, Total: 1/29 (3.45%), Surgery * [1]1/29 (3.45%) ',\n",
       " 'Neoadjuvant therapy will consist of epirubicin (100 mg/m2) + cyclophosphamide (600 mg/m2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m2) every 2 weeks for 4 cycles. ',\n",
       " 'Adverse Events 1:, Total: 0/15 (0.00%), Adverse Events 2:, Total:Adverse Events 1:, Total: 0/442 (0.00%), Adverse Events 2:, total: 0/442 (0.00%), Adverse Events 2:, total: 0/442 (0.00%), Adverse Events 2:, total: 0/442 (0.00%). ',\n",
       " \"breast tumor 1 centimeter (cm) in diameter, HR+, HER2-. neoadjuvant endocrine monotherapy is deemed to be a suitable therapy. measurable disease, Bone metastases requires other disease present that can be measured. no brain metastases, unless documented to be controlled post-completion of local therapy for at least 4 weeks, no meningeal carcinomatosis, no malignant effusion as the only site. hat in the opinion of the treating physician would make study protocol unreasonably hazardous for the patient. hat in the opinion of the treating physician would make study protocol unreasonably hazardous for the patient or would preclude the patient's ability to comply with the study protocol. \",\n",
       " 'patients who undergo surgical oophorectomy survive longer than patients who undergo this surgery in the history-estimated mid-luteal phase of their menstrual cycles. time frame: up to 9 years, Results 1:, Arm/Group Title: A Mid-luteal Surgery, Arm/Group Description: [Not Specified], Overall Number of participants Analyzed: 115, Median (95% Confidence Interval), Unit of Measure: years 2.14 (1.53 to 2.67), Results 2:, Arm ',\n",
       " 'ALT-801 0.015 mg/kg/Dose, 0.015 mg/kg/dose of ALT-801. ALT-801 0.040 mg/kg/Dose, 0.040 mg/kg/dose of ALT-801. ',\n",
       " '89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions. PET/CT imaging with these novel radiotracers will allow evaluation of all identifiable malignant lesions. ',\n",
       " 'patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3. overall number of participants Analyzed: 234, Mean (Standard Deviation), Unit of Measure: units on a scale 1.88 (1.27), Results 2:, Arm/Group Title: Arm III, Arm/Group Description: Patients receive palonosetron hydroch acebo: Given orally or IV, palonosetron hydrochloride : Given orally or IV, dexamethasone : Given orally or IV, overall number of participants Analyzed: 241, Mean (Standard Deviation), Unit of Measure: units on a scale 1.65 (1.15)_ ',\n",
       " '0/3 (0.00%)Adverse Events 1:, Total: 4/14 (28.57%), Duodenitis [1]1/14 (7.14%), Gastrooesophageal reflux disease [1]1/14 (7.14%), Vomiting [1]1/14 (7.14%), Ascites [1]1/14 (7.14%), Death [1]1/14 (7.14%), Asthenia [1]1/14 (7.14%), general physical health deterioration [1]1/14 ',\n",
       " 'INTERVENTION 1:, MM-111, All participants_. ',\n",
       " 'patients will take Vorinostat daily during radiation therapy. they will be recommended to swallow the capsule 60-90 minutes prior to estimate time of radiation. ',\n",
       " '3 patients were enrolled to the next cohort using a 5mg higher dose of ruxolitinib. the MTD is identified as the level BELOW the cohort where DLT occurred in less than one third of patients within the cohort. the maximum tolerated dose (MTD) was defined as the highest dose level in which a DLT is experienced by fewer than two patients in a cohort of 3 - 6 patients. if a DLT is observed in at least two patients in a cohort of 3 - 6 patients, the MTD will be determined to have been exceeded. all participants, Overall Number of Participants Analyzed: 20, Measure Type: Number, Unit of Measure: mg/kg NA [1] ',\n",
       " 'Adverse Events 1:, Total: 0/344 (0.00%), Adverse Events 2:, Total: 0/342 (0.00%), Adverse Events 2:, Total: 0/24 (0.00%), Adverse Events 2:, Total: 0/24 (0.00%), Adverse Events 2:, Total: 0/344 (0.00%). ',\n",
       " 'INTERVENTION 1:, MM-111, All participants_. ',\n",
       " 'Adverse Events 2:, Total: 3/6 (50.00%), Anaemia 0/6 (0.00%), Febrile neutropenia 0/6 (0.00%), Neutropenia 0/6 (0.00%), Bradycardia 0/6 (0.00%), Diarrhoea 0/6 (0.00%), Pancreatitis 0/6 (0.00%), Vomiting 0/6 (0.00%), Disease progression 0/6 (0.00%), Fatigue 0/6 (0.00%), Pyrexia ',\n",
       " 'subjects received a single bolus IV injection of 5 mg/kg FMX (up to 510 mg) on day 1. subjects received up to 70 mg/m2 MM-398 FBE (C1D1) administered as an IV infusion over 90 minutes, repeated every 2 weeks until disease progression. ',\n",
       " 'anemia*4 0/25 (0.00%), BLOOD/BONE MARROW:: Leukocytes (total WBC)*3 4/25 (16.00%), BLOOD/BONE MARROW:: Lymphopenia*3 2/25 (8.00%), BLOOD/BONE MARROW:: Neutrophils/granulocytes (ANC/AGC)*3 5/25 (20.00%), BLOOD/BONE MARROW:: Plate ',\n",
       " 'patients must have axillary lymph node involvement assessment and initiation of study treatment of less than or equal to 84 days. resected specimen must be free of invasive disease and/or ductal carcinoma in situ (DCIS) patients receiving anti-coagulation treatment with an agent such as warfarin may be allowed to participate. patients with HER2 positive breast cancer as determined by FISH or IHC3+ standing are ineligible for this trial. c blood pressure > 100 mmHg on antihypertensive medications. current therapy with raloxifene, tamoxifen or other selective estrogen receptor modulator. women who are pregnant must use effective birth control measures. g event NCI CTCAE v3.0 Grade 3 within 4 weeks of first dose of study drug. submit unstained representative tumor specimen, either as a paraffin block (preferred) or 10 unstained slides. ation known to be a potent CYP3A4 inducer or inhibitor. ',\n",
       " 'memantine hydrochloride: Estimate participation, accrual, adherence, and retention of cancer survivors who smoke. randomized to receive memantine (10 mg twice daily) or a matching placebo. ',\n",
       " 'Anaemia 1/106 (0.94%), Febrile neutropenia 1/106 (0.94%), Thrombocytopenia 1/106 (0.94%), Atrial fibrillation 1/106 (0.94%), Cardio-respiratory arrest 1/106 (0.94%), Palpitations 1/106 (0.94%), Pericardial effusion 2/106 (1.89%), Abdominal pain upper 1/106 (0.94%), Ascite 1/106 (0.94%), Constipation 1/106 ( ',\n",
       " 'Outcome Measurement:, Recurrence-free Survival, 2 years for the primary analysis + 3 additional years for secondary analysis. Time frame: 5 years, Results 1:, Arm/Group Title: Ketorolac 30 mg, Arm/Group Description: Active drug to be compared with placebo, Ketorolac 30 mg IV, Overall number of participants Analyzed: 96, Measure Type: Count of participants, Unit of Measure: Participants 80 83.3%, Results 2:, Arm/ ',\n",
       " 'neutropenic fever, weakness 1/50 (2.00%), urinary tract infection 1/50 (2.00%), cellulitis 4/50 (8.00%), wound dehiscence 1/50 (2.00%), hematoma 1/50 (2.00%), seroma 1/50 (2.00%), inflammation (red breast syndrome) 2/50 (4.00%) ',\n",
       " 'cases with stage II-IIIA breast cancer have completed adjuvant treatment with anthracyclines and/or taxanes + or -Radiation therapy within past 6 months(+/- 7 days) Must be aware of the nature of his current medical condition and must be willing to give consent after being informed of the experimental nature of therapy, alternatives, potential benefits, side-effects, risks and discomfort. use of estrogens (oral, dermal or vaginal), progesterone (oral or topical), androgens, androgens, Raloxifene or Tamoxifen during the previous 3 months. use of over the counter steroid hormonal supplements including dehydroepiandrosterone (DHEA), patients with advanced or Stage IIIIB or IV breast cancer or other cancers. l or psychiatric condition or laboratory abnormality may increase risk associated with study participation or study drug administration. investigator would make potential participant inappropriate for entry into this study. ',\n",
       " 'participants received 120 milligrams of denosumab injected subcutaneously every 4 weeks until denosumab was approved and available for sale. ',\n",
       " \"breast tumor 1 centimeter (cm) in diameter, HR+, HER2-. neoadjuvant endocrine monotherapy is deemed to be a suitable therapy. measurable disease, Bone metastases requires other disease present that can be measured. no brain metastases, unless documented to be controlled post-completion of local therapy for at least 4 weeks, no meningeal carcinomatosis, no malignant effusion as the only site. hat in the opinion of the treating physician would make study protocol unreasonably hazardous for the patient. hat in the opinion of the treating physician would make study protocol unreasonably hazardous for the patient or would preclude the patient's ability to comply with the study protocol. \",\n",
       " 'INTERVENTION 1:, Arm 1, Herceptin/navelbine, INTERVENTION 2:, Arm 2, Taxotere/carboplatin/herceptin_. ',\n",
       " 'patients will receive acupuncture treatment twice weekly for six consecutive weeks. each treatment will be 30 minutes in duration. patients will be advised to continue their standard lymphedema treatments. follow-up objective and subjective assessments of lymphedema will be performed after approximately 6 weeks on the wait-list. follow-up objective and subjective assessments of lymphedema will be performed after approximately 6 weeks on the wait-list, before onset of acupuncture treatment. ',\n",
       " '3/37 (8.11%), Sinus tachycardia 0/37 (0.00%), Heart failure 0/37 (0.00%), Dehydration 1/37 (2.70%), Death Not Associated with CTCAE: Death NOS 1/37 (2.70%), Lymphopenia 1/37 (2.70%), Neutropenia 1/37 (2.70%), Thrombocytopenia 0/37 (0.00%), Hyponatremia 1/37 (2.70%), Weight loss 0/37 ( ',\n",
       " 'participants received intravenous infusion of PF-05212384 90 mg once on Day -7 and Cycle 1 Day 2. docetaxel 75 mg/m2 1-hour IV infusion once followed by PF-05212384 90 mg once. maximum duration of docetaxel treatment was 445 days. participants received docetaxel 75 mg/m2 1-hour IV infusion once on cycle 1 Day 1. maximum duration of PF-05212384 treatment was 505 days. maximum duration of docetaxel treatment was 445 days. ',\n",
       " 'patients must have axillary lymph node involvement assessment and initiation of study treatment of less than or equal to 84 days. resected specimen must be free of invasive disease and/or ductal carcinoma in situ (DCIS) patients receiving anti-coagulation treatment with an agent such as warfarin may be allowed to participate. patients with HER2 positive breast cancer as determined by FISH or IHC3+ standing are ineligible for this trial. c blood pressure > 100 mmHg on antihypertensive medications. current therapy with raloxifene, tamoxifen or other selective estrogen receptor modulator. women who are pregnant must use effective birth control measures. g event NCI CTCAE v3.0 Grade 3 within 4 weeks of first dose of study drug. submit unstained representative tumor specimen, either as a paraffin block (preferred) or 10 unstained slides. ation known to be a potent CYP3A4 inducer or inhibitor. ',\n",
       " 'have received at least 1 but no more than 4 prior systemic therapies, have adequate organ function, have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale, have estimated life expectancy greater than or equal to (12 weeks), have fully recovered from radiation therapy or surgery. have discontinued all chemotherapy, investigational therapy, molecularly-targeted therapy, and cancer-related hormonal therapy at least 14 days prior, biologic or immunotherapeutic therapy at least 21 days prior, or mit atic (excluding primary brain tumor), Phase 2 Have disease measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1, Have disease measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1, Have evidence of a solid tumor that is locally advanced and/or metastatic, and in:, Small Cell Lung Cancer (SCLC), must have failed platinum-containing therapy, be Estrogen Receptor positive and/or Progesterone Receptor positive disorder, organ transplant, pregnant or nursing, HIV, active Hepatitis B or C, cardiac disease, history of major surgery in upper gastrointestinal (GI) tract or GI disease, hypokalemia, hypomagnesaemia or hypocalcaemia that cannot be controlled. ',\n",
       " \"in case of Gilbert's syndrome, 2 x ULN is allowed, AST (SGOT/ALT(SGPT)= 2.5 X institutional upper limit of normal, Alkaline phosphatase = 2.5 x ULN, Creatinine within normal institutional limits, Cardiac ejection fraction within the institutional range of normal as measured by echocardiogram or MUGA scan. eligibility of patients receiving medications or substances known to affect, or with the potential to affect, the effects of lapatinib on the developing human fetus at the recommended therapeutic dose are unknown. women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation. prior treatment with EGFR targeting therapies, treatment with any other investigational agents, or with all herbal (alternative) medicines. history of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib. uncontrolled inter-current illness including, but not limited to, ongoing or active infection. ammatory GI disease (e.g., Crohn's, ulcerative colitis), concomitant requirement for medication classified as CYP3A4 inducers or inhibitors. \",\n",
       " 'Response is defined as corrected serum calcium (CSC) 11.5 mg/dL within 10 days after the first dose of denosumab. for all CSC values, if albumin was  4 g/dL, the following formula was used to calculate CSC. 8 subjects to receive 40 mg d-Methadone twice a day. overall number of participants analyzed. ',\n",
       " 'inTERVENTION 1:, Placebo, Buminate solution, Placebo: 20 transendocardial injections of 0.4ml allo-MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure) ',\n",
       " 'Adverse Events 1:, Total: 8/87 (9.20%), Death * [1]8/87 (9.20%), Hospitalization [2]1/87 (1.15%), Hospitalization [3]1/87 (1.15%), Adverse Events 2:, Total: 0/28 (0.00%), Death * [1]0/28 (0.00%), Hospitalization [3]0/28 (0.00%)_______________________ ',\n",
       " 'result at baseline minus result at baseline as a percentage of the result at baseline. back transformation of the least squares mean based on log transformed data. ',\n",
       " 'Adverse Events 1:, Total: 1/13 (7.69%), Rapid disease progression [1]1/13 (7.69%), Increased pleural effusion [2]0/13 (0.00%), Adverse Events 2:, Total: 1/4 (25.00%), Rapid disease progression [1]0/4 (0.00%), Increased pleural effusion [2]1/4 (25.00%). ',\n",
       " \"19/149 (12.75%), Anaemia 0/149 (0.00%), Anaemia 0/149 (0.00%), Acute myocardial infarction 1/149 (0.67%), Prinzmetal angina 1/149 (0.67%), Meniere's disease 0/149 (0.00%), Vertigo 0/149 (0.00%), Cataract 2/149 (1.34%), Colitis ischaemic 1/149 (0.67%), Nausea 0/149 (0.00 \",\n",
       " 'aprepitant plus standard therapy to placebo plus standard therapy in control of nausea and vomiting during conditioning therapy for autologous or allogeneic hematopoietic stem cell transplantation. retch/emesis free days during the study period, time frame: up to three weeks. ure: Participants 5__ ',\n",
       " 'the baseline dose is 100 mg three times daily for four months. the baseline dose is 100 mg three times daily for four months. participants in Cohort 1 received necitumumab Process C drug product. ',\n",
       " '0/21 (0.00%)Adverse Events 1:, Total: 3/8 (37.50%), Anaemia 0/8 (0.00%), Febrile neutropenia 0/8 (0.00%), Polycythaemia 0/8 (0.00%), Acute coronary syndrome 0/8 (0.00%), Vertigo 0/8 (0.00%), Eyelid oedema 1/8 (12.50%), Constipation 0/8 (0.00%), Diarrhoea 0/8 ',\n",
       " 'inTERVENTION 1:, Zoledronic Acid, Zoledronic acid, vitamin D and calcium supplements, plus Sr-89 or Sm-153. ',\n",
       " 'neutropenic fever, weakness 1/50 (2.00%), urinary tract infection 1/50 (2.00%), cellulitis 4/50 (8.00%), wound dehiscence 1/50 (2.00%), hematoma 1/50 (2.00%), seroma 1/50 (2.00%), inflammation (red breast syndrome) 2/50 (4.00%) ',\n",
       " 'FEBRILE NEUTROPENIA * 0/3 (0.00%), ANAEMIA * 0/3 (0.00%), THROMBOCYTOPENIA * 0/3 (0.00%), ATRIAL FLUTTER * 0/3 (0.00%), BRADYCARDIA * 0/3 (0.00%), VOMITING * 0/3 (0.00%), Adverse Events 2:, Total: 0/3 (0.00%), FEBRILE NEUTROPENIA * 0/3 ',\n",
       " 'AINTERVENTION 1:, Phase 1: MLN8237 10 mg, MLN8237 (alisertib) 10 milligram (mg), enteric-coated tablets, orally, twice daily for 7 days followed by 14 days of rest period in 21-day treatment cycles. or until progressive disease, unacceptable treatment-related toxicity, or initiation of a different anticancer therapy during Phase 1 portion of the study. treatment-related toxicity, or initiation of a different anticancer therapy during Phase 1 portion of the study. ',\n",
       " 'participants received 120 milligrams of denosumab injected subcutaneously every 4 weeks until denosumab was approved and available for sale. ',\n",
       " 'INTERVENTION 1:, Phase 2 Triple -ve, Phase 2, Triple - Negative cohort, INTERVENTION 2:, Phase 2 HER2+, Phase 2, HER2 - Amplified (HER2-Positive) cohort. ',\n",
       " 'patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3. overall number of participants Analyzed: 234, Mean (Standard Deviation), Unit of Measure: units on a scale 1.88 (1.27), Results 2:, Arm/Group Title: Arm III, Arm/Group Description: Patients receive palonosetron hydroch acebo: Given orally or IV, palonosetron hydrochloride : Given orally or IV, dexamethasone : Given orally or IV, overall number of participants Analyzed: 241, Mean (Standard Deviation), Unit of Measure: units on a scale 1.65 (1.15)_ ',\n",
       " '5/11 (45.45%), Hemorrhage, GI-abdomen NOS 21/11 (9.09%), Pain-liver 21/11 (9.09%), Infection-ulcer 20/11 (0.00%), Pain-rib cage due to vomiting 20/11 (0.00%), Obstruction-gu ureter 1/11 (9.09%), Pain-breast 21/11 (9.09%), Pleural effusion 22/11 (18.18%), Adverse Events 2:, Total: 0 ',\n",
       " 'patients must have metastatic or unresectable non-small cell lung cancer, head and neck cancer, urothelial transitional cell carcinoma, or breast cancer whose disease has progressed after at least one line of standard therapy. patients must have measurable disease defined as at least one lesion that can be accurately measured in at least one dimension. patients should be at least six weeks out from nitrosoureas and mitomycin C. prior radiation should have been completed greater than or equal to 4 weeks prior to study enrollment. patients must be greater than or equal to 2 weeks since any investigational agent administered as part of a Phase 0 study. cytidine (FdCyd) and Tetrahydrouridine (THU) in patients less than 18 years of age are excluded from this study. children are excluded from this study, but may be eligible for future pediatric Phase I combination trials. pregnant women will be excluded from this trial. nursing women are also excluded. there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother. active or uncontrolled infection, immune deficiencies or confirmed diagnosis of human immunodeficiency virus (HIV) infection, active infection with Hepatitis B or Hepatitis C, uncontrolled diabetes, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia. ',\n",
       " 'INTERVENTION 1:, MM-111, All participants_. ',\n",
       " 'results 1:, Arm/Group Title: Arm 1: Paclitaxel + Trastuzumab Then A C, Arm/Group Description: 4 cycles of paclitaxel 80 mg/m2 on days 1, 8 and 15 of a 28-day cycle. follow paclitaxel/trastuzumab, standard AC every 21 days for 4 cycles. Neratinib 240 mg orally once daily beginning on Day 1 of paclitaxel. standard AC every 21 days for 4 cycles. following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy. ',\n",
       " 'inTERVENTION 1:, Imaging Session 1, Fluciclatide Injection (AH111585 (18F) Injection)INTERVENTION 1:, Chloroquine Standard Dose (500mg/week) patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month standard dose chloroquine (500 mg/week) patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month low dose chloroquine (250mg/week) for 1 month prior to surgical removal of the DCIS lesion. this biopsy is entirely voluntary and is not required to remain in the study. ',\n",
       " 'women may receive the AI on this study as initial adjuvant hormonal treatment or following tamoxifen. patients may have received preoperative chemotherapy, Postmenopausal status, defined as: >= 60 years of age; or  60 years of age and amenorrheic for >= 12 months prior to day 1 if intact uterus/ovaries. istory of bilateral oophorectomy; or prior radiation castration with amenorrhea for at least 6 months; or prior radiation castration with amenorrhea for at least 6 months;  60 years of age and taking medication designed to suppress ovarian function. women would have had to be taking the drug for at least 30 days prior to day 1. current bisphosphonate use (oral or intravenous); prior bisphosphonate users would be eligible as long as the use was > 1 month ago for oral bisphosphonates. prior bisphosphonate users would be eligible as long as the use was > 12 months ago for intravenous bisphosphonates. ',\n",
       " 'inTERVENTION 1:, intervention, Validated, web-based risk assessment is being used to assess personalized risk and generate a risk report. inTERVENTION 2:, Control, Usual care. ',\n",
       " 'patient must have histologically or cytologically confirmed locally advanced, unresectable or metastatic carcinoma of the breast. patient must have performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) performance scale and life expectancy > 3 months. female patient of childbearing potential must have a negatio. ve serum or urine pregnancy test quantitative human chorionic gonadotropin (-hCG) within 72 hours prior to receiving the first dose of study medication is allowed. patients with stable and clinically insignificant CNS disease are allowed. patients must be off steroids with no new CNS symptoms. bevacizumab, hormone therapy within one week, trastuzumab within 2 weeks or lapatinib within one week of study Day 1. patients with known active central nervous system metastases and/or carcinomatous meningitis eligible for study. patients with clinically insignificant brain metastases that do not require treatment are eligible. clinically significant cardiac arrhythmia, history or current evidence of a myocardial infarction during the last 6 months, and/or a current ECG tracing that is abnormal in the opinion of the treating Investigator. patients with other active, current primary malignancies, other than carcinoma in situ of the cervix or non-melanoma skin cancer. ',\n",
       " 'inTERVENTION 2:, Trabectedin, 1.3 mg/m2 of trabectedin was administered as a 3-hour intravenous infusion on Day 1. ',\n",
       " '3 patients were enrolled to the next cohort using a 5mg higher dose of ruxolitinib. the MTD is identified as the level BELOW the cohort where DLT occurred in less than one third of patients within the cohort. the maximum tolerated dose (MTD) was defined as the highest dose level in which a DLT is experienced by fewer than two patients in a cohort of 3 - 6 patients. if a DLT is observed in at least two patients in a cohort of 3 - 6 patients, the MTD will be determined to have been exceeded. all participants, Overall Number of Participants Analyzed: 20, Measure Type: Number, Unit of Measure: mg/kg NA [1] ',\n",
       " 'asymptomatic women scheduled for screening mammography or have completed a screening mammogram within the past 30 days. subjects with prior lumpectomy (> 5 years prior) who receive only routine screening mammography views can be included. x 31 centimeter (cm) FFDM digital receptor without anatomical cut off during either FFDM or DBT examination. have participated in (within the prior 30 days) another trial of an investigational product expected to interfere with study procedures or outcomes. ',\n",
       " \"2.3 Dental evaluation according to the dental exam checklist (carried out by the investigator, the investigator's designee, or by a qualified dental professional [dental hygienist or dentist]) if the patient has received prior oral bisphosphonate therapy within 8 weeks of registration, the evaluation should not be revoked. complete blood count (CBC)/differential within 2 weeks prior to registration, with adequate bone marrow function defined as follows: White blood cell count (WBC) 2400 cells/mm3; Absolute neutrophil count (ANC) 1,800 cells/mm3; Platelets 60,000 cells/mm3; Hemoglobin 8.0 g/dl (Note: The use of transfusion or other intervention to achieve the required hemoglobin is permitted) beam radiation therapy must be completed 14 days prior to registration. patients with no evidence of disease in the brain after treatment for brain metastases are eligible. prior treatment with Strontium-89 or Samarium-153 for bone metastases. prior treatment with IV bisphosphonates prior to study entry. current, active dental problems within 4 weeks of registration. the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. pregnant or lactating patients are excluded as treatment may be harmful to embryos and/or nursing infants. the study should be finished 30 days before the beginning of the study. if the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose of anthracyclines should not exceed 250 mg/m2 for doxorubicin or 540 mg/m2 for epirubicin. n or 660 mg/m2 for epirubicin, if in this study planned 4 cycles of chemotherapy. patients of childbearing potential must implement reliable contraceptive measures. f bone metastases) administration of any experimental drugs within 30 days prior randomization. conditions limiting patient's ability to follow protocol. \",\n",
       " 'participants will be excluded for:, any active neurologic and/or psychiatric disease, history of significant head trauma followed by persistent neurologic deficits, or known structural brain abnormalities. current major depression or another major psychiatric disorder as described in DSM-5 criteria. lness or unstable medical condition which could lead to difficulty complying with protocol including: history of myocardial infarction in the past year or unstable, severe cardiovascular disease including angina or CHF with symptoms at rest. clinically significant and/or unstable pulmonary, gastrointestinal, hepatic, or renal disease, Insulin-requiring diabetes or uncontrolled diabetes mellitus, uncontrolled hypertension. AST and ALT 3 times upper limit of normal (ULN), Bilirubin 3 times ULN, alkaline phosphatase 3 times ULN, Creatinine 2 mg/dL, no known hypersensitivity to any component of the study regimen, PRIOR CONCURRENT THERAPY:, no chronic therapeutic warfarin > 1 mg dose per day, no other concurrent investigational agents, no concurrent oral contraceptives (except for stopping menses) ',\n",
       " '0/33 (0.00%)Adverse Events 1:, Total: 5/16 (31.25%), ANAEMIA 1/16 (6.25%), LEUKOPENIA 1/16 (6.25%), NEUTROPENIA 3/16 (18.75%), THROMBOCYTOPENIA 1/16 (6.25%), FEBRILE INFECTION 1/16 (6.25%), PNEUMONIA 1/16 (6.25%), PNEUMONIA 1/16 (6.25%), PNEUMONIA 1/16 ( ',\n",
       " 'the primary endpoint will allow to compare the efficacy of the single dose of Extimia® versus nonpegylated daily filgrastim. patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously. Placebo No2 is supplied as solution for injection 0.0083 ml/kg. overall number of participants Analyzed: 43, Mean (Standard Deviation), Unit of Measure: days 0.791 (1.013) empegfilrastim: Empegfilgrastim is to be administered 24 h after the chemotherapy at a dose of 6 mg subcutaneously. Empegfilrastim: Empegfilgrastim is supplied as solution for injection 3 mg/ml. ',\n",
       " \"breast tumor 1 centimeter (cm) in diameter, HR+, HER2-. neoadjuvant endocrine monotherapy is deemed to be a suitable therapy. measurable disease, Bone metastases requires other disease present that can be measured. no brain metastases, unless documented to be controlled post-completion of local therapy for at least 4 weeks, no meningeal carcinomatosis, no malignant effusion as the only site. hat in the opinion of the treating physician would make study protocol unreasonably hazardous for the patient. hat in the opinion of the treating physician would make study protocol unreasonably hazardous for the patient or would preclude the patient's ability to comply with the study protocol. \",\n",
       " 'Avastin treatment must have been a minimum of 4 cycles (15 mg/kg) or 6 cycles (10 mg/kg) in combination with chemotherapy, ECOG performance status 0-2, At least 28 days since prior radiation therapy or surgery and recovery from treatment. Exclusion Criteria:, Anti-angiogenic therapy or anti-vascular endothelial growth factors other than Avastin for first-line treatment. ER-positive is defined as 1% immunohistochemical staining of any intensity. patients with stage II-III breast cancer are eligible if they are deemed appropriate for neoadjuvant endocrine therapy by the referring or treating medical oncologist. tmenopausal for at least 1 year before the screening visit, OR, Are surgically sterile, OR agree to practice 1 effective method of contraception and 1 additional effective (barrier) method, at the same time, from the time of signing the ICF through 90 days. male patients, even if surgically sterilized (i.e., status post-vasectomy) days after the last dose of the study drugs, OR, Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient. Agree not to donate sperm during the course of the study or within 120 days after receiving their last dose. consent must be given before performing any study-related procedure not part of standard medical care. patient must be accessible for treatment and follow-up. patient must be willing to undergo breast biopsies as required by study protocol. patients with non-melanoma skin cancer or carcinoma in situ are not excluded if they have undergone complete resection. patients with enteric stomata are also excluded. roid administration may be enrolled in the study if all other inclusion criteria and none of the other exclusion criteria are met. roid administration may be enrolled in the study if all other inclusion criteria and none of the other exclusion criteria are met. use of antihypertensive agents to control hypertension before week. patients receiving systemic corticosteroids within 1 week before administration of the first dose of the study drugs. daily or chronic use of a proton pump inhibitor (PPI) and/or having taken a PPI wit. patients unwilling or unable to comply with the study protocol. patients previously treated with hormonal therapy (tamoxifen, AI) or PI3K, AKT, dual PI3K/mTOR, TORC1/2, or mTORC1 inhibitors. ',\n",
       " 'all subjects treated under this protocol will have histologically documented cancer of one of the following types:, A. Metastatic breast cancer (7 triple negative, 23 ER+ after the first 15 patients are enrolled on the non-CCND1cohort; in addition 10 HER2+ for combination trastuzumab and PD0332991 therapy) up to 55 total enrollment slots B. Advanced or metastatic esophageal and/or gastric cancer (15-30 enrollment slots) D. Cisplatin subjects will be > 18 years old, The subject has disease that is assessable by tumor marker, physical, or radiologic means. the subject has an Eastern Cooperative Oncology Group performance status of 0 or 1. subject is capable of understanding and complying with protocol requirements. sexually active subjects (male and female) must use accepted methods of contraception. female subjects of childbearing potential must have negative pregnancy test at screening. patients with HER2-overexpressing tumors may receive trastuzumab. subject has received any other type of investigational agent within 28 days. subject has not recovered from clinically-meaningful toxicity due to prior therapy. subject has untreated or uncontrolled brain metastases. the subject has a baseline corrected QT interval (QTc) > 470 ms. the subject is known to be positive for the human immunodeficiency virus. ',\n",
       " 'patients must have had exposure to at least 1 and no more than 3 prior chemotherapy regimens for the treatment of metastatic breast cancer. must have tissue (excluding bone or brain) that is amenable to biopsy, ECOG performance status 0-1, Life expectancy of greater than 3 months. all prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events version 4 (CTCAE v4) grade = 1 (except alopecia) at the time of enrollment, Absolute neutrophil count >= 1,500/mcL, Platelets >= 75,000/mcL, Total bilirubin = 1.5  institutional upper limit of normal, Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal by echocardiogram (ECHO) or patients must be at least 4 weeks from last surgical procedure and recovered from all post-operative complications. women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study. patients with symptomatic or progressive brain metastases are ineligible. subjects with treated brain metastases are eligible if they have no radiographic or other signs of progression in the brain for >= 3 weeks. any corticosteroid use for brain metastases must have been discontinued without the subsequent appearance of symptoms for >= 3 weeks prior to study enrollment. history of allergic reactions attributed to compounds of similar chemical or biologic composition to trametinib monotherapy or trametinib in combination with GSK2141795, Current use of a prohibited medication. uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, history of hyperviscosity or hypercoagulability syndromes. visible retinal pathology as assessed by ophthalmic exam is considered a risk factor for RVO or CSR. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit ',\n",
       " 'patient must have histologically or cytologically confirmed locally advanced, unresectable or metastatic carcinoma of the breast. patient must have performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) performance scale and life expectancy > 3 months. female patient of childbearing potential must have a negatio. ve serum or urine pregnancy test quantitative human chorionic gonadotropin (-hCG) within 72 hours prior to receiving the first dose of study medication is allowed. patients with stable and clinically insignificant CNS disease are allowed. patients must be off steroids with no new CNS symptoms. bevacizumab, hormone therapy within one week, trastuzumab within 2 weeks or lapatinib within one week of study Day 1. patients with known active central nervous system metastases and/or carcinomatous meningitis eligible for study. patients with clinically insignificant brain metastases that do not require treatment are eligible. clinically significant cardiac arrhythmia, history or current evidence of a myocardial infarction during the last 6 months, and/or a current ECG tracing that is abnormal in the opinion of the treating Investigator. patients with other active, current primary malignancies, other than carcinoma in situ of the cervix or non-melanoma skin cancer. ',\n",
       " 'Adverse Events 1:, Total: 2/35 (5.71%), Gastroesophageal reflux disease * 1/35 (2.86%), Ductal carcinoma in situ * 1/35 (2.86%). ',\n",
       " '0/49 (0.00%)Adverse Events 1:, Total: 12/20 (60.00%), Recurrent malignancy *1/20 (5.00%), Graft-versus-host disease *7/20 (35.00%), Infection *7/20 (35.00%), Altered mental status *2/20 (10.00%), Diffuse alveolar hemorrhage *1/20 (5.00%) ',\n",
       " 'cases with stage II-IIIA breast cancer have completed adjuvant treatment with anthracyclines and/or taxanes + or -Radiation therapy within past 6 months(+/- 7 days) Must be aware of the nature of his current medical condition and must be willing to give consent after being informed of the experimental nature of therapy, alternatives, potential benefits, side-effects, risks and discomfort. use of estrogens (oral, dermal or vaginal), progesterone (oral or topical), androgens, androgens, Raloxifene or Tamoxifen during the previous 3 months. use of over the counter steroid hormonal supplements including dehydroepiandrosterone (DHEA), patients with advanced or Stage IIIIB or IV breast cancer or other cancers. l or psychiatric condition or laboratory abnormality may increase risk associated with study participation or study drug administration. investigator would make potential participant inappropriate for entry into this study. ',\n",
       " 'inTERVENTION 2:, arm B: 3 Days/Week Schedule, CUDC-101: CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 consecutively. ',\n",
       " '8/20 (40.00%), Anaemia 1/20 (5.00%), Lymphadenopathy 0/4 (0.00%), Thrombocytopenia 0/4 (0.00%), Acute coronary syndrome 0/4 (0.00%), Atrial fibrillation 0/4 (0.00%), Cardiac failure congestive 0/4 (0.00%), Cardiac tamponade 0/4 (0.00%), Adverse Events 2:, Total: 8/20 (40.00%), Anaemia 1 ',\n",
       " 'CBT-I: Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)INTERVENTION 1:, Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W, Phase Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W, INTERVENTION 2:, Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W, INTERVENTION 2:, ',\n",
       " 'optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W. Durvalumab and tremelimumab were administered as IV infusions over 60 (5) minutes. durvalumab infusions started at least 60 minutes after the end of the tremelimumab infusion on dual dosing days. ',\n",
       " 'circulating tumor cells (CTCs) measured at one month post autologous hematopoietic stem cell transplantation (AHST), considered both longitudinal values and compared to the baseline number of CTCs. circulating tumor cells (CTCs) measured at one month post AHST. ',\n",
       " 'Suramin and Paclitaxel will be infused weekly over 30 minutes. four hours after the completion of the suramin infusion the 1 hour infusion of paclitaxel will begin. ',\n",
       " 'patients with histologically documented cancer of the breast or DCIS or head and neck referred for definitive radiation with curative intent. minimum life expectancy of at least 12 months., Aged greater than 20 years., If female, pregnancy excluded., no documented history of collagen vascular disease., Exclusion Criteria:, Cognitively impaired patients, Prisoners, No histology available, Documented metastatic disease, Allergy to Trental, Life expectance of less than 12 months., Aged less tase inhibitors for breast cancer in women and anti-LHRH therapy for prostate cancer in men will be permitted. have a BMI of 25 kg/m2 or greater and weight =400 lbs., Willingness to accept randomization to each of the three arms, Willingness to change diet, physical activity, and weight. prior or planned bariatric surgery, have significant renal disease or dysfunction defined as Estimated glomerular filtration rate (eGFR)45, Have significant renal disease or dysfunction defined as Estimated glomerular filtration rate (eGFR)45, Have significant hepatic dysfunction [Aspartate aminotransferase (AST)/Alanine transaminase (ALT) 2 x upper limit of normal (ULN) or reported liver disease], Self-reported ',\n",
       " 'Anaemia 1/106 (0.94%), Febrile neutropenia 1/106 (0.94%), Thrombocytopenia 1/106 (0.94%), Atrial fibrillation 1/106 (0.94%), Cardio-respiratory arrest 1/106 (0.94%), Palpitations 1/106 (0.94%), Pericardial effusion 2/106 (1.89%), Abdominal pain upper 1/106 (0.94%), Ascite 1/106 (0.94%), Constipation 1/106 ( ',\n",
       " '0/104 (0.00%)Adverse Events 1:, Total: 45/128 (35.16%), Anaemia 3/128 (2.34%), Febrile neutropenia 2/128 (1.56%), Arrhythmia 1/128 (0.78%), Cardiac arrest 1/128 (0.78%), Cardiopulmonary failure 1/128 (0.78%), Abdominal pain 2/128 (1.56%), Ascite 2/128 (1.56%), Intestinal obstruction 2/128 (1.56%), Melaena ',\n",
       " \"the subject must be a breast cancer survivor, at least three years beyond completion of cancer therapy, free of clinical disease, and eligible for surgical intervention. the subject must be a breast cancer survivor, at least three years beyond completion of cancer therapy, free of clinical disease. two consecutive measurements of limb volume (LV) in the affected limb must be within 10% of each other. a maximum of 3 measurements can be taken. clinical trial of any other investigational drug or therapy, regardless of indication, within 1 month before screening or 5 times the drug's half-life, whichever is longer, Recent initiation of ( 8 weeks), or intention to initiate, CDPT or maintenance physiotherapy for lymphedema at any time during the duration of the study. other medical condition that could result in symptoms overlapping those of lymphedema in the affected limb. patients with a high risk of recurrence based on multi-gene signatures, e.g. BRCA1, BRCA 2, Oncotype DX (high risk recurrence score) or Mammaprint (poor risk signature), undergoing chemotherapy or radiation therapy. women aged 30 years or older ( 30 years old); women scheduled for screening mammography or have completed a screening mammogram within the past 30 days. subjects with a history of breast cancer and are in active treatment. prior lumpectomy may include breasts too large to be adequately positioned on 24 x 31 centimeter (cm) FFDM digital receptor without anatomical cut off during either FFDM or DBT examination. \",\n",
       " 'patients with glioblastoma multiforme undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks. participants will be injected with less than 10 mCi of 18F-FPPRGD2. mCi of 18F-FPPRGD2 of 18F-FPPRGD2. ',\n",
       " 'Results 1:, Arm/Group Title: Aprepitant, Dexamethasone, Cytoxan & Kytril. Day 1: 1 mg of Kytril orally or I.V., 10 mg of Dexamethasone orally, and Aprepitant 125 mg orally. ',\n",
       " 'menopausal: 12 months spontaneous amenorrhea or > 6 but  12 months amenorrhea with a serum follicle stimulating hormone (FSH) level of > 40 mIU/mL. able to read, understand and complete the required subject diary. legal incapacity or limited legal capacity. chronic renal (serum creatinine > 2.0 mg/dL) or hepatic disease. untreated overt hyperthyroidism. rmal (a subject will not be excluded if a second measurement is less than twice the upper limit of normal), Creatinine > 2.0 mg/dLInclusion Criteria: adult patients, >=18 years of age; HER2-negative metastatic breast cancer candidates for taxane-based chemotherapy; ECOG performance status of 0 or 1. ',\n",
       " 'overall response rate measured by physical exam and MRI if indicated using following definition. Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR = CR + PR., Time frame: Up to 8 months, Arm/Group Title: Arm A, Arm/Group Description: Arm A overall number of participants Analyzed: 37, Measure Type: Count of Participants, Unit of Measure: Participants 25 67.6%, Results 2:, Arm/Group Title: Arm B, Arm/Group Description: Arm B: Docetaxel 75 mg/m2 IV day 1 plus Capecitabine 1000 mg/m2/dose bid x 14d q3w, then surgery, then Epirubicin 90 mg/m2 day 1 IV and Cyclophosphamide 600 mg/m2 day 1 median time to first skeletal-related event could not be estimated in one treatment arm. median time to first skeletal-related event could not be estimated. ',\n",
       " 'inTERVENTION 1:, arm II, Patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1. oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3. r IV, dexamethasone: Given orally or IV, dexamethasone: Given orally or IV, dexamethasone: Given orally or IV, dexamethasone: Given orally or IV, dexamethasone: Given orally orally or IV, dexamethasone: Given orally orally or IV, dexamethasone: Given orally orally or IV, dexamethasone: Given orally orally ',\n",
       " 'patients are excluded if they are unable to give informed consent or pass screening for impaired mental function or psychosis. they are unable to hear or understand English. ',\n",
       " 'perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell), Intraoperatively prior to mastectomy. following the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction). following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement. ',\n",
       " '8/20 (40.00%), Anaemia 1/20 (5.00%), Lymphadenopathy 0/4 (0.00%), Thrombocytopenia 0/4 (0.00%), Acute coronary syndrome 0/4 (0.00%), Atrial fibrillation 0/4 (0.00%), Cardiac failure congestive 0/4 (0.00%), Cardiac tamponade 0/4 (0.00%), Adverse Events 2:, Total: 8/20 (40.00%), Anaemia 1 ',\n",
       " 'Adverse Events 1:, Total: 0/4 (0.00%), Adverse Events 2:, Total: 0/5 (0.00%), Lymphoma [1]1/50 (2.00%), Adverse Events 2:, Total: 0/11 (0.00%), Lymphoma [1]0/11 (0.00%) ',\n",
       " \"breast tumor 1 centimeter (cm) in diameter, HR+, HER2-. neoadjuvant endocrine monotherapy is deemed to be a suitable therapy. measurable disease, Bone metastases requires other disease present that can be measured. no brain metastases, unless documented to be controlled post-completion of local therapy for at least 4 weeks, no meningeal carcinomatosis, no malignant effusion as the only site. hat in the opinion of the treating physician would make study protocol unreasonably hazardous for the patient. hat in the opinion of the treating physician would make study protocol unreasonably hazardous for the patient or would preclude the patient's ability to comply with the study protocol. \",\n",
       " 'Adverse Events 1:, Total: 3/12 (25.00%), Hemoglobin 1/12 (8.33%), Alkaline phosphatase 1/12 (8.33%), Dehydration 1/12 (8.33%), Syncope 2/12 (16.67%), Dyspnea 1/12 (8.33%), Hypotension 1/12 (8.33%)Adverse Events 1:, Total: 0/115 (0.00%), Deep vein thrombosis * [1]0/115 ',\n",
       " \"patients undergoing immediate tissue expander reconstruction following mastectomy by any of the surgeon co-investigator co-investigators are eligible for the study. patients 18 years of age or older are eligible for the study. oprosthetic mesh are eligible for the study. patients who have not undergone autologous tissue breast reconstruction. patients who intend to remain under the surgeon's care until completion. \",\n",
       " \"participants must have histologically or cytologically proven metastatic or locally advanced solid tumors. no standard therapy exists or standard therapy has failed. disease must be measurable with at least 1 uni-dimensional measurable lesion by RECIST 1.1, except for participants with metastatic castrate-resistant prostate cancer. participants in the MBC cohort must have relapsed, refractory, or progressive disease following last line of treatment. Availability of tumor archival material or fresh biopsies is mandatory for eligibility in the expansion cohorts. participants in the NSCLC cohort will only be enrolled in USA, NSCLC first line: Stage IV or recurrent NSCLC that is histologically proven. participants should have received no more than 1 line of treatment for metastatic disease. participants with gastric cancer can enter in the study if their white blood cell (WBC) and lymphocyte count is as defined in the protocol, MBC: Participants must have histologically confirmed locally advanced or MBC. participants must have received no more than 3 prior lines of cytotoxic therapy for metastatic disease. pansion cohorts include gastric and GEJ cancer (third line), ovarian cancer (platinum Refractory + liposomal doxorubicin), urothelial carcinoma, and HNSCC. other protocol defined inclusion criteria for expansion phase could apply. basal or squamous cell carcinoma of the skin or cervical carcinoma in situ, Rapidly progressive disease (for example, tumor lysis syndrome), Active or history of central nervous system metastases, Receipt of any organ transplantation including allogeneic stem-cell transplantation. Known severe hypersensitivity reactions to monoclonal antibodies, any history of anaphylaxis, or uncontrolled asthma, Persisting toxicity related to prior therapy greater than Grade 1 NCI-CTCAE inflammatory bowel disease may impair Participant's tolerance of trial treatment. legal incapacity or limited legal capacity, non-oncology vaccine therapies for prevention of infection disease. vaccination while on study is also prohibited except for administration of the inactivated influenza vaccine. \",\n",
       " 'postmenopausal breast cancer (adenocarcinoma) estrogen (ER) and/or progesterone (PR) receptor positive that is locally advanced or locally recurrent and not able to be surgically removed OR with measurable and/or disease that is able to be assessed including isolated bone metastasis, Female patients 18 years or older. sient ischemic attacks in the last 6 months, no symptoms of peripheral vascular disease, no history of abdominal fistula, gastrointestinal perforation or intrabdominal abscess in the past 6 months. no known hypersensitivity to phosphate, trehalose or polysorbate, no serious non-healing wound, ulcer or bone fracture. ',\n",
       " 'inTERVENTION 1:, wait-list, patients in wait-list control group will cross over and receive acupuncture twice weekly for six consecutive weeks. patients will be advised to continue their standard lymphedema treatments such as exercise or use of compression garments if these were in use prior to clinical trial participation. rmed after approximately 6 weeks on wait-list, before onset of acupuncture treatment. BMI will be measured at the same timepoints. ',\n",
       " 'measurable disease defined as at least one lesion 10 mm by CT or MRI that can be accurately measured in at least one dimension. bone lesions: lytic or mixed (lytic + blastic) in the absence of measurable disease. at least 18 years of age. Able to understand and willing to sign an IRB-approved written informed consent document. ',\n",
       " 'women 18 years, Histologically or cytologically confirmed diagnosis of metastatic breast cancer, Measurable or nonmeasurable disease defined by Response Evaluation Criteria In Solid Tumors (RECIST), Exclusion Criteria:, Number of prior chemotherapy lines of treatment in the metastatic setting. ',\n",
       " 'women and men ages 18 or older have an anticipated treatment-free life span of 12 months or longer. have a BMI of 25 kg/m2 or greater and weight =400 lbs., Willingness to accept randomization to each of the three arms, Willingness to change diet, physical activity, and weight. abetes, fasting blood glucose >=200 mg/dL, or fasting blood glucose >=126 and 200 mg/dL and HbA1C >=7%, Current or prior regular use of metformin within the past 3 months, Uncontrolled concurrent medical condition likely to limit compliance with the study interventions, Received any chemotherapy (unless anti-hormonal therapy) and/or radiation three months or less prior to the proposed intervention date, Have significant renal disease or dysfunction defined as Estimated glomerular  lorcaserin, topiramate/phentermine, phentermine, liraglutide, and bupropion/naltrexone have been prescribed weight loss medication(s) or over-the-counter weigh loss medications such as Orlistat within the past 6 months. ',\n",
       " 'average pain was measured using a 0 (no pain) to 10 (worst pain imaginable) numeric rating scale on a daily basis. change in average pain intensity between the two intervention groups was evaluated from enrollment to the end of the study. follow-up visits to assess the sustainability of the intervention will be done at 2 weeks, 1 month and 3 months after the intervention. patients in both groups will be seen in their homes over the course of 10 weeks with phone calls conducted in between the home visits. patients in the LOW-DOSE group will receive 4 visits and 6 phone calls. follow-up visits to assess the sustainability of the intervention will be done at 2 weeks, 1 month and 3 months after the intervention. ',\n",
       " 'Avastin treatment must have been a minimum of 4 cycles (15 mg/kg) or 6 cycles (10 mg/kg) in combination with chemotherapy, ECOG performance status 0-2, At least 28 days since prior radiation therapy or surgery and recovery from treatment. Exclusion Criteria:, Anti-angiogenic therapy or anti-vascular endothelial growth factors other than Avastin for first-line treatment. ER-positive is defined as 1% immunohistochemical staining of any intensity. patients with stage II-III breast cancer are eligible if they are deemed appropriate for neoadjuvant endocrine therapy by the referring or treating medical oncologist. tmenopausal for at least 1 year before the screening visit, OR, Are surgically sterile, OR agree to practice 1 effective method of contraception and 1 additional effective (barrier) method, at the same time, from the time of signing the ICF through 90 days. male patients, even if surgically sterilized (i.e., status post-vasectomy) days after the last dose of the study drugs, OR, Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient. Agree not to donate sperm during the course of the study or within 120 days after receiving their last dose. consent must be given before performing any study-related procedure not part of standard medical care. patient must be accessible for treatment and follow-up. patient must be willing to undergo breast biopsies as required by study protocol. patients with non-melanoma skin cancer or carcinoma in situ are not excluded if they have undergone complete resection. patients with enteric stomata are also excluded. roid administration may be enrolled in the study if all other inclusion criteria and none of the other exclusion criteria are met. roid administration may be enrolled in the study if all other inclusion criteria and none of the other exclusion criteria are met. use of antihypertensive agents to control hypertension before week. patients receiving systemic corticosteroids within 1 week before administration of the first dose of the study drugs. daily or chronic use of a proton pump inhibitor (PPI) and/or having taken a PPI wit. patients unwilling or unable to comply with the study protocol. patients previously treated with hormonal therapy (tamoxifen, AI) or PI3K, AKT, dual PI3K/mTOR, TORC1/2, or mTORC1 inhibitors. ',\n",
       " \"participants must have histologically or cytologically proven metastatic or locally advanced solid tumors. no standard therapy exists or standard therapy has failed. disease must be measurable with at least 1 uni-dimensional measurable lesion by RECIST 1.1, except for participants with metastatic castrate-resistant prostate cancer. participants in the MBC cohort must have relapsed, refractory, or progressive disease following last line of treatment. Availability of tumor archival material or fresh biopsies is mandatory for eligibility in the expansion cohorts. participants in the NSCLC cohort will only be enrolled in USA, NSCLC first line: Stage IV or recurrent NSCLC that is histologically proven. participants should have received no more than 1 line of treatment for metastatic disease. participants with gastric cancer can enter in the study if their white blood cell (WBC) and lymphocyte count is as defined in the protocol, MBC: Participants must have histologically confirmed locally advanced or MBC. participants must have received no more than 3 prior lines of cytotoxic therapy for metastatic disease. pansion cohorts include gastric and GEJ cancer (third line), ovarian cancer (platinum Refractory + liposomal doxorubicin), urothelial carcinoma, and HNSCC. other protocol defined inclusion criteria for expansion phase could apply. basal or squamous cell carcinoma of the skin or cervical carcinoma in situ, Rapidly progressive disease (for example, tumor lysis syndrome), Active or history of central nervous system metastases, Receipt of any organ transplantation including allogeneic stem-cell transplantation. Known severe hypersensitivity reactions to monoclonal antibodies, any history of anaphylaxis, or uncontrolled asthma, Persisting toxicity related to prior therapy greater than Grade 1 NCI-CTCAE inflammatory bowel disease may impair Participant's tolerance of trial treatment. legal incapacity or limited legal capacity, non-oncology vaccine therapies for prevention of infection disease. vaccination while on study is also prohibited except for administration of the inactivated influenza vaccine. \",\n",
       " 'intra-operative digital mammography compared with standard specimen mammography. overall number of participants Analyzed: 36, Median (Full Range), Unit of Measure: Minutes Procedure Time: 48.5 (17 to 138), OR Time: 68 (29 to 180), Results 2:, Arm/Group Title: Standard Mammography, Arm/Group Description: Standard Specimen Mammography, Standard Mammography: There is not an added device associated with this arm. participants received immediate breast reconstruction using a sub-muscular tissue expander (TE) and acellular dermal matrix (ADM) sling during the same surgery. post-mastectomy radiation therapy (PMRT) no sooner than a minimum of 6 weeks and optimally 6 months. the prescribed chest-wall dose was 50 -50.4 gray (Gy) in 25-28 fractions given once daily over 5-7 weeks with a 0.5-centimeter (cm) bolus to the scar every other day. ',\n",
       " 'inTERVENTION 1:, Zoledronic Acid, Zoledronic acid, vitamin D and calcium supplements, plus Sr-89 or Sm-153. ',\n",
       " 'patients with vitamin D deficiency who experience myalgias, arthralgias and/or joint stiffness received epoetin beta (NeoRecormon®) at a dose of 30000 International Units (IU) as subcutaneous (SC) injection once every week. ',\n",
       " '0/49 (0.00%)Adverse Events 1:, Total: 12/20 (60.00%), Recurrent malignancy *1/20 (5.00%), Graft-versus-host disease *7/20 (35.00%), Infection *7/20 (35.00%), Altered mental status *2/20 (10.00%), Diffuse alveolar hemorrhage *1/20 (5.00%) ',\n",
       " 'inTERVENTION 2:, arm B: 3 Days/Week Schedule, CUDC-101: CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 consecutively. ',\n",
       " \"dose-limiting toxicities are assessed according to the national Cancer Institute's Common Terminology Criteria for Adverse Events classification. the classification usually encompasses all grade 3 or higher toxicities, Time frame: 28 days. given IV, pegylated liposomal doxorubicin hydrochloride: Given IV, overall number of participants Analyzed: 6, Measure Type: Number, Unit of Measure: participants 1__________________________________________________________________ \",\n",
       " 'participants with metastatic breast cancer received a loading dose of 4 milligrams per kilograms (mg/kg) of trastuzumab intravenously (IV) followed by 2 mg/kg of trastuzumab IV once a week along with docetaxel 100 milligrams per meter square (mg/m2), every 3 weeks or paclitaxel 90 mg/m2 once a week. Herceptin 2 mg/kg by IV infusion weekly starting from Day 8. docetaxel 100 mg/m2 IV infusion on Day 2 of cycle 5. after completion of last cycle of chemotherapy, Herceptin 6 mg/kg IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose. ',\n",
       " '0/3 (0.00%)Adverse Events 1:, Total: 4/14 (28.57%), Duodenitis [1]1/14 (7.14%), Gastrooesophageal reflux disease [1]1/14 (7.14%), Vomiting [1]1/14 (7.14%), Ascites [1]1/14 (7.14%), Death [1]1/14 (7.14%), Asthenia [1]1/14 (7.14%), general physical health deterioration [1]1/14 ',\n",
       " 'inTERVENTION 2:, Trabectedin, 1.3 mg/m2 of trabectedin was administered as a 3-hour intravenous infusion on Day 1. ',\n",
       " 'inTERVENTION 1:, Placebo, Buminate solution, Placebo: 20 transendocardial injections of 0.4ml allo-MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure) ',\n",
       " 'anemia*4 0/25 (0.00%), BLOOD/BONE MARROW:: Leukocytes (total WBC)*3 4/25 (16.00%), BLOOD/BONE MARROW:: Lymphopenia*3 2/25 (8.00%), BLOOD/BONE MARROW:: Neutrophils/granulocytes (ANC/AGC)*3 5/25 (20.00%), BLOOD/BONE MARROW:: Plate ',\n",
       " \"patients undergoing immediate tissue expander reconstruction following mastectomy by any of the surgeon co-investigator co-investigators are eligible for the study. patients 18 years of age or older are eligible for the study. oprosthetic mesh are eligible for the study. patients who have not undergone autologous tissue breast reconstruction. patients who intend to remain under the surgeon's care until completion. \",\n",
       " 'Febrile neutropenia * 2/5 (40.00%), Anaemia * 0/4 (0.00%), Vertigo * 0/4 (0.00%), Nausea * 0/4 (0.00%), Stomatitis * 0/4 (0.00%), Vomiting * 0/4 (0.00%), Disease progression * 0/4 (0.00%), Mucosal inflammation * 0/4 (0.00%), Fatigue * 0/4 (0.00%), Pyrexia * 0/4 (0.00%), Ga ',\n",
       " 'Adverse Events 1:, Total: 8/87 (9.20%), Death * [1]8/87 (9.20%), Hospitalization [2]1/87 (1.15%), Hospitalization [3]1/87 (1.15%), Adverse Events 2:, Total: 0/28 (0.00%), Death * [1]0/28 (0.00%), Hospitalization [3]0/28 (0.00%)_______________________ ',\n",
       " 'inTERVENTION 1:, Patients - Intervention, Patients will be invited to view the educational DVD explaining end-of-life care options and meet with a lay health advisor for discussion. ',\n",
       " '1/9 (11.11%), Death, not otherwise specified 0/9 (0.00%), Pain, bone 1/9 (11.11%), Adverse Events 2:, Total: 1/9 (11.11%), Death, not otherwise specified 1/9 (11.11%), Pain, bone 0/9 (0.00%)Adverse Events 1:, Total: 1/208 (0.48%), Neutrophils/granulocytes (ANC/AGC) 1/208 (0.48%), Adverse Events 2:, Total: 0/ ',\n",
       " 'dexamethasone 8 mg, Dexamethasone 8 mg pre-operative, Dexamethasone: pre-operative intravenous administration. inTERVENTION 2:, Dexamethasone 24 mg, Dexamethasone 24 mg pre-operative. ',\n",
       " 'Adverse Events 1:, Total: 17/50 (34.00%), Fatigue 4/50 (8.00%), Papulopustular rash 1/50 (2.00%), Alanine aminotransferase increased 5/50 (10.00%), Alkalosis 1/50 (2.00%), Anorexia 1/50 (2.00%), Hyperglycemia 2/50 (4.00%), Nervous system disorders. ',\n",
       " 'the EORTC CIPN20 scoring algorithm was used for the sensory (items 31-36, 39, 40 and 48) subscale scores on a 0-100 scale. the aAUCpa for the subscale is calculated as the average of each AUC between each sequential assessment from pre-treatment-initiation to the week-12 assessment. positive scores represent symptoms has improved from baseline and negative scores represent symptoms has worsen from baseline. therapy repeats every week for a planned course of 12 weeks of adjuvant paclitaxel. overall number of participants Analyzed: 19, Median (Full Range), Unit of Measure: Average(subscale value*assessment) -1.4 (-11.7 to 6.8), Results 2:, Arm/Group Title: Arm II (Control), Arm/Group Description: Patients receive the standard of care only (paclitaxel at a dose of 80 mg/m2 IV) every week for ',\n",
       " 'invasive disease-free survival time is defined as the time from date of randomization until time of event up to 2 years. time is defined as the time from date of randomization until time of event up to 2 years. patients who completed prior adjuvant trastuzumab received six placebo tablets (240 mg) taken orally once daily with food, preferably in the morning, continuously for one year. therapy continued until unacceptable toxicity, recurrent disease, death, or withdrawal of consent occurred. ',\n",
       " 'Anaemia 1/106 (0.94%), Disseminated intravascular coagulation 1/106 (0.94%), Febrile neutropenia 1/106 (0.94%), Lymph node pain 1/106 (0.94%), Neutropenia 2/106 (1.89%), Sinus tachycardia 1/106 (0.94%), Abdominal pain upper 0/106 (0.00%), Diarrhoea 2/106 (1.89%), Nausea 1/106 (0.94%), ',\n",
       " \"the participant has a histopathologically or cytologically confirmed diagnosis of breast adenocarcinoma that is metastatic or locally-recurrent and inoperable with curative intent. the participant has measurable and/or non-measurable disease, The participant's primary and/or metastatic tumor is human Epidermal Growth Factor Receptor 2 (HER2) negative. participants of reproductive potential agree to use adequate contraceptive methods during the study period and for 12 weeks after the last dose of study medication. participant has a concurrent active malignancy other than breast adenocarcinoma, adequately treated non-melanomatous skin cancer, or other non-invasive carcinoma or in situ neoplasm. articipant has received any experimental agents within 4 weeks prior to the study registration date, The participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders. the participant has an ongoing or active infection requiring antibiotic, antifungal, or antiviral therapy. for bone disease, stable disease (SD) is allowed. patient must have tumor assessed for estrogen-receptor (ER) and progesterone-receptor (PR) prior HDCT with autologous hematopoietic stem cell transplantation (AHST) in adjuvant setting. history of other malignancies except cured non-melanoma skin cancer. \",\n",
       " 'prior anthracycline, taxane, and capecitabine therapy may have been as neoadjuvant, or adjuvant therapy. prior anthracycline and taxane therapy may have been as neoadjuvant, or adjuvant therapy if disease progression is documented within a year. in normal or hyperbilirubinemia  grade 1 (unless due to Gilbert syndrome with elevated total but normal levels of conjugated bilirubin) not pregnant or nursing, Fertile patients must use effective contraception, No other non-breast malignancy, except nonmelanoma skin cancer, No other serious underlying medical condition, that would make study protocol unreasonably hazardous for the patient. pitant_ ',\n",
       " 'Results 1:, Arm/Group Title: Aprepitant, Dexamethasone, Cytoxan & Kytril. Day 1: 1 mg of Kytril orally or I.V., 10 mg of Dexamethasone orally, and Aprepitant 125 mg orally. ',\n",
       " \"participants must have histologically or cytologically proven metastatic or locally advanced solid tumors. no standard therapy exists or standard therapy has failed. disease must be measurable with at least 1 uni-dimensional measurable lesion by RECIST 1.1, except for participants with metastatic castrate-resistant prostate cancer. participants in the MBC cohort must have relapsed, refractory, or progressive disease following last line of treatment. Availability of tumor archival material or fresh biopsies is mandatory for eligibility in the expansion cohorts. participants in the NSCLC cohort will only be enrolled in USA, NSCLC first line: Stage IV or recurrent NSCLC that is histologically proven. participants should have received no more than 1 line of treatment for metastatic disease. participants with gastric cancer can enter in the study if their white blood cell (WBC) and lymphocyte count is as defined in the protocol, MBC: Participants must have histologically confirmed locally advanced or MBC. participants must have received no more than 3 prior lines of cytotoxic therapy for metastatic disease. pansion cohorts include gastric and GEJ cancer (third line), ovarian cancer (platinum Refractory + liposomal doxorubicin), urothelial carcinoma, and HNSCC. other protocol defined inclusion criteria for expansion phase could apply. basal or squamous cell carcinoma of the skin or cervical carcinoma in situ, Rapidly progressive disease (for example, tumor lysis syndrome), Active or history of central nervous system metastases, Receipt of any organ transplantation including allogeneic stem-cell transplantation. Known severe hypersensitivity reactions to monoclonal antibodies, any history of anaphylaxis, or uncontrolled asthma, Persisting toxicity related to prior therapy greater than Grade 1 NCI-CTCAE inflammatory bowel disease may impair Participant's tolerance of trial treatment. legal incapacity or limited legal capacity, non-oncology vaccine therapies for prevention of infection disease. vaccination while on study is also prohibited except for administration of the inactivated influenza vaccine. \",\n",
       " 'at least 18 years of age, Female, Able to understand and willing to sign an IRB-approved written informed consent document, Exclusion Criteria:, Pregnant and/or breastfeeding, Prior history of breast cancer, Prior history of chest wall radiation, Prior history of breast reconstruction, reduction, or augmentationInclusion Criteria:, Patient must be 18 and older, Patients must have histologically confirmed (by routine H&E staining) invasive adenocarcinoma or Ductal Carcino women of child-bearing potential must use effective non-hormonal contraception while undergoing radiation therapy. patients must not have a serious medical or psychiatric illness which prevents informed consent or compliance with treatment. ',\n",
       " \"the subject must be a breast cancer survivor, at least three years beyond completion of cancer therapy, free of clinical disease, and eligible for surgical intervention. the subject must be a breast cancer survivor, at least three years beyond completion of cancer therapy, free of clinical disease. two consecutive measurements of limb volume (LV) in the affected limb must be within 10% of each other. a maximum of 3 measurements can be taken. clinical trial of any other investigational drug or therapy, regardless of indication, within 1 month before screening or 5 times the drug's half-life, whichever is longer, Recent initiation of ( 8 weeks), or intention to initiate, CDPT or maintenance physiotherapy for lymphedema at any time during the duration of the study. other medical condition that could result in symptoms overlapping those of lymphedema in the affected limb. patients with a high risk of recurrence based on multi-gene signatures, e.g. BRCA1, BRCA 2, Oncotype DX (high risk recurrence score) or Mammaprint (poor risk signature), undergoing chemotherapy or radiation therapy. women aged 30 years or older ( 30 years old); women scheduled for screening mammography or have completed a screening mammogram within the past 30 days. subjects with a history of breast cancer and are in active treatment. prior lumpectomy may include breasts too large to be adequately positioned on 24 x 31 centimeter (cm) FFDM digital receptor without anatomical cut off during either FFDM or DBT examination. \",\n",
       " 'Adverse Events 1:, Total: 4/9 (44.44%), Pericardial effusion 1/9 (11.11%), Corneal deposits 0/9 (0.00%), Stomatitis 0/9 (0.00%), Mucosal inflammation 0/9 (0.00%), Influenza 1/9 (11.11%), Pneumonia 1/9 (11.11%), Adenocarcinoma of colon 1/9 (11.11%), Presyncope 1/9 (11.11%), ',\n",
       " 'at least 18 years of age, Female, Able to understand and willing to sign an IRB-approved written informed consent document, Exclusion Criteria:, Pregnant and/or breastfeeding, Prior history of breast cancer, Prior history of chest wall radiation, Prior history of breast reconstruction, reduction, or augmentationInclusion Criteria:, Patient must be 18 and older, Patients must have histologically confirmed (by routine H&E staining) invasive adenocarcinoma or Ductal Carcino women of child-bearing potential must use effective non-hormonal contraception while undergoing radiation therapy. patients must not have a serious medical or psychiatric illness which prevents informed consent or compliance with treatment. ',\n",
       " 'Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W, Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W, INTERVENTION 2:, Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W. ',\n",
       " \"patients must have a tissue diagnosis of low, intermediate or high grade ductal carcinoma in situ or ductal carcinoma in situ with microinvasion. patients must be female at least 18 years of age. patients must have a signed tissue acquisition consent. subjects should be willing to abstain from use of hormonal therapies. hormone replacement therapy, oral contraceptive pills, hormone-containing intra-uterine devices, and E-string. if a woman becomes pregnant, she should inform her study physician. if a subject is of child-bearing potential, she must have a documented negative serum or urine pregnancy test before starting treatment. if a subject is of child-bearing potential, she must have a documented negative serum or urine pregnancy test. active diagnosis of psoriasis or currently receiving treatment for psoriasis. history of known Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency. history of epilepsy or seizures in the past 20 years. women enrolled in STAR trial at site participating in co-STAR, 65 years of age or older, have not started taking the study drug OR enrolled in STAR for a minimum of one year. previous diagnoses of chronic neurologic disease (Parkinson's disease, stroke, epilepsy, multiple sclerosis), history of head injury, depression, alcohol addiction, drug addiction, and other neurologic or psychiatric conditions will be recorded but will not serve as exclusion factors. \",\n",
       " 'inTERVENTION 2:, arm B: 3 Days/Week Schedule, CUDC-101: CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 consecutively. ',\n",
       " 'inTERVENTION 1:, Placebo, Buminate solution, Placebo: 20 transendocardial injections of 0.4ml allo-MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure) ',\n",
       " \"patients undergoing immediate tissue expander reconstruction following mastectomy by any of the surgeon co-investigator co-investigators are eligible for the study. patients 18 years of age or older are eligible for the study. oprosthetic mesh are eligible for the study. patients who have not undergone autologous tissue breast reconstruction. patients who intend to remain under the surgeon's care until completion. \",\n",
       " 'Adverse Events 1:, Total: 8/87 (9.20%), Death * [1]8/87 (9.20%), Hospitalization [2]1/87 (1.15%), Hospitalization [3]1/87 (1.15%), Adverse Events 2:, Total: 0/28 (0.00%), Death * [1]0/28 (0.00%), Hospitalization [3]0/28 (0.00%)_______________________ ',\n",
       " 'one to three presumed brain metastases must be from a histologically confirmed extracerebral site (e.g., lung, breast, prostate), Histologic confirmation may have been from the primary tumor site, from another metastatic site (e.g., osseous metastasis, adrenal metastasis), or from the metastatic brain lesion(s) Each lesion must measure less than 3.0 cm by contrast MRI of the brain performed within the past 21 days. male patients must continue to use contraception for 3 months after the completion of radiotherapy. no pacemaker or other MRI-incompatible metal in the body, no known allergy to gadolinium, no known allergy to gadolinium. volunteers may have had a prior history of other cancers > 3 years which required only local resection, local radiation and/or hormonal therapy such as androgen blockade. d risk of the proposed study and be able to sign consent. e influenza vaccine, On-going neurologic disorder (mental status change, uncontrolled seizures, encephalopathy), Treatment or planned treatment with cyclophosphamide, ifosphamide, or > or = to 1 mg/kg prednisone or its equivalent 12 weeks within 12 weeks of vaccination. patients receiving the seasonal influenza vaccine may not have had it within 6 months of enrollment. ',\n",
       " 'adults with histologically or cytologically confirmed breast adenocarcinoma, radiographic evidence of at least one bone mets, Easter Cooperative Oncology Group status of 0, 1 or 2; adequate organ function, Exclusion Criteria:, Current or prior IV bisphosphonate administration, current or prior oral bisphosphonates for bone mets, life expectancy of less than 6 monthsInclusion Criteria:, Patients must have disease that is metastatic (stage IV), HER2/neu negative disease histologic and/or cytologic confirmation of metastatic disease is encouraged whenever feasible, furthermore, the biopsy should confirm that the primary tumor is ER and/or PR-positive and HER2/neu negative. measurable disease (RECIST 1.1) or non-measurable (assessable) disease, patients must have had progressive disease during at least one line of endocrine therapy for metastatic disease or have recurrent disease while or within 12 months of receiving adjuvant endocrine therapy  patients must have normal organ and marrow function as defined below. postmenopausal status, defined as 60 years and older, being 45 years and older, having amenorrhea x 12 months or follicle stimulating hormone levels within postmenopausal range. on combination of exemestane with everolimus less than 4 weeks prior to study entry and discontinued everolimus due to poor tolerability. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris. ',\n",
       " 'an AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. treatment-emergent are events between first dose and up to 28 days after last dose that were absent before treatment or worsened relative to pretreatment state. docetaxel 75 milligram/square meter (mg/m2) intravenous infusion over 1 hour on Day 1 of each cycle and trastuzumab either weekly. loading dose of 4 milligram/kilogram (mg/kg) intravenous infusion over 90 minutes on Day 1 followed by weekly maintenance doses of 2 mg/kg intravenous infusion over 30 minutes. cycle length was 3 weeks. ',\n",
       " 'AINTERVENTION 1:, Phase 1: MLN8237 10 mg, MLN8237 (alisertib) 10 milligram (mg), enteric-coated tablets, orally, twice daily for 7 days followed by 14 days of rest period in 21-day treatment cycles. or until progressive disease, unacceptable treatment-related toxicity, or initiation of a different anticancer therapy during Phase 1 portion of the study. treatment-related toxicity, or initiation of a different anticancer therapy during Phase 1 portion of the study. ',\n",
       " 'participants received intravenous infusion of PF-05212384 90 mg once on Day -7 and Cycle 1 Day 2. docetaxel 75 mg/m2 1-hour IV infusion once followed by PF-05212384 90 mg once. maximum duration of docetaxel treatment was 445 days. participants received docetaxel 75 mg/m2 1-hour IV infusion once on cycle 1 Day 1. maximum duration of PF-05212384 treatment was 505 days. maximum duration of docetaxel treatment was 445 days. ',\n",
       " '0/3 (0.00%)Adverse Events 1:, Total: 4/14 (28.57%), Duodenitis [1]1/14 (7.14%), Gastrooesophageal reflux disease [1]1/14 (7.14%), Vomiting [1]1/14 (7.14%), Ascites [1]1/14 (7.14%), Death [1]1/14 (7.14%), Asthenia [1]1/14 (7.14%), general physical health deterioration [1]1/14 ',\n",
       " 'ECOG performance status of 0, Previous non-metastatic operable primary invasive HER2-positive breast cancer, Baseline LVEF >55%, Exclusion Criteria:, Healthy Participants (Part 1 only), Clinically significant abnormalities in laboratory test results or electrocardiogram. history of significant allergies, gastrointestinal, renal, hepatic, cardiovascular, or pulmonary disease, hypersensitivity or allergic reaction, spontaneous or following drug administration. bothersome hot flashes for 1 month prior to study entry, PATIENT CHARACTERISTICS:, Eastern Cooperative Oncology Group (ECOG) performance status 0-1, Life expectancy 6 months, Able to complete questionnaire(s) by themselves or with assistance, Women of childbearing potential not eligible. al estrogen is allowed if used for the past month and not planned to be discontinued, concurrent adjuvant targeted therapy (i.e., lapatinib, trastuzumab [Herceptin®] allowed in patients with no evidence of disease, Concurrent tamoxifen, raloxifene, or aromatase inhibitors on a constant dose for at least 4 weeks allowed provided the medication will not be stopped during the study period. ',\n",
       " '89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions. PET/CT imaging with these novel radiotracers will allow evaluation of all identifiable malignant lesions. ',\n",
       " '0/4 (0.00%), Anaemia 0/4 (0.00%), Febrile neutropenia 0/4 (0.00%), Leukocytosis 0/4 (0.00%), Neutropenia 0/4 (0.00%), Pancytopenia 0/4 (0.00%), Acute coronary syndrome 0/4 (0.00%), Atrial fibrillation 0/4 (0.00%), Cardiac arrest 0/4 (0.00%), Pericardial effusion 0/4 (0.00%), Ad ',\n",
       " '3/37 (8.11%), Sinus tachycardia 0/37 (0.00%), Heart failure 0/37 (0.00%), Dehydration 1/37 (2.70%), Death Not Associated with CTCAE: Death NOS 1/37 (2.70%), Lymphopenia 1/37 (2.70%), Neutropenia 1/37 (2.70%), Thrombocytopenia 0/37 (0.00%), Hyponatremia 1/37 (2.70%), Weight loss 0/37 ( ',\n",
       " 'Adverse Events 1:, Total: 1/13 (7.69%), Rapid disease progression [1]1/13 (7.69%), Increased pleural effusion [2]0/13 (0.00%), Adverse Events 2:, Total: 1/4 (25.00%), Rapid disease progression [1]0/4 (0.00%), Increased pleural effusion [2]1/4 (25.00%). ',\n",
       " 'women with a clinically or mammographically identified suspicious breast mass likely to be biopsied or surgically removed. Exclusion Criteria:, Pregnancy, Ferromagnetic implants, history of shotgun wounds and shrapnel, Obesity (>250 pounds), Cardiac pacemaker, Incompatible implanted medical device, Severe asthma and allergies. ',\n",
       " 'Chemotherapy with GM-CSF, Doxorubicin and Cyclophosphamide (AC) followed by Weekly Carboplatin/Nab- PaclitaxelINTERVENTION 1:, Neoadjuvant Chemotherapy, Doxorubicin (Adriamycin) + cyclophosphamide (Cytoxan) with pegfilgrastim or filgrastim growth factor support every 2 weeks for 4 cycles ',\n",
       " 'inTERVENTION 1:, Subjects enrolled with device placed and treated with partial breast irradiation. ',\n",
       " 'Hemoglobin decreased 2/30 (6.67%), Abdominal pain 1/30 (3.33%), Colitis 1/30 (3.33%), Diarrhea 7/30 (23.33%), Nausea 2/30 (6.67%), Rectal hemorrhage 1/30 (3.33%), Fatigue 1/30 (3.33%), Skin infection 1/30 (3.33%), Neutrophil count decreased 1/30 (3.33%), Platelet count decreased 3/30 (10.00%), Dehydration 1/30 (3.33%) holelithiasis 0/6 (0.00%), Hepatic pain 1/6 (16.67%), Bacteraemia 0/6 (0.00%) holelithiasis 0/6 (0.00%), Hepatic pain 1/6 (16.67%), bacteraemia 0/6 (0.00%) ',\n",
       " 'overall response rate measured by physical exam and MRI if indicated using following definition. Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR = CR + PR., Time frame: Up to 8 months, Arm/Group Title: Arm A, Arm/Group Description: Arm A overall number of participants Analyzed: 37, Measure Type: Count of Participants, Unit of Measure: Participants 25 67.6%, Results 2:, Arm/Group Title: Arm B, Arm/Group Description: Arm B: Docetaxel 75 mg/m2 IV day 1 plus Capecitabine 1000 mg/m2/dose bid x 14d q3w, then surgery, then Epirubicin 90 mg/m2 day 1 IV and Cyclophosphamide 600 mg/m2 day 1 median time to first skeletal-related event could not be estimated in one treatment arm. median time to first skeletal-related event could not be estimated. ',\n",
       " '0/33 (0.00%)Adverse Events 1:, Total: 5/16 (31.25%), ANAEMIA 1/16 (6.25%), LEUKOPENIA 1/16 (6.25%), NEUTROPENIA 3/16 (18.75%), THROMBOCYTOPENIA 1/16 (6.25%), FEBRILE INFECTION 1/16 (6.25%), PNEUMONIA 1/16 (6.25%), PNEUMONIA 1/16 (6.25%), PNEUMONIA 1/16 ( ',\n",
       " 'locally recurrent or metastatic breast cancer must not be amenable to resection with curative intent. prior hormonal therapy in adjuvant, recurrent, or metastatic setting allowed but must have been discontinued at least 2 weeks before randomization. at least 1 week since minor surgery and/or focal/palliative radiation therapy. at least 3 weeks from radiation; at least 4 weeks from major surgery. at least 8 weeks from liver resection, thoracotomy, or neurosurgery. cBP unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months after treatment with bevacizumab. women with a positive pregnancy test on enrollment or prior to study drug administration. thracyclines not within institutional normal limits. history of high dose chemotherapy with bone marrow transplant or peripheral blood stem cell transplant within 2 years. ',\n",
       " 'the EORTC CIPN20 scoring algorithm was used for the sensory (items 31-36, 39, 40 and 48) subscale scores on a 0-100 scale. the aAUCpa for the subscale is calculated as the average of each AUC between each sequential assessment from pre-treatment-initiation to the week-12 assessment. positive scores represent symptoms has improved from baseline and negative scores represent symptoms has worsen from baseline. therapy repeats every week for a planned course of 12 weeks of adjuvant paclitaxel. overall number of participants Analyzed: 19, Median (Full Range), Unit of Measure: Average(subscale value*assessment) -1.4 (-11.7 to 6.8), Results 2:, Arm/Group Title: Arm II (Control), Arm/Group Description: Patients receive the standard of care only (paclitaxel at a dose of 80 mg/m2 IV) every week for ',\n",
       " 'women may receive the AI on this study as initial adjuvant hormonal treatment or following tamoxifen. patients may have received preoperative chemotherapy, Postmenopausal status, defined as: >= 60 years of age; or  60 years of age and amenorrheic for >= 12 months prior to day 1 if intact uterus/ovaries. istory of bilateral oophorectomy; or prior radiation castration with amenorrhea for at least 6 months; or prior radiation castration with amenorrhea for at least 6 months;  60 years of age and taking medication designed to suppress ovarian function. women would have had to be taking the drug for at least 30 days prior to day 1. current bisphosphonate use (oral or intravenous); prior bisphosphonate users would be eligible as long as the use was > 1 month ago for oral bisphosphonates. prior bisphosphonate users would be eligible as long as the use was > 12 months ago for intravenous bisphosphonates. ',\n",
       " 'patients with vitamin D deficiency who experience myalgias, arthralgias and/or joint stiffness received epoetin beta (NeoRecormon®) at a dose of 30000 International Units (IU) as subcutaneous (SC) injection once every week. ',\n",
       " 'CR is defined as the disappearance of all lesions (target and/or non-target) PR is defined as at least a 30% decrease in the sum of the longest dimensions (LD) of target lesions taking as a reference the baseline sum LD, with non-target lesions not increased or absent. ast 6 cycles., Overall Number of Participants Analyzed: 60, Measure Type: Number, Unit of Measure: percentage of participants 53_. ',\n",
       " 'patients must have metastatic or unresectable non-small cell lung cancer, head and neck cancer, urothelial transitional cell carcinoma, or breast cancer whose disease has progressed after at least one line of standard therapy. patients must have measurable disease defined as at least one lesion that can be accurately measured in at least one dimension. patients should be at least six weeks out from nitrosoureas and mitomycin C. prior radiation should have been completed greater than or equal to 4 weeks prior to study enrollment. patients must be greater than or equal to 2 weeks since any investigational agent administered as part of a Phase 0 study. cytidine (FdCyd) and Tetrahydrouridine (THU) in patients less than 18 years of age are excluded from this study. children are excluded from this study, but may be eligible for future pediatric Phase I combination trials. pregnant women will be excluded from this trial. nursing women are also excluded. there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother. active or uncontrolled infection, immune deficiencies or confirmed diagnosis of human immunodeficiency virus (HIV) infection, active infection with Hepatitis B or Hepatitis C, uncontrolled diabetes, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia. ',\n",
       " 'ORR was defined as the proportion of participants who achieved a best response of either CR or PR. time frame: baseline & every 2 cycles (approximately 8 weeks) of treatment. bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days. overall number of participants Analyzed: 94, Mean (95% Confidence Interval), Unit of Measure: proportion of responders 0.489 (0.385 to 0.595), Results 2:, Arm/Group Title: paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G), Arm/Group Description: paclitaxel 90 mill ',\n",
       " 'a higher serum total bilirubin ( 2 x ULN) is allowed, aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 2.5 times ULN, Alkaline phosphatase 2.5 times ULN, Renal status: Creatinine. patients must use effective contraception (barrier method - condoms, diaphragm - also in conjunction with spermicidal jelly, or total abstinence) patient accepts to make available tumour samples for submission to central laboratory to conduct translation studies. han 10 years prior to randomisation may enter the study. patients must have been curatively treated with surgery alone. prior diagnoses of breast cancer or melanoma are excluded. subjects with ulcerative colitis are also excluded. subjects with ulcerative colitis are also excluded. rdiogram (ECG), 18 years of age or above, Able to understand and sign informed consent, Pilot study only:, CRC, TNBC, ER/PR Breast Cancer, NSCLC, Pancreatic Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal Junction (GEJ) adenocarcinoma, Head and Neck Cancer, Expansion Phase Additional Criteria:, Locally advanced or metastatic breast cancer, Received at least one cytotoxic xytol, Inability to undergo MRI, Active infection, Pregnant or breast feeding, Prior chemotherapy administered within 3 weeks, or within a time interval less than at least 5 half-lives of the agent. prior to the first scheduled day of dosing in this study, received radiation therapy in the last 14 days, Treated with parenteral iron in the previous 4 weeks. ',\n",
       " 'Adverse Events 1:, Total: 0/20 (0.00%)Adverse Events 1:, Total: 2/35 (5.71%), Gastroesophageal reflux disease * 1/35 (2.86%), Ductal carcinoma in situ * 1/35 (2.86%) ',\n",
       " 'Adverse Events 1:, Total: 0/20 (0.00%)Adverse Events 1:, Total: 2/35 (5.71%), Gastroesophageal reflux disease * 1/35 (2.86%), Ductal carcinoma in situ * 1/35 (2.86%) ',\n",
       " 'Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (ACT), Doxorubicin 60 mg/m2 IV bolus injection in combination with cyclophosphamide 600 mg/m2 IV bolus injection on Day 1 of every 3 weeks for 4 cycles. docetaxel 100 mg/m2 IV infusion every 3 weeks for another 4 cycles. ',\n",
       " 'ductal breast carcinoma in situ (DCIS), or lobular carcinoma in situ (LCIS) (currently without evidence of malignant disease) OR a concern about taking estrogen for fear of breast cancer, Bothersome hot flashes (defined by their occurrence of >= 28 times per week) se inhibitors/serotonin?norepinephrine reuptake inhibitors are allowed. patient must have been on a constant dose for at least 28 days. if patient has history of GERD despite appropriate therapy. symptoms are well-controlled with medical treatment, patient is eligible, patient is eligible, Ulcerative colitis, Narrow-angle glaucoma, Urinary retention, Hypersensitivity to oxybutynin or any other components of the product, Current uncontrolled hyperthyroidism, Coronary heart disease (angina or prior myocardial infarction), congestive heart failure, Symptomatic cardiac arrhythmias, Current uncontrolled hypertension, Myasthenia gravis, Dement ',\n",
       " 'adverse events for all systems are graded on a scale of 1-5 and attribution is assigned. DLT is defined as any incidence of Grade 3 hematologic and non-hematologic toxicity (excluding: fever, hypoxia, and urticaria) if a subject develops a Grade 3 toxicity will be considered excessive toxicity. patients receive cyclophosphamide IV once on day -1 and autologous ex vivo-expanded HER2-specific T cell IV over 30 minutes on day 1. patients receive a booster HER2/neu peptide vaccine 1 month after the final T-cell infusion, followed by 2 additional booster vaccines at 2-month intervals. rade >/= 3, specifically, hepatic events, allergic reactions, thrombocytopenia and hemorrhage events, all Grade >/= 3 AEs related to trastuzumab emtansine. participants received trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression. sian race participants with HER2-positive, unresectable, LABC or mBC had progressed on or after the most recent treatment for LABC or mBC. participants received trastuzumab emtansine every 3 weeks. ',\n",
       " 'patients with histologically documented cancer of the breast or DCIS or head and neck referred for definitive radiation with curative intent. minimum life expectancy of at least 12 months., Aged greater than 20 years., If female, pregnancy excluded., no documented history of collagen vascular disease., Exclusion Criteria:, Cognitively impaired patients, Prisoners, No histology available, Documented metastatic disease, Allergy to Trental, Life expectance of less than 12 months., Aged less tase inhibitors for breast cancer in women and anti-LHRH therapy for prostate cancer in men will be permitted. have a BMI of 25 kg/m2 or greater and weight =400 lbs., Willingness to accept randomization to each of the three arms, Willingness to change diet, physical activity, and weight. prior or planned bariatric surgery, have significant renal disease or dysfunction defined as Estimated glomerular filtration rate (eGFR)45, Have significant renal disease or dysfunction defined as Estimated glomerular filtration rate (eGFR)45, Have significant hepatic dysfunction [Aspartate aminotransferase (AST)/Alanine transaminase (ALT) 2 x upper limit of normal (ULN) or reported liver disease], Self-reported ',\n",
       " 'a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 will be explored and will follow a 6 + 3 dose de-escalation design. participants with one of the following tumor types will be eligible for enrollment. ',\n",
       " 'the primary endpoint will allow to compare the efficacy of the single dose of Extimia® versus nonpegylated daily filgrastim. patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously. Placebo No2 is supplied as solution for injection 0.0083 ml/kg. overall number of participants Analyzed: 43, Mean (Standard Deviation), Unit of Measure: days 0.791 (1.013) empegfilrastim: Empegfilgrastim is to be administered 24 h after the chemotherapy at a dose of 6 mg subcutaneously. Empegfilrastim: Empegfilgrastim is supplied as solution for injection 3 mg/ml. ',\n",
       " 'aprepitant plus standard therapy to placebo plus standard therapy in control of nausea and vomiting during conditioning therapy for autologous or allogeneic hematopoietic stem cell transplantation. retch/emesis free days during the study period, time frame: up to three weeks. ure: Participants 5__ ',\n",
       " 'patients must have histologically confirmed breast cancer that is ER positive and/or PR positive, and HER2/neu negative disease determined using commercially available/approved assay in local institutional or reference laboratory. ER/PR expression performed by standard immunohistochemical assay and classified as ER and/or PR-positive according to ASCO/CAP guidelines (1-100% expression) patients must have had progressive disease during at least one line of endocrine therapy. prior treatments include a non-steroidal aromatase inhibitor, tamoxifen, fulvestrant or combinations. patients taking bisphosphonates for bone disease are permitted to enter the trial. postmenopausal status defined as 60 years and older, 45 years and older, having amenorrhea x 12 months or follicle stimulating hormone levels within postmenopausal range, OR having a bilateral oophorectomy. patients may not be receiving any other investigational agents. having at least 6 weeks of treatment remaining, 21 years old, Able to understand written and spoken English, Able to swallow medication (until amendment omitting armodafinil treatment), Score of 3+ on the Sleep Disruption Evaluation form, OR a score of 8+ on Insomnia Severity Index (ISI), EXCLUSION CRITERIA, Prior treatment with armodafinil or modafinil (until amendment omitting armodafini history of uncontrolled, cardiac disease, hypertension, severe headaches, glaucoma, or seizures (until amendment omitting armodafinil treatment) of chronic, preexisting insomnia, sleep apnea, or restless leg syndrome (RLS) ',\n",
       " 'Adverse Events 1:, Total: 0/344 (0.00%), Adverse Events 2:, Total: 0/342 (0.00%), Adverse Events 2:, Total: 0/24 (0.00%), Adverse Events 2:, Total: 0/24 (0.00%), Adverse Events 2:, Total: 0/344 (0.00%). ',\n",
       " 'dexamethasone 8 mg, Dexamethasone 8 mg pre-operative, Dexamethasone: pre-operative intravenous administration. inTERVENTION 2:, Dexamethasone 24 mg, Dexamethasone 24 mg pre-operative. ',\n",
       " 'postmenopausal breast cancer (adenocarcinoma) estrogen (ER) and/or progesterone (PR) receptor positive that is locally advanced or locally recurrent and not able to be surgically removed OR with measurable and/or disease that is able to be assessed including isolated bone metastasis, Female patients 18 years or older. sient ischemic attacks in the last 6 months, no symptoms of peripheral vascular disease, no history of abdominal fistula, gastrointestinal perforation or intrabdominal abscess in the past 6 months. no known hypersensitivity to phosphate, trehalose or polysorbate, no serious non-healing wound, ulcer or bone fracture. ',\n",
       " 'intraoperative handheld gamma camera (pIHGC) involves injection of 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid around at the tumor site. ',\n",
       " 'Chemotherapy with GM-CSF, Doxorubicin and Cyclophosphamide (AC) followed by Weekly Carboplatin/Nab- PaclitaxelINTERVENTION 1:, Neoadjuvant Chemotherapy, Doxorubicin (Adriamycin) + cyclophosphamide (Cytoxan) with pegfilgrastim or filgrastim growth factor support every 2 weeks for 4 cycles ',\n",
       " 'patients will take Vorinostat daily during radiation therapy. they will be recommended to swallow the capsule 60-90 minutes prior to estimate time of radiation. ',\n",
       " 'all patients receive 3 doses of high-dose Methotrexate (HD-MTX) every 2 weeks given intravenously and 3 doses of Intrathecal (IT) Liposomal Cytarabine (Depocyt) every 2 weeks over 6 weeks. ',\n",
       " 'doxorubicin hydrochloride: Given IV, cyclophosphamide: Given PO, paclitaxel: Given IV, filgrastim: Given SC, capecitabine: Given PO, methotrexate: Given IV, vinorelbine tartrate: Given IV, needle biopsy: Correlative studies, therapeutic conventional surgery: Undergo definitive breast surgery, immunohistochemistry staining method: Correlative studies, trastuzumab: Given ',\n",
       " 'doxorubicin and cyclophosphamide may alter the concentration-time profile of doxorubicin or cyclophosphamide. the effects of doxorubicin and cyclophosphamide on pregnancy are unknown. participants unwilling to comply with study procedures. all other drugs will be reviewed during screening of the patientINCLUSION CRITERIA:, patients with histologically documented:, BRCA-positive ovarian cancer (documented deleterious BRCA1/2 mutation or a BRCAPRO score of greater than or equal to 30%), serous carcinoma or fallopian tube cancer (no requirement for BRCA status), triple-negative breast cancer (documented estrogen receptor (ER) negative, progesterone receptor (PR) negative, and human epidermal patients must have measurable disease defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as greater than or equal to 20 mm with conventional techniques or as greater than or equal to 10 mm with spiral computed tomography (CT scan) any prior therapy or radiotherapy must have been completed greater than or equal to 4 weeks. patients must be greater than or equal to 2 weeks since any investigational agent administered as part of a Phase 0 study. patients who have had prior treatment with any PARP inhibitors are eligible unless the PARP inhibitor was administered in combination with cyclophosphamide. children are excluded from this study. the effects of ABT-888 on the developing human fetus are unknown. cyclophosphamide hydrochloride is known to be teratogenic. women of childbearing potential must agree to use adequate contraception. breastfeeding should be discontinued while the patient is on this trial. there is a risk for adverse events in nursing infants secondary to treatment of the mother with cyclophosphamide. patients with history of central nervous system (CNS) metastases who have received treatment and have had no seizures x 3 months will be eligible. subjects with ulcerative colitis, inflammatory bowel disease, or a partial or complete small bowel obstruction are also excluded. ups are eligible for this trial. ',\n",
       " 'ductal breast carcinoma in situ (DCIS), or lobular carcinoma in situ (LCIS) (currently without evidence of malignant disease) OR a concern about taking estrogen for fear of breast cancer, Bothersome hot flashes (defined by their occurrence of >= 28 times per week) se inhibitors/serotonin?norepinephrine reuptake inhibitors are allowed. patient must have been on a constant dose for at least 28 days. if patient has history of GERD despite appropriate therapy. symptoms are well-controlled with medical treatment, patient is eligible, patient is eligible, Ulcerative colitis, Narrow-angle glaucoma, Urinary retention, Hypersensitivity to oxybutynin or any other components of the product, Current uncontrolled hyperthyroidism, Coronary heart disease (angina or prior myocardial infarction), congestive heart failure, Symptomatic cardiac arrhythmias, Current uncontrolled hypertension, Myasthenia gravis, Dement ',\n",
       " 'treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity. cyclophosphamide, paclitaxel, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab subjects 98 (92.2 to 99.5). subjects 98 (92.2 to 99.5) ',\n",
       " 'Adverse Events 1:, Total: 1/208 (0.48%), Neutrophils/granulocytes (ANC/AGC) 1/208 (0.48%), Adverse Events 2:, Total: 0/201 (0.00%), Neutrophils/granulocytes (ANC/AGC) 0/201 (0.00%)Adverse Events 1:, Total: 0/34 (0.00%) ',\n",
       " 'inTERVENTION 2:, Part 1: Cohort 2a, MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW, inTERVENTION 2:, Part 1: Cohort 2a, MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW. ',\n",
       " 'Capcitabine will be administered twice weekly for 14 days out of every 21 days. treatment cycles will be 21 days in length. 10 additional patients will be treated at the determined MTD. Capecitabine will be paired with LBH589. treatment cycles will be 21 days in length. 10 additional patients will be treated at the determined MTD to further assess safety. ',\n",
       " 'optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W. Durvalumab and tremelimumab were administered as IV infusions over 60 (5) minutes. durvalumab infusions started at least 60 minutes after the end of the tremelimumab infusion on dual dosing days. ',\n",
       " 'Adverse Events 1:, Total: 3/12 (25.00%), Hemoglobin 1/12 (8.33%), Alkaline phosphatase 1/12 (8.33%), Dehydration 1/12 (8.33%), Syncope 2/12 (16.67%), Dyspnea 1/12 (8.33%), Hypotension 1/12 (8.33%)Adverse Events 1:, Total: 0/115 (0.00%), Deep vein thrombosis * [1]0/115 ',\n",
       " 'no evidence of disease outside the breast or chest wall, except ipsilateral axillary lymph nodes. Final eligibility for a clinical trial is determined by the health professionals conducting the trial. ',\n",
       " 'adults with histologically or cytologically confirmed breast adenocarcinoma, radiographic evidence of at least one bone mets, Easter Cooperative Oncology Group status of 0, 1 or 2; adequate organ function, Exclusion Criteria:, Current or prior IV bisphosphonate administration, current or prior oral bisphosphonates for bone mets, life expectancy of less than 6 monthsInclusion Criteria:, Patients must have disease that is metastatic (stage IV), HER2/neu negative disease histologic and/or cytologic confirmation of metastatic disease is encouraged whenever feasible, furthermore, the biopsy should confirm that the primary tumor is ER and/or PR-positive and HER2/neu negative. measurable disease (RECIST 1.1) or non-measurable (assessable) disease, patients must have had progressive disease during at least one line of endocrine therapy for metastatic disease or have recurrent disease while or within 12 months of receiving adjuvant endocrine therapy  patients must have normal organ and marrow function as defined below. postmenopausal status, defined as 60 years and older, being 45 years and older, having amenorrhea x 12 months or follicle stimulating hormone levels within postmenopausal range. on combination of exemestane with everolimus less than 4 weeks prior to study entry and discontinued everolimus due to poor tolerability. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris. ',\n",
       " 'Adverse Events 1:, Total: 11/25 (44.00%), Febrile neutropenia * 4/25 (16.00%), Neutropenia * 3/25 (12.00%), Diarrhoea * 1/25 (4.00%), Intestinal perforation * 1/25 (4.00%), Rectal haemorrhage * 1/25 (4.00%), Stomatitis * 1/25 (4.00%), Vomiting * 1/25 (4.00%), Fatigue * 1/25 (4.00%), ',\n",
       " 'if the patient had received the chemotherapy for breast cancer, it should be finished 30 days before the beginning of the study. if the patient had received the chemotherapy for breast cancer, it should be finished 30 days before the beginning of the study. patients of childbearing potential must implement reliable contraceptive measures during the study treatment, starting 4 weeks prior randomization and for 6 months after the last administration of the study drug. equirements: patient has received two or more chemotherapy regimens for metastatic breast cancer. uropathy, HIV, HCV, HBV, T.Pallidum infection(s);, acute or active chronic infections. patients must have a life expectancy of at least 1 year, excluding cancer diagnosis. patients must have a mass on clinical or radiological examination of >1 cm. bilirubin, serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate oxaloacetate transaminase (SGPT), alkaline phosphatase, and serum creatinine must all be  1.2 x upper limit of normal. patients with benign hyperbilirubinemia are also excluded. patients with non-breast malignancies are eligible if they have not received prior chemotherapy or extensive radiation therapy. patients with squamous or basal carcinoma of the skin that has been effectively treated are eligible. patients with prior or simultaneous lobular or ductal carcinoma in situ of the ipsilateral or contralateral breast are also eligible. patients will agree to continue contraception for 30 days from the date of the last study drug administration. patients who have received prior anthracycline therapy for any malignancy are not eligible. patients with a cardiac arrhythmia are eligible, provided the arrhythmia is not associated with concomitant heart failure or cardiac dysfunction. patients with a cardiac arrhythmia are eligible, provided the arrhythmia is not associated with concomitant heart failure or cardiac dysfunction. ness to give written informed consent. Unwillingness to participate or inability to comply with the protocol for the duration of the study. ',\n",
       " 'Progression Free Survival (PFS) was defined as the time from first study drug dosing (during the maintenance treatment phase) to the first documented disease progression or death, whichever occurred first. Progressive Disease (PD) was defined as a 20 percent increase in the sum of the Longest Diameter (LD) of the target lesions taking as reference the smallest sum LD recorded or appearance of new lesions. ll participants received bevacizumab 15 mg/kg IV on Day 1 of each 3 week cycle for a minimum of 3 cycles and a maximum of 6 cycles or until disease progression, unacceptable toxicity or participant request for withdrawal. participants with an objective response (PR or CR) or SD received 15 mg/kg bevacizumab IV on Day 1 of each 3 week cycle for a minimum of 3 cycles and a maximum of 6 cycles. ek cycle for a minimum of 3 cycles and a maximum of 6 cycles or until disease progression, unacceptable toxicity or withdrawal, whichever occurred first. participants with an objective response were randomized to receive bevacizumab 15 mg/kg IV on Day 1 of each 3-week cycle plus capecitabine 1000 mg/m2 twice daily on Days 1 to 14 of each 3 week cycle. if one of the drugs was discontinued before disease progression, treatment was continued with the second drug until disease progression, unacceptable ',\n",
       " '3/37 (8.11%), Sinus tachycardia 0/37 (0.00%), Heart failure 0/37 (0.00%), Dehydration 1/37 (2.70%), Death Not Associated with CTCAE: Death NOS 1/37 (2.70%), Lymphopenia 1/37 (2.70%), Neutropenia 1/37 (2.70%), Thrombocytopenia 0/37 (0.00%), Hyponatremia 1/37 (2.70%), Weight loss 0/37 ( ',\n",
       " 'Neoadjuvant therapy will consist of epirubicin (100 mg/m2) + cyclophosphamide (600 mg/m2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m2) every 2 weeks for 4 cycles. ',\n",
       " 'anemia 3/75 (4.00%), Febrile Neutropenia 0/75 (0.00%), Neutrophil Count 1/75 (1.33%), Chest Pain 0/75 (0.00%), Diarrhea 1/75 (1.33%), Dry Mouth 1/75 (1.33%), Mucositis Oral 1/75 (1.33%), Fatigue 1/75 (1.33%), Pain 1/75 (1.33%), Bladder Infection 1/75 (1.33%), Adverse Events ',\n",
       " 'patients will be instructed to apply a thin layer of the Hydrophor daily. the application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. patients should not apply the Hydrophor within 4 hours of receiving RT. Medihoney application should include the entire treatment area. patients should not apply the Medihoney within 4 hours of receiving RT. patients should wash the application area daily with perfume-free soap and tap water. each treatment cycle was defined as 21 days. participants received intravenous infusion of PF-05212384 90 mg once on Day -7 and Cycle 1 Day 2. participants received docetaxel 75 mg/m2 1-hour IV infusion once. the maximum duration of PF-05212384 treatment was 505 days. the maximum duration of docetaxel treatment was 445 days. ',\n",
       " 'oral lapatinib, oral tamoxifen citrate, given orally, citrate, given orally. lapatinib ditosylate, given orally, citrate, given orally. ',\n",
       " 'Adverse Events 1:, Total: 0/34 (0.00%), Adverse Events 2:, Total: 0/27 (0.00%), Adverse Events 2:, Total: 0/27 (0.00%) ',\n",
       " 'unilateral breast cancer with ipsilateral lumpectomy or mastectomy and lymph node dissection (sentinel biopsy or axillary dissection), stage II or III unilateral secondary upper extremity lymphedema. girth 2 cm circumferential difference and/or volume 200 mL compared to the uninvolved upper extremity at any 4 cm segment. 0 (morbid obesity) ',\n",
       " 'Isothiocyanate included sulforaphane in micromolar (M) concentration was measured following standard chemical measurement procedures and divided by creatinine values in millimolar (mM) concentration. patients receive oral placebo supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity. Numeric Pain Rating Scale - pain rating scale 0-10 (0= no pain to 10= most pain imaginable) participants were re-assessed after the 2 round of TC and 4th round of FECD. atment, Overall Number of Participants Analyzed: 22, Measure Type: Number, Unit of Measure: percentage of participants Percentage of Participants with Pain (1-10): 30, Percentage of Participants with no pain (0): 70, Results 2:, Arm/Group Title: Control, Arm/Group Description: chemotherapy as usual without physical therapy. ',\n",
       " 'participants with metastatic breast cancer received a loading dose of 4 milligrams per kilograms (mg/kg) of trastuzumab intravenously (IV) followed by 2 mg/kg of trastuzumab IV once a week along with docetaxel 100 milligrams per meter square (mg/m2), every 3 weeks or paclitaxel 90 mg/m2 once a week. Herceptin 2 mg/kg by IV infusion weekly starting from Day 8. docetaxel 100 mg/m2 IV infusion on Day 2 of cycle 5. after completion of last cycle of chemotherapy, Herceptin 6 mg/kg IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose. ',\n",
       " 'women were instructed to do slow, deep, abdominal breathing in through the nose and out through the mouth as per international recommendations. the second and third tracks contained specially composed, digitally recorded music to help entrain the breath rate and structure the length of practice. erall number of participants Analyzed: 88, Mean (Standard Deviation), Unit of Measure: Hot flashes per 24 hr 3.48 (3.45), Results 2:, Arm/Group Title: Fast, Shallow Breathing, Arm/Group Description: The fast, shallow comparator group received a digital videodisc with paper booklet. ',\n",
       " 'if the patient had received the chemotherapy for breast cancer, it should be finished 30 days before the beginning of the study. if the patient had received the chemotherapy for breast cancer, it should be finished 30 days before the beginning of the study. patients of childbearing potential must implement reliable contraceptive measures during the study treatment, starting 4 weeks prior randomization and for 6 months after the last administration of the study drug. equirements: patient has received two or more chemotherapy regimens for metastatic breast cancer. uropathy, HIV, HCV, HBV, T.Pallidum infection(s);, acute or active chronic infections. patients must have a life expectancy of at least 1 year, excluding cancer diagnosis. patients must have a mass on clinical or radiological examination of >1 cm. bilirubin, serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate oxaloacetate transaminase (SGPT), alkaline phosphatase, and serum creatinine must all be  1.2 x upper limit of normal. patients with benign hyperbilirubinemia are also excluded. patients with non-breast malignancies are eligible if they have not received prior chemotherapy or extensive radiation therapy. patients with squamous or basal carcinoma of the skin that has been effectively treated are eligible. patients with prior or simultaneous lobular or ductal carcinoma in situ of the ipsilateral or contralateral breast are also eligible. patients will agree to continue contraception for 30 days from the date of the last study drug administration. patients who have received prior anthracycline therapy for any malignancy are not eligible. patients with a cardiac arrhythmia are eligible, provided the arrhythmia is not associated with concomitant heart failure or cardiac dysfunction. patients with a cardiac arrhythmia are eligible, provided the arrhythmia is not associated with concomitant heart failure or cardiac dysfunction. ness to give written informed consent. Unwillingness to participate or inability to comply with the protocol for the duration of the study. ',\n",
       " 'Response Evaluation Criteria in Solid Tumors (RECIST) criteria to evaluate tumor response after 24 doses. Complete Response (CR)= disappearance of all target lesions, Partial Response (PR) = at least 30% decrease in sum of longest diameter of target lesions, Progressive Disease = at least 25% increase in sum of longest diameter of target lesions. patients receive oral letrozole once daily for 12 months in absence of disease progression or unacceptable toxicity. letrozole is given orally, given orally, given zoledronic acid. ',\n",
       " '0/4 (0.00%), Anaemia 0/4 (0.00%), Febrile neutropenia 0/4 (0.00%), Leukocytosis 0/4 (0.00%), Neutropenia 0/4 (0.00%), Pancytopenia 0/4 (0.00%), Acute coronary syndrome 0/4 (0.00%), Atrial fibrillation 0/4 (0.00%), Cardiac arrest 0/4 (0.00%), Pericardial effusion 0/4 (0.00%), Ad ',\n",
       " '0/21 (0.00%)Adverse Events 1:, Total: 3/8 (37.50%), Anaemia 0/8 (0.00%), Febrile neutropenia 0/8 (0.00%), Polycythaemia 0/8 (0.00%), Acute coronary syndrome 0/8 (0.00%), Vertigo 0/8 (0.00%), Eyelid oedema 1/8 (12.50%), Constipation 0/8 (0.00%), Diarrhoea 0/8 ',\n",
       " 'result at baseline minus result at baseline as a percentage of the result at baseline. back transformation of the least squares mean based on log transformed data. ',\n",
       " 'adverse events for all systems are graded on a scale of 1-5 and attribution is assigned. DLT is defined as any incidence of Grade 3 hematologic and non-hematologic toxicity (excluding: fever, hypoxia, and urticaria) if a subject develops a Grade 3 toxicity will be considered excessive toxicity. patients receive cyclophosphamide IV once on day -1 and autologous ex vivo-expanded HER2-specific T cell IV over 30 minutes on day 1. patients receive a booster HER2/neu peptide vaccine 1 month after the final T-cell infusion, followed by 2 additional booster vaccines at 2-month intervals. rade >/= 3, specifically, hepatic events, allergic reactions, thrombocytopenia and hemorrhage events, all Grade >/= 3 AEs related to trastuzumab emtansine. participants received trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression. sian race participants with HER2-positive, unresectable, LABC or mBC had progressed on or after the most recent treatment for LABC or mBC. participants received trastuzumab emtansine every 3 weeks. ',\n",
       " 'inTERVENTION 1:, Zoledronic Acid, Zoledronic acid, vitamin D and calcium supplements, plus Sr-89 or Sm-153. ',\n",
       " 'Variation in Serum Levels of Follicle Stimulating Hormone (FSH) compare to natural physiological variability (screening-baseline variation), Time frame: from baseline to 12 weeks of treatment. lacebo, Overall Number of Participants Analyzed: 11, Median (Inter-Quartile Range), Unit of Measure: mIU/ml 1.4 (-5.4 to 15.7)Outcome Measurement:, Ruxolitinib MTD in combination with paclitaxel 80 mg/m2 intravenously (IV) weekly is determined by the number of patients who have dose limiting toxicity (DLT) the observation period for MTD evaluation was the first 2 cycles of treatment. participants with stable disease or better will have the opportunity to continue on single agent Ruxolitinib. ',\n",
       " 'intravascular coagulation * 1/32 (3.13%), Febrile neutropenia * 1/32 (3.13%), Adrenal insufficiency * 1/32 (3.13%), Endocrine disorder * 1/32 (3.13%), Chills * 1/32 (3.13%), Fatigue * 1/32 (3.13%), Fever * 1/32 (3.13%), Multi-organ failure * 1/32 (3.13%), Hepatic failure * 1/32 (3.13%), Infection * 1/32 (3.13%), Sepsis 0/5 (0.00%), Platelet count decreased 0/5 (0.00%), Dehydration 1/5 (20.00%), Dysarthria 0/5 (0.00%). ',\n",
       " 'Adverse Events 1:, Total: 0/4 (0.00%), Adverse Events 2:, Total: 0/5 (0.00%), Lymphoma [1]1/50 (2.00%), Adverse Events 2:, Total: 0/11 (0.00%), Lymphoma [1]0/11 (0.00%) ',\n",
       " \"breast tumor 1 centimeter (cm) in diameter, HR+, HER2-. neoadjuvant endocrine monotherapy is deemed to be a suitable therapy. measurable disease, Bone metastases requires other disease present that can be measured. no brain metastases, unless documented to be controlled post-completion of local therapy for at least 4 weeks, no meningeal carcinomatosis, no malignant effusion as the only site. hat in the opinion of the treating physician would make study protocol unreasonably hazardous for the patient. hat in the opinion of the treating physician would make study protocol unreasonably hazardous for the patient or would preclude the patient's ability to comply with the study protocol. \",\n",
       " 'patients must have had exposure to at least 1 and no more than 3 prior chemotherapy regimens for the treatment of metastatic breast cancer. must have tissue (excluding bone or brain) that is amenable to biopsy, ECOG performance status 0-1, Life expectancy of greater than 3 months. all prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events version 4 (CTCAE v4) grade = 1 (except alopecia) at the time of enrollment, Absolute neutrophil count >= 1,500/mcL, Platelets >= 75,000/mcL, Total bilirubin = 1.5  institutional upper limit of normal, Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal by echocardiogram (ECHO) or patients must be at least 4 weeks from last surgical procedure and recovered from all post-operative complications. women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study. patients with symptomatic or progressive brain metastases are ineligible. subjects with treated brain metastases are eligible if they have no radiographic or other signs of progression in the brain for >= 3 weeks. any corticosteroid use for brain metastases must have been discontinued without the subsequent appearance of symptoms for >= 3 weeks prior to study enrollment. history of allergic reactions attributed to compounds of similar chemical or biologic composition to trametinib monotherapy or trametinib in combination with GSK2141795, Current use of a prohibited medication. uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, history of hyperviscosity or hypercoagulability syndromes. visible retinal pathology as assessed by ophthalmic exam is considered a risk factor for RVO or CSR. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit ',\n",
       " 'subjects received a single bolus IV injection of 5 mg/kg FMX (up to 510 mg) on day 1. subjects received up to 70 mg/m2 MM-398 FBE (C1D1) administered as an IV infusion over 90 minutes, repeated every 2 weeks until disease progression. ',\n",
       " 'Adverse Events 1:, Total: 8/30 (26.67%), Heart Failure 1/30 (3.33%), Vertigo 1/30 (3.33%), Small intestinal obstruction 1/30 (3.33%), Fever 1/30 (3.33%), Aspartate aminotransferase increased 1/30 (3.33%), Alanine aminotransferase increased 1/30 (3.33%), Back Pain 1/30 (3.33%), Pleural effusion 1/30 (3.33%), Rash maculo-papular 1/30 (3.33%) ',\n",
       " \"breast tumor 1 centimeter (cm) in diameter, HR+, HER2-. neoadjuvant endocrine monotherapy is deemed to be a suitable therapy. measurable disease, Bone metastases requires other disease present that can be measured. no brain metastases, unless documented to be controlled post-completion of local therapy for at least 4 weeks, no meningeal carcinomatosis, no malignant effusion as the only site. hat in the opinion of the treating physician would make study protocol unreasonably hazardous for the patient. hat in the opinion of the treating physician would make study protocol unreasonably hazardous for the patient or would preclude the patient's ability to comply with the study protocol. \",\n",
       " 'patients must have histologically confirmed breast cancer that is ER positive and/or PR positive, and HER2/neu negative disease determined using commercially available/approved assay in local institutional or reference laboratory. ER/PR expression performed by standard immunohistochemical assay and classified as ER and/or PR-positive according to ASCO/CAP guidelines (1-100% expression) patients must have had progressive disease during at least one line of endocrine therapy. prior treatments include a non-steroidal aromatase inhibitor, tamoxifen, fulvestrant or combinations. patients taking bisphosphonates for bone disease are permitted to enter the trial. postmenopausal status defined as 60 years and older, 45 years and older, having amenorrhea x 12 months or follicle stimulating hormone levels within postmenopausal range, OR having a bilateral oophorectomy. patients may not be receiving any other investigational agents. having at least 6 weeks of treatment remaining, 21 years old, Able to understand written and spoken English, Able to swallow medication (until amendment omitting armodafinil treatment), Score of 3+ on the Sleep Disruption Evaluation form, OR a score of 8+ on Insomnia Severity Index (ISI), EXCLUSION CRITERIA, Prior treatment with armodafinil or modafinil (until amendment omitting armodafini history of uncontrolled, cardiac disease, hypertension, severe headaches, glaucoma, or seizures (until amendment omitting armodafinil treatment) of chronic, preexisting insomnia, sleep apnea, or restless leg syndrome (RLS) ',\n",
       " 'results 1:, Arm/Group Title: Arm 1: Paclitaxel + Trastuzumab Then A C, Arm/Group Description: 4 cycles of paclitaxel 80 mg/m2 on days 1, 8 and 15 of a 28-day cycle. follow paclitaxel/trastuzumab, standard AC every 21 days for 4 cycles. Neratinib 240 mg orally once daily beginning on Day 1 of paclitaxel. standard AC every 21 days for 4 cycles. following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy. ',\n",
       " 'change in Ki67 expression in tumors with 7 days of pre-surgical tamoxifen. all patients will take tamoxifen 20 mg po daily for 7 days prior to surgery. ',\n",
       " 'participants will be excluded for:, any active neurologic and/or psychiatric disease, history of significant head trauma followed by persistent neurologic deficits, or known structural brain abnormalities. current major depression or another major psychiatric disorder as described in DSM-5 criteria. lness or unstable medical condition which could lead to difficulty complying with protocol including: history of myocardial infarction in the past year or unstable, severe cardiovascular disease including angina or CHF with symptoms at rest. clinically significant and/or unstable pulmonary, gastrointestinal, hepatic, or renal disease, Insulin-requiring diabetes or uncontrolled diabetes mellitus, uncontrolled hypertension. AST and ALT 3 times upper limit of normal (ULN), Bilirubin 3 times ULN, alkaline phosphatase 3 times ULN, Creatinine 2 mg/dL, no known hypersensitivity to any component of the study regimen, PRIOR CONCURRENT THERAPY:, no chronic therapeutic warfarin > 1 mg dose per day, no other concurrent investigational agents, no concurrent oral contraceptives (except for stopping menses) ',\n",
       " 'Hemoglobin decreased 2/30 (6.67%), Abdominal pain 1/30 (3.33%), Colitis 1/30 (3.33%), Diarrhea 7/30 (23.33%), Nausea 2/30 (6.67%), Rectal hemorrhage 1/30 (3.33%), Fatigue 1/30 (3.33%), Skin infection 1/30 (3.33%), Neutrophil count decreased 1/30 (3.33%), Platelet count decreased 3/30 (10.00%), Dehydration 1/30 (3.33%) holelithiasis 0/6 (0.00%), Hepatic pain 1/6 (16.67%), Bacteraemia 0/6 (0.00%) holelithiasis 0/6 (0.00%), Hepatic pain 1/6 (16.67%), bacteraemia 0/6 (0.00%) ',\n",
       " \"if a taxane had been administered in the neoadjuvant or adjuvant setting, progression must have occurred >12 months after completion of this treatment. radiotherapy as palliative treatment for painful metastatic disease is permitted but must have been stopped within 2 weeks prior to any investigational treatment. ning disease is considered to be inapplicable to hormonal therapy. ning disease must have been stopped before the first dose of investigational treatment. an investigational drug within 30 days or five half-lives preceding the first dose of investigational treatment. unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or prior anti-cancer treatment. subjects with ulcerative colitis are excluded. metastases or leptomeningeal carcinomatosis would make subject inappropriate for study participation or any serious medical disorder that would interfere with subject's safety. subject must have histologically confirmed invasive breast cancer with Stage IV disease at primary diagnosis or at relapse after curative-intent surgery. neoplastic nature of the disease should have been confirmed by cytology or histology. subjects must have received no more than one prior chemotherapeutic regimen in the metastatic setting. prior therapy with radiation for this breast cancer population was permitted if it was administered in the neoadjuvant or adjuvant non metastatic setting. subject must have completed radiation treatment and recovered from all related toxicities. subject must have received all prior chemo treatment at least 4 weeks prior to enrollment in this study. prior therapy with trastuzumab in the neoadjuvant, adjuvant or metastatic setting was permitted. prior diagnosis of cancer was allowed as long as the subject was free of disease for 5 years. subjects with completely resected basal or squamous cell skin cancer, thyroid cancer or successfully treated cervical carcinoma in-situ were allowed into the study. women with oligomenorrhoea (severe), women who were perimenopausal and young women who had begun to menstruate must provide a negative serum pregnancy test at Screening. subjects must provide a negative serum pregnancy test and agree to 1 of the following: Complete abstinence from intercourse from 2 weeks prior to administration of the first dose of study medication until 5 days after the final dose of study medication. e Investigator to have a life expectancy of 6 months. Subjects must have had normal organ and marrow function as below. subject must have been free of gastrointestinal diseases that impede swallowing and retaining oral medications. bisphosphonate therapy for bone metastases was allowed; treatment must be initiated prior to the first dose of study medication. subjects without bone disease, except for osteoporosis, were included in the study if they met the following criteria. subjects who received more than one prior chemotherapeutic regimen were not eligible for the study. this included human immunodeficiency virus-positive subjects receiving combination anti-retroviral therapy because of possible pharmacokinetic interactions with lapatinib. uncontrolled inter-current illness includes, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would have limited compliance with study requirements. subjects with diseases affecting gastrointestinal function resulting in an inability to take oral medication. ation, prior surgical procedures affecting absorption e.g. gastric resection and uncontrolled inflammatory bowel disease (e.g., Crohn's, ulcerative colitis). subjects who had been disease-free for 5 years, or subjects with completely resected basal or squamous cell skin cancer, thyroid cancer or successfully treated cervical carcinoma in situ were eligible if it had been at least 1 year since definitive surgery. clinical investigator's Brochure (IB), SPM, and the nab-paclitaxel product label. \",\n",
       " 'inTERVENTION 2:, Part 1 and Part 2: Talazoparib (Ovarian/ Peritoneal Cancer) Participants with ovarian/ peritoneal cancer who received talazoparib capsules in Part 1 and 2 at a dose of either 600 mcg/day, 900 mcg/day, 1000 mcg/day, 1100 mcg/day. ',\n",
       " '0/3 (0.00%)Adverse Events 1:, Total: 4/14 (28.57%), Duodenitis [1]1/14 (7.14%), Gastrooesophageal reflux disease [1]1/14 (7.14%), Vomiting [1]1/14 (7.14%), Ascites [1]1/14 (7.14%), Death [1]1/14 (7.14%), Asthenia [1]1/14 (7.14%), general physical health deterioration [1]1/14 ',\n",
       " 'Progression Free Survival (PFS) was defined as the time from first study drug dosing (during the maintenance treatment phase) to the first documented disease progression or death, whichever occurred first. Progressive Disease (PD) was defined as a 20 percent increase in the sum of the Longest Diameter (LD) of the target lesions taking as reference the smallest sum LD recorded or appearance of new lesions. ll participants received bevacizumab 15 mg/kg IV on Day 1 of each 3 week cycle for a minimum of 3 cycles and a maximum of 6 cycles or until disease progression, unacceptable toxicity or participant request for withdrawal. participants with an objective response (PR or CR) or SD received 15 mg/kg bevacizumab IV on Day 1 of each 3 week cycle for a minimum of 3 cycles and a maximum of 6 cycles. ek cycle for a minimum of 3 cycles and a maximum of 6 cycles or until disease progression, unacceptable toxicity or withdrawal, whichever occurred first. participants with an objective response were randomized to receive bevacizumab 15 mg/kg IV on Day 1 of each 3-week cycle plus capecitabine 1000 mg/m2 twice daily on Days 1 to 14 of each 3 week cycle. if one of the drugs was discontinued before disease progression, treatment was continued with the second drug until disease progression, unacceptable ',\n",
       " 'Isothiocyanate included sulforaphane in micromolar (M) concentration was measured following standard chemical measurement procedures and divided by creatinine values in millimolar (mM) concentration. patients receive oral placebo supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity. Numeric Pain Rating Scale - pain rating scale 0-10 (0= no pain to 10= most pain imaginable) participants were re-assessed after the 2 round of TC and 4th round of FECD. atment, Overall Number of Participants Analyzed: 22, Measure Type: Number, Unit of Measure: percentage of participants Percentage of Participants with Pain (1-10): 30, Percentage of Participants with no pain (0): 70, Results 2:, Arm/Group Title: Control, Arm/Group Description: chemotherapy as usual without physical therapy. ',\n",
       " 'menopausal: 12 months spontaneous amenorrhea or > 6 but  12 months amenorrhea with a serum follicle stimulating hormone (FSH) level of > 40 mIU/mL. able to read, understand and complete the required subject diary. legal incapacity or limited legal capacity. chronic renal (serum creatinine > 2.0 mg/dL) or hepatic disease. untreated overt hyperthyroidism. rmal (a subject will not be excluded if a second measurement is less than twice the upper limit of normal), Creatinine > 2.0 mg/dLInclusion Criteria: adult patients, >=18 years of age; HER2-negative metastatic breast cancer candidates for taxane-based chemotherapy; ECOG performance status of 0 or 1. ',\n",
       " 'the outcome is reported as the proportion of subjects with a discernible pattern for expression of the set of 40 evaluated genes. the outcome is reported as the proportion of subjects with a discernible pattern for expression of the set of 40 evaluated genes. ',\n",
       " 'blood bilirubin increased 1/11 (9.09%), Febrile neutropenia [1]1/11 (9.09%), Ejection fraction decreased 1/11 (9.09%), Supraventricular and nodal arrhythmia::Sinus tachycardia 1/11 (9.09%), Lymphocyte count decreased 1/11 (9.09%), Neutrophil count decreased 1/11 (9.09%), Neutrophils/granulocytes (ANC/AGC) 1/11 (9.09 ',\n",
       " 'the investigator must confirm postmenopausal status. postmenopausal status is defined either by:, age 55 years and one year or more of amenorrhea, age  55 years and one year or more of amenorrhea and postmenopausal levels of FSH and LH per local institutional standards. non-steroidal aromatase inhibitors (i.e. letrozole or anastrozole) do not have to be the last treatment prior to enrollment. other prior anticancer therapy, e.g. tamoxifen, fulvestrant, exemestane are also allowed. serum bilirubin 1.5  ULN, fasting serum cholesterol 300 mg/dl or 7.75 mmol/L and fasting triglycerides 2.5  ULN. alanine aminotransferase (ALT) 2.5  ULN (or 5 if hepatic metastases are present). patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose galactose malabsorption must have recovered from radiotherapy toxicities prior to enrollment. radiotherapy within four weeks prior to enrollment except in case of localized radiotherapy for analgesic purpose. patients with symptomatic visceral metastasis (e.g. significant dyspnoea related to pulmonary lymphangitic carcinomatosis and lung metastases), symptomatic brain or other central nervous system metastases (CNS) metastases. active, bleeding diathesis, or on oral anti-vitamin K medication. uncontrolled or whose control may be jeopardized by the complications of this study therapy. pulmonary function tests should be considered to exclude restrictive pulmonary disease, pneumonitis or pulmonary infiltrates. patients being treated with drugs recognized as strong inhibitors or inducers of the isoenzyme CYP3A. patients must have metastatic breast cancer; tissue (a minimum of 3 slides) from most recent biopsy is required for review and confirmation of eligibility. patients must have stage IV breast cancer, patients must have metastatic tumors (primary or metastatic) that stain positively for the prolactin receptor. women of childbearing potential must commit to the use of effective barrier (non-hormonal) contraception while on study. patients must have a life expectancy of greater than 12 weeks. patients must have a life expectancy of greater than 12 weeks. patients may have had a prior diagnosis of cancer if it has been > 5 years since their last treatment. systemic treatment is allowed with a 2 week washout period prior to registration. patients who are taking herbal (alternative) medicines are NOT eligible for participation. patients must be off any such medications by the time of registration. nary, pericardial, cardiac valvular, or retroperitoneal fibrotic disorders, Gastrointestinal (GI) tract disease resulting in an inability to take oral medication, Malabsorption syndrome, Require intravenous (IV) alimentation, Uncontrolled inflammatory GI disease. ',\n",
       " 'a higher serum total bilirubin ( 2 x ULN) is allowed, aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 2.5 times ULN, Alkaline phosphatase 2.5 times ULN, Renal status: Creatinine. patients must use effective contraception (barrier method - condoms, diaphragm - also in conjunction with spermicidal jelly, or total abstinence) patient accepts to make available tumour samples for submission to central laboratory to conduct translation studies. han 10 years prior to randomisation may enter the study. patients must have been curatively treated with surgery alone. prior diagnoses of breast cancer or melanoma are excluded. subjects with ulcerative colitis are also excluded. subjects with ulcerative colitis are also excluded. rdiogram (ECG), 18 years of age or above, Able to understand and sign informed consent, Pilot study only:, CRC, TNBC, ER/PR Breast Cancer, NSCLC, Pancreatic Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal Junction (GEJ) adenocarcinoma, Head and Neck Cancer, Expansion Phase Additional Criteria:, Locally advanced or metastatic breast cancer, Received at least one cytotoxic xytol, Inability to undergo MRI, Active infection, Pregnant or breast feeding, Prior chemotherapy administered within 3 weeks, or within a time interval less than at least 5 half-lives of the agent. prior to the first scheduled day of dosing in this study, received radiation therapy in the last 14 days, Treated with parenteral iron in the previous 4 weeks. ',\n",
       " 'Adverse Events 1:, Total: 0/34 (0.00%), Adverse Events 2:, Total: 0/27 (0.00%), Adverse Events 2:, Total: 0/27 (0.00%) ',\n",
       " 'Adverse Events 1:, Total: 8/30 (26.67%), Heart Failure 1/30 (3.33%), Vertigo 1/30 (3.33%), Small intestinal obstruction 1/30 (3.33%), Fever 1/30 (3.33%), Aspartate aminotransferase increased 1/30 (3.33%), Alanine aminotransferase increased 1/30 (3.33%), Back Pain 1/30 (3.33%), Pleural effusion 1/30 (3.33%), Rash maculo-papular 1/30 (3.33%) ',\n",
       " 'patients receive doxorubicin HCl liposome IV 40mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28. inTERVENTION 2:, Placebo, Arm II: Patients receive doxorubicin HCl liposome IV 40mg/m2 over 1 hour on day 1. ',\n",
       " 'participants continued treatment until progressive disease (PD), unacceptable toxicity, required palliative radiotherapy or surgical intervention of lesion(s) participants continued treatment until progressive disease (PD), unacceptable toxicity, required palliative radiotherapy or surgical intervention of lesion(s), withdrawal from study treatment, withdrawal of study consent, participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment. study treatment, withdrawal of study consent, participant refusal or investigator felt it was no longer in the best interest of the participant to continue on treatment. ',\n",
       " 'Suramin and Paclitaxel will be infused weekly over 30 minutes. four hours after the completion of the suramin infusion the 1 hour infusion of paclitaxel will begin. ',\n",
       " 'prior anthracycline, taxane, and capecitabine therapy may have been as neoadjuvant, or adjuvant therapy. prior anthracycline and taxane therapy may have been as neoadjuvant, or adjuvant therapy if disease progression is documented within a year. in normal or hyperbilirubinemia  grade 1 (unless due to Gilbert syndrome with elevated total but normal levels of conjugated bilirubin) not pregnant or nursing, Fertile patients must use effective contraception, No other non-breast malignancy, except nonmelanoma skin cancer, No other serious underlying medical condition, that would make study protocol unreasonably hazardous for the patient. pitant_ ',\n",
       " 'inTERVENTION 1:, arm II, Patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1. oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3. r IV, dexamethasone: Given orally or IV, dexamethasone: Given orally or IV, dexamethasone: Given orally or IV, dexamethasone: Given orally or IV, dexamethasone: Given orally orally or IV, dexamethasone: Given orally orally or IV, dexamethasone: Given orally orally or IV, dexamethasone: Given orally orally ',\n",
       " 'patient must have histologically or cytologically confirmed locally advanced, unresectable or metastatic carcinoma of the breast. patient must have performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) performance scale and life expectancy > 3 months. female patient of childbearing potential must have a negatio. ve serum or urine pregnancy test quantitative human chorionic gonadotropin (-hCG) within 72 hours prior to receiving the first dose of study medication is allowed. patients with stable and clinically insignificant CNS disease are allowed. patients must be off steroids with no new CNS symptoms. bevacizumab, hormone therapy within one week, trastuzumab within 2 weeks or lapatinib within one week of study Day 1. patients with known active central nervous system metastases and/or carcinomatous meningitis eligible for study. patients with clinically insignificant brain metastases that do not require treatment are eligible. clinically significant cardiac arrhythmia, history or current evidence of a myocardial infarction during the last 6 months, and/or a current ECG tracing that is abnormal in the opinion of the treating Investigator. patients with other active, current primary malignancies, other than carcinoma in situ of the cervix or non-melanoma skin cancer. ',\n",
       " 'pain intensity was assessed using a 0-100 mm visual analog scale. 0 represented \"no pain\" and 100 represented \"worst possible pain\" at 0. SPID30 was calculated as the time-weighted sum of the PID scores. patients received a dose of 100 to 1600 g determined in the open-label dose titration period of the current study. overall number of participants Analyzed: 92, Mean (Standard Deviation), Unit of Measure: Units on a scale 640.3 (458.8), Results 2:, Arm/Group Title: Placebo, Arm/Group Description: Participants received placebo 3 times randomly (out of 10 treatments total) to treat up to a maximum of 2 breakthrough pain episodes per day the effect of zoledronic acid administered every 6 months on bone loss associated with surgery is to be evaluated by measuring the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine. beginning 60-90 days after surgery, patients receive zoledronate IV over 15 minutes once in months 3, 9 and 15. Mean (Full Range), Unit of Measure: g/cm2 -0.086 (-0.308 to 0.067). ',\n",
       " 'doxorubicin hydrochloride: Given IV, cyclophosphamide: Given PO, paclitaxel: Given IV, filgrastim: Given SC, capecitabine: Given PO, methotrexate: Given IV, vinorelbine tartrate: Given IV, needle biopsy: Correlative studies, therapeutic conventional surgery: Undergo definitive breast surgery, immunohistochemistry staining method: Correlative studies, trastuzumab: Given ',\n",
       " '0/33 (0.00%)Adverse Events 1:, Total: 5/16 (31.25%), ANAEMIA 1/16 (6.25%), LEUKOPENIA 1/16 (6.25%), NEUTROPENIA 3/16 (18.75%), THROMBOCYTOPENIA 1/16 (6.25%), FEBRILE INFECTION 1/16 (6.25%), PNEUMONIA 1/16 (6.25%), PNEUMONIA 1/16 (6.25%), PNEUMONIA 1/16 ( ',\n",
       " 'Stratum 1 (AC->T + Bevacizumab), HER2-negative participants administered, doxorubicin and cyclophosphamide (AC) + bevacizumab for 4 cycles followed by, docetaxel (T) + bevacizumab for 4 cycles followed by, bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed. ',\n",
       " 'Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W, Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W, INTERVENTION 2:, Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W. ',\n",
       " 'inTERVENTION 1:, Imaging Session 1, Fluciclatide Injection (AH111585 (18F) Injection)INTERVENTION 1:, Chloroquine Standard Dose (500mg/week) patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month standard dose chloroquine (500 mg/week) patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month low dose chloroquine (250mg/week) for 1 month prior to surgical removal of the DCIS lesion. this biopsy is entirely voluntary and is not required to remain in the study. ',\n",
       " 'Hemoglobin decreased 2/30 (6.67%), Abdominal pain 1/30 (3.33%), Colitis 1/30 (3.33%), Diarrhea 7/30 (23.33%), Nausea 2/30 (6.67%), Rectal hemorrhage 1/30 (3.33%), Fatigue 1/30 (3.33%), Skin infection 1/30 (3.33%), Neutrophil count decreased 1/30 (3.33%), Platelet count decreased 3/30 (10.00%), Dehydration 1/30 (3.33%) holelithiasis 0/6 (0.00%), Hepatic pain 1/6 (16.67%), Bacteraemia 0/6 (0.00%) holelithiasis 0/6 (0.00%), Hepatic pain 1/6 (16.67%), bacteraemia 0/6 (0.00%) ',\n",
       " 'all subjects treated under this protocol will have histologically documented cancer of one of the following types:, A. Metastatic breast cancer (7 triple negative, 23 ER+ after the first 15 patients are enrolled on the non-CCND1cohort; in addition 10 HER2+ for combination trastuzumab and PD0332991 therapy) up to 55 total enrollment slots B. Advanced or metastatic esophageal and/or gastric cancer (15-30 enrollment slots) D. Cisplatin subjects will be > 18 years old, The subject has disease that is assessable by tumor marker, physical, or radiologic means. the subject has an Eastern Cooperative Oncology Group performance status of 0 or 1. subject is capable of understanding and complying with protocol requirements. sexually active subjects (male and female) must use accepted methods of contraception. female subjects of childbearing potential must have negative pregnancy test at screening. patients with HER2-overexpressing tumors may receive trastuzumab. subject has received any other type of investigational agent within 28 days. subject has not recovered from clinically-meaningful toxicity due to prior therapy. subject has untreated or uncontrolled brain metastases. the subject has a baseline corrected QT interval (QTc) > 470 ms. the subject is known to be positive for the human immunodeficiency virus. ',\n",
       " \"2.3 Dental evaluation according to the dental exam checklist (carried out by the investigator, the investigator's designee, or by a qualified dental professional [dental hygienist or dentist]) if the patient has received prior oral bisphosphonate therapy within 8 weeks of registration, the evaluation should not be revoked. complete blood count (CBC)/differential within 2 weeks prior to registration, with adequate bone marrow function defined as follows: White blood cell count (WBC) 2400 cells/mm3; Absolute neutrophil count (ANC) 1,800 cells/mm3; Platelets 60,000 cells/mm3; Hemoglobin 8.0 g/dl (Note: The use of transfusion or other intervention to achieve the required hemoglobin is permitted) beam radiation therapy must be completed 14 days prior to registration. patients with no evidence of disease in the brain after treatment for brain metastases are eligible. prior treatment with Strontium-89 or Samarium-153 for bone metastases. prior treatment with IV bisphosphonates prior to study entry. current, active dental problems within 4 weeks of registration. the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. pregnant or lactating patients are excluded as treatment may be harmful to embryos and/or nursing infants. the study should be finished 30 days before the beginning of the study. if the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose of anthracyclines should not exceed 250 mg/m2 for doxorubicin or 540 mg/m2 for epirubicin. n or 660 mg/m2 for epirubicin, if in this study planned 4 cycles of chemotherapy. patients of childbearing potential must implement reliable contraceptive measures. f bone metastases) administration of any experimental drugs within 30 days prior randomization. conditions limiting patient's ability to follow protocol. \",\n",
       " \"if a taxane had been administered in the neoadjuvant or adjuvant setting, progression must have occurred >12 months after completion of this treatment. radiotherapy as palliative treatment for painful metastatic disease is permitted but must have been stopped within 2 weeks prior to any investigational treatment. ning disease is considered to be inapplicable to hormonal therapy. ning disease must have been stopped before the first dose of investigational treatment. an investigational drug within 30 days or five half-lives preceding the first dose of investigational treatment. unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or prior anti-cancer treatment. subjects with ulcerative colitis are excluded. metastases or leptomeningeal carcinomatosis would make subject inappropriate for study participation or any serious medical disorder that would interfere with subject's safety. subject must have histologically confirmed invasive breast cancer with Stage IV disease at primary diagnosis or at relapse after curative-intent surgery. neoplastic nature of the disease should have been confirmed by cytology or histology. subjects must have received no more than one prior chemotherapeutic regimen in the metastatic setting. prior therapy with radiation for this breast cancer population was permitted if it was administered in the neoadjuvant or adjuvant non metastatic setting. subject must have completed radiation treatment and recovered from all related toxicities. subject must have received all prior chemo treatment at least 4 weeks prior to enrollment in this study. prior therapy with trastuzumab in the neoadjuvant, adjuvant or metastatic setting was permitted. prior diagnosis of cancer was allowed as long as the subject was free of disease for 5 years. subjects with completely resected basal or squamous cell skin cancer, thyroid cancer or successfully treated cervical carcinoma in-situ were allowed into the study. women with oligomenorrhoea (severe), women who were perimenopausal and young women who had begun to menstruate must provide a negative serum pregnancy test at Screening. subjects must provide a negative serum pregnancy test and agree to 1 of the following: Complete abstinence from intercourse from 2 weeks prior to administration of the first dose of study medication until 5 days after the final dose of study medication. e Investigator to have a life expectancy of 6 months. Subjects must have had normal organ and marrow function as below. subject must have been free of gastrointestinal diseases that impede swallowing and retaining oral medications. bisphosphonate therapy for bone metastases was allowed; treatment must be initiated prior to the first dose of study medication. subjects without bone disease, except for osteoporosis, were included in the study if they met the following criteria. subjects who received more than one prior chemotherapeutic regimen were not eligible for the study. this included human immunodeficiency virus-positive subjects receiving combination anti-retroviral therapy because of possible pharmacokinetic interactions with lapatinib. uncontrolled inter-current illness includes, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would have limited compliance with study requirements. subjects with diseases affecting gastrointestinal function resulting in an inability to take oral medication. ation, prior surgical procedures affecting absorption e.g. gastric resection and uncontrolled inflammatory bowel disease (e.g., Crohn's, ulcerative colitis). subjects who had been disease-free for 5 years, or subjects with completely resected basal or squamous cell skin cancer, thyroid cancer or successfully treated cervical carcinoma in situ were eligible if it had been at least 1 year since definitive surgery. clinical investigator's Brochure (IB), SPM, and the nab-paclitaxel product label. \",\n",
       " 'post-menopausal women newly diagnosed with early stage breast cancer, who would be treated with an aromatase inhibitor, Serum 25OHD levels  40 ng/ml, Exclusion Criteria:, Severe or debilitating musculoskeletal pain, Known metastatic disease, History of renal stones, History of hypercalcemia or hyperthyroidism, Currently receiving adjuvant or neoadjuvant chemotherapy. history of hypersensitivity or allergic reaction, spontaneous or following drug administration, history of cardiac conditions, HER2-Positive females, Metastatic disease, concurrent other malignancy requiring therapy of any modality. ',\n",
       " 'Objective cognitive function measured with a computerized test battery of 7 tasks. performance speed is measured for Detection/Identification/Monitoring. performance accuracy is measured for memory/Learning/ISLT/ISLT-Delayed Recall. negative standardized score indicates below average results. patients complete assessments at baseline and 1 year after randomization to parent IBCSG 24-02 study. the analysis plan was revised to pre-specify collective analysis for all patients receiving OFS. overall number of participants Analyzed: 54, Mean (Standard Deviation), Unit of Measure: standardized units -0.21 (0.92). ',\n",
       " 'menopausal: 12 months spontaneous amenorrhea or > 6 but  12 months amenorrhea with a serum follicle stimulating hormone (FSH) level of > 40 mIU/mL. able to read, understand and complete the required subject diary. legal incapacity or limited legal capacity. chronic renal (serum creatinine > 2.0 mg/dL) or hepatic disease. untreated overt hyperthyroidism. rmal (a subject will not be excluded if a second measurement is less than twice the upper limit of normal), Creatinine > 2.0 mg/dLInclusion Criteria: adult patients, >=18 years of age; HER2-negative metastatic breast cancer candidates for taxane-based chemotherapy; ECOG performance status of 0 or 1. ',\n",
       " 'participants received enzalutamide 80 mg (two 40 mg) capsules orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including any seizure), noncompliance, withdrawal of consent, discontinuation by sponsor, or investigator. participants were followed-up until 30 days after last dose of study drug or before initiation of a new antitumor or investigational therapy, whichever occurred first. ver occurred first. ',\n",
       " 'breast cancer has continued to grow after receiving treatment with an anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor. postmenopausal women have stopped having menstrual periods. ',\n",
       " 'blood bilirubin increased 1/11 (9.09%), Febrile neutropenia [1]1/11 (9.09%), Ejection fraction decreased 1/11 (9.09%), Supraventricular and nodal arrhythmia::Sinus tachycardia 1/11 (9.09%), Lymphocyte count decreased 1/11 (9.09%), Neutrophil count decreased 1/11 (9.09%), Neutrophils/granulocytes (ANC/AGC) 1/11 (9.09 ',\n",
       " 'INTERVENTION 1:, MM-111, All participants_. ',\n",
       " 'Progression Free Survival (PFS) was defined as the time from first study drug dosing (during the maintenance treatment phase) to the first documented disease progression or death, whichever occurred first. Progressive Disease (PD) was defined as a 20 percent increase in the sum of the Longest Diameter (LD) of the target lesions taking as reference the smallest sum LD recorded or appearance of new lesions. ll participants received bevacizumab 15 mg/kg IV on Day 1 of each 3 week cycle for a minimum of 3 cycles and a maximum of 6 cycles or until disease progression, unacceptable toxicity or participant request for withdrawal. participants with an objective response (PR or CR) or SD received 15 mg/kg bevacizumab IV on Day 1 of each 3 week cycle for a minimum of 3 cycles and a maximum of 6 cycles. ek cycle for a minimum of 3 cycles and a maximum of 6 cycles or until disease progression, unacceptable toxicity or withdrawal, whichever occurred first. participants with an objective response were randomized to receive bevacizumab 15 mg/kg IV on Day 1 of each 3-week cycle plus capecitabine 1000 mg/m2 twice daily on Days 1 to 14 of each 3 week cycle. if one of the drugs was discontinued before disease progression, treatment was continued with the second drug until disease progression, unacceptable ',\n",
       " 'Adverse Events 1:, Total: 0/60 (0.00%), Adverse Events 2:, Total: 0/60 (0.00%). ',\n",
       " 'result at baseline minus result at baseline as a percentage of the result at baseline. back transformation of the least squares mean based on log transformed data. ',\n",
       " 'ORR was defined as the proportion of participants who achieved a best response of either CR or PR. time frame: baseline & every 2 cycles (approximately 8 weeks) of treatment. bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days. overall number of participants Analyzed: 94, Mean (95% Confidence Interval), Unit of Measure: proportion of responders 0.489 (0.385 to 0.595), Results 2:, Arm/Group Title: paclitaxel Plus Bevacizumab Plus Gemcitabine (PB+G), Arm/Group Description: paclitaxel 90 mill ',\n",
       " 'patients with glioblastoma multiforme undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks. participants will be injected with less than 10 mCi of 18F-FPPRGD2. mCi of 18F-FPPRGD2 of 18F-FPPRGD2. ',\n",
       " 'participants received enzalutamide 80 mg (two 40 mg) capsules orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including any seizure), noncompliance, withdrawal of consent, discontinuation by sponsor, or investigator. participants were followed-up until 30 days after last dose of study drug or before initiation of a new antitumor or investigational therapy, whichever occurred first. ver occurred first. ',\n",
       " 'ER positive, HER2 negative invasive breast cancer (Group 1) or invasive triple-negative breast cancer (Group 2), Free of metastatic disease, 18 years old, Female, Had no prior treatment for any cancer, Eligible for treatment with paclitaxel, doxorubicin and cyclophosphamide. ',\n",
       " 'patients with vitamin D deficiency who experience myalgias, arthralgias and/or joint stiffness who experience joint stiffness and joint stiffness. ',\n",
       " 'results 1:, Arm/Group Title: Arm 1: Paclitaxel + Trastuzumab Then A C, Arm/Group Description: 4 cycles of paclitaxel 80 mg/m2 on days 1, 8 and 15 of a 28-day cycle. follow paclitaxel/trastuzumab, standard AC every 21 days for 4 cycles. Neratinib 240 mg orally once daily beginning on Day 1 of paclitaxel. standard AC every 21 days for 4 cycles. following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy. ',\n",
       " 'participants received 120 milligrams of denosumab injected subcutaneously every 4 weeks until denosumab was approved and available for sale. ',\n",
       " 'blood bilirubin increased 1/11 (9.09%), Febrile neutropenia [1]1/11 (9.09%), Ejection fraction decreased 1/11 (9.09%), Supraventricular and nodal arrhythmia::Sinus tachycardia 1/11 (9.09%), Lymphocyte count decreased 1/11 (9.09%), Neutrophil count decreased 1/11 (9.09%), Neutrophils/granulocytes (ANC/AGC) 1/11 (9.09 ',\n",
       " 'Adverse Events 1:, Total: 0/0, Adverse Events 2:, Total: 0/0Adverse Events 1:, Total: 0/15 (0.00%) ',\n",
       " 'post-menopausal women newly diagnosed with early stage breast cancer, who would be treated with an aromatase inhibitor, Serum 25OHD levels  40 ng/ml, Exclusion Criteria:, Severe or debilitating musculoskeletal pain, Known metastatic disease, History of renal stones, History of hypercalcemia or hyperthyroidism, Currently receiving adjuvant or neoadjuvant chemotherapy. history of hypersensitivity or allergic reaction, spontaneous or following drug administration, history of cardiac conditions, HER2-Positive females, Metastatic disease, concurrent other malignancy requiring therapy of any modality. ',\n",
       " 'inTERVENTION 2:, Part A: V934 LD(3)+V935 LD, 3 IM injections of V934 (LD) were administered, 1 given every other week over a 3-week period. following a 4 week observation period, 2 IM injections of V935 (LD) were administered. ',\n",
       " 'Variation in Serum Levels of Follicle Stimulating Hormone (FSH) compare to natural physiological variability (screening-baseline variation), Time frame: from baseline to 12 weeks of treatment. lacebo, Overall Number of Participants Analyzed: 11, Median (Inter-Quartile Range), Unit of Measure: mIU/ml 1.4 (-5.4 to 15.7)Outcome Measurement:, Ruxolitinib MTD in combination with paclitaxel 80 mg/m2 intravenously (IV) weekly is determined by the number of patients who have dose limiting toxicity (DLT) the observation period for MTD evaluation was the first 2 cycles of treatment. participants with stable disease or better will have the opportunity to continue on single agent Ruxolitinib. ',\n",
       " '0/33 (0.00%)Adverse Events 1:, Total: 5/16 (31.25%), ANAEMIA 1/16 (6.25%), LEUKOPENIA 1/16 (6.25%), NEUTROPENIA 3/16 (18.75%), THROMBOCYTOPENIA 1/16 (6.25%), FEBRILE INFECTION 1/16 (6.25%), PNEUMONIA 1/16 (6.25%), PNEUMONIA 1/16 (6.25%), PNEUMONIA 1/16 ( ',\n",
       " 'patient must have histologically or cytologically confirmed locally advanced, unresectable or metastatic carcinoma of the breast. patient must have performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) performance scale and life expectancy > 3 months. female patient of childbearing potential must have a negatio. ve serum or urine pregnancy test quantitative human chorionic gonadotropin (-hCG) within 72 hours prior to receiving the first dose of study medication is allowed. patients with stable and clinically insignificant CNS disease are allowed. patients must be off steroids with no new CNS symptoms. bevacizumab, hormone therapy within one week, trastuzumab within 2 weeks or lapatinib within one week of study Day 1. patients with known active central nervous system metastases and/or carcinomatous meningitis eligible for study. patients with clinically insignificant brain metastases that do not require treatment are eligible. clinically significant cardiac arrhythmia, history or current evidence of a myocardial infarction during the last 6 months, and/or a current ECG tracing that is abnormal in the opinion of the treating Investigator. patients with other active, current primary malignancies, other than carcinoma in situ of the cervix or non-melanoma skin cancer. ',\n",
       " 'Adverse Events 1:, Total: 11/25 (44.00%), Febrile neutropenia * 4/25 (16.00%), Neutropenia * 3/25 (12.00%), Diarrhoea * 1/25 (4.00%), Intestinal perforation * 1/25 (4.00%), Rectal haemorrhage * 1/25 (4.00%), Stomatitis * 1/25 (4.00%), Vomiting * 1/25 (4.00%), Fatigue * 1/25 (4.00%), ',\n",
       " 'all subjects treated under this protocol will have histologically documented cancer of one of the following types:, A. Metastatic breast cancer (7 triple negative, 23 ER+ after the first 15 patients are enrolled on the non-CCND1cohort; in addition 10 HER2+ for combination trastuzumab and PD0332991 therapy) up to 55 total enrollment slots B. Advanced or metastatic esophageal and/or gastric cancer (15-30 enrollment slots) D. Cisplatin subjects will be > 18 years old, The subject has disease that is assessable by tumor marker, physical, or radiologic means. the subject has an Eastern Cooperative Oncology Group performance status of 0 or 1. subject is capable of understanding and complying with protocol requirements. sexually active subjects (male and female) must use accepted methods of contraception. female subjects of childbearing potential must have negative pregnancy test at screening. patients with HER2-overexpressing tumors may receive trastuzumab. subject has received any other type of investigational agent within 28 days. subject has not recovered from clinically-meaningful toxicity due to prior therapy. subject has untreated or uncontrolled brain metastases. the subject has a baseline corrected QT interval (QTc) > 470 ms. the subject is known to be positive for the human immunodeficiency virus. ',\n",
       " 'patients undergoing mastectomy surgery, number of individuals having mastectomy surgery who were approached for participation in the trialINTERVENTION 1:, HR+: MM-121+ Paclitaxel, Hormone-receptor positive (HR+) sub-group randomized to receive:, 2 week run-in of MM-121 (20 mg/kg weekly IV infusion over 60 minutes following a 40 mg/kg loading dose. ',\n",
       " 'Adverse Events 1:, Total: 17/50 (34.00%), Fatigue 4/50 (8.00%), Papulopustular rash 1/50 (2.00%), Alanine aminotransferase increased 5/50 (10.00%), Alkalosis 1/50 (2.00%), Anorexia 1/50 (2.00%), Hyperglycemia 2/50 (4.00%), Nervous system disorders. ',\n",
       " 'treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity. cyclophosphamide, paclitaxel, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab subjects 98 (92.2 to 99.5). subjects 98 (92.2 to 99.5) ',\n",
       " 'Adverse Events 1:, Total: 0/10 (0.00%)Adverse Events 1:, Total: 0/1699 (0.00%), Adverse Events 2:, Total: 0/2004 (0.00%) ',\n",
       " 'ECOG performance status of 0 to 2, Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST), Exclusion Criteria:, prior or concurrent hormonal therapy for breast cancer, Histologically confirmed breast cancer, stage I-III disease, scheduled to undergo definitive surgery or other primary treatment. nant or nursing, Negative pregnancy test, Fertile patients must use effective contraception, No ongoing or active infection, No psychiatric illness or social situation that would preclude study compliance, No other uncontrolled intercurrent illness, No other uncontrolled intercurrent illness, No history of allergic reaction attributed to compounds of similar chemical or biologic composition to vorinostat, Concurrent vaginal hormone preparations (e.g., vagifem or estring) allowed, No concurrent birth control pills, No prior patients may not be taking valproic acid or another histone deacetylase inhibitor for at least 2 weeks prior to initiating SAHA. women who are pregnant may not be taking valproic acid or another histone deacetylase inhibitor for at least 2 weeks before initiating SAHA. ',\n",
       " 'participants continued treatment until progressive disease (PD), unacceptable toxicity, required palliative radiotherapy or surgical intervention of lesion(s) participants continued treatment until progressive disease (PD), unacceptable toxicity, required palliative radiotherapy or surgical intervention of lesion(s), withdrawal from study treatment, withdrawal of study consent, participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment. study treatment, withdrawal of study consent, participant refusal or investigator felt it was no longer in the best interest of the participant to continue on treatment. ',\n",
       " 'patients will receive whole breast radiation therapy at a dose of 180-200 cGy per fraction for 23-27 fractions to a total dose of 4600 - 4860 cGy. additional radiation to the lumpectomy bed (Boost) is at the discretion of the treating physician. participants received enzastaurin (250 mg; 2 tablets) or placebo administered orally twice daily (BID) in a 28-day cycle. ',\n",
       " 'metastatic disease (M1), Multiple sites of new disease that is clinically obvious metastatic disease (e.g., multiple sites of new osseous disease), Measurable or nonmeasurable disease, No known brain or CNS metastases, Hormone receptor status:, Estrogen-receptor positive* AND/OR, Progesterone-receptor positive* NOTE:. hepatic, INR 1.6, Renal, Not specified, Other, HIV negative, No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer currently in complete remission. Biologic therapy, No prior immunotherapy for recurrent or metastatic disease, Chemotherapy, No concurrent chemotherapy for recurrent or metastatic disease, Endocrine therapy, Prior more than 12 months since prior fulvestrant, no prior hormonal therapy for recurrent or metastatic disease, no other concurrent hormonal therapy for malignancy, no concurrent hormone replacement therapy, Radiotherapy, Not specified, Surgery, Not specified, Other, No long-term anticoagulant therapy (except antiplatelet therapy) ',\n",
       " 'Adverse Events 1:, Total: 11/25 (44.00%), Febrile neutropenia * 4/25 (16.00%), Neutropenia * 3/25 (12.00%), Diarrhoea * 1/25 (4.00%), Intestinal perforation * 1/25 (4.00%), Rectal haemorrhage * 1/25 (4.00%), Stomatitis * 1/25 (4.00%), Vomiting * 1/25 (4.00%), Fatigue * 1/25 (4.00%), ',\n",
       " 'CBT-I: Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)INTERVENTION 1:, Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W, Phase Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W, INTERVENTION 2:, Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W, INTERVENTION 2:, ',\n",
       " 'INTERVENTION 1:, MM-111, All participants_. ',\n",
       " 'Benign breast disease amenable to hormonal therapy. high risk breast lesions like epitheliosis, atypia or atypical hyperplasia. ECOG performance status 0 or 1, Pre- or post-menopausal, Must possess a compact disc player, Able to complete questionnaires alone or with assistance, No active medical conditions preventing compliance with a practice of slow deep breathing including active asthma, chronic obstructive pulmonary disease, or congestive heart failure. ntidepressants started within the past 30 days allowed. no concurrent hormonal agents and/or antineoplastic chemotherapy are allowed. ',\n",
       " 'AINTERVENTION 1:, Phase 1: MLN8237 10 mg, MLN8237 (alisertib) 10 milligram (mg), enteric-coated tablets, orally, twice daily for 7 days followed by 14 days of rest period in 21-day treatment cycles. or until progressive disease, unacceptable treatment-related toxicity, or initiation of a different anticancer therapy during Phase 1 portion of the study. treatment-related toxicity, or initiation of a different anticancer therapy during Phase 1 portion of the study. ',\n",
       " 'patients without liver involvement or history of liver disease will be treated at a dose of 98.7 mg/m2. patients will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance. patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2. patients will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance. CR and PR (for solid tumors) required a confirmation at least 4 weeks after the initial response observation. any pathological lymph nodes must have had reduction in short axis to 10 mm, PR=At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, SD=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. nt cycle was defined as 28 days. overall number of participants Analyzed: 105, Measure Type: Count of participants. ',\n",
       " 'ECOG performance status of 0, Previous non-metastatic operable primary invasive HER2-positive breast cancer, Baseline LVEF >55%, Exclusion Criteria:, Healthy Participants (Part 1 only), Clinically significant abnormalities in laboratory test results or electrocardiogram. history of significant allergies, gastrointestinal, renal, hepatic, cardiovascular, or pulmonary disease, hypersensitivity or allergic reaction, spontaneous or following drug administration. bothersome hot flashes for 1 month prior to study entry, PATIENT CHARACTERISTICS:, Eastern Cooperative Oncology Group (ECOG) performance status 0-1, Life expectancy 6 months, Able to complete questionnaire(s) by themselves or with assistance, Women of childbearing potential not eligible. al estrogen is allowed if used for the past month and not planned to be discontinued, concurrent adjuvant targeted therapy (i.e., lapatinib, trastuzumab [Herceptin®] allowed in patients with no evidence of disease, Concurrent tamoxifen, raloxifene, or aromatase inhibitors on a constant dose for at least 4 weeks allowed provided the medication will not be stopped during the study period. ',\n",
       " 'Isothiocyanate included sulforaphane in micromolar (M) concentration was measured following standard chemical measurement procedures and divided by creatinine values in millimolar (mM) concentration. patients receive oral placebo supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity. Numeric Pain Rating Scale - pain rating scale 0-10 (0= no pain to 10= most pain imaginable) participants were re-assessed after the 2 round of TC and 4th round of FECD. atment, Overall Number of Participants Analyzed: 22, Measure Type: Number, Unit of Measure: percentage of participants Percentage of Participants with Pain (1-10): 30, Percentage of Participants with no pain (0): 70, Results 2:, Arm/Group Title: Control, Arm/Group Description: chemotherapy as usual without physical therapy. ',\n",
       " 'inTERVENTION 2:, Part A: V934 LD(3)+V935 LD, 3 IM injections of V934 (LD) were administered, 1 given every other week over a 3-week period. following a 4 week observation period, 2 IM injections of V935 (LD) were administered. ',\n",
       " 'Anaemia 0/37 (0.00%), Febrile neutropenia 0/37 (0.00%), leukopenia 0/37 (0.00%), Neutropenia 0/37 (0.00%), arrhythmia 0/37 (0.00%), Abdominal pain 1/37 (2.70%), Diarrhoea 1/37 (2.70%), Intestinal obstruction 0/37 (0.00%), Fatigue 0/37 (0.00%), Pyrexia 0/37 ( Colitis 1/93 (1.08%), Constipation 1/93 (1.08%), Diarrhea 4/93 (4.30%), Duodenal ulcer 1/93 (1.08%), Dysphagia 4/93 (4.30%), Adverse Events 2: ',\n",
       " 'Measure Yourself Medical Outcome Profile (MYMOP) is a questionnaire widely used for evaluating interventions based on holistic and participative principles. it allows respondants to specify and measure the treatment outcomes that are important to them. asured following standard chemical measurement procedures. divided by creatinine values in millimolar (mM) concentration. placebo: Given orally, Overall Number of participants Analyzed: 27, Mean (Standard Error), Unit of Measure: M/mM creatinine 1.00 (0.334) ',\n",
       " 'Eribulin+Cyclophosphamide (ErC), Eribulin (Er): 1.4mg/m2 (Days 1 and 8 of each treatment cycle) by IV infusion, Cyclophosphamide (C): 600 mg/m2 IV (Day 1 of each treatment cycle) by IV infusion. inTERVENTION 2: Docetaxel+Cyclophosphamide (TC), Docetaxel (T): 75 mg ',\n",
       " 'Adverse Events 1:, Total: 0/0, Adverse Events 2:, Total: 0/0Adverse Events 1:, Total: 0/15 (0.00%) ',\n",
       " 'a log ratio of expression was generated relative to reference in both the Up and DOWN arms of the gene signature. a log ratio value of zero indicated no change in expression between the two samples. overall number of participants Analyzed: 14, Measure Type: Number, Unit of Measure: Percentage of participants 28.6 (13.1 to 49.2), Results 2:, Arm/Group Title: Triple Negative (TN), Arm/Group Description: Triple Negative participants received a single dose of dalotuzumab 20 mg/kg infused over 60-120 minutes. ',\n",
       " 'adverse events for all systems are graded on a scale of 1-5 and attribution is assigned. DLT is defined as any incidence of Grade 3 hematologic and non-hematologic toxicity (excluding: fever, hypoxia, and urticaria) if a subject develops a Grade 3 toxicity will be considered excessive toxicity. patients receive cyclophosphamide IV once on day -1 and autologous ex vivo-expanded HER2-specific T cell IV over 30 minutes on day 1. patients receive a booster HER2/neu peptide vaccine 1 month after the final T-cell infusion, followed by 2 additional booster vaccines at 2-month intervals. rade >/= 3, specifically, hepatic events, allergic reactions, thrombocytopenia and hemorrhage events, all Grade >/= 3 AEs related to trastuzumab emtansine. participants received trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression. sian race participants with HER2-positive, unresectable, LABC or mBC had progressed on or after the most recent treatment for LABC or mBC. participants received trastuzumab emtansine every 3 weeks. ',\n",
       " 'participants received lenalidomide 5mg orally daily for 57 +/- 3 daysINTERVENTION 1:, Lapatinib 1500 mg, Oral lapatinib (1500 milligrams [mg] daily) for 6 weeks, followed by lapatinib plus weekly paclitaxel (80 mg per meters squared [mg/m2]) intravenous (IV) for an additional 12 weeks. ',\n",
       " 'patient must have histologically or cytologically confirmed locally advanced, unresectable or metastatic carcinoma of the breast. patient must have performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) performance scale and life expectancy > 3 months. patients with stable and clinically insignificant CNS disease are allowed. patients must be off steroids with no new CNS symptoms or findings on radiographic imaging for 1 month. patients must be off steroids with no new CNS symptoms or findings. patients with known active central nervous system metastases and/or carcinomatous meningitis would be eligible for the study provided they are clinically stable for at least 1 month prior to entry. patients with clinically insignificant brain metastases that do not require treatment are eligible for the study. rrent illness/infection, patients with other active, current primary malignancies, other than carcinoma in situ of the cervix or non-melanoma skin cancer, patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative, patients are pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study. ',\n",
       " 'one to three presumed brain metastases must be from a histologically confirmed extracerebral site (e.g., lung, breast, prostate), Histologic confirmation may have been from the primary tumor site, from another metastatic site (e.g., osseous metastasis, adrenal metastasis), or from the metastatic brain lesion(s) Each lesion must measure less than 3.0 cm by contrast MRI of the brain performed within the past 21 days. male patients must continue to use contraception for 3 months after the completion of radiotherapy. no pacemaker or other MRI-incompatible metal in the body, no known allergy to gadolinium, no known allergy to gadolinium. volunteers may have had a prior history of other cancers > 3 years which required only local resection, local radiation and/or hormonal therapy such as androgen blockade. d risk of the proposed study and be able to sign consent. e influenza vaccine, On-going neurologic disorder (mental status change, uncontrolled seizures, encephalopathy), Treatment or planned treatment with cyclophosphamide, ifosphamide, or > or = to 1 mg/kg prednisone or its equivalent 12 weeks within 12 weeks of vaccination. patients receiving the seasonal influenza vaccine may not have had it within 6 months of enrollment. ',\n",
       " \"dose-limiting toxicities are assessed according to the national Cancer Institute's Common Terminology Criteria for Adverse Events classification. the classification usually encompasses all grade 3 or higher toxicities, Time frame: 28 days. given IV, pegylated liposomal doxorubicin hydrochloride: Given IV, overall number of participants Analyzed: 6, Measure Type: Number, Unit of Measure: participants 1__________________________________________________________________ \",\n",
       " '89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions. only those foci qualitatively positive by both readers will be considered as \"positive\" ',\n",
       " 'breast cancer has continued to grow after receiving treatment with an anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor. postmenopausal women have stopped having menstrual periods. ',\n",
       " 'patients are excluded if they are unable to give informed consent or pass screening for impaired mental function or psychosis. they are unable to hear or understand English. ',\n",
       " 'inTERVENTION 1:, Subjects enrolled with device placed and treated with partial breast irradiation. ',\n",
       " 'participants able to receive iron supplement, if necessary, Exclusion Criteria:, Known or suspected contraindications to epoetin beta, Pregnancy or lactation period, Diagnosis of anemia only due to iron-deficiency, Epilepsy and/or cerebral metastasis, Blood transfusion or treatment with any erythropoietic factor within 4 weeks. patient has score of 0 or 1 on the neurotoxicity evaluation. previous diagnosis of diabetic neuropathy or peripheral neuropathy from any cause, Diagnosis of fibromyalgia. ',\n",
       " 'Isothiocyanate included sulforaphane in micromolar (M) concentration was measured following standard chemical measurement procedures and divided by creatinine values in millimolar (mM) concentration. patients receive oral placebo supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity. Numeric Pain Rating Scale - pain rating scale 0-10 (0= no pain to 10= most pain imaginable) participants were re-assessed after the 2 round of TC and 4th round of FECD. atment, Overall Number of Participants Analyzed: 22, Measure Type: Number, Unit of Measure: percentage of participants Percentage of Participants with Pain (1-10): 30, Percentage of Participants with no pain (0): 70, Results 2:, Arm/Group Title: Control, Arm/Group Description: chemotherapy as usual without physical therapy. ',\n",
       " 'Eribulin+Cyclophosphamide (ErC), Eribulin (Er): 1.4mg/m2 (Days 1 and 8 of each treatment cycle) by IV infusion, Cyclophosphamide (C): 600 mg/m2 IV (Day 1 of each treatment cycle) by IV infusion. inTERVENTION 2: Docetaxel+Cyclophosphamide (TC), Docetaxel (T): 75 mg ',\n",
       " 'patients must have histologically confirmed breast cancer that is ER positive and/or PR positive, and HER2/neu negative disease determined using commercially available/approved assay in local institutional or reference laboratory. ER/PR expression performed by standard immunohistochemical assay and classified as ER and/or PR-positive according to ASCO/CAP guidelines (1-100% expression) patients must have had progressive disease during at least one line of endocrine therapy. prior treatments include a non-steroidal aromatase inhibitor, tamoxifen, fulvestrant or combinations. patients taking bisphosphonates for bone disease are permitted to enter the trial. postmenopausal status defined as 60 years and older, 45 years and older, having amenorrhea x 12 months or follicle stimulating hormone levels within postmenopausal range, OR having a bilateral oophorectomy. patients may not be receiving any other investigational agents. having at least 6 weeks of treatment remaining, 21 years old, Able to understand written and spoken English, Able to swallow medication (until amendment omitting armodafinil treatment), Score of 3+ on the Sleep Disruption Evaluation form, OR a score of 8+ on Insomnia Severity Index (ISI), EXCLUSION CRITERIA, Prior treatment with armodafinil or modafinil (until amendment omitting armodafini history of uncontrolled, cardiac disease, hypertension, severe headaches, glaucoma, or seizures (until amendment omitting armodafinil treatment) of chronic, preexisting insomnia, sleep apnea, or restless leg syndrome (RLS) ',\n",
       " \"breast tumor 1 centimeter (cm) in diameter, HR+, HER2-. neoadjuvant endocrine monotherapy is deemed to be a suitable therapy. measurable disease, Bone metastases requires other disease present that can be measured. no brain metastases, unless documented to be controlled post-completion of local therapy for at least 4 weeks, no meningeal carcinomatosis, no malignant effusion as the only site. hat in the opinion of the treating physician would make study protocol unreasonably hazardous for the patient. hat in the opinion of the treating physician would make study protocol unreasonably hazardous for the patient or would preclude the patient's ability to comply with the study protocol. \",\n",
       " 'inTERVENTION 2:, Part A: V934 LD(3)+V935 LD, 3 IM injections of V934 (LD) were administered, 1 given every other week over a 3-week period. following a 4 week observation period, 2 IM injections of V935 (LD) were administered. ',\n",
       " 'a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 will be explored and will follow a 6 + 3 dose de-escalation design. participants with one of the following tumor types will be eligible for enrollment. ',\n",
       " 'Benign breast disease amenable to hormonal therapy. high risk breast lesions like epitheliosis, atypia or atypical hyperplasia. ECOG performance status 0 or 1, Pre- or post-menopausal, Must possess a compact disc player, Able to complete questionnaires alone or with assistance, No active medical conditions preventing compliance with a practice of slow deep breathing including active asthma, chronic obstructive pulmonary disease, or congestive heart failure. ntidepressants started within the past 30 days allowed. no concurrent hormonal agents and/or antineoplastic chemotherapy are allowed. ',\n",
       " 'participants received enzalutamide 80 mg (two 40 mg) capsules orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including any seizure), noncompliance, withdrawal of consent, discontinuation by sponsor, or investigator. participants were followed-up until 30 days after last dose of study drug or before initiation of a new antitumor or investigational therapy, whichever occurred first. ver occurred first. ',\n",
       " 'Contour Profile Tissue Expander is a tissue expander with a greater height to width ratio than traditional tissue expanders. this increased ratio allows for greater lower pole expansion, thus creating a more natural looking, ptotic breast. ',\n",
       " \"patients must be taking chronic opioid therapy at a stable dose for a minimum of four days. the dose of as needed short acting oxycodone does not need to be stable. patients must have cancer related neuropathic pain secondary to post-chemotherapy. patients taking methadone or with a history of methadone treatment within one month of study enrollment. neurologic or psychiatric disease sufficient, in the investigator's opinion, to compromise data collection. contralateral surgery (lumpectomy/mastectomy) at time of mastectomy, surgery cannot be performed. glucocorticoids are used in the study period. \",\n",
       " 'Adverse Events 1:, Total: 6/50 (12.00%), Ventricular tachycardia 1/50 (2.00%), Fever [1]1/50 (2.00%), Flu like symptoms 1/50 (2.00%), Catheter related infection 2/50 (4.00%), Suicidal ideation * [2]1/50 (2.00%), Thromboembolic event 1/50 (2.00%). ',\n",
       " 'Adverse Events 1:, Total: 6/8 (75.00%), Thrombocytopenia 1/8 (12.50%), Hypertension 1/8 (12.50%), Hepatotoxicity 3/8 (37.50%), Pancreatectomy * 1/8 (12.50%). ',\n",
       " 'inTERVENTION 2:, arm B: 3 Days/Week Schedule, CUDC-101: CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 consecutively. ',\n",
       " 'Bisphosphonate IV Q4W, Open-label intravenous (IV) bisphosphonate once every 4 weeks (Q4W), INTERVENTION 2: Denosumab 180 mg Q12W, Open-label denosumab 180 mg by subcutaneous injection once every 12 weeks (Q12W) ',\n",
       " '0/25 (0.00%)Adverse Events 1:, Total: 10/30 (33.33%), Hemoglobin decreased 2/30 (6.67%), Abdominal pain 1/30 (3.33%), Colitis 1/30 (3.33%), Diarrhea 7/30 (23.33%), Nausea 2/30 (6.67%), Rectal hemorrhage 1/30 (3.33%), Fatigue 1/30 (3.33%), Skin infection 1/30 (3.33%), Neutrophil count decreased 1/30 ( ',\n",
       " 'participants received 1250 milligram (mg) tablets lapatinib once a day and vinorelbine 20 mg/meters squared (m2) intravenously on Day 1 and Day 8, and every 3 weeks. participants received 1250 milligram (mg) tablets lapatinib once a day. ticipants Analyzed: 25, Measure Type: Number, Unit of Measure: participants Week 12, CR: 0, Week 12, PR: 4, Week 12, SD: 12, Week 24, CR: 0, Week 24, PR: 4, Week 24, SD: 10_ ',\n",
       " 'inTERVENTION 1:, Paced Breathing (15 Min Twice Daily, 6 Breaths/Min), Patients practice paced breathing for 15 minutes once daily, 6 breaths/min, 5-7 days weekly. ',\n",
       " 'inTERVENTION 1:, arm II, Patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1. oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3. r IV, dexamethasone: Given orally or IV, dexamethasone: Given orally or IV, dexamethasone: Given orally or IV, dexamethasone: Given orally or IV, dexamethasone: Given orally orally or IV, dexamethasone: Given orally orally or IV, dexamethasone: Given orally orally or IV, dexamethasone: Given orally orally ',\n",
       " 'Anaemia 0/37 (0.00%), Febrile neutropenia 0/37 (0.00%), leukopenia 0/37 (0.00%), Neutropenia 0/37 (0.00%), arrhythmia 0/37 (0.00%), Abdominal pain 1/37 (2.70%), Diarrhoea 1/37 (2.70%), Intestinal obstruction 0/37 (0.00%), Fatigue 0/37 (0.00%), Pyrexia 0/37 ( Colitis 1/93 (1.08%), Constipation 1/93 (1.08%), Diarrhea 4/93 (4.30%), Duodenal ulcer 1/93 (1.08%), Dysphagia 4/93 (4.30%), Adverse Events 2: ',\n",
       " '5/18 (27.78%), Anaemia 1/18 (5.56%), Febrile neutropenia 1/18 (5.56%), Pancytopenia 0/18 (0.00%), Thrombocytopenia 1/18 (5.56%), Acute myocardial infarction 1/18 (5.56%), Eye pain 1/18 (5.56%), Diarrhoea 1/18 (5.56%), Intestinal obstruction 1/18 (5.56%), Nausea 0/18 (0.00%), Small intestinal obstruction 0 ',\n",
       " 'patients are excluded if they are unable to give informed consent or pass screening for impaired mental function or psychosis. they are unable to hear or understand English. ',\n",
       " 'participants received lenalidomide 5mg orally daily for 57 +/- 3 daysINTERVENTION 1:, Lapatinib 1500 mg, Oral lapatinib (1500 milligrams [mg] daily) for 6 weeks, followed by lapatinib plus weekly paclitaxel (80 mg per meters squared [mg/m2]) intravenous (IV) for an additional 12 weeks. ',\n",
       " \"the participant has a histopathologically or cytologically confirmed diagnosis of breast adenocarcinoma that is metastatic or locally-recurrent and inoperable with curative intent. the participant has measurable and/or non-measurable disease, The participant's primary and/or metastatic tumor is human Epidermal Growth Factor Receptor 2 (HER2) negative. participants of reproductive potential agree to use adequate contraceptive methods during the study period and for 12 weeks after the last dose of study medication. participant has a concurrent active malignancy other than breast adenocarcinoma, adequately treated non-melanomatous skin cancer, or other non-invasive carcinoma or in situ neoplasm. articipant has received any experimental agents within 4 weeks prior to the study registration date, The participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders. the participant has an ongoing or active infection requiring antibiotic, antifungal, or antiviral therapy. for bone disease, stable disease (SD) is allowed. patient must have tumor assessed for estrogen-receptor (ER) and progesterone-receptor (PR) prior HDCT with autologous hematopoietic stem cell transplantation (AHST) in adjuvant setting. history of other malignancies except cured non-melanoma skin cancer. \",\n",
       " 'a non-serious adverse event is any untoward medical occurrence. a serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions. congenital anomaly/birth defect or important medical events that jeopardize the patient or subject may require medical or surgical intervention. Total Dose 2 x 108 IU, Arm/Group Description: Participants received Modified Vaccinia Ankara (MVA)-brachyury-TRICOM vaccine administered subcutaneously as 1 injection (I injection = 2 x 108 IU) of study drug at monthly (28 days +/- 4 days) intervals for 3 months. patients with stable disease may continue to receive vaccine for up to 6 monthly doses. ',\n",
       " 'Neoadjuvant therapy will consist of epirubicin (100 mg/m2) + cyclophosphamide (600 mg/m2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m2) every 2 weeks for 4 cycles. ',\n",
       " \"2.3 Dental evaluation according to the dental exam checklist (carried out by the investigator, the investigator's designee, or by a qualified dental professional [dental hygienist or dentist]) if the patient has received prior oral bisphosphonate therapy within 8 weeks of registration, the evaluation should not be revoked. complete blood count (CBC)/differential within 2 weeks prior to registration, with adequate bone marrow function defined as follows: White blood cell count (WBC) 2400 cells/mm3; Absolute neutrophil count (ANC) 1,800 cells/mm3; Platelets 60,000 cells/mm3; Hemoglobin 8.0 g/dl (Note: The use of transfusion or other intervention to achieve the required hemoglobin is permitted) beam radiation therapy must be completed 14 days prior to registration. patients with no evidence of disease in the brain after treatment for brain metastases are eligible. prior treatment with Strontium-89 or Samarium-153 for bone metastases. prior treatment with IV bisphosphonates prior to study entry. current, active dental problems within 4 weeks of registration. the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. pregnant or lactating patients are excluded as treatment may be harmful to embryos and/or nursing infants. the study should be finished 30 days before the beginning of the study. if the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose of anthracyclines should not exceed 250 mg/m2 for doxorubicin or 540 mg/m2 for epirubicin. n or 660 mg/m2 for epirubicin, if in this study planned 4 cycles of chemotherapy. patients of childbearing potential must implement reliable contraceptive measures. f bone metastases) administration of any experimental drugs within 30 days prior randomization. conditions limiting patient's ability to follow protocol. \",\n",
       " 'Objective cognitive function measured with a computerized test battery of 7 tasks. performance speed is measured for Detection/Identification/Monitoring. performance accuracy is measured for memory/Learning/ISLT/ISLT-Delayed Recall. negative standardized score indicates below average results. patients complete assessments at baseline and 1 year after randomization to parent IBCSG 24-02 study. the analysis plan was revised to pre-specify collective analysis for all patients receiving OFS. overall number of participants Analyzed: 54, Mean (Standard Deviation), Unit of Measure: standardized units -0.21 (0.92). ',\n",
       " 'the investigator must confirm postmenopausal status. postmenopausal status is defined either by:, age 55 years and one year or more of amenorrhea, age  55 years and one year or more of amenorrhea and postmenopausal levels of FSH and LH per local institutional standards. non-steroidal aromatase inhibitors (i.e. letrozole or anastrozole) do not have to be the last treatment prior to enrollment. other prior anticancer therapy, e.g. tamoxifen, fulvestrant, exemestane are also allowed. serum bilirubin 1.5  ULN, fasting serum cholesterol 300 mg/dl or 7.75 mmol/L and fasting triglycerides 2.5  ULN. alanine aminotransferase (ALT) 2.5  ULN (or 5 if hepatic metastases are present). patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose galactose malabsorption must have recovered from radiotherapy toxicities prior to enrollment. radiotherapy within four weeks prior to enrollment except in case of localized radiotherapy for analgesic purpose. patients with symptomatic visceral metastasis (e.g. significant dyspnoea related to pulmonary lymphangitic carcinomatosis and lung metastases), symptomatic brain or other central nervous system metastases (CNS) metastases. active, bleeding diathesis, or on oral anti-vitamin K medication. uncontrolled or whose control may be jeopardized by the complications of this study therapy. pulmonary function tests should be considered to exclude restrictive pulmonary disease, pneumonitis or pulmonary infiltrates. patients being treated with drugs recognized as strong inhibitors or inducers of the isoenzyme CYP3A. patients must have metastatic breast cancer; tissue (a minimum of 3 slides) from most recent biopsy is required for review and confirmation of eligibility. patients must have stage IV breast cancer, patients must have metastatic tumors (primary or metastatic) that stain positively for the prolactin receptor. women of childbearing potential must commit to the use of effective barrier (non-hormonal) contraception while on study. patients must have a life expectancy of greater than 12 weeks. patients must have a life expectancy of greater than 12 weeks. patients may have had a prior diagnosis of cancer if it has been > 5 years since their last treatment. systemic treatment is allowed with a 2 week washout period prior to registration. patients who are taking herbal (alternative) medicines are NOT eligible for participation. patients must be off any such medications by the time of registration. nary, pericardial, cardiac valvular, or retroperitoneal fibrotic disorders, Gastrointestinal (GI) tract disease resulting in an inability to take oral medication, Malabsorption syndrome, Require intravenous (IV) alimentation, Uncontrolled inflammatory GI disease. ',\n",
       " 'Chemotherapy with GM-CSF, Doxorubicin and Cyclophosphamide (AC) followed by Weekly Carboplatin/Nab- PaclitaxelINTERVENTION 1:, Neoadjuvant Chemotherapy, Doxorubicin (Adriamycin) + cyclophosphamide (Cytoxan) with pegfilgrastim or filgrastim growth factor support every 2 weeks for 4 cycles ',\n",
       " 'participants must have histologically or cytologically confirmed breast cancer or non-hodgkin lymphoma. doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2. doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2 and docetaxel 75 mg/m2. ncer in marrow), absolute neutrophil count >1,500/mcL (unless due to cancer in marrow), platelets >100,000/mcL (unless due to cancer in marrow), total bilirubin 1.5 X normal institutional limits, aspartate aminotransferase (AST) or serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase patients with known brain metastases should be excluded from this clinical trial. progressive neurologic dysfunction would confound evaluation of neuro-cognitive outcomes. patients requiring ongoing pharmacologic treatment of dementia excluded. e heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations would limit compliance with study requirements. pregnant women are excluded from this study because the chemotherapy agents have known teratogenic or abortifacient effects. allergy to all three antibiotics: cephalosporin, trimethoprim/sulfamethoxazole, and levofloxacin. non-English speaking patients without adequate interpreter assistance. ',\n",
       " '77/122 (63.11%), Anaemia 1/122 (0.82%), Thrombocytopenia 1/122 (0.82%), Pericardial effusion 3/122 (2.46%), Supraventricular tachycardia 2/122 (1.64%), Atrial fibrillation 1/122 (0.82%), Sinus tachycardia 1/122 (0.82%), Hypothyroidism 1/122 (0.82%), Abdominal pain 4/122 (3.28%)Adverse ',\n",
       " 'Adverse Events 1:, Total: 5/14 (35.71%), Ileus 1/14 (7.14%), General disorders and administration site conditions - Other, disease progression 2/14 (14.29%), Infections and infestations - Other, pneumonia 1/14 (7.14%) ',\n",
       " 'results 1:, Arm/Group Title: Arm 1: Paclitaxel + Trastuzumab Then A C, Arm/Group Description: 4 cycles of paclitaxel 80 mg/m2 on days 1, 8 and 15 of a 28-day cycle. follow paclitaxel/trastuzumab, standard AC every 21 days for 4 cycles. Neratinib 240 mg orally once daily beginning on Day 1 of paclitaxel. standard AC every 21 days for 4 cycles. following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy. ',\n",
       " 'Eribulin+Cyclophosphamide (ErC), Eribulin (Er): 1.4mg/m2 (Days 1 and 8 of each treatment cycle) by IV infusion, Cyclophosphamide (C): 600 mg/m2 IV (Day 1 of each treatment cycle) by IV infusion. inTERVENTION 2: Docetaxel+Cyclophosphamide (TC), Docetaxel (T): 75 mg ',\n",
       " 'Adverse Events 1:, Total: 3/12 (25.00%), Hemoglobin 1/12 (8.33%), Alkaline phosphatase 1/12 (8.33%), Dehydration 1/12 (8.33%), Syncope 2/12 (16.67%), Dyspnea 1/12 (8.33%), Hypotension 1/12 (8.33%)Adverse Events 1:, Total: 0/115 (0.00%), Deep vein thrombosis * [1]0/115 ',\n",
       " 'at least 18 years of age, Female, Able to understand and willing to sign an IRB-approved written informed consent document, Exclusion Criteria:, Pregnant and/or breastfeeding, Prior history of breast cancer, Prior history of chest wall radiation, Prior history of breast reconstruction, reduction, or augmentationInclusion Criteria:, Patient must be 18 and older, Patients must have histologically confirmed (by routine H&E staining) invasive adenocarcinoma or Ductal Carcino women of child-bearing potential must use effective non-hormonal contraception while undergoing radiation therapy. patients must not have a serious medical or psychiatric illness which prevents informed consent or compliance with treatment. ',\n",
       " 'inTERVENTION 1:, arm II, Patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1. oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3. r IV, dexamethasone: Given orally or IV, dexamethasone: Given orally or IV, dexamethasone: Given orally or IV, dexamethasone: Given orally or IV, dexamethasone: Given orally orally or IV, dexamethasone: Given orally orally or IV, dexamethasone: Given orally orally or IV, dexamethasone: Given orally orally ',\n",
       " 'results 1:, Arm/Group Title: Arm 1: Paclitaxel + Trastuzumab Then A C, Arm/Group Description: 4 cycles of paclitaxel 80 mg/m2 on days 1, 8 and 15 of a 28-day cycle. follow paclitaxel/trastuzumab, standard AC every 21 days for 4 cycles. Neratinib 240 mg orally once daily beginning on Day 1 of paclitaxel. standard AC every 21 days for 4 cycles. following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy. ',\n",
       " 'participants able to receive iron supplement, if necessary, Exclusion Criteria:, Known or suspected contraindications to epoetin beta, Pregnancy or lactation period, Diagnosis of anemia only due to iron-deficiency, Epilepsy and/or cerebral metastasis, Blood transfusion or treatment with any erythropoietic factor within 4 weeks. patient has score of 0 or 1 on the neurotoxicity evaluation. previous diagnosis of diabetic neuropathy or peripheral neuropathy from any cause, Diagnosis of fibromyalgia. ',\n",
       " 'all subjects treated under this protocol will have histologically documented cancer of one of the following types:, A. Metastatic breast cancer (7 triple negative, 23 ER+ after the first 15 patients are enrolled on the non-CCND1cohort; in addition 10 HER2+ for combination trastuzumab and PD0332991 therapy) up to 55 total enrollment slots B. Advanced or metastatic esophageal and/or gastric cancer (15-30 enrollment slots) D. Cisplatin subjects will be > 18 years old, The subject has disease that is assessable by tumor marker, physical, or radiologic means. the subject has an Eastern Cooperative Oncology Group performance status of 0 or 1. subject is capable of understanding and complying with protocol requirements. sexually active subjects (male and female) must use accepted methods of contraception. female subjects of childbearing potential must have negative pregnancy test at screening. patients with HER2-overexpressing tumors may receive trastuzumab. subject has received any other type of investigational agent within 28 days. subject has not recovered from clinically-meaningful toxicity due to prior therapy. subject has untreated or uncontrolled brain metastases. the subject has a baseline corrected QT interval (QTc) > 470 ms. the subject is known to be positive for the human immunodeficiency virus. ',\n",
       " 'unilateral breast cancer with ipsilateral lumpectomy or mastectomy and lymph node dissection (sentinel biopsy or axillary dissection), stage II or III unilateral secondary upper extremity lymphedema. girth 2 cm circumferential difference and/or volume 200 mL compared to the uninvolved upper extremity at any 4 cm segment. 0 (morbid obesity) ',\n",
       " 'inTERVENTION 2:, Part 1: Cohort 2a, MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW, inTERVENTION 2:, Part 1: Cohort 2a, MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW. ',\n",
       " 'an AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. treatment-emergent are events between first dose and up to 28 days after last dose that were absent before treatment or worsened relative to pretreatment state. docetaxel 75 milligram/square meter (mg/m2) intravenous infusion over 1 hour on Day 1 of each cycle and trastuzumab either weekly. loading dose of 4 milligram/kilogram (mg/kg) intravenous infusion over 90 minutes on Day 1 followed by weekly maintenance doses of 2 mg/kg intravenous infusion over 30 minutes. cycle length was 3 weeks. ',\n",
       " 'Adverse Events 1:, Total: 0/10 (0.00%)Adverse Events 1:, Total: 0/1699 (0.00%), Adverse Events 2:, Total: 0/2004 (0.00%) ',\n",
       " 'patients with vitamin D deficiency who experience myalgias, arthralgias and/or joint stiffness who experience joint stiffness and joint stiffness. ',\n",
       " 'locally recurrent or metastatic breast cancer must not be amenable to resection with curative intent. prior hormonal therapy in adjuvant, recurrent, or metastatic setting allowed but must have been discontinued at least 2 weeks before randomization. at least 1 week since minor surgery and/or focal/palliative radiation therapy. at least 3 weeks from radiation; at least 4 weeks from major surgery. at least 8 weeks from liver resection, thoracotomy, or neurosurgery. cBP unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months after treatment with bevacizumab. women with a positive pregnancy test on enrollment or prior to study drug administration. thracyclines not within institutional normal limits. history of high dose chemotherapy with bone marrow transplant or peripheral blood stem cell transplant within 2 years. ',\n",
       " 'Progression Free Survival (PFS) was defined as the time from first study drug dosing (during the maintenance treatment phase) to the first documented disease progression or death, whichever occurred first. Progressive Disease (PD) was defined as a 20 percent increase in the sum of the Longest Diameter (LD) of the target lesions taking as reference the smallest sum LD recorded or appearance of new lesions. ll participants received bevacizumab 15 mg/kg IV on Day 1 of each 3 week cycle for a minimum of 3 cycles and a maximum of 6 cycles or until disease progression, unacceptable toxicity or participant request for withdrawal. participants with an objective response (PR or CR) or SD received 15 mg/kg bevacizumab IV on Day 1 of each 3 week cycle for a minimum of 3 cycles and a maximum of 6 cycles. ek cycle for a minimum of 3 cycles and a maximum of 6 cycles or until disease progression, unacceptable toxicity or withdrawal, whichever occurred first. participants with an objective response were randomized to receive bevacizumab 15 mg/kg IV on Day 1 of each 3-week cycle plus capecitabine 1000 mg/m2 twice daily on Days 1 to 14 of each 3 week cycle. if one of the drugs was discontinued before disease progression, treatment was continued with the second drug until disease progression, unacceptable ',\n",
       " 'women and men ages 18 or older have an anticipated treatment-free life span of 12 months or longer. have a BMI of 25 kg/m2 or greater and weight =400 lbs., Willingness to accept randomization to each of the three arms, Willingness to change diet, physical activity, and weight. abetes, fasting blood glucose >=200 mg/dL, or fasting blood glucose >=126 and 200 mg/dL and HbA1C >=7%, Current or prior regular use of metformin within the past 3 months, Uncontrolled concurrent medical condition likely to limit compliance with the study interventions, Received any chemotherapy (unless anti-hormonal therapy) and/or radiation three months or less prior to the proposed intervention date, Have significant renal disease or dysfunction defined as Estimated glomerular  lorcaserin, topiramate/phentermine, phentermine, liraglutide, and bupropion/naltrexone have been prescribed weight loss medication(s) or over-the-counter weigh loss medications such as Orlistat within the past 6 months. ',\n",
       " '0/33 (0.00%)Adverse Events 1:, Total: 5/16 (31.25%), ANAEMIA 1/16 (6.25%), LEUKOPENIA 1/16 (6.25%), NEUTROPENIA 3/16 (18.75%), THROMBOCYTOPENIA 1/16 (6.25%), FEBRILE INFECTION 1/16 (6.25%), PNEUMONIA 1/16 (6.25%), PNEUMONIA 1/16 (6.25%), PNEUMONIA 1/16 ( ',\n",
       " 'neutropenic fever, weakness 1/50 (2.00%), urinary tract infection 1/50 (2.00%), cellulitis 4/50 (8.00%), wound dehiscence 1/50 (2.00%), hematoma 1/50 (2.00%), seroma 1/50 (2.00%), inflammation (red breast syndrome) 2/50 (4.00%) ',\n",
       " '1/9 (11.11%), Death, not otherwise specified 0/9 (0.00%), Pain, bone 1/9 (11.11%), Adverse Events 2:, Total: 1/9 (11.11%), Death, not otherwise specified 1/9 (11.11%), Pain, bone 0/9 (0.00%)Adverse Events 1:, Total: 1/208 (0.48%), Neutrophils/granulocytes (ANC/AGC) 1/208 (0.48%), Adverse Events 2:, Total: 0/ ',\n",
       " 'cases with stage II-IIIA breast cancer have completed adjuvant treatment with anthracyclines and/or taxanes + or -Radiation therapy within past 6 months(+/- 7 days) Must be aware of the nature of his current medical condition and must be willing to give consent after being informed of the experimental nature of therapy, alternatives, potential benefits, side-effects, risks and discomfort. use of estrogens (oral, dermal or vaginal), progesterone (oral or topical), androgens, androgens, Raloxifene or Tamoxifen during the previous 3 months. use of over the counter steroid hormonal supplements including dehydroepiandrosterone (DHEA), patients with advanced or Stage IIIIB or IV breast cancer or other cancers. l or psychiatric condition or laboratory abnormality may increase risk associated with study participation or study drug administration. investigator would make potential participant inappropriate for entry into this study. ',\n",
       " 'change in total body lean mass measured by dual energy x-ray absorptiometry (DEXA) from baseline to 4 months. time frame: Baseline to four months. ',\n",
       " 'Contour Profile Tissue Expander is a tissue expander with a greater height to width ratio than traditional tissue expanders. this increased ratio allows for greater lower pole expansion, thus creating a more natural looking, ptotic breast. ',\n",
       " 'inTERVENTION 1:, arm A (ANA), patients receive oral anastrozole as 1 mg film-coated tablets. patients receive fulvestrant intramuscularly (250 mg/5 ml solution) on days 1, 14 and 28. ',\n",
       " 'all patients receive 3 doses of high-dose Methotrexate (HD-MTX) every 2 weeks given intravenously and 3 doses of Intrathecal (IT) Liposomal Cytarabine (Depocyt) every 2 weeks over 6 weeks. ',\n",
       " 'patients without liver involvement or history of liver disease will be treated at a dose of 98.7 mg/m2. patients will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance. patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2. patients will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance. ',\n",
       " 'intra-operative digital mammography compared with standard specimen mammography. overall number of participants Analyzed: 36, Median (Full Range), Unit of Measure: Minutes Procedure Time: 48.5 (17 to 138), OR Time: 68 (29 to 180), Results 2:, Arm/Group Title: Standard Mammography, Arm/Group Description: Standard Specimen Mammography, Standard Mammography: There is not an added device associated with this arm. participants received immediate breast reconstruction using a sub-muscular tissue expander (TE) and acellular dermal matrix (ADM) sling during the same surgery. post-mastectomy radiation therapy (PMRT) no sooner than a minimum of 6 weeks and optimally 6 months. the prescribed chest-wall dose was 50 -50.4 gray (Gy) in 25-28 fractions given once daily over 5-7 weeks with a 0.5-centimeter (cm) bolus to the scar every other day. ',\n",
       " \"2.3 Dental evaluation according to the dental exam checklist (carried out by the investigator, the investigator's designee, or by a qualified dental professional [dental hygienist or dentist]) if the patient has received prior oral bisphosphonate therapy within 8 weeks of registration, the evaluation should not be revoked. complete blood count (CBC)/differential within 2 weeks prior to registration, with adequate bone marrow function defined as follows: White blood cell count (WBC) 2400 cells/mm3; Absolute neutrophil count (ANC) 1,800 cells/mm3; Platelets 60,000 cells/mm3; Hemoglobin 8.0 g/dl (Note: The use of transfusion or other intervention to achieve the required hemoglobin is permitted) beam radiation therapy must be completed 14 days prior to registration. patients with no evidence of disease in the brain after treatment for brain metastases are eligible. prior treatment with Strontium-89 or Samarium-153 for bone metastases. prior treatment with IV bisphosphonates prior to study entry. current, active dental problems within 4 weeks of registration. the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. pregnant or lactating patients are excluded as treatment may be harmful to embryos and/or nursing infants. the study should be finished 30 days before the beginning of the study. if the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose of anthracyclines should not exceed 250 mg/m2 for doxorubicin or 540 mg/m2 for epirubicin. n or 660 mg/m2 for epirubicin, if in this study planned 4 cycles of chemotherapy. patients of childbearing potential must implement reliable contraceptive measures. f bone metastases) administration of any experimental drugs within 30 days prior randomization. conditions limiting patient's ability to follow protocol. \",\n",
       " 'Bisphosphonate IV Q4W, Open-label intravenous (IV) bisphosphonate once every 4 weeks (Q4W), INTERVENTION 2: Denosumab 180 mg Q12W, Open-label denosumab 180 mg by subcutaneous injection once every 12 weeks (Q12W) ',\n",
       " 'patient must have histologically or cytologically confirmed locally advanced, unresectable or metastatic carcinoma of the breast. patient must have performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) performance scale and life expectancy > 3 months. patients with stable and clinically insignificant CNS disease are allowed. patients must be off steroids with no new CNS symptoms or findings on radiographic imaging for 1 month. patients must be off steroids with no new CNS symptoms or findings. patients with known active central nervous system metastases and/or carcinomatous meningitis would be eligible for the study provided they are clinically stable for at least 1 month prior to entry. patients with clinically insignificant brain metastases that do not require treatment are eligible for the study. rrent illness/infection, patients with other active, current primary malignancies, other than carcinoma in situ of the cervix or non-melanoma skin cancer, patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative, patients are pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study. ',\n",
       " 'Anaemia 1/106 (0.94%), Febrile neutropenia 1/106 (0.94%), Thrombocytopenia 1/106 (0.94%), Atrial fibrillation 1/106 (0.94%), Cardio-respiratory arrest 1/106 (0.94%), Palpitations 1/106 (0.94%), Pericardial effusion 2/106 (1.89%), Abdominal pain upper 1/106 (0.94%), Ascite 1/106 (0.94%), Constipation 1/106 ( ',\n",
       " '3/37 (8.11%), Sinus tachycardia 0/37 (0.00%), Heart failure 0/37 (0.00%), Dehydration 1/37 (2.70%), Death Not Associated with CTCAE: Death NOS 1/37 (2.70%), Lymphopenia 1/37 (2.70%), Neutropenia 1/37 (2.70%), Thrombocytopenia 0/37 (0.00%), Hyponatremia 1/37 (2.70%), Weight loss 0/37 ( ',\n",
       " 'ovarian cancer patients should have one prior platinum-based, chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound. patients with platinum-sensitive and platinum resistant disease are NOT eligible. the effects of BMN 673 on the developing human fetus are unknowable. the effects of BMN 673 on the developing human fetus are unknown. men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 30 days after completing study treatment. men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for the duration of study participation. human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer should have received at least two lines of systemic therapy. patients with prostate cancer can continue to receive treatment with GnRH agonists while on study, as long as there is evidence of disease progression on therapy. nt of brain metastases are eligible to participate at the discretion of the principal investigator. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations would limit compliance with study requirements. patients who require use of coumarin-derivative anticoagulants are excluded. low-dose warfarin (less than or equal to 1 mg/day) is permitted. in subjects with documented liver metastases, the AST/ALT may be 5x ULN, Prothrombin time 1.5x ULN, unless receiving therapeutic anticoagulation, Serum magnesium and potassium within normal limits. subjects with documented liver metastases are eligible if controlled on a stable dose 10mg prednisone/day or its equivalent dose of steroids. Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C. subjects with liver cancer and hepatitis may be eligible. ',\n",
       " 'participants received lenalidomide 5mg orally daily for 57 +/- 3 daysINTERVENTION 1:, Lapatinib 1500 mg, Oral lapatinib (1500 milligrams [mg] daily) for 6 weeks, followed by lapatinib plus weekly paclitaxel (80 mg per meters squared [mg/m2]) intravenous (IV) for an additional 12 weeks. ',\n",
       " 'Phase 2 requires Non-small cell lung cancer (NSCLC); Small-cell lung cancer; Breast adenocarcinoma (female patients only); or Gastroesophageal adenocarcinoma. Male patients who are post menopausal, surgically sterile, agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse. teria are not to be enrolled in the study: female patients who are pregnant or lactating, Serious medical or psychiatric illness that could interfere with protocol completion. there is no limit on the number of prior noncytotoxic therapies, prior treatment with Aurora A-targeted agents, including MLN8237. ctive infection requiring systemic therapy, or other serious infection, Inability to swallow oral medication, Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C, Patients requiring full systemic anticoagulation, History of uncontrolled sleep apnea syndrome, treatment with clinically significant enzyme inducers within 14 days prior to the first dose of MLN8237. ansion cohorts must have tumor available for biopsy and agree to pre-treatment and on-treatment tumor biopsies. Subject has measurable or evaluable disease by response evaluation criteria in solid tumors. Subject is aged greater than or equal to (>=) 18 years. subject has been previously treated with a PI3K inhibitor or a MEK inhibitor. Subject has received:, Chemotherapy, immunotherapy, hormonal therapy, biologic therapy, or any other anti-cancer therapy within 28 days of trial drug treatment. Subject has poor organ and marrow function as defined in the protocol. Subject has participated in another clinical trial within the past 30 days. Other protocol-defined exclusion criteria could apply. ',\n",
       " 'ECOG performance status of 0 to 2, Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST), Exclusion Criteria:, prior or concurrent hormonal therapy for breast cancer, Histologically confirmed breast cancer, stage I-III disease, scheduled to undergo definitive surgery or other primary treatment. nant or nursing, Negative pregnancy test, Fertile patients must use effective contraception, No ongoing or active infection, No psychiatric illness or social situation that would preclude study compliance, No other uncontrolled intercurrent illness, No other uncontrolled intercurrent illness, No history of allergic reaction attributed to compounds of similar chemical or biologic composition to vorinostat, Concurrent vaginal hormone preparations (e.g., vagifem or estring) allowed, No concurrent birth control pills, No prior patients may not be taking valproic acid or another histone deacetylase inhibitor for at least 2 weeks prior to initiating SAHA. women who are pregnant may not be taking valproic acid or another histone deacetylase inhibitor for at least 2 weeks before initiating SAHA. ',\n",
       " 'treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity. cyclophosphamide, paclitaxel, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab subjects 98 (92.2 to 99.5). subjects 98 (92.2 to 99.5) ',\n",
       " \"dose-limiting toxicities are assessed according to the national Cancer Institute's Common Terminology Criteria for Adverse Events classification. the classification usually encompasses all grade 3 or higher toxicities, Time frame: 28 days. given IV, pegylated liposomal doxorubicin hydrochloride: Given IV, overall number of participants Analyzed: 6, Measure Type: Number, Unit of Measure: participants 1__________________________________________________________________ \",\n",
       " 'patients must have axillary lymph node involvement assessment and initiation of study treatment of less than or equal to 84 days. resected specimen must be free of invasive disease and/or ductal carcinoma in situ (DCIS) patients receiving anti-coagulation treatment with an agent such as warfarin may be allowed to participate. patients with HER2 positive breast cancer as determined by FISH or IHC3+ standing are ineligible for this trial. c blood pressure > 100 mmHg on antihypertensive medications. current therapy with raloxifene, tamoxifen or other selective estrogen receptor modulator. women who are pregnant must use effective birth control measures. g event NCI CTCAE v3.0 Grade 3 within 4 weeks of first dose of study drug. submit unstained representative tumor specimen, either as a paraffin block (preferred) or 10 unstained slides. ation known to be a potent CYP3A4 inducer or inhibitor. ',\n",
       " \"19/149 (12.75%), Anaemia 0/149 (0.00%), Anaemia 0/149 (0.00%), Acute myocardial infarction 1/149 (0.67%), Prinzmetal angina 1/149 (0.67%), Meniere's disease 0/149 (0.00%), Vertigo 0/149 (0.00%), Cataract 2/149 (1.34%), Colitis ischaemic 1/149 (0.67%), Nausea 0/149 (0.00 \",\n",
       " 'memantine hydrochloride: Estimate participation, accrual, adherence, and retention of cancer survivors who smoke. inTERVENTION 2:, Arm II - Placebo. ',\n",
       " 'participants able to receive iron supplement, if necessary, Exclusion Criteria:, Known or suspected contraindications to epoetin beta, Pregnancy or lactation period, Diagnosis of anemia only due to iron-deficiency, Epilepsy and/or cerebral metastasis, Blood transfusion or treatment with any erythropoietic factor within 4 weeks. patient has score of 0 or 1 on the neurotoxicity evaluation. previous diagnosis of diabetic neuropathy or peripheral neuropathy from any cause, Diagnosis of fibromyalgia. ',\n",
       " 'Febrile neutropenia * 2/5 (40.00%), Anaemia * 0/4 (0.00%), Vertigo * 0/4 (0.00%), Nausea * 0/4 (0.00%), Stomatitis * 0/4 (0.00%), Vomiting * 0/4 (0.00%), Disease progression * 0/4 (0.00%), Mucosal inflammation * 0/4 (0.00%), Fatigue * 0/4 (0.00%), Pyrexia * 0/4 (0.00%), Ga ',\n",
       " 'patients 18 years of age or older are eligible for the study. patients undergoing skin-sparing mastectomy are eligible for the study. patients who have not undergone autologous tissue breast reconstruction. must have completed surgery for stage I-III breast cancer. must have a plasma c-reactive protein level of >3mg/L. must have score of 4 (out of 10 points, 0 being no fatigue and 10 being severe, incapacitating fatigue) on a single Item Screening Scale for Fatigue. uncontrolled cardiovascular, metabolic, pulmonary or renal disease (as determined by medical history and laboratory testing), Current or past history of schizophrenia, Individuals with bipolar disorder who have experienced a manic episode within 6 months of study entry, or at the discretion of the study doctor. Individuals receiving antidepressants, mood stabilizers, antipsychotic medications or benzodiazepines or drugs known to affect the immune system (e.g. glucocorticoids, methotrexate), or at the ',\n",
       " 'invasive disease-free survival time is defined as the time from date of randomization until time of event up to 2 years. time is defined as the time from date of randomization until time of event up to 2 years. patients who completed prior adjuvant trastuzumab received six placebo tablets (240 mg) taken orally once daily with food, preferably in the morning, continuously for one year. therapy continued until unacceptable toxicity, recurrent disease, death, or withdrawal of consent occurred. ',\n",
       " 'AINTERVENTION 1:, Phase 1: MLN8237 10 mg, MLN8237 (alisertib) 10 milligram (mg), enteric-coated tablets, orally, twice daily for 7 days followed by 14 days of rest period in 21-day treatment cycles. or until progressive disease, unacceptable treatment-related toxicity, or initiation of a different anticancer therapy during Phase 1 portion of the study. treatment-related toxicity, or initiation of a different anticancer therapy during Phase 1 portion of the study. ',\n",
       " 'inTERVENTION 2:, Part 1: Cohort 2a, MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW, inTERVENTION 2:, Part 1: Cohort 2a, MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW. ',\n",
       " \"participants must have histologically or cytologically proven metastatic or locally advanced solid tumors. no standard therapy exists or standard therapy has failed. disease must be measurable with at least 1 uni-dimensional measurable lesion by RECIST 1.1, except for participants with metastatic castrate-resistant prostate cancer. participants in the MBC cohort must have relapsed, refractory, or progressive disease following last line of treatment. Availability of tumor archival material or fresh biopsies is mandatory for eligibility in the expansion cohorts. participants in the NSCLC cohort will only be enrolled in USA, NSCLC first line: Stage IV or recurrent NSCLC that is histologically proven. participants should have received no more than 1 line of treatment for metastatic disease. participants with gastric cancer can enter in the study if their white blood cell (WBC) and lymphocyte count is as defined in the protocol, MBC: Participants must have histologically confirmed locally advanced or MBC. participants must have received no more than 3 prior lines of cytotoxic therapy for metastatic disease. pansion cohorts include gastric and GEJ cancer (third line), ovarian cancer (platinum Refractory + liposomal doxorubicin), urothelial carcinoma, and HNSCC. other protocol defined inclusion criteria for expansion phase could apply. basal or squamous cell carcinoma of the skin or cervical carcinoma in situ, Rapidly progressive disease (for example, tumor lysis syndrome), Active or history of central nervous system metastases, Receipt of any organ transplantation including allogeneic stem-cell transplantation. Known severe hypersensitivity reactions to monoclonal antibodies, any history of anaphylaxis, or uncontrolled asthma, Persisting toxicity related to prior therapy greater than Grade 1 NCI-CTCAE inflammatory bowel disease may impair Participant's tolerance of trial treatment. legal incapacity or limited legal capacity, non-oncology vaccine therapies for prevention of infection disease. vaccination while on study is also prohibited except for administration of the inactivated influenza vaccine. \",\n",
       " 'ductal breast carcinoma in situ (DCIS), or lobular carcinoma in situ (LCIS) (currently without evidence of malignant disease) OR a concern about taking estrogen for fear of breast cancer, Bothersome hot flashes (defined by their occurrence of >= 28 times per week) se inhibitors/serotonin?norepinephrine reuptake inhibitors are allowed. patient must have been on a constant dose for at least 28 days. if patient has history of GERD despite appropriate therapy. symptoms are well-controlled with medical treatment, patient is eligible, patient is eligible, Ulcerative colitis, Narrow-angle glaucoma, Urinary retention, Hypersensitivity to oxybutynin or any other components of the product, Current uncontrolled hyperthyroidism, Coronary heart disease (angina or prior myocardial infarction), congestive heart failure, Symptomatic cardiac arrhythmias, Current uncontrolled hypertension, Myasthenia gravis, Dement ',\n",
       " 'ER positive, HER2 negative invasive breast cancer (Group 1) or invasive triple-negative breast cancer (Group 2), Free of metastatic disease, 18 years old, Female, Had no prior treatment for any cancer, Eligible for treatment with paclitaxel, doxorubicin and cyclophosphamide. ',\n",
       " 'menopausal: 12 months spontaneous amenorrhea or > 6 but  12 months amenorrhea with a serum follicle stimulating hormone (FSH) level of > 40 mIU/mL. able to read, understand and complete the required subject diary. legal incapacity or limited legal capacity. chronic renal (serum creatinine > 2.0 mg/dL) or hepatic disease. untreated overt hyperthyroidism. rmal (a subject will not be excluded if a second measurement is less than twice the upper limit of normal), Creatinine > 2.0 mg/dLInclusion Criteria: adult patients, >=18 years of age; HER2-negative metastatic breast cancer candidates for taxane-based chemotherapy; ECOG performance status of 0 or 1. ',\n",
       " \"tivantinib-naive participants must have a negative pregnancy test performed within 14 days of the start of study drug. both men and women must agree to use adequate birth control measures while enrolled in this study. on study, Exclusion Criteria:, Known or suspected allergy to ARQ 197, Substance abuse, medical, psychological or social conditions that may interfere with the participant's participation in the study. A serious uncontrolled medical disorder/condition that in the opinion of the Investigator would impair the ability of the participant to receive protocol therapy. participants must have histologically or cytologically proven metastatic or locally advanced solid tumors. no standard therapy exists or standard therapy has failed. disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1. participants must have relapsed, refractory, or progressive disease following last line of treatment. Availability of tumor archival material or fresh biopsies is mandatory for eligibility in the expansion cohorts. participants in the NSCLC cohort will only be enrolled in USA, NSCLC first line. participants must not have received treatment for their metastatic or recurrent disease. participants should have received no more than 1 line of treatment. participants with gastric cancer can enter in the study if their white blood cell and lymphocyte count is as defined in the protocol, MBC. participants must have histologically confirmed locally advanced or MBC. participants must have received no more than 3 prior lines of cytotoxic therapy for metastatic disease. ovarian cancer (platinum Refractory + liposomal doxorubicin), urothelial carcinoma, and HNSCC as defined in the protocol. other protocol defined inclusion criteria for expansion phase could apply. Exclusion criteria for dose escalation and expansion phase could apply. s cell carcinoma of the skin or cervical carcinoma in situ, Rapidly progressive disease (for example, tumor lysis syndrome), Active or history of central nervous system metastases, Receipt of any organ transplantation including allogeneic stem-cell transplantation. s cell carcinoma of the skin or cervical carcinoma in situ, Rapidly progressive disease (for example, tumor lysis syndrome), Active or history of any organ transplantation including allogeneic stem-cell transplantation. investigator's opinion might impair Participant's tolerance of trial treatment. legal incapacity or limited legal capacity, Non-oncology vaccine therapies for prevention of infection disease (for example, seasonal flu vaccine, human papilloma virus vaccine) Vaccination while on study is also prohibited except for administration of inactivated influenza vaccine. \",\n",
       " '77/122 (63.11%), Anaemia 1/122 (0.82%), Thrombocytopenia 1/122 (0.82%), Pericardial effusion 3/122 (2.46%), Supraventricular tachycardia 2/122 (1.64%), Atrial fibrillation 1/122 (0.82%), Sinus tachycardia 1/122 (0.82%), Hypothyroidism 1/122 (0.82%), Abdominal pain 4/122 (3.28%)Adverse ',\n",
       " 'Total: 16/51 (31.37%), Blood disorder 1/51 (1.96%), Hypomagnesemia 1/51 (1.96%), Platelets count decrease 1/51 (1.96%), Thrombosis 1/51 (1.96%), Vision-blurred vision 1/51 (1.96%), Constipation 1/51 (1.96%), Radiation oesophagitis 1/51 (1.96%), Nausea 2/51 (3.92%), Vomiting 2/51 (3.92%), Head ',\n",
       " 'CR is defined as the disappearance of all lesions (target and/or non-target) PR is defined as at least a 30% decrease in the sum of the longest dimensions (LD) of target lesions taking as a reference the baseline sum LD, with non-target lesions not increased or absent. ast 6 cycles., Overall Number of Participants Analyzed: 60, Measure Type: Number, Unit of Measure: percentage of participants 53_. ',\n",
       " 'treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity. cyclophosphamide, paclitaxel, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab, trastuzumab subjects 98 (92.2 to 99.5). subjects 98 (92.2 to 99.5) ',\n",
       " 'inTERVENTION 1:, arm II, Patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1. oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3. r IV, dexamethasone: Given orally or IV, dexamethasone: Given orally or IV, dexamethasone: Given orally or IV, dexamethasone: Given orally or IV, dexamethasone: Given orally orally or IV, dexamethasone: Given orally orally or IV, dexamethasone: Given orally orally or IV, dexamethasone: Given orally orally ',\n",
       " 'an AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. treatment-emergent are events between first dose and up to 28 days after last dose that were absent before treatment or worsened relative to pretreatment state. docetaxel 75 milligram/square meter (mg/m2) intravenous infusion over 1 hour on Day 1 of each cycle and trastuzumab either weekly. loading dose of 4 milligram/kilogram (mg/kg) intravenous infusion over 90 minutes on Day 1 followed by weekly maintenance doses of 2 mg/kg intravenous infusion over 30 minutes. cycle length was 3 weeks. ',\n",
       " 'one to three presumed brain metastases must be from a histologically confirmed extracerebral site (e.g., lung, breast, prostate), Histologic confirmation may have been from the primary tumor site, from another metastatic site (e.g., osseous metastasis, adrenal metastasis), or from the metastatic brain lesion(s) Each lesion must measure less than 3.0 cm by contrast MRI of the brain performed within the past 21 days. male patients must continue to use contraception for 3 months after the completion of radiotherapy. no pacemaker or other MRI-incompatible metal in the body, no known allergy to gadolinium, no known allergy to gadolinium. volunteers may have had a prior history of other cancers > 3 years which required only local resection, local radiation and/or hormonal therapy such as androgen blockade. d risk of the proposed study and be able to sign consent. e influenza vaccine, On-going neurologic disorder (mental status change, uncontrolled seizures, encephalopathy), Treatment or planned treatment with cyclophosphamide, ifosphamide, or > or = to 1 mg/kg prednisone or its equivalent 12 weeks within 12 weeks of vaccination. patients receiving the seasonal influenza vaccine may not have had it within 6 months of enrollment. ',\n",
       " \"if a taxane had been administered in the neoadjuvant or adjuvant setting, progression must have occurred >12 months after completion of this treatment. radiotherapy as palliative treatment for painful metastatic disease is permitted but must have been stopped within 2 weeks prior to any investigational treatment. ning disease is considered to be inapplicable to hormonal therapy. ning disease must have been stopped before the first dose of investigational treatment. an investigational drug within 30 days or five half-lives preceding the first dose of investigational treatment. unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or prior anti-cancer treatment. subjects with ulcerative colitis are excluded. metastases or leptomeningeal carcinomatosis would make subject inappropriate for study participation or any serious medical disorder that would interfere with subject's safety. subject must have histologically confirmed invasive breast cancer with Stage IV disease at primary diagnosis or at relapse after curative-intent surgery. neoplastic nature of the disease should have been confirmed by cytology or histology. subjects must have received no more than one prior chemotherapeutic regimen in the metastatic setting. prior therapy with radiation for this breast cancer population was permitted if it was administered in the neoadjuvant or adjuvant non metastatic setting. subject must have completed radiation treatment and recovered from all related toxicities. subject must have received all prior chemo treatment at least 4 weeks prior to enrollment in this study. prior therapy with trastuzumab in the neoadjuvant, adjuvant or metastatic setting was permitted. prior diagnosis of cancer was allowed as long as the subject was free of disease for 5 years. subjects with completely resected basal or squamous cell skin cancer, thyroid cancer or successfully treated cervical carcinoma in-situ were allowed into the study. women with oligomenorrhoea (severe), women who were perimenopausal and young women who had begun to menstruate must provide a negative serum pregnancy test at Screening. subjects must provide a negative serum pregnancy test and agree to 1 of the following: Complete abstinence from intercourse from 2 weeks prior to administration of the first dose of study medication until 5 days after the final dose of study medication. e Investigator to have a life expectancy of 6 months. Subjects must have had normal organ and marrow function as below. subject must have been free of gastrointestinal diseases that impede swallowing and retaining oral medications. bisphosphonate therapy for bone metastases was allowed; treatment must be initiated prior to the first dose of study medication. subjects without bone disease, except for osteoporosis, were included in the study if they met the following criteria. subjects who received more than one prior chemotherapeutic regimen were not eligible for the study. this included human immunodeficiency virus-positive subjects receiving combination anti-retroviral therapy because of possible pharmacokinetic interactions with lapatinib. uncontrolled inter-current illness includes, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would have limited compliance with study requirements. subjects with diseases affecting gastrointestinal function resulting in an inability to take oral medication. ation, prior surgical procedures affecting absorption e.g. gastric resection and uncontrolled inflammatory bowel disease (e.g., Crohn's, ulcerative colitis). subjects who had been disease-free for 5 years, or subjects with completely resected basal or squamous cell skin cancer, thyroid cancer or successfully treated cervical carcinoma in situ were eligible if it had been at least 1 year since definitive surgery. clinical investigator's Brochure (IB), SPM, and the nab-paclitaxel product label. \",\n",
       " 'asymptomatic women scheduled for screening mammography or have completed a screening mammogram within the past 30 days. subjects with prior lumpectomy (> 5 years prior) who receive only routine screening mammography views can be included. x 31 centimeter (cm) FFDM digital receptor without anatomical cut off during either FFDM or DBT examination. have participated in (within the prior 30 days) another trial of an investigational product expected to interfere with study procedures or outcomes. ',\n",
       " 'inTERVENTION 1:, Placebo, Buminate solution, Placebo: 20 transendocardial injections of 0.4ml allo-MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure) ',\n",
       " 'all patients receive 3 doses of high-dose Methotrexate (HD-MTX) every 2 weeks given intravenously and 3 doses of Intrathecal (IT) Liposomal Cytarabine (Depocyt) every 2 weeks over 6 weeks. ',\n",
       " 'women and men ages 18 or older have an anticipated treatment-free life span of 12 months or longer. have a BMI of 25 kg/m2 or greater and weight =400 lbs., Willingness to accept randomization to each of the three arms, Willingness to change diet, physical activity, and weight. abetes, fasting blood glucose >=200 mg/dL, or fasting blood glucose >=126 and 200 mg/dL and HbA1C >=7%, Current or prior regular use of metformin within the past 3 months, Uncontrolled concurrent medical condition likely to limit compliance with the study interventions, Received any chemotherapy (unless anti-hormonal therapy) and/or radiation three months or less prior to the proposed intervention date, Have significant renal disease or dysfunction defined as Estimated glomerular  lorcaserin, topiramate/phentermine, phentermine, liraglutide, and bupropion/naltrexone have been prescribed weight loss medication(s) or over-the-counter weigh loss medications such as Orlistat within the past 6 months. ',\n",
       " 'FEBRILE NEUTROPENIA * 0/3 (0.00%), ANAEMIA * 0/3 (0.00%), THROMBOCYTOPENIA * 0/3 (0.00%), ATRIAL FLUTTER * 0/3 (0.00%), BRADYCARDIA * 0/3 (0.00%), VOMITING * 0/3 (0.00%), Adverse Events 2:, Total: 0/3 (0.00%), FEBRILE NEUTROPENIA * 0/3 ',\n",
       " 'INCLUSION CRITERIA, Female, Diagnosis of Breast Cancer (Stage I-IIIA), Scheduled for planned cancer treatment (eg, chemotherapy or biologic agents) or treatment is continuing, Has 6 weeks of cancer treatment (eg, chemotherapy or biologic agents) remaining, 21 years of age. have an unstable self-reported medical or psychiatric illness (Axis I - current or within the last 5 years) participants must have histologically or cytologically confirmed breast cancer or non-hodgkin lymphoma. doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2 and docetaxel 75 mg/m2. doxorubicin 50 mg/m2, vincristine 1.4 mg/m2. leukocytes >3,000/microliter (mcL) (unless due to cancer in marrow), neutrophil count >1,500/mcL (unless due to cancer in marrow), platelets >100,000/mcL (unless due to cancer in marrow), total bilirubin 1.5 X normal institutional limits, aspartate aminotransferase (AST) or serum glutamic oxaloacetic transaminase (SGOT) udy participant should inform treating physician immediately. patients who have had chemotherapy or radiotherapy within 4 weeks. patients with known brain metastases should be excluded from this clinical trial. treatment of dementia is excluded from this study. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia. ',\n",
       " '3 patients were enrolled to the next cohort using a 5mg higher dose of ruxolitinib. the MTD is identified as the level BELOW the cohort where DLT occurred in less than one third of patients within the cohort. the maximum tolerated dose (MTD) was defined as the highest dose level in which a DLT is experienced by fewer than two patients in a cohort of 3 - 6 patients. if a DLT is observed in at least two patients in a cohort of 3 - 6 patients, the MTD will be determined to have been exceeded. all participants, Overall Number of Participants Analyzed: 20, Measure Type: Number, Unit of Measure: mg/kg NA [1] ',\n",
       " 'FEBRILE NEUTROPENIA * 0/3 (0.00%), ANAEMIA * 0/3 (0.00%), THROMBOCYTOPENIA * 0/3 (0.00%), ATRIAL FLUTTER * 0/3 (0.00%), BRADYCARDIA * 0/3 (0.00%), VOMITING * 0/3 (0.00%), Adverse Events 2:, Total: 0/3 (0.00%), FEBRILE NEUTROPENIA * 0/3 ',\n",
       " 'women may receive the AI on this study as initial adjuvant hormonal treatment or following tamoxifen. patients may have received preoperative chemotherapy, Postmenopausal status, defined as: >= 60 years of age; or  60 years of age and amenorrheic for >= 12 months prior to day 1 if intact uterus/ovaries. istory of bilateral oophorectomy; or prior radiation castration with amenorrhea for at least 6 months; or prior radiation castration with amenorrhea for at least 6 months;  60 years of age and taking medication designed to suppress ovarian function. women would have had to be taking the drug for at least 30 days prior to day 1. current bisphosphonate use (oral or intravenous); prior bisphosphonate users would be eligible as long as the use was > 1 month ago for oral bisphosphonates. prior bisphosphonate users would be eligible as long as the use was > 12 months ago for intravenous bisphosphonates. ',\n",
       " 'inTERVENTION 1:, Imaging Session 1, Fluciclatide Injection (AH111585 (18F) Injection)INTERVENTION 1:, Chloroquine Standard Dose (500mg/week) patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month standard dose chloroquine (500 mg/week) patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month low dose chloroquine (250mg/week) for 1 month prior to surgical removal of the DCIS lesion. this biopsy is entirely voluntary and is not required to remain in the study. ',\n",
       " 'no evidence of disease outside the breast or chest wall, except ipsilateral axillary lymph nodes. Final eligibility for a clinical trial is determined by the health professionals conducting the trial. ',\n",
       " 'if the patient had received the chemotherapy for breast cancer, it should be finished 30 days before the beginning of the study. if the patient had received the chemotherapy for breast cancer, it should be finished 30 days before the beginning of the study. patients of childbearing potential must implement reliable contraceptive measures during the study treatment, starting 4 weeks prior randomization and for 6 months after the last administration of the study drug. equirements: patient has received two or more chemotherapy regimens for metastatic breast cancer. uropathy, HIV, HCV, HBV, T.Pallidum infection(s);, acute or active chronic infections. patients must have a life expectancy of at least 1 year, excluding cancer diagnosis. patients must have a mass on clinical or radiological examination of >1 cm. bilirubin, serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate oxaloacetate transaminase (SGPT), alkaline phosphatase, and serum creatinine must all be  1.2 x upper limit of normal. patients with benign hyperbilirubinemia are also excluded. patients with non-breast malignancies are eligible if they have not received prior chemotherapy or extensive radiation therapy. patients with squamous or basal carcinoma of the skin that has been effectively treated are eligible. patients with prior or simultaneous lobular or ductal carcinoma in situ of the ipsilateral or contralateral breast are also eligible. patients will agree to continue contraception for 30 days from the date of the last study drug administration. patients who have received prior anthracycline therapy for any malignancy are not eligible. patients with a cardiac arrhythmia are eligible, provided the arrhythmia is not associated with concomitant heart failure or cardiac dysfunction. patients with a cardiac arrhythmia are eligible, provided the arrhythmia is not associated with concomitant heart failure or cardiac dysfunction. ness to give written informed consent. Unwillingness to participate or inability to comply with the protocol for the duration of the study. ',\n",
       " 'no evidence of disease outside the breast or chest wall, except ipsilateral axillary lymph nodes. Final eligibility for a clinical trial is determined by the health professionals conducting the trial. ',\n",
       " 'participants received intravenous infusion of PF-05212384 90 mg once on Day -7 and Cycle 1 Day 2. docetaxel 75 mg/m2 1-hour IV infusion once followed by PF-05212384 90 mg once. maximum duration of docetaxel treatment was 445 days. participants received docetaxel 75 mg/m2 1-hour IV infusion once on cycle 1 Day 1. maximum duration of PF-05212384 treatment was 505 days. maximum duration of docetaxel treatment was 445 days. ',\n",
       " 'ANAEMIA 13/2002 (0.65%), BONE MARROW FAILURE 1/2002 (0.05%), FEBRILE NEUTROPENIA 1/2002 (0.05%), THROMBOCYTOPENIA 11/2002 (0.55%), ACUTE CORONARY SYNDROME 3/2002 (0.15%), ANGINA PECTORIS 1/2002 (0.05%), CARDIAC ARREST 1/2002 (0.05%), CARDIAC TAMPONADE 1/2002 ',\n",
       " 'ANAEMIA 13/2002 (0.65%), BONE MARROW FAILURE 1/2002 (0.05%), FEBRILE NEUTROPENIA 1/2002 (0.05%), THROMBOCYTOPENIA 11/2002 (0.55%), ACUTE CORONARY SYNDROME 3/2002 (0.15%), ANGINA PECTORIS 1/2002 (0.05%), CARDIAC ARREST 1/2002 (0.05%), CARDIAC TAMPONADE 1/2002 ',\n",
       " \"2.3 Dental evaluation according to the dental exam checklist (carried out by the investigator, the investigator's designee, or by a qualified dental professional [dental hygienist or dentist]) if the patient has received prior oral bisphosphonate therapy within 8 weeks of registration, the evaluation should not be revoked. complete blood count (CBC)/differential within 2 weeks prior to registration, with adequate bone marrow function defined as follows: White blood cell count (WBC) 2400 cells/mm3; Absolute neutrophil count (ANC) 1,800 cells/mm3; Platelets 60,000 cells/mm3; Hemoglobin 8.0 g/dl (Note: The use of transfusion or other intervention to achieve the required hemoglobin is permitted) beam radiation therapy must be completed 14 days prior to registration. patients with no evidence of disease in the brain after treatment for brain metastases are eligible. prior treatment with Strontium-89 or Samarium-153 for bone metastases. prior treatment with IV bisphosphonates prior to study entry. current, active dental problems within 4 weeks of registration. the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. pregnant or lactating patients are excluded as treatment may be harmful to embryos and/or nursing infants. the study should be finished 30 days before the beginning of the study. if the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose of anthracyclines should not exceed 250 mg/m2 for doxorubicin or 540 mg/m2 for epirubicin. n or 660 mg/m2 for epirubicin, if in this study planned 4 cycles of chemotherapy. patients of childbearing potential must implement reliable contraceptive measures. f bone metastases) administration of any experimental drugs within 30 days prior randomization. conditions limiting patient's ability to follow protocol. \",\n",
       " 'Isothiocyanate included sulforaphane in micromolar (M) concentration was measured following standard chemical measurement procedures and divided by creatinine values in millimolar (mM) concentration. patients receive oral placebo supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity. Numeric Pain Rating Scale - pain rating scale 0-10 (0= no pain to 10= most pain imaginable) participants were re-assessed after the 2 round of TC and 4th round of FECD. atment, Overall Number of Participants Analyzed: 22, Measure Type: Number, Unit of Measure: percentage of participants Percentage of Participants with Pain (1-10): 30, Percentage of Participants with no pain (0): 70, Results 2:, Arm/Group Title: Control, Arm/Group Description: chemotherapy as usual without physical therapy. ',\n",
       " 'average pain was measured using a 0 (no pain) to 10 (worst pain imaginable) numeric rating scale on a daily basis. change in average pain intensity between the two intervention groups was evaluated from enrollment to the end of the study. follow-up visits to assess the sustainability of the intervention will be done at 2 weeks, 1 month and 3 months after the intervention. patients in both groups will be seen in their homes over the course of 10 weeks with phone calls conducted in between the home visits. patients in the LOW-DOSE group will receive 4 visits and 6 phone calls. follow-up visits to assess the sustainability of the intervention will be done at 2 weeks, 1 month and 3 months after the intervention. ',\n",
       " 'a higher serum total bilirubin ( 2 x ULN) is allowed, aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 2.5 times ULN, Alkaline phosphatase 2.5 times ULN, Renal status: Creatinine. patients must use effective contraception (barrier method - condoms, diaphragm - also in conjunction with spermicidal jelly, or total abstinence) patient accepts to make available tumour samples for submission to central laboratory to conduct translation studies. han 10 years prior to randomisation may enter the study. patients must have been curatively treated with surgery alone. prior diagnoses of breast cancer or melanoma are excluded. subjects with ulcerative colitis are also excluded. subjects with ulcerative colitis are also excluded. rdiogram (ECG), 18 years of age or above, Able to understand and sign informed consent, Pilot study only:, CRC, TNBC, ER/PR Breast Cancer, NSCLC, Pancreatic Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal Junction (GEJ) adenocarcinoma, Head and Neck Cancer, Expansion Phase Additional Criteria:, Locally advanced or metastatic breast cancer, Received at least one cytotoxic xytol, Inability to undergo MRI, Active infection, Pregnant or breast feeding, Prior chemotherapy administered within 3 weeks, or within a time interval less than at least 5 half-lives of the agent. prior to the first scheduled day of dosing in this study, received radiation therapy in the last 14 days, Treated with parenteral iron in the previous 4 weeks. ',\n",
       " 'Adverse Events 1:, Total: 1/13 (7.69%), Rapid disease progression [1]1/13 (7.69%), Increased pleural effusion [2]0/13 (0.00%), Adverse Events 2:, Total: 1/4 (25.00%), Rapid disease progression [1]0/4 (0.00%), Increased pleural effusion [2]1/4 (25.00%). ',\n",
       " 'patients without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis using the Response Evaluation Criteria in Solid Tumors criteria. the human epidermal growth factor receptor 2 status of the tumor will be used to stratify patients. patients may have received prior chemotherapy and/or hormonal therapy for early stage breast cancer. the chemotherapy regimen may have included an anthracycline and/or a taxane as long as it has been > 6 months since completion. patients must have normal organ and marrow function. tests should be completed within 14 days prior to starting study treatment. patients must have normal organ and marrow function. mab must have received a cumulative dose of doxorubicin less than 360mg/m2 and/or an epirubicin cumulative dose less than 720mg/m2 for study entry. patients with known leptomeningeal carcinomatosis are excluded from this clinical trial. ',\n",
       " 'ductal breast carcinoma in situ (DCIS), or lobular carcinoma in situ (LCIS) (currently without evidence of malignant disease) OR a concern about taking estrogen for fear of breast cancer, Bothersome hot flashes (defined by their occurrence of >= 28 times per week) se inhibitors/serotonin?norepinephrine reuptake inhibitors are allowed. patient must have been on a constant dose for at least 28 days. if patient has history of GERD despite appropriate therapy. symptoms are well-controlled with medical treatment, patient is eligible, patient is eligible, Ulcerative colitis, Narrow-angle glaucoma, Urinary retention, Hypersensitivity to oxybutynin or any other components of the product, Current uncontrolled hyperthyroidism, Coronary heart disease (angina or prior myocardial infarction), congestive heart failure, Symptomatic cardiac arrhythmias, Current uncontrolled hypertension, Myasthenia gravis, Dement ',\n",
       " 'Adverse Events 1:, Total: 0/4 (0.00%), Adverse Events 2:, Total: 0/5 (0.00%), Lymphoma [1]1/50 (2.00%), Adverse Events 2:, Total: 0/11 (0.00%), Lymphoma [1]0/11 (0.00%) ',\n",
       " 'locally recurrent or metastatic breast cancer must not be amenable to resection with curative intent. prior hormonal therapy in adjuvant, recurrent, or metastatic setting allowed but must have been discontinued at least 2 weeks before randomization. at least 1 week since minor surgery and/or focal/palliative radiation therapy. at least 3 weeks from radiation; at least 4 weeks from major surgery. at least 8 weeks from liver resection, thoracotomy, or neurosurgery. cBP unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months after treatment with bevacizumab. women with a positive pregnancy test on enrollment or prior to study drug administration. thracyclines not within institutional normal limits. history of high dose chemotherapy with bone marrow transplant or peripheral blood stem cell transplant within 2 years. ',\n",
       " 'participants received enzalutamide 80 mg (two 40 mg) capsules orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including any seizure), noncompliance, withdrawal of consent, discontinuation by sponsor, or investigator. participants were followed-up until 30 days after last dose of study drug or before initiation of a new antitumor or investigational therapy, whichever occurred first. ver occurred first. ',\n",
       " 'colorectal, breast, and cervical cancer screenings up to date status. participants assigned to the CCI group received the Prevention Care Management intervention. overall number of participants Analyzed: 378, Measure Type: Number, Unit of Measure: Percentage (%) of Participants Colorectal Cancer Screening - Baseline: 22.0, Colorectal Cancer Screening - Follow Up: 56.9, Breast Cancer Screening - Baseline: 43.9, Cervical Cancer Screening - Follow the PCM intervention consisted of cancer screening telephone support, including education, patient navigation, and motivational interviewing. overall number of participants Analyzed: 379, Measure Type: Number, Unit of Measure: Percentage (%) of Participants Colorectal Cancer Screening - Baseline: 26.9, Colorectal Cancer Screening - Follow Up: 52.8, Breast Cancer Screening - Follow Up: 66.8, Cervical Cancer Screening - Baseline: 41.7, Cerv ',\n",
       " 'if the patient had received the chemotherapy for breast cancer, it should be finished 30 days before the beginning of the study. if the patient had received the chemotherapy for breast cancer, it should be finished 30 days before the beginning of the study. patients of childbearing potential must implement reliable contraceptive measures during the study treatment, starting 4 weeks prior randomization and for 6 months after the last administration of the study drug. equirements: patient has received two or more chemotherapy regimens for metastatic breast cancer. uropathy, HIV, HCV, HBV, T.Pallidum infection(s);, acute or active chronic infections. patients must have a life expectancy of at least 1 year, excluding cancer diagnosis. patients must have a mass on clinical or radiological examination of >1 cm. bilirubin, serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate oxaloacetate transaminase (SGPT), alkaline phosphatase, and serum creatinine must all be  1.2 x upper limit of normal. patients with benign hyperbilirubinemia are also excluded. patients with non-breast malignancies are eligible if they have not received prior chemotherapy or extensive radiation therapy. patients with squamous or basal carcinoma of the skin that has been effectively treated are eligible. patients with prior or simultaneous lobular or ductal carcinoma in situ of the ipsilateral or contralateral breast are also eligible. patients will agree to continue contraception for 30 days from the date of the last study drug administration. patients who have received prior anthracycline therapy for any malignancy are not eligible. patients with a cardiac arrhythmia are eligible, provided the arrhythmia is not associated with concomitant heart failure or cardiac dysfunction. patients with a cardiac arrhythmia are eligible, provided the arrhythmia is not associated with concomitant heart failure or cardiac dysfunction. ness to give written informed consent. Unwillingness to participate or inability to comply with the protocol for the duration of the study. ',\n",
       " 'Anaemia 1/106 (0.94%), Disseminated intravascular coagulation 1/106 (0.94%), Febrile neutropenia 1/106 (0.94%), Lymph node pain 1/106 (0.94%), Neutropenia 2/106 (1.89%), Sinus tachycardia 1/106 (0.94%), Abdominal pain upper 0/106 (0.00%), Diarrhoea 2/106 (1.89%), Nausea 1/106 (0.94%), ',\n",
       " \"severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 4.03. an AE that met one or more of the following outcomes was classified as serious:, Fatal, Life-threatening, Disabling/incapacitating. st Cancer (mBC) population, metastatic Urothelial cancer (mUC) population, and overall safety population. 68 participants with non-TNBC were enrolled in the study and received at least one dose of SG. hese 68 participants, 54 were confirmed as Hormone receptor-positive/Human epidermal growth factor receptor 2-negative (HR+/HER2-), had progressed on at least one prior hormonal therapy in the metastatic setting. these 54 participants were included in the analysis of safety and were referred to as the HR+/HER2-mBC Population. PR was defined by a 30% or more decrease in the sum of the longest diameters (SLD) + sum of shortest diameters (SSD) of target lesions, taking as reference the baseline SLD+SSD. participants with breast cancer who received talazoparib capsules at a dose of either 600 mcg/day, 900 mcg/day, 1000 mcg/day, 1100 mcg/day. a dose of either 25 mcg/day, 50 mcg/day, 100 mcg/day, 200 mcg/day, 200 mcg/day, 400 mcg/day, 600 mcg/day, 900 mcg/day, 1000 mcg/day, 1100 mcg/day. \",\n",
       " 'Adverse Events 1:, Total: 8/87 (9.20%), Death * [1]8/87 (9.20%), Hospitalization [2]1/87 (1.15%), Hospitalization [3]1/87 (1.15%), Adverse Events 2:, Total: 0/28 (0.00%), Death * [1]0/28 (0.00%), Hospitalization [3]0/28 (0.00%)_______________________ ',\n",
       " 'Adverse Events 2:, Total: 3/6 (50.00%), Anaemia 0/6 (0.00%), Febrile neutropenia 0/6 (0.00%), Neutropenia 0/6 (0.00%), Bradycardia 0/6 (0.00%), Diarrhoea 0/6 (0.00%), Pancreatitis 0/6 (0.00%), Vomiting 0/6 (0.00%), Disease progression 0/6 (0.00%), Fatigue 0/6 (0.00%), Pyrexia ',\n",
       " 'Response Evaluation Criteria in Solid Tumors (RECIST) criteria to evaluate tumor response after 24 doses. Complete Response (CR)= disappearance of all target lesions, Partial Response (PR) = at least 30% decrease in sum of longest diameter of target lesions, Progressive Disease = at least 25% increase in sum of longest diameter of target lesions. patients receive oral letrozole once daily for 12 months in absence of disease progression or unacceptable toxicity. letrozole is given orally, given orally, given zoledronic acid. ',\n",
       " '0/4 (0.00%), Anaemia 0/4 (0.00%), Febrile neutropenia 0/4 (0.00%), Leukocytosis 0/4 (0.00%), Neutropenia 0/4 (0.00%), Pancytopenia 0/4 (0.00%), Acute coronary syndrome 0/4 (0.00%), Atrial fibrillation 0/4 (0.00%), Cardiac arrest 0/4 (0.00%), Pericardial effusion 0/4 (0.00%), Ad ',\n",
       " 'invasive disease-free survival time is defined as the time from date of randomization until time of event up to 2 years. time is defined as the time from date of randomization until time of event up to 2 years. patients who completed prior adjuvant trastuzumab received six placebo tablets (240 mg) taken orally once daily with food, preferably in the morning, continuously for one year. therapy continued until unacceptable toxicity, recurrent disease, death, or withdrawal of consent occurred. ',\n",
       " 'results 1:, Arm/Group Title: Arm 1: Paclitaxel + Trastuzumab Then A C, Arm/Group Description: 4 cycles of paclitaxel 80 mg/m2 on days 1, 8 and 15 of a 28-day cycle. follow paclitaxel/trastuzumab, standard AC every 21 days for 4 cycles. Neratinib 240 mg orally once daily beginning on Day 1 of paclitaxel. standard AC every 21 days for 4 cycles. following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy. ',\n",
       " '5/11 (45.45%), Hemorrhage, GI-abdomen NOS 21/11 (9.09%), Pain-liver 21/11 (9.09%), Infection-ulcer 20/11 (0.00%), Pain-rib cage due to vomiting 20/11 (0.00%), Obstruction-gu ureter 1/11 (9.09%), Pain-breast 21/11 (9.09%), Pleural effusion 22/11 (18.18%), Adverse Events 2:, Total: 0 ',\n",
       " 'INTERVENTION 1:, MM-111, All participants_. ',\n",
       " 'anemia*4 0/25 (0.00%), BLOOD/BONE MARROW:: Leukocytes (total WBC)*3 4/25 (16.00%), BLOOD/BONE MARROW:: Lymphopenia*3 2/25 (8.00%), BLOOD/BONE MARROW:: Neutrophils/granulocytes (ANC/AGC)*3 5/25 (20.00%), BLOOD/BONE MARROW:: Plate ',\n",
       " 'Adverse Events 1:, Total: 0/60 (0.00%), Adverse Events 2:, Total: 0/60 (0.00%). ',\n",
       " '3/37 (8.11%), Sinus tachycardia 0/37 (0.00%), Heart failure 0/37 (0.00%), Dehydration 1/37 (2.70%), Death Not Associated with CTCAE: Death NOS 1/37 (2.70%), Lymphopenia 1/37 (2.70%), Neutropenia 1/37 (2.70%), Thrombocytopenia 0/37 (0.00%), Hyponatremia 1/37 (2.70%), Weight loss 0/37 ( ',\n",
       " '8/20 (40.00%), Anaemia 1/20 (5.00%), Lymphadenopathy 0/4 (0.00%), Thrombocytopenia 0/4 (0.00%), Acute coronary syndrome 0/4 (0.00%), Atrial fibrillation 0/4 (0.00%), Cardiac failure congestive 0/4 (0.00%), Cardiac tamponade 0/4 (0.00%), Adverse Events 2:, Total: 8/20 (40.00%), Anaemia 1 ',\n",
       " ...]"
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# test_LTS = Long_texts_Summarizartion(Data.test_df.MergedColumn.tolist())\n",
    "# test_LTS.texts_summary"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "id": "0afc92c6",
   "metadata": {},
   "outputs": [],
   "source": [
    "Data.train_df['Trials_Summary'] = train_LTS.texts_summary\n",
    "Data.val_df['Trials_Summary'] = val_LTS.texts_summary\n",
    "Data.test_df['Trials_Summary'] = test_LTS.texts_summary"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "id": "a49e8cc9",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Data.test_df.to_csv('Test.csv', index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "id": "5ff95b0c",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Data.train_df.drop(columns=['trail1', 'trail2', '#Words1', '#Words2', '#Words3', 'MergedColumn'], inplace=True, axis=1)\n",
    "# Data.val_df.drop(columns=['trail1', 'trail2', '#Words1', '#Words2', '#Words3', 'MergedColumn'], inplace=True, axis=1)\n",
    "# Data.test_df.drop(columns=['trail1', 'trail2', '#Words1', '#Words2', '#Words3', 'MergedColumn'], inplace=True, axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 100,
   "id": "35639e82",
   "metadata": {},
   "outputs": [],
   "source": [
    "from sentence_transformers import SentenceTransformer, util\n",
    "\n",
    "class SemEval2024():\n",
    "    def __init__(self, file_path):\n",
    "        \n",
    "        self.model_names = {'Roberta':'stsb-roberta-base-v2', \n",
    "                            'MiniLM':'sentence-transformers/all-MiniLM-L6-v2', \n",
    "                            'Marco':'pritamdeka/S-PubMedBert-MS-MARCO', \n",
    "                            'distilroberta':'sentence-transformers/paraphrase-distilroberta-base-v1'}\n",
    "        \n",
    "        self.df = pd.read_csv(file_path)\n",
    "        \n",
    "        for i, name in enumerate(self.model_names):\n",
    "            print(f\"\\r{name} Index: {i}\", end=\"\")\n",
    "            self.text_similarity(name)\n",
    "            \n",
    "    def text_similarity(self, model_name):\n",
    "        model = SentenceTransformer(self.model_names[model_name])\n",
    "        \n",
    "        # Sample text lists\n",
    "        texts1 = self.df['statement'].tolist()\n",
    "        texts2 = self.df['Trials_Summary'].tolist()\n",
    "\n",
    "        # Tokenize and encode the texts using GPU\n",
    "        with torch.no_grad():\n",
    "            embeddings1 = model.encode(texts1, convert_to_tensor=True, device='cuda')\n",
    "            embeddings2 = model.encode(texts2, convert_to_tensor=True, device='cuda')\n",
    "\n",
    "        similarity_scores = []\n",
    "        for emb1, emb2 in zip(embeddings1, embeddings2):\n",
    "            similarity_score = util.pytorch_cos_sim(emb1.unsqueeze(0), emb2.unsqueeze(0))\n",
    "            similarity_scores.append(similarity_score.item())\n",
    "            \n",
    "        self.df[model_name] = similarity_scores"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 125,
   "id": "30e92f0a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>preferred_text</th>\n",
       "      <th>statement</th>\n",
       "      <th>section</th>\n",
       "      <th>label</th>\n",
       "      <th>Trials_Summary</th>\n",
       "      <th>Roberta</th>\n",
       "      <th>MiniLM</th>\n",
       "      <th>Marco</th>\n",
       "      <th>distilroberta</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Oral cavity,Primary operation,Oral Dosage Form</td>\n",
       "      <td>All the primary trial participants do not rece...</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>0</td>\n",
       "      <td>the surgery follows 1-7 days after the second ...</td>\n",
       "      <td>0.49</td>\n",
       "      <td>0.50</td>\n",
       "      <td>0.92</td>\n",
       "      <td>0.48</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Blood Platelets,Platelet Count measurement,Hem...</td>\n",
       "      <td>Patients with Platelet count over 100,000/mm¬¨...</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>0</td>\n",
       "      <td>clinical evidence of metastatic disease, Measu...</td>\n",
       "      <td>0.35</td>\n",
       "      <td>0.36</td>\n",
       "      <td>0.93</td>\n",
       "      <td>0.39</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Related personal status,Heart,Primary operation</td>\n",
       "      <td>Heart-related adverse events were recorded in ...</td>\n",
       "      <td>Adverse Events</td>\n",
       "      <td>1</td>\n",
       "      <td>Febrile neutropenia 1/32 (3.13%), Supraventric...</td>\n",
       "      <td>0.36</td>\n",
       "      <td>0.42</td>\n",
       "      <td>0.90</td>\n",
       "      <td>0.27</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Both breasts,Breast Carcinoma,Primary operation</td>\n",
       "      <td>Adult Patients with histologic confirmation of...</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>0</td>\n",
       "      <td>patients with bilateral breast cancer are elig...</td>\n",
       "      <td>0.69</td>\n",
       "      <td>0.54</td>\n",
       "      <td>0.95</td>\n",
       "      <td>0.61</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Laser Therapy</td>\n",
       "      <td>Laser Therapy is in each cohort of the primary...</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>0</td>\n",
       "      <td>inTERVENTION 2:, Part B Abemaciclib: HR+, HER2...</td>\n",
       "      <td>0.42</td>\n",
       "      <td>0.37</td>\n",
       "      <td>0.89</td>\n",
       "      <td>0.34</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1695</th>\n",
       "      <td>Liver function,Blood,Disease,Primary operation</td>\n",
       "      <td>Adequate blood, kidney, and hepatic function a...</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>1</td>\n",
       "      <td>postmenopausal women, Stage III or axillary no...</td>\n",
       "      <td>0.44</td>\n",
       "      <td>0.26</td>\n",
       "      <td>0.90</td>\n",
       "      <td>0.38</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1696</th>\n",
       "      <td>Primary operation,dalotuzumab</td>\n",
       "      <td>The Ridaforolimus + Dalotuzumab + Exemestane g...</td>\n",
       "      <td>Results</td>\n",
       "      <td>0</td>\n",
       "      <td>progressive disease (PD) was defined as a 20% ...</td>\n",
       "      <td>0.42</td>\n",
       "      <td>0.68</td>\n",
       "      <td>0.95</td>\n",
       "      <td>0.42</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1697</th>\n",
       "      <td>Patient position finding,Primary operation</td>\n",
       "      <td>The only difference between the interventions ...</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>1</td>\n",
       "      <td>inTERVENTION 1:, Prone, Prone position, INTERV...</td>\n",
       "      <td>0.26</td>\n",
       "      <td>0.44</td>\n",
       "      <td>0.93</td>\n",
       "      <td>0.26</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1698</th>\n",
       "      <td>Leukocytes,White Blood Cell Count procedure</td>\n",
       "      <td>Patients must have a white blood cell count ab...</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>1</td>\n",
       "      <td>breast cancer meeting 1 of the following crite...</td>\n",
       "      <td>0.33</td>\n",
       "      <td>0.25</td>\n",
       "      <td>0.92</td>\n",
       "      <td>0.35</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1699</th>\n",
       "      <td>Neoplasms,Primary operation</td>\n",
       "      <td>the primary trial and the secondary trial both...</td>\n",
       "      <td>Results</td>\n",
       "      <td>0</td>\n",
       "      <td>CNS objective response rate is the percentage ...</td>\n",
       "      <td>0.44</td>\n",
       "      <td>0.64</td>\n",
       "      <td>0.94</td>\n",
       "      <td>0.41</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1700 rows × 9 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                         preferred_text  \\\n",
       "0        Oral cavity,Primary operation,Oral Dosage Form   \n",
       "1     Blood Platelets,Platelet Count measurement,Hem...   \n",
       "2       Related personal status,Heart,Primary operation   \n",
       "3       Both breasts,Breast Carcinoma,Primary operation   \n",
       "4                                         Laser Therapy   \n",
       "...                                                 ...   \n",
       "1695     Liver function,Blood,Disease,Primary operation   \n",
       "1696                      Primary operation,dalotuzumab   \n",
       "1697         Patient position finding,Primary operation   \n",
       "1698        Leukocytes,White Blood Cell Count procedure   \n",
       "1699                        Neoplasms,Primary operation   \n",
       "\n",
       "                                              statement         section  \\\n",
       "0     All the primary trial participants do not rece...    Intervention   \n",
       "1     Patients with Platelet count over 100,000/mm¬¨...     Eligibility   \n",
       "2     Heart-related adverse events were recorded in ...  Adverse Events   \n",
       "3     Adult Patients with histologic confirmation of...     Eligibility   \n",
       "4     Laser Therapy is in each cohort of the primary...    Intervention   \n",
       "...                                                 ...             ...   \n",
       "1695  Adequate blood, kidney, and hepatic function a...     Eligibility   \n",
       "1696  The Ridaforolimus + Dalotuzumab + Exemestane g...         Results   \n",
       "1697  The only difference between the interventions ...    Intervention   \n",
       "1698  Patients must have a white blood cell count ab...     Eligibility   \n",
       "1699  the primary trial and the secondary trial both...         Results   \n",
       "\n",
       "      label                                     Trials_Summary  Roberta  \\\n",
       "0         0  the surgery follows 1-7 days after the second ...     0.49   \n",
       "1         0  clinical evidence of metastatic disease, Measu...     0.35   \n",
       "2         1  Febrile neutropenia 1/32 (3.13%), Supraventric...     0.36   \n",
       "3         0  patients with bilateral breast cancer are elig...     0.69   \n",
       "4         0  inTERVENTION 2:, Part B Abemaciclib: HR+, HER2...     0.42   \n",
       "...     ...                                                ...      ...   \n",
       "1695      1  postmenopausal women, Stage III or axillary no...     0.44   \n",
       "1696      0  progressive disease (PD) was defined as a 20% ...     0.42   \n",
       "1697      1  inTERVENTION 1:, Prone, Prone position, INTERV...     0.26   \n",
       "1698      1  breast cancer meeting 1 of the following crite...     0.33   \n",
       "1699      0  CNS objective response rate is the percentage ...     0.44   \n",
       "\n",
       "      MiniLM  Marco  distilroberta  \n",
       "0       0.50   0.92           0.48  \n",
       "1       0.36   0.93           0.39  \n",
       "2       0.42   0.90           0.27  \n",
       "3       0.54   0.95           0.61  \n",
       "4       0.37   0.89           0.34  \n",
       "...      ...    ...            ...  \n",
       "1695    0.26   0.90           0.38  \n",
       "1696    0.68   0.95           0.42  \n",
       "1697    0.44   0.93           0.26  \n",
       "1698    0.25   0.92           0.35  \n",
       "1699    0.64   0.94           0.41  \n",
       "\n",
       "[1700 rows x 9 columns]"
      ]
     },
     "execution_count": 125,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = pd.read_csv('Train.csv')\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 101,
   "id": "d9042054",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "distilroberta Index: 3"
     ]
    }
   ],
   "source": [
    "Train_SemEval = SemEval2024('Train.csv')\n",
    "Val_SemEval = SemEval2024('Validation.csv')\n",
    "Test_SemEval = SemEval2024('Test.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 124,
   "id": "4ee8b1f6",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Train_SemEval.df.drop(columns=['trail1', 'trail2', '#Words1', '#Words2', '#Words3', 'MergedColumn'], inplace=True, axis=1)\n",
    "# Val_SemEval.df.drop(columns=['trail1', 'trail2', '#Words1', '#Words2', '#Words3', 'MergedColumn'], inplace=True, axis=1)\n",
    "# Test_SemEval.df.drop(columns=['trail1', 'trail2', '#Words1', '#Words2', '#Words3', 'MergedColumn'], inplace=True, axis=1)\n",
    "\n",
    "# Train_SemEval.df.to_csv('Train.csv', index=False)\n",
    "# Val_SemEval.df.to_csv('Validation.csv', index=False)\n",
    "# Test_SemEval.df.to_csv('Test.csv', index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 115,
   "id": "ddb35621",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>preferred_text</th>\n",
       "      <th>statement</th>\n",
       "      <th>trail1</th>\n",
       "      <th>trail2</th>\n",
       "      <th>section</th>\n",
       "      <th>label</th>\n",
       "      <th>#Words1</th>\n",
       "      <th>#Words2</th>\n",
       "      <th>#Words3</th>\n",
       "      <th>MergedColumn</th>\n",
       "      <th>Trials_Summary</th>\n",
       "      <th>Roberta</th>\n",
       "      <th>MiniLM</th>\n",
       "      <th>Marco</th>\n",
       "      <th>distilroberta</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Oral cavity,Primary operation,Oral Dosage Form</td>\n",
       "      <td>All the primary trial participants do not rece...</td>\n",
       "      <td>INTERVENTION 1:, Diagnostic (FLT PET), Patient...</td>\n",
       "      <td>INTERVENTION 1:, Arm A, Patients receive oral ...</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>0</td>\n",
       "      <td>26</td>\n",
       "      <td>78</td>\n",
       "      <td>97</td>\n",
       "      <td>INTERVENTION 1:, Diagnostic (FLT PET), Patient...</td>\n",
       "      <td>the surgery follows 1-7 days after the second ...</td>\n",
       "      <td>0.49</td>\n",
       "      <td>0.50</td>\n",
       "      <td>0.92</td>\n",
       "      <td>0.48</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Blood Platelets,Platelet Count measurement,Hem...</td>\n",
       "      <td>Patients with Platelet count over 100,000/mm¬¨...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:, Histologically or cy...</td>\n",
       "      <td>_</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>0</td>\n",
       "      <td>24</td>\n",
       "      <td>700</td>\n",
       "      <td>1</td>\n",
       "      <td>DISEASE CHARACTERISTICS:, Histologically or cy...</td>\n",
       "      <td>clinical evidence of metastatic disease, Measu...</td>\n",
       "      <td>0.35</td>\n",
       "      <td>0.36</td>\n",
       "      <td>0.93</td>\n",
       "      <td>0.39</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Related personal status,Heart,Primary operation</td>\n",
       "      <td>Heart-related adverse events were recorded in ...</td>\n",
       "      <td>Adverse Events 1:, Total: 5/32 (15.63%), Febri...</td>\n",
       "      <td>Adverse Events 1:, Total: 285/752 (37.90%), An...</td>\n",
       "      <td>Adverse Events</td>\n",
       "      <td>1</td>\n",
       "      <td>14</td>\n",
       "      <td>26</td>\n",
       "      <td>84</td>\n",
       "      <td>Adverse Events 1:, Total: 5/32 (15.63%), Febri...</td>\n",
       "      <td>Febrile neutropenia 1/32 (3.13%), Supraventric...</td>\n",
       "      <td>0.36</td>\n",
       "      <td>0.42</td>\n",
       "      <td>0.90</td>\n",
       "      <td>0.27</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Both breasts,Breast Carcinoma,Primary operation</td>\n",
       "      <td>Adult Patients with histologic confirmation of...</td>\n",
       "      <td>Inclusion Criteria:, Patients with histologic ...</td>\n",
       "      <td>_</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>0</td>\n",
       "      <td>19</td>\n",
       "      <td>409</td>\n",
       "      <td>1</td>\n",
       "      <td>Inclusion Criteria:, Patients with histologic ...</td>\n",
       "      <td>patients with bilateral breast cancer are elig...</td>\n",
       "      <td>0.69</td>\n",
       "      <td>0.54</td>\n",
       "      <td>0.95</td>\n",
       "      <td>0.61</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Laser Therapy</td>\n",
       "      <td>Laser Therapy is in each cohort of the primary...</td>\n",
       "      <td>INTERVENTION 1:, Laser Therapy Alone, therapis...</td>\n",
       "      <td>INTERVENTION 1:, Part A Abemaciclib: HR+, HER2...</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>0</td>\n",
       "      <td>18</td>\n",
       "      <td>29</td>\n",
       "      <td>130</td>\n",
       "      <td>INTERVENTION 1:, Laser Therapy Alone, therapis...</td>\n",
       "      <td>inTERVENTION 2:, Part B Abemaciclib: HR+, HER2...</td>\n",
       "      <td>0.42</td>\n",
       "      <td>0.37</td>\n",
       "      <td>0.89</td>\n",
       "      <td>0.34</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1695</th>\n",
       "      <td>Liver function,Blood,Disease,Primary operation</td>\n",
       "      <td>Adequate blood, kidney, and hepatic function a...</td>\n",
       "      <td>Inclusion Criteria:, Postmenopausal women, Sta...</td>\n",
       "      <td>Inclusion Criteria:, Pathologically confirmed ...</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>1</td>\n",
       "      <td>24</td>\n",
       "      <td>34</td>\n",
       "      <td>133</td>\n",
       "      <td>Inclusion Criteria:, Postmenopausal women, Sta...</td>\n",
       "      <td>postmenopausal women, Stage III or axillary no...</td>\n",
       "      <td>0.44</td>\n",
       "      <td>0.26</td>\n",
       "      <td>0.90</td>\n",
       "      <td>0.38</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1696</th>\n",
       "      <td>Primary operation,dalotuzumab</td>\n",
       "      <td>The Ridaforolimus + Dalotuzumab + Exemestane g...</td>\n",
       "      <td>Outcome Measurement:, 1. Progression-free Surv...</td>\n",
       "      <td>_</td>\n",
       "      <td>Results</td>\n",
       "      <td>0</td>\n",
       "      <td>19</td>\n",
       "      <td>301</td>\n",
       "      <td>1</td>\n",
       "      <td>Outcome Measurement:, 1. Progression-free Surv...</td>\n",
       "      <td>progressive disease (PD) was defined as a 20% ...</td>\n",
       "      <td>0.42</td>\n",
       "      <td>0.68</td>\n",
       "      <td>0.95</td>\n",
       "      <td>0.42</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1697</th>\n",
       "      <td>Patient position finding,Primary operation</td>\n",
       "      <td>The only difference between the interventions ...</td>\n",
       "      <td>INTERVENTION 1:, Prone, Prone position, INTERV...</td>\n",
       "      <td>_</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>1</td>\n",
       "      <td>15</td>\n",
       "      <td>10</td>\n",
       "      <td>1</td>\n",
       "      <td>INTERVENTION 1:, Prone, Prone position, INTERV...</td>\n",
       "      <td>inTERVENTION 1:, Prone, Prone position, INTERV...</td>\n",
       "      <td>0.26</td>\n",
       "      <td>0.44</td>\n",
       "      <td>0.93</td>\n",
       "      <td>0.26</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1698</th>\n",
       "      <td>Leukocytes,White Blood Cell Count procedure</td>\n",
       "      <td>Patients must have a white blood cell count ab...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:, Histologically confi...</td>\n",
       "      <td>_</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>1</td>\n",
       "      <td>16</td>\n",
       "      <td>365</td>\n",
       "      <td>1</td>\n",
       "      <td>DISEASE CHARACTERISTICS:, Histologically confi...</td>\n",
       "      <td>breast cancer meeting 1 of the following crite...</td>\n",
       "      <td>0.33</td>\n",
       "      <td>0.25</td>\n",
       "      <td>0.92</td>\n",
       "      <td>0.35</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1699</th>\n",
       "      <td>Neoplasms,Primary operation</td>\n",
       "      <td>the primary trial and the secondary trial both...</td>\n",
       "      <td>Outcome Measurement:, Central Nervous System (...</td>\n",
       "      <td>Outcome Measurement:, Objective Response Rate ...</td>\n",
       "      <td>Results</td>\n",
       "      <td>0</td>\n",
       "      <td>21</td>\n",
       "      <td>313</td>\n",
       "      <td>133</td>\n",
       "      <td>Outcome Measurement:, Central Nervous System (...</td>\n",
       "      <td>CNS objective response rate is the percentage ...</td>\n",
       "      <td>0.44</td>\n",
       "      <td>0.64</td>\n",
       "      <td>0.94</td>\n",
       "      <td>0.41</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1700 rows × 15 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                         preferred_text  \\\n",
       "0        Oral cavity,Primary operation,Oral Dosage Form   \n",
       "1     Blood Platelets,Platelet Count measurement,Hem...   \n",
       "2       Related personal status,Heart,Primary operation   \n",
       "3       Both breasts,Breast Carcinoma,Primary operation   \n",
       "4                                         Laser Therapy   \n",
       "...                                                 ...   \n",
       "1695     Liver function,Blood,Disease,Primary operation   \n",
       "1696                      Primary operation,dalotuzumab   \n",
       "1697         Patient position finding,Primary operation   \n",
       "1698        Leukocytes,White Blood Cell Count procedure   \n",
       "1699                        Neoplasms,Primary operation   \n",
       "\n",
       "                                              statement  \\\n",
       "0     All the primary trial participants do not rece...   \n",
       "1     Patients with Platelet count over 100,000/mm¬¨...   \n",
       "2     Heart-related adverse events were recorded in ...   \n",
       "3     Adult Patients with histologic confirmation of...   \n",
       "4     Laser Therapy is in each cohort of the primary...   \n",
       "...                                                 ...   \n",
       "1695  Adequate blood, kidney, and hepatic function a...   \n",
       "1696  The Ridaforolimus + Dalotuzumab + Exemestane g...   \n",
       "1697  The only difference between the interventions ...   \n",
       "1698  Patients must have a white blood cell count ab...   \n",
       "1699  the primary trial and the secondary trial both...   \n",
       "\n",
       "                                                 trail1  \\\n",
       "0     INTERVENTION 1:, Diagnostic (FLT PET), Patient...   \n",
       "1     DISEASE CHARACTERISTICS:, Histologically or cy...   \n",
       "2     Adverse Events 1:, Total: 5/32 (15.63%), Febri...   \n",
       "3     Inclusion Criteria:, Patients with histologic ...   \n",
       "4     INTERVENTION 1:, Laser Therapy Alone, therapis...   \n",
       "...                                                 ...   \n",
       "1695  Inclusion Criteria:, Postmenopausal women, Sta...   \n",
       "1696  Outcome Measurement:, 1. Progression-free Surv...   \n",
       "1697  INTERVENTION 1:, Prone, Prone position, INTERV...   \n",
       "1698  DISEASE CHARACTERISTICS:, Histologically confi...   \n",
       "1699  Outcome Measurement:, Central Nervous System (...   \n",
       "\n",
       "                                                 trail2         section  \\\n",
       "0     INTERVENTION 1:, Arm A, Patients receive oral ...    Intervention   \n",
       "1                                                     _     Eligibility   \n",
       "2     Adverse Events 1:, Total: 285/752 (37.90%), An...  Adverse Events   \n",
       "3                                                     _     Eligibility   \n",
       "4     INTERVENTION 1:, Part A Abemaciclib: HR+, HER2...    Intervention   \n",
       "...                                                 ...             ...   \n",
       "1695  Inclusion Criteria:, Pathologically confirmed ...     Eligibility   \n",
       "1696                                                  _         Results   \n",
       "1697                                                  _    Intervention   \n",
       "1698                                                  _     Eligibility   \n",
       "1699  Outcome Measurement:, Objective Response Rate ...         Results   \n",
       "\n",
       "      label  #Words1  #Words2  #Words3  \\\n",
       "0         0       26       78       97   \n",
       "1         0       24      700        1   \n",
       "2         1       14       26       84   \n",
       "3         0       19      409        1   \n",
       "4         0       18       29      130   \n",
       "...     ...      ...      ...      ...   \n",
       "1695      1       24       34      133   \n",
       "1696      0       19      301        1   \n",
       "1697      1       15       10        1   \n",
       "1698      1       16      365        1   \n",
       "1699      0       21      313      133   \n",
       "\n",
       "                                           MergedColumn  \\\n",
       "0     INTERVENTION 1:, Diagnostic (FLT PET), Patient...   \n",
       "1     DISEASE CHARACTERISTICS:, Histologically or cy...   \n",
       "2     Adverse Events 1:, Total: 5/32 (15.63%), Febri...   \n",
       "3     Inclusion Criteria:, Patients with histologic ...   \n",
       "4     INTERVENTION 1:, Laser Therapy Alone, therapis...   \n",
       "...                                                 ...   \n",
       "1695  Inclusion Criteria:, Postmenopausal women, Sta...   \n",
       "1696  Outcome Measurement:, 1. Progression-free Surv...   \n",
       "1697  INTERVENTION 1:, Prone, Prone position, INTERV...   \n",
       "1698  DISEASE CHARACTERISTICS:, Histologically confi...   \n",
       "1699  Outcome Measurement:, Central Nervous System (...   \n",
       "\n",
       "                                         Trials_Summary  Roberta  MiniLM  \\\n",
       "0     the surgery follows 1-7 days after the second ...     0.49    0.50   \n",
       "1     clinical evidence of metastatic disease, Measu...     0.35    0.36   \n",
       "2     Febrile neutropenia 1/32 (3.13%), Supraventric...     0.36    0.42   \n",
       "3     patients with bilateral breast cancer are elig...     0.69    0.54   \n",
       "4     inTERVENTION 2:, Part B Abemaciclib: HR+, HER2...     0.42    0.37   \n",
       "...                                                 ...      ...     ...   \n",
       "1695  postmenopausal women, Stage III or axillary no...     0.44    0.26   \n",
       "1696  progressive disease (PD) was defined as a 20% ...     0.42    0.68   \n",
       "1697  inTERVENTION 1:, Prone, Prone position, INTERV...     0.26    0.44   \n",
       "1698  breast cancer meeting 1 of the following crite...     0.33    0.25   \n",
       "1699  CNS objective response rate is the percentage ...     0.44    0.64   \n",
       "\n",
       "      Marco  distilroberta  \n",
       "0      0.92           0.48  \n",
       "1      0.93           0.39  \n",
       "2      0.90           0.27  \n",
       "3      0.95           0.61  \n",
       "4      0.89           0.34  \n",
       "...     ...            ...  \n",
       "1695   0.90           0.38  \n",
       "1696   0.95           0.42  \n",
       "1697   0.93           0.26  \n",
       "1698   0.92           0.35  \n",
       "1699   0.94           0.41  \n",
       "\n",
       "[1700 rows x 15 columns]"
      ]
     },
     "execution_count": 115,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Train_SemEval.df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 118,
   "id": "afc490db",
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(array([  1.,  16., 141., 415., 434., 321., 195., 103.,  60.,  14.]),\n",
       " array([-0.11255282, -0.00825021,  0.09605241,  0.20035502,  0.30465764,\n",
       "         0.40896025,  0.51326287,  0.61756548,  0.7218681 ,  0.82617071,\n",
       "         0.93047333]),\n",
       " <BarContainer object of 10 artists>)"
      ]
     },
     "execution_count": 118,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.hist(Train_SemEval.df[\"MiniLM\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 119,
   "id": "74fad00a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(-0.11255282163619995, 0.9304733276367188)"
      ]
     },
     "execution_count": 119,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Train_SemEval.df[\"MiniLM\"].to_numpy().min(), Train_SemEval.df[\"MiniLM\"].to_numpy().max()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 108,
   "id": "00cbb599",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████████████████████████████████████████████████████████████████████████████| 29/29 [00:02<00:00, 13.23it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[LightGBM] [Info] Number of positive: 850, number of negative: 850\n",
      "[LightGBM] [Info] Auto-choosing col-wise multi-threading, the overhead of testing was 0.000100 seconds.\n",
      "You can set `force_col_wise=true` to remove the overhead.\n",
      "[LightGBM] [Info] Total Bins 1020\n",
      "[LightGBM] [Info] Number of data points in the train set: 1700, number of used features: 4\n",
      "[LightGBM] [Info] [binary:BoostFromScore]: pavg=0.500000 -> initscore=0.000000\n",
      "                               Accuracy  Balanced Accuracy  ROC AUC  F1 Score  \\\n",
      "Model                                                                           \n",
      "NuSVC                              0.55               0.55     0.55      0.54   \n",
      "LinearSVC                          0.54               0.54     0.54      0.53   \n",
      "LinearDiscriminantAnalysis         0.54               0.54     0.54      0.53   \n",
      "RidgeClassifierCV                  0.54               0.54     0.54      0.53   \n",
      "RidgeClassifier                    0.54               0.54     0.54      0.53   \n",
      "LogisticRegression                 0.54               0.54     0.54      0.53   \n",
      "AdaBoostClassifier                 0.53               0.53     0.53      0.53   \n",
      "CalibratedClassifierCV             0.53               0.53     0.53      0.53   \n",
      "LGBMClassifier                     0.52               0.52     0.52      0.52   \n",
      "SVC                                0.52               0.52     0.52      0.52   \n",
      "GaussianNB                         0.52               0.52     0.52      0.51   \n",
      "KNeighborsClassifier               0.52               0.52     0.52      0.51   \n",
      "RandomForestClassifier             0.52               0.52     0.52      0.51   \n",
      "DecisionTreeClassifier             0.51               0.51     0.51      0.51   \n",
      "BernoulliNB                        0.51               0.51     0.51      0.51   \n",
      "PassiveAggressiveClassifier        0.51               0.51     0.51      0.50   \n",
      "NearestCentroid                    0.51               0.51     0.51      0.51   \n",
      "SGDClassifier                      0.51               0.51     0.51      0.50   \n",
      "DummyClassifier                    0.50               0.50     0.50      0.33   \n",
      "Perceptron                         0.50               0.50     0.50      0.50   \n",
      "QuadraticDiscriminantAnalysis      0.50               0.50     0.50      0.50   \n",
      "XGBClassifier                      0.50               0.50     0.50      0.50   \n",
      "LabelPropagation                   0.48               0.48     0.48      0.48   \n",
      "LabelSpreading                     0.48               0.48     0.48      0.48   \n",
      "BaggingClassifier                  0.47               0.47     0.47      0.46   \n",
      "ExtraTreeClassifier                0.47               0.47     0.47      0.47   \n",
      "ExtraTreesClassifier               0.46               0.46     0.46      0.46   \n",
      "\n",
      "                               Time Taken  \n",
      "Model                                      \n",
      "NuSVC                                0.23  \n",
      "LinearSVC                            0.04  \n",
      "LinearDiscriminantAnalysis           0.04  \n",
      "RidgeClassifierCV                    0.01  \n",
      "RidgeClassifier                      0.02  \n",
      "LogisticRegression                   0.02  \n",
      "AdaBoostClassifier                   0.14  \n",
      "CalibratedClassifierCV               0.14  \n",
      "LGBMClassifier                       0.20  \n",
      "SVC                                  0.14  \n",
      "GaussianNB                           0.01  \n",
      "KNeighborsClassifier                 0.03  \n",
      "RandomForestClassifier               0.50  \n",
      "DecisionTreeClassifier               0.02  \n",
      "BernoulliNB                          0.01  \n",
      "PassiveAggressiveClassifier          0.01  \n",
      "NearestCentroid                      0.01  \n",
      "SGDClassifier                        0.01  \n",
      "DummyClassifier                      0.01  \n",
      "Perceptron                           0.01  \n",
      "QuadraticDiscriminantAnalysis        0.01  \n",
      "XGBClassifier                        0.11  \n",
      "LabelPropagation                     0.06  \n",
      "LabelSpreading                       0.11  \n",
      "BaggingClassifier                    0.08  \n",
      "ExtraTreeClassifier                  0.01  \n",
      "ExtraTreesClassifier                 0.21  \n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "from lazypredict.Supervised import LazyClassifier\n",
    "\n",
    "features = ['Roberta', 'MiniLM', 'Marco', 'distilroberta']\n",
    "\n",
    "X_train = Train_SemEval.df[features]\n",
    "y_train = Train_SemEval.df.label\n",
    "\n",
    "X_val = Val_SemEval.df[features]\n",
    "y_val = Val_SemEval.df.label\n",
    "\n",
    "X_test = Test_SemEval.df[features]\n",
    "y_test = Test_SemEval.df.label\n",
    "\n",
    "clf = LazyClassifier(verbose=0,ignore_warnings=True, custom_metric=None)\n",
    "models, predictions = clf.fit(X_train, X_val, y_train, y_val)\n",
    "\n",
    "print(models)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 114,
   "id": "971e0a28",
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.svm import NuSVC\n",
    "\n",
    "clf = NuSVC()\n",
    "\n",
    "clf.fit(X_train, y_train)\n",
    "preds = clf.predict(X_test)\n",
    "np.save('TestSecond.npy', preds)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
